

STIC-Biotech/ChemLib

170813

11/9

From: Swope, Sheridan
Sent: Friday, November 04, 2005 7:20 PM
To: STIC-Biotech/ChemLib
Subject: FW: 10/791,980

Jan De Groot

-----Original Message-----

From: Low, Christopher
Sent: Friday, November 04, 2005 7:19 PM
To: Swope, Sheridan; Woodward, Michael
Cc: Page, Thurman; Richter, Johann
Subject: RE: 10/791,980

RECEIVED
NOV - 7 2005
STIC/BIOTECH/CHM LIB
(STIC)

Rush approved.

-----Original Message-----

From: Swope, Sheridan
Sent: Fri 11/4/2005 4:42 PM
To: Woodward, Michael
Cc: Low, Christopher; Page, Thurman; Richter, Johann
Subject: FW: 10/791,980

Please reply all, so we know there's been a response.
Thanks,

-----Original Message-----

From: Swope, Sheridan
Sent: Friday, November 04, 2005 4:41 PM
To: Chan, Christina
Subject: 10/791,980

Jan, 22504
11/7 - 11/14

Chris, May I have this rushed for an allowance?
Not enough hits were retrieved to cover the recited scope.

For 10/791,980, pls search--only the requested databases:

SID 6 against the Published Applications (.rnpb) database.
Collect the top 250 alignments.

SID 6 against the N_Geneseq_16Dec04 (.rng) database.
Collect the top 250 alignments.

Sheridan Swope, Ph.D.
Patent Examiner, AU 1656
Recombinant Enzymes
571-272-0943 (voice)

11/7/2005

THIS PAGE BLANK (USPTO)

E02B71 Remsen Bld (Office)
E03C70 Remsen Bld (Mailbox)

11/7/2005

THIS PAGE BLANK (USPTO)

GenCore version 5.1.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: November 14, 2005, 11:19:51 ; Search time 695 Seconds
(without alignments)
4429.159 Million cell updates/sec

Title: US-10-791-980-6

Perfect score: 2834

Sequence: 1 MVARVGLLRLLQLLLWGHLL.....WATELPMGWCWANGSALF 520

Scoring table:

BLOSUM62
Xgapop 10.0, Xgapext 0.5
Ygapop 10.0, Ygapext 0.5
Fgapop 6.0, Fgapext 7.0
Delop 6.0, Delext 7.0

Searched: 4390206 seqs, 2959870667 residues

Total number of hits satisfying chosen parameters: 8780412

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 300 summaries

Command line parameters:

-MODEL=frame+ p2n.model -DEV=xlp
-Q/cgn2_1/USFTO_spoor_p/US10791980/runat_09112005_121055_27725/app_query.fasta_1.711
-DB=N Geneseq 16Dec04 -QFWT=fastcap -SUFFIX=rng -MINMATCH=0.1 -LOOPEL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=300 -DOCALIGN=200 -THR SCORE=pct -THR MAX=100 -THR MIN=0 -ALIGN=250
-MODE=LOCAL -OUTFMT=ptc -NORM=ext -HEAPSIZ=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US10791980 @CGN_1.1.708 @runat_09112005_121055_27725 -NCPU=6 -ICPU=3
-NO_WMAP -LARGEQUERY -NEG SCORES=0 -WAIT -DSPBLOCK=100 -LONGLOG
-DEV TIMEOUT=120 -WARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database :

N Geneseq 16Dec04: *
1: Geneseqn1980s: *
2: Geneseqn1990s: *
3: Geneseqn2000s: *
4: Geneseqn2001s: *
5: Geneseqn2001bs: *
6: Geneseqn2002as: *
7: Geneseqn2002bs: *
8: Geneseqn2003as: *
9: Geneseqn2003bs: *
10: Geneseqn2003cs: *
11: Geneseqn2003ds: *
12: Geneseqn2004as: *
13: Geneseqn2004bs: *

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2834	100.0	1597	6	Aad23965 Human mat
2	2792	98.5	1563	4	Aah23373 Human MPR
3	2792	98.5	1563	4	Aah23373 Human MPR
4	2792	98.5	1563	4	Aah23373 Human MPR
5	2792	98.5	1563	4	Aah23373 Human MPR

6	2792	98.5	1985	8	ACD41866	Ac41866 Human sec
7	2792	98.5	1985	8	ACA04095	Ac404095 Human CDN
8	2792	98.5	1985	9	ADA45662	Ada45662 Novel hum
9	2792	98.5	1985	9	ADA76093	Ada76093 Human PRO
10	2792	98.5	1985	9	ADA18743	Ada18743 Human PRO
11	2792	98.5	1985	9	ADA61366	Ada61366 Homo sapi
12	2792	98.5	1985	9	ADB19151	Adb19151 Novel hum
13	2792	98.5	1985	9	ADB27692	Adb27692 cDNA enco
14	2792	98.5	1985	9	ADA86171	Ada86171 Novel hum
15	2792	98.5	1985	9	ADB15735	Adb15735 Human PRO
16	2792	98.5	1985	9	ADA47521	Ada47521 Human PRO
17	2792	98.5	1985	9	ADA67316	Ada67316 Human PRO
18	2792	98.5	1985	9	ADB30323	Adb30323 cDNA enco
19	2792	98.5	1985	9	ADA85619	Ada85619 Novel hum
20	2792	98.5	1985	9	ADA96831	Ada96831 Human PRO
21	2792	98.5	1985	9	ADA79135	Ada79135 Human PRO
22	2792	98.5	1985	9	ADA87274	Ada87274 Novel hum
23	2792	98.5	1985	9	ADB16476	Adb16476 Human PRO
24	2792	98.5	1985	9	ADA91568	Ada91568 Novel hum
25	2792	98.5	1985	9	ADB14631	Adb14631 Human PRO
26	2792	98.5	1985	9	ADB18592	Adb18592 Novel hum
27	2792	98.5	1985	9	ADA93807	Ada93807 Human PRO
28	2792	98.5	1985	9	ADB19703	Adb19703 Novel hum
29	2792	98.5	1985	9	ADB13015	Adb13015 Human PRO
30	2792	98.5	1985	9	ACD98495	Ac98495 Novel hum
31	2792	98.5	1985	9	ADA74269	Ada74269 Human PRO
32	2792	98.5	1985	9	ADB24502	Adb24502 Human PRO
33	2792	98.5	1985	9	ADA82026	Ada82026 Human PRO
34	2792	98.5	1985	9	ADA74989	Ada74989 Human PRO
35	2792	98.5	1985	9	ADA85067	Ada85067 Novel hum
36	2792	98.5	1985	9	ADA84515	Ada84515 Novel hum
37	2792	98.5	1985	9	ADB29771	Adb29771 cDNA enco
38	2792	98.5	1985	9	ADA80299	Ada80299 Human PRO
39	2792	98.5	1985	9	ADA75541	Ada75541 Human PRO
40	2792	98.5	1985	9	ADA46766	Ada46766 Human PRO
41	2792	98.5	1985	9	ADB25062	Adb25062 Human PRO
42	2792	98.5	1985	9	ADA93238	Ada93238 Human PRO
43	2792	98.5	1985	9	ADB26588	Adb26588 cDNA enco
44	2792	98.5	1985	9	ADB30875	Adb30875 cDNA enco
45	2792	98.5	1985	9	ADA60803	Ada60803 Homo sapi
46	2792	98.5	1985	9	ADB23950	Adb23950 Human PRO
47	2792	98.5	1985	9	ADA96279	Ada96279 Human PRO
48	2792	98.5	1985	9	ADA80851	Ada80851 Human PRO
49	2792	98.5	1985	9	ADA95727	Ada95727 Human PRO
50	2792	98.5	1985	9	ADB26036	Adb26036 cDNA enco
51	2792	98.5	1985	9	ADB21521	Adb21521 Novel hum
52	2792	98.5	1985	9	ADA77300	Ada77300 Human PRO
53	2792	98.5	1985	9	ADB18040	Adb18040 cDNA enco
54	2792	98.5	1985	9	ADA86723	Ada86723 Novel hum
55	2792	98.5	1985	9	ADA87826	Ada87826 Novel hum
56	2792	98.5	1985	9	ADA46214	Ada46214 Novel hum
57	2792	98.5	1985	9	ADB28244	Adb28244 cDNA enco
58	2792	98.5	1985	9	ADB28796	Adb28796 cDNA enco
59	2792	98.5	1985	9	ADA76748	Ada76748 Human PRO
60	2792	98.5	1985	9	ADA88378	Ada88378 Novel hum
61	2792	98.5	1985	9	ADA97383	Ada97383 Human PRO
62	2792	98.5	1985	9	ADB27140	Adb27140 cDNA enco
63	2792	98.5	1985	9	ADB22073	Adb22073 Novel hum
64	2792	98.5	1985	9	ADA66764	Ada66764 Human PRO
65	2792	98.5	1985	9	ADB22625	Adb22625 Human PRO
66	2792	98.5	1985	9	ADB23398	Adb23398 Human PRO
67	2792	98.5	1985	9	ADA92120	Ada92120 Novel hum
68	2792	98.5	1985	9	ADB15183	Adb15183 Human PRO
69	2792	98.5	1985	9	ADB38435	Adb38435 Novel hum
70	2792	98.5	1985	9	ADB37883	Adb37883 Novel hum
71	2792	98.5	1985	9	ADB66355	Adb66355 Novel hum
72	2792	98.5	1985	10	ADB89435	Adb89435 Human PRO
73	2792	98.5	1985	10	ADB90167	Adb90167 Human PRO
74	2792	98.5	1985	10	ADB39268	Adb39268 Novel hum
75	2792	98.5	1985	10	ADB46891	Adb46891 Novel hum
76	2792	98.5	1985	10	ADB86498	Adb86498 Novel hum
77	2792	98.5	1985	10	ADB77103	Adb77103 cDNA enco
78	2792	98.5	1985	10	ADB34260	Adb34260 Human PRO

79	2792	98.5	1985	10	ADB35364	Human PRO	152	2792	98.5	1985	10	ACD23924	Novel hum
80	2792	98.5	1985	10	ADB33708	Human PRO	153	2792	98.5	1985	10	ACA67065	cDNA enco
81	2792	98.5	1985	10	ADB34812	Human PRO	154	2792	98.5	1985	11	ADM82323	Novel hum
82	2792	98.5	1985	10	ADB35916	Human PRO	155	2792	98.5	1985	11	ADN15722	Novel hum
83	2792	98.5	1985	10	ADB46311	Novel hum	156	2792	98.5	1985	11	ADN16351	Novel hum
84	2792	98.5	1985	10	ADC50184	Novel hum	157	2792	98.5	1985	11	ADN15170	Novel hum
85	2792	98.5	1985	10	ADC71731	Novel hum	158	2792	98.5	1985	11	ADN14618	Novel hum
86	2792	98.5	1985	10	ADC59710	Novel hum	159	2792	98.5	1985	11	ADI63844	Novel hum
87	2792	98.5	1985	10	ADC57171	Novel hum	160	2792	98.5	1985	11	ADI64793	Novel hum
88	2792	98.5	1985	10	ADC57071	Novel hum	161	2792	98.5	1985	11	ADI64793	Novel hum
89	2792	98.5	1985	10	ADC60262	Novel hum	162	2792	98.5	1985	12	ADC80880	Novel hum
90	2792	98.5	1985	10	ADC50737	Novel hum	163	2792	98.5	1985	12	ADD76328	Human PRO
91	2792	98.5	1985	10	ADC65264	Human PRO	164	2792	98.5	1985	12	ADD87692	Human PRO
92	2792	98.5	1985	10	ADC54362	Novel hum	165	2792	98.5	1985	12	ADD86096	Human PRO
93	2792	98.5	1985	10	ADC53323	Novel hum	166	2792	98.5	1985	12	ADN15722	Novel hum
94	2792	98.5	1985	10	ADC58846	Novel hum	167	2792	98.5	1985	12	ADN16351	Novel hum
95	2792	98.5	1985	10	ADC55724	Novel hum	168	2792	98.5	1985	12	ADN14618	Novel hum
96	2792	98.5	1985	10	ADC58294	Novel hum	169	2792	98.5	1985	12	ADI63844	Novel hum
97	2792	98.5	1985	10	ADD02968	Novel hum	170	2792	98.5	1985	12	ADI64793	Novel hum
98	2792	98.5	1985	10	ADC89960	Novel hum	171	2792	98.5	1985	12	ADD76328	Human PRO
99	2792	98.5	1985	10	ADC89960	Novel hum	172	2792	98.5	1985	12	ADD87692	Human PRO
100	2792	98.5	1985	10	ADC63379	Novel hum	173	2792	98.5	1985	12	ADD86096	Human PRO
101	2792	98.5	1985	10	ADC48268	Human PRO	174	2792	98.5	1985	12	ADN15722	Novel hum
102	2792	98.5	1985	10	ADD09797	Human PRO	175	2792	98.5	1985	12	ADN16351	Novel hum
103	2792	98.5	1985	10	ADD04372	Novel hum	176	2792	98.5	1985	12	ADN14618	Novel hum
104	2792	98.5	1985	10	ADC80328	Novel hum	177	2792	98.5	1985	12	ADI63844	Novel hum
105	2792	98.5	1985	10	ADD10835	Human PRO	178	2792	98.5	1985	12	ADI64793	Novel hum
106	2792	98.5	1985	10	ADC47716	Human PRO	179	2792	98.5	1985	12	ADD76328	Human PRO
107	2792	98.5	1985	10	ADC79776	Novel hum	180	2792	98.5	1985	12	ADD87692	Human PRO
108	2792	98.5	1985	10	ADD09245	Human PRO	181	2792	98.5	1985	12	ADD86096	Human PRO
109	2792	98.5	1985	10	ADD40958	Novel hum	182	2792	98.5	1985	12	ADN15722	Novel hum
110	2792	98.5	1985	10	ADD52097	cDNA enco	183	2792	98.5	1985	12	ADN16351	Novel hum
111	2792	98.5	1985	10	ADD52837	cDNA enco	184	2792	98.5	1985	12	ADN14618	Novel hum
112	2792	98.5	1985	10	ADD53389	Novel hum	185	2792	98.5	1985	12	ADI63844	Novel hum
113	2792	98.5	1985	10	ADD51545	cDNA enco	186	2792	98.5	1985	12	ADI64793	Novel hum
114	2792	98.5	1985	10	ADD02344	Human PRO	187	2792	98.5	1985	12	ADD76328	Human PRO
115	2792	98.5	1985	10	ADD01778	Human PRO	188	2792	98.5	1985	12	ADD87692	Human PRO
116	2792	98.5	1985	10	ADD53960	Novel hum	189	2792	98.5	1985	12	ADD86096	Human PRO
117	2792	98.5	1985	10	ADD92277	Human PRO	190	2792	98.5	1985	12	ADN15722	Novel hum
118	2792	98.5	1985	10	ADD91173	Human PRO	191	2792	98.5	1985	12	ADN16351	Novel hum
119	2792	98.5	1985	10	ADE03787	Human PRO	192	2792	98.5	1985	12	ADN14618	Novel hum
120	2792	98.5	1985	10	ADE32084	Novel hum	193	2792	98.5	1985	12	ADI63844	Novel hum
121	2792	98.5	1985	10	ADE22016	cDNA enco	194	2792	98.5	1985	12	ADI64793	Novel hum
122	2792	98.5	1985	10	ADE41776	Human PRO	195	2792	98.5	1985	12	ADD76328	Human PRO
123	2792	98.5	1985	10	ADE17593	Human PRO	196	2792	98.5	1985	12	ADD87692	Human PRO
124	2792	98.5	1985	10	ADD91725	Human PRO	197	2792	98.5	1985	12	ADD86096	Human PRO
125	2792	98.5	1985	10	ADE33188	Novel hum	198	2792	98.5	1985	12	ADN15722	Novel hum
126	2792	98.5	1985	10	ADE33740	Novel hum	199	2792	98.5	1985	12	ADN16351	Novel hum
127	2792	98.5	1985	10	ADD79792	cDNA enco	200	2792	98.5	1985	12	ADN14618	Novel hum
128	2792	98.5	1985	10	ADD92829	Human PRO	201	2792	98.5	1985	12	ADI63844	Novel hum
129	2792	98.5	1985	10	ADE19249	Human PRO	202	2792	98.5	1985	12	ADI64793	Novel hum
130	2792	98.5	1985	10	ADE18697	Human PRO	203	2792	98.5	1985	12	ADD76328	Human PRO
131	2792	98.5	1985	10	ADE42893	Novel hum	204	2792	98.5	1985	12	ADD87692	Human PRO
132	2792	98.5	1985	10	ADD95682	Human PRO	205	2792	98.5	1985	12	ADD86096	Human PRO
133	2792	98.5	1985	10	ADE22568	cDNA enco	206	2792	98.5	1985	12	ADN15722	Novel hum
134	2792	98.5	1985	10	ADD78686	cDNA enco	207	2792	98.5	1985	12	ADN16351	Novel hum
135	2792	98.5	1985	10	ADE32636	Novel hum	208	2792	98.5	1985	12	ADN14618	Novel hum
136	2792	98.5	1985	10	ADE42328	Human PRO	209	2792	98.5	1985	12	ADI63844	Novel hum
137	2792	98.5	1985	10	ADD80344	cDNA enco	210	2792	98.5	1985	12	ADI64793	Novel hum
138	2792	98.5	1985	10	ADD89372	Human PRO	211	2792	98.5	1985	12	ADD76328	Human PRO
139	2792	98.5	1985	10	ADE40656	Human PRO	212	2792	98.5	1985	12	ADD87692	Human PRO
140	2792	98.5	1985	10	ADE04455	Human PRO	213	2792	98.5	1985	12	ADD86096	Human PRO
141	2792	98.5	1985	10	ADE92584	Human PRO	214	2792	98.5	1985	12	ADN15722	Novel hum
142	2792	98.5	1985	10	ADG21293	Novel hum	215	2792	98.5	1985	12	ADN16351	Novel hum
143	2792	98.5	1985	10	ADG22934	Novel hum	216	2792	98.5	1985	12	ADN14618	Novel hum
144	2792	98.5	1985	10	ADF97269	Human PRO	217	2792	98.5	1985	12	ADI63844	Novel hum
145	2792	98.5	1985	10	ADG80333	Human PRO	218	2792	98.5	1985	12	ADI64793	Novel hum
146	2792	98.5	1985	10	ADG79781	Human PRO	219	2792	98.5	1985	12	ADD76328	Human PRO
147	2792	98.5	1985	10	ADH55073	Novel hum	220	2792	98.5	1985	12	ADD87692	Human PRO
148	2792	98.5	1985	10	ADH55625	Novel hum	221	2792	98.5	1985	12	ADD86096	Human PRO
149	2792	98.5	1985	10	ADI63292	Novel hum	222	2792	98.5	1985	12	ADN15722	Novel hum
150	2792	98.5	1985	10	ADH81706	Novel hum	223	2792	98.5	1985	12	ADN16351	Novel hum
151	2792	98.5	1985	10	ADH81154	Novel hum	224	2792	98.5	1985	12	ADN14618	Novel hum

225	2792	98.5	1985	12	ADG59508	Novel hum	Adg59508	Novel hum	298	566.5	20.0	4245	10	ADB53340	Primary r
226	2792	98.5	1985	12	ADI80932	CDNA enco	Adi80932	CDNA enco	299	566.5	20.0	4245	12	ADP72762	Adp72762 Renal tox
227	2792	98.5	1985	12	ADG09675	Novel hum	Adg09675	Novel hum	300	566	20.0	1674	13	ADG73998	Adg73998 A. gossyp
228	2792	98.5	1985	12	ADI15146	Novel hum	Adi15146	Novel hum							
229	2792	98.5	1985	12	ADG09023	Novel hum	Adg09023	Novel hum							
230	2792	98.5	1985	12	ADI14478	Novel hum	Adi14478	Novel hum							
231	2792	98.5	1985	12	ADI18073	Novel hum	Adi18073	Novel hum							
232	2792	98.5	1985	12	ADJ63354	Novel hum	Adj63354	Novel hum							
233	2792	98.5	1985	12	ADJ77249	Human PRO	Adj77249	Human PRO							
234	2792	98.5	1985	12	ADJ65371	CDNA enco	Adj65371	CDNA enco							
235	2792	98.5	1985	12	ADM27507	CDNA enco	Adm27507	CDNA enco							
236	2792	98.5	1985	12	ADM42231	CDNA enco	Adm42231	CDNA enco							
237	2792	98.5	1985	12	ADM28093	CDNA enco	Adm28093	CDNA enco							
238	2792	98.5	1985	13	ADI95575	CDNA enco	Adi95575	CDNA enco							
239	2792	98.5	1985	13	ADI96127	Novel hum	Adi96127	Novel hum							
240	2792	98.5	2241	4	Aaf81736	Human pro	Aaf81736	Human pro							
241	2792	98.5	2527	6	ABK48980	CDNA enco	Abk48980	CDNA enco							
242	2792	98.5	2527	6	ABK91096	CDNA enco	Abk91096	CDNA enco							
243	2764	97.5	2275	6	ABL57676	Human mat	Abi57676	Human mat							
244	2721	96.0	2336	12	ADQ63889	Novel hum	Adq63889	Novel hum							
245	2566	90.5	1983	10	ADE07322	Novel cod	Adg07322	Novel cod							
246	2527	89.2	1717	2	AAV08170	MMP19 cod	Aav08170	MMP19 cod							
247	2324.5	82.0	2310	6	ABK48982	CDNA enco	Abk48982	CDNA enco							
248	2324.5	82.0	2310	6	ABK91095	CDNA enco	Abk91095	CDNA enco							
249	1981	69.9	1355	12	ADJ72039	Human PMM	Adj72039	Human PMM							
250	1867.5	65.9	1144	12	ADJ72037	Human PMM	Adj72037	Human PMM							
251	1856.5	65.5	1855	10	ADG75815	Human pro	Adg75815	Human pro							
252	1494.5	52.7	997	4	ABA06516	Human cDN	Abg06516	Human cDN							
253	1494.5	52.7	997	4	ABV83853	Human pol	Abv83853	Human pol							
254	1187	41.9	7346	6	AAU05261	Human rep	Aai05261	Human rep							
255	1187	41.9	7346	6	ABL98145	Human tes	Abi98145	Human tes							
256	1067	37.6	1145	10	ADE09569	Novel DNA	Adg09569	Novel DNA							
257	866	30.6	1156	5	ADM19413	Novel hum	Adm19413	Novel hum							
258	741	26.1	596	4	AAS40873	CDNA enco	Aas40873	CDNA enco							
259	741	26.1	596	4	AAK88329	Human dig	Aak88329	Human dig							
260	741	26.1	596	4	ABA06706	Human cDN	Abg06706	Human cDN							
261	741	26.1	596	6	ABV84043	Human pol	Abv84043	Human pol							
262	654	23.1	962	12	ADN05647	Antipigori	Adn05647	Antipigori							
263	636	22.4	364	5	ADM19653	Novel hum	Adm19653	Novel hum							
264	617	21.8	368	4	AAS59069	Human can	Aas59069	Human can							
265	602	21.2	1707	4	ABL08339	Drosophil	Abi08339	Drosophil							
266	602	21.2	2010	6	ABV78220	Human MMP	Abv78220	Human MMP							
267	602	21.2	2010	6	ABZ35796	Human MMP	Abz35796	Human MMP							
268	602	21.2	2010	6	ABX10039	Human MMP	Abx10039	Human MMP							
269	602	21.2	2010	6	ABL91761	Human pol	Abi91761	Human pol							
270	602	21.2	2010	10	ADL13779	Osteoarth	Adl13779	Osteoarth							
271	602	21.2	2010	10	ADL13778	Osteoarth	Adl13778	Osteoarth							
272	602	21.2	3514	10	ADL13781	Human mat	Adl13781	Human mat							
273	602	21.2	3530	2	AAT03438	Human mat	Aat03438	Human mat							
274	602	21.2	3530	4	AAH28232	Nucleotid	Aah28232	Nucleotid							
275	602	21.2	3530	10	ADL13777	Osteoarth	Adl13777	Osteoarth							
276	602	21.2	3530	10	ADL24784	Intestina	Adl24784	Intestina							
277	583	20.6	6594	4	ABL08338	Drosophil	Abi08338	Drosophil							
278	578	20.4	1811	3	AAK55711	Human mat	Aac55711	Human mat							
279	578	20.4	1811	4	AAH28235	Nucleotid	Aah28235	Nucleotid							
280	578	20.4	1811	9	ACD81703	Human mat	Acd81703	Human mat							
281	578	20.4	1811	13	ADQ88279	Human 139	Adq88279	Human 139							
282	578	20.4	3222	2	AAK66735	DNA enco	Aak66735	DNA enco							
283	578	20.4	3222	6	ABZ34929	Human gen	Abz34929	Human gen							
284	576	20.3	1972	2	AAV17185	Rabbit me	Aav17185	Rabbit me							
285	575	20.3	1524	2	AAT93025	Human liv	Aat93025	Human liv							
286	575	20.3	1524	6	ABK47532	DNA enco	Abk47532	DNA enco							
287	575	20.3	2248	6	AAK435049	Human ade	Aak435049	Human ade							
288	575	20.3	2248	3	AAK21171	Human low	Aaf21171	Human low							
289	575	20.3	2248	10	ABZ96865	Human nuc	Abz96865	Human nuc							
290	575	20.3	2248	11	ABD20714	Human pul	Abd20714	Human pul							
291	575	20.3	9137	3	AAK35055	Human ade	Aaa35055	Human ade							
292	575	20.3	9137	3	AAK21177	Human low	Aaf21177	Human low							
293	575	20.3	9137	10	ABZ96871	Human nuc	Abz96871	Human nuc							
294	575	20.3	9137	11	ABD20720	Human pul	Abd20720	Human pul							
295	571	20.1	1524	10	ADH54844	Human mat	Adh54844	Human mat							
296	570	20.1	3339	2	AAV61096	Mouse mem	Aav61096	Mouse mem							
297	570	20.1	3339	10	ADL24785	Intestina	Adl24785	Intestina							

ALIGNMENTS

RESULT 1

AAD23965

ID AAD23965 standard; cDNA; 1597 BP.

XX

AC AAD23965;

XX

DT 16-OCT-2002 (first entry)

XX

DE Human matrix metalloproteinase MMP10 cDNA.

XX

KW Matrix metalloproteinase; MMP; extracellular matrix; ECM;

KW embryonic development; morphogenesis; reproduction; tissue repair;

KW mental disorder; Alzheimer's disease; multiple sclerosis; obesity;

KW Parkinson's disease; motorneuron disease; metabolic disease; retinopathy;

KW type 2 diabetes; cardiovascular; dyslipidaemia; adipogenesis; neuropathy;

KW nephropathy; proliferative disease; cancer; psoriasis;

KW prostate hyperplasia; hormonal disorder; alopecia; Crohn's disease;

KW central nervous system disorder; CNS; inflammatory condition; arthritis;

KW periodontal disease; wound healing; human; MMP10; ss.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

CDS 35..1597

/*tag= a

/product= "Matrix metalloproteinase MMP10"

XX

WO200190326-A2.

XX

29-NOV-2001.

XX

22-MAY-2001; 2001WO-US016563.

XX

22-MAY-2000; 2000US-0206119P.

XX

(PHAA) PHARMACIA & UPJOHN CO.

XX

Holmgren E, Kihlen M, Wood T, Ekblom J;

XX

WPI; 2002-083105/11.

XX

P-PSDB; AAE14394.

XX

New matrix metalloproteinases (MMP) genes and polypeptides, useful for

treating diseases or for screening modulators of MMP to treat such

diseases, e.g. mental disorders, Parkinson's disease, cancers or

inflammatory conditions.

XX

Claim 4; Page 60; 94pp; English.

XX

The invention relates to genes encoding matrix metalloproteinases (MMP).

The MMP genes are useful for producing MMP polypeptides and for screening

modulators of MMP. The MMPs are useful for breaking down extracellular

matrix (ECM), which is essential for processes including embryonic

development, morphogenesis, reproduction, or tissue repair and

remodelling. The MMPs are particularly useful for identifying compounds

that modulate the activity of genes to treat pathologies, e.g. mental

disorders, Alzheimer's disease, multiple sclerosis, Parkinson's disease

or motorneuron disease. The MMP polypeptides and genes, as well as their

modulators, are useful for treating metabolic diseases and disorders

(e.g. type 2 diabetes, obesity, cardiovascular, dyslipidaemias,

adipogenesis, retinopathies, neuropathies or nephropathies).

CC proliferative diseases and cancers (e.g. breast, colon or lung cancer,

CC tumour growth, tumour invasion, psoriasis or prostate hyperplasia),

CC hormonal disorders (e.g. male/female hormonal replacement, polycystic

ovarian syndrome or alopecia), central nervous system (CNS) disorders,

CC inflammatory conditions (e.g. Crohn's disease or arthritis), periodontal

CC

CC diseases or wound healing. The present sequence is human matrix
XX metalloproteinase MMP10 cDNA

SQ Sequence 1597 BP; 287 A; 532 C; 498 G; 280 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 6,36e-152 Length: 1597
Score: 2834.00 Matches: 520
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 6 Gaps: 0

US-10-791-980-6 (1-520) x AAD23965 (1-1597)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 35 ATGGTGGCGCGGTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 94
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 95 GACGCCCGCGCGGAGCGCGAGCCAGGAGCTGGCAGAGGCGCGAGGCGCATTCCTA 154
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 155 GAGAAAGTACGGATAGCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGAC 214
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 215 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGACGGCGGTGTGGACCG 274
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 275 GCCACCTCGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 334
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 335 GCCTGGGCTGAGAGGATCAGTACTGTTGTTGTAGACACCGGACCCAAATGAGGCGTAAG 394
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 395 AAACCTTTGCMAGCAAGTTAACAAATGGTACAGCAGCACCTCTCTACCGGCTGGTG 454
QY 141 AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSer 160
Db 455 AACTGGCTGAGCATCTCCGAGCGCGCAGTTTCGGGGCGCGTGGCGCGCCCTTCCAGT 514
QY 161 CysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuThr 180
Db 515 TGTGGAGCAACGTTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGGCCCGCTGACA 574
QY 181 SerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAla 200
Db 575 TCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGGCTGGGAATGCCCTTTGATGGCC 634
QY 201 GlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGln 220
Db 635 CAGGGGGCGCCCTGGCGCACGCCCTTCTGCGCCCGCGCGGAGCGCATTCGACCAA 694
QY 221 AspGluArgTrpSerLeuSerArgArgGlyArgLysGlnLeuPheValValLeuAlaHis 240
Db 695 GATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTCTGGCGCAC 754
QY 241 GluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPro 260
Db 755 GAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGGCC 814
QY 261 TyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGln 280
Db 815 TACTACAAAGGCTGGGCGCGGACGCGCTGCTCAGCTGGGACGACGTGTGGCGGTGCAG 874
QY 281 SerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPhe 300
```

```
Db 875 AGCCTGTATGGGAAGCCCTAGGGGGTCTAGTGGCCGTCCAGCTCCAGGAAAGCTGTTC 934
QY 301 ThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGly 320
Db 935 ACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGMAACGACGGGC 994
QY 321 ProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 995 CCTAATATCTGCCACTCTTCTTCGATGCCATCTGTAGACAGGCAACAGCAACTGTAC 1054
QY 341 IlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProArg 360
Db 1055 ATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCGT 1114
QY 361 ProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLeu 380
Db 1115 CCACCTGAGGAAAGATGGTGGGCTGCCGCCCAACATTTAGGCTGGCGAGTGTCTATTG 1174
QY 381 AsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLys 400
Db 1175 ATGATGAGGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCAAG 1234
QY 401 ProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAla 420
Db 1235 CCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTCTGACGCC 1294
QY 421 AlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVal 440
Db 1295 GCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGTGT 1354
QY 441 LeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGly 460
Db 1355 CTGGCCCGAGGGGACTGTGAGTGGAGCCCTACTACCCCCGAGCTGCGAGACTGGGA 1414
QY 461 GlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePhe 480
Db 1415 GGCATCTCTGAGGAGTTCAGCGCGCGCTGCGAGGCCCGATGGCTCCATCATCTTCTTC 1474
QY 481 ArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyArg 500
Db 1475 CGAGATACCCGCTACTGGCGCCTCGACAGGCCAAACTGCAGGCAACCACTCGGGCGGC 1534
QY 501 TrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPhe 520
Db 1535 TGGGCCACCGAGCTGCCCTGATGGGTGTGTGGCATGCCAACTCGGGGAGGCCCTGTTC 1594
RESULT 2
AAH23373
ID AAH23373 standard; cDNA; 1563 BP.
XX
AC AAH23373;
XX
DT 25-SEP-2001 (first entry)
XX
DE Human MPROT45 polypeptide encoding cDNA.
XX
KW MPROT45; antiarthritic; thrombolytic; antidiabetic; cytostatic; human;
KW antiinflammatory; osteopathic; cardiant; hypotensive; cerebroprotective;
KW antiathmatic; nootropic; neuroprotective; vaccine; ss.
XX
OS Homo sapiens.
XX
PH Key Location/Qualifiers
FT CDS 1..1563
FT /tag= a
FT /product= "MPROT45 polypeptide"
XX
XX WO200155428-A2.
XX
XX 02-AUG-2001.
XX
XX 10-JAN-2001; 2001WO-EP000189.
XX
```

AAS21315
 ID AAS21315 standard; cDNA; 1985 BP.
 XX AC AAS21315;
 XX DT 24-OCT-2001 (first entry)
 XX DE Human cDNA sequence encoding for PRO4339 polypeptide.
 XX KW Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast;
 XX KW prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage;
 KW ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte;
 KW A-peptide; factor VIIA; gene therapy; ss.
 XX OS Homo sapiens.
 XX PN WO200140466-A2.
 XX PD 07-JUN-2001.
 XX PF 01-DEC-2000; 2000WO-US032678.
 XX PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 09-DEC-1999; 98US-0170262P.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 03-MAR-2000; 2000US-0187202P.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 05-JUN-2000; 2000US-0209832P.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 XX (GETH) GENENTECH INC.
 XX PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Geritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
 XX WPI: 2001-408281/43.
 DR P-PSDB; AAU12243.
 XX Isolated , secretory and transmembrane PRO polypeptide used to detect
 PT other PRO polypeptides, link bioactive molecules to cells expressing PRO

polypeptides, and detect the presence of mammalian tumors e.g. lung,
 breast, prostate, cervical.
 Claim 3; Fig 143; 813pp; English.
 AAS21244-AAS21518 encode for novel human secretory and transmembrane PRO
 polypeptides. The PRO polypeptides are useful to detect other PRO
 polypeptides, to link bioactive molecules to cells expressing PRO
 polypeptides, to modulate biological activities of cells expressing PRO
 polypeptides, and to detect the presence of mammalian lung, colon,
 breast, prostate, rectal, cervical or liver tumours by comparing PRO
 polypeptide expression in a cell sample to that in a control sample. Some
 of the 275 sequences are also useful to stimulate the release of tumour
 necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or
 differentiation of chondrocytes, the proliferation or gene expression in
 pericyte cells, the release of proteoglycans from cartilage, the
 proliferation of inner ear utricular supporting cells or of T-
 lymphocytes, the release of a cytokine from peripheral blood monocytes
 (PBMCs), or the proliferation of endothelial cells. Some of the PRO
 polypeptides may modulate glucose or free fatty acid uptake by skeletal
 muscle cells or by adipocytes; or inhibit binding of A-peptide to factor
 VIIA. The PRO polypeptides can be used in assays to identify molecules
 involved in binding interactions. The polynucleotides encoding PRO
 polypeptides can be used to generate probes, antisense RNA/DNA,
 transgenic or knock out animals and can be used in gene therapy
 SQ Sequence 1985 BP; 403 A; 646 C; 504 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 4 Gaps: 0

US-10-791-980-6 (1-520) x AAS21315 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGGCGCGTGGCGCTCTCTGGCGCCCTGCAGCTGCTACTGTGGGCGCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCAGCCCGCGGAGCGGAGCGAGCTGCGCAAGAGGCGGAGGCGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCACCTCCACTCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGCGCTTTCAGTGGGTGTCCAGCTACTGTTCAGCGGGCGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTAGACACCGGACCAAAATAGGCGTAAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCCTGAGCATCTGCCGAGCCGCGATTCGGGGCGCGTGGCGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCGTGGAGGAGGCCAGCCAGCCAGGCCCCGCTGAC 745

PR 27-JAN-2000; 2000GB-00001898.
XX (SMIK) SMITHKLINE BEECHAM PLC.
XX
XX Southern CD, Hughes AS;
XX
XX WPI; 2001-457732/49.
DR P-PSDB; AAB85427.
XX
XX An isolated polypeptide treatment of diseases relating to MPROT45
PT polypeptide including arthritis, respiratory diseases, thrombosis,
PT diabetes, cancer.
XX
XX Claim 4; Page 22; 28pp; English.
XX
XX This cDNA encodes a human MPROT45 polypeptide. The polypeptide can be
CC expressed by standard recombinant methodology. The MPROT45 polypeptide,
CC antibodies and their agonists or antagonists are useful in the treatment
CC of diseases relating to MPROT45 polypeptide including arthritis,
CC respiratory diseases, thrombosis, diabetes, cancer, inflammatory
CC disorders, osteoporosis, cardiovascular disorders, hypertension, stroke,
CC asthma, neurodegenerative diseases such as Alzheimer's, Parkinson's,
CC depression and other CNS disorders or as a vaccine. They are also useful
CC for diagnosis or determining susceptibility
XX
XX Sequence 1563 BP; 283 A; 519 C; 484 G; 277 T; 0 U; 0 Other;
SQ

Alignment Scores:
Pred. No.: 1.5e-149 Length: 1563
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 4 Gaps: 0

US-10-791-980-6 (1-520) x AAH23373 (1-1563)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 1 ATGGTCGCGCGGCTCGGCTCTCTGCTGCGCGCTGACGTGCTACTGTGGGGCCACCTG 60
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 61 GAGCCCGAGCCCGGAGCGGAGCCAGGAGCTGCGCAAGGAGCGGAGGCAITCTCTA 120
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 121 GAGAGTAGCGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTTCAGC 180
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 181 GATGCCATCAGACGGTTTCAGTGGGTGCCAGCTACCTGTCAGCGCGCTGTGGACCC 240
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 241 GCCACCTGCGCCAGATGACTGCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 300
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 301 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGGGCGTAAG 360
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 361 AAACGCTTTGCAAGACAGGTAACTAATGGTACAGCAGCACCTCTCTACCGCTGGTG 420
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 421 AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 480
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 481 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCAGCGCCCGCTGAC 540

RESULT 3

QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB 541 ATCCGGCTCACCTTCTTCCAGGGGACCAACGATGGCTGGGCANTGCTTTGATGGC 600
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 601 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 659
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 660 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGGTGGCTGGCGCA 719
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 720 CGAATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 779
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 780 CTACTACAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 839
QY 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 840 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAACTGTT 899
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 900 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGACGG 959
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 960 CCCTAAATACCTGCCACACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1019
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1020 CATTTTAAAGGGAGCCATTTCTGGAGGTGGAGCTGATGCGCAACGCTCAGAGCCCCG 1079
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1080 TCCACTGCAGGAAGATGGTGGGTCGGCTGCCCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1139
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
DB 1140 GAATGATGGAGATTTCTACTTTCTCAAAGGGGTGATGTGGAGGTTCCGGGGCCCCAA 1199
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1200 GCCAGTGGGGTCTCCACAGCTGTGCGGCGAGGGGCTGCCCCGCCATCTGTAGCGC 1259
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrvA 440
DB 1260 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1319
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
DB 1320 GCTGGCCGAGGGGAGCTGCAAGTGAGCCCTTACTACCCCCGAACTGTGAGGACTGGGG 1379
QY 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1380 AGGCATCTCTGAGGAGGTGAGGGCGCTTCCCGAGGCCGATGCTCCATCATCTTCTT 1439
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1440 CCGAGATGACCGCTACTGGCGCTCGACCGAGCCAACTGCAAGGCAACACCTCCGGCGC 1499
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1500 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGGCGCCCTGTT 1559
QY 520 e 520
DB 1560 C 1560

QY		180	rSerGlySerProSerSerSerysGlyThrThrMetGlyTyrAlaMetProLeuMetAl	200	RESULT 4
Db		746	ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGCAATGCTTGTATGGC	805	ACA03674
QY		200	aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1	220	XX ACA03674 standard; cDNA; 1985 BP.
Db		806	CCAGGGGGGGCCCTGGCGCACGCTTC-CTGGCCCCCGCGCGAAGCGCACTTCGACCA	864	XX AC ACA03674;
QY		220	nAepGluArgTyrSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi	240	XX 23-MAY-2003 (first entry)
Db		865	AGATGAGCGCTGCTCTGAGCGCGCCGCGGCGCAACCTGTTCTGTGGTGTGGCGCA	924	XX cDNA encoding human PRO polypeptide #72.
QY		240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260	XX Human; PRO polypeptide; secreted and transmembrane protein;
Db		925	CGAGATCGGTCAACAGCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984	KW tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
QY		260	oTyrTyrLysArgLeuGlyArgAspAlaLeuSerTyrAspAspValLeuAlaValG1	280	KW differentiation; chondrocyte; tumour; genetic disorder; cytostatic; gene;
Db		985	CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTCTGGCGGTGCA	1044	XX ss.
QY		280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300	XX Homo sapiens.
Db		1045	GAGCCTGTATGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT	1104	XX OS US2003036180-Al.
QY		300	eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1	320	XX PD 20-FEB-2003.
Db		1105	CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGAGCGCCCTGAAACGACGG	1164	XX PF 09-MAY-2002; 2002US-00143114.
QY		320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340	XX PR 31-MAR-1997; 97WO-US005230.
Db		1165	CCCTAAATATGCTCACTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA	1224	PR 12-JUN-1998; 98WO-US012456.
QY		340	rIlePheLysGlySerHisPheThrGluValAlaAspGlyAenValSerGluProAr	360	PR 14-JUL-1998; 98WO-US014552.
Db		1225	CATTTTAAAGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG	1284	PR 28-AUG-1998; 98WO-US017888.
QY		360	gProLeuGlnGluArgTyrValGlyLeuProProAenIleGluAlaAlaValSerIe	380	PR 10-SEP-1998; 98WO-US018824.
Db		1285	TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTCTATT	1344	PR 14-SEP-1998; 98WO-US019093.
QY		380	uAenAspGlyAspPheTyrPhePheLysGlyArgCysTyrPArgPheArgGlyProLy	400	PR 14-SEP-1998; 98WO-US019177.
Db		1345	GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCAA	1404	PR 16-SEP-1998; 98WO-US019330.
QY		400	sProValTyrGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl	420	PR 17-SEP-1998; 98WO-US019437.
Db		1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGGCCCTGCCCGCCCATCTCGAGCG	1464	PR 29-OCT-1998; 98WO-US021141.
QY		420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa	440	PR 29-OCT-1998; 98WO-US022991.
Db		1465	CGCCCTCTTCTTCCCTCTCGCGCGCTCATCTCTTCAAGGTGCGCGTACTAGT	1524	PR 29-OCT-1998; 98WO-US022992.
QY		440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1	460	PR 01-DEC-1998; 98WO-US021547.
Db		1525	GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG	1584	PR 05-OCT-1999; 99WO-US023089.
QY		460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480	PR 29-NOV-1999; 99WO-US028214.
Db		1585	AGGCATCTCTGAGGAGGTGAGCGGGCCCTGCCGAGGCGCGATGCTCCATCATCTTCTT	1644	PR 30-NOV-1999; 99WO-US028313.
QY		480	eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500	PR 30-NOV-1999; 99WO-US028409.
Db		1645	CCGAGATGACCCCTACTGGCGCTTGACCAAGGCGCAACTGCAGGCAACACCTTCGGGCG	1704	PR 01-DEC-1999; 99WO-US028301.
QY		500	gTyrAlaThrGluLeuProTyrMetGlyCysTyrPheHisAlaAenSerGlySerAlaLeuPh	520	PR 01-DEC-1999; 99WO-US028634.
Db		1705	CTGGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGAGGCGCCTGT	1764	PR 02-DEC-1999; 99WO-US028551.
QY		520 e	520		PR 02-DEC-1999; 99WO-US028564.
Db		1765 c	1765		PR 02-DEC-1999; 99WO-US028565.

Db 925 CGAGATCGGTACACGCTTGGCTCTACCCACTGCGCGCGCGCGCTCATGCGCGC 984
Qy 260 oTyrTyTyAsrLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGGCGCGAGCGCTGTCTAGCTGGGACGAGCTGTGCGCGTGA 1044
Qy 280 nSerLeuTyGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 GACTGACTTTGAGACTGGGACTCTTACAGCCCAAGAGCGCCCTGAAACGAGGG 1164
Qy 320 yProLysTyCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGTCATCATCTGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaValSerLe 380
Db 1285 TCACCTGCAGGAAGATGGTCCGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGAGGGGCTGCCCCCGCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lIleAlaArgGlyGlyLeuGlnValGluProTyTyTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGNAGCTGACGAGCTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGGCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 5
ID ABX89212
XX ID ABX89212 standard; cDNA; 1985 BP.
XX AC ABX89212;
XX AC ABX89212;
XX AC ABX89212;
DT 13-MAY-2003 (first entry)
DE DNA encoding novel secreted and transmembrane protein PRO4339.
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;

KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disorder;
KW mammalian kidney meangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis; gene; ss.
XX Homo sapiens.
OS US2003017563-A1.
XX PN 23-JAN-2003.
XX PD 07-MAY-2002; 2002US-00140808.
XX PF 31-MAR-1997; 97WO-US005230.
XX PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028851.
PR 02-DEC-1999; 99WO-US028854.
PR 02-DEC-1999; 99WO-US028855.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 20-DEC-1999; 99WO-US030999.
PR 30-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACACGCTTGGCTCACCACCTCGCCCGCGCGCGCTCATGGCGGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAAGAGCTGGCGCGCACCGCTGCTCAGCTGGGACGACGTGCGCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAAGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTTAATAACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGGAGTGCATT 1344
QY 380 uAenAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCGAGTGGGGTCTCCCAAGCTGTGGCGGAGGGGCGCTGCCCCGCATCTCGAGCG 1464
QY 420 alaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGI 460
Db 1525 GTGGCCCCAGGGGAGCTCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGGATGGCTCATCTCTTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCCAGGCCAATCTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGGCTGGATGGGCTGCTGGCATGCCAATCGGGAGCGCGCTGTT 1764
QY 520 e 520
Db 1765 c 1765
RESULT 6
ACD41866
ID ACD41866 standard; cDNA; 1995 BP.
XX ACD41866;
AC ACD41866;
XX
XX
DT 05-SEP-2003 (first entry)
XX Human secreted/transmembrane protein (PRO) cDNA #72.
DE
XX Human; ss; gene; PRO; secreted protein; transmembrane protein; tumour;
KW cytostatic; gene therapy; tumour necrosis factor-alpha; TNF-alpha; blood;
KW proteoglycan; cartilage; cytokine; peripheral blood mononuclear cell;

KW PBMC; glucose uptake; FFA; skeletal muscle cell; adipocyte cell;
KW chondrocyte cell proliferation; chondrocyte cell differentiation;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell; A-peptide; factor VIIA.

OS Homo sapiens.

XX US2003036179-A1.

XX 20-FEB-2003.

PF 10-MAY-2002; 2002US-00142431.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 10-MAR-2000; 2000WO-US006319.

PR 15-MAR-2000; 2000WO-US006884.

PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.


```
QY 200 aGInGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGCGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerIleuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATAGCGCTGGTCTCCTAGCGCGCGCGCGCAACCTGTTCTGTTGGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGNGATCGGTACACGCTGGCTGACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyTyTyArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAAGAGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGACGTCTGGCGGTGCA 1044
QY 280 nSerLeuTyGlyIleProLeuGlyGlySerValAlaValGlnLeuProGlyIleLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyxSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGATCTCTACAGCCCCAAGAGCGCCCTGAAACCGCAGGG 1164
QY 320 yProIleTyxCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheIleGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGCGAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCACCTGCGAGGAAGATGGTGGCTGCGCTGCCCCCAACATTGAGGCTGGCGAGTGTGATT 1344
QY 380 uAsnAspGlyAspPheTyxPhePheIleGlyArgCysTrpArgPheArgGlyProIly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGCAGGGGCGCTGCCCGCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIleGlyAlaArgTyxVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGCT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyxTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGGCGCTTGGCGGAGCGCGATGGCTCATCTTCTT 1644
QY 480 eArgAspAspArgTyxTrpArgLeuAspGlnAlaIleLeuGlnAlaThrSerGlyAr 500
Db 1645 CCGAGATGACCCCTACTGGCGCTTCGACGAGGCCAACTGCAGGCAACACCTCTGGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 7
ACA04095
ID ACA04095 standard; cDNA; 1985 BP.
XX
AC ACA04095;
```

```
XX
DT 27-MAY-2003 (first entry)
XX
DE Human cDNA encoding a secreted/transmembrane protein, SEQ ID 143.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW infertility; birth defects; premature aging; AIDS; biosensor;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW bioindicator; tumour.
XX
OS Homo sapiens.
XX
PN US2003032155-A1.
XX
PD 13-FEB-2003.
XX
PF 03-MAY-2002; 2002US-00137865.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
```


Db 806 CAGAGGGGCGCCCTGGCGACGCCCTTC-CTGCCCGCGCGCGAAGCGCACTTCGACCA 864
Qy 220 nAepGluArgTtpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCTGAGCGCGCGCGCGCAACCTGTTCTGTTGGTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTTGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 tTyTyTyLysArgLeuGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAAAGAGCTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGGCCCTTAGGGGCTCAGTGGCGGTCCAGCTCCACAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACCTTGAGACTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACCGAGGG 1164
Qy 320 yProLysTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTtpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGGCCCAA 1404
Qy 400 aProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGGCTCATCTCTTCAAGGTGGCGGTACTACTGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGI 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCCCTTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValLeuProArgProArgProArgGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGGCGCTTCCGAGGGCCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGGCCAACTGCAGGCAACCACTCTGGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACGAGCTGCCCTGATGGGTGCTGGTCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 8
ADA45662
ID ADA45662 standard; cDNA; 1985 BP.
XX
AC ADA45662;
XX

DT 20-NOV-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
DE Human; secreted and transmembrane protein; PRO; gene; ss;
XX Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX US2003022328-A1.
XX 30-JAN-2003.
XX 16-APR-2002; 2002US-00123904.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.

Db	806	CCAGGGGGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaIh	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTCTGGTGTCTGGCGCA	924
Qy	240	sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTGGCGCTCACCCACTCGCGCGCGCGCGCTCATGCGCGC	984
Qy	260	oTrpTrpLeuArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1	280
Db	985	CTACTACAGAGCGTGGCGCGCGCGCTGCTCAGCTGGGACGAGTGTGGCGGTGCA	1044
Qy	280	nSerLeuTrpGlyLeuProLeuGlyGlySerValAlaValGlnLeuProGlyLeuPh	300
Db	1045	GAGCTGTATGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1	320
Db	1105	CACCTGACTTTGAGAGCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGCGGG	1164
Qy	320	yProlySerTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLeuGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGGCACTTTCTGGGAGGTGGCAGCTGATGGCAGCTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe	380
Db	1285	TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGGCGGAGTGTCAAT	1344
Qy	380	uAsnAspGlyAspPheTrpPhePheLeuGlyArgCysTrpArgPheArgGlyProly	400
Db	1345	GAATGATGGAGATTCTACTCTTCAAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA	1404
Qy	400	pProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCCGCCATCTTGAGCG	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLeuGlyAlaArgTrpTrVa	440
Db	1465	CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGGCTACTAGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTrpTrpProArgSerLeuGlnAspTrpG1	460
Db	1525	GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTTACCCCCGAAGTCTGCAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCTCTGAGGAGGTGAGCGGCGCTTCCGAGGCGCGATGCTCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CGAGATGACCGCTACTTGGCGCTCGACCAGGCCAACTGCAGGCAACCACTCGGGCGG	1704
Qy	500	gTrpAlaThrGluLeuProTrpTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCCGGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGGCTGT	1764
Qy	520 e	520	
Db	1765 c	1765	

RESULT 9
 ADA76093
 ID ADA76093 standard; cDNA; 1985 BP.
 XX
 AC ADA76093;
 XX
 DT 20-NOV-2003 (first entry)

XX	Human PRO polynucleotide #72.
DE	Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX	tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW	liver; microvascular endothelial cell; glucose; FFA;
KW	skeletal muscle cell; adipocyte cell; pericyte cell;
KW	inner ear utricular supporting cell; T-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW	immune system cell infiltration.
XX	Homo sapiens.
OS	US2003073212-A1.
XX	17-APR-2003.
PD	16-APR-2002; 2002US-00123903.
XX	31-MAR-1997; 97WO-US005230.
PR	12-JUN-1998; 98WO-US012456.
PR	14-JUL-1998; 98WO-US014552.
PR	28-AUG-1998; 98WO-US017888.
PR	10-SEP-1998; 98WO-US018824.
PR	14-SEP-1998; 98WO-US019093.
PR	14-SEP-1998; 98WO-US019094.
PR	14-SEP-1998; 98WO-US019177.
PR	16-SEP-1998; 98WO-US019330.
PR	17-SEP-1998; 98WO-US019437.
PR	07-OCT-1998; 98WO-US021141.
PR	29-OCT-1998; 98WO-US022991.
PR	29-OCT-1998; 98WO-US022992.
PR	20-NOV-1998; 98WO-US024855.
PR	01-DEC-1998; 98WO-US025108.
PR	05-JAN-1999; 99WO-US000106.
PR	08-MAR-1999; 99WO-US005028.
PR	10-MAR-1999; 99WO-US005190.
PR	20-APR-1999; 99WO-US008615.
PR	14-MAY-1999; 99WO-US010733.
PR	02-JUN-1999; 99WO-US012252.
PR	01-SEP-1999; 99WO-US020111.
PR	08-SEP-1999; 99WO-US020594.
PR	13-SEP-1999; 99WO-US020944.
PR	15-SEP-1999; 99WO-US021090.
PR	15-SEP-1999; 99WO-US021547.
PR	05-OCT-1999; 99WO-US023089.
PR	29-NOV-1999; 99WO-US028214.
PR	30-NOV-1999; 99WO-US028313.
PR	01-DEC-1999; 99WO-US028409.
PR	01-DEC-1999; 99WO-US028301.
PR	01-DEC-1999; 99WO-US028634.
PR	02-DEC-1999; 99WO-US028551.
PR	02-DEC-1999; 99WO-US028564.
PR	02-DEC-1999; 99WO-US028565.
PR	16-DEC-1999; 99WO-US030095.
PR	20-DEC-1999; 99WO-US030911.
PR	20-DEC-1999; 99WO-US030999.
PR	22-DEC-1999; 99WO-US030720.
PR	30-DEC-1999; 99WO-US031243.
PR	30-DEC-1999; 99WO-US031274.
PR	05-JAN-2000; 2000WO-US000219.
PR	06-JAN-2000; 2000WO-US000277.
PR	06-JAN-2000; 2000WO-US000376.
PR	11-FEB-2000; 2000WO-US003565.
PR	18-FEB-2000; 2000WO-US004341.
PR	18-FEB-2000; 2000WO-US004342.
PR	22-FEB-2000; 2000WO-US004414.
PR	24-FEB-2000; 2000WO-US004914.
PR	24-FEB-2000; 2000WO-US005004.
PR	01-MAR-2000; 2000WO-US005601.

QY 180 rSerGlySerProSerSerIysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
DB 806 CCAGGGGGGGCCCTGGCGACGCTTC-CTGGCCCGCGCGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTTPSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
DB 865 AGATAGCCCTGTCTCCAGCCCGCCGCGCGCAACCTGTTCTGTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACACGCTTGGCCCTACCCCACTCGCCCGCGCGCGCTCATGGCGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAAGAGCTGGGCGCGACGCGCTGCTCAGCTGGGACGACGCTGCGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAGACCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGACAGG 1164
QY 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTAAATACTGCACACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGCATTTCTGGGAGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
QY 380 uAenAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCGCCCATCTCGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGTCTGAGGGGCGCTGCGAGGCGCGATGGCTCCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGNTAGCCGCTACTGGCGCTCGACCGGCGCAACTGCGAGGCACCACTTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGGCGCCAGAGTGCCTCGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 c 1765
RESULT 10

ADA18743
ID ADA18743 standard; cDNA; 1985 BP.
XX
AC ADA18743;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;
KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;
KW glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;
KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;
KW factor VIIA; endothelial cell.
XX
OS Homo sapiens.
XX
PN US2003054517-A1.
XX
PD 20-MAR-2003.
XX
PF 08-MAY-2002; 2002US-00141755.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 05-OCT-1999; 99WO-US021547.
PR 15-SEP-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.

Db 806 CCAGGGGGCGCTGGCGCACGCCCTTC-CTGGCCCCCGCGCGAAGCGCACTTCGACCA 864
Qy 220 nAepGluAArgTtpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaIhi 240
Db 865 AGATGAGCGCTGGTCTCGAGCGCGCGCGCGCAACCTGTTCTGTGTGTGTGCGCA 924
Qy 240 gGluleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTGGGCTCACCCACTCGCGCGCGCGCGCTCATGCGCGC 984
Qy 260 ofYrTyLyAsArgLeuGlyArgAspAlaLeuLeuSerTtpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGCGCGCGACGCGCTGCTCAGCTGGGACGAGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyRgLyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTtpAspSerTyRserProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTyRysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACCTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTtpGluValAlaAlaAepGlyAenValSerGluProAr 360
Db 1225 CATTTTTAANGAGGCCATTTCTGGAGGTGCGAGCTGATGGCAACGCTTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluAArgTtpValGlyLeuProProAenIleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGCGGCACTGCTATT 1344
Qy 380 uAenAspGlyAspPheTyRPhPheLysGlyArgCysTtpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 eProValTtpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGGCGGCGAGGGGCTTGGCCCCGCACTCCGAGCGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyRrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGTGCGCGCTACTAGT 1524
Qy 440 lIleuAlaArgGlyLeuGlnValGluProTyRtyrProArgSerLeuGlnAspTtpGl 460
Db 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCGCTACTTACCCCGAAGCTTCGAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProArgProArgGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTGAGAGGTGAGCGGGCGCTTGGCGAGCGCGGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyRtyrTtpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGCGGCAAACTGCAGGCAACCACTTCGGGCG 1704
Qy 500 gTtpAlaThrGluLeuProTtpMetGlyCysTtpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 11
ID ADA61366
XX ADA61366 standard; cDNA; 1985 BP.
AC ADA61366;
XX

DT 20-NOV-2003 (first entry)
XX Homo sapiens.
XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker.
OS Novel.
OS human.
OS secreted.
OS and.
OS transmembrane.
OS protein.
OS PRO439.
OS CDNA.
XX US2003049816-A1.
XX 13-MAR-2003.
PF 15-APR-2002; 2002US-00123262.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030955.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.


```
QY 180 rSerGlySerProSerSerSerGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCCTTTGATGC 805
QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTyrSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCAGCGCGCGCGCGGCGCAACCTGTTCTGTTGCTGCGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGCGCGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGCTGGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAGGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACCTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGCGAG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATAGTCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGCCATTTCTGGGAGTGGCAGCTGATGCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCGGCCCAACATTGAGGCTGGCGCAGTGTCATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrProArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTyrGlyLeuProGlnLysCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGTCTCCACAGCTGTGGCGGAGGGGCCCTGCCCGCCATCCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1 460
Db 1525 GCTGGCGCGAGGGGACTCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGCATCTCTGAGGAGTTCAGCGGCGCTGCGGAGGCCGATGGCTCCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGCCAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrrAlaThrGluLeuProTrrMetGlyCysTrrPheHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCGACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 c 1765
RESULT 12
```

```
ADB19151
ID ADB19151 standard; cDNA; 1985 BP.
XX
AC ADB19151;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokin.
XX
OS Homo sapiens.
XX
PN US2003068796-A1.
XX
PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123261.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 29-OCT-1999; 99WO-US021547.
PR 05-DEC-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
```



```
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATAGTGCACCTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224

QY 340 rIlePheTyrGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCATTTCTGGGAGGTGCAGCTGATGCAACGCTCTCAGAGCCCG 1284

QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCGCCCAACATTGAGGTGCGGAGTGTCAAT 1344

QY 380 uhenAspGlyAspPheTyrPhePheTyrGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGCCCTGCCCGCCATCTCTGACGC 1464

QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGTGCCCGCTACTAGT 1524

QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCCGAGGCCGATGCTCCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCCTACTGGCGCTCGACGAGCCAACTGCAAGCAACACCTCGGGCGG 1704

QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGTGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764

QY 520 e 520
Db 1765 C 1765

RESULT 13
ADB27692
ID ADB27692 standard; cdNA; 1985 BP.
AC ADB27692;
XX 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082704-A1.
XX
PD 01-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131819.
XX
```

```
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-765415/72.
DR P-PSDB; ADB27693.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
XX e.g., tumor or for tissue typing.
XX Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting the uptake of
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
```

```
Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0
```

US-10-791-980-6 (1-520) x ADB27692 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGTGGGCTCTCTGCGGCCCTCGAGCTGCTACTGTGGGGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCCGCGGAGCGCGGAGCTGCGCAAGGAGCGGAGGCGGATTCCTA 325
QY 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
```

Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCACCTCCACTCGATTACGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCACAGCTACCTGTCCAGCGGGTGTGTGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCACATGACTCGTCCCGCTGCGGGGTACAGATACCACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGCTGAGAGGATCAGTCACTTGTGTGACACCGGACCAAAATGAGGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCCTACCGCGCTGGT 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCGGAGCGCGCAGTTCGGGGCGCGTCCGGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGAGAGCCCGCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTCTTCCAAAGGGACCAACAGATGGGCTGGGCAATGSCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
Db 806 CCAGGGGGCGCCTGGCGCACCGCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CAGATTCGCTCACGCTGGCTCACCACCTCGCCCGCGCGCGCGCTCATGTGGCGCC 984
Qy 260 tTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGAGCGACGCTGTCGGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGCCCCCAAGAGGCGCCCTGAAACGCGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCATAAATACTGCCACTCTCTCTTCGATGCCATCACTGTAGACGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCGCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAGATGGTGGCTGCCCGCCCAACAACTTGGAGGTTCGGGCGCCCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCGGGCGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420

Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCATCTCGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCTACTACTAGCT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCAAGCGCGCTGCGGAGCCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGCCAACTGCAGGCAACCACTCGGCGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGTCATGTCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 14
ADA86171
ID ADA86171 standard; cDNA; 1985 BP.
XX
AC ADA86171;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
OS
US2003082711-A1.
XX
PD 01-MAY-2003.
XX
PF 16-MAY-2002; 2002US-00147508.
XX
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUN-1999; 99WO-US012252.
PR 07-JUL-1999; 99US-0143048P.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Deenoysers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786914/74.
DR P-PSDB; ADA86172.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX

Claim 2; Fig 143; 637pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF- α from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADA86171 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuAlaArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGTCTGGCTCTGGTCGGCCCTGTCAGCTGCTACTGTGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgIysGluAlaGluAlaPheLeu	40
Db	266	GAGCGCCAGCCGCGAGCGCGAGGCCAGAGCTGGCGAAGGAGCGGAGGCAATTCCTA	325
Qy	41	GluLeuValTyrglyTyrLeuAsnGlnValProIysAlaProThrSerThrArgPheSer	60
Db	326	GAGAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCCACTCCATCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGGTTTCAGTGGGTGTCCCAGTACTCTGCAGCGCGGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGGCGCAGATCACTCGTCCCGCTGGCGGGTTACAGATCAACACAGTTATGGC	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisargThrIysMetArgArgLys	120
Db	506	GCTTGGCTTGAGAGGATCAGTGACTTGTTGCTCTAGACACCGGACCAAAATGAGCGGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnIysTrpTyrIysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTGGCAACAGGTAACAATGGTTACAGCAGCACCTCTCTACCGCTCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160

```
QY      520 e 520
Db      1765 C 1765

RESULT 15
ADB15735
ID      ADB15735 standard; cDNA; 1985 BP.
AC
AC      ADB15735;
DT      20-NOV-2003 (first entry)
XX
DE      Human PRO polynucleotide #72.
XX
KW      Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW      tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW      cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW      liver; microvascular endothelial cell; glucose; FFA;
KW      skeletal muscle cell; adipocyte cell; pericyte cell;
KW      inner ear utricular supporting cell; T-lymphocyte cell;
KW      endothelial cell tube formation; bone disorder; cartilage disorder;
KW      sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW      rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW      immune system cell infiltration.
XX
OS      Homo sapiens.
XX
XX      US2003087350-A1.
XX
PD      08-MAY-2003.
XX
PF      22-APR-2002; 2002US-00127821.
XX
PR      04-AUG-1998; 98US-0095301P.
PR      25-JUN-1999; 99WO-US012252.
PR      02-AUG-1999; 99US-00380137.
PR      30-MAR-2000; 2000WO-US008439.
PR      01-DEC-2000; 2000WO-US032678.
PR      19-DEC-2001; 2001US-00028072.
XX
XX      (GETH ) GENENTECH INC.
XX
XX      Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI      Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI      Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX      WPI; 2003-786941/74.
XX      P-PSDB; ADB15736.
XX
XX      New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
XX      and for manufacturing a medicament for diagnosing or treating tumor.
XX
XX      Claim 2; Fig 143; 637pp; English.
XX
XX      The invention relates to isolated human PRO polypeptides (secreted and
XX      transmembrane polypeptides) and the polynucleotides encoding them. The
XX      invention also relates to an antibody which specifically binds to a PRO
XX      polypeptide, a method for stimulating the release of tumour necrosis
XX      factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX      proliferation or differentiation of chondrocyte cells and a method for
XX      detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX      colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX      polynucleotides are useful in molecular biology, including uses as
XX      hybridisation probes, in chromosome and gene mapping, in generating
XX      antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX      be used in preparing PRO polypeptides by recombinant techniques and in
XX      generating either transgenic animals or knock-out animals which are
XX      useful in the development and screening of therapeutically useful
XX      reagents. The PRO polypeptides or antibodies are used in preparing a
XX      medicament for treating a condition responsive to the polypeptides or
XX      antibodies, such as tumours, for stimulating and inhibiting proliferation
XX      of human microvascular endothelial cells, for modulating the uptake of
```

```
CC      glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC      stimulating differentiation of adipocyte cells, for stimulating
CC      proliferation of or gene expression in pericyte cells, for stimulating
CC      the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC      cells, for inducing endothelial cell tube formation and for treating
CC      various bone and/or cartilage disorders such as sports injuries and
CC      arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC      from cartilage are useful for treating sports-related joint problems, PRO
CC      articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC      polypeptides are also useful for treating various mammalian haemoglobin-
CC      associated disorders such as various thalassaemias and conditions which
CC      may benefit from enhanced local immune system cell infiltration. Note:
CC      sequence represents a human PRO polynucleotide of the invention. This:
CC      The sequence data for this patent is also available in electronic format
CC      from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX      SQ      Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
XX
XX      Alignment Scores:
XX      Pred. No.:      1.93e-149      Length:      1985
XX      Score:          2792.00      Matches:      519
XX      Percent Similarity: 99.62%      Conservative: 0
XX      Best Local Similarity: 99.62%      Mismatches: 1
XX      Query Match:      98.52%      Indels:      2
XX      DB:              9      Gaps:        0

US-10-791-980-6 (1-520) x ADB15735 (1-1985)
QY      1 MetValAlaArgValGlyLeuLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
      |||||
Db      206 ATGGTCGGCGCGCTGCGCCTCTCTGTCGGCGCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
      |||||

QY      21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
      |||||
Db      266 GAGCGCCAGCCCGCGGAGCGCGAGCGCTGCGAAGGAGCGCGAGGCAATTCCTA 325
      |||||

QY      41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
      |||||
Db      326 GAGAAGTACCGATACCTCAATGAACAGGTCTCCCAAGCTCCCACTCCATTCGATTTCAGC 385
      |||||

QY      61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
      |||||
Db      386 GATGCCATCAGAGCGTTTTCAGTGGTGTCTCCAGCTACTGTCAGCGCGGTGTGGACCGC 445
      |||||

QY      81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
      |||||
Db      446 GCCACCTCGCCAGATGACTCGTCCCGTGGGGGTTACAGATACCAACAGTTATGCG 505
      |||||

QY      101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
      |||||
Db      506 GCCTGGGCTGAGAGGATCAGTGACTTGTGCTAGACACCGGACCAAAATGAGCGGTAAAG 565
      |||||

QY      121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
      |||||
Db      566 AAACGCTTTCAAAGCAAGGTAACAAATGTTACAAAGCAGCACCTCTCTCCGCGCTGGTG 625
      |||||

QY      141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
      |||||
Db      626 AACTGGCCTGAGCATATCGCCGAGCGCGAGTGTGGGGCGCGCGCGCGCTTCAG 685
      |||||

QY      160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
      |||||
Db      686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCGCCAGCCACAGGCCCGCTGAC 745
      |||||

QY      180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
      |||||
Db      746 ATCCGGCTCACTTCTTCCAAAGGGGACACAAACGATGGGCTGGGCAATGCCCTTGTATGGC 805
      |||||

QY      200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
      |||||
Db      806 CCAGGGGGCGCGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGCGGCAAGCGCACTTCGACCA 864
      |||||

QY      220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
      |||||
```

```
Db      865  |||||AGATGAGCGCTGCTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGCTGGTGGCGCA 924
Qy      240  sGIuIlleGIyHieThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMethIaPr 260
Db      925  CGAGATCGGTTCACACGCTTGCGCTCACCCACTCGCGCGCGCGCGCTCATGCGCGC 984
Qy      260  oTyTyTyLysATgLeuGIyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db      985  CTACTACAGAGAGCTGGCGCGCGAGCGCTGCTCAGCTGGGAGCAGCTGCTGGCGCTGCA 1044
Qy      280  nSerLeuTyTyGlyLeuProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy      300  eThrAspPheGluThrTrpAsnSerTyTySerProGlnGlyArgAtgProGluThrGlnGI 320
Db      1105  CACTGACTTTGAGACCTGGGACTTCCTACAGCCCCCAAGGAAGCGCCCTGAAACGGCAGG 1164
Qy      320  yProLysTyTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCTTAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheTrpGluValAlaIaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAAGTCTCAGAGGCCCG 1284
Qy      360  gProLeuGlnGluAtgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerIe 380
Db      1285  TCACATGCAAGGAAGATGGTGGGCTGCGCCCAACATTGAGGCTGCGGCGCTGCAAT 1344
Qy      380  uAsnAspGlyAspPheTyTyPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345  GAATGATGAGATTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
Qy      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGGGGCGCTGCCCGGCATCTCTGACGC 1464
Qy      420  aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyVa 440
Db      1465  CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyTyTrpProArgSerLeuGlnAspTrpGI 460
Db      1525  GTGGCGCGAGGGGACTGCAGTGGAGGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584
Qy      460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCCCTGAGGAGGTGAGCGGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy      480  eArgAspAspArgTyTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAAACTGCAGGCAACACCTCGGGCGG 1704
Qy      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCGCACGAGTGGCTTGGATGGGCTGCTGGCATGCGCAACTGGGGAGCGCCCTGTT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 16
ADA47521
ID   ADA47521 standard; cDNA; 1985 BP.
XX
AC   ADA47521;
XX
DT   20-NOV-2003 (first entry)
XX
DE   Human PRO polynucleotide #72.
XX
```

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; r-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

XX Homo sapiens.

OS US2003073215-A1.

PN 17-APR-2003.

PD 07-MAY-2002; 2002US-00140925.

PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 05-OCT-1999; 99WO-US021547.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 02-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 11-FEB-2000; 2000WO-US00376.

PR 18-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 10-MAR-2000; 2000WO-US005841.

PR 10-MAR-2000; 2000WO-US006319.

PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX
DR WPI; 2003-644801/61.
DR P-PSDB; ADA47522.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 2; Fig 143; 659pp; English.
PS
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA47521 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrrGlyHisLeu 20
Db 206 ATGTTCGGCGCGTCGCGCCCTCTGCTGCGCGCCCTGCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluA 40
Db 266 GAGCCCGAGCGCGGAGCGCGGAGCGCGAGCTGCGCAAGGAGCGGAGGCATTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGAGCTCCACCTCCATTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCCATCAGAGCGTTTCAGTGGGTGTCACGCTACTGTACGGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTCAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrrTrrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTCCAAAGCAGAGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCCGTCGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACCTCTCAGCGCTGGAGTTCCTGGAGGCGCCACGACACAGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrrAlaMetProLeuMetAl 200

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCACGACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerIysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGCTGGGCAATGCTTTTGATGGC 805
QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGGGCGCTGGCGACGCTTC-CTGCGCCCGCGGCGCAACCTGTTCTGGTGTGGCGCA 864
QY 220 nAspGluArgTyrSerSerArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
DB 865 AGATAGCGCTGGTCTCCCTGAGCGCGCGCGCGCGCAACCTGTTCTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTCAACGCTTGGCTTCCACCTGCGCGCGCGCGCGCTCATGCGCGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValG 280
DB 985 CTACTACAGAGCTGGGCGCGCGCGCTGCTCAGCTGGAGCGCTGCTGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAAAGCCCTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
DB 1105 CACTGACTTGTAGACCTGGGACTCTTACAGCGCGCGCGCGCGCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCTTAATACTGCACCTCTTCTTCATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAGGAGGCAATTTCTGGGAGGTGGCAGCTGATGCACAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnAlaArgTyrValGlyLeuProProLeuIleGluAlaAlaValSerIe 380
DB 1285 TCCACTGCAGGAAGATGGTGGGCTGCGCGCTGCGCGCGCGCGCTGCGCGCTGCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrArgPheArgGlyProly 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCCGGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCGCGCCATCTGTAGCG 1464
QY 420 aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrGl 460
DB 1525 GCTGCGCGGAGGGGACTGCAAGTGGAGCGCTTACTACCGCGGAGTGTGAGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCTTGAGGAGGTGAGCGGCGCTTCCGAGGGCGGATGGCTCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGAGCGCAAACTGACGCAACCCACCTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCGCCCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCGCTGTT 1764
QY 520 e 520

DB 1765 C 1765

RESULT 18

ADB30323

ID ADB30323 standard; cDNA; 1985 BP.

XX

AC ADB30323;

XX 20-NOV-2003 (first entry)

XX cDNA encoding human PRO polypeptide #72.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003068794-A1.

XX 10-APR-2003.

XX 15-APR-2002; 2002US-00123155.

PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 01-DEC-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

Db 566 AACCGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCAGCTCTCTACCGCCCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGGAGTTGCGGGGCGCGTGGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACGATGGGCTGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTGGCGCACGCTTC-CTGCCCCCGCGGGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTGCTGGTGTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCACCCACTCGCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTrVrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCTGGGCGCGGACCGCTGCTCAGCTGGGAGCAGCTGCTGGCGTGA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGACTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrsSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGGAGGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAATACTGCCACTCTTCTTCCATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGACATTTCTGGAGGTGGCGAGCTGATGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnAluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGTGATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCCGCCATCTCGAGCG 1464
Qy 420 aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGTGGCGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGTGCCCGAGGGGAGCTCAAGTGGAGCCCTTACCCCCGAACTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTTGAAGAGTTCAGCGGCGCTGCGGAGGCGCGAGTGGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAAATGTCAGGCAACCACTCGGGCGG 1704

Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 19
ADA85619
ID ADA85619 standard; cDNA; 1985 BP.
XX
AC ADA85619;
DT 20-NOV-2003 (first entry)
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX Human; secreted and transmembrane protein; PRO; Gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
OS
XX US2003082693-A1.
XX 01-MAY-2003.
XX 22-APR-2002; 2002US-00127843.
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786907/74.
DR P-ESDB; ADA85620.
XX New PRO nucleic acid, useful for preparing a composition for treating
e.g., tumor or for tissue typing.
PT
XX Claim 2; Fig 143; 637pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
transmembrane) polypeptides (I). (I) is useful for stimulating the
release of TNF-alpha from human blood, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating the proliferation or differentiation of chondrocyte cells,
for stimulating the proliferation of or gene expression in pericyte
cells, for stimulating the release of proteoglycans from cartilage, for
stimulating the proliferation of inner ear utricular supporting cells,
for stimulating the proliferation of T-lymphocyte cells, for stimulating
the release of a cytokine from BMC cells, for inhibiting the binding of
A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
cells, for stimulating proliferation of endothelial cells, for detecting
the presence of tumour in a mammal. The tumour is lung, colon, breast,
prostate, rectal, cervical or liver tumour. The oligonucleotide probes
are useful for isolating genomic and cDNA nucleotide sequences or
antisense probes. (I) is also useful as therapeutic agent. PRO is useful
in assays to identify other proteins or molecules involved in binding
interaction. A polynucleotide (II) encoding (I) is useful in chromosome
and gene mapping, in generation of antisense RNA and DNA, in the

CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Scores: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA85619 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTCGCGCGCTCGGCTCTCTGCTGGCGCGCTCGACGTGCTACTGTGGGGCCACCTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACAGCCGCGAGCGCGGAGCGGAGGCTGGCCAAAGGAGCGGAGGCAATCTCTA 325
 Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGTCCCACTCCACTCGATTACG 385
 Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGACCGCTTTTCAGTGGGTGTCCACGTACCTGTCCAGCGCGGTGTGGACGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGATCAGTGACTGTGTTGCTAGACACCGGACCAAAATGAGCGCTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCATCTCCGAGCGCGGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGACACAGCTCTACAGCTGGAGTTCCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACACGATGGGCTGGGCAATGCTTTGTGGC 805
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGCCCTGGCGACGCTTC-CTGCCCGCGCGCGGAGCGACCTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGGGGCGCAACCTGTTCGTGGTGTGGCGCA 924
 Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACGCTTGGCTCACCCTACTCGCCCGCGCGCGGCTCATGGCGCC 984

Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 Db 985 CTACTACAAGAGGCTGGGCGCGGACGCGCTGCTCAGCTGGGACACGTGCTGGCGGTGCA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGGNAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGAGAAAGCTGTT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCAAGGAAGGCGCTCTGAACGCGAGG 1164
 Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCCTAAATATCGCCACTCTTCTTCGATGCCATCCTGTTAGACAGGCAACAGCAACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCAGAAAGATGGGTTCGGCTGCCCCCAACATTGAGCTCGGCAGTGTCAAT 1344
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTCTGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCGCCGCCATCTGACGC 1464
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAAGGCTGCGCTACTACGT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 Db 1525 GCTGGCCGAGAGGGAGCTGCAAGTGGAGCCCTACTCCCCGAAGTCTGACGAGCTGGG 1584
 Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGTACAGCGCGCCTCGCGAGGCCGATGGCTCCATCATCTTCTT 1644
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACCGAGGCAAACTGCAGGCAACACCTCGGCGC 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCNACTCGGGAGCGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 C 1765

RESULT 20
 ADA96831
 ID ADA96831 standard; cDNA; 1985 BP.
 XX
 AC ADA96831;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polynucleotide #72.
 XX
 KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;

Db	1225	CAITTTTAAAGGAGCCATTCTGGAGGTGCACGTGATGCACACGCTCAGAGCCCCG	1284	PR	14-SEP-1998;	98WO-US019093.
				PR	14-SEP-1998;	98WO-US019094.
Qy	360	gProLeuGlnGluA-rGfTpValGlyLeuProProAenIleGluAlaAaValSerLe	380	PR	14-SEP-1998;	98WO-US019177.
				PR	16-SEP-1998;	98WO-US019330.
Db	1285	TCACCTGCAGGAAGATGGTCGGCTGCCCCCAACATTGAGGCTGCGGCAGTGTCAAT	1344	PR	17-SEP-1998;	98WO-US019437.
				PR	07-OCT-1998;	98WO-US021141.
Qy	380	uAenAepGlyAepPheTyPhePheIleGlyClyArgCysTrpArgPheArgGlyProLy	400	PR	29-OCT-1998;	98WO-US022991.
				PR	29-OCT-1998;	98WO-US022992.
Db	1345	GAATGATGGAGATTCTACTCTTCAAAGGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA	1404	PR	20-NOV-1998;	98WO-US024855.
				PR	01-DEC-1998;	98WO-US025108.
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420	PR	05-JAN-1999;	99WO-US000106.
				PR	08-MAR-1999;	99WO-US005028.
Db	1405	GCCAGTGTGGGTCTCCACACGCTGTGCGGSCAGGGGCCCTGCCCCCACTCTGACGC	1464	PR	10-MAR-1999;	99WO-US005190.
				PR	20-APR-1999;	99WO-US008615.
Qy	420	aAlaLeuPheProProLeuArgArgLeuIleLeuPheIysGlyAlaA-rGfTyTrVa	440	PR	14-MAY-1999;	99WO-US010733.
				PR	02-JUN-1999;	99WO-US012252.
Db	1465	CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGCCCGCTACTACGT	1524	PR	01-SEP-1999;	99WO-US020111.
				PR	08-SEP-1999;	99WO-US020594.
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAepTrpGl	460	PR	13-SEP-1999;	99WO-US020944.
				PR	15-SEP-1999;	99WO-US021090.
Db	1525	GCTGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584	PR	15-SEP-1999;	99WO-US021547.
				PR	05-OCT-1999;	99WO-US023089.
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAepGlySerIleIlePhePh	480	PR	29-NOV-1999;	99WO-US028214.
				PR	30-NOV-1999;	99WO-US028313.
Db	1585	ASGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGGCCGATGGCTCCATCATCTTCTT	1644	PR	01-DEC-1999;	99WO-US028409.
				PR	01-DEC-1999;	99WO-US028301.
Qy	480	eAArgAepA-rGfTyTrpArgLeuAepAlaIalysLeuGlnAlaThrThrSerGlyAr	500	PR	02-DEC-1999;	99WO-US028634.
				PR	02-DEC-1999;	99WO-US028551.
Db	1645	CCGAGATGACCGCTACTGCGGCTCGACGAGGCCAACTGCAGGCAACCACTCGGGCGC	1704	PR	02-DEC-1999;	99WO-US028564.
				PR	16-DEC-1999;	99WO-US030095.
Qy	500	gTrpAlaThrGluLeuProTrpMetClyCysTrpHisAlaAenSerGlySerAlaLeuPh	520	PR	20-DEC-1999;	99WO-US030911.
				PR	20-DEC-1999;	99WO-US030999.
Db	1705	CTGGGCCACCGAGTGCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGGCCCTGTT	1764	PR	30-DEC-1999;	99WO-US030720.
				PR	30-DEC-1999;	99WO-US031243.
Qy	520	e	520	PR	05-JAN-2000;	99WO-US031274.
				PR	06-JAN-2000;	2000WO-US000219.
Db	1765	C	1765	PR	06-JAN-2000;	2000WO-US000277.
				PR	06-JAN-2000;	2000WO-US000376.
RESULT 21				PR	11-FEB-2000;	2000WO-US003565.
ADA79135				PR	18-FEB-2000;	2000WO-US004341.
ID ADA79135 standard; cdNA; 1985 BP.				PR	18-FEB-2000;	2000WO-US004342.
XX				PR	22-FEB-2000;	2000WO-US004414.
AC ADA79135;				PR	24-FEB-2000;	2000WO-US004914.
XX				PR	24-FEB-2000;	2000WO-US005004.
DT 20-NOV-2003 (first entry)				PR	01-MAR-2000;	2000WO-US005601.
XX				PR	02-MAR-2000;	2000WO-US005746.
DE				PR	02-MAR-2000;	2000WO-US005841.
XX				PR	10-MAR-2000;	2000WO-US006319.
KW				PR	15-MAR-2000;	2000WO-US006884.
KW				PR	20-MAR-2000;	2000WO-US007377.
KW				PR	21-MAR-2000;	2000WO-US007532.
KW				PR	30-MAR-2000;	2000WO-US008439.
KW				PR	17-MAY-2000;	2000WO-US013705.
KW				PR	22-MAY-2000;	2000WO-US014042.
KW				PR	30-MAY-2000;	2000WO-US014941.
KW				PR	02-JUN-2000;	2000WO-US015264.
KW				PR	28-JUL-2000;	2000WO-US020710.
KW				PR	11-AUG-2000;	2000WO-US022031.
KW				PR	23-AUG-2000;	2000WO-US023522.
XX				PR	24-AUG-2000;	2000WO-US023328.
OS				PR	08-NOV-2000;	2000WO-US030952.
XX				PR	10-NOV-2000;	2000WO-US030873.
XX				PR	01-DEC-2000;	2000WO-US032678.
XX				PR	20-DEC-2000;	2000US-00747259.
PD				PR	28-FEB-2001;	2001US-00796498.
XX				PR	28-FEB-2001;	2001US-00796498.
XX				PR	01-MAR-2001;	2001WO-US006520.
PR				PR	09-MAR-2001;	2001US-00802706.
PR				PR	14-MAR-2001;	2001US-00808689.
PR				PR	22-MAR-2001;	2001US-00816744.
PR				PR	05-APR-2001;	2001US-00828366.


```
QY      320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
          |||||
Db      1165 CCTAAATACTGCCACTTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224

QY      340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
          |||||
Db      1225 CATTTTAAAGGAGCCATTCTGGAGGTGCAGCTGATGCCACAGTCTCAGAGCCCG 1284

QY      360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
          |||||
Db      1285 TCACACTGCAGGAAGATGGTCCGGCTGCCCCCAACATTGAGGTGCGGAGTGTCAATT 1344

QY      380 uAsnAspGlyAspPheTyrPhePheLysGlyCysTrpArgPheArgGlyProLys 400
          |||||
Db      1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404

QY      400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
          |||||
Db      1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCGCTGCCCCCAATCTTGACGC 1464

QY      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
          |||||
Db      1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGCCTACTACGT 1524

QY      440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
          |||||
Db      1525 GTTGCCCCGAGGGGACTGCAAGTGGAGCCCTTACCCCCGAACTGCGAGGACTGGGG 1584

QY      460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLePhePh 480
          |||||
Db      1585 AGGCATCCTGAGGAGTCCAGGGCGCCCTGCCGAGGGCCGATGGCTCATCATCTTCTT 1644

QY      480 eArgPheAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
          |||||
Db      1645 CCGAGATCACCGCTACTGCGCGCTCGACAGGCCAAACTGCAGGCCAACCACTCGGGCG 1704

QY      500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
          |||||
Db      1705 CTGGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764

QY      520 e 520
          |
Db      1765 C 1765

RESULT 22
ADA87274
ID ADA87274 standard; cDNA; 1985 BP.
XX
AC ADA87274;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087345-A1.
XX
PD 08-MAY-2003.
XX
PF 16-APR-2002; 2002US-00123907.
XX
PR 31-MAR-1997; 97WO-US005230.
```



```
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGAGCTCCACCTCCATCGATTGACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATCCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTGACGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGCTGAGAGGATCAGTACTGTGTTGTAGACACCGACCAAAATGAGCGGTAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTrpLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCCGGAGCGCGAGTTGCGGGCGCGGTGCGCGCGCTTCCAG 685
QY 160 rCysGlyValaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGGCCCTTGGCGCAGCGCTTC-CTGCCCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGTGTCTCTGAGCGCGCGCGCGCGCGCACTGTTGTGTGTGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTCAACAGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGCGGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGCTGGCGCGCAGCGCTGCTCAGCTGGGACGAGCTGCGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGAGAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGMAACGCAAGG 1164
QY 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACGCGACTCTTCTTCGATGCGCATCTGCTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCAATTTCTGGAGGTGGGAGCTGATGGCACTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGTGGCTGGCTGCCCCCAACATTGAGCTGCGCGAGTGTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTTTCTACTTCTTCAAGGGGTGATGCTGAGAGTTCCGGGGGCCCCAA 1404
```

400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCGCTCCCGCCCATCTGACGC 1464
420 alaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
1465 CGCCCTTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTTACGT 1524
440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTCAGAGCTGGG 1584
460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
1585 AGGCATCCTTGAGAGGTGAGCGGCCCTTCCGAGGCCGATGGCTCCATCATCTTCTT 1644
480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
1645 CCGAGATGACCGCTACTGCGGCTCGACCCAGGCCAACTGCAGGCAACACCTCGGGCG 1704
500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
520 e 520
1765 C 1765

RESULT 24
ADA91568
ID ADA91568 standard; cDNA; 1985 BP.
XX
AC ADA91568;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; as;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; PFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX Gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX
XX US2003082694-A1.
XX
XX PD 01-MAY-2003.
XX
XX PF 22-APR-2002; 2002US-00127845.
XX
XX PR 03-MAR-2000; 2000US-0187202P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX
XX PA (GETH) GENENTECH INC.
XX
XX PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX DR WPI; 2003-786908/74.
XX DR P-PSDB; ADA91569.
XX
XX PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
XX PT or a composition for treating e.g., tumor or for tissue typing.
XX
XX PS Claim 2; Fig 143; 637pp; English.

CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear intracellular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA91568 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTTCGGCGCGTGGCCCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGAGCGCGAGCGCCAGGAGCTGCGCAAGAGCGCGAGGCATTCCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGGTCCCAACCTCCACCTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATGCCATCAGACGTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGGGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgProCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTCGGGGTTCACAGATACCAACAGTTATGCG 505
Qy 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACATTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCGAAGCAAGGTAAACAAATGGTACACAGCAGCACTCTCTACCGCCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AAATGGCTTGCATCTGCGGAGCGGCGAGTTCGGGGCGCGTTCGGCGCCGCTTCACG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnPProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTAGCGCTCGAGTTCGGGAGGCCCCCAGGCACAGGCCCTCGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTCCAAAGGGGACCAACAGTGGCTGGGCAATGCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuLeuProArgArgGlyGluAlaHisPheAspG 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgAcArgGlyArgHisLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGCAACTGTTTCGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
Db 985 CTACTACAAGAGGTGGGCGCGACGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGACGTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGAGGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCGCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTTAAGGAGGCCATTTCGGAGGTGGAGCTGATGGCAACGCTTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCGCCCAACATCATTGAGGTGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTTCATCTTTCAAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCAAGGGGSCCTGCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCTCTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCCCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAAAGTCTGCAAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTACAGCGCGCCCTGCCGAGGCGCCGATGGCTCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACACAGGCAAACTGCAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGTGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520

Db 1765 C 1765
RESULT 25
ADBI4631
ID ADBI4631 standard; cDNA; 1985 BP.
XX
AC ADBI4631;
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087351-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127822.
XX
PR 17-JUN-1998; 98US-0089532P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2003-786942/74.
DR P-PSDB; ADBI4632.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.
XX
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADBI4631 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGCGCTCGGCTCTCTGTCGGCGCTTGCAGCTGCTACTGTGGGGCCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCCAGCCGCGGAGCGCGGAGCGCTGCCAGGAGCGCGGAGCATTCCTTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGTCCCACTCCCATCGATTACG 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGCGGGGTGTGGACCC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGGCTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTCCCGGAGCGCGCAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCCTGGGAGGCGCCACGACAGGCGCCGCTGAC 745

QY 180 rSerGlySerProSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTATGGC 805

QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGGCGCTTGGCGCACGCTTC-CTGCCCGCGCGCGGAGGCGGAGCTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCGTGGTGGTGGCGCA 924

PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe K, Wood WI, Zhang Z;
 XX
 DR WPI: 2003-695954/66.
 DR P-PSDB; ADB18593.
 XX
 PT New isolated nucleic acid and encoded PRO polypeptide, are useful in the
 PT diagnosis and treatment of cancer.
 XX
 PS Claim 2; Fig 143; 638pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyt
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: 1,938-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0
 US-10-791-980-6 (1-520) x ADB18592 (1-1985)

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCAGCCCGCGAGCGCGAGGAGCTGCGCAAGAGCGGAGGAGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAAACAGGTCCCAAGCTCCACACCTCCACTCGATTGAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
 DB 386 GATGCCATCAGACCGCTTTCAGTGGGTGTCCACGACTACCTGTGAGCGGCTGTGTGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCCAGATGACTGCTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCATCTCCGAGCGCGGAGCTTGGGGGCGCGCTGCGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCCACAGGCGCCCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTCTTGTATGCG 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
 DB 806 CACGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgHisLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTGCTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTCAACGCTTGGCTTCCACCTCCGCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCGTGA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACGCCCCCAAGGAAGGCGCGCTCAAGACGACGG 1164
 QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCTAAATATGCGCCACTCTTCTTCGATGCCATCAGTGTAGACAGCGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTGAGGAAAGATGGGTGCGGCTCGCCCCCAACATTGAGGCTGCGGAGTGTTCATT 1344

```
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTTCGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCGCCGCATCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTGCGCGGCTCATCTCTTCAAGGGTGCCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTTCGACGAGTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh 480
Db 1585 AGGCATCCCTGAGGAGGTTCAGGGGGCCCTGCCGAGGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCCAAACTGCAGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 27
ADA93807
ID ADA93807 standard; cdNA; 1985 BP.
XX
AC ADA93807;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
DE
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077722-A1.
XX
PD 24-APR-2003.
XX
PF 03-MAY-2002; 2002US-00137872.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WI; 2003-755077/71.
DR P-PSDB; ADA93808.
```

```
XX
PT New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT breast, prostate, rectal, cervical and/or liver tumors.
XX
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
```

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADA93807 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGTCGGCCCTCCTGCTGGGGCCCTGCAGCTGTCTACTGTGGGGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGCGGAGCGCGAGGCTGCGAAGGAGGAGGCGGAGGCGGAGGCGGAGGCGG	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGTGTCCCAAGCTCCACCTCCATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTGTGTCAGCGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGGCCAGATGATCTGTCCTCCCGCTGCGGGGTTCAGATACCAACAGTTATCGG	505

101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHieArgThrLysMetArgArgLys 120
Db GCCTGGGCTGAGAGGATCAGTGAATGTTTGTCTAGACACCGGACCAAAATGAGCGCTAAG 565
121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db AAACGGCTTTGCCAAGCAAGGTAACAAAATGGTATACAGCAGCACCTCTCTACCGCTGGTG 625
141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db AACTGGCCCTGAGCATCTCGGAGCGCGCAGTTCGGGGCGCGCTGGCGCGCTTCCAG 685
160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGAGCGCCCGCAGCCACAGCCCGCTGAC 745
180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGGCAATGCTTGTATGCG 805
200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
Db CAGGGGGGGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAAGCGACCTTCGACCA 864
220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGGCGCA 924
240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db CGAGATCGGTTCACACCTTGGCTTCCACCTCCCGCGCGCGCGCTCATGGCGCG 984
260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
Db CTACTACAAAGAGCTGGGCGCGCGACGCTGCTCAGCTGGGACGAGCTGGCGGTGCA 1044
280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db GAGCGTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG 320
Db CACTGACTTTGAGACCTGGGACTCTTACAGCGCCCAAGGAAGCGCGCTGAAACGCGGG 1164
320 vProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db CCTTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db CATTTTAAAGGAGGACCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerIe 380
Db TCCACTGCAGGAAGATGGTGGGCTGCGGCTGCCCCCAACATTAGGCTGGCGCATGTCA 1344
380 uAsnAspGlyAspPheTrpPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
Db GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db GCCAGTGTGGGTCTTCCACAGCTGTGGCGGAGGGGCGCTGCCCGCCATCTCTGAGCG 1464
420 alaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa 440
Db CGCCCTCTTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGTGGCGCTACTAGT 1524
440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG 460
Db GCTGGCCCGAGGGGACTTCAAGTGGAGCCCTACTACCCCGCAAGCTTGCAGGACTGGG 1584
460 yGlyIleProGluGluValSerGlyAlaLeuProArgProArgGlySerIlePhePh 480

1585 AGGCATCCTGAGGAGGTGAGCGCGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCTCGACCCAGGCCAACTGCAGGCAACACCTCGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGGCGCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 28
ADB19703
ID ADB19703 standard; cDNA; 1985 BP.
XX
AC ADB19703;
XX 20-NOV-2003 (first entry)
DT
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082691-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127838.
XX
PR 17-NOV-1998; 98US-0108802P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755108/71.
DR P-PSDB; ADB19704.
XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
XX tumor or for tissue typing.
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,

Db	1045	GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT	1104	PR	14-JUL-1998;	98WO-US014552.
				PR	28-AUG-1998;	98WO-US017888.
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG	320	PR	10-SEP-1998;	98WO-US018824.
				PR	14-SEP-1998;	98WO-US019093.
Db	1105	CAC TGACTTTGAGACTCGGACTCTACAGCCCCCAAGGAAGGGCCCTGAAAGCGCAGG	1164	PR	14-SEP-1998;	98WO-US019094.
				PR	14-SEP-1998;	98WO-US019177.
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340	PR	16-SEP-1998;	98WO-US019330.
				PR	17-SEP-1998;	98WO-US019437.
Db	1165	CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGT	1244	PR	07-OCT-1998;	98WO-US021141.
				PR	29-OCT-1998;	98WO-US022991.
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr	360	PR	20-NOV-1998;	98WO-US024855.
				PR	01-DEC-1998;	98WO-US025108.
Db	1225	CATTTTAAAGGAGCCATTCTGGAGGTGGCAGCTGATGCCAAGCTCAGAGCCCG	1284	PR	05-JAN-1999;	99WO-US000106.
				PR	08-MAR-1999;	99WO-US005028.
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380	PR	10-MAR-1999;	99WO-US005190.
				PR	20-APR-1999;	99WO-US008615.
Db	1285	TCCACTGCAGGAAGAATGGTGGGCTGCCCTCCCCCAACATTGAGGTGGCGAGTGTCATT	1344	PR	14-MAY-1999;	99WO-US010733.
				PR	02-JUN-1999;	99WO-US012252.
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy	400	PR	01-SEP-1999;	99WO-US020111.
				PR	08-SEP-1999;	99WO-US020594.
Db	1345	GAATGATGAGATTCTACTCTTCTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA	1404	PR	13-SEP-1999;	99WO-US020944.
				PR	15-SEP-1999;	99WO-US021090.
Qy	400	eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420	PR	05-OCT-1999;	99WO-US023089.
				PR	29-NOV-1999;	99WO-US028214.
Db	1405	GCAGTGTGGGTCTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGGCCATCCTGACGC	1464	PR	30-NOV-1999;	99WO-US028313.
				PR	01-DEC-1999;	99WO-US028301.
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440	PR	02-DEC-1999;	99WO-US028551.
				PR	02-DEC-1999;	99WO-US028564.
Db	1465	CGCCCTCTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGCT	1524	PR	16-DEC-1999;	99WO-US030095.
				PR	20-DEC-1999;	99WO-US030911.
Qy	440	lIleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460	PR	22-DEC-1999;	99WO-US030720.
				PR	30-DEC-1999;	99WO-US031243.
Db	1525	GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTATCCCCCGAAGTCTGCAGGACTGGG	1584	PR	05-JAN-2000;	2000WO-US000219.
				PR	05-JAN-2000;	2000WO-US000277.
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480	PR	06-JAN-2000;	2000WO-US000376.
				PR	11-FEB-2000;	2000WO-US003565.
Db	1585	AGGCATCCCTGAGGAGGTACGGGGCGCTGCGAGGGCCGATGGCTCCATCATCTTCTT	1644	PR	18-FEB-2000;	2000WO-US004341.
				PR	18-FEB-2000;	2000WO-US004342.
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysIleuGlnAlaThrThrSerGlyAr	500	PR	22-FEB-2000;	2000WO-US004414.
				PR	24-FEB-2000;	2000WO-US004914.
Db	1645	CCGAGATGACCGCTACTGGCGCCTCGACAGGCCAACTGCAGGCCAACCACTCGGGCCG	1704	PR	01-MAR-2000;	2000WO-US005004.
				PR	02-MAR-2000;	2000WO-US005601.
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520	PR	02-MAR-2000;	2000WO-US005746.
				PR	10-MAR-2000;	2000WO-US005841.
Db	1705	CTGGGCCACCGAGTGCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT	1764	PR	15-MAR-2000;	2000WO-US006319.
				PR	20-MAR-2000;	2000WO-US006884.
Qy	520	e 520		PR	21-MAR-2000;	2000WO-US007532.
				PR	30-MAR-2000;	2000WO-US008439.
Db	1765	C 1765		PR	17-MAY-2000;	2000WO-US013705.
				PR	22-MAY-2000;	2000WO-US014042.
RESULT 30				PR	30-MAY-2000;	2000WO-US014941.
ACD98495				PR	02-JUN-2000;	2000WO-US015264.
ID ACD98495 standard; cDNA; 1985 BP.				PR	11-AUG-2000;	2000WO-US022031.
XX				PR	28-JUL-2000;	2000WO-US020710.
XX				PR	28-JUL-2000;	2000WO-US020710.
AC ACD98495;				PR	23-AUG-2000;	2000WO-US023522.
XX				PR	24-AUG-2000;	2000WO-US023328.
DT 26-SEP-2003 (first entry)				PR	08-NOV-2000;	2000WO-US030952.
XX				PR	10-NOV-2000;	2000WO-US030873.
DE Novel human secreted and transmembrane protein PRO4339 cDNA.				PR	01-DEC-2000;	2000WO-US032678.
XX				PR	20-DEC-2000;	2000WO-US034956.
KW Human; secreted and transmembrane protein; PRO; gene therapy;				PR	28-FEB-2001;	2001US-00796498.
KW chromosome identification; tissue typing; gene; ss.				PR	28-FEB-2001;	2001WO-US006520.
XX				PR	01-MAR-2001;	2001WO-US006666.
OS Homo sapiens.				PR	09-MAR-2001;	2001US-00802706.
XX						
PN US200304945-A1.						
XX						
PD 06-MAR-2003.						
XX						
PF 10-MAY-2002; 2002US-00142419.						
XX						
XX 31-MAR-1997; 97WO-US005230.						
PR 12-JUN-1998; 98WO-US012456.						

PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00871092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-008717800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00819692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001US-00820116.
PR 29-JUN-2001; 2001US-00821066.
PR 09-JUL-2001; 2001US-00821735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX

(GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
P-PSDB; ABO43220.
XX WPI; 2003-492275/46.
XX P-PSDB; ABO43220.

XX New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.

XX Claim 2; Fig 143; 660pp; English.

XX The invention describes an isolated nucleic acid encoding a PRO (secreted
CC and transmembrane) polypeptide. Nucleic acids which encode PRO can be
CC used to generate either transgenic animals or knock-out animals useful in
CC developing and screening of therapeutically useful reagents. The nucleic
CC acids may also be used in gene therapy, in chromosome identification, as
CC chromosome markers, or in generating probes. The PRO polypeptides are
CC useful as molecular markers for protein electrophoresis, and the isolated
CC nucleic acids may be used for recombinantly expressing those markers. The
CC PRO polypeptides and nucleic acids may also be used in tissue typing.
CC Anti-PRO antibodies are useful in diagnostic assays for PRO, and in
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This sequence encodes a novel human secreted and transmembrane
CC PRO polypeptide

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,938-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ACD98495 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGCGCGGTCTGGCTCTCTGTCGCGCGCTCTGAGCTGCTACTGTGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
DB 266 GACGCCCGCGCGGAGCGCGGAGGCCAGGAGCTGCGCAAGGAGCGGAGGACATTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTAGCGATACCTCAATGAACAGGTCCCAAGAGCTCCACCTCCACTCATGATCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGTACCTGTGTCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCGCAGATGACTCTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgAglYls 120
DB 506 GCCTGGGCTGAGAGGATCAGTACCTGTTTGTAGACACCGGACCAAAATAGGCGGTAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCAGCCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTCAGCATCTGCGGAGCGGAGTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGACAACGCTCTCAGCGCTGGAGTTCGGAGGGCCCCAGCCAGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGCTGGGCAATGCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGCGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyValArgHisLeuPheValValLeuAlaHi 240
DB 865 AGATAGCGCTGTGTCCTAGCGCGCGCGGGCGCAACCTTGTGTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGTTCACAGCTTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGCGCGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCCCTAGGGGGCTCAGTGGCGCTCCAGTCCCGAAGAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCNAGAGAGGCGCTGAAACGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACCTGCGCACCTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGAGCTGATGGCAACGCTCCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGGTGGGCTGGCGCTGCCCCCCCAACATTCAGGCTGGCGGAGTGCATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCA 1404

```
Qy 400 sproValTrpGlyLeuProGlnLeuCysArgAlaGlyVgLyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGCTGCCCGCCCATCTCAGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGCCTACTACGT 1524
Qy 440 lLeuAlaArgGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGATCCCTAGGAGGTACAGGGGCGCTGCCAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGTGTGCTGGATGGGCTGTGGATGCCAACTCGGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 31
ADA74269
ID ADA74269 standard; cDNA; 1985 BP.
XX
AC ADA74269;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068798-A1.
XX
PD 10-APR-2003.
XX
PF 07-MAY-2002; 2002US-00140928.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US003365.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032578.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
```


PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-625490/59.
 DR P-PSDB; ADA74270.
 XX
 Novel secreted and transmembrane PRO polypeptides and polynucleotides
 PT encoding them, useful for treating bone disorders, arthritis, heart
 PT attack, injuries, tumors, and stimulating release of Tumor Necrosis
 PT Factor-alpha from human blood.
 XX
 Claim 2; Fig 143; 659pp; English.
 XX
 The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADA74269 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGGCGCGCTCGGCTCTCTGCTGGCGGCTTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCAGCCCGCGGAGCGCGGAGGCTGCGCAAGGAGCGGAGGCGGAGGCGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCTCACTCGATTACGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGGGTGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCACAGATTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGGATCAGTGACTTTGTTGTACACACCGGACCAAAATGAGGGGTAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCANAGCAAGGTAACAAATGGTACAGCAGCAGCTCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCATCTCCCGAGCGCGGAGTTCGGGGCGCGCTGCGGCGCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGGGAGGCGCCAGCCAGGCGCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCCNAGGGGACCAACAGATGGCTGGGCAATGCTTTCATGCG 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CCAGGGGCGCGCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGGCGGCAACCTGTTCTGTGTCTCGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAAGAGGCTGGGCGCGCGCTCTCAGCTGGGAGCGAGCTGTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCGTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGANAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTCAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCTGAAACCGCAGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCCTAAATACCTGCCACTCTCTCTTCGATGCCCTCACTGTAGACAGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTTAAGGGAGGCCATTTCTGGAGGTGGCGCTGATGGCAACGCTCAGAGCCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380

Db 1285 TCCACTGACGAGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGGACGTGTCATT 1344
Qy 380 uAaAspGlyAspPheTyrPhePheGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTCTTCAAGGGGCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCGCCCATCTCGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuLeuPheLeuPheGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCTCTGCGCGCTCATCTCTTCAAGGTGGCCCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCCGAGGCGCCATGGCTCCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGTACTGGCGCTCGACCGCCAACTGCAGGCAACACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaLysSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 32
ADB24502
ID ADB24502 standard; cDNA; 1985 BP.
XX
AC ADB24502;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human PRO polynucleotide SEQ ID NO 143.
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
OS
XX
XX US200307713-A1.
PN
XX
XX 24-APR-2003.
PD
XX
XX 22-APR-2002; 2002US-00127839.
PF
XX
XX 05-JUN-2000; 2000US-0209832P.
PR
XX 01-DEC-2000; 2000WO-US032678.
PR
XX 19-DEC-2001; 2001US-00028072.
PR
XX (GETH) GENENTECH INC.
PA
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755068/71.
DR P-PSDB; ADB24503.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0
US-10-791-980-6 (1-520) x ADB24502 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCCCTCTGCTGCGCGCGCTGCAGCTGTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGGAGCGGAGCGGAGCTGCGAAGGAGCGGAGGACCTTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCATTCCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTTACGTGGGTGTCCAGCTACCTGTGACGGCGGTGTTGGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGGCCGACAGTACTCGTCCCGCTCGGGGTACAGATACCAACAGTTATGG 505
Qy 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTCGGCTGAGAGGATCAGTACTGTTTGTCTAGACACCGGACCAAAATGAGGGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTTPTrpLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGTAAACAAATGGTAAACAGCAGCACTCTCTTACCGCTGGTG 625
Qy 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGACATCTGCCGAGCGCGAGTTCCGGGGCGCGTGGCGGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGTCTCAGCGCTGGAGTTCTGGAGGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTCGCGCACGCTTC-CTGCCCGCGCGGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgGlyArgGlnPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCACTTGTGTGGTGTGGCGCA 924
Qy 240 aGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGCGGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGGACGCGCTGCTCAGCTGGGACGCTGCTGGCGGTCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCCCAAGGAGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAAATCTGCCACTTCTCTTCGATGCCATCTACTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCACTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnArgTTPValGlyProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTTPArgPheArgGlyProLy 400
Db 1345 GAATGATCGAGATTCTACTTCTTCAAGGGGGTCTGATCTGGAGGTTCCGGGGCCCCA 1404
Qy 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCGCTGCCCGGCCATCTCAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460

Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProArgProArgGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACAGGCCAACTGCAGGCAACCTCTCGGGCG 1704
Qy 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCCGAGCTGCCCTGGATGGGCTGTGGCATSCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 33
ADA82026
ID ADA82026 standard; cDNA; 1985 BP.
XX
AC ADA82026;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082701-A1.
XX
PD 01-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128686.
XX
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 02-JUN-2000; 2000WO-US015264.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-755110/71.
DR P-PSDB; ADA82027.
XX
XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT tumor or for tissue typing.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
Gaps: 0

US-10-791-980-6 (1-520) x ADA82026 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGCGTCTGCTGCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCCCAGCCGCGAGCGCGAGCCAGAGCTGCCAAGAGGCGCGAGGCATTCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAAACAGGTCCCAAGCTCCACCTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCAGCTACCTGTGACGGCGGTGTGGACGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGATTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGATCAGTACGTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCANAGCAGGTAAACAAATGGTACAGCAGCACCTCTCTCTACCGCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160

DB 626 AACTGGGCTGAGCATCTGCGGAGCCGCGAGTTCGGGGCGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCCTCAGCGCTGAGATTCTGGAGAGGCCCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACAACATGGGCTGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGCAACTGTTCTGTGTGGCGCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGTGTGTCCTGAGCGCGCGCGGGCGCAACTGTTCTGTGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGCGCTCAGCCACTCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCACAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCGCCCAAGGAAGCGCGCTGAAACGCA 1164
QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
DB 1165 CCTAAATATCGCATCTCTTCGTGATGCATCATCTGTAGACAGGACAGCACTGTGA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGACGAAAGATGGGTGGGCTGCCCGCCCAACATTTGAGGCTGCGCAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGNATGCTGGAGGTTCCGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCTCTCTTCCCTCTCTGCGCGCTCATCTCTTCAAAGGGGTGCGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrTrpProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCGAGGGGAGTCAAGTGGAGCCCTACTACCCCGCAAGTCTCGCAGNCTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
DB 1585 AGGCATCCCTCTGAGAGGTACAGCGCGCTGCGCGAGCGCGCGATGGCTCCATCATCTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCAGATGACCGCTACTTGGCGCTTCACACAGGCCAAACTGCAGGCAACCACTCTGGGCCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

Db 1705 CTGGGCCACCGAGCTCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Oy 520 e 520
Db 1765 C 1765

RESULT 34
ID ADA74989 standard; cDNA; 1985 BP.
XX
AC ADA74989;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073216-A1.
XX
PD 17-APR-2003.
XX
PF 30-MAY-2002; 2002US-00160498.
XX

31-MAR-1997; 99WO-US052330.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012253.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.

22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 28-JUL-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
XX
DR WPI; 2003-765392/72.
DR P-PSDB; ADA74990.
XX
PT New secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha in human blood and detecting

the presence of tumor in a mammal.

Claim 2; Fig 143; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADA74989 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20
Db	206	ATGTTGGCGCGCTCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACCGCCGAGCGCGAGGCCAGGAGCTGCGCAGAGGCGGAGGCATTCTCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCACCTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATTCAGACGCTTTCAGTGGGTGTCCAGCTACCTGTGCGGGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGCACAGATCACTCGTCCCGCTGCGGGTTACAGATACCACACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTACTTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG	565

Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACCTGGCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGGAGGCCCCCAGCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetClyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGGACCAACATGGGCTGGGCAATGCTTGTATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGCGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTCTGTTGCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACAGCTTGCCCTCACCCACTCGCCCGCGCGCGCTCATGGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTCTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CATGACTTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAACGAGGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACCTGCCACCTCTTCTTCGATGCTCATCTCAGTAGACAGGCAACAGCACTGA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG	1284
Qy	360	qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCAGAAAGATGGGTGGGCTGCCCTGCCCTCCACATTTGAGGCTCGGCGAGTGTCA	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTTACTTCTTCAAAGGGGTGCTGCTGGAGGTTCGGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTCCGCGGAGGGGGCTGCCCGGCCCATCTCGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGGCGCCCTCATCTCTTCAAGGGTGGCGGCTACTAGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCGAGGACTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGTCAAGCGCGCCCTGCGGAGGCCGATGGCTCCATCTCTTCT	1644


```
KY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACAGCTTGGCTTCCACCACTCGCCGCGCGCGCGCTCATGGGGCC 984
KY 260 oTyTrIlyysArgIleuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGGCGCGAGCGCTGCTCAGCTGGGACGACGCTGGCGGTGCA 1044
KY 280 nSerLeuTyTrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGAGACCCCTAGGGGCTCAGTGGCCGCTCCAGCTCCAGAAAGCTGT 1104
KY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCCTCAGCCCCCAAGGAAGGCGCCCTGAACGCGAGG 1164
KY 320 yProLysTyTrCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTAATATCTGCCACTCTTCTTCGATGCGCATCTCTGTAGACGGCAACAGCACTGTA 1224
KY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGCCATTTCTGGGAGGTGGAGCTCATGGCAAGCTCTCAGAGCCCCG 1284
KY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
KY 380 uAsnAspGlyAspPheTyPhePheLysGlyGlyValArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGTTCCGGGGCCCCAA 1404
KY 400 gProValTrpGlyLeuProGlnLeuCyeArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCGCCGCCATCTCTGAGCG 1464
KY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
DB 1465 CGCCCTCTTCTTCTCTCTGCGCGCGCTCATCTCTTCAAGGTGCGCCCTACTAGT 1524
KY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGCGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
KY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCCGAGGCGCGATGGCTCCATCTCTT 1644
KY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCCCTACTGGCGCTCTGACGAGCCAACTGACGGAACCACTCGGGCGG 1704
KY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCGTGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
KY 520 e 520
DB 1765 C 1765
```

RESULT 36

ID ADA84515 standard; cDNA; 1985 BP.

XX AC ADA84515;

XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

Glucose uptake modulator; FFA uptake modulator;
cell proliferation stimulator; cell differentiation stimulator;
cell differentiation inhibitor; cytokine release stimulator; tumour;
lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
cervical tumour; liver tumour; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker.

Homo sapiens.

US2003082708-A1.

01-MAY-2003.

15-MAY-2002; 2002US-00146729.

05-JUN-2000; 2000US-0209832P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-786911/74.

P-PSDB; ADA84515.

New PRO nucleic acid, useful for preparing a composition for treating
e.g. tumor or for tissue typing.

Claim 2; Fig 143; 637pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or TNF by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADA84515 (1-1985)


```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTTCGGCGGGTGGCCCTCTCTGCTCGCGGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgGlyGluAlaPheLeu 40
DB 266 GACGCCCGCCGCGAGCGCGAGGCGCAGGAGCTGCGCAAGGAGGCGGAGCATTCCTTA 325
QY 41 GluLeuTyrGlyTyrLeuLeuGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCTTGGGCTGAGAGGATCAGTGTGTTGTCTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAGGTAACTGTTGTTACAGACCGGACCAAAATGAGGCGTAAG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTGCGGAGCGGCGAGTTGCGGGCGCGTTCGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGAGTTCTGGGAGGCGCCACAGCCAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTTCTTCAGGGGACCAACAGATGGCTGGGCATGCTTTGATGGC 805
QY 200 sGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGCGCAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTGCGCGCGCGCGCGCGCTCATGCGGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGCTCCAGCTCCCGAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAGGAAGCGCCCTGAACACGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
```

```
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCCCCAACATTGAGGTGCGGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
DB 1465 CGCCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCGGAGGCGCGATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAATGTCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGAGCGCGCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 37
ADB29771
ID ADB29771 standard; cDNA; 1985 BP.
XX
AC ADB29771;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073214-A1.
XX
PD 17-APR-2003.
XX
PF 17-APR-2002; 2002US-00124822.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
```

```
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005094.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US032759.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-720081/68.
XX P-FSDB; ADB29772.
XX
XX Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha and detecting the presence of
PT a tumor in a mammal.
XX
XX Claim 2; Fig 143; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores: 1.93e-149 Length: 1985
Pred. No.: 2792.00 Matches: 519
Score:
```

Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	0
DB:	9	Gaps:	0
US-10-791-980-6 (1-520) x ADB29771 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTTGGCGCGCGTTCCTGCTGGCGCGCTTCAGCTCTACTGTGTGGCGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu	40
Db	266	GACGCCACCGCGCGGAGCGGAGCCAGGAGCTGCGCAGAGCGGAGGCAATTCCTTA	325
Qy	41	GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGATACCTCAATGAACAGGTCCCAAGACTCCCACTCCACTCGATTCCAG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	QATGCATCAGAGCGTTTCAGTGGGTGTCACAGCTACCTGTCCAGCGGGGTGTGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCGCAGATGACTGCTCCCGCTCGGGGTACAGATTACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTGAGCATCTCCCGAGCGCGCAGTTCCGGGCGCGCTGCGCGCGCGCTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTAGCGCTGGAGTCTTGGAGAGCGCCACGCCACAGCGCCCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGCTCACCTTCTTCCAAAGGGACCAACAGATGGCTGGGCAATGCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGCGCGCTTGGCGACCGCTTC-CTGCCCCCGCGCGGCAAGCGCATTCGACCA	864
Qy	220	nasGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHis	240
Db	865	AGATGAGCGCTGGTCCCTTGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGGCCGCGACCGCTGCTCAGCTGGGAGCAGCTGTGGCGGTGCA	1044
Qy	280	nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCCATGGGGGCTCAGTGGCCGCTCAGCTCCAGGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAGAGGGCGCTTGAAACGCGAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeu	340

PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019033.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028584.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 30-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US014941.
PR 28-JUL-2000; 2000WO-US015264.
PR 11-AUG-2000; 2000WO-US020710.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023528.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00823366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882536.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755115/71.
DR P-PSDB; ADA80300.
XX New PRO polypeptides useful for treating diabetes, hyper- or hypo-
PT insulinemia, sports injuries, arthritis, obesity, stroke, heart attack,
PT various coagulation disorders and tumors.
XX Claim 2; Fig 143; 638pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA80299 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTGGCGGGTGGCCCTCTGTGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCAGCCCGGAGCGGAGGCGGAGGAGGCTGGCAAGGAGGCGGAGGCAATTCCTA 325
 Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAAGTACGGATACCTCAATCAACAGAGTCCCAAGGCTCCACCTCCACTCGATTACG 385
 Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
 Db 386 GATGCCATCAGACGTTTCAGTGGGTGCCAGCTACCTGTGAGCGGGTGTGGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTGGCCAGATGACTCGTCCCGCTCGGGGTTCACAGATACCAACAGTTATGG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgGly 120
 Db 506 GCCTGGGTGAGAGGATCAGTCACTGTTTGTGTAGACACCGGACCAAAATGAGGGCTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAACTGTTACAAAGCAGCCTCTCTCCCGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCATCTCCGCGAGCGCGAGTTCCGGGCGCGTCCGCGCCCTTCCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTCTTCCAGGGGACCAACAGATGGGCTGGCAATGCTTTGATGGC 805
 Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 Db 806 CCAGGGGGCGCTGGCGCACGCTTC-CTGCCCCCGCGGCGAAGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGGTGGCGCA 924
 Qy 240 aGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACGCTGGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
 Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
 Db 985 CTACTACAGAGGCTGGGCGCGAGCGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGCTCCAGCTCCCGAGGAAGCTGTT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 Db 1105 CACTGACCTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTTGAACCCAGGG 1164
 Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 Db 1165 CCCTAAATACTGCGCACTCTCTCTTCGATGCATCACTGTAGACAGCAACAGCAACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 Db 1285 TCCACTGGAGAAAGATGGGTGGGCTGCCCGCCCAACATTTGAGGCTGGGCACTGTCTAT 1344
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyClyArgCysTrpArgPheArgGlyProly 400
 Db 1345 GAATGATGGAGATTTCTACTTTCTTCAAGGGGTGATGTCTGGAGGTTCCGGGGCCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuLysArgAlaGlyClyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCCGCCATCTCTGACGC 1464
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
 Db 1465 CGCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAGTCTGCGAGGACTGGGG 1584
 Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCCAGGCGCGATGCGTCCATCATCTTCT 1644
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCCAACTGCGAGGCAACCTCGGGCGG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGCCACCGAGCTGCCCTGATGGGCTGTGGCATGCCAACTCGGGGAGGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 C 1765
 RESULT 39
 ADA75541
 ID ADA75541 standard; cDNA; 1985 BP.
 XX
 AC ADA75541;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polynucleotide #72.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003082703-A1.
 XX

Db 1345 GAATGATGGAGATTCTTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 sProValTtpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCGGCATCCTGACGC 1464
QY 420 alaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGTGCCCGTACTACGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGGCCCGAGGGGGACTCAAGTGGAGCGCTACTACCCCGAAGTCTCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTGAGCGCGCCCTGCCGAGCCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAGGCCAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCACCGAGTCCCTGGATGGGCTGTGGCATGCGCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 c 1765
RESULT 40
ADA46766
ID ADA46766 standard; cDNA; 1985 BP.
XX
AC ADA46766;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; r-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073210-A1.
XX
PD 17-APR-2003.
XX
PF 11-APR-2002; 2002US-00121045.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00870392.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.

QY 360 gProLeuGlnGluArgTrrpValGlyLeuProAsnIleGluAlaAaValSerIe 380
 Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGCTGCGGAGTGTCAIT 1344
 QY 380 uAnAspGlyAspPheTyrPhePheLysGlyArgCysTrrpArgPheArgGlyProly 400
 Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProAsnIle 420
 Db 1405 GCCAGTGTGGGTCTCCCAACAGCTGTGCCGGGAGGGGGCTGCCCGCCATCTCGACGC 1464
 QY 420 aLaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrrpVa 440
 Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTCCCGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrrpTrrpProArgSerLeuGlnAspTrrpGl 460
 Db 1525 GTGGCCCCAGGGGAGTGCAGAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePhe 480
 Db 1585 AGCATCTCTGAGAGGTGAGCGGCCCTGCGAGGCCGAGTGGCTCATCTCTTCTTCT 1644
 QY 480 eArgAspAspArgTrrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar 500
 Db 1645 CCGAGATGACCGCTACTGCGGCTCGACCAGGCCAACTGCAGGCAACCACTCGGGCG 1704
 QY 500 gTrrpAlaThrGluLeuProTrrpMetGlyCysTrrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGTGCCTGGATGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
 QY 520 e 520
 Db 1765 c 1765
 RESULT 41
 ADB25062
 ID ADB25062 standard; cDNA; 1985 BP.
 XX
 AC ADB25062;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polynucleotide SEQ ID NO 143.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; Glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; r-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003077715-A1.
 XX
 PD 24-APR-2003.
 XX
 PF 23-APR-2002; 2002US-00128693.
 XX
 PR 31-AUG-1998; 98US-0098525P.
 PR 16-SEP-1998; 98US-0100634P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.

XX
 PA
 PI
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 WPI: 2003-755070/71.
 P-PSDB; ADB25063.
 New isolated, secreted and transmembrane PRO nucleic acids, useful for
 the diagnosis, prevention and/or treatment of tumors, such as lung,
 colon, breast, prostate, rectal, cervical and/or liver tumors.
 Claim 2; Fig 143; 637pp; English.
 The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating differentiation of adipocyte cells, for stimulating
 proliferation of or gene expression in pericyte cells, for stimulating
 cells, for inducing endothelial cell tube formation and for treating
 various bone and/or cartilage disorders such as sports injuries and
 arthritis. PRO polypeptides which stimulate the release of proteoglycans
 from cartilage are useful for treating sports-related joint problems,
 articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 polypeptides are also useful for treating various mammalian haemoglobin-
 associated disorders such as various thalassaemias and conditions which
 may benefit from enhanced local immune system cell infiltration. This
 sequence represents a human PRO polynucleotide of the invention. Note:
 The sequence data for this patent is also available in electronic format
 from USPTO at seqdata.uspto.gov/sequence.html.
 SQ Sequence 1985 BP; 403 A; 546 C; 604 G; 332 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservativity: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0
 US-10-791-980-6 (1-520) x ADB25062 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrrpGlyHisLeu 20
 Db 206 ATGGTCGCGCGCTCGGCTCTCTGCGGCCCTGCAGCTGCTACTTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCAGCCCGCGAGCGCGAGGCTGCGAGGAGGAGGCGGAGGCGGCGGCGGCGG 325
 QY 41 GlulysTyrGlyTrrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAATACGATACCTCAATGACAGGTCCCCCAAGCTCCCACTCCACTCGATTGAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTGCTGCTCCCGCTGCGGGTTACAGATACCACACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTCGGCTGAGAGATCAGTACTGTTTGTGTAGACACCGGACCCAAAATCAGGCGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCNACAGTGTACAAATGGTACAGCAGCAGCTCTCTCCACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGSCCTGAGCATCTGCCGAGCGCGAGTTCCGGGGCGCGTGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGGAGGCCACAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCCTCTTCCAGAGGAGCACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHi 240
Db 865 AGATAGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCAACCTGTTCTGCTGGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGTTGGCTCACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGCGTGGCGCGCGAGCGCTGCTCAGCTGGGACGCGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGCCCCCAGAGAGCGCCCTGAAACGACGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTCTCGATGCCACTCAGTGTAGACAGGCAACAGCAACTGA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAAGAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGCAGATTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCATCTCTGACGC 1464

QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGTGCCTACTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCCAGCGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCCCAAACTGCAGGCAACCCCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGCATGCCAACTCGGGGAGCGCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 42
ADA93238
ID ADA93238 standard; cDNA; 1985 BP.
XX AC ADA93238;
XX DT 20-NOV-2003 (first entry)
XX DE Human PRO polynucleotide #72.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX FN US2003077721-A1.
XX PD 24-APR-2003.
XX PF 24-APR-2002; 2002US-00131837.
XX PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755076/71.
DR P-PSDB; ADA93239.
XX New PRO nucleic acid, useful for recombinantly producing a PRO
PT polypeptide and for manufacturing a medicament for diagnosing or treating
PT tumor.
XX Claim 2; Fig 143; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC

transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of adipocyte cells, for stimulating differentiation of pericyte cells, for stimulating proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:		
Pred. No.:	1,938-149	1985
Score:	2792.00	Matches: 519
Percent Similarity:	99.63%	Conservative: 0
Best Local Similarity:	99.63%	Mismatches: 1
Query Match:	98.52%	Indels: 2
DB:	9	Gaps: 0

US-10-791-980-6 (1-520) x ADA93238 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGCTGGCGCGCTCGGCTCTCTGTGGCGCCCTGCAGCTGCTACTGTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluuArgGlyGlyGlnGluLeuArgGlyLeuAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCGCGAGCGCGAGCCAGGAGCTGCGCAGGAGCGGAGGCGATTCCTTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGAGTACTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCATCAGAGCGTTTCAGTGGGTGCCACAGCTACCTGTGCGGGCGTGTGGACGCG	445
Qy	81	AlaThrIleuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGGCGCCAGATGACTCGTCCCGCTCGGGGTTCAGATACCAACAGTTATGGG	505
Qy	101	AlaTrpAlaGluuArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTGTGTGCTAGACACCGGCCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgIleuVal	140
Db	566	AAACGGCTTTGCAACAGCAGGTAAACAAATGGTACAAGCAGCACCTCTCTACCGCTGGTG	625

Db 1705 CTGGGCCACGAGCTCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
 QY 520 e 520
 Db 1765 c 1765
 RESULT 43
 ADB26588
 ID ADB26588 standard; cDNA; 1985 BP.
 XX AC ADB26588;
 XX DT 20-NOV-2003 (first entry)
 XX DE cDNA encoding human PRO polypeptide #72.
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; r-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX OS Homo sapiens.
 XX PN US2003092147-A1.
 XX PD 15-MAY-2003.
 XX PF 11-APR-2002; 2002US-00121051.
 XX PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005190.
 PR 20-APR-1999; 98WO-US008615.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012252.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028213.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 18-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US030873.
 PR 20-DEC-2000; 2000US-00747259.
 PR 28-FEB-2001; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 01-MAR-2001; 2001WO-US006520.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2003-777245/73.
 DR P-PSDB; ADB26589.
 DR Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
 PT

PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
 XX attack, various coagulation disorders, tumors.

PS Claim 2; Fig 143; 660pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridization probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: Gaps: 0

US-10-791-980-6 (1-520) x ADB26588 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTTCGCGCGGTTCGCGCTCTGTCGCGCGCTCTGTCAGCTGCTACTGTGGGGCCACCTGT 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 265 GACGCCACCGCGGAGCGCGAGGCGGAGGCTGCGGACGAGGCGGAGGCGGAGGCTTCTCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCACTCGATTGACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACGCGTTTCAGTGGGTGTCACAGCTACCTGTGACGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCACCTCTGCCAGATGACTGTCTCCCGCTCGGGGGTTTACAGATACCAACAGATTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTAGACACCGGACCAAAATGAGCGCTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTAAAGCAGACCTCTCTCTACCGCTTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCATCTCGCGAGCGCGAGTTGGGCGCGCTGCGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGAGCAACAGTCTCAGCGCTGAGTTCTGGAGGCGCCACAGCAGCGCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAAGGGACCAACAGATGGCTGGCAATGCCCTTTGATGC 805
 QY 200 adGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CCAGCGGGCGCTCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGCTGCGCGCA 924
 QY 240 sGluileGlyHisThrLeuGlyLeuThrHiserProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTCGCGCTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCGCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCAGCCCCCAAGAGCGCGCTTGAACCGCAGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340
 DB 1165 CCCTAAATACTGCCACTCTCTCTTCGATGCCATCATCTGTAGACAGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGGCATTTCTGGGAGGTGGCAGCTGATGGAACAGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerIe 380
 DB 1285 TCCACTGAGGAAGATGGTGGGCTGCCCGCGCTGAGGCTGAGGCTGAGGCTGAGTTCATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
 DB 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGCTGATGCTGGAGGTTCCCGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCTCCACAGCTGTGCGGGGAGGGGCGCTGCCCGCGCATCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
 DB 1465 CGCCCTCTTCTTCTCTCTCTCTGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 DB 1525 GCTGGCGCGGAGGACTGCAAGTGGAGCCCTACTACCCCGAGCTGTCAGAGCTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644

```
OY 480 eArghspAargTyrrTpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTCGGCGCTCGACGAGCCAACTGCAGGCAACACCTCGGGCCG 1704
OY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGGCGCCCTGTT 1764
OY 520 e 520
Db 1765 C 1765

RESULT 44
ADB30875
ID ADB30875 standard; cDNA; 1985 BP.
XX
AC ADB30875;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003096386-A1.
XX
PD 22-MAY-2003.
XX
PF 11-APR-2002; 2002US-00121042.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US000508.
PR 10-MAR-1999; 98WO-US005130.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005501.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-008666034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
```

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786990/74.
DR P-PSDB; ADB30876.
XX
XX
PT Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
XX
XX
PS Claim 2; Fig 143; 639pp; English.
XX
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Watch: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB30875 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGTCCGGCTCTCTGTCGGCGCTCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGlnAlaPheLeu 40
Db 266 GACGCCACAGCCGCGAGCGCGGAGCCAGGAGCTGCCAGAGGCGGAGGCATTCCTCA 325
Qy 41 GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGGCTCCCACTCCACTCGATTCCAG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTCTGTCCAGCGGGGTGTTCAGCGC 445

```
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 YGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACGCGGCGCCTGCCGAGGCCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIyLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCCTCGACCGCAAACTGCAGGCAACCCCTCGGGCCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGTCTGTCGATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 45
ADA60803
ID ADA60803 standard; cDNA; 1985 BP.
XX
AC ADA60803;
XX
DT 20-NOV-2003 (first entry)
XX
DE Homo sapiens.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Novel.
OS human.
OS secreted.
OS and.
OS transmembrane.
OS protein.
OS PRO4339.
OS cDNA.
XX
PN US2003049817-A1.
XX
PD 13-MAR-2003.
XX
PF 10-MAY-2002; 2002US-00142423.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 21-JUN-2001; 2001WO-US019692.
PR 22-JUN-2001; 2001US-00887879.
PR 29-JUN-2001; 2001WO-US020116.
PR 09-JUL-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
```


PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 PR 10-MAR-2003; 2000WO-US006319.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart RA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-695893/66.
 DR P-PSDB; ADA60804.
 XX
 PT New secreted and transmembrane PRO polypeptide and nucleic acid, useful
 PT for manufacturing a medicament for diagnosing or treating tumor.
 XX
 PS Claim 2; Fig 143; 658pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADA60803 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGCGCGGTGGCGCTCTGCTGCGCGCGCTGAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GAGCCCGACCGCGGAGCGCGGAGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGGTCCCAACCTCCACTCGATTACGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGACTACCTGTCTCAGCGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCCGACATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
 QY 101 AlaTpaAlaGluAuaGillesSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCTTGGGTGAGAGGATCAGTGACTTGTGTACACACCGGACCAAAATGAGGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCCAAGCAAGGTAAACAAATGGTACAGCAGCAGCTCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCATCTCGGAGCGGCGAGTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGGAGGCCCCCAGCAGCGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACTTCTTCCAGGGGACCAACAGATGGGTGGGCAATGCTTGTATGGC 805
 QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CAGGGGGCGCGCTGGCGCAGCGCTTC-CTGCCCCCGCGCGGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTCTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACAGCGCTTGGCTTCCACCATCTCGCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAAGAGGTGGCGCGCGCGCTGCTCAGCTGGGAGCAGCGTGTGCGCGCTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGGAAGCGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGGCCCCNAGNAGGCGCCCTGAAACCGCAGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCCTAAATACCTGCGCACTCTCTCTTCGATGCTCCTCAGTACAGCGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGACCGCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 DB 1285 TCCACTGAGGAAGATGGGTGGGGTGGCGCTCCCGCCNACATTGANGGTGGGCGAGTGTCT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProly 400
 DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTGCATGTGGAGGTTCGGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCTCCACAGCTGTGCCCGGCGAGGGGGCTGGCCCCGCCCATCTCC 1464

QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTCCCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyLeuProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGATCCCTGAGGAGGTCAGCGCGCCCTGCCAGGCCCGCATCATCTCTCTT 1644
QY 480 eArgAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGTACTGCGCCCTCGACCGCCAACTGCAGCAACCACTCGGGCCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCyTrpHisAlaSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 46

ADB23950

ID ADB23950 standard; cDNA; 1985 BP.

AC ADB23950;

XX ADB23950;

DT 20-NOV-2003 (first entry)

XX Human PRO polynucleotide SEQ ID NO 143.

DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; pericyte cell;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003077714-A1.

XX 24-APR-2003.

XX 22-APR-2002; 2002US-00127901.

XX 17-JUN-1998; 98US-0089599P.

XX 02-JUN-1999; 99WO-US012252.

XX 25-AUG-1999; 99US-00380137.

XX 30-NOV-1999; 99WO-US028313.

XX 30-MAR-2000; 2000WO-US008439.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Baresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755069/71.

DR P-PSDB; ADB23951.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic

PT acids, useful for the diagnosis, prevention and/or treatment of tumors,

PT such as lung, colon, breast, prostate, rectal, cervical and/or liver

PT tumors.

XX Claim 2; Fig 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB23950 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTyrGlyHisLeu 20
Db 206 ATGTCGCGCGGTGCGCCCTCTCTGTCGCGCCCTGCTACTGTGTTGGGCGACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGAGGCCAGAGCTGCGCAAGGAGCGGAGGCATTCTTA 325
QY 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTGTCCTCCCAAGCTCCACCTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCTTTCAGTGGGTGTCAGCTACTGTCCAGCGCGGTGTTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAenLysTyrLysGlnHisLysSerTyrArgLeuVal 140
 Db 566 AAGCGCTTTGCAAGCAAGTAACTGTTACAGCAGCACTCTCTCCACCGCTGGTG 625
 QY 141 AenTyrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCCCTGAGCATCTGCGGAGCGCGCAGTTGCGGGCGCGGTGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCGCCCGCAGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCAAGGGGACACACAGATGGCTGGGCAATGCCCTTATGGC 805
 QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGCTGGCGCACGCCCTTC -CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTyrSerLysSerArgArgGlyArgGlnPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCAACCTTGTTCGTGGTCTGGCGCA 924
 QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACGCTTGGCTTACCACCTCGCCGCGCGCGCGCTCATGGCGCC 984
 QY 260 tTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValGl 280
 Db 985 CTACTACAGAGCGCTGGCGCGCGCGCTGTCTGAGTGGGACGAGCTGTGCGCGTGA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValalaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCGTCCAGCTCCCGAGGAAGCTGT 1104
 QY 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTTGAGACTGGGATCTCTACAGCCCCCAAGAGCGCGCTGAAACGACGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCCTAAATACTGCCACTCTCTTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheThrProGluValalaAlaAspGlyAenValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGACCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAenIleGluAlaAlaValSerLe 380
 Db 1285 TCACCTGAGGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGCTGCTGGAGTTCCGGGGCCCCAA 1404
 QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGGGGTCTCCACACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 Db 1465 CGCCCTCTTCTTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrGl 460
 Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAGCTGTGAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCTGAGGAGGTGAGCGGGCGCTGCGAGGGCGCGATGGCTCCATCATCTTCT 1644

QY 480 eArgAspAspArgTyrTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTGCGCTCGACAGGCCAACTGCAGGCAACCACTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCCACTCGGGAGCGCCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 47
 ADA96279
 ID ADA96279 standard; cDNA; 1985 BP.
 XX
 AC ADA96279;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polynucleotide #72.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; lymphocyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone cartilage defect; osteoarthritis;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003082690-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 22-APR-2002; 2002US-00127837.
 XX
 PR 01-SEP-1998; 98US-0098750P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 WPI: 2003-755107/71.
 DR P-PSDB; ADA96280.
 XX
 PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
 tumor or for tissue typing.
 XX
 PS Claim 2; Fig 143; 637pp; English.
 CC
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating

ADA80851 standard; cDNA; 1985 BP.
ADA80851; .
20-NOV-2003 (first entry)
Human PRO polynucleotide #72.
Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor- α ; TNF- α ; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
Homo sapiens.
US2003082702-A1.
01-MAY-2003.
23-APR-2002; 2002US-00128690.
02-MAR-2000; 2000WO-US005841.
30-MAY-2000; 2000WO-US014941.
01-DEC-2000; 2000WO-US032678.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff B, Gao W;
Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-755111/71.
P-PSDB; ADA80852.
New PRO nucleic acid, useful for preparing a composition for treating
e.g., tumor or for tissue typing.
Claim 2; Fig 143; 637pp; English.
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor- α (TNF- α) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridization probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0
US-10-791-980-6 (1-520) x ADA80851 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
DB ATGTTCTGGCGCGCTCGGCTCTCTGCTGGCGGCTTCTACTGTTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB GACGCCAGCCCGCGGAGCGGAGAGCTGCCAAGAGCGCGGAGGCGGAGGCGATTCTCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB GAGAGTACCGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATCCTCATGTTACG 385
QY 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTTCAGCGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTGTACAGATACCAACAGATTATGCG 505
QY 101 AlaTyrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB GCCTGGGCTGAGAGGATCAGTACTGTTTGTCTAGACACCGGACCCAAATAGAGCGTAA 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB AAACGCTTTCAGACAGGTAAACAAATGGTACAGCAGCAGCCTCTCTTACCGCTGTGTG 625
QY 141 AsnTyrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB AACTGGCCTGAGCATCTCGCGAGCGCGGAGTTCGGGGCGCGGTGCGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB TTGTGGGCAACAGCTCTACGCGTGGAGTTCCTGGGAGGCGGCGGCGGCGGCGGCGTAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB ATCCGGCTCAGCTTCTTCCAGGGGAGCCACAAACGATGGGCTGGGCAATGCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGGCGGCGGCGGCGGCGG 864
QY 220 nAspGluArgTyrSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCG 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB CGAGATCGTCCACAGCTTGGGCTTCCACCTTGGCGGCGGCGGCGGCGGCGGCGGCGG 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspValLeuAlaValGl 280

Db	985	CTACTACAAGAGGCTGGGCGCGAGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGCA	1044	KW	immune system cell infiltration.
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValAlnLeuProGlyLysLeuPh	300	XX	Homo sapiens.
Db	1045	GAGCTGTATGGGAAGCCCTAGGGGGCTAGTGGCGTCCAGCTCCAGGAAGCTGTT	1104	XX	US2003082759-A1.
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnG1	320	XX	01-MAY-2003.
Db	1105	CACGTACTTTCAGACCTGGGACTCCTACAGCCCCCAGGAAGGCGCCTGAAACGCAGGG	1164	XX	11-APR-2002; 2002US-00121040.
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340	XX	31-MAR-1997; 97WO-US005230.
Db	1165	CCCTAAATACCTGCCACTCTTCCTTCGATGCCCTCACTGTAGACAGCAACAGCAACTGA	1224	PR	12-JUN-1998; 98WO-US012456.
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360	PR	14-JUL-1998; 98WO-US014552.
Db	1225	CATTTTAAAGGGAGCCATTCTGGAGGTGGACGTGATGGCAACGCTCTCAGAGCCCCG	1284	PR	28-AUG-1998; 98WO-US017888.
Qy	360	qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380	PR	10-SEP-1998; 98WO-US018824.
Db	1285	TCCACTCGAGAAAGATGGGTGGGGTGGCCCCCAACATTGAGGCTGGGCGAGTGTATT	1344	PR	14-SEP-1998; 98WO-US019093.
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400	PR	14-SEP-1998; 98WO-US019094.
Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGATGCTGAGGTTCCGGGGCCCA	1404	PR	16-SEP-1998; 98WO-US019177.
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420	PR	17-SEP-1998; 98WO-US019437.
Db	1405	CCCAAGTGGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCGCCCATCTGACGC	1464	PR	07-OCT-1998; 98WO-US021141.
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440	PR	29-OCT-1998; 98WO-US022991.
Db	1465	CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTCCCGCTACTAGT	1524	PR	20-OCT-1998; 98WO-US022992.
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl	460	PR	01-DEC-1998; 98WO-US024855.
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAAGTCTGCAGGACTGGG	1584	PR	05-JAN-1999; 99WO-US000106.
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480	PR	08-MAR-1999; 99WO-US005028.
Db	1585	AGGCATCCCTGAGGAGGTACGGCGGCTCCCGAGGCGGATGGCTCCATCTCTCTT	1644	PR	10-MAR-1999; 99WO-US005190.
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500	PR	20-APR-1999; 99WO-US008615.
Db	1645	CCGAGATGACCGCTACTTGGCGCTCGACCGCCAAACTGCAGGCAACCACTCGGGCCG	1704	PR	14-MAY-1999; 99WO-US010733.
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520	PR	01-SEP-1999; 99WO-US020111.
Db	1705	CTGGCCCAACGAGTGGCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764	PR	08-SEP-1999; 99WO-US020594.
Qy	520 e 520			PR	13-SEP-1999; 99WO-US020944.
Db	1765 C 1765			PR	15-SEP-1999; 99WO-US021090.
RESULT 49				PR	05-OCT-1999; 99WO-US021547.
ADA95727				PR	29-NOV-1999; 99WO-US028214.
ID ADA95727 standard; cDNA; 1985 BP.				PR	30-NOV-1999; 99WO-US028313.
XX				PR	01-DEC-1999; 99WO-US028301.
AC ADA95727;				PR	02-DEC-1999; 99WO-US028551.
XX				PR	16-DEC-1999; 99WO-US030095.
DT				PR	20-DEC-1999; 99WO-US030911.
XX				PR	22-DEC-1999; 99WO-US030720.
XX				PR	30-DEC-1999; 99WO-US031243.
XX				PR	05-JAN-2000; 2000WO-US000219.
DE				PR	06-JAN-2000; 2000WO-US000277.
XX				PR	11-FEB-2000; 2000WO-US000376.
KW				PR	18-FEB-2000; 2000WO-US003565.
KW				PR	18-FEB-2000; 2000WO-US004341.
KW				PR	22-FEB-2000; 2000WO-US004342.
KW				PR	24-FEB-2000; 2000WO-US004414.
KW				PR	01-MAR-2000; 2000WO-US005004.
KW				PR	02-MAR-2000; 2000WO-US005601.
KW				PR	10-MAR-2000; 2000WO-US005811.
KW				PR	15-MAR-2000; 2000WO-US006319.
KW				PR	20-MAR-2000; 2000WO-US006884.
KW				PR	21-MAR-2000; 2000WO-US007377.
KW				PR	30-MAR-2000; 2000WO-US007532.
KW				PR	17-MAY-2000; 2000WO-US008439.
KW				PR	22-MAY-2000; 2000WO-US013705.
KW				PR	30-MAY-2000; 2000WO-US014042.
KW				PR	02-JUN-2000; 2000WO-US014941.
KW				PR	28-JUL-2000; 2000WO-US015264.
KW				PR	28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-0074259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PA (GETH) GENENTECH INC.
XX
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
XX
DR WPI: 2003-755114/71.
DR P-PSDB; ADA95728.
XX
PT New isolated PRO polypeptides, useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders and tumors.
XX
PS Claim 2; Fig 143; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalasaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA95727 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20
DB	206	ATFGTGGCGCGCTCGGCTCTCTGCTGGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GAGCCCCAGCCGCGGAGCGGAGGCTGCGCAAGGCGGAGGCGGAGCATTCCTTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAGCTCCCACTCCCATCTCAGCTCAGC	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80
DB	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGCGGGCGGTGTGGACCCG	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTATGCG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys	120
DB	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAAGCTTTGCAAGCAAGGTAAACAAATGGGTACAGCAGCACCTCTCTCCCGCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCTGAGCATCTGCGGAGCGGCGAGTTCGGGGCGCGGTGCGCGCCCTTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGGAGGCGCCAGCCACAGGCGCCGCTGAC	745
QY	180	rSerGlySerProSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACCTTCTTCAAGGGGACCAACATGGGCTGGGCAATGCCTTTTGTATGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
DB	806	CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGAGGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValLeuAlaHi	240
DB	865	AGATGAGCGCTGGTGGTCCCTGAGCCGCGCGGGGCGCAACCTGTTCTGCTGGTGGCGCA	924

Db 806 CCAGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluAArgTrpSerLeuSerAArgAArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGGGCGCACTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProAArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTCAACGCTGGCCCTCACCACTCGCCGCGCGCGCTCATGTGGCGCC 984
Qy 260 oTyTrpIysArgLeuGlyAArgAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGAGCGCTCTCAGCTGGGACGAGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGAGCCCGCAAGGAAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCTACTGTAGACGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACCTGACGAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGTGGCGAGTGTCAIT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 alaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGGCTCTATCTCTTCAAGGTGGCGGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVaR 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAAGGCGCAACTGCAGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 c 1765
RESULT 51
ADB21521
ID ADB21521 standard; cDNA; 1985 BP.
XX
AC ADB21521;
XX

DT 20-NOV-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
DE
XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; PFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
OS
XX US2003082765-A1.
XX
XX 01-MAY-2003.
XX
XX 17-MAY-2002; 2002US-00147492.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.

PR 02-MAR-2000; 2000WO-US0005841.
 PR 10-MAR-2000; 2000WO-US0006319.
 PR 15-MAR-2000; 2000WO-US0006884.
 PR 20-MAR-2000; 2000WO-US0007377.
 PR 21-MAR-2000; 2000WO-US0007532.
 PR 30-MAR-2000; 2000WO-US0008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 28-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
 XX

WPI; 2003-786920/74.

P-PSDB; ADB21522.

PT New secreted and transmembrane PRO polypeptide useful for detecting the
 PT presence of tumor in a mammal, or modulating the uptake of glucose or
 PT free fatty acid by skeletal muscle cells or adipocyte cells.

XX Claim 2; Fig 143; 638pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of

CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumor in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromsome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB21521 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 |||||
 Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGAGCTGCTACTGTGGGGCCACCTG 265
 |||||
 QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 |||||
 Db 266 GACGCCAGCCCGCGAGCGCGAGCGAGCTCGCCAGAGCGCGAGCGCGGCGCATTCCTA 325
 |||||
 QY 41 GluLysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 |||||
 Db 326 GAGAAATACGGATACCTCAATGAACAGGTCCCAAGTCCCACTCCATCGATTCAGC 385
 |||||
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 |||||
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTCTCAGCGGGGTGTGGACCCG 445
 |||||
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 |||||
 Db 446 GCCACCCCTGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGTTATGCG 505
 |||||
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 |||||
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCCTAGACACCGGACCCAAATAGGCGGTAA 565
 |||||
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTyrArgLeuVal 140
 |||||
 Db 566 AAAGCCTTGGCAAGCAAGGTAACTAATGGTACAGCAGCAGCCTCTCTCCCGCCTGGTG 625
 |||||
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 |||||
 Db 626 AACTGGCCTGAGCATCTGCCGAGCGCGAGTCTGGGGCGCGCGTGGCGCGCTTCCAG 685
 |||||
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 |||||
 Db 686 TTGTGGAGCAACGCTCAGCGCTGGAGTTCCTGGAGGGCCCCCAGCCACAGGCCCTCCAC 745
 |||||
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 |||||
 Db 746 ATCCGGCTCACCTTCTTCCAGAGGGGAGCCACCAACGATGGGCTGGGCATGCTTGTGATGC 805
 |||||
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 |||||

Db	806	CCAGGGGGCCCTGGCGCACGCCTTC-CTGCCCCCGCGCGGCGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTCGAGCGCGCGCGCGCAACCTGTTGCTGGTGGCGCA	924
Qy	240	sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCCTCACCACTCGCGCCGCGCGCGGCTCATGGCGCC	984
Qy	260	oTyrTyrIysArgLeuGlyArgAspAlaLeuSerTrrpAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGCGCGACGCGCTGCTCAGCTGGGACGCGTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCGCTCCAGGTCCCGAAGAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTCTCGATGCGATCCTAGCAGGCGCCCTGAAACGCGAGGG	1164
Qy	320	yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTCTCTCGATGCGATCCTAGCAGGCGCAACAGCAACTGTA	1224
Qy	340	rIlePheIysGlySerHisPheTrrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGAGGAAGATGGTGGGCTGCCGCCCCCAACATTGAGGCTGGCGAGTGTCAATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheIysGlyIleArgCysTrrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGGTGGATGCTGGAGTTTCGGGGCCCCAA	1404
Qy	400	sProValTrrpGlyLeuProGlnLeuCysArgAlaGlyIleGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGCGAGGGGCGCTGCCCGCCATCTCGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGTGCGCCGCTACTAGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrrpProArgSerLeuGlnAspTrrpGl	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTGACGGCGCCCTGCCGAGGCCGATGGCTCCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATACCGCTACTGGCGCCTCGACAGGCCAACTGCAGGCAACCACTCGGGCCG	1704
Qy	500	gTrrpAlaThrGluLeuProTrrpMetGlyCysTrrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGTGCCTGGATGGGTGTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 52			
ADA77300			
ID	ADA77300 standard; cDNA; 1985 BP.		
XX			
AC	ADA77300;		
XX			
DT	20-NOV-2003 (first entry)		

XX	Human PRO polynucleotide #72.	
DE	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;	XX
XX	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;	XX
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;	KW
KW	liver; microvascular endothelial cell; glucose; FFA;	KW
KW	skeletal muscle cell; adipocyte cell; pericyte cell;	KW
KW	inner ear utricular supporting cell; T-lymphocyte cell;	KW
KW	endothelial cell tube formation; bone disorder; cartilage disorder;	KW
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	KW
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;	KW
XX	immune system cell infiltration.	XX
OS	Homo sapiens.	OS
XX	US2003068797-A1.	XX
PN	10-APR-2003.	PN
XX	07-MAY-2002; 2002US-00140921.	XX
PD	31-MAR-1997; 97WO-US005230.	PD
XX	12-JUN-1998; 98WO-US012456.	XX
PR	14-JUL-1998; 98WO-US014552.	PR
PR	28-AUG-1998; 98WO-US017888.	PR
PR	10-SEP-1998; 98WO-US018824.	PR
PR	14-SEP-1998; 98WO-US019094.	PR
PR	14-SEP-1998; 98WO-US019177.	PR
PR	16-SEP-1998; 98WO-US019330.	PR
PR	17-SEP-1998; 98WO-US019437.	PR
PR	07-OCT-1998; 98WO-US021141.	PR
PR	29-OCT-1998; 98WO-US022991.	PR
PR	20-NOV-1998; 98WO-US024855.	PR
PR	01-DEC-1998; 98WO-US025108.	PR
PR	05-JAN-1999; 99WO-US000106.	PR
PR	08-MAR-1999; 99WO-US0005028.	PR
PR	10-MAR-1999; 99WO-US0005190.	PR
PR	20-APR-1999; 99WO-US0008615.	PR
PR	14-MAY-1999; 99WO-US010733.	PR
PR	02-JUN-1999; 99WO-US012252.	PR
PR	01-SEP-1999; 99WO-US020111.	PR
PR	08-SEP-1999; 99WO-US020594.	PR
PR	13-SEP-1999; 99WO-US020944.	PR
PR	15-SEP-1999; 99WO-US021090.	PR
PR	05-OCT-1999; 99WO-US023089.	PR
PR	29-NOV-1999; 99WO-US028214.	PR
PR	30-NOV-1999; 99WO-US028313.	PR
PR	30-NOV-1999; 99WO-US028409.	PR
PR	01-DEC-1999; 99WO-US028301.	PR
PR	01-DEC-1999; 99WO-US028634.	PR
PR	02-DEC-1999; 99WO-US028551.	PR
PR	02-DEC-1999; 99WO-US028564.	PR
PR	16-DEC-1999; 99WO-US030095.	PR
PR	20-DEC-1999; 99WO-US030911.	PR
PR	22-DEC-1999; 99WO-US030999.	PR
PR	30-DEC-1999; 99WO-US030720.	PR
PR	30-DEC-1999; 99WO-US031243.	PR
PR	05-JAN-2000; 2000WO-US000219.	PR
PR	06-JAN-2000; 2000WO-US000277.	PR
PR	06-JAN-2000; 2000WO-US000376.	PR
PR	11-FEB-2000; 2000WO-US003565.	PR
PR	18-FEB-2000; 2000WO-US004341.	PR
PR	18-FEB-2000; 2000WO-US004342.	PR
PR	22-FEB-2000; 2000WO-US004414.	PR
PR	24-FEB-2000; 2000WO-US004914.	PR
PR	24-FEB-2000; 2000WO-US005004.	PR
PR	01-MAR-2000; 2000WO-US005601.	PR

```
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008435.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUL-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-625489/59.
XX P-PSDB; ADA77301.
XX
XX Novel isolated, secreted and transmembrane PRO polypeptides e.g. PRO1801
XX and PRO1114, useful in the preparation of a medicament for treating a
XX condition responsive to PRO polypeptide, and as therapeutic agents e.g.
XX vaccines.
XX
XX Claim 2; Fig 143; 659pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
```

```
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
```

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADA77300 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCGTCGGCCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGCGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCCGAGCCCGGAGCGCGGAGCCAGAGCTGCCAAGAGGCGCGGAGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTCAGCGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATCG	505
Qy	101	AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTACTTGTTCGTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGGAAAGCAAGGTAAACAAATGGTACAAAGCAGACACCTCTCTCCGCTGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACCTGGCTGAGCATCTGCCGAGACCGCGAGTTCGGGGCGCGCTGCGCGCCCTCCAG	685
Qy	160	rCyGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTTGGGAGGCGCCCGACGACAGGCGCGCTGAC	745

```
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CAGGGGGGGCCCTGGGCACGCCCTTC-CTGCCCCCGCGCGGAGCGACTTCGACCA 864
QY 220 nAspGluArgTrrSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTGTGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CAGATCGGTACACGCTGGCCTCACCACACTCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 ofTrrLysArgLeuGlyArgAspAlaLeuLeuSerTrrAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGAGCTGTGGCGTGCA 1044
QY 280 nSerLeuTrrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrrAspSerTrrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTCAGCCCCCAAGGAAGGGCGCCCTGAAGCGCAGGG 1164
QY 320 yProLysTrrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCATGTCATCTGTACAGCGCAACAGCAACTGTGA 1224
QY 340 rIlePheLysGlySerHisPheTrrPgluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTGATT 1344
QY 380 uAsnAspGlyAspPheTrrPhePheLysGlyGlyArgCysTrrArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGTTCCGGGGCCCCAA 1404
QY 400 sProValTrrGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACACAGCTGTGCCGGGCGAGGGGCGCTGCCCGCCATCCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrrTrrVa 440
Db 1465 CGCCCTCTTCTTCTTCTTGGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrrTrrProArgSerLeuGlnAspTrrPgl 460
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
Db 1585 AGGCATCCTTGGAGAGTTCAGCGCGCGCTTCCCGAGGCGCGATGGCTCATCTCTTCTT 1644
QY 480 eArgAspAspArgTrrTrrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGGCTTCGACCGCCCAACTGCAGCGCAACCCCTCGGGCCG 1704
QY 500 gTrrAlaThrGluLeuProTrrMetGlyCysTrrPheAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
```

```
RESULT 53
ADB18040
ID ADB18040 standard; cDNA; 1985 BP.
XX
AC ADB18040;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; macrovascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077710-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127825.
XX
PR 22-OCT-1998; 98US-0105169P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
( GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WI: 2003-755065/71.
P-PSDB; ADB18041.
XX
New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in gene therapy, in chromosome and gene mapping, as chromosome markers,
in tissue typing, and in identifying chromosomes.
XX
Claim 2; Fig 143; 637pp; English.
XX
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
```

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2752.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB18040 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTGGCGCGGTGGCCCTCTGTCGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgGlyGluAlaGluAlaPheLeu 40
 DB 266 GAGCGCCAGCGCGGAGCGCGGAGCGGAGGAGCTGCGCAAGGCGGCGGAGGCAATTCCTA 325
 QY 41 GluLeuTrpGlyLeuLeuGlnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACCTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
 DB 386 GATGCCATCAGACGTTTCAGTGGGTGTCAGTACCTGTCAGCGGGGTGTGGACGCG 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTCGCGGTGTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGGATCAGTACCTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTGCAGACGAGTAAACAAATGGTACAGCAGCAGCTCTCTACCGCTGTGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 NAATGGCTTGCATCTGCGGAGCGGCGAGTTCGGGCGCGCGTTCGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCGGGAGGCGCCACAGCGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCNAGGGGACCAACAGATGGGTGGGCAATGCCCTTGTATGGC 805
 QY 200 gGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGCGCGCTGCGGACGCGCTTC-CTGCCCCGCGCGGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGGCGCAACCTGTTTCGTGGTGTGGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTTCCCTCCTCAGCTCGCGCGCGCGCTCATGGCGGC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 DB 985 CTACTACAAAGAGCTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
 QY 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGAAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACTTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGNAACGACGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
 DB 1165 CCTAAATACTGCCACTCTCTCTCGATGCCATCATCTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 DB 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGGCAAGTGTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTGCATGTGGAGGTTCGGGGGCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
 DB 1465 CGCCTCTCTTCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGGAGGTGAGCGCGCTCTGCCAGGGCCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGCCCAAACTGCAGGCAACCACTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGTGGCATGCCAACTCGGAGGAGCGCCCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765
 RESULT 54
 ID ADA86723 standard; cDNA; 1985 BP.
 XX ADA86723;
 AC ADA86723;
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX Homo sapiens.
 XX US2003082709-A1.
 XX 01-MAY-2003.
 XX 15-MAY-2002; 2002US-00146791.
 XX 17-AUG-1998; 98US-0096895P.
 XX 02-JUN-1999; 99WO-US012252.
 XX 25-AUG-1999; 99US-00380137.
 XX 30-MAR-2000; 2000WO-US008439.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-786912/74.
 XX P-PSDB; ADA86724.
 XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
 PT for preparing a composition for treating e.g., tumor, or for tissue
 PT typing.
 XX Claim 2; Fig 143; 637pp; English.
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMC cells, for inhibiting the binding of
 CC A-peptide to factor VITA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2

DB:	9	Gaps:	0
US-10-791-980-6 (1-520) x ADA86723 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGCTCGGCTCTCTGCGCGCTCTGCTACTGTGGGCGACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu	40
Db	266	GAGCGCCAGCCCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGG	325
Qy	41	GluIysTyrGlyTyrLeuAenGluGlnValProIysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGTGTCCAGCTACCTGTACGCGCGGTGTTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGTTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLysSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAACMAATGTTACAAAGCAGCACCTCTCTTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTGAGCATCTGCGGAGCGCGGAGTTGCGGGCGCGGCGCGCGCTTCCAG	685
Qy	160	rCysGlyValThr-SerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCGACGACGAGCGCGTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACTTCTTCCAAAGGGGACCAACAGTGGGCTGGGCAATGCTTTGATGGC	805
Qy	200	aGlnGlyValAProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGGCGCAGCGCTTC-CTGCCCCCGCGCGGAGCGGACGACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGACGCTGGTCTCTGAGCGCGCGCGCGCGCAACCTGTTCTGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTTCCACCTCCCGCGCGCGCGCGCTCATGGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGluValArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAGAGGCTGGGCGCGCGCGCGCTGTCTGCTGGGACGACGCTGTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCGAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAGGCGCGCTTGAACGCGAGG	1164
Qy	320	yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy	340
Db	1165	CCCTAAATACGACCACTCTTCTTCGATGCCATCCTGCTAGACAGGCAACAGCACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360

Db	506	GCCTGGGCTGAGGATCAGTACTTGTTCCTAGACACCGGACCAAAATGAGCGCTAAG	565	Db	1585	AGGCATCCTCAGGAGGTCAGGGCGCCCTCCGAGGGCCCGATCCATCATCTTCTT	1644
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140	Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCCTACCGCCTGGTG	625	Db	1645	CCGAGATGACCGCTACTGGCGCTCGACCGCCAACTGCAGGCCAACCCACTCGGGCCG	1704
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe	160	Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaLeuSerGlySerAlaLeuPh	520
Db	626	AACTGGGCTGAGCATCTCCCGAGCGCGGAGTTTCGGGGCGCCGTGCGCGCGCTTCCAG	685	Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180	Qy	520 e	520	
Db	686	TTGTGGAGCAAGCTCTCAGCGTGGAGTTCTGGGAGGCCCCAGCACAGGCCCGCTGAC	745	Db	1765 C	1765	
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal	200	Db	1765 C	1765	
Db	746	ATCCGGCTCACCTCTTCCAAAGGGGACCCACAAACGATGGGCTGGGCAATGCCCTTTGATGGC	805	Db	1765 C	1765	
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220	Db	1765 C	1765	
Db	806	CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGAGCGCACCTTCGACCA	864	Db	1765 C	1765	
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgHisnLeuPheValValLeuAlaHi	240	Db	1765 C	1765	
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACTGTTCGTGGTGTCTGGCGCA	924	Db	1765 C	1765	
Qy	240	sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalaPr	260	Db	1765 C	1765	
Db	925	CCAGATCGGTACAGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC	984	Db	1765 C	1765	
Qy	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280	Db	1765 C	1765	
Db	985	CTACTACAAGAGCTGGGCGCGAGCGCTGCTCAGCTGGGACGACGTCTGGCGGTGCA	1044	Db	1765 C	1765	
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300	Db	1765 C	1765	
Db	1045	GAGCCTGTATGGAGACCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGNAAGCTGT	1104	Db	1765 C	1765	
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320	Db	1765 C	1765	
Db	1105	CACCTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAGCGCCCTGAAACGACGG	1164	Db	1765 C	1765	
Qy	320	yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy	340	Db	1765 C	1765	
Db	1165	CCCTAAATATCGCACTCTTCTTCGATGCCATCCTGTAGACAGCAACAGCAACTGTA	1224	Db	1765 C	1765	
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360	Db	1765 C	1765	
Db	1225	CATTTTAAAGGAGCCATTTCTGGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG	1284	Db	1765 C	1765	
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle	380	Db	1765 C	1765	
Db	1285	TCCACTGCAGAAAGATGGTTCGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAIT	1344	Db	1765 C	1765	
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly	400	Db	1765 C	1765	
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA	1404	Db	1765 C	1765	
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl	420	Db	1765 C	1765	
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTCCCGGAGGGGGCTGCCCGCCATCTCTGACGC	1464	Db	1765 C	1765	
Qy	420	aAlaLeuPhePheProPheLeuArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa	440	Db	1765 C	1765	
Db	1465	CGCCCTCTTCTCCCTCTCTGGCGCCCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524	Db	1765 C	1765	
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl	460	Db	1765 C	1765	
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGCTGCGAGACTGGGG	1584	Db	1765 C	1765	
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480	Db	1765 C	1765	

PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00892636.
PR 19-JUN-2001; 2001US-00896342.
PR 20-JUN-2001; 2001US-00919692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX WPI: 2003-521853/49.
DR P-PSDB; ADA46215.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor.
XX
PS Claim 2; Fig 143; 200pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in paricycle
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear intracellular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from BMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA46214 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db ATGTCGCGCGCTCGCGCTCTCTGTCGCGCCCTGACAGTGTCTACTGTGGGCGACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db GACGCCAGCCCGCGGAGCGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGG 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db GAGAAGTACGAGTACCTCAATGAACAGGTCTCCCAAGCTCCACCTCCACCTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGGTACTGTGTCAGCGCGGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db GCCACCTCGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgLleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db GCCTGGGCTGAGAGGATCAGTACTTGTCTGTAGACACCGGACCGGACCAAAATGAGCGTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAGCAGCACTCTCTACTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCGGAGCGCGCAGTTCTGGGGCGCGTGGCGCCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCTGGAGAGCCCGACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCACCAACGATGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCCTGGCGCACGCTTC-CTGCCCGCGCGCGAAGGCACATTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCTGAGCGCGCGCGGGCGCAACCTGTTGCTGTGCTGGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGCGCTCACCACTCGCCCGCGCGCGCGCTCATGGGGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGCGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGCGCCCAAGAAAGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaileThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTTCGATGCTCCTCAGTGGGACGCAACGCACTGA 1224
QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnileGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAGATGGTGGGCTGCCGCCCAACATTGAGCTGGGCGAGTGTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTCGATGCTGGAGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGAGGAGGGGCGCTGCCCGCCATCTCGACG 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuileLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
Db 1585 AGGCATCCTCAGGAGGTGAGCGGCGCCTCCGAGGGCCGATGGCTCCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACCGGCAAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTtpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCCAGCTGCTCCCTGGATGGGCTGTCGATGCCAATCGGGAGCGCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 57
ADB28244
ID ADB28244 standard; cDNA; 1985 BP.
XX
AC ADB28244;
XX
DT 20-NOV-2003 (first entry)
XX
DB cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
FN US2003082699-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127851.
XX
PR 17-JUN-1998; 98US-0089599P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2003-777202/73.
DR P-PSDB; ADB28245.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence encodes a human PRO polypeptide of the invention. Note: The
 CC sequence data for this patent is also available in electronic format from
 CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Align. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: Gaps: 0

US-10-791-980-6 (1-520) x ADB28244 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGGCGCGTCTCGCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgGlyGlnAlaGluAlaPheLeu 40
 DB 266 GACGCCACGCCCGCGAGCGCGAGGCCAGGAGCTGCGCAAGAGCGGAGGCATTCCTTA 325
 QY 41 GluLysTyrGlyTyrLeuLeuGlnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACCTGTGAGCGGCGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTCGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
 DB 506 GCTTGGGCTGAGAGGATCAGTACTTGTGTGTAGACACCGGACCAAAATGAGGGGTAAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAACTAATGGTACACCGGACCAAAATGAGGGGTAAAG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCCCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProleuTh 180
 DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGAGGAGGAGGAGGAGGAGGAGGAG 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200

DB 746 ATCCGGCTCACCTTCTTCAAGGGGACACACAGGATGGCTGGCAATGCCCTTGTATGC 805
 QY 200 aGlnGlyAlaProTrpArgTrpPheLeuProArgArgGlyGluAlaHisPheAspG 220
 DB 806 CCAGGGGGCGCGCTCGCGCACGCCCTTC-CTGCCCCGCGCGCGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGGGGCGCAACCTTGTCTGGTGTCTGGCGCA 924
 QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCTCATGCGCGC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
 DB 985 CTACTACAGAGGCTGGGCGCGCGCTGCTCAGTGGGACGAGCTGCTGGCCGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCCGTCCAGCTCCGAGGAAAGTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
 DB 1105 CACTGACTTTGAGACTCTGGGACTCTACAGCCCCCAAGGAAGCGCGCTGAAACGCGAG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCCTAAATACTGCGCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACACGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCAAGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTGCAGGAAGATGGGTGCGGCTGCCCGCCCAACATTGAGGTGCGCGAGTGCAATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysCysTrpArgPheArgGlyLysProly 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
 QY 400 pProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCGCTGCCCGCCATCTCTGACCG 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGI 460
 DB 1525 GCTGCGCGGAGGGGACTGCAAGTGGAGCCCTTACACCCCGAAGTCTCAGAGCTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGGAGGTACGCGGCGCTTCCCGAGGCGCGATGGCTCCATCTCTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAACTGCAGGCAACACCCCTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765

RESULT 58
 ADB28796


```
Db      985 CTACTACAAGAGCGCTGGGCGCGAGCGCGTGTCTCAGCTGGGACGACGTCGTCTGCCCGCTGCA 1044
Qy      280 nSerLeuTyRgLyLeuProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045 GAGCGTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGGTCCAGCTCCACAGGAAGCTGTT 1104
Qy      300 eThrAspPheGluThrTrpAspSerTyRserProGlnGlyArgArgProGluThrGlnG 320
Db      1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCGCCCAAGGAGGCGCCCTGAACGCGAGG 1164
Qy      320 yProLysTyRcYeHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165 CCTTAATACTGCCACTCTTCCTTCGATGCCATFCACTGTAGACAGCAACACCAACTGTA 1224
Qy      340 rIlePheLysGlySerHisPheTrpGluValAlaAspGlyAsnValSerGluProAr 360
Db      1225 CATTTTAANGGAGGCATTTCTGGAGGTGGCAGCTGATGCAAGCTCTCAGAGCCCG 1284
Qy      360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db      1285 TCCTACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAIT 1344
Qy      380 uAsnAspGlyAspPheTyRPhelYsGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy      400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405 GCCAGTGTGGGTCTCCACACTGTGCCGGCAGGGGCCCTGCCCGGCATCTCTGAGCG 1464
Qy      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyRTrVa 440
Db      1465 CGCCCTCTTCTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy      440 lleuAlaArgGlyGlyLeuGlnValGluProTyRTrpProArgSerLeuGlnAspTrpGl 460
Db      1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCTTACTACCCCGAAGCTTGCAGGACTGGGG 1584
Qy      460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585 AGGCATCTCTGAGAGGTGAGCGGGCCCTGCCGAGGCCGATGGCTCATCATCTTCT 1644
Qy      480 eArgAspAspArgTyRTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGCAGGCAACCACTCGGGCG 1704
Qy      500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705 CTGGGCCACCGAGTGCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy      520 e 520
Db      1765 C 1765

RESULT S9
ADA76748
ID ADA76748 standard; cDNA; 1985 BP.
XX
AC ADA76748;
XX
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
```

immune system cell infiltration.

Homo sapiens.

US2003059909-A1.

27-MAR-2003.

10-MAY-2002; 2002US-00143032.

31-MAR-1997; 97WO-US005230.

12-JUN-1998; 98WO-US012456.

14-JUL-1998; 98WO-US014552.

28-AUG-1998; 98WO-US017888.

10-SEP-1998; 98WO-US018824.

14-SEP-1998; 98WO-US019093.

14-SEP-1998; 98WO-US019094.

14-SEP-1998; 98WO-US019177.

16-SEP-1998; 98WO-US019330.

17-SEP-1998; 98WO-US019437.

07-OCT-1998; 98WO-US021141.

29-OCT-1998; 98WO-US022991.

29-OCT-1998; 98WO-US022992.

20-NOV-1998; 98WO-US024855.

01-DEC-1998; 98WO-US025108.

05-JAN-1999; 99WO-US000106.

08-MAR-1999; 99WO-US005028.

10-MAR-1999; 99WO-US005190.

20-APR-1999; 99WO-US008615.

14-MAY-1999; 99WO-US010733.

02-JUN-1999; 99WO-US012252.

01-SEP-1999; 99WO-US020111.

08-SEP-1999; 99WO-US020594.

13-SEP-1999; 99WO-US020944.

15-SEP-1999; 99WO-US021090.

15-SEP-1999; 99WO-US021547.

05-OCT-1999; 99WO-US023089.

29-NOV-1999; 99WO-US028214.

30-NOV-1999; 99WO-US028313.

30-NOV-1999; 99WO-US028409.

01-DEC-1999; 99WO-US028301.

02-DEC-1999; 99WO-US028551.

02-DEC-1999; 99WO-US028564.

16-DEC-1999; 99WO-US030095.

20-DEC-1999; 99WO-US030911.

20-DEC-1999; 99WO-US030999.

22-DEC-1999; 99WO-US030720.

30-DEC-1999; 99WO-US031243.

30-DEC-1999; 99WO-US031274.

05-JAN-2000; 2000WO-US000219.

06-JAN-2000; 2000WO-US000277.

06-JAN-2000; 2000WO-US000376.

11-FEB-2000; 2000WO-US003565.

18-FEB-2000; 2000WO-US004341.

18-FEB-2000; 2000WO-US004342.

22-FEB-2000; 2000WO-US004414.

24-FEB-2000; 2000WO-US004914.

01-MAR-2000; 2000WO-US005004.

02-MAR-2000; 2000WO-US005601.

02-MAR-2000; 2000WO-US005746.

02-MAR-2000; 2000WO-US005841.

10-MAR-2000; 2000WO-US006319.

15-MAR-2000; 2000WO-US006884.

20-MAR-2000; 2000WO-US007377.

21-MAR-2000; 2000WO-US007532.

30-MAR-2000; 2000WO-US008439.

17-MAY-2000; 2000WO-US013705.

22-MAY-2000; 2000WO-US014042.

30-MAY-2000; 2000WO-US014941.

02-JUN-2000; 2000WO-US015264.

28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908927.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2003-540684/51.
DR P-FSDB; ADA76749.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 2; Fig 143; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: Gaps: 0

US-10-791-980-6 (1-520) x ADA76748 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCCCTCTCTCGCGCGCTGCTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGGAGCGCGGAGCGGAGCTGCGAAGGAGGCGGAGGCAATTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCGATTCCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTCTCCAGCTACCTGTACGCGCGCTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTGTGCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTCAGAGGATCAGTGACTTGTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAAACGCTTTTCAAGCAAGGTAACAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGlnHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGGAGTTGCGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTCTTCTTCAAGGGGACCAACAGATGGGTGGGCAATGCTTTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGGCCCTTGGCGCACGCTTC-CTGCCCGCGCGGCGGAGGAGGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCCCTGAGCGCGCGCGGCGCAACCTGTTCGTGCTGCTGGCGCA 924

Qy 240 sGluileGlyHisThrLeuGlyLeuThHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTGGCTCACCACCTGCCCGCCGCGGGCTCATCGGCC 984
Qy 260 oTyrTyrlsArGLeuGlyArGAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGACGCGCTGCTCAGCTGGGACGACGTCTGGCGGTGA 1044
Qy 280 nSerLeuTyrlsGlyProLeuGlyGlySerValalaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCGCTCCAGTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrlsSerProGlnGlyArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCAAGGAGCGCCCTGAACCGCAGGG 1164
Qy 320 yProLysTyrlsCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValalaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGACGAAAGATGGTGGCTGCCGCCCAACATTGAGGTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrlsPhePheGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGGGGCAGGGGGCTGCCCGCCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrlsVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lleualaArgGlyGlyLeuGlnValGluProTyrlsTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCGCTTACCCCGAGCTGTGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCGCTGCGAGGCGCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrlsTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCCTACTGCGCTCGACAGGCCAACTGACAGGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCCAACGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 60

ADA88378

ID ADA88378 standard; cDNA; 1985 BP.

XX AC

ADA88378;

XX DT 20-NOV-2003 (first entry)

XX DE

DE Novel human secreted and transmembrane protein PRO4339 cDNA.

XX KW

KW Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; PFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX OS
XX US2003073213-A1.
XX PD 17-APR-2003.
XX PF 17-APR-2002; 2002US-00124819.
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021347.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004514.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.

QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaBr 260
Db CGAGATCGGTCAACACGCTTGGCTCACCCACCTCGCCGCGCGCGCTCATGCGGC 984
QY 260 oTyrTyrLysArgLeuGlyLysArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db CTACTACAGAGCGTGGCGCGCGAGCGCTGCTCAGCTGGGACGAGCTGCGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db GAGCCTGTATGGAGGCCCTTAGGGGCTCAGTGGCCGTCCAGCTCCCGAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db CACTGACTTTGAGACCTGGACTCTCTACAGCCCCCAAGGAGCGCCCTGNAACGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
Db CTTTAAAGGAGGACCTTCTGGAGGTGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db CATTTTAAAGGAGGACCTTCTGGAGGTGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db TCCACTGCAGGAAGATGGCTGGGCTGCCCCCAACATTGAGGTGCGGCGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db GAATATGAGATTTCTACTTCTTCAAGGGGTGCTGATGCTGGAGGTTCGCGGGCCCCAA 1404
QY 400 aProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db GCCAGTGGGGTCTCCACAGCTGTCCGGGAGGGGCTGCCCCGCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGTGCGCGCTACTAGT 1524
QY 440 lIleAlaArgGlyLysLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db GTGCGCGAGGGGACTGCAAGTGGAGCGCTTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyLeuProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
Db AGGCATCCCTGAGGAGGTGAGCGCGCTGCGGAGGGCCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db CCGAGATGACCGCTACTGCGGCTCGACCGGCCAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db CTGGGCCACCGAGCTGCGCTGATGGGTGCTGGATGCCAATCGGAGCGGCGCTGTT 1764
QY 520 e 520
Db 1765 c 1765

RESULT 61

ID ADA97383

AC ADA97383;

XX ADA97383;

XX 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #72.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FPA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003082686-A1.

XX 01-MAY-2003.

XX 19-APR-2002; 2002US-00125926.

XX 05-JUN-2000; 2000US-0209832P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755106/71.

XX P-FSDB; ADA97384.

Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or PRO4978, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 143; 666pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting the proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FPA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089593P.
PR 17-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096771P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.

```
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-JAN-1999; 99US-0115549P.
PR 12-JAN-1999; 99US-0115557P.
PR 12-JAN-1999; 99US-0115560P.
PR 12-JAN-1999; 99US-0115562P.
PR 12-JAN-1999; 99US-0115564P.
PR 12-JAN-1999; 99US-0115630P.
PR 12-JAN-1999; 99US-0115705P.
PR 12-JAN-1999; 99US-0115733P.

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB27140 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrrpGlyHisLeu 20
DB 206 ATGGTCGCGCGCTGGCGCTCTCTGCGCGCGCTGCGAGCTGCTACTGTGGGGCCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACGCGCGGACGCGGAGCTGCGCAGAGCTGCGCAGGAGCGGAGGCATTCTTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCGATTTCAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGACGCGCGTGTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGCACAGATCACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505

QY 101 AlaTrrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACTGTTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrrpTrrpLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCACCGCTGGTG 625

QY 141 AsnTrrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTGGCGCGCTCCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCCTCAGCGCTGAGTTCCTGGGAGGCCCGGAGCCACAGGCGCGCTGAC 745
```

```
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCCTTCCAAGGGGACCAACATGGCTGGCAATGCTTCCTTGATGGC 805

QY 200 aGlnGlyAlaProTrrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCTGGGGCGACGCCCTTC-CTGCCCCCGCGCGGCGAAGGCGACATTCGACCA 864

QY 220 nAspGluArgTrrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGCTGCTGAGCGCGCGCGCGCAACCTGTTCTGCTGCTGCTGGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCACTGGCGGCC 984

QY 260 oTrrpTrrpLysArgLeuGlyArgAspAlaLeuLeuSerTrrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044

QY 280 nSerLeuTrrpGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGTCCAGAAAAGCTGTT 1104

QY 300 eThrAspPheGluThrTrrpAspSerTrrpSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCTCGAAACGCGAGG 1164

QY 320 YProLysTrrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrrp 340
DB 1165 CCTAATACTGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284

QY 360 gProLeuGlnGluArgTrrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTCAGAAAGATGGGTGGGGCTGGCCCCCAACATTAGGCTCGGCAGTGTCTATT 1344

QY 380 uAsnAspGlyAspPheTrrpPhePheLysGlyGlyArgCysTrrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA 1404

QY 400 sProValTrrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGCGAGGGGGCTGCCCGGCCATCTGACGC 1464

QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrrpTrrVa 440
DB 1465 CGCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGGTGCGCGCTACTAGT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrrpTrrpProArgSerLeuGlnAspTrrpG1 460
DB 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584

QY 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGAGGTGAGCGCGCCCTGCGGAGGCCGATGGCTCCATCATCTCTT 1644

QY 480 eArgAspAspArgTrrpTrrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGNATGACCGCTACTGGGGCTCTCGACGAGGCCAANAACATGCAGGCAACCACTCGGGCG 1704

QY 500 gTrrpAlaThrGluLeuProTrrpMetGlyCysTrrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGTCCAACTCGGGGAGCGGCCCTGTT 1764

QY 520 e 520
DB 1765 C 1765
```

RESULT 63
ADB22073
ID ADB22073 standard; cDNA; 1985 BP.
XX AC ADB22073;
XX DT 20-NOV-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW Cell proliferation stimulator; cell differentiation stimulator;
KW Cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX PN US2003087344-A1.
XX PD 08-MAY-2003.
XX PF 16-APR-2002; 2002US-00123905.
XX PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 12-MAY-1998; 98US-0084637P.
PR 13-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98US-0088858P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98US-0091455P.
PR 30-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98US-0099824P.
PR 14-SEP-1998; 98US-0100262P.

PR	14-SEP-1998;	98US-0100263P.	PR	Db	266	GACGCCAGCCCGGAGCGGAGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCTCTA	325
PR	14-SEP-1998;	98WO-US019033.	PR	Qy	41	GlulysTyrGlyTyrLeuAenGluInValProLysAlaProThrSerThrArgPheSer	60
PR	14-SEP-1998;	98WO-US019094.	PR	Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTTCAGC	385
PR	15-SEP-1998;	98US-0100390P.	PR	Qy	61	AspAlaIleArgAlaPheGlnTrrpValSerGlnLeuProValSerGlyValLeuAenArg	80
PR	16-SEP-1998;	98US-0100634P.	PR	Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGGTACTCTGTACGCGCGTGTGGACCGC	445
PR	16-SEP-1998;	98WO-US019330.	PR	Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
PR	17-SEP-1998;	98US-0100710P.	PR	Db	446	GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
PR	17-SEP-1998;	98US-0100858P.	PR	Qy	101	AlaTrrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys	120
PR	17-SEP-1998;	98WO-US019437.	PR	Db	506	GCCTGGGCTGAGAGGATCAGTACTTGTTCGTAGACACCGGACCAAAATGAGCGTAAG	565
PR	23-SEP-1998;	98US-0101474P.	PR	Qy	121	LysArgPheAlaLysGlnGlyAenLysTrrpTrrpLysGlnHisLeuSerTyrArgLeuVal	140
PR	23-SEP-1998;	98US-0101477P.	PR	Db	566	AAACGCTTTGAAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCCGCTGGTG	625
PR	24-SEP-1998;	98US-0101741P.	PR	Qy	141	AsnTrrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
PR	07-OCT-1998;	98US-0103315P.	PR	Db	626	AACTGGCTGAGCATCTGCCGAGCGGAGTTTCGGGCGCGCTGCGCGCGCTTCCAG	685
PR	07-OCT-1998;	98WO-US03288P.	PR	Qy	160	rCysGlyAlaThrSerGlnArgTrrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
PR	13-OCT-1998;	98WO-US021141.	PR	Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTTGGGAGGCCCCAGCACAGGCCCGCTGAC	745
PR	20-OCT-1998;	98US-0104080P.	PR	Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrrpAlaMetProLeuMetAl	200
PR	22-OCT-1998;	98US-0104987P.	PR	Db	746	ATCCGGCTCACCTTCTTCCAAAGGGGACCACACATGGCTGGGCAATGCTTTGTATGGC	805
PR	28-OCT-1998;	98US-0105169P.	PR	Qy	200	aGlnGlyAlaProTrrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
PR	29-OCT-1998;	98WO-US022931.	PR	Db	806	CCAGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA	864
PR	30-OCT-1998;	98US-0106464P.	PR	Qy	220	nAspGluArgTrrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
PR	03-NOV-1998;	98US-0106856P.	PR	Db	865	AGATGAGCGTGGTCCCTGAGCCGCGCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA	924
PR	03-NOV-1998;	98US-0106934P.	PR	Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
PR	10-NOV-1998;	98US-0107783P.	PR	Db	925	CGAGATCGGTACACGCTTGGCTCACCTCCACTCGCCCGCGCGCGCGCTCATGGGGCC	984
PR	17-NOV-1998;	98US-0108775P.	PR	Qy	260	oTyrTrrpLysArgLeuGlyArgAspAlaLeuLeuSerTrrpAspAspValLeuAlaValGl	280
PR	17-NOV-1998;	98US-0108801P.	PR	Db	985	CTACTACAGAGGCTGGGCGCGACGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA	1044
PR	17-NOV-1998;	98US-0108802P.	PR	Qy	280	nSerLeuTyrGlyLysPProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
PR	17-NOV-1998;	98US-0108925P.	PR	Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT	1104
PR	20-NOV-1998;	98WO-US024855.	PR	Qy	300	eThrAspPheGluThrTrrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
PR	01-DEC-1998;	98WO-US025108.	PR	Db	1105	CATGACTTTGAGACCTGGGACTCTCTACACGCCCCCAAGGAGGCGCCCTGNAACGCGAGG	1164
PR	15-DEC-1998;	98US-0112743P.	PR	Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
PR	16-DEC-1998;	98US-0112850P.	PR	Db	1165	CCCTAAATACTGCGCACCTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA	1224
PR	22-DEC-1998;	98US-0113296P.	PR	Qy	340	rIlePheLysGlySerHisPheThrPLeuValAlaAlaAspGlyAsnValSerGluProAr	360
PR	22-DEC-1998;	98US-0113310P.	PR	Db	1225	CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGGAGCTGTATGGCAACGCTCTCAGAGCCCCG	1284
PR	22-DEC-1998;	98US-0113300P.	PR	Qy	360	gProLeuGlnGluArgTrrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
PR	22-DEC-1998;	98US-0113314P.	PR	Db	1285	TCCACTGCAGAAAGATGGGTTCGGGCTGCCCGCCCAACATATTGAGGCTCGGCGAGTGCATT	1344
PR	22-DEC-1998;	98US-0113315P.	PR	Qy	380	uAsnAspGlyAspPheTrrpPhePheLysGlyArgCysTrrpArgPheArgGlyProLy	400
PR	22-DEC-1998;	98US-0113510P.	PR	Db	1345	GAATGATGGAGATTTTCTACTTCTTCAAAGGGGGTTCGATGTGGAGGTTCCGGGGCCCCAA	1404

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADB22073 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGGTTCGGCTCTCTGTCGCGCCCTTCGAGCTGTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40


```
QY 400 sProValTrpGlyLeuProGlnLeuCyseArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCGCTGCCCCGCATCTCGACGC 1464
QY 420 alaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCAGGGGAGCTCAAGTGGAGCGCTACTACCCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGGCTCCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACCGAGCCAACTGCAGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 64
ADA66764
ID ADA66764 standard; cDNA; 1985 BP.
XX ADA66764;
AC ADA66764;
XX
XX
XX 20-NOV-2003 (first entry)
XX Human PRO polynucleotide #72.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US2003068793-A1.
XX
XX 10-APR-2003.
XX
XX 15-APR-2002; 2002US-00123108.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005601.
PR 01-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
```



```

Db      1285  TCCACTGCGAGGAAGATGGTTCGGGCTGCCCCCAACATTGAGCTCGCGCATTCATT 1344
Qy      380  uAanAspGlyAspPheTyrPhePheLysGlyArgCysTyrTrpAtqPheArgGlyProly 400
Db      1345  GAATGATGAGATTCTTACTCTTCAAGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCGCTGCCCGGCATCTCGACGC 1464
Qy      420  alalaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db      1465  CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGCCTACTACGT 1524
Qy      440  lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db      1525  GCTGGCCCCGAGGGGAGTCAAGTGGAGCCCTACTACCCCGAAGTCTCGAGACTGGGG 1584
Qy      460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCCCTGAGGAGTTCAGCGGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy      480  eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTCGCGCTCGACCGAGCCAACTGCAGGCCAACCCACCTCGGGCG 1704
Qy      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAanSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 65
ADB22625
ID      ADB22625 standard; cDNA; 1985 BP.
XX
AC      ADB22625;
XX
DT      20-NOV-2003 (first entry)
XX
DE      Human PRO polynucleotide #72.
XX
KW      Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW      tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW      cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW      liver; microvascular endothelial cell; glucose; FFA;
KW      skeletal muscle cell; adipocyte cell; pericyte cell;
KW      inner ear utricular supporting cell; T-lymphocyte cell;
KW      endothelial cell tube formation; bone disorder; cartilage disorder;
KW      sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW      rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW      immune system cell infiltration.
XX
OS      Homo sapiens.
XX
PN      US2003077711-A1.
XX
PD      24-APR-2003.
XX
PF      22-APR-2002; 2002US-00127829.
XX
PR      22-OCT-1998; 98US-0105169P.
PR      01-SEP-1999; 99WO-US020111.
PR      18-OCT-1999; 99US-00403297.
PR      30-NOV-1999; 99WO-US028313.
PR      18-FEB-2000; 2000WO-US004342.
PR      01-DEC-2000; 2000WO-US032678.
PR      19-DEC-2001; 2001US-00028072.
XX
PA      (GETH ) GENENTECH INC.

```

```

XX
PI      Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI      Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI      Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX      WPI; 2003-755066/71.
DR      P-PSDB; ADB22626.
XX
XX      New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT      in gene therapy, as diagnostic markers for the presence of a disease,
PT      condition, or as therapeutic targets for treating tumors, diabetes,
PT      obesity or arthritis.
XX
XX      Claim 2; Fig 143; 637pp; English.
XX
XX      The invention relates to isolated human PRO polypeptides (secreted and
CC      transmembrane polypeptides) and the polynucleotides encoding them. The
CC      invention also relates to an antibody which specifically binds to a PRO
CC      polypeptide, a method for stimulating the release of tumour necrosis
CC      factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC      proliferation or differentiation of chondrocyte cells and a method for
CC      detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC      colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC      polynucleotides are useful in molecular biology, including uses as
CC      hybridisation probes, in chromosome and gene mapping, in generating
CC      antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC      be used in preparing PRO polypeptides by recombinant techniques and in
CC      generating either transgenic animals or knock-out animals which are
CC      useful in the development and screening of therapeutically useful
CC      reagents. The PRO polypeptides or antibodies are used in preparing a
CC      medicament for treating a condition responsive to the polypeptides or
CC      antibodies, such as tumours, for stimulating and inhibiting proliferation
CC      of human microvascular endothelial cells, for modulating the uptake of
CC      glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC      stimulating differentiation of adipocyte cells, for stimulating
CC      proliferation of or gene expression in pericyte cells, for stimulating
CC      the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC      cells, for inducing endothelial cell tube formation and for treating
CC      various bone and/or cartilage disorders such as sports injuries and
CC      arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC      from cartilage are useful for treating sports-related joint problems,
CC      articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC      polypeptides are also useful for treating various mammalian haemoglobin-
CC      associated disorders such as various thalassaemias and conditions which
CC      may benefit from enhanced local immune system cell infiltration. This
CC      sequence represents a human PRO polynucleotide of the invention. Note:
CC      The sequence data for this patent is also available in electronic format
CC      from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ      Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

```

```

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB22625 (1-1985)
Qy      1  MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db      206  ATGTCGCGCGGTTCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
Qy      21  AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GACGCCACAGCCCGGAGCGCGAGCCGAGAGCTGCCAAGAGGCGGAGGAGCATTCCTA 325
Qy      41  GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326  GAGAAGTACGATACCTCAATGAACAGGTCCCAAGTCCACCTCCACTCGATTACG 385

```

QY 61 AspaIaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTACGCGCGTGTGGACGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGACGACCTCTCCCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGTGGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTACAGCGCTGAGTTCCTGGAGGCGCCAGGCACAGGCGCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGAGCACCAACATGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGCCTGGCGCACGCTTC-CTGCCCGCGCGCGAGCGCACCTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTGCTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACAGCGTGTGGCTTCCACCTCTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGCGCGCGCGCTCTCAGCTGGGACGACGCTGGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTTAGCGCCCAAGGAAGGCGCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACCTGCACCTCTCTTCGTGATGCCATCCTGTAGACAGGCAACGCACTGA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGCCATTTCTGGGAGTGGGAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGCTGGGAGTGTCAATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTCTTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGCGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCGCGCCATCTCTGACG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440

DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGTGGCCCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
DB 1585 AGGCATCCCTGAGAGGTGAGCGGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGCCAACTGCAGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTCGCATGCCAACTCGGGGAGCGCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 66
ADB23398
ID ADB23398 standard; cDNA; 1985 BP.
XX AC ADB23398;
XX XX 20-NOV-2003 (first entry)
XX DE Human PRO polynucleotide SEQ ID NO 143.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX XX US2003077712-A1.
XX XX 24-APR-2003.
XX PF 22-APR-2002; 2002US-00127835.
XX XX 20-OCT-1998; 98US-0104987P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755067/71.
DR P-PSDB; ADB23399.
XX New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT breast, prostate, rectal, cervical and/or liver tumors.
XX Claim 2; Fig 143; 637pp; English.
PS

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor- α (TNF- α) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	9	Gaps:	0

US-10-791-980-6 (1-520) x ADB23398 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGGCGCGCTCGCTCTGTCGGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCGCGAGCGGAGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCTCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluClnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCCGCTACTGTGTCAGCGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140

Db	566	AAACGCTTTTGCACAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSerSe	160
Db	626	AACTGGGCTTGAGCATCTGCCGAGACCGGACGTTCGGGGCGCGCTGCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTspSerSerGlyVArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCCTCAGCGCTGAGTTCCTGGAGAGGCCCCAGGCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSertysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAGGGGACCAACACGATGGCTGGGCAATGCTTTCATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGCGCGCTTGGCGACGCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyVArgAenLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGTCTCCCTGAGCCCGCGCGGCGCAACTGTTCTGTGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrIlybArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGCGCGCGCGCTCTCAGCTGGGACGACGTCTGGCGCTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACCTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGGCCCTCTGAAACG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTTAAATACTGCGCACTCTCTCTTCGATGCCATCACTGTGTAGACAGGCAACAGCA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr	360
Db	1225	CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGGTGCGGCTGCCGCCCAACATTCAGGCTGCGGCGAGTGTCA	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGCGGGCCCA	1404
Qy	400	sProValTrpGlyLeuProGlnCysArgAlaGlyVgLyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACACAGCTGTCGCGGCGAGGGGCGCTGCCGCCCATCTCTAG	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCGCTCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCGCGAGGGGACTGCAAGTGGAGCGCTACTCCCGCGAAAGTCTGCGAGGACTGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh	480
Db	1585	AGGCATCCCTGAGGAGGTGAGCGCGCTGCCGAGGCCCGATGCTCCATCATCTCTTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGGCGCTCGACCGCCCAACTGCGAGGCAACACCTCGGGCGG	1704

QY 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAnsSerGlySerAlaLeuPh 520
 Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 67
 ADA92120
 ID ADA92120 standard; cDNA; 1985 BP.
 XX
 AC ADA92120;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 XX US2003082712-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 16-MAY-2002; 2002US-00147512.
 XX
 PR 15-MAY-1998; 98US-0085697P.
 PR 08-MAR-1999; 99WO-US005028.
 PR 25-AUG-1999; 99US-00380138.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786915/74.
 DR P-PSDB; ADA92121.
 XX
 PT New PRO nucleic acid, useful for preparing a composition for treating
 PT e.g., tumor or for tissue typing.
 XX
 PS Claim 2; Fig 143; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding

CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADA92120 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTTPGlyHisLeu 20
 Db 206 ATGTGTGCGGCGGTGGCCCTCTGCTGCGGCGCCCTGCAGCTGTCTACTGTGGGGCCACTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACGCCCGGAGCGGAGGCCAGAGCTGCGCAAGGAGGCGGAGGCATTCTCTA 325
 QY 41 GluLysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCCATCAGAGGTTTCAGTGGGTGTCCAGTCTGTCTGCGGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCCCTGCGCCAGATGACTCTGCTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
 QY 101 AlaTTPAlaGluArgLleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGCTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTTACNAGCAGCACCTCTCTACCGCTGGTG 625
 QY 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGAACGCTCTCAGCGCTGGAGTTCCTGGAGAGCCCCCAGCACAGGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACTTCTTCCNAGGGGACCAACATGGGTGGCTGGGCAATGCTTTGTATGGC 805
 QY 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTTPSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATAGCGCTGTGTCTCTGAGCGCGCGCGGCGCAACTGTTCGTGTGTGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProAlaLeuMetAlaPr 260

```
Db      925  CGAGATCGGTCAACACCTTGGCGCTACCCACCTCGCGCGCGCGCGCTATGCGGC 984
Qy      260  oTyTyTyLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db      985  CTACTACAAGAGCTGGCGCGACCGCTGCTCAGCTGGAGCAGCTGCTGGCGGTGCA 1044
Qy      280  nSerLeuTyGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCCTGTATGGAGGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCACAGAAAGCTGTT 1104
Qy      300  eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db      1105  CACTGACTTTGAGACCTGGGACTCTCTACAGCCGCCCAAGGAGCGCCCTGAAACGCGGG 1164
Qy      320  vProLysTyCyvHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCTTAATACTGCCACTTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGGAGCAATTTCTGGAGGTGGCAGCTGATGCAAGCTCTCAGAGCCCG 1284
Qy      360  gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db      1285  TCCACTGCAGGAAGATGGCTCGGCTGCCGCCCAACATTGAGGCTCGGCAGTGTCAATT 1344
Qy      380  uAsnAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
Db      1345  GAATGATGGAGATTTCTACTCTTCAAGGGGGTGGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCACACACTGTGCGGGCAGGGGCGCTGCCCGCCATCTTGAGCG 1464
Qy      420  aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyVa 440
Db      1465  CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGCT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyTyTrpProArgSerLeuGlnAspTrpG1 460
Db      1525  GCTGGCCCGAGGGGAGCTCAAGTGGAGCCCTACTACCCCGAAGTGTGAGGACTGGGG 1584
Qy      460  yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCTCTGAGGAGTTCAGCGGCGCTGCGGAGGCCGATGGCTTCATCATCTTCTT 1644
Qy      480  eArgAspAspArgTyTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CGAGATGACCGCTACTGGCGCTCGACCGGCCAAACTGCAGGCAACACCCTCGGGCGG 1704
Qy      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGATGCCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy      520  e 520
Db      1765  C 1765
```

RESULT 68

ADB15183

ID ADB15183 standard; cDNA; 1985 BP.

XX ADB15183;

XX ADB15183;

XX 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #72.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX OS

XX US2003087352-A1.

XX PD

XX 08-MAY-2003.

XX PF

XX 22-APR-2002; 2002US-00127824.

XX PR

XX 17-AUG-1998; 98US-0096891P.

XX PR

XX 02-JUN-1999; 99WO-US012252.

XX PR

XX 25-AUG-1999; 99US-00380137.

XX PR

XX 30-MAR-2000; 2000WO-US008439.

XX PR

XX 30-MAY-2000; 2000WO-US014941.

XX PR

XX 01-DEC-2000; 2000WO-US032678.

XX PR

XX 19-DEC-2001; 2001US-00028072.

XX XX

XX (GETH) GENENTECH INC.

XX PA

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX XX

XX WPI; 2003-786943/74.

XX DR

XX P-PSDB; ADB15184.

XX XX

XX New PRO nucleic acid, useful for producing a recombinant PRO polypeptide

XX and for manufacturing a medicament for diagnosing or treating tumor.

XX Claim 2; Fig 143; 637pp; English.

XX XX

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

XX invention also relates to an antibody which specifically binds to a PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX proliferation or differentiation of chondrocyte cells and a method for

XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

XX polynucleotides are useful in molecular biology, including uses as

XX hybridisation probes, in chromosome and gene mapping, in generating

XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX be used in preparing PRO polypeptides by recombinant techniques and in

XX generating either transgenic animals or knock-out animals which are

XX useful in the development and screening of therapeutically useful

XX reagents. The PRO polypeptides or antibodies are used in preparing a

XX medicament for treating a condition responsive to the polypeptides or

XX antibodies, such as tumours, for stimulating and inhibiting proliferation

XX of human microvascular endothelial cells, for modulating the uptake of

XX glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX stimulating differentiation of adipocyte cells, for stimulating

XX the proliferation of or gene expression in pericyte cells, for stimulating

XX the proliferation of inner ear utricular supporting cells or T-lymphocyte

XX cells, for inducing endothelial cell tube formation and for treating

XX various bone and/or cartilage disorders such as sports injuries and

XX arthritis. PRO polypeptides which stimulate the release of proteoglycans

XX from cartilage are useful for treating sports-related joint problems,

XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

XX polypeptides are also useful for treating various mammalian haemoglobin-

XX associated disorders such as various thalassemias and conditions which

XX may benefit from enhanced local immune system cell infiltration. This

XX sequence represents a human PRO polynucleotide of the invention. Note:

XX The sequence data for this patent is also available in electronic format

XX from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

XX SQ

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB15183 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACCGCGCGAGCGGAGCGGAGCTGCGCAAGAGGCGGAGGCATTCCTA 325
 Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGACG 385
 Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGCTTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGCGGTGTGGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTTCGCGCAGATCACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTGTAGACACCGGACCAAAATCAGCGCTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCAATCTCCGAGCGCGCATGTTGCGGGCGCGCTGCGCGCCCTTCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGACACAGCTCTACGCGTGGAGTCTTGGAGGCGCCAGCACAGGCGCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTTCTTCAAGGGGACCAACACGATGGCTGGGCAATGCTTTGATGCG 805
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGGCTGGCGCAGCCCTTC-CTGCCCGCGCGGCGGAGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyValArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCACTGTTCGTGGTGTCTGGCGCA 924
 Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCGCGCGCGCGGCTCATGGGCGCC 984
 Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 Db 985 CTACTACAAGAGGCTGGGCGCGAGCGCTGCTCAGCTGGGACCGAGTGTGGCGGTGCA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTTGAGACCTCGGACTCCTACAGCCCCCAAGGAAGGCGCCCTGAAACGACGGG 1164

Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 Db 1165 CCCTAAATATGCGCACACTCTCTTCGATGCGCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTCAGAAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTCGGCGAGTGTCAAT 1344
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGCGATGCTGGAGGTTCGCGGGCCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCTGCGCCGCCATCTCTGACGC 1464
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
 Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGCCTGCTACTACGT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
 Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGCATCCCTGAGGAGTACGCGGCGCCTGCGGAGCGCCGATGGCTCCATCATCTTCTT 1644
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACGAGGCAAACTGCAGGCAACCACTCGGCGCG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGTCATGCCAACCTCGGGGAGCGCCCTGT 1764
 Qy 520 e 520
 Db 1765 C 1765
 RESULT 69
 ADB38435
 ID ADB38435 standard; cDNA; 1985 BP.
 XX AC ADB38435;
 XX AC ADB38435;
 DT 04-DEC-2003 (first entry)
 XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX Homo sapiens.
 OS US2003082766-A1.
 PN 01-MAY-2003.
 PD 30-MAY-2002; 2002US-00158782.
 XX 31-MAR-1997; 97WO-US005230.
 PF
 PR

PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025106.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013709.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2003-786921/74.
DR P-PSDB; ADB38436.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
XX Claim 2; Fig 143; 660pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMBC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I) -antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

[illegible]

US-10-791-980-6 (1-520) x ADB38435 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCTCGCGCTCTCTGTCGCGCCCTGCACTGCTACTGTGGGGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCCGGAGCGCGAGCTGCGCAAGGAGCGGAGCATTCCTCA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTTCGATTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGACGGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGCGCCAGATGACTGCTGCCCGCTGCGGGGTTCAGATATCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTCTAGACACCGACCAAAATGAGCGGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAAAGCAAGGTAACAAAATGGTACAAAGCAGCACCTCTCTACCGCTCGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe	160
Db	626	AACTGGGCTGAGCATCTGCCGGAGCCGGCAGTTCGGGGCGCGTGGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCCTCAGCGCTCGAGTCTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAGGGAGCCACCAACGATGGGCTGGGCAATGCCCTTGGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCGCGCGCGGCGAAGCGCATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCCCGCGCGGGCGCAACTGTTCGTGGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACAGCTTGGCCCTCACCCACTCGCCCGCGCGCGCTCATGGGGGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTCAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGTGTGGCGCGTGA	1044
Qy	280	nSerLeuTyr-GlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGATCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACTGACTTTGAGACCTTGGGACTCTTACAGCCCTCAAGGAAGCGGCTCTGAACGCAAGG	1164

Qy	320	yProLyTyTyCyGHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGGCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLyGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGACCATTTCTGGGAGGTGGCAGTGTATGGCAAGCTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGATGGTTCGGCTGCCCCCAACATTGAGCTCGGCAGTGTCAIT	1344
Qy	380	uAsnAspGlyAspPheTyTrPhePheIysGlyIArgCySTrpArpPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCySArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCATCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLySGLyAlaArgTyTrVa	440
Db	1465	CGCCCTCTTCTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyTrTyProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGACATGCAAGTGGAGGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584
Qy	460	YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTTGAGAGGTACGGCGCCCTGCCGAGGCCGATGGGTCCATCATCTCTT	1644
Qy	480	eArgAspAspArgTyTrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCCTCGACCAGGCCAAACTGCAGGCCAACCACTCGGGCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCySTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT	70		
ADB37883			
ID	ADB37883	standard; cDNA; 1985 BP.	
XX	ADB37883;		
AC	ADB37883;		
XX			
DT	04-DEC-2003	(first entry)	
XX			
DE	Novel human secreted and transmembrane protein PRO4339	CDNA.	
XX			
KW	Human; secreted and transmembrane protein; PRO; gene; ss;		
KW	Tumour necrosis factor alpha release; INF-alpha release;		
KW	Glucose uptake modulator; FFA uptake modulator;		
KW	cell proliferation stimulator; cell differentiation stimulator;		
KW	cell differentiation inhibitor; cytokine release stimulator; tumour;		
KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;		
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;		
KW	gene therapy; chromosome identification; chromosome marker.		
OS	Homo sapiens.		
XX			
FN	US2003087347-A1.		
XX			
PD	08-MAY-2003.		
XX			
PF	19-APR-2002; 2002US-00125921.		
XX			
PR	17-AUG-1998; 98US-0096791P.		

PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritson ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786938/74.
 DR P-PSDB; ADB37884.
 XX
 PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 XX
 PS Claim 2; Fig 143; 637pp; English.
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (II) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1,938-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB37883 (1-1985)

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB |||||
 QY 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTGAGGGGGTGTGGACCGC 445
 DB |||||
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB |||||
 QY 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
 DB |||||
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB |||||
 QY 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTGTAGACACCGGACCAAAATGAGGGCGTAG 565
 DB |||||
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB |||||
 QY 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCAGCTCTCTCTACCGCTGGTG 625
 DB |||||
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSer 160
 DB |||||
 QY 626 AACTGGCTTGAGCATCTGCGGAGCGGCGAGTTGCGGGCGCGTTCGCGGCGCTTCCAG 685
 DB |||||
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB |||||
 QY 686 TTGTGGAGCAACGCTCTAGCGCTGGAGTCTGGGAGGCCCCAGCCAGGCCCCGCTGAC 745
 DB |||||
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB |||||
 QY 746 ATCCGGCTCACTTCTTCCAAAGGGGACCACAAAGATGGCTGGGCAATGCTTGTATGGC 805
 DB |||||
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB |||||
 QY 806 CCAGGGGCGCGCTGGCGCAGCGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
 DB |||||
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
 DB |||||
 QY 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGTGGTGTCTGGCGCA 924
 DB |||||
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB |||||
 QY 925 CGAGATCGGTACACAGCTTGGCGCTCACCCACTCGCGCGCGCGCGCGCTCATGCGGCC 984
 DB |||||
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB |||||
 QY 985 CTACTACAAGAGGTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGA 1044
 DB |||||
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB |||||
 QY 1045 GAGCGTGTATGGGAGGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
 DB |||||
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB |||||
 QY 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAGNAGGCGCTGAAACGCGAGGG 1164
 DB |||||
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB |||||
 QY 1165 CCCTAAATACCTGCCACTCTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA 1224
 DB |||||
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
 DB |||||
 QY 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGAGCTAGTGGCAACGCTCAGAGCCCCG 1284
 DB |||||
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB |||||
 QY 1285 TCCACTGAGGAAAGATGGGTGGGCTGCCGCCCAACATTCAGGCTGGCGGAGTGTCA 1344
 DB |||||
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 DB |||||
 QY 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGCGGGCCCCAA 1404
 DB |||||
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB |||||
 QY 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCCGCCCATCTCCAGCGC 1464
 DB |||||
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440

Db	1465	CGCCCTCTTCTCCCTCTCTGCGCGGCTATCTCTTCAAGGTGCGCCCTACTAGT	1524	PR	13-SEP-1999;	99WO-US020944.
				PR	15-SEP-1999;	99WO-US021090.
Qy	440	lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTrpGl	460	PR	15-SEP-1999;	99WO-US021547.
				PR	05-OCT-1999;	99WO-US023089.
Db	1525	GCTGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGCTGCGAGGACTGGGG	1584	PR	29-NOV-1999;	99WO-US028214.
				PR	30-NOV-1999;	99WO-US028313.
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480	PR	30-NOV-1999;	99WO-US028409.
				PR	01-DEC-1999;	99WO-US028301.
Db	1585	AGGCATCCTGAGGAGGTAGCGGCGCCTGCCGAGGCCCATGCTCCATCATCTTCTT	1644	PR	01-DEC-1999;	99WO-US028634.
				PR	02-DEC-1999;	99WO-US028551.
Qy	480	eArgAspAspArgTTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500	PR	02-DEC-1999;	99WO-US028565.
				PR	16-DEC-1999;	99WO-US030095.
Db	1645	CGAGATGACCGCTACTGCGGCTCGACGAGCCAACTGAGGCAACCACTCGGGCGG	1704	PR	20-DEC-1999;	99WO-US030911.
				PR	20-DEC-1999;	99WO-US030999.
Qy	500	gTrpAlaThrGluLeuProTTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520	PR	22-DEC-1999;	99WO-US030720.
				PR	30-DEC-1999;	99WO-US031243.
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCTGTT	1764	PR	30-DEC-1999;	99WO-US031274.
				PR	05-JAN-2000;	2000WO-US000219.
Qy	520 e	520		PR	05-JAN-2000;	2000WO-US000277.
				PR	06-JAN-2000;	2000WO-US000376.
Db	1765 c	1765		PR	11-FEB-2000;	2000WO-US003565.
				PR	18-FEB-2000;	2000WO-US004341.
RESULT 71				PR	18-FEB-2000;	2000WO-US004342.
ID ADB66355				PR	22-FEB-2000;	2000WO-US004414.
AC ADB66355;				PR	24-FEB-2000;	2000WO-US004914.
XX				PR	24-FEB-2000;	2000WO-US005004.
XX				PR	01-MAR-2000;	2000WO-US005601.
DT	04-DEC-2003	(first entry)		PR	02-MAR-2000;	2000WO-US005746.
XX				PR	10-MAR-2000;	2000WO-US005841.
DE		Novel human secreted and transmembrane protein PRO4339 cDNA.		PR	10-MAR-2000;	2000WO-US006319.
XX				PR	15-MAR-2000;	2000WO-US006884.
KW		Human; secreted and transmembrane protein; PRO; gene; ss;		PR	20-MAR-2000;	2000WO-US007377.
KW		Tumour necrosis factor alpha release; TNF-alpha release;		PR	21-MAR-2000;	2000WO-US007532.
KW		glucose uptake modulator; FFA uptake modulator;		PR	30-MAR-2000;	2000WO-US008439.
KW		cell proliferation stimulator; cell differentiation stimulator;		PR	17-MAY-2000;	2000WO-US013705.
KW		cell differentiation inhibitor; cytokine release stimulator; tumour;		PR	22-MAY-2000;	2000WO-US014042.
KW		lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;		PR	30-MAY-2000;	2000WO-US014941.
KW		cervical tumour; liver tumour; chromosome mapping; gene mapping;		PR	02-JUN-2000;	2000WO-US015264.
XX		gene therapy; chromosome identification; chromosome marker.		PR	28-JUL-2000;	2000WO-US020710.
OS		Homo sapiens.		PR	11-AUG-2000;	2000WO-US022031.
XX				PR	23-AUG-2000;	2000WO-US023522.
XX				PR	24-AUG-2000;	2000WO-US023328.
PN	US2003082689-A1.			PR	08-NOV-2000;	2000WO-US030952.
XX				PR	10-NOV-2000;	2000WO-US030873.
PD	01-MAY-2003.			PR	01-DEC-2000;	2000WO-US032678.
XX				PR	20-DEC-2000;	2000US-00747259.
XX				PR	20-DEC-2000;	2000WO-US034956.
PF				PR	28-FEB-2001;	2001US-00796498.
XX				PR	28-FEB-2001;	2001WO-US006520.
PR	31-MAR-1997;	97WO-US005230.		PR	01-MAR-2001;	2001WO-US006666.
PR	12-JUN-1998;	98WO-US012456.		PR	09-MAR-2001;	2001US-00802706.
PR	14-JUL-1998;	98WO-US014552.		PR	14-MAR-2001;	2001US-00808689.
PR	28-AUG-1998;	98WO-US017888.		PR	22-MAR-2001;	2001US-00816744.
PR	10-SEP-1998;	98WO-US018824.		PR	05-APR-2001;	2001US-00828366.
PR	14-SEP-1998;	98WO-US019033.		PR	10-MAY-2001;	2001US-00854208.
PR	14-SEP-1998;	98WO-US019094.		PR	10-MAY-2001;	2001US-00854280.
PR	16-SEP-1998;	98WO-US019177.		PR	18-MAY-2001;	2001US-00860216.
PR	17-SEP-1998;	98WO-US019330.		PR	25-MAY-2001;	2001US-00866028.
PR	07-OCT-1998;	98WO-US021141.		PR	25-MAY-2001;	2001US-00866034.
PR	29-OCT-1998;	98WO-US022991.		PR	01-JUN-2001;	2001WO-US017092.
PR	20-NOV-1998;	98WO-US024855.		PR	01-JUN-2001;	2001US-00872035.
PR	01-DEC-1998;	98WO-US025108.		PR	03-JUN-2001;	2001US-00874503.
PR	05-JAN-1999;	99WO-US0250106.		PR	14-JUN-2001;	2001US-00882636.
PR	08-MAR-1999;	99WO-US005028.		PR	19-JUN-2001;	2001US-00886342.
PR	10-MAR-1999;	99WO-US005190.		PR	20-JUN-2001;	2001WO-US019692.
PR	20-APR-1999;	99WO-US008615.		PR	21-JUN-2001;	2001US-00887879.
PR	14-MAY-1999;	99WO-US010733.		PR	22-JUN-2001;	2001WO-US020116.
PR	02-JUN-1999;	99WO-US012252.		PR	23-JUN-2001;	2001WO-US021066.
PR	01-SEP-1999;	99WO-US020111.		PR	09-JUL-2001;	2001WO-US021735.
PR	08-SEP-1999;	99WO-US020594.		PR	18-JUL-2001;	2001US-00908827.
				PR	06-AUG-2001;	2001US-00924419.

PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 DR WPI; 2003-786905/74.
 DR P-PSDB; ADB66356.
 XX
 PT New PRO nucleic acid, useful for preparing a composition for treating
 PT e.g. tumor or for tissue typing.
 XX
 PS Claim 2; Fig 143; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,938-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x ADB66355 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGCGCGCTCGGCCCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCACCGCGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCATTTCCTA 325
 QY 41 GluLysTyGlyTyrluAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCACTCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80

DB 386 GATGCCATCAGACGCGTTTTCAGTGGGTGTCCACGACTACCTGTTCAGCGGCGGTGTGGACCGC 445
 QY 81 AlaThrIleuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
 DB 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTATTATGGC 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTACACACCGGACCAAAATGAGGGGTAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrlsGlnHisLeuSerTyArgLeuVal 140
 DB 566 AAACCTTTGCAAGCAAGSTAACAATGGTACAAGCAGACCTCTCTCATCCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCATCTCCGAGGCGGAGTTCGGGGCGCGTGGCGGCGCCCTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCTTTCATGCG 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG 220
 DB 806 CCAGGGGGCGGCGCTGGCGACGCTTC-CTGCGCGCGCGCGGCGGAGCGCATTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGTGCTGGCGCA 924
 QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTCAGCACTCGCGCGCGCGCGCGCTCATGCGCGC 984
 QY 260 oTyrlsArgLeuGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValG 280
 DB 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCTGGCGTGA 1044
 QY 280 nSerLeuTyrlsGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrlsProGlnGlyArgArgProGluThrGlnG 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCGCGCGCGCGCGCGCTGAAACGCGGG 1164
 QY 320 yProLysTyrlsHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 DB 1165 CCCTAAATACGTGCCACTCTCTCTCGATGCCATCATCTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGCCATTTCTGGAGTGGCAGCTGATGGCAACGCTTCAGAGCCCG 1284
 QY 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
 DB 1285 TCCACTGCAGAAAGATGGGTGGGTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1344
 QY 380 uAsnAspGlyAspPheTyrlsPheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGCGGGGCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGGAGGGGGCGCTGCCCGCCCATCTCTGAGCG 1464
 QY 420 aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrlsVa 440
 DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524

QY 440 lleuAlaargGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTACGGGGCCCTGCCGAGGCCCATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGGCTCGACCGCCAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 72
ADB89435
ID ADB89435 standard; cDNA; 1985 BP.
XX
AC ADB89435;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082698-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127850.
XX
PR 20-AUG-1998; 98US-0097218P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2003-743896/70.
DR P-PSDB; ADB89436.
XX
PT New PRO nucleic acids and encoded polypeptides, useful in the treatment
PT of cancer.
XX
PS Claim 2; Fig 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and

transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADB89435 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTCGCGCGCGTCGGCCCTCCTGCTGCGGCGCCCTGCTACTGTGGGGCCACTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCGAGCCCGGAGCGCGGAGCCAGAGCTGCGAAGGAGCGGAGGACTTCTTA 325

QY 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCGATTTCAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTCTGACGCGCGTGTGGAGCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCACCCCTGCGCCAGATGACTCTGCCCGCTGCGGGGTTCACAGATACACACAGTTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTCAGAGGATCAGTACTTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTTCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCGCGCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGGAGTTGCGGGCGCGTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTGGCGCA 924
QY 240 eGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTrpTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 TCTACTAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGAGTGTGGCGGTGCA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGACTCTCAGCCCCCAAGAGCGCCCTGAAACCGCAGGG 1164
QY 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGAGAGAGATGGTGGGCTGCCCGCCCAATTTGAGGCTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTCGATGCTGGAGTTCCGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCCCGCCCATCTCGAGCG 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTrpTyVa 440
Db 1465 CGCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrpTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCGGAGGGGACTGCAAGTGGAGGCCCTTACTACCCCGGAGTCTGCAGGACTGGG 1584
QY 460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
Db 1585 AGGATCTCTGAGGAGGTACGGCGCGCTTCCCGAGGCCGATGGCTCATCATCTCTT 1644
QY 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTGCGCGCTCGACCAAGCCAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 73
ADB90167
ID ADB90167 standard; cDNA; 1985 BP.
XX
AC ADB90167;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082762-A1.
XX
PD 01-MAY-2003.
XX
PF 15-APR-2002; 2002US-00123235.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.


```
QY 121 LysArgPheAlaLysGlnGlySerLysHisLeuSerTyrArgLeuVal 140
Db 566 AAACGGCTTTGCAAGCAAGGTAACTGATACAGCAGCACCCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTACGATCTGCGGAGCGGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTACCGCTTGAGTTCTGGAGGCCCCCAGCCACAGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCTTCATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCTGAGCGCGCGCGCGGCGCAACCTGTGTGGTGTCTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTCAACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGCGGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGTCTAGCTGGGACGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAAGACCTTAGGGGGCTCAGTGGCGCTGCTCCAGTCCCGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGNAGCGCCCTGAAACGACGG 1164
QY 320 yProLysTrpCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCATCTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCGCCCAACATTGAGGTGGCGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTCTTCAAGGGGTGATGCTGGAGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGCTGCCGCCCAATCCCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTCTCTCTCTCTGCGCGCTCTATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCCGAGGGCCGATGGCTCCATCTCTTCT 1644
```

480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
1645 CCGAGATGACCGCTACTGCGGCTCGACCGGCAAACTGCGAGGCAACACCTCGGGCG 1704
500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTGGTGGATGCCAACTCGGGAGCGCTGTT 1764

520 e 520
1765 C 1765

RESULT 74
ADB39268
ID ADB39268 standard; cDNA; 1985 BP.
XX ADB39268;
AC ADB39268;
XX 04-DEC-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX US2003082764-A1.
XX 01-MAY-2003.
XX 03-MAY-2002; 2002US-00137868.
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99WO-US005190.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 05-OCT-1999; 99WO-US023089.
XX 29-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 30-NOV-1999; 99WO-US028409.
XX 01-DEC-1999; 99WO-US028301.
XX 01-DEC-1999; 99WO-US028634.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015284.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786919/74.

DR P-PSDB; ADB39269.
XX New secreted and transmembrane PRO polypeptide useful for detecting the presence of tumor in a mammal, or modulating the uptake of glucose or free fatty acid by skeletal muscle cells or adipocyte cells.
PT Claim 2; Fig 143; 659pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADB39268 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCCCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGAGCCAGAGCTGCGCAAGAGGCGCGGAGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATTCCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTTGCTTAGACACCGGACCAAAATAGGCGCTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGGCTTTGCAAAAGCAAGTAACAAATGGTACAAGCAGCAGCACTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTACGCGCTGGAGTTCTGGAGGCCCCCAGCCACAGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGGCAATGCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGGCTGGCGCACGCTTC-CTGGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCTCCGAGCGCGCGCGCGGCAACCTGTTCGTGGTGTGGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGTCAACGCTTGGCTCACCCACTCGCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuSerTrpAspValLeuAlaValGl 280
DB 985 TCTACTACAAGAGCGCTGGCGCGCGCGCTGTCTAGCTGGGACGAGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTrpGlyLysPheProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACITTTGAGACTGGGACTCTCTACAGCCCCCAAGGAGCGGCTGAAACCGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGTGGGCTGGGCTGCCCCCAACATTGAGGTGGGCAAGTGTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTCTACTTCTTCAAGGGGCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGTCTCCACAGCTGTGGCGGAGGGGCGCTGCCCCGCCATCTTCGACGC 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGTGGCGGCTACTAGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTTACTACCCCCGAACTGTGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTAGCGGCGCCCTGCGGAGGCCGATGCTCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500

DB 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCCAACTGCAGGCAACACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCCAACGAGCTGCCCTGGATGGGCTGTGGATGCCCACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 75
ASB46891
ID ADB46891 standard; cDNA; 1985 BP.
XX ADB46891;
AC ADB46891;
XX 04-DEC-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
DE Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX US2003082687-A1.
XX 01-MAY-2003.
XX 19-APR-2002; 2002US-00125930.
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Bresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786904/74.
DR P-PSDB; ADB46892.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; Fig 143; 627pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful

in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADB46891 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTCGGCGGCTCGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGGCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GAGCGCCACGCGCGGAGCGGAGCGGAGAGCTGCCAAGAGGCGGAGGCATTCTCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAGTACGGATACCTCAATGAACAGGTCCTCCCAAGCTCCACCTCGATTTCAGC	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
DB	386	GATGCCATCAGACGCTTCAGTGGGTGTCCTAGCTACCTGTGAGCGGCGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCAACCTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys	120
DB	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTTGCAAGCAAGGTAACTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCTGAGCATCTGCGGAGCGGCGAGTTCGGGGCGCGTTCGGCGCGCTTCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCCGCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTACCTTCTTCNAGGGGACCAACAGATGGGCTGGGCAATGCCCTTGTATGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
DB	806	CCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGGCGGAAGCGCACTTCGACA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
DB	865	AGATGAGCGCTGGTCCCTGAGCCCGCCCGCGGCGCAACCTGTTCTGTGTCTGGCGCA	924

QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGGTACACGCTTGGCTCACCACATCGCGCGCGCGCGCGCTCATGGCGCC	984
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG	280
DB	985	CTACTACAGAGGCTGGGCGCGGACGGCTGTAGCTGGGACGAGCTGCTGGCGTGCA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCTGTATGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG	320
DB	1105	CACTGACTTGTAGACCTGGGACTCTTACAGCCCCCAAGAGGCGCCCTGAAACGCGAGG	1164
QY	320	YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy	340
DB	1165	CCCTAAATACTGCCACTCTTCTTCGATGCCATCAGTAGACAGGCAACAGCAACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTAAAGGAGGCCATTCTTGGAGGTGGCAGCTGATGGCACTCTCAGAGGCCCG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
DB	1285	TCCACTGCAGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGCGCAGTGTCAAT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
DB	1345	GAATGATGGAGATTCTTCTTCAAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
DB	1405	GCCAGTGTGGGGTCTCCACAGCTGTCGGGCGAGGGGCTGCCCGCCATCCTGACGC	1464
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa	440
DB	1465	CGCCCTCTTCTCTCTCTCTGCGCGCTCATCTCTTCAAGGCTGCGCGCTACTACGT	1524
QY	440	LeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG	460
DB	1525	GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTCGAGGACTGGG	1584
QY	460	YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
DB	1585	AGGATCCCTGAGGAGGTACAGCGCGCTGCCGAGCGCGATGGCTCCATCATCTTCTT	1644
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
DB	1645	CCGAGATGACCGCTACTGGCGCTTCGACCAAGGCGCAAACTGCAGGCAACCACTCGGCGCG	1704
QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
DB	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCCACTCGGGGAGCGCCCTGTT	1764
QY	520	e 520	
DB	1765	C 1765	

RESULT 76

ADB86498
ID ADB86498 standard; cDNA; 1985 BP.

XX AC ADB86498;

XX DT 04-DEC-2003 (first entry)

XX DE Human PRO polynucleotide #72.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;

liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

Homo sapiens.

US2003082697-A1.

01-MAY-2003.

22-APR-2002; 2002US-00127849.

20-OCT-1998; 98US-0104987P.

01-SEP-1999; 99WO-US020111.

18-OCT-1999; 99US-00403297.

18-FEB-2000; 2000WO-US004342.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-743895/70.

P-PSDB; ADB86499.

New secreted and transmembrane PRO polypeptides, useful in the diagnosis and treatment of cancer.

Claim 2; Fig 143; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, PRO articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADB86498 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGCTCGCGCGCTCGGCTCTCTGCTCGCGCGCTCTGCTACTGTGGGGCCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCGAGCCCGGAGCGGAGGCTGCCAGAGCTGCCAAGGAGGCGGCGCATTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGGCTCCCACTCCACTCGATTGACG 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTCCAGCGGCGTGTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCGCAGATCACTGCTCCCGCTGCGGGGTTCACAGATACCAACAGTATTGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTGCAGAGCAAGGTAACAAATGGTACAGCAGACCTCTCTCCACCGCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGACCAAGCTCTACGCTGGAGTTCGGAGGCGCCAGCCAGCCCGCTGATGCG 745

QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTGTGTCG 805

QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGCGCTTGGCGCACGCTTC-CTGCCCCCGCGCGCGGCGCAACCTGTTCGTGGTGGCGCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGTCTCCCTGAGCGCGCGCGCGCGCGCAACCTGTTCGTGGTGGCGCA 924

QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCCTCACCCTGCGCGCGCGCGCGCGCTCATGGCGCGC 984

QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
DB 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGTGGGACGACGCTGCTGGCGCGTGA 1044

QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCGCCCCCAAGGAGCGCGCTTGAACGAGGG 1164

```
QY 320 yProLysTyrCYsHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACGCCACTCTCTTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGAGCTGATGCCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCCCAACATTGAGGCTGGCAGTGTCAATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGGAGGGGCTGCCCGGCCATCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 GCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGCT 1524
QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 CTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTTCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCCCTCGACACGGCCAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGTGCCTGGATGGGCTGTGGATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 77
ADB77103
ID ADB77103 standard; cDNA; 1985 BP.
XX
AC ADB77103;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082696-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127848.
XX
PR 03-NOV-1998; 98US-0106934P.
```

```
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 05-JAN-2000; 2000WO-US000219.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Deaneyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755109/71.
DR P-PSDB; ADB77104.
XX
PRO nucleic acid, useful for preparing a composition for treating e.g.,
tumor or for tissue typing.
Claim 2; Fig 143; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
transmembrane) polypeptides (I). (I) is useful for stimulating the
release of TNF-alpha from human blood, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating the proliferation or differentiation of chondrocyte cells,
for stimulating the proliferation of or gene expression in pericyte
cells, for stimulating the release of proteoglycans from cartilage, for
stimulating the proliferation of inner ear utricular supporting cells,
for stimulating the proliferation of T-lymphocyte cells, for stimulating
the release of a cytokine from BMC cells, for inhibiting the binding of
A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
cells, for stimulating proliferation of endothelial cells, for detecting
the presence of tumour in a mammal. The tumour is lung, colon, breast,
prostate, rectal, cervical or liver tumour. The oligonucleotide probes
are useful for isolating genomic and cDNA nucleotide sequences or
antisense probes. (I) is also useful as therapeutic agent. PRO is useful
in assays to identify other proteins or molecules involved in binding
interaction. A polynucleotide (II) encoding (I) is useful in chromosome
and gene mapping, in generation of antisense RNA and DNA, in the
preparation of PRO polypeptide, for generating transgenic animals or
knockout animals which in turn are useful in the development and
screening of therapeutically useful reagents, in gene therapy, for
chromosome identification, as chromosome marker, and for generating
probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
detecting its expression in specific cells, tissues or serum, and for
affinity purification of PRO from recombinant cell culture or natural
sources. (I) and (II) are useful for tissue typing. This sequence encodes
a novel human secreted and transmembrane PRO polypeptide.
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADB77103 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCCCTCTCTGTCGCGCCCTGCAGCTGTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGGAGCGGAGCGGAGCTGCGAGGCTGCGAAGGAGCGGAGGACTTCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 419 |||||
```

Db 326 GAGAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCACTCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCAGCTACCTGTCCAGCGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
 Db 446 GCCACCCTCGCCAGATGACTCGTCCCGCTCGGGGTTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgArgLys 120
 Db 506 GCGTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAenLysTTPValLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGGTTTGCAAGCAGAGTAACAAATGGTACAGCAGCCTCTCTACCGCTGGTG 625
 QY 141 AenTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCGCCACAGCCAGCGCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCITTTGATGGC 805
 QY 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGCTGGCGACGCTTC-CTGCCCCCGCGCGGCGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTTPSerSerArgArgArgGlyArgAenLeuPheValLeuAlaHi 240
 Db 865 AGATGAGCGCTGCTCCTGAGCGCGCGCGCGGCAACCTGTTCTGGTGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CCAGATCGGTACACGCTTGGCTTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValGl 280
 Db 985 CTACTACAGAGCTGGGCGCGGACGCGCTGCTCAGCTGGGACGAGTCTGCGCGTGA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGGTCCAGCTCCAGGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCGCCCAAGGAGCGCCCTGNAACGACGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 Db 1165 CCTAAATACTGCCACTTCTCTTCATGCCATCTGTAGACGACGCAACACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAenValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnAlaArgTTPValGlyLeuProProAenIleGluAlaAlaAlaValSerIle 380
 Db 1285 TCACATGCAAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
 QY 380 uAenAspGlyAspPheTyrPhePheLysGlyGlyArgCysTTPArgPheArgGlyProly 400
 Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTCGAGGTTCCGGGGCCCA 1404
 QY 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGACGAGGGGCGCTGCCCGCCATCTCTGACG 1464

QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGCCCGCTACTACGT 1524
 QY 440 lleuAlaArgGlyGlyLeuGlnValIgluProTyrTyrProArgSerLeuGlnAspTTPGl 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGGAAGTCTGCAGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCTCTGAGAGGTCAGCGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACGACGCAAACTGCAGGACCAACCTCGGGCCG 1704
 QY 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAenSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCGTGT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 78
 ADB34260
 ID ADB34260 standard; cDNA; 1985 BP.
 XX ADB34260;
 DT 04-DEC-2003 (first entry)
 XX Human PRO polynucleotide SEQ ID NO 143.
 DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 OS US2003077717-A1.
 XX 24-APR-2003.
 XX 24-APR-2002; 2002US-00131818.
 XX 07-OCT-1998; 98US-0103328P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 30-NOV-1999; 99WO-US028313.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2003-755072/71.
 DR P-PSDB; ADB34261.
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,

PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.

XX Claim 2; Fig 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADB34260 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGCGCGCGTCTGGCTCTCTGCGCGCTCTGCGAGCTGCTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGGAGGCGCAGGAGCTGCGCAAGGAGGCGGAGGCGATTCTCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGACAGAGTCCCAAGCTCCACCTCCATCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCAGGTACCTGTCCAGCGCGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGGACATGACTCGTCCCGCTGCGGGGTATCAGATACCACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTAGACACCGGACCAAAATGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCAGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlnValaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCGGACCGGAGTTCTGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTCTCTGGGAGGCCCCAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTTTTCCAAAGGGGACACAAACGATGGGTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGACGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTTGTTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACCTCGCGCGCGCGCGCTCATGSGGCGC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTCTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGATATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCACAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAGCGCGCTGAAACGCGAGG 1164
Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATATGCACTCTTCTTCGATGCGATCCTCAGTACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAGAAAGATGGGTGGGCTGCGCGCTGCCCGCCCAACATTTGAGGCTCGCGCAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGTCTGATGCTGGAGGTTCCGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGGAGGGGCTTGCCTGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCTCTTCTTCTCTCTGCGCGCTCATCTCTCTCAAAGGGGTGCGCTACTACTAGT 1524
Qy 440 lLeuAlaArgGlyLysLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGAGCTGCAAGTGGAGCCCTACTCCCGCGAAGTCTGCGAGGCTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGCATCCCTGAGGAGGTACGCGGCGCTTGGCGGAGGCCGATGGCTCCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyr-TirArgLeuAspGlnAlaLysLeuGlnAlaThr-Thr-SerGlyVar 500
 |||||
 Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCGCAACTGCAGGCAACCACTTCGGGCGG 1704
 |||||
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 |||||
 Db 1705 CTGGGCGACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
 |||||
 QY 520 e 520
 |||||
 Db 1765 c 1765
 |||||
 RESULT 79
 ADB35364
 ID ADB35364 standard; cDNA; 1985 BP.
 XX ADB35364;
 AC ADB35364;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Human PRO polynucleotide SEQ ID NO 143.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003077719-A1.
 XX
 PD 24-APR-2003.
 XX
 PF 24-APR-2002; 2002US-00131824.
 XX
 PR 09-FEB-1999; 99US-0119341P.
 PR 01-DEC-1999; 99WO-US028634.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-755074/71.
 DR P-PSDB; ADB35365.
 XX
 PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
 PT tumors.
 XX
 PS Claim 2; Fig 143; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a-PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 Ds: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADB35364 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 |||||
 Db 206 ATGTTGCGCGCGCTCGCGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGCCACCTG 265
 |||||
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 |||||
 Db 266 GACGCCAGCCGCGGAGCGCGAGGCGAGAGCTGGCAAGGAGGCGGAGCATTCCTA 325
 |||||
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 |||||
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCGATTTCAGC 385
 |||||
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 |||||
 Db 386 GATCCCATCAGAGCGTTTCAGTGGGTGTCAGCTGCTGTCAGCGGGGTTCACAGATACCA 445
 |||||
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 |||||
 Db 446 GCCACCTGCGCCAGATGACTGCTGCCCGCTGCGGGGTTCACAGATACCAAGTATATCG 505
 |||||
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 |||||
 Db 506 GCCTGGGCTGAGAGGATCAGTCACTTGTGTTCTAGACACCGGACCAAAATGAGCGTAAG 565
 |||||
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 |||||
 Db 566 AAACGCTTTCGAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCACCGCTGGTG 625
 |||||
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
 |||||
 Db 626 AACTGGCTTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCGCGCTTCAG 685
 |||||
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 |||||
 Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTTGGAGGCGCCCGCAGCCAGGCGCGCTGAC 745
 |||||
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 |||||

Db 746 ATCCGGCTCACCTTCTTCCAGGGGACACACAGATGGCTGGGCAATGCCTTTGATGCG 805
Qy 200 adGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CAGGGGGCGCCCTGGCGACGCTTC-CTGCCCCCGCGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGluValValLeuAlaHis 240
Db 865 AGATGAGCGCTGGTCCCTTACGCGCGCGCGGCGCAACTGTTCTGGTGGCTGGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGCGCC 984
Qy 260 oTyrTrpYrsArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTCTGGCGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGATGGGAAGCCCTTAGGGGGCTCAGTGGCCGCTCCAGCTCCCGAAGAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGCGCCCTGAAACGCGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTCTGGAGGTGCGAGCTGATGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGCGCAGGGGGCTGCCGCCCATCTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGTGCGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGCCCGCGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCCCTGCCGAGGCGCCGATGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CGAGATGACCGCTACTGCGCTCGACCGCAAACTGCGAGGCAACCACTCTGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 80
ADB33708

ID XX ADB33708 standard; cDNA; 1985 BP.
AC ADB33708;
XX 04-DEC-2003 (first entry)
DT XX Human PRO polynucleotide SEQ ID NO 143.
DB XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX US2003077716-A1.
FN
XX 24-APR-2003.
PD
XX 24-APR-2002; 2002US-00131813.
PF
XX 07-OCT-1998; 98US-0103315P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 18-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Berezini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755071/71.
DR P-PSDB; ADB33709.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
PT in tissue typing, and in identifying chromosomes.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservatives: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADB33708 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTTCGGCGCGTGGCGCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCACAGCCCGGAGCGCGGAGCGCCAGAGCTGCGCAAGAGCGGAGGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProLysSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCAGTTCAGTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTCCAGCGCGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTCGCGCAGATGACTGCTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgTyrLysMetArgArgLys 120
 DB 506 GCCTGGCTGAGAGATCAGTGACTTGTGTGTAGACACCGGACCAATGAGGGCTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAAAGCAGCACTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTTACGATCTGCGGAGCGCGCAGTTCGCGGCGCGCTGCGCGCGCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyValArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGAGGCGCCACAGCCAGGCGCCCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTCCAGGGGACCAACAGATGGCTGGGCAATGCCCTTGTATGCG 805
 QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG 220
 DB 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGCAAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGGGTGCTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260

DB 925 CGAGATCGGTACACAGCTTGGCCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG 280
 DB 985 CTACTACAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACCGAGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 DB 1165 CCTAAATACCTGCGCACTCTCTCTGATGCATCACTGTAGACAGGCAACACACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGCATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIue 380
 DB 1285 TCCACTGCGAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTCA 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
 DB 1345 GAATGATGGAGATTTCTACTTTCTAAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCGCCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 DB 1525 GCTGGCGGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCGAGGACTGG 1584
 QY 460 yGlyIleProGluGluValSerGlyValLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGATCTCTCTGAGAGGTGACGGCGCTGCCGAGGCGCCATGGCTCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGGCGCTCTGACAGGCGCAACTGCGAGGCAACACCTCGGCGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGCATGCCAACTCGGAGGCGCCCTGT 1764
 QY 520 e 520
 DB 1765 C 1765
 RESULT 81
 ADB34812
 ID ADB34812 standard; cDNA; 1985 BP.
 XX ADB34812;
 AC ADB34812;
 XX 04-DEC-2003 (first entry)
 XX Human PRO polynucleotide SEQ ID NO 143.
 DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,938-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADB34812 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGCGCGCGGTCTGGCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACGCGCGAGCGCGAGCGCGAGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325
QY 41 GlyLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCACCTCCACTCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGCTTCAGTGGGTGTCCAGCTACCTGTGACGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCGCAGATCACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTpaAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGTGAGAGATCAGTACCTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAACCAAGGTAACTAATGGTACACAGACGACCTCTCTCCGCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCGGAGCGGCGAGTTGCGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGACAGCTCTCAGCGCTGAGGTTCGTGGAGGCGCCACGACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTCTTCCNAGGGGACCAACAGATGGGTGGGCAATGCCCTTTGATGCG 805
QY 200 sGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGGCGCCCTGGCGACGCTTC-CTGCCCCGCGCGGAGGCGGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHis 240
DB 865 AGATGAGCGCTGTCTCCCTGAGCCGCGCGCGGCGCAACCTGTGTGTGTGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACAGCTTGGCTTCCACCACTCGCGCGCGCGCGCGCTCATGGCGCG 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
DB 985 CTACTACAAGAGGCTGGGCGCGCGAGCGCTCTCTAGCTGGGACGACGCTGTGGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCGAG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAGGAGGCCATTTCTGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGAAAGATGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTTCTTCAAGGGGGTGGATGCTGGAGGTTCCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGAGCTGTGCGGGGCGAGGGGGCTGCGCGCGCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrTrpProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAAAGTCTGCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGAGGTACGCGGCGCTCTGCGAGGCGCCATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGGCGCTCGACGAGCGCAAACTGCGAGGCAACCACTCGGGCGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheIleAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCGCACCGAGCTGGCTGGATGGGTGTGTGATGTCGATGTCGCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 82.

ADB35916

ID ADB35916 standard; cDNA; 1985 BP.

XX ADB35916;

AC ADB35916;
DT 04-DEC-2003 (first entry)
XX

Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG	320
Db	1105	CACGTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGAAACGCGAGGG	1164
Qy	320	yProLysTyrCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACCTCTTCCTTCGATGCCATCACTGTAGACAGGCCAACAGCAACTGTGA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCACAATTCTCGGAGGTGCGAGCTGATGCCAACGTCTCAGAGCCCGC	1284
Qy	360	qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCGAGAAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTCGCGCAGTGTCA	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCystrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTCAAAGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTy	440
Db	1465	CGCCCTCTTCTTCCTCCTCTGCGCCGCTCATCTCTTCAAGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGCCCGCAGGGGAGATGCNAGTGGAGCCCTACTACCCCGAAGTCTGACGAGCTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTCAGCGCGCCCTGCGGAGGCCGATGGCTCCCATCTCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTCTGGCGCCTTCGACCAAGGCCAACTCGCAGGCACCACTCGGGCCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCystrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTCGATGGGCTGCTGGCATGCCNACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	c 1765	

RESIT.T 83

AA	Sequence	1985 BP;	403 A;	646 C;	604 G;	332 T;	0 U;	0 Other;
XX	ADB46311	standard;	cdna;	1985 BP.				
XX	ADB46311;							
XX	AC							
XX	DT	04-DEC-2003	(first entry)					
XX	DE	Novel human secreted and transmembrane protein PRO4339	cdna.					
XX	KW	Human; secreted and transmembrane protein; PRO; gene; ss;						
KW	KW	Tumour necrosis factor alpha release; TNF-alpha release;						
KW	KW	glucose uptake modulator; PFA uptake modulator;						
KW	KW	cell proliferation stimulator; cell differentiation stimulator;						
KW	KW	cell differentiation inhibitor; cytokine release stimulator; tumour;						
KW	KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;						
KW	KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;						
KW	KW	gene therapy; chromosome identification; chromosome marker.						
XX	XX							
XX	OS	Homo sapiens.						
OS	OS							
PN	PN	US2003082692-A1.						
XX	XX							
PD	PD	01-MAY-2003.						

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGCTTTTCAGTGGGTGTCCACGCTACCTGTTCAGCGCGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTCGGGCTGAGAGGATCAGTGACTTGTTCAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAACCAAGTAACAAATGGTACAGACGACCTCTCCTCAGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCGGAGCGCGAGTTCGGGGCGCGTGGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCAGCGCTGGAGTTCCTGGGAGGCCACAGGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCGCAACCTGTTCGTGGTGGCGCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGCGCAACCTGTTCGTGGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCCGTACACGCTTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGAGCAGCGTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGCGCCCCCAAGAGGCGCGCTGAAACGCGAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAATACTGCCACTCTTCTTCGATGCCATCCTGTACAGAGGCACACGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCGCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGCGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAGAGGGGTGCGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGCGAGGGGGCGCTGCCCGCCATCTCGACGC 1464

Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCGCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTTCAGCGCGCGCTCGCGAGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCGCTCGACCGGCGCAACTGCAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCGCTGGATGGGTGCTGTCATGCCAATCTCGGGGAGCGCGCTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 84
ADCS0184
ID ADCS0184 standard; cDNA; 1985 BP.
XX
AC ADCS0184;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX Homo sapiens.
XX OS
XX US2003092106-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131822.
XX
PR 19-AUG-1998; 98US-0097141P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Deenoers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WI; 2003-801171/75.
DR P-PSDB; ADCS0185.
XX
PT New secreted and transmembrane nucleic acid useful for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,

Qy 480 eArgAspAphArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTGGCCCTCGACCGCCAAATCGAGGCAACCACTCGGGCCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCytrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCCACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 85
ADCT1731
ID ADCT1731 standard; cDNA; 1985 BP.
XX AC ADCT1731;
XX 18-DEC-2003 (first entry)
XX Novel human secreted and transmembrane protein PR04339 cDNA.
DE Human; secreted and transmembrane protein; PRO; secreted polypeptide;
XX transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX Homo sapiens.
OS
XX US2003092107-A1.
PN
XX 15-MAY-2003.
PD
XX 24-APR-2002; 2002US-00131828.
XX
PR 07-OCT-1998; 98US-0103315P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX
DR WPI; 2003-801172/75.
DR P-PSDB; ADCT1732.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 2; Fig 143; 637pp; English.
PS
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon,
CC breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells, for
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC71731 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCGCTGCTACTGCTGCTGCTGCTGCTGCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGCGGAGCGCGAGGCTGCGCAAGGAGCGGAGGCATTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCTCCCAAGCTCCACCTCCACTCGATTAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTTCAGTGGTGTCTCCAGCTACTGTGTCAGCGCGCTGTTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTTGTTGTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCAGCAAGCGTAACTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGCGGAGGCTTCGCGGGCGCGCTTCAGCGCGCTTCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGGCGACGCCCTTC-CTGGCCCCCGCGGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCCAGCGCGCGCGCGGCAACCTGTTCTGTTGGTGGCGGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAGAGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGAGTGTGCGCGTGA 1044
QY 280 nSerLeuTyGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyfSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGGAAGCGCCCTCGAAACGACGG 1164
QY 320 yProLysTyfCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATCTGCCACTTCTTCGTGATGCCATCTAGTACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerle 380
Db 1285 TCACCTGCAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGTGGCGGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyfPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCA 1404
QY 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCTGCCCCGCCATCCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyfTyVa 440
Db 1465 CCCCCTCTTCTTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyfTyfProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGAGTCAAGTGGAGCCCTTACCCCCCAAGTCTGAGGAGTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGCGCTTGGCGAGGCGCGATGCTCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyfTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACGAGCCAACTGACGGAACCACTTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGTGATGGGCTGTGGCATGCCAACTCGGGAGGCCCTGT 1764
QY 520 e 520

Db 1765 C 1765

RESULT 86

ADCS9710

ID ADCS9710 standard; cDNA; 1985 BP.

XX AC ADCS9710;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;

XX KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;

XX KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;

XX KW rectum; kidney; cervix; liver; microvascular endothelial cell;

XX KW glucose uptake modulator; FFA uptake modulator; cell proliferation;

XX KW cell differentiation; skeletal muscle cell; adipocyte cell;

XX KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;

XX KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;

XX KW immune system cell infiltration; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker; gene; ss.

XX OS Homo sapiens.

XX PN US2003092105-A1.

XX PD 15-MAY-2003.

XX PF 24-APR-2002; 2002US-00131821.

XX PR 09-DEC-1999; 99US-0170262P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801170/75.

XX P-PSDB; ADCS9711.

XX PT New secreted and transmembrane nucleic acids and polypeptides, designated

XX PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,

XX PT cardiac injury, infertility, birth defects, premature aging, AIDS, or

XX PT cancer.

XX PS Claim 2; Fig 143; 637pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and

XX CC transmembrane polypeptides) and the polynucleotides encoding them. The

XX CC invention also relates to an antibody which specifically binds to a PRO

XX CC polypeptide, a method for stimulating the release of tumour necrosis

XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX CC proliferation or differentiation of chondrocyte cells and a method for

XX CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

XX CC polynucleotides are useful in molecular biology, including uses as

XX CC hybridisation probes, in chromosome and gene mapping, in generating

XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX CC be used in preparing PRO polypeptides by recombinant techniques and in

XX CC generating either transgenic animals or knock-out animals which are

XX CC useful in the development and screening of therapeutically useful

XX CC reagents. The PRO polypeptides or antibodies are used in preparing a

XX CC medicament for treating a condition responsive to the polypeptides or

XX CC antibodies, such as tumours, for stimulating and inhibiting proliferation

XX CC of human microvascular endothelial cells, for modulating the uptake of

XX CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte

CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polynucleotide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.42% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC59710 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGGCGCGTCTGGCTCTCTGGCGCGCTTGGAGCTGCTACTTGGGGGCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGlyAlaGluAlaPheLeu 40
 DB 266 GACGCCCGAGCGCGGAGCGGAGCGGAGCTGCGAAGGAGCGGAGCGGAGCTTCCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAGTAGCGATACCTCAATGAACAGAGCTCCCAAGCTCCACCTCGATTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCACGCTACCTGTGTCAGCGCGGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTCGCGCGATGACTGTCCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTAGACACCGAGCCCAAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGTTACAGAGCAGCCTCTCTCCACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValProCysAlaProProSerSe 160
 DB 626 AACTGGCTTGACATCTCCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGGAGGCGCCACAGGCCCGCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAAGGGGAGCCACACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGCGCTGGCGACGCGCTTC-CTGCCCCGCGCGGAGGCGACCTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240

DB 865 AGATGAGCGCTGGTCTCCTGAGCGCGCGCGCGCGCAACCTCTTCTGTGTGTCTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTTCACACGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 DB 985 CTACTTCAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGAGCAGCTGTGTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGCAAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTTGGAGACCTGGGACTCTTACAGCCCCCAAGGAAGCGGCTTCAAGACGAGG 1164
 QY 320 YProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
 DB 1165 CCTTAATACTGCACCTCTTCTTCGATGCATCCTGATAGACAGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGAGCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTGTCAGAAAGATGGGTGCGGCTGCCCCCAACATTTAGAGCTGCGCAGTGTCTT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GATGATGGAGATTTCTACTTCTTCAAAGGGGTTCGATGCTGGAGGTTCGCGGCCCCCA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCCACAGCTGTCGCGGCGAGGGGCTGCCCCGCGCATCTGTACGC 1464
 QY 420 aAlaLeuPhePheProLeuLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
 DB 1465 CGCCTCTTCTTCTCTCTCTCTGCGCGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCGCTACTACCCCGCAAGTCTGAGGACTGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCCCTGAGGAGTCCAGCGCGCTGCGGAGCGCGCTGCGGAGCGCGCTCTCTCT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTTCTGCGCGCTTCCAGAGGCCCAACTGAGGCAACACCTCGGCGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTGTGTCATGTCACACTCGGAGCGCGCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765
 RESULT 87
 ADC52717
 ID ADC52717 standard; cDNA; 1985 BP.
 XX AC ADC52717;
 XX AC
 DT 18-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein cDNA Seq ID143.
 XX human; PRO; membrane bound protein; membrane bound receptor;
 KW

KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophic factor; hormones; cell receptor;
KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour; ss; gene.

XX Homo sapiens.
XX US2003087365-A1.
XX 08-MAY-2003.
XX 23-APR-2002; 2002US-00128689.
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99WO-US005190.
XX 10-MAR-1999; 2000WO-US006319.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 29-OCT-1999; 99WO-US023089.
XX 30-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 01-DEC-1999; 99WO-US028301.
XX 01-DEC-1999; 99WO-US028634.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028564.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 20-DEC-1999; 99WO-US030911.
XX 20-DEC-1999; 99WO-US030999.
XX 22-DEC-1999; 99WO-US030720.
XX 30-DEC-1999; 99WO-US031243.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US003565.
XX 18-FEB-2000; 2000WO-US004341.
XX 18-FEB-2000; 2000WO-US004342.
XX 22-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US004914.
XX 24-FEB-2000; 2000WO-US005004.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005746.
XX 02-MAR-2000; 2000WO-US005841.
XX 15-MAR-2000; 2000WO-US006884.
XX 20-MAR-2000; 2000WO-US007377.
XX 21-MAR-2000; 2000WO-US007532.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021086.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerikteen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart JA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801150/75.
XX P-PSDB; ABC52718.
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present

CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC52717 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACGCCGCGAGCGGAGCGGAGAGCTGCGCAAGAGCGGAGGCGCAATTCCCTA 325
 Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGAGC 385
 Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGACGGTTTCAGTGGGTGCCAGCTACCTGTGAGCGGCGTGTGGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCCCTGCGCCAGATACACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGATCAGTACGTTGTTGCTAGACACCGGACCAAAATGAGCGGTAA 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGTTACAAAGCAGCACCTCTCTACCGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTTGAGCATCTCCCGAGCCGCGAGTTGCGGGCGCGTTCGCGCGCCCTTCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGACCAAGTCTCAGCGCTGGAGTTCTGGGAGGCCCCCAGCACAGGCCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACACGATGGGCTGGGCAATGCTTTGTATG 805
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
 Db 806 CCAGGGGGCGCCCTGGCGACGCTTC-CTGCCCCCGCGCGCGAAGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCAACCTGTTGCTGGTGTGGCGCA 924
 Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTCAACGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGGCGCC 984
 Qy 260 tTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG 280
 Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTGCTGGGACGACGCTGCTGGCGGTGCA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300

Db 1045 GAGCCTGTATGGAGCCCTCAGGGGCTCAGTGGCGCTCCAGTCCAGAGAAAGCTGTT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
 Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCAAGGAAGCGCCCTGAAACGCAGGG 1164
 Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCCTAAATATCGCACCTCTTCCATGATGCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACCTCTCAGAGCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaIleValSerLe 380
 Db 1285 TCCACTGCAGAAAGATGGGTGCGGCTGCCCCCAACATTTGAGGCTCGGCGAGTGTCA 1344
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGGAGATTCTTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGCCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGCGAGGGGCTGCCCCGCATCCTGACGC 1464
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGGTGCGCTACTACTG 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 Db 1525 GCTGGCCCGAGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
 Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGCATCCCTGAGGAGTTCAGCGCGCTGCGGAGGCCGATGGCTCCATCATCTTCTT 1644
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGGCAACTCGAGCAACACCTCGGGCGC 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTyrHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTCATGCCAATCGGAGGCGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 C 1765
 RESULT 88
 ADC57071
 ID ADC57071 standard; cDNA; 1985 BP.
 XX
 AC ADC57071;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein cDNA Seq ID143.
 KW human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuro peptide; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
 OS Homo sapiens.
 XX
 XX US2003087366-A1.
 XX
 PD 08-MAY-2003.
 XX
 PF 23-APR-2002; 2002US-00128694.

```
XX 02-MAR-2000; 2000WO-US005841.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801151/75.
DR P-PSDB; ADC57072.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytosolic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX
XX SEQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC57071 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGCGAGCGCGAGCGGAGGCTGCGCAAGGAGGCGGCGGCAATTCCTA 325
Qy 41 GluLysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCATGACACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCACAGCTACCTGTGACGCGGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
```

```
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGCTTTGTGTAGACACCGGACCAAAATGAGGCGTAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 MAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAGCAGCACCTCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCGGAGCGGCGAGTTCGGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCCAGCCACAGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTCCAAAGGGGACCAACAGATGGCTGGGCAATGCGCTTGTATGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGCGGCGGAGCGCACTTGCACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGGCAACCTGTTCTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATCGCGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGTGGGCGCGCGCTGCTCAGCTGGGACGCGCTGCTGGCGCTGCA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGNAAGGCGCTGAAACCGCAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTTAAGGGAGGCCAATTTCTGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTCAGAGAAAGATGGGTGCGGCTGCCCGCGCGCGCTGCGGCGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCCGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTTCTCCACAGCTGTCCCGGCGAGGGGCTGCCCGCGCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTCTCTCTCTCTCTCTGCGCGCGCTCATCTCTTCAAAGGGTGGCGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyClyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCGAGGGGAGTGCAGAGTGGAGCGCTACTACCCCGCGAGAGTCTGCGAGGACTGGG 1584
```



```
Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTGACGGCGCCTGCCAGGCCGATGCTCCATCATCTCTTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACCAGGCCAATCGAGCAACCACTCGGGCCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTGGCATGTCACCACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 89
ID ADC60262 standard; cDNA; 1985 BP.
AC ADC60262;
XX
XX
XX 18-DEC-2003 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
XX Homo sapiens.
OS
XX
XX US2003087367-A1.
XX
XX
XX 08-MAY-2003.
XX
XX 24-APR-2002; 2002US-00131825.
XX
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 98WO-US000106.
XX 08-MAR-1999; 98WO-US005028.
XX 10-MAR-1999; 98WO-US005190.
XX 10-MAR-1999; 2000WO-US006319.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001US-00908827.
PR 18-JUL-2001; 2001US-00921735.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
```


XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
XX WPI; 2003-801152/75.
DR P-PSDB; ADC60263.
XX
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
XX and for manufacturing a medicament for diagnosing or treating tumor.
XX
XX Claim 2; Fig 143; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
XX cells, for stimulating differentiation of adipocyte cells, for
XX stimulating proliferation of or gene expression in pericyte cells, for
XX stimulating the proliferation of inner ear utricular supporting cells or
XX T-lymphocyte cells, for inducing endothelial cell tube formation and for
XX treating various bone and/or cartilage disorders such as sports injuries
XX and arthritis. PRO polypeptides which stimulate the release of
XX proteoglycans from cartilage are useful for treating sports-related joint
XX problems, articular cartilage defects, osteoarthritis and rheumatoid
XX arthritis. PRO polypeptides are also useful for treating various
XX mammalian haemoglobin-associated disorders such as various thalassaemias
XX and conditions which may benefit from enhanced local immune system cell
XX infiltration. This sequence represents a human PRO polynucleotide of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC60262 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGGCTCGGCTCTCTGTCGGCCCTCGAGCTGCTACTGTGGGCCACCTG 265

QY 21 AppAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCGCGAGCGCGAGGCGCAGAGCTGCGCAAGGAGCGGAGGCGCATTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTAGCGATACCTCAATGAACAGGTGCCCAAGCTCCCAAGCTCCACCTCGATTACG 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGCTTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGCGGTGTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGATCAGTACTTGTTCGTAGACACCGGACCAAAATGAGGGGTAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAGCAGCACCTCTCTCTACCGCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCCCGAGCGCGAGTTCGGGGCGCGTGCAGCGCTTCACG 685

QY 160 rCysGlyAlaThrSerGlnArgTTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGACCAACGCTCTAGCGCTGGAGTTCGGGAGGCCCCAGCCACAGGCCCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCTTCATGGC 805

QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGCGCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGAAGCGACATTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGCGCGCAACCTGTTCGTGGTCTGGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984

QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGCGCTGGCGCGTGCA 1044

QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAACTGTT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGCGAGG 1164

QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATATCTGCACCTCTTCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGAGCTGATGGCAACGTCTCAGAGCCCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTCAGGAAGATGGGTGGGCTGCCGCCCAACATTCAGGCTGGCGGAGTGTCTATT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGCGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGTCTCCACAGCTGTCCCGGGCAGGGGGCTGCCCGCCCATCTCTGAGCG 1464

QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440

Db 1465 GCCTCTTCTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGTGCGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPgI 460
Db 1525 GCTGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCGAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACGCGCGCCCTGCGGAGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACGCTACTGCGCGCTCGACGAGCCAACTGCGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTfMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 90

ADCS0737

ID ADC50737 standard; cDNA; 1985 BP.

XX AC

XX ADC50737;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PR04339 cDNA.

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.

XX OS Homo sapiens.

XX NC US2003087361-A1.

XX PN 08-MAY-2003.

XX PD

XX PF 22-APR-2002; 2002US-00127841.

XX PP 09-SEP-1998; 98US-0099536P.

XX PR 01-SEP-1999; 98WO-US020111.

XX PR 18-OCT-1999; 99US-00403297.

XX PR 18-FEB-2000; 2000WO-US004342.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801146/75.

XX DR P-FSDB; ADC50738.

XX DR New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
XX PT and for manufacturing a medicament for diagnosing or treating tumor.
XX

PS Claim 2; Fig 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 10.52% Indels: 2
DB: Gaps: 0

US-10-791-980-6 (1-520) x ADC50737 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuTTPGlyHisLeu 20

Db 206 ATGTCGCGCGGTGCGCCCTCTGCTGCGCGCCCTGCTACTGTGGGGCCACTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40

Db 266 GACGCCCCAGCCCGGAGCGCGGAGCCAGAGCTGCGAAGGAGCGGAGGCATTCTTA 325

Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60

Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCATTCGATTTCAGC 385

Qy 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80

Db 386 GATGCCCATCAGCGTTTCAGTGGGTGTCAGCTACTCTGACGCGCGGTGTTGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100

Db 446 GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140

Db 566 AAACGCTTTGCAAGCAAGTAACTGATCAAGCAGCAGCTCTCTCTACCGCTGGTG 625
Qy 141 AantTpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSe 160
Db 626 AACTGGCCCTGAGCATCTGGCGAGCGCGGAGTTCGGGGCGCGCTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGAGGCCCCCAGCCACAGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACGATGGGCTGGGCAATGCCCTTGTATGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGCGCCCTGGCGCAGCCCTTC-CTGGCCCCCGCGCGGAGCGCACTTGCACCA 864
Qy 220 nAspGluArgTpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCACTTGTCTGTGTCTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGCGCGC 984
Qy 260 oTyTyTyTyArgLeuGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGCGCTGGCGCGCGAGCGCTGTCTAGCTGGGACGAGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyTyGlyTyLeuProLeuGlyGlySerValAlaValGlnLeuProGlyTyLeuPh 300
Db 1045 GAGCCTGTATGGAGAGCCCTTAGGGGCTCAGTGGCGGTCCAGCTCCCGAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGACGG 1164
Qy 320 yProTyTyTyCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATATCTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCGCAACACAACTGTA 1224
Qy 340 rIlePheTyGlySerHisPheThrPgluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGACATTTCTGGAGGTGCAGCTGATGCAAGCTCTCAGACCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGCTGCGGCACTGTCT 1344
Qy 380 uAsnAspGlyAspPheTyTyPhePheTyTyGlyArgCysTrpArgPheArgGlyProIly 400
Db 1345 GAATCATGAGATTTCTACTCTTCAAGGGGGTGTGATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGTCTCCACAGCTGTGGCGGAGGGGCTGCCCCGCACTCTGAGCGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheTyTyValArgTyTyVa 440
Db 1465 CGCCCTCTTCT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyTyTyProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCCGAGCTGCGAGGCTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGGGGCGCTGCGAGGGCCGATGCTCCATCTCTCTCTCT 1644
Qy 480 eArgAspAspArgTyTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500

Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCCAGGCCAACTGCAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTGGATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 91
ID ADC65264
XX ADC65264 standard; cDNA; 1985 BP.
XX AC ADC65264;
XX 18-DEC-2003 (first entry)
XX Human PRO polynucleotide #72.
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003087362-A1.
XX 08-MAY-2003.
XX 22-APR-2002; 2002US-00127844.
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801147/75.
DR P-PSDB; ADC65265.
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
PS Claim 2; Fig 143; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC65264 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGTCGGCGCTCGGCTCTCTGTCGGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCGCCAGCGCGGAGCGGAGCGGAGCTGCGCAAGGAGGCGGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCAGTTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGTACCTGTCCAGCGGCTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCTTGGGCTGAGAGGATCAGTACTTGTTCGTAGACACCGGACCAAAATGAGCGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGTAAACAAATGGTACAGAGCAGCACTCTCTCCCGGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTCCCGAGCGGCGAGTTGCGGGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGAGTCTTGGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACTTCTTCCAGGGGAGGACCAACAGATGGGCTGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGGCGCTGGCGAGCGCTTC-CTGCGCGCGCGCGGAGCGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGACGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTCGTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTTCCACCTCCCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCGCTGAAACGCAAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
DB 1165 CCCTAAATACTGGCCACTCTTCTTCGATGCCATCCTCTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGGCGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGCGATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCAGTGTGGGGTCTCCCAAGCTGCGGGGAGGGGGCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCTCTTCTTCCCTCTCTGCGCGCCTCATCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGAGGTGAGCGCGCGCTGCGAGGCGCGATGGCTCCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCAGATGACCGTACTTGGGCGCTTCGACGAGGCGCAACTCGAGGCAACACCTCGGCGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGCGCACCGAGTGGCTGGATGGCTGCTGCATGCGCAACTCGGGGAGCGCGCTGTT 1764
QY 520 e 520
DB 1765 c 1765
RESULT 92
ADC54362
ID ADC54362 standard; cDNA; 1985 BP.
XX
AC ADC54362;
XX
DT 18-DEC-2003 (first entry)
XX

DE Novel human secreted and transmembrane protein cDNA Seq ID143.
 XX human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neurotrophin; hormone; cell receptor;
 KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour; ss; gene.
 XX Homo sapiens.
 XX OS
 XX US2003087363-A1.
 XX 08-MAY-2003.
 XX 23-APR-2002; 2002US-00128687.
 XX 10-SEP-1998; 98US-0099816P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-801148/75.
 DR P-PSDB; ADC54363.
 XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 PT Claim 2; SEQ ID NO 143; 637pp; English.
 XX This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neurotrophins and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytoskeletal activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 332 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0
 US-10-791-980-6 (1-520) x ADC54362 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 |||||||

Db 206 ATGTGCGCGCGCTCGCTCTCTGCTGCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGlyAlaGluAlaPheLeu 40
 |||||||
 Db 266 GACGCCAGCCCGCGAGCGCGAGCGCGAGCTGCGCAAGAGCGCGGAGCATTCCTTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 |||||||
 Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATCGATTGACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 |||||||
 Db 386 GATCCATCAGAGCGTTTCAGTGGGTGTCCTCCAGCTACCTGTGAGCGGCTGTGACCGC 445
 QY 81 AlaThrIleuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 |||||||
 Db 446 GCCACCTTGCCTCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 |||||||
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 |||||||
 Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 |||||||
 Db 626 AACTGGGCTGAGCATCTGCGGAGCGCGCATGTTGCGGGCGCGCTGCGCGCGCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 |||||||
 Db 686 TTGTGGAGCAACGCTCTAGCGCTGGAGTTCCTGGGAGCGCCGACACAGGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 |||||||
 Db 746 ATCCGGCTCACCTTTTCCAAAGGGGACCAACATGGCTGGGCAATGCTTTGATGCG 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG 220
 |||||||
 Db 806 CCAGGGGGCGCGCTTGGGCGACGCTTC-CTCCCGCGCGCGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 |||||||
 Db 865 AGATGAGCGTGGTCCCTGAGCGCGCGCGGGGCGCACTGTTCTGTTGGTGTGGCGCA 924
 QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 |||||||
 Db 925 CGAGATCGGTCAACGCTTGGCTTACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
 |||||||
 Db 985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGAGCGCGCTGGCGCGTGA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 |||||||
 Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
 |||||||
 Db 1105 CACTGACTTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCGCTGAAACGCGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 |||||||
 Db 1165 CCCTAAATATCTGCGCACCTCTCTTCGATGCGCATCCTGTGTAGACAGGCAACAGCACTGA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 |||||||
 Db 1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGTATGGCAACGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 |||||||
 Db 1285 TCCACTGCAGGAAAGATGGGTGCGGCTGCCCGCCCAACATTGAGGCTGCGGCGAGTGTCA 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAAAGGGGTGATGCTGGAGGTTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTTGACGC 1484
QY 420 aAlaLeuPheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 GCGCTCTCTTCCCTCTCTGGCGGCTCATCTCTTCAAGGGTGCGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACATGCAAGTGTGAGCCCTACTACCCCGAAATCTGCAAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACAGGGGCGCTTCCGAGGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGGCTCGACAGGCCAAACTGCAGGCCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 93
ADCS3323
ID ADCS3323 standard; cDNA; 1985 BP.
XX
AC ADCS3323;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein cDNA Seq ID143.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuro peptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003087364-A1.
XX
PD 08-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128688.
XX
PR 09-FEB-1999; 99US-0119341P.
PR 01-DEC-1999; 99WO-US028634.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801149/75.
DR P-PSDB; ADCS3324.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.

XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuro peptides or hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0
US-10-791-980-6 (1-520) x ADCS3323 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGGTGCGCCCTCTGCTGCGCGCCCTGCAGCTGTCTACTGTGGGGCCACTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGGAGGCCAGAGCTGCGCAGGAGGGGGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACTTCGATTGAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTTCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTGTTGTAGACACCGGACCAAAATGAGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAATAATGGTACAAAGCAGCACCTCTCTCCCGGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGCTTCCTCCCGGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGAGCCCGCAGCCAGCGCCCGCTGAC 745

```
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
Db 806 CCAGGGGGGGCCCTGGCGCACGCTTC-CTGCCCGCCCGCGCGCAAGCGCACTTCGACCA 864
Qy 220 nAepGluAArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValAlaHis 240
Db 865 AGATGAGCGCTGGTCTCTGAGCCCGCCCGCGGCGCAACCTGTTCTGTGGTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTGGCTCAACCCACTCGCCCGCGCGCGCTCATGGCGC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAepAlaLeuLeuSerTrpAspValLeuAlaValG 280
Db 985 CTACTACAAGAGCTGGCGCGACGCGCTGCTCAGCTGGGACGACGCTGCGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysPheProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGACCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATATGCTCACTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTITTAAGGAGGAGCAATTTCTGGAGGTGGAGCTGATGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluAArgTrpValGlyLeuProProAenIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTCAIT 1344
Qy 380 uAenAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 CAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGAGGGGCGCTGCCCGCCCACTCCGTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTGCGCGGCTCATCTCTTCAAGGTGGCGGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG 460
Db 1525 GCTGGCGCGAGGGGACTCAAGTGGAGGCCCTTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTGAGGAGGTGAGCGGCGCTGCGGAGGGCCGATGCTCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CGAGATGACCGCTACTGGCGCTGACCAAGGCCAACTGCAAGGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACGAGCTGCCGTGGTGGCTGCTGGCATGCCAATCGGAGGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 94
```

ADC58846

ID ADC58846 standard; cDNA; 1985 BP.

AC ADC58846;

XX 18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein cDNA Seq ID143.

XX human; PRO; membrane bound protein; membrane bound receptor;

KW cell proliferation; cell migration; cell differentiation;

KW mitogenic factor; survival factor; cytotoxic factor;

KW differentiation factor; neurotrophin; hormone; cell receptor;

KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.

XX Homo sapiens.

XX US2003087359-A1.

XX 08-MAY-2003.

XX 22-APR-2002; 2002US-00127834.

XX 17-SEP-1998; 98US-0100710P.

XX 01-SEP-1999; 99WO-US020111.

XX 18-OCT-1999; 99US-00403297.

XX 30-NOV-1999; 99WO-US028313.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;

XX WPI; 2003-801144/75.

XX P-PSDB; ADC58847.

XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide

and for manufacturing a medicament for diagnosing or treating tumor.

XX Claim 2; SEQ ID NO 143; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted and transmembrane proteins. Extracellular proteins play important roles in the formation, differentiation and maintenance of multicellular organisms. The fate of many individual cells (for example proliferation, migration or differentiation) is typically governed by information received from other cells and the immediate environment. The information is often transmitted by secreted polypeptides (for example mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neurotrophins or hormones) which are received and interpreted by diverse cell receptors or membrane bound proteins. These membrane bound proteins and receptors may be of use as pharmaceutical and diagnostic agents, such as in the blocking of receptor-ligand interactions. The current invention provides the amino acid sequences of novel human membrane bound receptors and proteins, along with the cDNA sequences encoding them. The novel proteins of the invention may have cytostatic activities through the stimulation of chondrocytes. The nucleic acids of the invention may be used for the manufacture of a medicament for diagnosing or treating a tumour in a mammal. In addition, they may be useful for measuring or detecting the expression of a tumour associated gene. The present sequence is a cDNA sequence which encodes a human PRO protein of the invention.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. NO.: 1.93e-149 Length: 1985

Score: 2792.00 Matches: 519

Percent Similarity: 99.62% Conservativity: 0

Best Local Similarity: 99.62% Mismatches: 1


```
QY 300 eThrAspPheGluThrTrpAspSerTy-SerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAGAGAGCCCTGAAACCGAGGG 1164
QY 320 yProLysTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCATTTCTGGAGGTGCGACTGATGCCAACGTCCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGAATGGTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTCTTCAAGGGGTCGATGCTGAGAGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCCCACTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCTATCTTTCAGAGGTGCCGCTACTAGT 1524
QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTyTyTyProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCGCTGCGGAGCGCGATGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGTACCCCTACTGCGGCTCGACCGGCAACTGCGAGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGAGGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 97
ADD02968
ID ADD02968 standard; cDNA; 1985 BP.
XX
AC ADD02968;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
```

```
PR 08-NOV-2000; 200WO-US030952.
PR 10-NOV-2000; 200WO-US030873.
PR 01-DEC-2000; 200WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 200WO-US034956.
PR 28-FEB-2001; 2000US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801169/75.
XX P-PSDB; ADD02969.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
XX PRO4978, useful in molecular biology, chromosome and gene mapping, in
XX generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 143; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
XX cells, for stimulating differentiation of adipocyte cells, for
XX stimulating proliferation of or gene expression in pericyte cells, for
XX stimulating the proliferation of inner ear utricular supporting cells or
XX T-lymphocyte cells, for inducing endothelial cell tube formation and for
XX treating various bone and/or cartilage disorders such as sports injuries
```

```
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
XX
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0
US-10-791-980-6 (1-520) x ADD02968 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCGCGCTCTCTGTCGCGCCCTGCAGTGTCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGCGGAGCGAGAGTCGCGAAGGAGGCGGAGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTCTCCAGCTACCTGTGAGCGCGGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAnserSerYAla 100
Db 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTGGCGGGTTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTTCGTAGACACCGGACCAAAATGAGCGGTAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAAGCAGCACCTCTCTACCGGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTCAGCATCTGCGGAGCGCGAGTTCGGGGCGCGGTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACAGTCTCAGCGCTGGAGTTCTGGAGAGCCCCCAGCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAAGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGAGCAACGACATTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATAGCGCTGTCTCCCTGAGCGCGCGCGCGGGCGCAACTGTTCGTGTGTGTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTGGCTCACCCTCCCACTCGCCCGCGCGCGCTCATGGCGCC 984
```

```
QY 260 oTyrTyrlsArGLyArGLyAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGAGCTGTCGGCGTGA 1044
QY 280 nSerLeuTyrlsArGLyArGLySerValAlaValGlnLeuProGLyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTCAGGGGGCTCAGTGGCCGCTCCAGCTCCAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGLyArGLyArGLyProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCGCAAGGAGCGCCCTGAAACGAGCG 1164
QY 320 yProLysTyrlsArGLySerPheAspAlaIleThrValAspArGLyGlnGlnLeuTy 340
Db 1165 CCCTAAATACCTCCACTCTCTCGATGCCATCATCTGACAGCGCAACACTGTA 1224
QY 340 rIlePheLysGLySerHisPheTrpGluValAlaAlaAspGLyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCG 1284
QY 360 gProLeuGlnGLyArGLyTrpValGLyLeuProPheSerLeuGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGCATT 1344
QY 380 uAenAspGLyAspPheTyrlsPhePheLysGLyArGLyArGLyCysTrpArGLyPheArGLyProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTCTCANAGGGGGTGTGATGCTGGAGGTTCGGGGCCCA 1404
QY 400 sProValTrpGLyLeuProGlnLeuCysArgAlaGLyGLyLeuProArGLyHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGGCAGGGGCTGCCCGCCATCTCTGACGC 1464
QY 420 alaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGLyAlaArGLyTyrlsVa 440
Db 1465 CCGCCCTCTTCTTCCCTCTCTCGCGGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArGLyGLyLeuGlnValGluProTyrlsTrpProArGLySerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAGTGGAGCCCTACTACCCCGAGTGTGCAGGACTGGGG 1584
QY 460 yGlyLeuProGluValSerGLyAlaLeuProArGLyProAspGLySerIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTGCAGGGCGCCCTGCGAGGCGCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArGLyTrpArGLyLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCCTCGACAGGCCAACTGCAGGCAACACCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGGATGGGTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 98

ADC89960
ID ADC89960 standard; cDNA; 1985 BP.

XX AC ADC89960;

DT 01-JAN-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO4339 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene: ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW Glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

PN US2003087348-A1.

XX 08-MAY-2003.

XX 19-APR-2002; 2002US-00125923.

XX 05-JUN-2000; 2000US-0209832P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786939/74.

DR P-PsDB; ADC89961.

PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.

XX Claim 2; SEQ ID NO 143; 637pp; English.

CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from BMC cells, for inhibiting the binding of
CC A-peptide to factor VITA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Scores:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	99.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADC89960 (1-1985)

QY 1 MetValAlaArgValGLyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20

Db 206 ATGGTCGGCGCTCGGCTCTCTGTCGCGCCTGCGAGCTGCTACTGTGGGCCACCTG 265

```
QY 21 AspaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGGAGCGGAGCGGAGCGTGCAGAGCTGCAGAAAGGAGCGGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCGATTCAGC 385
QY 61 AspaLalleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGCTTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCACAGATGACTGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATCAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGAGGCGCCGACACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGSGCTCAGCTTCTTCAAGGGGACCAACACATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCGCTGGCGACGCTTC-CTGCCCCCGCGCGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTGCGTGGTGTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTGGCTCACCCTCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGGCGCGGACCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTGTATGGGAAGCCCTTAGGGGCTCAGTGGCCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTTGGACCTTGGGACTCTCCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATCTGCCACTCTTCTTCGATGCTCATCTGTAGACGCGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGGAAAGATGGGTGGGCTGCGCCCTGCCCCCCCAACATTGAGGCTGCGGAGTGTCA 1344
```

```
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCAGGGGCTGCCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGCCTGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTCAAGCGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTTCGACCGAGGCCAACTGCAGGCAACCACTCGGGCCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCAGCTGCTGGATGGCTGCTGCATGCCNACTCGGGGAGCGCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 99
ADC69379
ID ADC69379 standard; cDNA; 1985 BP.
XX AC ADC69379;
XX DT 01-JAN-2004 (first entry)
XX DE cDNA encoding human PRO polypeptide #72.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX OS Homo sapiens.
XX EN US2003194770-A1.
XX PD 16-OCT-2003.
XX PF 21-MAY-2002; 2002US-00152375.
XX PR 03-MAR-2000; 2000US-0187202P.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-844453/78.
DR
```

P-PSDB; ADC69380.

New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in preicyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. The sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

US-10-791-980-6 (1-520) x ADC69379 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGGTGGCGCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGCGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnLeuLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACCGCGGAGCGCGAGGCAGGAGCTGCGAAGGAGCGGAGGCATTCCTTA	325
Qy	41	GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAGTACGGATACCTCAATGAACAGTCCCCAAGCTCCCACTCCACTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCCATCAGACGCTTCAGTGGGTGCCCAGCTACTGTCTACGCGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100

Qy 460 YGlyIleProGluuValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGAGGTTCAGCGCGCTCCGAGGCCGATGGCTCCATCATCTTCTT 1644
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATACCGCTACTGGCGCTCGACCAAGCCAACTGCAGGCAACCACTCGGGCCG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCybTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 C 1765
 RESULT 100
 ADC48268
 ID ADC48268 standard; cDNA; 1985 BP.
 XX
 AC ADC48268;
 DT 01-JAN-2004 (first entry)
 XX
 XX Human PRO polynucleotide #72.
 DE
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 XX Homo sapiens.
 OS
 XX US2003194773-A1.
 PN
 XX 16-OCT-2003.
 PD
 XX 21-MAY-2002; 2002US-00152391.
 PF
 XX 09-DEC-1999; 98US-0170262P.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2003-844455/78.
 DR P-PSDB; ADC48269.
 DR
 XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
 PT for detecting a tumor, stimulating the release of tumor necrosis factor
 PT alpha and stimulating the proliferation of endothelial cells.
 PT
 XX Claim 2; Fig 143; 637pp; English.
 PS
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADC48268 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGCGCGGTTCAGTGGGTTCACAGTCTGTCCAGCTGTCTACTGTGGGGCCACTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGGAGCGGAGCGCCAGAGCTGCGCAAGGAGCGGAGGCATTCTTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCACCTCCATTCGATTGCG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATCCCATCAGAGCGTTTCAGTGGGTTCACAGTCTGTCCAGCGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTACTTGTTCAGTACACCGGACCAAAATGAGCGGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACCCCTTGCAGCAAGCAAGTACAAATGGTACAGCAGCACCTCTCTCCACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTGAGCATCTGCGGAGCGCGAGCTTCGGGGCGCGCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnAlaProLeuTh	180

Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCCAGCCACACAGCCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGCAATCCCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTTPArThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCGCTGGCGCACGCTTC -CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATAGAGCGCTGGTCCCTCAGCGCGCGCGCGGCGCAACCTGTGTGTGTGTGTGTGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTACACGCTTGGCTTACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGAGCGCTGTCTCAGCTGGAGCGAGTGTCTGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGGAGCGCCCTGAAACGAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTTAATATCTCCACTTCTTCGTGATGCTATCTGTAGACAGGCAACACACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGCAACGCTTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTTPValGlyLeuProProHsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAAGAAAGATGGTGGGCTGCCCCCAACATTTAGGCTGGCGAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTTPArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGTGATGCTGGAGTTCCGGGGCCCCA 1404
Qy 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
Db 1525 GTGGCCCCGAGGGGAGCTCAAGTGGAGGCTTACTACCCCGAGTGTGAGGACTGGGG 1584
Qy 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGAGGCGCGGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTATGCGCGCTCGACCGAGCCAACTGCAAGGCAACACCTCGGGCGG 1704
Qy 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGGCCACGAGTGGCTTGGATGGGCTGTGGATGCCAACTCGGGAGGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 101

ADD09797

XX ADD09797 standard; cDNA; 1985 BP.

AC ADD09797;

DT 01-JAN-2004 (first entry)

XX Human PRO polynucleotide #72.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003194776-A1.

XX 16-OCT-2003.

XX 29-MAY-2002; 2002US-00157785.

XX 05-JUN-2000; 2000US-0209832P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-852596/79.
DR P-PSDB; ADD09798.

XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
for detecting a tumor, stimulating the release of proteoglycans from
cartilage and inhibiting the differentiation of adipocyte cells.

XX Claim 2; Fig 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC the sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,938-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADD09797 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuTrpGlyHisLeu	20
Db	206	ATGCTCGCGCGGTCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGCGCACCTG	365
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GAGCCCGAGCCCGGAGCGCGGAGCGCAGAGCTGCGCAAGGAGCGGAGGACTTCCTA	325
Qy	41	GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAGTACGGATACCTCAATGAAcAGGTCCCCAAGCTCCACCTCCACTCGATTTCAGC	395
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGCTTTCAGTGGGTGTCCAGGTACTCTGTcAGCGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCTCGCCAGATGACTCGTCCCCGCTGCGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGNTCAGTGACTTGTTGCTAGACACCGGACCAAAATGAGCGGTAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGGCTTTGCAAAAGCAAGGTAAcAAATGGTAcAAGCAGCACCTCTCTcACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTTGAGCATCTGCGGAGCGCGAGTTcGGGGCGCGTGTGGCGCGCTTCACAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCNAcGTCTCAGCGCTGAGTTCTGGGAGGCCCCAGCCACcAGGCCCGGTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCcAAGGGACCAcAACATGGGCTGGGCAATGCTTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGln	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGGCGAAGCGACTTCACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATGAGCGCTGGTCCCTGAGCCGCGCGCGGGCGCNAcCTGTTCGTGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTCAcAGCTTGGCTCTCAcCACTCGCCCGCGCGCGCGCGCATGGCGCC	984

QY 320 yProlystYrCySHisSerSerPheAspAlaIlethrrValaspArgGInGInLeuTy 340
Db 1165 CCTAAATACGCCACTCTTCCTCGATGCCATCACTGTAGACAGCGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpTgLuValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGInGluArgTrpValGlyLeuProProhenIleGluLaAlaAlaValSerLe 380
Db 1285 TCCACTGAGAAAGATGGTGGCTGCCGCCCAACATTGAGGTGGCGAGTGTCAATT 1344
QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyVgLyArgCystrPArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTCTTCTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGInLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCATCTGAGCG 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaAArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lIeuAlaArgGlyGlyLeuGInValGluProTyrTrpProArgSerLeuGInAspTrpGl 460
Db 1525 GCTGCGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTGTGCAAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGGGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTCGCGCTCGACAGGCCAAACTGCAGGCGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCystrPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGATGGGTCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 103
ADC80328
ID ADC80328 standard; cDNA; 1985 BP.
XX
AC ADC80328;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; haemoglobin-associated disorder; thalassemia;
KW gene therapy; chromosome identification; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
OS Homo sapiens.
XX
PN US20003092103-A1.
XX
PD 15-MAY-2003.

XX 24-APR-2002; 2002US-00131815.
PF 22-DEC-1998; 98US-0113511P.
XX 01-DEC-1999; 99WO-US028634.
PR 22-FEB-2000; 2000WO-US004414.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
PI
XX WPI; 2003-801168/75.
DR P-PSDB; ADC80329.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PR04978, useful in molecular biology, chromosome and gene mapping, in
FT generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; Fig 143; 637bp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0
US-10-791-980-6 (1-520) x ADC80328 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTGGCCCTCCTGTCGCGCCCTGCTGCTACTGTGGGCCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuAtrGlyLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCAGCCGCGGAGCGCGAGGCGAGGAGCTGCGCAAGAGGCGGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACACTCCACTCGATTGAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGGTGTGTGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCGCAGATGACTCGTCCCGCTCGGGGTACAGATACCAACAGTTATGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGCTGAGAGGATCAGTCACTTGTGTGTAGACACCGGACCAAAATGAGCGTAAG 565
QY 121 LysArgPheAlaLysGlnClyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAACAATGGTAAAGCAGCAGCTCTCCTACCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCCGAGCGCGGAGTTCGGGGCGCGTCCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGAGTTCTGGAGGCGCCACAGCCAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGACCAACAGATGGGCTGGCAATGCTCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGTCTCCTGAGCGCGCGCGCGCAACCTGTTCGTGTGTGTCGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTCAACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuSerTrpAspValLeuAlaValG1 280
DB 985 CTACTACAGAGGCTGGCGCGCGCGCTGTCTCAGCTGGGACGAGCTGTGGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAGAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTCGGACTCTCAGACCGCCCAAGAGCGCGCTCGAAACGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTTCCTCGATGCCATCACTGTAGACAGGCAACAGCACTGA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGTCCGGCTGCGCGCTGCGCCCAACATTGAGGTGCGCGAGTGTCTATT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGATGCTGGAGTTCCGGGGCCCCNA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGCAGGGGCTGCCCGCCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGCCTGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAGTCTGAGGACTGGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCTCAGGAGGTGAGCGCGCTCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCAGATGACCGCTACTGCGCGCTCGACGAGGCAACTGCGAGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGTGGCTGGATGGGTGTGGCATGCGCAACTCGGGAGGCGCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 104
ADD10835
ID ADD10835 standard; cDNA; 1985 BP.
AC ADD10835;
XX 01-JAN-2004 (first entry)
XX Human PRO polynucleotide #72.
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS US2003194774-A1.
PN 16-OCT-2003.
XX 21-MAY-2002; 2002US-00152399.
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000MO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-852594/79.
DR P-PSDB; ADD10836.

XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the proliferation or differentiation
PT of chondrocyte cells and stimulating the release of tumor necrosis factor
PT alpha.

PS Claim 2; SEQ ID NO 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADD10835 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGGCGCGCTCTCTGTCGGCCCTGACGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCGCGAGCGGGAGCGCCAGAGCTGCGCAAGAGGCGCGGAGCCATTCCTA	325
Qy	41	GluIysTyrGlyTyrLeuAsnGluGlnValProIlysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGTGTCCCAAGCTCCACCTCCACCTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGGTTTCAGTGGGTGTCACGACTACCTGTGACGGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCGCAGATGACTGTCCTCCCGCTGCGGGGTACAGATACCACAGATTATGCG	505

Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgArgIys	120
Db	506	GCTTGGGCTCAGAGGATCAGTGCTGTTTGTAGACACCGGACCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGGTTTGCAAAGCAGGTACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACCTGGCTCAGCATCTGCGGAGCGGCACTTGGGGCGCGTGGCGCGCTTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnhArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTTGGAGGCCCCCAGCAGCCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerIysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCGGCTCACCTTCTTCCAGGGGACCACACGATGGGTGGGCAATGCTTTGTATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyGlyAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCTTGGCGCACGCTTC-CTGCCCCCGCGCGGAGCGGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgGlyArgGlyValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCTCTGAGCGCGCGCGGGGCGCACTGTTCGTGTGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCCCGCGCGCTCATGCGGCC	984
Qy	260	oTyrTyrArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAGCCCTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACCTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGCAAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGCGACCTCTTCTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGCCATTTCTGGGAGGTGGGAGCTGATGGGACGCTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCAGAGAAAGATGGGTGCGGCTGCCCCCAACATTTGAGGCTCGGCGAGTGTCAAT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyIysArgCysTrpArgPheArgGlyProLy	400
Db	1345	GATATGATGGAGATTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTCGAGCGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCGGCTCTACTAGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGGAGCTGCAAGTGGAGGCCCTACTACCCCGGAAAGTCTGCAAGGACTGGG	1584

QY 460 yGlylleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlelePhePh 480
 Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCTGCGAGCGCGATGGCTCATCTCTT 1644
 QY 480 eArgPAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGTACTGCGCGCTCGACGAGCGCAACATGCGAGCAACCATCGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGTGCCTCGATGGCTGCTGGCATGCCAATCGGGAGCGCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 105
 ADC47716
 ID ADC47716 standard; cDNA; 1985 BP.
 XX
 AC ADC47716;
 DT 01-JAN-2004 (first entry)
 XX
 DE Human PRO polynucleotide #72.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 XX US2003194771-A1.
 XX
 PD 16-OCT-2003.
 XX
 PF 21-MAY-2002; 2002US-00152377.
 XX
 PR 09-DEC-1999; 99US-0170262P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Gurney SL, Smith V;
 PI Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI: 2003-844454/78.
 DR P-PSDB; ADC47717.
 XX
 XX New secreted and transmembrane PRO polypeptides and nucleic acids useful
 PT for detecting a tumor, stimulating the release of proteoglycans from
 PT cartilage and stimulating the proliferation of endothelial cells.
 XX
 PS Claim 2; Fig 143; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC47716 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTCTCGCGCGCTCGGCTCTCTGCTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACGCCGCGGAGCGCGGAGGCTGCGCAAGGAGCGGAGGCGGATTCCTTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGGCTCCACCTCCACTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGGCGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGATTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGGACGACCTCTCTCCCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCATCTGCCGAGCGCGGCACTTCGGGGCGCGTGGCGCGCGCTTCCAG 685
 QY 160 rCyGAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCGCCAGGCCACAGGCCCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTCTTCAAAGGGACACACAGATGGGCTGGGCAATGCGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGAGCGACTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGGCGCAACCTGTTCGTGGTCTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlApr 260
Db 925 CGAGATCGGTACAGCTTGGCTCACCACCTGCGCCCGCGCGCGGCTCATGGCGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGTCTGGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGCGCCCCAAGAAAGGGCGCTGAAACGCGAGGG 1164
QY 320 yProLysTyrCySHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTCCACTCTCTTCGATGCCACTCCTAGACAGCGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCGCCCCAACCAATTGAGGCTGGCGCAGTGTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCystrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGTCGATGCTGGAGTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCyseArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCGCTGCCCGCCATCCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTAGCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGAGGCCCTACTACCCCGGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCGCTGCCGAGGGCCGATGGCTCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTCGCGGCTCGACAGGCCAACTGAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTTPMetGlyCystrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTCTGGCATGCCCACTCGGGAGCGCGCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 106

ADC79776
ID ADC79776 standard; cDNA; 1985 BP.
XX AC ADC79776;
XX DT 01-JAN-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
XX KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX OS Homo sapiens.
XX US US2003087358-A1.
XX PD 08-MAY-2003.
XX XX 22-APR-2002; 2002US-00127833.
XX PF 01-SEP-1998; 98US-0098750P.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 18-OCT-1999; 99US-00403297.
XX PR 18-FEB-2000; 2000WO-US004342.
XX PR 08-NOV-2000; 2000WO-US030952.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX XX (GETH) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801143/75.
XX DR P-PSDB; ADC79777.
XX PT New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.
XX PS Claim 2; Fig 143; 637pp; English.
XX XX The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
cells, for stimulating differentiation of adipocyte cells, for
stimulating proliferation of or gene expression in pericyte cells, for

CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polynucleotide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,936-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADC79776 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTGGCGCGGTGGCGCTCTCTGTCGGCGCCCTGCAGCTCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GAGCGCCAGCGCGGAGCGCGGAGGAGCTGGCAAGGAGCGGAGGCGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTAGCGATACCTCAATGAACAGAGTCCCAAGCTCCACACCTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
 DB 386 GATGCGATCAGAGCGTTTCAGTGGGTGTCCTCCAGCTACCTGTGAGCGGCGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgProCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTCGCGCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAACTAAATGGTAAAGAGCACCTCTCTCCCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCATCTGCGGAGCGGCGAGTTCGGGGCGCGTGGCGCGCCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCACAGGCGCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTCTTCCAAAGGGGACCAACACGATGGGCTGGGCAATGCCCTTTGATGCG 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGCGCCCTGGCGACGCGCTTC-CTGCGCGCGCGCGGAGGCGCATTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTCTCGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACAGCTTGGCCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAAGAGGTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACCTTTCAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACACGAG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCTAAATACCTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTAGAGCCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
 DB 1285 TCCACTGAGGAAAGATGGTGGGTCGCCGCCCAACATTGAGGCTGGCGCAGTGTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCCGGGGCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGGGGGTCTCCACAGCTGTGCGCGGAGGGGCGCTGCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
 DB 1465 CGCCTCTTCTTCTCTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 DB 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTTACTACCCCGCAAGCTGTGACGAGCTGGG 1584
 QY 460 yGlyLeuProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGGAGGTGAGCGCGCGCTGCCGAGGCGCGGATGGCTCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGGCCAAATCGCAGGCAACACCTCGGGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCCACTCGGAGGAGCGCGCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765
 RESULT 107
 ADD09245
 ID ADD09245 standard; cDNA; 1985 BP.
 XX
 AC ADD09245;
 XX
 DT 01-JAN-2004 (first entry)
 XX
 DE Human PRO polynucleotide #72.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW	liver; microvascular endothelial cell; glucose; FFA;
KW	skeletal muscle cell; adipocyte cell; pericyte cell;
KW	inner ear utricular supporting cell; T-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW	immune system cell infiltration.
XX	
OS	Homo sapiens.
XX	
PN	US2003194775-A1.
XX	
PD	16-OCT-2003.
XX	
PF	28-MAY-2002; 2002US-00156849.
XX	
PR	03-MAR-2000; 2000US-0187202P.
PR	01-DEC-2000; 2000WO-US032678.
PR	19-DEC-2001; 2001US-00028072.
XX	
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX	
DR	WPI; 2003-852595/'79.
DR	P-PSDB; ADD09246.
XX	
PT	New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT	for detecting a tumor, stimulating the release of tumor necrosis factor
PT	alpha from blood and stimulating the release of proteoglycans from
PT	cartilage.
XX	
PS	Claim 2; Fig 143; 637pp; English.
XX	
CC	The invention relates to isolated human PRO polypeptides (secreted and
CC	transmembrane polypeptides) and the polynucleotides encoding them. The
CC	invention also relates to an antibody which specifically binds to a PRO
CC	polypeptide, a method for stimulating the release of tumor necrosis
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC	proliferation or differentiation of chondrocyte cells and a method for
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC	polynucleotides are useful in molecular biology, including uses as
CC	hybridisation probes, in chromosome and gene mapping, in generating
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC	be used in preparing PRO polypeptides by recombinant techniques and in
CC	generating either transgenic animals or knock-out animals which are
CC	useful in the development and screening of therapeutically useful
CC	reagents. The PRO polypeptides or antibodies are used in preparing a
CC	medicament for treating a condition responsive to the polypeptides or
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation
CC	of human microvascular endothelial cells, for modulating the uptake of
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC	stimulating differentiation of adipocyte cells, for stimulating
CC	proliferation of or gene expression in pericyte cells, for stimulating
CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC	cells, for inducing endothelial cell tube formation and for treating
CC	various bone and/or cartilage disorders such as sports injuries and
CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC	from cartilage are useful for treating sports-related joint problems,
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC	polypeptides are also useful for treating various mammalian haemoglobin-
CC	associated disorders such as various thalassemias and conditions which
CC	may benefit from enhanced local immune system cell infiltration. This
CC	sequence represents a human PRO polynucleotide of the invention. Note:
CC	The sequence data for this patent is also available in electronic format
CC	from USPTO at seqdata.uspto.gov/sequence.html .

QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCTAAATAGTGCACCTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCGAGAAAGATGGTGGGCTGCCGCCCAACATGAGGTGCGGAGTGTCAIT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGCCCTGCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
 Db 1465 CGCCCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCAGGACTGGGG 1584
 QY 460 gGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCGGAGGCCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCCCTACTGGCGCTCGACAGGCCCAACTGCGAGGCAACACCTCGGGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGAGGCCCTGT 1764
 QY 520 e 520
 Db 1765 C 1765

RESULT 108
 ADD40958
 ID ADD40958 standard; cDNA; 1985 BP.
 AC ADD40958;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW Cell proliferation stimulator; cell differentiation stimulator;
 KW Cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 FN US2003203438-A1.
 XX
 PD 30-OCT-2003.
 XX
 PF 15-MAY-2002; 2002US-00146786.
 XX
 PR 24-NOV-1997; 97US-0066511P.
 PR 16-SEP-1998; 98WO-US019330.

PR 25-AUG-1999; 99US-00380139.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, DeForge L, Deenoyers L, Pilvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-875645/81.
 DR P-PSDB; ADD40959.
 XX
 PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 PS Claim 2; SEQ ID NO 143; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADD40958 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGGCGCTCGGCCCTCTCTGCGGCCCTCGAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCAGCCCGCGAGCGCGAGGCTGCGAGAGCTGCGAAGGAGGCGGAGGATTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACCTCGATTGAGC 385

Qy	61	AspAlaIleAArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTCAAGCGCGTGTTGACCCG	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla	100
Db	446	GCCACCCTGCGCCAGATGACTCGTCCCAGCTGCGGGGTTACAGATACCAAGATTATGCG	505
Qy	101	AlaTrpAlaGluArqIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTTCGTAGACACCCGGACCAAATGAGCGGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTryLysGlnHisLeuSerTyArgLeuVal	140
Db	566	AAACGCCTTTGCAAGCAAGGTAACAATAGGTACAAGCAGCACCTCTCTACCGCTGTGGT	625
Qy	141	AsnTrpProGluHuHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AAC TGCCCTGAGCATCTGCCGGAGCCGCGAGTTTCGGGGCGCGTGC CGCGCGCTTCCAG	689
Qy	160	rCysGlyAlaThrSerGlnArqTrpSerSerGlyVargProGlnProGlnAlaProLeuTh	180
Db	686	TFTGTGGAGCAACGCTCAGCGCTGGAGTTCTGGAGGGCCCCAGGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThr-ThrMetGlyTrpAlaMetProLeuMetal	200
Db	746	ATCCGGCTCACCTTCTTCCAAGGGAGCCACAACGATGGCTGGGCAATGCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTTGGCGCAGCCCTTC-CTGCCCCCGCGCGCGGAAGCGCACTTCGACCA	864
Qy	220	nAspGluArqTrpSerLeuSerArqArqArgGlyVargAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGTCTCCCTGACCGCCCGCGGGGGCAACTGTGTGTGTGTCGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalPr	260
Db	925	CGAGATCGGTACACAGCTTGGCCTCACCCACTCGCCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTryLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGGCGCGAGCGCGCTGCTCAGCTGGGACGACGTCGTGGCGCGTGA	1044
Qy	280	nSerLeuTryGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCCCTAGGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyTrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CAC TGACTTTTGAGACCTGGGACTCTACAGCCCCCAGAAGGCGCCCTGAAAACGACGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlalaaspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArqTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGATGGGTGGGCTGCCCTGCCCCCAACATTGAGGCTGGCGAGTGTCA	1344
Qy	380	uAsnAspGlyAspPheTyrrPhePheLysGlyGlyVargCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCCTACTTCTTCAAAGGGGGTCTGCTGTGGAGGTTTCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArqAlaGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCCCACAGCTGTGCCGGGAGGGGGCTGCCCGCCCACTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArqLeuIleLeuPheLysGlyAlaArqTrpTyrrVa	440

Db	1465	CGCCCTCTTCTTCCCTCCTCTGCGCGCCCTCATCTCTTCAAGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerIeuGlnAspTrpG1	460
Db	1525	GCTGGCCCGAGGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG	1584
Qy	460	YGLYILEProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGAGGTACAGCGGGCCCTGCCGAGGCCGATGGCTCCCATCATCTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgIeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTCTGGCGCCCTCGACACGAGGCCAACTGACAGCAACCACTCGGGCCG	1704
Qy	500	gTrpAlaThrCluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 109			
ADDS2097			
ID	ADDS2097 standard; cDNA; 1985 BP.		
XX			
AC	ADDS2097;		
XX			
DT	15-JAN-2004 (first entry)		
XX			
DE	cDNA encoding human PRO polypeptide #72.		
XX			
KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; FFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;		
XX	immune system cell infiltration.		
OS	Homo sapiens.		
XX			
PN	US2003194769-A1.		
PD			
XX	16-OCT-2003.		
PF			
PF	21-MAY-2002; 2002US-00152374.		
XX			
PR	09-DEC-1999; 99US-0170262P.		
PR	01-DEC-2000; 2000WO-US032678.		
PR	19-DEC-2001; 2001US-00028072.		
XX			
PA	(GETH) GENENTECH INC.		
XX			
PI	Baker KP, Beresini M, Deforge L, Deanoyers L, Filvaroff E, Gao W;		
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;		
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;		
XX			
DR	WPI; 2003-852593/79.		
DR	P-FSDB; ADDS2098.		
XX			
PT	New isolated, secreted and transmembrane PRO polypeptides and nucleic		
PT	acids, useful for detection of tumors, modulating the uptake of glucose		
PT	or free fatty acids and stimulating the release of proteoglycans from		
PT	cartilage.		
XX			
PS	Claim 2; Fig 143; 637pp; English.		
XX			
CC	The invention relates to isolated human PRO polypeptides (secreted and		

transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalasaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	99.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADD52097 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuA	ArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTGTCGCGCGTCTCTGTGTCGCGCCCTGCAGCTGCTACTGTGTGGCGGCACCTG		265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40	
Db	266	GACGCCCAGCCCGCGAGCGCGAGCCAGGAGCTGCACAAGGAGCGCGAGCAATTCCTTA	325	
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60	
Db	326	GAGAAGTACGGATACCTCAATGACAGAGTCCCAAAAGCTCCCACTCCACTCGATTACG	385	
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80	
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCCACTACCTGTTCAGCGCGGTGTGGACCGC	445	
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100	
Db	446	GCCACCTTGCCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATCGC	505	
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120	
Db	506	GCCTGGGCTGAGAGATCAGTGACTTGTTTGCTAGACACCGGACCAAAATNGGCGCTAAG	565	
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140	
Db	566	AAACGCTTTGCAAGCAGAGGTAAACAAATGGTATCAAGCAGCACCTCTCTACCGCTGGTG	625	

PT PRO4978, useful in chromosome and gene mapping, in generating antisense
PT RNA and DNA, and in the treatment of cancer.

XX Claim 2; Fig 143; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor- α (TNF- α) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADD52837 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTGGCGGGCTCGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
QY	21	AepAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GACGCCACAGCCCGGAGCGCGGAGCCAGGAGCTGCGCAGGAGCGGAGGCATTCTCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACG	385
QY	61	AepAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
DB	386	GATGCCATCAGACCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGGCTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTTGGCCAGATGACTCGTCCCGCTGGGGGTTCACGATACCAACAGTTATGCG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys	120

DB	506	GCCTGGGCTGAGAGGATCAGTGACTGTTTGTCTAGACACCGGACCAAAATGAGGGCTAAG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAAGCTTTGCAAGAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTTACCGCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCTGAGCATCTCCGGAGCGCGAGTTCGGGGCGCGTGGCGCGCTTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAACGTCTACGCGTGGAGTTCGGGAGGCGCCAGGCACAGGCCCGCTGAC	745
QY	180	rSerGlySerProSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCGGCTCACCTTCTTCAAGGGGACCACACGATGGGTGGGCAATGCTTTGATGGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
DB	806	CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGAAGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
DB	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTGTGTCGCGCA	924
QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGGTCAACAGCTTGGCCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC	984
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
DB	985	CTACTACAAGAGGCTGGGCGCGCGCGCTCTCAGCTGGGACGACGTGTGGCGGTGCA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
DB	1105	CACGTACTTTGAGACCTGGGACTCTCAGCCCCCAAGAAAGGCGCCCTGAACACCGAGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
DB	1165	CCCTAAATACTGCGCACCTCTCTTCGTGATGCCACTCAGTACAGGCAACAGCACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLue	380
DB	1285	TCCACTGGAGAAAGATGGGTGGGGTGCCTCCCAACATTGAGGCTGGCAGAGTGTCAAT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
DB	1345	GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGCATGCTGGAGTTCCTCGGGCCCCA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl	420
DB	1405	GCCAGTGTGGGGTCTCCACACAGCTGTGCGGGCAGGGGGCTGCCCCGCCCATCTCAGCGC	1464
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440
DB	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAANGGTGCCCCCTACTAGT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
DB	1525	GCTGGCCGAGGGGAGTGCAGAGTGGAGCCCTACTACCCCCGAAGTCTGCGAGGACTGGGG	1584
QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
DB	1585	AGGCATCCCTGAGGAGGTACGCGCGCGCTGCGCGAGGCCGATGGCTCCATCATCTTCTT	1644

QY 480 eARGspAhpArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTGCGCTCGACAGCCAACTGAGGCAACACCTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaSerGlySerAlaLeuPh 520
 Db 1705 CTGGCCACCGAGCTGCCCTGGATGGCTGTGGCATGCCAACTCGGGAGCGGCTGT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 111
 ADD53389
 ID ADD53389 standard; cDNA; 1985 BP.
 XX
 AC ADD53389;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; PFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 PN US2003203437-A1.
 XX
 PD 30-OCT-2003.
 XX
 PF 15-MAY-2002; 2002US-00146728.
 XX
 PR 01-JUL-1998; 98US-0091360P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-DEC-2000; 2000US-00380137.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
 PI Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-875644/81.
 DR P-PSDB; ADD53390.
 XX
 PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 PS Claim 2; SEQ ID NO 143; 659pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting

CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADD53389 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGGCGCGTCCGCCCTCTGCTGCGCGCCCTGCAGCTGTACTGTGGGGCCACTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GAGCCGCCAGCCCGGAGCGGAGCGGAGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
 QY 41 GluIysTyrGlyTyrLeuAenGluGlnValproIysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACATTCGATTGAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCACTGGGTGTCACAGTACTCTCAGCGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTGGCGGGTTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgAtgLys 120
 Db 506 GCTTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGGTAA 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTTCAAGCAAGGTAACTAATGTGTACAGCAGCACCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCCTGAGCATCTTCGCGAGCGGACATTTGCGGGCGCGCTGCGCGCGCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCAGCGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTTGTATGCG 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
 Db 806 CCAGGGGGCGCCCTGGCGCAGCCTTC-CTGCCCGCGCGCGGAGGAGCGCACTTCGACCA 864

Qy	220	nAspGluAArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTGTTGGTGTCTGGCGCA	924
Qy	240	eLluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTTCCACCACTCGCGCGCGCGCGCTCATGGGCGCC	984
Qy	260	oTyTrTyrsArgLeuGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValGl	280
Db	995	CTACTACAAGAGCTGGCGCGGAGCGCTGCTCAGCTGGAGCAGCTGTGTGGCGGTGCA	1044
Qy	280	nSerLeuTyrglyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCAGCTCCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrsSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCTCTGAACCGCAGGG	1164
Qy	320	yProLysTyrcysHisSerSerPheAspAlaileThrValAspArgGlnGlnGlnLeuTy	340
Db	1165	CCCTAATACTGCCACTTCTCTTCGATGCCCATCTGTAGACAGGCACAGCAACTGTGA	1224
Qy	340	rilePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCGAGAAAGATGGTTCGGGCTGCCGCCCAACATTGAGCGCTCGCGCAGTGTCTAT	1344
Qy	380	uAsnAspGlyAspPheTyrrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGAGATTTCTACTTCTTCAAAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGCTCTCCACAGCTGTGCCGGGCGAGGGGGCTGCCCCGCGCATCTCGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrrVa	440
Db	1465	CGCCCTCTTCTTCCCTCCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrrTyrrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGAGCTGCAGTGGAGCCCTACTACCCCCGAAGCTCGCAGGACTGGGG	1584
Qy	460	yGlyileProGluGluValSerGlyAlaLeuProArgProAspGlySerileilePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCCGAGGCGCGATGGCTCCCATCTCTT	1644
Qy	480	eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCTCTCGACCAAGGCCAACTCGCAGGCAACCACTCGGGCCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT i12			
ADD51545			
XX	ADD51545 standard; cDNA; 1985 BP.		
XX	AC		
XX	ADD51545;		
XX	15-JAN-2004 (first entry)		
XX	cDNA encoding human PRO polypeptide #72.		

Db 1285 TCCACTGCAGAAAGATGGTTCGGCTGCCGCCCCCAACATTGAGCTGCGCAGTGTTCATT 1344

Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400

Db 1345 GAATGATGGAGATTCTTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTTCGGGGCCCCAA 1404

Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420

Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGCAGGGGCTGCCGCCCATCTCTGACGC 1464

Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTrpVa 440

Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGCCTACTACGT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460

Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTTACCCCGAAGTCTGCAGGACTCGGG 1584

Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh 480

Db 1585 AGGCATCCCTGAGGAGGTACGGGGCTCTGCCAGGCGCATGGCTCCATCATCTTCTT 1644

Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500

Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGGCAAACTGCAGGCAACCACTCGGGCGC 1704

Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGTGGCTGTCGATGCCAATCGGGAGCGCCCTGTT 1764

Qy 520 e 520

Db 1765 C 1765

RESULT 114

ID ADD01778

XX ADD01778 standard; cDNA; 1985 BP.

XX AC ADD01778;

XX DE 15-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #72.

KW Human; gene; ss: PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX OS Homo sapiens.

XX OS US2003203430-A1.

XX FN 30-OCT-2003.

XX PD 23-APR-2002; 2002US-00128685.

XX PF 11-AUG-1998; 98US-0096143P.

PR 02-JUN-1999; 99WO-US012252.

PR 30-MAR-2000; 2000US-00380137.

PR 30-MAR-2000; 2000WO-US008439.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

FA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-875637/81.

DR P-PSDB; ADD01779.

XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or

PT PRO4978, useful in molecular biology, chromosome and gene mapping, in

PT generating antisense RNA and DNA, and in gene therapy.

XX Claim 2; Fig 143; 637bp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems, PRO

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This

CC sequence represents a human PRO polynucleotide of the invention. Note:

CC The sequence data for this patent is also available in electronic format

CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985

Score: 2792.00 Matches: 519

Percent Similarity: 99.62% Conservative: 0

Best Local Similarity: 99.62% Mismatches: 1

Query Match: 98.52% Indels: 2

DB: 10 Caps: 0

US-10-791-980-6 (1-520) x ADD01778 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeu 20

Db 206 ATGGTCGCGCGCTCGGCCCTCTGTCGCGCCCTGCAGCTGTACTGTGGGCGCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40

Db 266 GACGCCAGCCCGCGGAGCGCGGAGCCAGGAGCTGCGAAGGAGGCGGAGGCACTCTTA 325

Qy 41 GlulysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60

Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80

Db 386 GATGCCATCAGAGCGTTTTCAGTGGTGTCCAGCTACCTGTCCAGCGCGGTGTGGACCGC 445

```
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyraAla 100
DB 446 GCCACCCTCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACCTGTTGTTGTAGACACCGGACCAAAATGAGGGGTAA 565
QY 121 LysArgPheAlaLysGlnGlyAenLysTrpTyrrLysGlnHisLysSerTyrrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCCTCTCTTACCGCTGGTG 625
QY 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCGGAGCGGCGAGTTGCGGGCGCGTGGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCGCCCGCGCGGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGGCAACCTGTTCTGTTGCTGCGGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CCAGATCGGTACAGCTTGGCTTCCACCTCGCCCGCGCGCGGCTCATGGCGCC 984
QY 260 oTyrrTyrrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGCGCGTGCA 1044
QY 280 nSerLeuTyrrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAAGACCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGAGCGCCCTGAAACCGCAGGG 1164
QY 320 yProLysTyrrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTCTCTTCGATGCCATCATCTGTAGACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnArgTrpValGlyLeuProProAenIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTCTACTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 aProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGCGAGGGGCGCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrrTyrrVa 440
DB 1465 GCCTCTTCTTCTCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTAGT 1524
```

```
QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrrTyrrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGCCCGGAGGGGACTGCAAGTGGAGCCCTACTACCCCCCAAGTCTGCAGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGGAGGCGCGATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGATGACCGCTACTGCGCTCGACAGGCCAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 115
ADD53960
ID ADD53960 standard; cDNA; 1985 BP.
XX
AC ADD53960;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; PFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003203432-A1.
XX
PD 30-OCT-2003.
XX
PF 10-MAY-2002; 2002US-00142886.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2003-875639/81.
DR P-FSDB; ADD53961.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
```


AC ADD92277;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Human PRO polynucleotide #72.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor- α ; TNF- α ; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003199030-A1.
 XX
 PD 23-OCT-2003.
 XX
 PF 28-MAY-2002; 2002US-00156841.
 XX
 PR 03-MAR-2000; 2000US-0187202P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-900159/82.
 DR P-PSDB; ADD92278.
 DR
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX
 PS Claim 2; SEQ ID NO 143; 636pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor- α (TNF- α) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. No.: 1,938-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0
 US-10-791-980-6 (1-520) x ADD92277 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGCGCGCTCGGCTCTCTGCTGCGCGCTTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCAGCCGCGGAGCGCGAGGAGCTGCGCAAGGAGCGCGAGGCGGAGGCGGAGGCGG 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGACGGTTTCAGTGGGTGTCACAGCTACCTGTGTCAGCGGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
 QY 101 AlaTrpAlaGluArgLysAspLeuPheAlaArgHisArgThrLysMetArgLys 120
 Db 506 GCCTGGGTCTGAGAGGATCAGTGACTGTGTGTAGACACCGGACCAAAATGAGGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTCAGCAAGAGGTAAACAAATGGTACAGCAGCAGCCTCTCTACCGCCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCATCTCCGAGGCGCGAGTTCGGGGCGCGCTGCGGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGCTCTAGCGCTGAGTTCGTGGAGGCGCCGACAGGCGCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCCAGGGGAGGACACCAACGATGGCTGGGCAATGCTTTCATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGCGCGCTTGGCGGCGCGCTTC-CTGCCCGCGCGCGCGGCGGCGGCGCTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTTGGAGCGCGCGCGCGCGGCGGCGGCGGCTGTGTGGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACGCTTGGCGCTCACCACTCGCCCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
 Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTCTCAGCTGGGACGACGCTGTGGCGCGTGA 1044

Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300	OS	Homo sapiens.
Db	1045	GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGAAAGCTGTT	1104	XX	US2003199055-A1.
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyValArgProGluThrGlnGl	320	XX	23-OCT-2003.
Db	1105	CACGTACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCCCTGAAACGACAGG	1164	XX	12-APR-2002; 2002US-00121063.
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340	PR	31-MAR-1997; 97WO-US005230.
Db	1165	CCCTAAATACATGCCACTCTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA	1224	PR	12-JUN-1998; 98WO-US012456.
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360	PR	14-JUL-1998; 98WO-US014552.
Db	1225	CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG	1284	PR	28-AUG-1998; 98WO-US017888.
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380	PR	10-SEP-1998; 98WO-US018824.
Db	1285	TCCACTGCGAAGATGGTGGGGCTGCCGCCCAACATTGAGGCTGGGCAGTGTCAAT	1344	PR	14-SEP-1998; 98WO-US019093.
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400	PR	14-SEP-1998; 98WO-US019094.
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCA	1404	PR	14-SEP-1998; 98WO-US019177.
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420	PR	16-SEP-1998; 98WO-US019330.
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGGCCATCTGACGC	1464	PR	17-SEP-1998; 98WO-US019437.
Qy	420	aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440	PR	07-OCT-1998; 98WO-US021141.
Db	1465	CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTCAAGGGTGGCGCTACTACGT	1524	PR	23-OCT-1998; 98WO-US022991.
Qy	440	lIleAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460	PR	20-NOV-1998; 98WO-US024855.
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAAGTCTGCAGGACTGGG	1584	PR	01-DEC-1998; 98WO-US025108.
Qy	460	yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh	480	PR	05-JAN-1999; 99WO-US000106.
Db	1585	AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCT	1644	PR	08-MAR-1999; 99WO-US005028.
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500	PR	10-MAR-1999; 99WO-US005190.
Db	1645	CCGAGATGACCGCTACTGCGCGCTCGAACCAGGCCAACTGCAGGCAACACACTCGGGCG	1704	PR	2000WO-US006319.
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520	PR	99WO-US008615.
Db	1705	CTGGGCCACCGAGTGCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT	1764	PR	99WO-US010733.
Qy	520	e 520		PR	99WO-US012252.
Db	1765	C 1765		PR	99WO-US020111.
RESULT 117				PR	99WO-US020594.
ADD91173				PR	99WO-US020944.
ID	ADD91173	standard; cdna; 1985 BP.		PR	99WO-US021090.
XX				PR	99WO-US021547.
AC	ADD91173;			PR	99WO-US023089.
XX				PR	99WO-US028101.
DT	29-JAN-2004	(first entry)		PR	99WO-US028634.
DE				PR	99WO-US028551.
XX				PR	99WO-US028564.
XX				PR	99WO-US028565.
KW	Human	PRO polynucleotide #72.		PR	99WO-US030095.
KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;			PR	99WO-US030911.
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;			PR	99WO-US030999.
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;			PR	99WO-US030720.
KW	liver; microvascular endothelial cell; Glucose; FFA;			PR	99WO-US031243.
KW	skeletal muscle cell; adipocyte cell; pericyte cell;			PR	2000WO-US000219.
KW	inner ear utricular supporting cell; T-lymphocyte cell;			PR	06-JAN-2000; 2000WO-US000277.
KW	endothelial cell tube formation; bone disorder; cartilage disorder;			PR	06-JAN-2000; 2000WO-US000376.
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;			PR	11-FEB-2000; 2000WO-US003565.
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;			PR	18-FEB-2000; 2000WO-US004341.
XX	immune system cell infiltration.			PR	22-FEB-2000; 2000WO-US004414.
XX				PR	24-FEB-2000; 2000WO-US004914.
				PR	01-MAR-2000; 2000WO-US005004.
				PR	01-MAR-2000; 2000WO-US005601.
				PR	02-MAR-2000; 2000WO-US005746.
				PR	02-MAR-2000; 2000WO-US005841.
				PR	15-MAR-2000; 2000WO-US006884.
				PR	20-MAR-2000; 2000WO-US007377.
				PR	21-MAR-2000; 2000WO-US007532.
				PR	30-MAR-2000; 2000WO-US008439.
				PR	17-MAY-2000; 2000WO-US013705.
				PR	22-MAY-2000; 2000WO-US014042.
				PR	30-MAY-2000; 2000WO-US014941.
				PR	02-JUN-2000; 2000WO-US015264.
				PR	28-JUL-2000; 2000WO-US020710.
				PR	11-AUG-2000; 2000WO-US022031.
				PR	23-AUG-2000; 2000WO-US023522.

Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrlsArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAGAGCGTGGCGCGCGCGCTGTCTAGCTGGGACGACGTCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrlsGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAAGACCCCTTAGGGGGCTCAGTGGCGTCCAGCTCCAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyxserProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCGCCCAAGGAGCGCTTGAACGACAGG 1164
Qy 320 yProLysTyrlsCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTCCGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrlsPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATCTCTTCAAGGGTGGCGCTACTACGT 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCATCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrlsVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrlsTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAAAGTGTGCAAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTTCCGAGGCGCCGATGGCTCCATCTCTT 1644
Qy 480 eArgAspArgTyrlsTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTTGGCGCTCGACAGGCGCAAACTGCAAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTGCTGGATGCCAATCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 118
ADE03787
ID ADE03787 standard; cDNA; 1985 BP.
XX
AC ADE03787;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.

PN US2003199057-A1.

PD 23-OCT-2003.

PF 15-APR-2002; 2002US-00123213.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US006319.

PR 14-MAY-1999; 99WO-US008615.

PR 02-JUN-1999; 99WO-US010733.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 02-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 22-DEC-1999; 99WO-US030999.

PR 30-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 05-JAN-2000; 99WO-US031274.

PR 08-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 11-FEB-2000; 2000WO-US000376.

PR 18-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 22-FEB-2000; 2000WO-US004342.

PR 24-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 01-MAR-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 15-MAR-2000; 2000WO-US005841.

PR 20-MAR-2000; 2000WO-US006884.

PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.

22-MAY-2000; 2000WO-US014042.
30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US033678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006666.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00805689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritaisen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900167/82.
DR P-PSDB; ADE03788.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1-93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADE03787 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTCGCGCGCTCTGCTGCGCGCCCTGCAGTCTACTGTGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GACGCCACGCCGCGAGCGCGGAGCTGCGCAAGGAGCGCGGAGCATTCCTTA	325
QY	41	GluLysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAGTACGGATACCTCATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACGC	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
DB	386	GATGCCATCAGACGGTTTCAGTGGGTGCCAGCTACCTGTCCAGCGCGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys	120
DB	506	GCCTGGGCTGAGAGATCAGTGACTTGTTCAGACACCGGACCAAAATAGGGCGTAGG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCGCGCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCTGAGCATCTGCGGAGCCGCGAGTTCGGGGCGCGCTGCGCGCGCTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGACAGTCTCAGCGCTGAGTTCCTGGGAGGCGCCCGCACAGGCCCTCGAC	745
QY	180	rSerGlySerProSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGGCTGGGCAATGCCTTTGATGCG	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1	220
DB	806	CCAGGGGGCGCTGGCGCACGCTTC-CTGCCCCCGCGCGGAGGAGCATTCGACCA	864

```
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db |||||
QY 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCAACCTGTTCTGGTGGTGGCGCA 924
Db |||||
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db |||||
QY 925 CGAGATCGGTACACGCTGGCTCACCACCTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrpIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db |||||
QY 985 TCTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGCGCGCGTGA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyLysValAlaValAlaValGlnLeuProGlyLysLeuPh 300
Db |||||
QY 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCCCTCAGCTCCCGAAGAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGI 320
Db |||||
QY 1105 CACTGACTTTGAGACCTGGGACTCTCAGCGCCCAAGGAAGCGCCCTGAAACGCGAGG 1164
QY 320 yProIysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db |||||
QY 1165 CCCTAAATACTGCCACTCTCTCCGATGCCACTCTAGACAGGCAACGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db |||||
QY 1225 CATTTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db |||||
QY 1285 TCCACTGAGGAAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db |||||
QY 1345 GAATGATGGAGATTCTACTCTTCTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db |||||
QY 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCATCTTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db |||||
QY 1465 CGCCCTCTTCTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyLysLeuGlnValGluProTrpTyrProArgSerLeuGlnAspTrpGI 460
Db |||||
QY 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAACTCTGCGAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
Db |||||
QY 1585 AGGCATCCCTGAGGAGGTGAGGGGCGCTGCGGAGGCGCCATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db |||||
QY 1645 CCGAGATACCGCTACTGCGCGCTCGACAGGCCCAAACTGCGAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db |||||
QY 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATCCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 119

ADE32084

ID ADE32084 standard; cDNA; 1985 BP.

XX ADE32084;

AC ADE32084;

XX 29-JAN-2004 (first entry)

XX 29-JAN-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO4339 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX OS
XX US2003194765-A1.
XX 16-OCT-2003.
XX 09-MAY-2002; 2002US-00142889.
XX 03-MAR-2000; 2000US-0187202P.
XX 01-DEC-2000; 2000MO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart FA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-899784/82.
XX P-PSDB; ADE32085.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX Claim 2; SEQ ID NO 143; 636pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
XX a novel human secreted and transmembrane PRO polypeptide.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149

Score: 2792.00

Length: 1985

Percent Similarity: 99.62%

Matches: 519

Conservative: 0

Best Local Similarity: 99.62%

Mismatches: 1

Sequence 1985 BP: 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 98.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADE22016 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTGGCGGGTGGCGTCTCTGTCGGCGCCCTGACGTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
DB 266 GAGCGCCAGCCCGGAGCGCGAGGCCAGGAGCTGCGCAAGGCGGAGGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCTCCCAAGCTCCACCTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGCGGTGTGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTCGGGGTGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACCCGACCCANATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAACAATGGTACAAGCAGCACCTCTCTCCAGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTTCGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTTTCAGCGCTGAGTTCTGGGAGGCCCCACAGCCACAGGCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCTTTCATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATAGAGCGCTGGTCTCTGAGCGCGCGCGGGGGCAACCTGTTCGTGGTGTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGCGGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGCGTGGCGCGAGCGCTGTCTAGCTGGGACGACGTGTCGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAGAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320

DB 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCGCCCAAGAGAGCGCCCTCTGAACACGCGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValLeuArgGlnGlnLeuTyr 340
DB 1165 CCTAATATCTGCGCACTCTTCTTCGATGCCATCACTGTAGACAGCAACACAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTCATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLeu 380
DB 1285 TCCACTGCAGAAAGATGGTGGGCTGCCGCCCAACATTCAGGCTGGCGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyValArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTGTGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTTCAGCGCGCTGCCGAGGCGCGATGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCAAACTGCAGGCAACACCCCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 121
ADD79240
ID ADD79240 standard; cDNA; 1985 BP.
XX
AC ADD79240;
XX
XX 29-JAN-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003203428-A1.
XX
XX 30-OCT-2003.
XX

PF 22-APR-2002; 2002US-00127852.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875635/81.
XX P-PSDB; ADD79241.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADD79240 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGCTCTGTCGCGCGCTGACGCTGCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40

Db 266 GAGCCCCAGCCGCGGAGCGCGAGGCTGCGCAAGAGGCGGAGGCAATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProlysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACACTCCATTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACTGTCAGCGCGCTGTTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCCCAGATGACTCTGCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTCACTTGTGTTGTAGACACCGGACCAAAATGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCCGAGCGCGCAGTTCCGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCCCGCAGCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTCTTCTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyValaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGAGCGCACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGACGCTGGTCTCCAGCGCGCGCGCGCGCGCAACCTGTTCTGTTGGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGCCCTACCCACTCCCGCGCGCGCGCTCATGGGGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACCTTTGAGACCTGGGACTCTTACAGCCCCCAAGAGGCGCCCTGNAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACCTGCCACTCTTCTTCGATGCCATCCTCAGTACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGACATTTCTGGAGGTGGCAGCTGATGGCAACCTCTCAGAGCCCCG 1284
Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAAAGATGGGTGGGCTGCCCGCTGCCCGCACTTGAGGCTCGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgArgCysTrpArgPheArgGlyProLy 400

Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCCAAATGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCCTTGGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCCGAGGCCGCGAGTTGCGGCGCGCTGCGCGCCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTACGCGCTGGAGTTCTGGGAGGCCCCAGCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTTCTTCAAGGGGACACCAACGATGGGCTGGCAATGCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCCTCACCACTCGCCCGCGCGCGCGCTCATGGCGGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGTGGCGCGCGAGCGCTGCTCAGTGGGACGACGTCTGGCGGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACATTTGAGACCTGGGACTCTACAGCCCCCAAGAAAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCAGTGTAGACGGCAGACGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATCGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGCTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCCATCTCGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 GCCTCTTCTTCTCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGGCTACTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGGAGGCCGATGGCTCATCATCTTCTT 1644

Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGGCCAAACTGCAGGCAACCACTCGGGCGG 1704
Qy 500 gTTPAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTCGATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 123
ADE17593
ID ADE17593 standard; cDNA; 1985 BP.
XX
AC ADE17593;
XX 29-JAN-2004 (first entry)
XX Human PRO polynucleotide #72.
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endotherial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003199023-A1.
XX
XX 23-OCT-2003.
XX
PF 17-APR-2002; 2002US-00124821.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021094.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.

```

PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US011705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00871092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI: 2003-900155/82.
P-PSDB; ADE17594.
Two hundred and seventy five nucleic acids encoding PRO polypeptides,
useful for treating pericyte-associated tumors, diabetes and various bone
and/or cartilage disorders, e.g. arthritis.
Claim 2; SEQ ID NO 143; 637pp; English.
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
the proliferation of or gene expression in pericyte cells, for stimulating
cellular proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
from USPTO at seqdata.uspto.gov/sequence.html.
Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0
US-10-791-980-6 (1-520) x ADE17593 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeu 20
Db 206 ATGGTCGGCGCGCTCGGCTCTCTGTCGGCGCCCTGCTAGCTGCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnGluArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 325
QY 41 GluLysTyrGlyTyrLeuLeuAsnGluGlnValProLysValProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGTACCTTCATGAACAGAGTCCCAAGAGTCCCAAGAGTCCCAAGAGTCCCAAGAGT 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGCGGTTTCAGTGGGTGTCGCCAGCTACCTGTGTCAGCGCGGTGTGTGGACCGC 445
```

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCCCCAGATACCTCGTCCCGCGCTGCGGGGTTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTTTGCTAGACACCGGACCAAAATGAGCGGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCCTTGCACAGCAAGGTAAACAAATGGTACAAGCAGCACCTCTCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCCTGAGCATCTGCCGAGCGGCAGTTCTGGGGCGCGTGGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCAGCGCTGGAGTTCTGGGAGGCCCCCAGCACAGGCCCCGCTCAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACAACGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACACTCGCGCGCGCGCGCTCATGGCGGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCCTACAGCCCCCAAGAAAGGCGCCCTGAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTCATGGCAAGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAAAGATGGGTGGGCTCGCGGCTCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATCGAATTTCTACTTCTTCAAAGGGGGTGCATCTGGAGGTTCCGGGGCCCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGCAGGGGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460

Db 1525 GCTGGCCCGAGGGGGAAGTGCAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCTAGCGGCGCCTCGCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACCGCCAACTGCAGGCAACCCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGCATGCCNACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 124
ADD91725
ID ADD91725 standard; cDNA; 1985 BP.
XX
AC ADD91725;
XX
XX 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199053-A1.
XX
PD 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121053.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 14-SEP-1998; 98WO-US018824.
PR 10-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 2000WO-US006319.
PR 14-MAY-1999; 99WO-US008615.
PR 02-JUN-1999; 99WO-US010733.
PR 01-SEP-1999; 99WO-US012252.
PR 08-SEP-1999; 99WO-US020111.
PR 13-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.

```
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028311.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US043956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
XX WPI; 2003-900164/82.
DR P-PSDB; ADD91726.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 143; 636pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalasaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADD91725 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTCGGCCTCTCTGCGGCCCTCGCAGCTGCTACTGTGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCCGGAGCGCGGAGGCTGCGCAGAGCTGCCAAGAGCGCGAGGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
```

Db 326 GAGAGTACGGATACCTCAATGAACAGGTCCTCCAAAGCTCCACACCTCCACCTCGATTTCAGC 385
Qy 61 AspAlaIleAraGAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCATCAGAGCGTTTCAGTGGGTGTCCAGAGCTACCTGTCTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTGTCTCCCGCTGCGGGGTTACAGATACCACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTAGACACCGGACCAAAATCAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACCGCTTGCAAAGCAAGTAACAAATGGTACAGCAGCACCTCTCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCCGAGCGCGCAGATTCTGGAGGCGCCAGCCACAGGCCCGCTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGATTCTGGAGGCGCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTCTTCCAAAGGACCAACATGATGGGCTGGGCAATGSCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCAACCTGTTCTGGTGTCTGGCGCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACAGCTTGGCCTCACCATCTCGCCCGCGCGCGCGCTCATYGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGACGACGCTGCGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTCTGGACTCTCTCAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTTCATGATCCATCTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCCCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGGGCGAGGGGCGCTGCCCGCCCATCTCTGACG 1464

Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyValaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGTCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTATCCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTCAGAGGTCAGCGCGCCCTGCCAGGCCCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCCTCGACCGGCGCAACTGCAGCAACACCTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 125
ADE33188
ID ADE33188 standard; cDNA; 1985 BP.
XX
AC ADE33188;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003194767-A1.
XX
PD 16-OCT-2003.
XX
PP 16-MAY-2002; 2002US-00147497.
XX
PR 26-AUG-1998; 98US-0097951P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart FA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-899786/82.
DR P-PSDB; ADE33189.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 143; 636pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and CC transmembrane) polypeptides (I). (I) is useful for stimulating the CC release of TNF-alpha from human blood, for modulating the uptake of CC glucose or FFA by skeletal muscle cells or adipocyte cells, for CC stimulating the proliferation or differentiation of chondrocyte cells, CC for stimulating the proliferation of or gene expression in pericyte CC cells, for stimulating the release of proteoglycans from cartilage, for CC stimulating the proliferation of inner ear utricular supporting cells, CC for stimulating the proliferation of T-lymphocyte cells, for stimulating CC the release of a cytokine from PBMC cells, for inhibiting the binding of CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte CC cells, for stimulating proliferation of endothelial cells, for detecting CC the presence of tumour in a mammal. The tumour is lung, colon, breast, CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes CC are useful for isolating genomic and cDNA nucleotide sequences or CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful CC in assays to identify other proteins or molecules involved in binding CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome CC and gene mapping, in generation of antisense RNA and DNA, in the CC preparation of PRO polypeptide, for generating transgenic animals or CC knockout animals which in turn are useful in the development and CC screening of therapeutically useful reagents, in gene therapy, for CC chromosome identification, as chromosome marker, and for generating CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. CC detecting its expression in specific cells, tissues or serum, and for CC affinity purification of PRO from recombinant cell culture or natural CC sources. (I) and (II) are useful for tissue typing. This sequence encodes CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADE33188 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTGTCGGCGGCTGGGCTCTCTGTCGGGCCCTCGAGCTGCTACTGTGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCGCGAGCGGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCAATTCCTA	325
Qy	41	GluLysTyrGlyTyrIleuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValIleuAspArg	80
Db	386	GATGCCATCAGACCGTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspIleuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCTCGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnLysAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACCGCTTTCGAAGCAAGGTAAACAAATGGTAAAGAGCACCTCTCTACCGCCCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTGAGCACTCTCGCGAGCGGCGAGTTTCGGGGCGCGTTCGCGCGCCCTTCCAG	685

Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCCCTGGAGTTCGGAGGGCCCCAGCCAGGCCCTGCTAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGACCAACAACATGGCTGGGCAATGCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGAAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGTCCCTGACCGCGCGCGCGGCGCAACTGTTCTGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTCAACAGCTTGGCCTCACCACTCGCCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrIlySArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGCGCGCGCTGCTCAGCTGGAGCGACGCTGCTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCCGCTCCAGCTCCAGGNAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGGCGCTGAAACGACGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACCTGCGCACCTCTCTTCGATGCCATCCTCTAGACAGCAACAGCACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAGGAGGCCAATTTCTGGAGGTGGAGCTGATGGCAACGCTCTAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle	380
Db	1285	TCCACTGCAGAAAGATGGGTGCGGCTGCCGCCCAACATTCAGGCTGCGGCGTGTCAAT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTTCTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCGGCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrTrpArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTCCCCGAAAGTCTGCGAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCTCTGAGGAGGTACGCGCGCCCTGCCAGGCCCGGATGGCTCCATCATCTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGGCGCTCGACCGCCAAACTGCAGGCCAACCTCTCGGGCGG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheIleAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGTCACCACTCGGGGAGCGCCCTGT	1764

Qy	520 e 520	05-JAN-2000; 2000WO-US000219.	PR
Db	1765 C 1765	06-JAN-2000; 2000WO-US000277.	PR
RESULT 126		06-JAN-2000; 2000WO-US000376.	PR
ADE33740		11-FEB-2000; 2000WO-US003565.	PR
ID ADE33740 standard; cDNA; 1985 BP.		18-FEB-2000; 2000WO-US004341.	PR
XX		22-FEB-2000; 2000WO-US004414.	PR
AC ADE33740;		24-FEB-2000; 2000WO-US004914.	PR
XX		01-MAR-2000; 2000WO-US005004.	PR
DT 29-JAN-2004 (first entry)		02-MAR-2000; 2000WO-US005601.	PR
XX		02-MAR-2000; 2000WO-US005746.	PR
DE	Novel human secreted and transmembrane protein PRO4339 cDNA.	15-MAR-2000; 2000WO-US005841.	PR
XX	Human; secreted and transmembrane protein; PRO; gene; ss;	20-MAR-2000; 2000WO-US007377.	PR
KW	Tumour necrosis factor alpha release; TNF-alpha release;	21-MAR-2000; 2000WO-US007532.	PR
KW	glucose uptake modulator; FFA uptake modulator;	30-MAR-2000; 2000WO-US008439.	PR
KW	cell proliferation stimulator; cell differentiation stimulator;	17-MAY-2000; 2000WO-US013705.	PR
KW	cell differentiation inhibitor; cytokine release stimulator; tumour;	22-MAY-2000; 2000WO-US014042.	PR
KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;	30-MAY-2000; 2000WO-US014941.	PR
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;	02-JUN-2000; 2000WO-US015264.	PR
KW	Gene therapy; chromosome identification; chromosome marker.	28-JUL-2000; 2000WO-US020710.	PR
XX		11-AUG-2000; 2000WO-US022031.	PR
OS	Homo sapiens.	23-AUG-2000; 2000WO-US023522.	PR
XX		24-AUG-2000; 2000WO-US023328.	PR
PN	US2003194791-A1.	08-NOV-2000; 2000WO-US030952.	PR
XX		10-NOV-2000; 2000WO-US030873.	PR
XX		01-DEC-2000; 2000WO-US032678.	PR
PD	16-OCT-2003.	20-DEC-2000; 2000US-00747259.	PR
XX		20-DEC-2000; 2000WO-US034956.	PR
PF	11-APR-2002; 2002US-00121046.	28-FEB-2001; 2001US-00796498.	PR
XX		28-FEB-2001; 2001WO-US006520.	PR
XX		01-MAR-2001; 2001WO-US006666.	PR
PR	31-MAR-1997; 97WO-US005230.	09-MAR-2001; 2001US-00802706.	PR
PR	12-JUN-1998; 98WO-US012456.	14-MAR-2001; 2001US-00808689.	PR
PR	14-JUL-1998; 98WO-US014552.	22-MAR-2001; 2001US-00816744.	PR
PR	28-AUG-1998; 98WO-US017888.	05-APR-2001; 2001US-00828366.	PR
PR	10-SEP-1998; 98WO-US018824.	10-MAY-2001; 2001US-00854208.	PR
PR	14-SEP-1998; 98WO-US019093.	18-MAY-2001; 2001US-00860216.	PR
PR	14-SEP-1998; 98WO-US019094.	25-MAY-2001; 2001US-00866028.	PR
PR	14-SEP-1998; 98WO-US019177.	25-MAY-2001; 2001US-00866034.	PR
PR	16-SEP-1998; 98WO-US019330.	25-MAY-2001; 2001WO-US017092.	PR
PR	17-SEP-1998; 98WO-US019437.	01-JUN-2001; 2001US-00872035.	PR
PR	07-OCT-1998; 98WO-US021141.	05-JUN-2001; 2001US-00874503.	PR
PR	29-OCT-1998; 98WO-US022991.	14-JUN-2001; 2001US-00882536.	PR
PR	29-OCT-1998; 98WO-US022992.	19-JUN-2001; 2001US-00886342.	PR
PR	20-NOV-1998; 98WO-US024855.	21-JUN-2001; 2001US-00887879.	PR
PR	01-DEC-1998; 98WO-US025108.	22-JUN-2001; 2001WO-US020116.	PR
PR	05-JAN-1999; 99WO-US000106.	09-JUL-2001; 2001WO-US021735.	PR
PR	08-MAR-1999; 99WO-US005028.	18-JUL-2001; 2001US-00908827.	PR
PR	10-MAR-1999; 99WO-US005190.	06-AUG-2001; 2001US-00924419.	PR
PR	10-MAR-1999; 2000WO-US006319.	09-AUG-2001; 2001US-00927796.	PR
PR	20-APR-1999; 99WO-US008615.	16-AUG-2001; 2001US-00931836.	PR
PR	14-MAY-1999; 99WO-US010733.	19-DEC-2001; 2001US-00028072.	XX
PR	02-JUN-1999; 99WO-US012252.	(GETH) GENENTECH INC.	FA
PR	01-SEP-1999; 99WO-US020111.	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	XX
PR	08-SEP-1999; 99WO-US020594.	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	PI
PR	13-SEP-1999; 99WO-US020944.	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	PI
PR	15-SEP-1999; 99WO-US021090.	WPI; 2003-899790/82.	XX
PR	15-SEP-1999; 99WO-US021547.	P-PSDB; ADE33741.	DR
PR	05-OCT-1999; 99WO-US023089.	Two hundred and seventy five nucleic acids encoding PRO polypeptides,	XX
PR	29-NOV-1999; 99WO-US028214.	useful for treating pericyte-associated tumors, diabetes and various bone	PT
PR	30-NOV-1999; 99WO-US028313.	and/or cartilage disorders, e.g. arthritis.	PT
PR	30-NOV-1999; 99WO-US028409.	Claim 2; SEQ ID NO 143; 636pp; English.	XX
PR	01-DEC-1999; 99WO-US028301.		PS
PR	01-DEC-1999; 99WO-US028634.		XX
PR	02-DEC-1999; 99WO-US028531.		XX
PR	02-DEC-1999; 99WO-US028564.		XX
PR	02-DEC-1999; 99WO-US028565.		XX
PR	16-DEC-1999; 99WO-US030095.		XX
PR	20-DEC-1999; 99WO-US030911.		XX
PR	20-DEC-1999; 99WO-US030999.		XX
PR	22-DEC-1999; 99WO-US030720.		XX
PR	30-DEC-1999; 99WO-US031243.		XX
PR	30-DEC-1999; 99WO-US031274.		XX

Db 1765 C 1765
 RESULT 127
 ADD79792
 ID ADD79792 standard; cDNA; 1985 BP.
 XX AC ADD79792;
 XX DT 29-JAN-2004 (first entry)
 XX DE cDNA encoding human PRO polypeptide #72.
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX OS Homo sapiens.
 XX PN US2003207417-A1.
 XX PD 06-NOV-2003.
 XX PF 07-MAY-2002; 2002US-00140805.
 XX PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 10-MAR-1999; 2000WO-US006319.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US021090.
 PR 29-NOV-1999; 99WO-US023089.
 PR 30-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 22-DEC-1999; 99WO-US030999.
 PR 30-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 18-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 01-MAR-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 15-MAR-2000; 2000WO-US005841.
 PR 20-MAR-2000; 2000WO-US006884.
 PR 21-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US007532.
 PR 17-MAY-2000; 2000WO-US008439.
 PR 22-MAY-2000; 2000WO-US013705.
 PR 30-MAY-2000; 2000WO-US014042.
 PR 02-JUN-2000; 2000WO-US014941.
 PR 28-JUL-2000; 2000WO-US015264.
 PR 11-AUG-2000; 2000WO-US020710.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00860216.
 PR 18-MAY-2001; 2001US-00860208.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001US-00887879.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Debnovers L, Filvaroff E, Gao W;
 PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-875867/81.
 XX P-PSDB; ADD79793.
 XX DR
 XX New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor, for chromosome mapping or for tissue
 PT typing.
 XX
 PS Claim 2; Fig 143; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. The sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:				
Pred. No.:	1.93e-149	Length:	1985	
Score:	2792.00	Matches:	519	
Percent Similarity:	99.62%	Conservative:	0	
Best Local Similarity:	99.62%	Mismatches:	1	
Query Match:	98.52%	Indels:	2	
DB:	10	Gaps:	0	
US-10-791-980-6 (1-520) x ADD79792 (1-1985)				
QY	1	MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu	20	
DB	206	ATGTGTCGGCGGTCTGCTGCTGGCGCCCTCGAGTGTACTGTGGGGCCACCTG	265	
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40	
DB	266	GACGCCACGCCCGGAGCGCGGAGCCGAGGCTGGCGAAGGAGCGGAGGCAATTCCTA	325	
QY	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60	
DB	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACCTCCATCGATTCA	385	
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80	
DB	386	GATGCCATCAGACGGTTTCAGTGGGTGTCCCGACTACCTGTGACGGCGGTGTGGACCG	445	
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100	
DB	446	GCACCCCTGCCGCACATGACTGTGCCCGCTGCGGGGTTACAGATACCAACAGTTATGG	505	
QY	101	AlaTtpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120	
DB	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGCGGTAG	565	
QY	121	LysArgPheAlaLysGlnGlyAsnLysTyrTrpLysGlnHisLeuSerTyrArgLeuVal	140	

QY 500 qTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaHisSerGlySerAlaLeuPh 520
 Db 1705 CRGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGGCGCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 128
 ADD92829
 ID ADD92829 standard; cDNA; 1985 BP.
 XX AC
 XX ADD92829;
 DT 29-JAN-2004 (first entry)
 XX DE Human PRO polynucleotide #72.
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX OS Homo sapiens.
 XX US2003194768-A1.
 XX 16-OCT-2003.
 XX 21-MAY-2002; 2002US-00152371.
 XX 03-MAR-2000; 2000US-0187202P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski P, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-899787/82.
 DR P-PSDB; ADD92830.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; SEQ ID NO 143; 636pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADD92829 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTTCGGCGCGTGGCCCTCTCTGTCGGCGCCCTGCAGCTGTACTGTGGGGCCACTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GAGCCCGAGCCCGCGGAGCGCGAGGCGCGAGAGCTGCGAAGGAGGCGGAGGCATTCTTA 325
 QY 41 GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACTGTCCAGCGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTCGCGCCAGATGATCTGTCGCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTTGTAGACACCGGACCAAAATGAGCGCTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTCAAAGCAAGGTAACAATGGTACAGCAGCACCTCTCTCCCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCATCTGCGGAGCGCGAGCTTCGGGGCGCGTTCGGCGCGCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTTGGAGAGCCCGCCAGCAGCGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCGGCTCACTCTCTCCAAAGGGGACCAACAGATGGGTGGGCAATGCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCGCGCGGCGGAGCGACATTCGACCA 864

QY 220 nAspGluuArgTtpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCTCTGAGCGCGCGCGGCGCAACCTGTTCTGTGTCTGCGGCA 924
 QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTTCACACCGTTGGCTCACCACCTCGCGCGCGCGCGCTCATGCGCGC 984
 QY 260 oTyrtTyrlsArgLeuGlyArgAspAlaLeuSerTtpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCGCGCGTGA 1044
 QY 280 nSerLeuTyrlsGlySerProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCGTGTATGAGGAGCGCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTtpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCGCGCGCGCGCTGAAACGCGGG 1164
 QY 320 yProlystYrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 DB 1165 CCTTAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCGCAACAGCACTGTA 1224
 QY 340 xIlePheLysGlySerHisPheTtpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGCGAGCTGATGCAACGCTCTCAGAGCGCGG 1284
 QY 360 gProLeuGlnGluArgTtpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
 DB 1285 TCCACTGCAGGAAAGATGGTGGGCTGCGCGCGCGCGCGCGCTGCGGAGTGTGCTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTtpArgPheArgGlyProly 400
 DB 1345 GAATGATGGAGATTTCTACTTCTCAAGGGGGTCTGATGCTGGAGGTTCGCGGCGCGCAA 1404
 QY 400 sProValTtpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGGGGTCTCCACACGCTGTCGCGGCGAGGGGCTTGCCTCCGCGCATCTGAGCG 1464
 QY 420 alAlaLeuPheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTTCTCTCTCTGCGCGCGCTCATCTCTTCAAGGTGCGCGCTACTAGT 1524
 QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTtpGl 460
 DB 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCGCTTACTACCCCGAAGTCTGCGAGGCTGGGG 1584
 QY 460 yGlyTleProGluGluValSerGlyValLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGCATCTCTGAGGAGTTCAGCGCGCGCTGCGGAGGCGCGGATGCTCATCTCTT 1644
 QY 480 eArgAspAspArgTyrTtpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CGAGATGACCGCTACTGCGCGCTCGACCGAGCGCAACCTGCGAGCAACACCTCGGCGG 1704
 QY 500 gTtpAlaThrGluLeuProTtpMetGlyCysTtpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCCGAGCTGCCCTGTGATGGGCTGCTGGCATGCCAATCTCGGCGAGCGCGCTGTT 1764
 QY 520 e 520
 DB 1765 c 1765
 RESULT 129
 ADE19249
 ID ADE19249 standard; cDNA; 1985 BP.
 XX
 AC ADE19249;
 XX
 DT 29-JAN-2004 (first entry)
 XX

Human PRO polynucleotide #72.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

Homo sapiens.

US2003199025-A1.

23-OCT-2003.

21-MAY-2002; 2002US-00152385.

03-MAR-2000; 2000US-0187202P.

10-NOV-2000; 2000WO-US030873.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-900156/82.

P-P8DB; ADE19250.

Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.

Claim 2; SEQ ID NO 143; 648pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format

```
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
SQ

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADE19249 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTTGCGCGCGTGGCGCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGAGGCCAGAGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
Qy 41 GluIysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCACAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTTGTGTAGACACCGGACCAAAATGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCGAGCGCGCAGTTCCGGGCGCGGTGGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCACAGGCGCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCGGGCTCACCCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGGGCGCAACCTGTGTGGTGGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCCATCTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCTGGGCGCGACGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCAGGAAAGCTGTT 1104
```

```
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCCCTCTGAACGCGAGG 1164
Qy 320 YProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
Db 1165 CCCTAATACTGCCACTCTCTTCGATGTCATCCTGTAGACAGGCACACGCAACTGTGA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAGAAAGATGGGTGCGGGCTGCCCCCAACATTTAGAGCTGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGCGCTGCCCGGCCATCTCGAGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCTCTTCTTCCCTCTCTGCGCCGCTCACTCTTCAAGGGTGCCTACTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCTCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTGAGCGCGCTGCCGAGCGCGCTGCCAGTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGTACTTGGCGCTCGACCGAGCCCAACTGCAGGCACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGTCGATGCCAATCTCGGGAGCGGCTGT 1764
Qy 520 e 520
Db 1765 c 1765

RESULT 130
ADE18697
ID ADE18697 standard; cDNA; 1985 BP.
XX AC ADE18697;
XX DT 29-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #72.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX FN US2003199026-A1.
```


Qy	101	AlaTrpAlaGluAArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGCGCTGAGAGGATCAGTGACTGTGTTCCTAGACACCGGACCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCANAGCAGGTAAACAAATGGTACAAGCAGCACCTCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCCTGAGCATCTCCCGAGCGCGCAGTTTGGGGCGCGCTGCGCGCGCTTCCTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnAlaProLeuLys	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTCGAGTCTCTGGAGGCGCCAGACACAGGCGCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTCTTCCAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC	805
Qy	200	aglnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGCGCCCTGGCGCACGCCTTC-CTGCCCGCGCGCGCAAGCGCATCTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgGlnPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTGTGTGTCTGGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTCAACAGCTTTGGCTTACCCTCATCGCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyTrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl	280
Db	985	CTACTACAGAGGCTGGGCGCGAGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA	1044
Qy	280	nSerLeuTrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCTGAAACGCGAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTTCTTCGATGCCATCAGTGAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGTTCGGGCTGCCCGCCCAACATTGAGGCTCGCGCAGTGTATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTCAAGGGGGTTCGATGCTGGAGGTTTCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACACAGCTGTGCGGGCAGGGGGCGCTGCCCGCCATCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCGCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAAGGACTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480

Db	1585	AGGCATCCCTGAGAGGTCAGCCGCGCCCTGCGAGGCGCGATGGCTCCATCATCTCTT	1644
Qy	480	eA:gAspAspArgTy:rTIpArgLeuAaspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGGCGCCCTCGACCAAGGCCAAACTGCAGGCAACCACTCGGGCGG	1704
Qy	500	gTTPAlaThrGluLeuProTTPMetGLYCYbTTPHi:AlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCGCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 132			
ID	ADD95682	standard; cDNA; 1985 BP.	
XX	AC	ADD95682;	
XX	XX		
DT	29-JAN-2004	(first entry)	
XX	XX		
DE	Human PRO polynucleotide #72.		
XX	XX		
KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; FFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;		
KW	immune system cell infiltration.		
XX	XX		
OS	Homo sapiens.		
XX	XX		
PN	US2003199059-A1.		
XX	XX		
PD	23-OCT-2003.		
XX	XX		
PF	15-APR-2002; 2002US-00123322.		
XX	XX		
PR	31-MAR-1997; 97WO-US0005230.		
PR	12-JUN-1998; 98WO-US012456.		
PR	14-JUL-1998; 98WO-US014552.		
PR	28-AUG-1998; 98WO-US017888.		
PR	10-SEP-1998; 98WO-US018824.		
PR	14-SEP-1998; 98WO-US019093.		
PR	14-SEP-1998; 98WO-US019094.		
PR	14-SEP-1998; 98WO-US019177.		
PR	16-SEP-1998; 98WO-US019330.		
PR	17-SEP-1998; 98WO-US019437.		
PR	07-OCT-1998; 98WO-US021141.		
PR	29-OCT-1998; 98WO-US022991.		
PR	29-OCT-1998; 98WO-US022992.		
PR	20-NOV-1998; 98WO-US024855.		
PR	01-DEC-1998; 98WO-US025108.		
PR	03-JAN-1999; 99WO-US000106.		
PR	08-MAR-1999; 99WO-US005028.		
PR	10-MAR-1999; 99WO-US005190.		
PR	10-MAR-1999; 2000WO-US006319.		
PR	20-APR-1999; 99WO-US008615.		
PR	14-MAY-1999; 99WO-US010733.		
PR	02-JUN-1999; 99WO-US012252.		
PR	01-SEP-1999; 99WO-US020111.		
PR	08-SEP-1999; 99WO-US020594.		
PR	13-SEP-1999; 99WO-US020944.		
PR	15-SEP-1999; 99WO-US021090.		
PR	15-SEP-1999; 99WO-US021547.		
PR	05-OCT-1999; 99WO-US023089.		
PR	29-NOV-1999; 99WO-US028214.		

Db 386 GATGCCATCAGACCGCTTTCAGTGGGTGTCCTCCAGCTACCTGTCCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyraLa 100
Db 446 GCCACCTCGCCAGATGACTGTCCTCCCGCTCGGGGTTCAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGCTGAGAGGATCAGTCACTTGTGTGTAGACACCGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnClyAsnLysTrpTyrlLysGlnHisLysSerTyrlArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGTAACTAAGTACAGCAGCACCCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCAGTCTCGGAGCGCGGAGTTCGGGGCGCGTGGCGGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCCCTCGGCGACGCCCTTC-CTGGCCCGCGCGCGGAGGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCCTCGAGCGCGCGCGCGCAACCTGTTGGTGTCTGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrlLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGCTGGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCGCGCGTCA 1044
Qy 280 nSerLeuTyrlLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrlSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 vProLysTyrlCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAAATACTCCCACTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAanValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGACAGTGTATGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGCTGGCGGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheThrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGGTTCATGCTGGAGGTTCGGGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACACACTGTGCGGGCAGGGGGGCTGCCCCCGCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrlTyraVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCGCGCTACTACGT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrlTyrlProArgSerLeuGlnAspTrpG1 460
Db 1525 CTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACTACCCCGAGCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTGAGCGGCGCTGCGAGGCGCGATGGCTCCATCATCTCTTT 1644
Qy 480 eArgAspAspArgTyrlTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGACGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGTGGCTGGTGGCTGGTGGCATGCCAACTCGGGGAGCGCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 133
ADE22568
ID ADE22568 standard; cDNA; 1985 BP.
XX AC ADE22568;
XX XX
XX 29-JAN-2004 (first entry)
XX DE cDNA encoding human PRO polypeptide #72.
XX KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003199064-Al.
XX PD 23-OCT-2003.
XX PF 19-APR-2002; 2002US-00125932.
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.

QY 41 GluLysTrpGlyTyrLeuAsnGluInValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCCACTCCATCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGTACCTGTTCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTCGGGGTTACAGATACCAACAGTATTATGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGCTGACAGGATCAGTACGTTGTTTGTAGACACCGGACCAAAATGAGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTTGAAGCAAGGTAAACAAATGGTAAACAGCAGCACCTCTCTACCGCCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGACATCTGCCGAGCGGCGAGTTCGGGGCGCGTGGCGCGCCCTTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCCTACGCGTGGAGTTCGGAGGCGCCACAGCCAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGCG 805
QY 200 sGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGGCGCGCTGGCGACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGTCCTCGAGCGCGCGCGCGCGCAACCTGTTCTGGTGTCTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCCACCTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG 280
DB 985 CTACTACAGAGCGTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGCGCCCTCGAAACGACGG 1164
QY 320 vProLysTrpCysHisSerPheAspAlaIleThrValLeuAspArgGlnGlnLeuTy 340
DB 1165 CCGTAAATACTCCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
DB 1285 TCCACTGCAGGAAGATGGTGGGCTGGCGCTGCCCGCCCAACATTCAGGCTGGCGAGTCTATT 1344
QY 380 uAsnAspGlyAspPheThrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATATGGAGATTTCTACTCTTCAAGGGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420

DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrpVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG 460
DB 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTGACGGCGCTGCGAGGCGCCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACCAAGCCCAACTGCAGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 134
ADD78686
ID ADD78686 standard; cDNA; 1985 BP.
XX AC ADD78686;
XX DT 29-JAN-2004 (first entry)
XX DE cDNA encoding human PRO polypeptide #72.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003203429-A1.
XX PD 30-OCT-2003.
XX PF 22-APR-2002; 2002US-00127900.
XX PR 05-JUN-2000; 2000US-0209832P.
XX PR 01-DEC-2000; 2000WO-US032878.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WIPI; 2003-875636/81.
XX DR P-PSDB; ADD78687.
XX PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.

Db 1645 CCGAGATACCGCTACTGCGGCTCGACAGGCCAAATGCAAGCAACCACTCGGGCGG 1704
Qy 500 gTtpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCAACTGGGAGGCGCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 135
ADE32636
ID ADE32636 standard; cDNA; 1985 BP.
XX
AC ADE32636;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003194766-A1.
XX
PD 16-OCT-2003.
XX
PF 14-MAY-2002; 2002US-00145874.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2003-899785/82.
DR P-PSDB; ADE32637.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 143; 636pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PMBC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful

CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1-936-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADE32636 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGCGAGCGGAGCGGAGCTGCGCAAGAGGCGGAGGCATTCCTTA	325
Qy	41	GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACCCTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGGTTTCAGTGGGTGTCACGCTACCTGTGAGCGGCGTGTGGACCG	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGATTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGATCAGTGACTTGTTCCTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTGCAGAGCAAGGTAAACAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGGCTGAGCATCTGCGGAGCGGAGTTCGGGCGCGCTGCGCGCGCTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCGCTCGAGTTCCTGGAGGCGCCAGCCACAGGCCCCCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACTTCTCCAGAGGACCACCAACGATGGGCTGGGCAATGCTTGTATGCG	805
Qy	200	agInGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
Db	806	CCAGGGGCGCGCTGGCGGACGCCCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCTTCCTAGAGCCCGCGCGGCGGCGCAACCTGTTCTGGTGGCGCA	924

Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0
US-10-791-980-6 (1-520) x ADE42328 (1-1985)			
QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTCGGCGGCTCGGCTCTCTGTCGGCGGCTCGAGCTGCTACTGTGGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GAGCCCGACCCCGGAGCGCGAGGCGCAGGAGCTGCGCAAGGAGCGGAGGCAATTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
DB	386	GATGCCATCAGACGGTTTCAGTGGGTGTCCTCAGCTACCTGTGAGCGGCGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTCGCCAGATGACTGTCCTCCGCTGCGGGTTACAGATACCAACAGTTATGCG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
DB	506	GCCTGGCTGAGAGGATCAGTACTGTTTGTGTAGACACCGCACCAAAATGAGGCGTAAG	565
QY	121	LysArgPheAlaLysGlnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
DB	566	AAACGCTTTGCAAGCAAGTAACTGTTGTTACAGACGACCTCTCTACCGCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	NACTGGCTGAGCATCTGCGGAGCGCGGAGTTGCGGGCGCGTGGCGCCGCTTCGAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCGCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACCTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
DB	806	CCAGGGGGGCGCTGGCGACCGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
DB	865	AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGCAACCTGTTCTGCTGCTGCTGGCGCA	924
QY	240	sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CCAGATCCGCTCACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGCGCGC	984
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
DB	985	CTACTACAGAGGCTGGGCGCGGACCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCTGTATGGAGACCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
DB	1105	CACTGACTTTGAGCTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACGAGGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340

DB	1165	CCCTAAATACTGCCACTCTCTCTCGATGCCATCATCTGTAGACAGGCAACAGCACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe	380
DB	1285	TCCACTGGAGAAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTGCGGCGAGTGCATT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
DB	1345	GAATCATGGAGATTTCTACTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
DB	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCCATCTGACGC	1464
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
DB	1465	CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
DB	1525	GCTGSCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584
QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
DB	1585	AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGCTCCATCATCTTCTT	1644
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVa	500
DB	1645	CGAGATGACCGCTACTGCGGCTCGACAGGCCAACTGCAGGCCAACCCCTCGGGCGC	1704
QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
DB	1705	CTGGSCCACCAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGAGCGCGCTGTT	1764
QY	520	e 520	
DB	1765	C 1765	
RESULT 137			
ADD80344			
ID	ADD80344 standard; cDNA; 1985 BP.		
XX	AC ADD80344;		
AC	29-JAN-2004 (first entry)		
DT	cDNA encoding human PRO polypeptide #72.		
XX	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
XX	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; FFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		
XX	immune system cell infiltration.		
OS	Homo sapiens.		
XX	US2003207418-A1.		
PN	06-NOV-2003.		
XX	07-MAY-2002; 2002US-00140809.		
PD	31-MAR-1997; 97WO-US005230.		

PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 16-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030939.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875866/81.
DR P-PSDB; ADD80345.
XX
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX
PS Claim 2; Fig 143; 638pp; English.
XX
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from

CC the USPTO website at seqdata.uspto.gov.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADD80344 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTTCGGCGGCTCGCCCTCTCTGTCGGCGCCCTGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGAGCGCGAGGCGCAGGAGCTGCGCAAGAGCGGCGGAGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuLeuGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGAGTACCTCAATGAACAGAGTCCCAAGAGCTCCACCTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACCTGTGAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGATTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaValGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAACTGTTGTAAGCAGCAGCTCTCTCTACCGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCAATCTGCGGAGCGCGAGTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGGCCCGCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGGCTCACCTCTTCCAAAGGAGCAACACAGATGGGCTGGGCAATGCCCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGGACAGCCCTTC-CTGCCCCCGCGCGGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGGCGGCAACCTGTGTGCTGGTGTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CCAGATCGGTTCACGCTTGGCTTCCACCTACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAGAGGCTGGGCGCGAGCGGCTGTCTAGCTGGGACGAGCTGTGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
```

```
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCAAGGAGCGCCCTTAAACGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCATCACTAGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGAGGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGTGCGGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGATGCTGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGCGCAGGGGGCGCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCTATCTCTTCAAGGGTGCCCGTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTTACCCCCAGTCTGCAGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCTCAGGAGGTGAGCGGGCGCTGCGGAGGCGCGATGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGluAlaLysLeuGlnAlaThrThrSerGlyVa 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGCAGGCCAACCCCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGAGGCGCGCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 138
ADD89372
ID ADD89372 standard; cDNA; 1985 BP.
XX
AC ADD89372;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.
XX
Homo sapiens.
XX
PN US2003199028-A1.
```


QY 380 uAenAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
 DB 1345 GAATGATGAGATTCTTCTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCCAAGCTGTGCCGGGAGGGGCGCTGCCCGGCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTTCTTCCCTCTCTTGGCCCGCTCATCTCTTCAAGGGTGGCCCGCTACTACT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCAGGACTGGGG 1584
 QY 460 yGlylleProGluGluValSerGlyAlaLeuProArgProAspGlySerlleIlePhePh 480
 DB 1585 AGGCATCCCTGAGGAGGTGAGGGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGCGGCCCTCGACCAGGCCAAACTGCAGGCAACCACTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCGACCGAGTGCCTCGATGGGCTGTGGCATGCCAACTCGGGGAGGCCCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765

RESULT 139
 ADE40656
 ID ADE40656 standard; cdNA; 1985 BP.
 XX AC ADE40656;
 XX DT 29-JAN-2004 (first entry)
 XX DE Human PRO polynucleotide #72.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 liver; microvascular endothelial cell; glucose; FFA;
 skeletal muscle cell; adipocyte cell; pericyte cell;
 inner ear utricular supporting cell; T-lymphocyte cell;
 endothelial cell tube formation; bone disorder; cartilage disorder;
 sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 immune system cell infiltration.

Homo sapiens.
 OS
 XX
 XX US2003199031-Al.
 XX
 XX 23-OCT-2003.
 XX
 XX 28-MAY-2002; 2002US-00156842.
 XX
 XX 05-JUN-2000; 2000US-0209832P.
 PR 01-DEC-2000; 2000WO-05032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
 XX WPI; 2003-900160/82.
 DR P-PSDB; ADE40657.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; Fig 143; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADE40656 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTGGCGCGCTCGGCTCTCTGCTGGCGGCCCTGACAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCAGCCCGCGGAGCGCGGAGCCAGAGCTGGCAAGGAGCGGAGGCAATTCCTA 325
 QY 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATCGATTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGAGGCTTCAGTGGGTGTCCAGCTACTCTGTCAGCGGCGTGTGTGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGATTATCGG 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 CCTGGGCTGAGAGATCAGTACTTGTGTTGCTAGACACCGGACCAAAATAGGCGGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCCTTGCACAGCAAGTAAACAAATGGTTACAAAGCAGCACCTCTCTCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCGAGCGCGCATGTTCCGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGACACGTCCTAGCGCTGGAGTTCCTGGGAGGCCCCAGCCAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGACCAACAACGATGGCTGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCAGCCCTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTGGTGTCTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCTTGGCT 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAAGAGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTTCTCTCGATGCCATCACTGTAGACGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCTCCCGCCCAACATTGAGCTGGCGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGGCGGCGAGGGGCTGCGCGCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 GCCTCTTCTTCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAGCTGTGAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480

Db 1585 AGGCATCCCTGAGAGGTGAGCGGCGCTGCGGAGCCCGATGCTCCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTTACTTGGCGCTCGACCGAGGCGCAACTGCAGGCAACCACTCGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCCAGCTGCCCTGGATGGGCTGCTGCAATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 140
ADE04455
ID ADE04455 standard; cDNA; 1985 BP.
AC ADE04455;
XX 29-JAN-2004 (first entry)
DT Human PRO polynucleotide #72.
DE
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalasassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX OS
XX US2003199034-A1.
PN
XX 23-OCT-2003.
PD
XX 28-MAY-2001; 2001US-00156846.
PF
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-900163/82.
DR P-PSDB; ADE04456.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
PS Claim 2; Fig 143; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADE804455 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu	20
Db	206	ATGGTCGCGCGGCTGGCCCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCGCGGAGCGCGAGGAGCTGCGCAAGGAGCGCGAGGCAATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACGC	385
Qy	61	AspAlaLeuArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCCTGCGCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCCTGGGTGAGAGATCAGTACATTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAACCAAGGTAACAAATGGTACAGAGCAGCCTCTCTCCGCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG	685
Qy	160	CysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCAGCGCTGAGTTCTGGGAGGCGCCACAGCCAGGCGCCGCTAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl	200

Db	746	ATCGGGCTCACTTCTTCCAAAGGGGACCAACAGATGGGTGGGCAATGCTTTGATGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGGCTTGGCGCACGCCCTTC-CTGCCCCCGCGCGGCAAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGTCTTCCCTGAGCGCGCGGGGGGCAACCTGTTCGTGGTGTGGCGCA	924
Qy	240	sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTCAACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGCGCGC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGGCGCGCGAGCGCTGCTCAGCTGGGACGAGTGTGCGCGTGA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCCGCTCCAGCTCCACAGGAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGGCGCCCTGAAACGACGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACCTGCGCACCTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCACTGA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr	360
Db	1225	CATTTTTAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle	380
Db	1285	TCCACTGCAGGAAAGATGGGTGCGGCTGCCGCCCAACATTGAGGCTGCGGAGTGTCA	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTTCCACAGCTGTCCGGGCGAGGGGGCTTGCCTCCGCCCATCTCTG	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrTrpProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGAGTGCAGTGAAGTGGAGCCCTACTACCCCGCAAGTCTTCAGGAG	1584
Qy	460	yGlyLeuProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCTCTGAGGAGGTACGCGCGCCCTCCCGAGGGCCCATGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGGCGGCTCGACCGCCCAAACTGCAGGCAACACCACTCGGGCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGTGTGTGCATGTCCCAACTCGGGGAGCGCCCTGT	1764
Qy	520	e 520	
Db	1765	c 1765	

RESULT 141
ADE92584

Db 985 CTACTACAAGAGCTGGCGCGACGCGCTGCTCAGCTGGGACGAGCTGCTGCCCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyValGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAGCCCTTAGGGGCTCAGTGGCCGTCCAGCTCCAGGAAGAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGNAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
Db 1165 CCTAAATACCTCCACTCTCTCCATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyClyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTCAAGGGGTGCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGGGCGCTGCCCCGCCATCTCTGAGCGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyValAlaArgTyrTyVa 440
Db 1465 CGCCCTCTTCTCTCTCTGCGCGCTCATCTCTTCAGGGTGGCCGCTACTAGT 1524
Qy 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTAGAGAGGTGAGCGGCGCTGCGGAGGCCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGCGAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 142
ADG21293
ID ADG21293 standard; cDNA; 1985 BP.
XX AC ADG21293;
XX DT 26-FEB-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker; gene; ss.
XX Homo sapiens.
XX US2003207355-A1.
XX PN 06-NOV-2003.
XX PD 06-NOV-2003.
XX PF 07-MAY-2002; 2002US-00140923.
XX PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-901058/82.
DR P-PSDB; ADG21294.
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or PFA (free fatty acid) by skeletal muscle cells or adipocyte
XX cells, for stimulating differentiation of adipocyte cells, for
XX stimulating proliferation of or gene expression in pericyte cells, for
XX stimulating the proliferation of inner ear utricular supporting cells or
XX T-lymphocyte cells, for inducing endothelial cell tube formation and for
XX treating various bone and/or cartilage disorders such as sports injuries
XX and arthritis. PRO polypeptides which stimulate the release of
XX proteoglycans from cartilage are useful for treating sports-related joint
XX problems, articular cartilage defects, osteoarthritis and rheumatoid
XX arthritis. PRO polypeptides are also useful for treating various
XX mammalian haemoglobin-associated disorders such as various thalassaemias
XX and conditions which may benefit from enhanced local immune system cell
XX infiltration. This sequence represents a human PRO polynucleotide of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Align. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2

DB:	10	Gaps:	0	
US-10-791-980-6 (1-520) x ADG21293 (1-1985)				
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu	20	
Db	206	ATGTCGCGCGCGTCTGCTGCGCGCTCTGAGCTGCTACTGTGGGCGCACCTG	265	
Qy	21	AspAlaGlnProAlaGluArgGlyClyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40	
Db	266	GACGCCACGCCGCGAGCGGAGCGGAGGCTGCGCAAGAGGCGGAGGCAATTCCTA	325	
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60	
Db	326	GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACCTCGATTACG	385	
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80	
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGCGTGTGGACCGC	445	
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100	
Db	446	GCCACCCCTGCGCAGATCACTCGTCCCGCTGCGGGGTTACAGATACCAACAGATTATGCG	505	
Qy	101	AlaTrpAlaGluAtqIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120	
Db	506	GCCTGGGCTGAGAGATCAGTACCTTGTTGCTAGACACCGGACCAAAANTGAGCGGTAA	565	
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140	
Db	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTTACAAAGCAGCACCTCTCTCCACCGCTGGTG	625	
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160	
Db	626	AACTGGCTGAGCAATCTCCGAGCCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG	685	
Qy	160	rCysGlyAlaThrSerGlnArgTTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180	
Db	686	TTGTGGACACGTTCTCAGCGCTGGAGTTCTGGGAGGGCCCCAGCCAGGCCCGCTGAC	745	
Qy	180	rSetGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200	
Db	746	ATCCGGCTCACCTTCTCAAGGGGACCACCAACGATGGCTGGGCAATGCTTTGATGGC	805	
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1	220	
Db	806	CCAGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA	864	
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240	
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACTGTTCGTGGTCTGGCGCA	924	
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260	
Db	925	CGAGATCGGTACACGCTTGCGCTCACCACTCGCGCGCGCGCGCTCATGGCGCC	984	
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1	280	
Db	985	CTACTACAAAGAGCTGGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGA	1044	
Qy	280	nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300	
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGAAAGCTGTT	1104	
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1	320	
Db	1105	CACCTGACTTTGAGACCTGGGACTCTCAGCGCCCCCAAGAGGCGCCCTGAAACGCGAGG	1164	
Qy	320	yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340	
Db	1165	CCCTAAATACGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224	
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360	
Db	1225	CATTTTTAAAGGAGCCATTTCTGGGAGGTGGAGCTGATGGCAACGCTCTCAGAGCCCCG	1284	
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380	
Db	1285	TCCACTCAGAGAAAGATGGGTGCGGCTGCCCCCAACATTTAGGCTCGGCGAGTGTCAAT	1344	
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy	400	
Db	1345	GAATGATGGAGATTCTTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA	1404	
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl	420	
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCTGCGCGCCATCTCTGACGC	1464	
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440	
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGCCTACTACTAGCT	1524	
Qy	440	lLeuAlaArgGlyClyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1	460	
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG	1584	
Qy	460	YGLyleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480	
Db	1585	AGGCATCCCTGAGAGGTTCAGCGCGCTGCGGAGGCCCGATGGCTCCATCTTCTT	1644	
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500	
Db	1645	CCGAGATGACCGCTACTTGGGCGCTCGACCAAGGCCAACTGCAGGCAACACCTCGGCGC	1704	
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520	
Db	1705	CTGGGCCACCAGAGTCCCTGGATGGGTGCTGTGGCACTGCCAGGCGGCGCTGT	1764	
Qy	520	e 520		
Db	1765	C 1765		
RESULT 143				
ADG22934				
ID	ADG22934 standard; cDNA; 1985 BP.			
XX	ADG22934;			
XX	26-FEB-2004 (first entry)			
XX	Novel human secreted and transmembrane protein PRO4339 cDNA.			
DE	Human; secreted and transmembrane protein; PRO; secreted polypeptide;			
KW	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;			
KW	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;			
KW	rectum; kidney; cervix; liver; microvascular endothelial cell;			
KW	glucose uptake modulator; FFA uptake modulator; cell proliferation;			
KW	cell differentiation; skeletal muscle cell; adipocyte cell;			
KW	pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;			
KW	endothelial cell tube formation; bone disorder; cartilage disorder;			
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;			
KW	rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;			
KW	immune system cell infiltration; chromosome mapping; gene mapping;			
KW	gene therapy; chromosome identification; chromosome marker; gene; ss.			
XX	Homo sapiens.			
XX	US2003207384-A1.			
FN	XX			
XX	06-NOV-2003.			
PD	XX			
XX	22-MAY-2002; 2002US-00153585.			
PF	XX			
XX	03-MAR-2000; 2000US-0187202P.			
PR	01-DEC-2000; 2000WO-US032678.			
PR	19-DEC-2001; 2001US-00028072.			

XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-901065/82.
 DR P-PSDB; ADG22935.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides, bone
 PT useful for treating pericyte-associated tumors, diabetes and various
 PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; SEQ ID NO 143; 637pp; English.
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassaemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polynucleotide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADG22934 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGGCGGCTGGCCCTCTGCTGGCGGCCCTGACAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgLysGluAlaAlaPheLeu 40
 DB 266 GAGCCACCCCGGAGCGCGGAGCCAGAGAGCTGCGCAGAGGGCGGAGGAGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGGTCCCAACCTCCACTCGATTACG 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGTACCTGTCTCAGCGGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTCGGGGTTCACAGATACCAACAGTTATGCG 505
 QY 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCTTGGGCTGAGAGGATCAGTGTGTTGTAGACACCGGACCAAAATGAGGCGTAG 565
 QY 121 LysArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
 DB 566 AAACCTTTGCAAGCAAGTAACTGTTACAGCAGCACCTCTCTCCACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTGGGAGGCCCCAGCCACAGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAGGGGACCAACAGATGGCTGGGCAATGCTTGTATGCG 805
 QY 200 adGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CCAGGGGGCGGCGCTGGCGACGCTTC-CTGGCCCGCGCGGCGGAGGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGGCAACCTGTTGCTGTGCTGCGCGCA 924
 QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACAGCTTGGCTCACCCACTCGCCCGCGCGCGCGCGCTCATGGCGGC 984
 QY 260 rTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAAGAGGCTGGCGCGCGCTGCTGCTAGTGGGACGAGTGTGCGCGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCACAGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACCTTGAGACCTGGGACTCTCTACAGCCCGCCAGAGGCGCCCTGAAACCGAGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCCTAAATACTGCCACTCTCTCTTCGATGCTCCTCAGTACAGAGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLue 380
 DB 1285 TCCACTGAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGGCGAGTGTCAAT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLys 400
 DB 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTTCGATGTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGTCGGGCGAGGGGCGCTGCCCGCCCATCTCTGACGC 1464

```
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaAArgTyrTyrVa 440
Db 1465 CGCCCTCTTCCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGCCTCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
Db 1525 CTGGCCGAGGGGAGTGCAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyLeProGluValSerGlyAlaLeuProArgProAspGlySerLeuLeuPhePh 480
Db 1585 AGGCATCCTCAGGAGGTGAGCGCGCCCTCCGAGGCCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTGGCGCTCGACAGGCCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTTPMetGlyCyseTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 144
ADF97269
ID ADF97269 standard; cDNA; 1985 BP.
XX
AC ADF97269;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003207370-A1.
XX
PD 06-NOV-2003.
XX
PF 14-MAY-2002; 2002US-00145632.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-901059/82.
DR P-PSDB; ADF97270.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
```

```
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
```

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	10	Gaps:	0

US-10-791-980-6 (1-520) x ADF97269 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGCTCGCGCGCTCGCGCTCTCTGCTCGCGCCCTGCAGCTGTCTACTGTGGGGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GAGCCCGAGCCCGGAGCGGAGCGGAGCTGCGAAGGGGAGGCGGATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGNAGTACGGATACCTCAATGACAGGTCCCCAAGCTCCACCTCCACTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTCTCAGCGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCCCATGATGACTCGTCCCCCGCTGCGGGGTTCAGATACCAACAGTTATCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGGAGTACGTACTTCTTTGCTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGAAAGCAAGGTAACAATGGTACAAAGCAGCACCTCTCTCCCGCTGTGTG	625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGCGCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGTGGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCCCGCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLeuGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACTCTTCCAGGGGACCAACAGATGGGCTGGCAATGCCCTTTGATGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC -CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTGCTGTGTGTCGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CCAGATCGGTCAACGCTTGGCTCACCCACCTCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 oTrpTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAGAGGCTGGGCGCGGCGCGCTGCTCAGCTGGGACGAGCTGTGCGCGTGA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACCGAGG 1164
QY 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCCG 1284
QY 360 qProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGTGATGCTGGAGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGAGGGGCGCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrpVa 440
DB 1465 CGCCCTCTTCTTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrpTrpProArgSerLeuGlnAspTrpG1 460
DB 1525 GTGGCCCGAGGGGACTGCAGTGGAGCCCTACTACCCCCGNACTTCGAGGACTGGGG 1584
QY 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCCGAGGCCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

DB 1705 CTGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 145
ADG80333
ID ADG80333 standard; cDNA; 1985 BP.
XX
AC ADG80333;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003207373-A1.
XX
PD 06-NOV-2003.
XX
PF 14-MAY-2002; 2002US-00145871.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000MO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-901061/82.
DR P-PSDB; ADG80334.
XX
XX
PT New secreted and transmembrane PRO polypeptides useful for inhibiting the
PT differentiation of adipocyte cells, stimulating the proliferation of T-
PT lymphocyte cells and detecting the presence of a tumor in a mammal.
XX
XX
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. Note:
 CC sequence represents a human PRO polynucleotide of the invention. This
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADG80333 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACGCGCGAGCGCGAGCGGAGGCTGCGCAAGAGGCGGAGGCAATCCCTA 325
 Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGATACCTCAATGACAGGTCCCAAGGCTCCACCTCCACTCGATTGAGC 385
 Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCAGAGTACCTGTCCAGCGGGGTGTGGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTTGCGCCAGATACCTGCTCCCGCTGCGGGGTGTACAGATACCACAGATTATGCG 505
 Qy 101 AlaTpaAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTTACAAGCAGCACCTCTCTCCACCGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTTGAGCATCTCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCGAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTtpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGACAACTCTCAGCGCTGAGTTCCTGGGAGGCGCCACGACAGGCCCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCCAAAGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGGC 805
 Qy 200 aGlnGlyAlaProTpaArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 Db 806 CCAGGGGGCGGCTTGGCGACGCTTC-CTGCCCCGCGCGGAGCGACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240

Db 865 AGATAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTGTCTGGCGCA 924
 Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTCAACACGCTTGGCTTCCACCACTGCCCGCGCGCGCGCTCAATGGCGCC 984
 Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTGTGGCGGTGCA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCTCTATGGGAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCTGAAAGCGCAGG 1164
 Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCCTAAATACCTGCGCACCTTCTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTCAGGAAAGATGGGTGCGGCTGCGCCCCCAACATTTGAGGCTGCGGCGAGTGTATT 1344
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCCGCATCTCGAGCG 1464
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAAGGGTGCCTACTACTAGT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTCCCCGAAAGTCTGACAGGACTGGGG 1584
 Qy 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGGTACGCGCGCGCTTCCGAGGCGCGATGGCTCCATCTTCTT 1644
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTTGGCGCTTCGACGAGGCGCAAACTGCAGGCAACACCTCGGGCG 1704
 Qy 500 qTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGTGCTGTCGCAACTCGGGGAGGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 C 1765
 RESULT 146
 ADG79781
 ID ADG79781 standard; cDNA; 1985 BP.
 XX
 AC ADG79781;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DB Human PRO polynucleotide #72.
 XX

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor- α ; TNF- α ; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.

XX US2003207372-A1.

XX 06-NOV-2003.

XX 14-MAY-2002; 2002US-00145753.

XX 03-NOV-1997; 97US-0064248P.

XX 16-SEP-1998; 98WO-US019330.

XX 13-OCT-1998; 98US-0104080P.

XX 25-AUG-1999; 99US-00380139.

XX 05-OCT-1999; 99WO-US023089.

XX 22-FEB-2000; 2000WO-US004414.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Deenoyers L, Filvaroff E, Gao W;

XX Geritene ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-901060/82.

XX P-PSDB; ADG79782.

XX New PRO nucleic acid, useful for manufacturing a medicament for

XX diagnosing or treating tumor, for chromosome mapping or for tissue

XX typing.

XX Claim 2; SEQ ID NO 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

XX invention also relates to an antibody which specifically binds to a PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor- α (TNF- α) from human blood, a method for stimulating the

XX proliferation or differentiation of chondrocyte cells and a method for

XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

XX polynucleotides are useful in molecular biology, including uses as

XX hybridisation probes, in chromosome and gene mapping, in generating

XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX be used in preparing PRO polypeptides by recombinant techniques and in

XX generating either transgenic animals or knock-out animals which are

XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This


```
Db 1045 GAGCCTGTATGGAGACCCCTAGGGGCTCAGTGGCCCTCCAGCTCCAGAAAGCTGTT 1104
Qy 300 eThraspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGAGCCCTCAAGAGAGGGCCCTGAAACGCAGGG 1164
Qy 320 yProlystYrCyvHsIsSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCCACTCTTCTTCGATGCCATCACTGTAGACGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrPgluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGACCAATTTCTGGAGGTGGCAGCTGATGCCAACGTCCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAATT 1344
Qy 380 uAsnAspGlyVAspPheTyrPhePheLysGlyGlyVArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTyrPglYLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCGAGGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGI 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTGTGCAAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCGAGGAGGTGAGGGGCGCTCGCCAGAGCCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCCAAACTGACGGCAACACCTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGTGGCATGCCAACTCGGGAGCGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 147
ID ADH55073 standard; cDNA; 1985 BP.
XX
AC ADH55073;
XX
DT 25-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
```

```
XX OS Homo sapiens.
XX
FN US2003207381-A1.
XX
PD 06-NOV-2003.
XX
PF 21-MAY-2002; 2002US-00152376.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2003-901064/82.
DR P-PSDB; ADH55074.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
XX
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0
US-10-791-980-6 (1-520) x ADH55073 (1-1985)
```


QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTyrGlyHisLeu 20
DB 206 ATGGTCGCGCGCTGCGCTCTCTGCTGCGCGCTCGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGlnArgGlyGlyGlnGlnLeuLeuArgGlyGlnAlaGlnAlaPheLeu 40
DB 266 GAGCCCGAGCGCGGAGCGCGAGGCGAGGAGCTGCGAAGGAGCGGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGATACCTCAATGAACAGGTCCTCCAAAGCTCCCACTCCACTCGATTACAG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCGAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCTTGGCTTGAGAGGATCAGTGACTTGTTCGTAGACACCGGACCAAAATGAGCGGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAAAGCAAGGTAACTAATGGTACACGACGACCACTCTCTACCGCTGGT 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCGAGCGGAGTTGCGGGGCGCGTGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCCGACGACGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB 746 ATCCGCTCACCTCTCTCCAGGGGACCAACAGATGGCTGGCAATGCTTGTATGCG 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCTGCGCACGCTTC-CTGCGCGCGCGCGCGGCGCAAGCGCACTTGCACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGCTCTCAGCGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
DB 985 CTACTACAAAGAGCTGGGCGCGAGCGCGTGTCTCAGCTGGGACGACGCTGCGCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCGCCCAAGGAGCGCCCTGAACCGCAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTAAATACGCACTCTCTCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProArg 360
DB 1225 CATTTTAAAGGAGCACTTTCTGGGAGGTGCGAGCTGATGGCAACGCTCTCAGAGCCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAAGATGGTGGGCTGCGGCTGCCCCCAACATTAGGCTGCGGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCTGCCCCGCCATCTGACGC 1464
QY 420 alaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTGCGGAGGCGCGATGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGGCTCGACCCAGGCCAACTGCAGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCCAAGAGTGGCTGGATGGCTGGTGGATGCCAATCTCGGGAGCGCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 148
ADH55625
ID ADH55625 standard; cDNA; 1985 BP.
XX ADH55625;
AC ADH55625;
XX XX
DT 25-MAR-2004 (first entry)
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX Homo sapiens.
XX OS
XX US2003207379-A1.
XX PN
XX 06-NOV-2003.
XX PD
XX 17-MAY-2002; 2002US-00147537.
XX PF
XX 10-SEP-1998; 98US-0099816P.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 18-OCT-1999; 99US-00403297.
XX PR 18-FEB-2000; 2000WO-US004342.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;

XX WPI; 2003-901063/82.

XX P-PSDB; ADH55626.

XX New PRO nucleic acid, useful for manufacturing a medicament for

XX diagnosing or treating tumor, for chromosome mapping or for tissue

XX typing.

XX Claim 2; SEQ ID NO 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

XX invention also relates to an antibody which specifically binds to a PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX proliferation or differentiation of chondrocyte cells and a method for

XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

XX polynucleotides are useful in molecular biology, including uses as

XX hybridisation probes, in chromosome and gene mapping, in generating

XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX be used in preparing PRO polypeptides by recombinant techniques and in

XX generating either transgenic animals or knock-out animals which are

XX useful in the development and screening of therapeutically useful

XX reagents. The PRO polypeptides or antibodies are used in preparing a

XX medicament for treating a condition responsive to the polypeptides or

XX antibodies, such as tumours, for stimulating and inhibiting proliferation

XX of human microvascular endothelial cells, for modulating the uptake of

XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte

XX cells, for stimulating differentiation of adipocyte cells, for

XX stimulating proliferation of or gene expression in pericyte cells, for

XX stimulating the proliferation of inner ear utricular supporting cells or

XX T-lymphocyte cells, for inducing endothelial cell tube formation and for

XX treating various bone and/or cartilage disorders such as sports injuries

XX and arthritis. PRO polypeptides which stimulate the release of

XX proteoglycans from cartilage are useful for treating sports-related joint

XX problems, articular cartilage defects, osteoarthritis and rheumatoid

XX arthritis. PRO polypeptides are also useful for treating various

XX mammalian haemoglobin-associated disorders such as various thalassemias

XX and conditions which may benefit from enhanced local immune system cell

XX infiltration. This sequence represents a human PRO polynucleotide of the

XX invention. Note: The sequence data for this patent is also available in

XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1985 BP; 403 A; 646 G; 604 G; 332 T; 0 U; 0 Other;

SQ

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985

Score: 2792.00 Matches: 519

Percent Similarity: 99.62% Conservative: 0

Best Local Similarity: 99.62% Mismatches: 1

Query Match: 98.52% Indels: 2

DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADH55625 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuLeuTrpGlyHisLeu 20

DB 206 ATGTGTCGCGCGGTGGGCTCTCTGCGCGCCCTGCAGCTGCTACTGTGTGGGGCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40

DB 266 GACGCCACCGCGGAGCGGGAGCCAGAGCTGCGCAGAGGAGCGGAGCATTCCTA 325

QY 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60

DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGATTTCAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80

DB 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTGTTCAGCGCGGTGTTCGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100

DB 446 GCCACCCTGCGCCAGATGACTCGTCCCCTGCGGGGTTCAGATACCAACAGATTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140

DB 566 AAACGCTTTCAAGCAAGGTAACAAATGGTACAAAGCAGCACCTCTCTCCCGCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160

DB 626 AACTGGCTTGAGCATTCTCCGAGCCGCGAGTTTCGGGGCGCGGTTCGGCGCGCTTCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180

DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200

DB 746 ATCCGGCTCACTCTTCTCCAAAGGGGACCAACAGATGGCTGGGCAATGCTTTTGATGGC 805

QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220

DB 806 CCAGGGGGCGCCCTGGCGGACGCTTC-CTGCCCGCGCGGGGAGGAGGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240

DB 865 AGATGAGCGTGTGCTCCAGCGCGCGCGCGCAACCTGTTCTGTGTGTGTGGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260

DB 925 CGAGATCGGTACACGCTTGGCTCACCCTCGCGCGCGCGCGCGCTCATGTGGCGCC 984

QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280

DB 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTGTGGCGGTGCA 1044

QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300

DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyValArgProGluThrGlnGl 320

DB 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGGCGCTTGAACGCGAGG 1164

QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340

DB 1165 CCCTAATACTGCCACTCTTCTTCGATGTCATCCTGTAGACAGGCAACAGCAACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360

DB 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380

DB 1285 TCCACTCAGAAAGATGGGTGCGGCTGCCCGCCCAACATTGAGGCTCGGCAGTGTCTATT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400

DB 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420

DB 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGCGGAGGGGGGCTGCCCCGCCATCTCTGACGC 1464

Qy 420 alalaLeuPheProLeuArgArgLeuLeuLeuPheLeuGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lleualaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyileProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGAGGTGAGCGGCGCTCTGCGAGGCCGATGCTCATCACTTCTT 1644
Qy 480 eArgPhePheArgTyrTyrArgLeuAspGlnAlaLeuThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGGCCAACTGCAGGCAACACCCCTGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaLeuSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAAGTGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 149
ID ADI63292
XX ADI63292 standard; cDNA; 1985 BP.
AC ADI63292;
DT 22-APR-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003207387-A1.
XX
PD 06-NOV-2003.
XX
XX 29-MAY-2002; 2002US-00157801.
XX
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-901068/82.
DR P-PSDB; ADI63293.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; SEQ ID NO 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or PFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ADI63292 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTyrGlyHisLeu 20
Db 206 ATGGTCGGCGCGTGGCGCTCTCTGCGCGCCCTGCAGCTGTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCGCGGAGCGCGAGGCTGCGCAAGGAGGCGGAGGCGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTCAGTGGGTGTCCAGCTACTGTCTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGATTATCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140

Db 566 AAACGCTTTTCAAAGCAAGGTAAACAAATGGTTACAAGCAGCACCTCTCTCTACCGCCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCGGAGCGCGAGTCTGGGGCGCGCTGGCGCGCGCTTCGAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyValArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTGAGCGCTGGAGTCTTGGGAGGCCCCAGCCAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerSerGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCGGCTCACTCTTCCAAAGGGACCAACAACGATGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyValArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGCGCAACTGTTCGTGTCTGGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTCAACGCTTGGCTCACCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTrpIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCTGGCGCGCGCGCTGCTCAGCTGGAGCAGCGCTGGCGCGTGCA 1044
Qy 280 nSerLeuTyTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGCGCCCTGAAACGCGAGG 1164
Qy 320 yProIysTyTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCGCACTCTCTCTCGATGCGCATCATCTGACAGGCAACAGCAACTGT 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyTrpPhePheLysGlyGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTCAGCG 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuLeuLeuPheLysGlyAlaAlaArgTyTrVa 440
Db 1465 GCGCTCTCTTCCCTCTCGCGCGCGCTCATCTCTTCAAGGTGGCGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyLysLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCGCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAAGTCTGCAAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTCAGCGCGCGCTGCCGAGGCGCGATGCGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTGCGCGCTCGACAGGCCAAACTGACAGGCCAACACCTCGGGCGC 1704

Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTCGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 150
ADH81706
ID ADH81706 standard; cDNA; 1985 BP.
XX
AC ADH81706;
XX
DT 22-APR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
FN US2003207388-A1.
XX
PD 06-NOV-2003.
XX
PF 29-MAY-2002; 2002US-00157802.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2003-901069/82.
DR P-PSDB; ADH81707.
DR
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 143; 648pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful

DT	22-APR-2004	(first entry)	CC	and conditions which may benefit from enhanced local immune system cell
XX			CC	infiltration. This sequence represents a human PRO polynucleotide of the
DE	Novel human secreted and transmembrane protein PR04339 cDNA.		CC	invention. Note: The sequence data for this patent is also available in
XX			CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html .
KW	Human; secreted and transmembrane protein; PRO; secreted polypeptide;		XX	Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
KW	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;			
KW	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;			
KW	rectum; kidney; cervix; liver; microvascular endothelial cell;			
KW	glucose uptake modulator; FFA uptake modulator; cell proliferation;			
KW	cell differentiation; skeletal muscle cell; adipocyte cell;			
KW	pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;			
KW	endothelial cell tube formation; bone disorder; cartilage disorder;			
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;			
KW	rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;			
KW	immune system cell infiltration; chromosome mapping; gene mapping;			
KW	gene therapy; chromosome identification; chromosome marker; gene; ss.			
XX				
OS	Homo sapiens.			
XX				
PN	US2003207377-A1.			
XX				
PD	06-NOV-2003.			
XX				
PF	17-MAY-2002; 2002US-00147507.			
XX				
PR	05-JUN-2000; 2000US-0209832P.			
PR	01-DEC-2000; 2000WO-US032678.			
PR	19-DEC-2001; 2001US-00028072.			
XX				
PA	(GETH) GENENTECH INC.			
XX				
PI	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;			
PI	Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;			
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;			
XX				
DR	WPI; 2003-901062/82.			
DR	P-PSDB; ADH81155.			
XX				
PT	New secreted and transmembrane PRO polypeptides, useful for inhibiting			
PT	the differentiation of adipocyte cells, stimulating the proliferation of			
PT	T-lymphocyte cells and detecting the presence of a tumor.			
XX				
PS	Claim 2; SEQ ID NO 143; 637pp; English.			
XX				
CC	The invention relates to isolated human PRO polypeptides (secreted and			
CC	transmembrane polypeptides) and the polynucleotides encoding them. The			
CC	invention also relates to an antibody which specifically binds to a PRO			
CC	polypeptide, a method for stimulating the release of tumour necrosis			
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the			
CC	proliferation or differentiation of chondrocyte cells and a method for			
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,			
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The			
CC	polynucleotides are useful in molecular biology, including uses as			
CC	hybridisation probes, in chromosome and gene mapping, in generating			
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also			
CC	be used in preparing PRO polypeptides by recombinant techniques and in			
CC	generating either transgenic animals or knock-out animals which are			
CC	useful in the development and screening of therapeutically useful			
CC	reagents. The PRO polypeptides or antibodies are used in preparing a			
CC	medicament for treating a condition responsive to the polypeptides or			
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation			
CC	of human microvascular endothelial cells, for modulating the uptake of			
CC	glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte			
CC	cells, for stimulating differentiation of adipocyte cells, for			
CC	stimulating proliferation of or gene expression in pericyte cells, for			
CC	stimulating the proliferation of inner ear utricular supporting cells or			
CC	T-lymphocyte cells, for inducing endothelial cell tube formation and for			
CC	treating various bone and/or cartilage disorders such as sports injuries			
CC	and arthritis. PRO polypeptides which stimulate the release of			
CC	proteoglycans from cartilage are useful for treating sports-related joint			
CC	problems, articular cartilage defects, osteoarthritis and rheumatoid			
CC	arthritis. PRO polypeptides are also useful for treating various			
CC	mammalian haemoglobin-associated disorders such as various thalassemias			

CC	and conditions which may benefit from enhanced local immune system cell
CC	infiltration. This sequence represents a human PRO polynucleotide of the
CC	invention. Note: The sequence data for this patent is also available in
CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html .
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX	
XX</	

```
Qy 280 nserLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAGGCCCTAGGAGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThraPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCCTAGAGCCCCCAAGGAGGCCCTGAAACGACGGG 1164
Qy 320 yProLysTyrCyvHisSerSerPheAspAlaIleThrValLeuPheArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyVargCyvTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCyvArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCGCCCATCTGAGGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaAa-gTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAAGTCTGCGAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGGGGCGCTGCCGAGGCCGATGGCTCATCTCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCCAACTGCGAGGCCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCyvTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGGCTGGATGGGCTGTGGATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 152
ACD23924
ID ACD23924 standard; cDNA; 1985 BP.
XX
XX ACD23924;
AC
AC ACD23924;
DT 26-AUG-2003 (first entry)
DE
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
KW Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
KW antidiabatic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW TNF-alpha release; cell proliferation; cell differentiation;
KW gene expression modulator; proteoglycan release; cytokine release;
KW tumour; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW bioreactor; tissue typing; gene; ss.
XX
```

```
OS Homo sapiens.
XX
XX US2003032156-A1.
PD
XX 13-FEB-2003.
PF
XX 06-MAY-2002; 2002US-00140474.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
```



```
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnI 320
Db 1105 CACTGACCTTTGAGACTGGGACTCTACAGCCCCCAAGGAAGCGCCCTGAAACGACGG 1164
QY 320 yProlystTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCATAAATACTGCCACTCTTCCTCGATGCCATCACTGTAGACAGGCCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAGCTCTAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAGATGGTCCGGCTGCCGCCCAACATTGAGGCTGCCGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyCysArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTTCTACTCTTCAAAGGGGGTCCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCATCTCGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGCTGCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTAGCGGGCCCTGCCGAGGCCGCGATGCTCATCATCTTCT 1644
QY 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCCGCCGAGCTGCCCTGGATGGGCTGCTGGCATGCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 153
ACA67065
ID ACA67065 standard; cDNA; 1985 BP.
XX ACA67065;
AC ACA67065;
XX
DT 23-JUN-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW anti-PRO antibody; diagnostic assay; gene expression; diabetes;
KW bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
KW sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
KW hearing loss; coagulation disorder; stroke; heart attack; cardiac;
KW antidiabetic; anorectic; vulnerable; antiarthritic; osteopathic;
KW antirheumatic; auditory; cerebroprotective; angiogenic; gene; ss.
XX
OS Homo sapiens.
XX
US 2003004311-A1.
PN
XX
PD 02-JAN-2003.
XX
PF 19-DEC-2001; 2001US-00028072.
XX
18-JUN-1997; 97US-0049911P.
26-AUG-1997; 97US-0056974P.
17-SEP-1997; 97US-0059113P.
17-SEP-1997; 97US-0059115P.
17-SEP-1997; 97US-0059117P.
17-SEP-1997; 97US-0059122P.
17-SEP-1997; 97US-0059184P.
18-SEP-1997; 97US-0059263P.
19-SEP-1997; 97US-0059352P.
19-SEP-1997; 97US-0059588P.
24-SEP-1997; 97US-0059836P.
17-OCT-1997; 97US-0062250P.
17-OCT-1997; 97US-0062285P.
17-OCT-1997; 97US-0062287P.
17-OCT-1997; 97US-0063755P.
24-OCT-1997; 97US-0062814P.
24-OCT-1997; 97US-0062816P.
24-OCT-1997; 97US-0063045P.
24-OCT-1997; 97US-0063082P.
24-OCT-1997; 97US-0063127P.
27-OCT-1997; 97US-0063327P.
27-OCT-1997; 97US-0063329P.
28-OCT-1997; 97US-0063550P.
28-OCT-1997; 97US-0063561P.
29-OCT-1997; 97US-0063704P.
29-OCT-1997; 97US-0063733P.
29-OCT-1997; 97US-0063735P.
29-OCT-1997; 97US-0063738P.
03-NOV-1997; 97US-0064248P.
07-NOV-1997; 97US-0064809P.
12-NOV-1997; 97US-0065186P.
17-NOV-1997; 97US-0065846P.
21-NOV-1997; 97US-0066364P.
24-NOV-1997; 97US-0066453P.
24-NOV-1997; 97US-0066511P.
24-NOV-1997; 97US-0066770P.
11-DEC-1997; 97US-0069212P.
11-DEC-1997; 97US-0069278P.
11-DEC-1997; 97US-0069334P.
16-DEC-1997; 97US-0069694P.
23-JAN-1998; 98US-0072320P.
04-FEB-1998; 98US-0073612P.
09-FEB-1998; 98US-0074086P.
09-FEB-1998; 98US-0074092P.
12-MAR-1998; 98US-0077791P.
20-MAR-1998; 98US-0078910P.
25-MAR-1998; 98US-0079294P.
27-MAR-1998; 98US-0079663P.
31-MAR-1998; 98US-0079728P.
12-JUN-1998; 98WO-US012456.
14-JUL-1998; 98WO-US014552.
28-AUG-1998; 98WO-US017888.
10-SEP-1998; 98WO-US018824.
14-SEP-1998; 98WO-US019093.
14-SEP-1998; 98WO-US019094.
14-SEP-1998; 98WO-US019177.
16-SEP-1998; 98WO-US019330.
17-SEP-1998; 98WO-US019437.
07-OCT-1998; 98WO-US021141.
29-OCT-1998; 98WO-US022991.
29-OCT-1998; 98WO-US022992.
20-NOV-1998; 98WO-US024855.
01-DEC-1998; 98WO-US025108.
05-JAN-1999; 99WO-US000106.
08-MAR-1999; 99WO-US005028.
10-MAR-1999; 99WO-US005190.
20-APR-1999; 99WO-US008615.
14-MAY-1999; 99WO-US010733.
02-JUN-1999; 99WO-US012252.
01-SEP-1999; 99WO-US020111.
08-SEP-1999; 99WO-US020594.
```

PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-352836/33.
 DR P-PSDB; ABU80941.
 XX
 PT New isolated PRO polypeptide useful for treating diabetes, rheumatoid
 PT arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or
 PT heart attack.
 XX
 PS Claim 2; Fig 143; 643pp; English.
 XX
 CC The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides and polynucleotides are useful for preparing a medicament
 CC useful in the treatment of diabetes, bone and/or cartilage disorders
 CC (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
 CC hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders
 CC (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
 CC assays for PRO, by detecting its expression in specific cells, tissues or
 CC serum, and for affinity purification of PRO from recombinant cell culture
 CC or natural sources. ACA66994-ACA67268 represent cDNA sequences encoding
 CC the human PRO polypeptides of the invention. Note: The sequence data for
 CC this patent was obtained in electronic format directly from the USPTO web
 CC site at seqdata.uspto.gov/psipdsIDentry.html
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 10 Gaps: 0

US-10-791-980-6 (1-520) x ACA67065 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 |||

Db 206 ATGTCGCGCGCTGCGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGTGGGCGCACCTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 |||
 Db 266 GACGCCAGCCGCGGAGCGCGGAGCGCTGCGCAAGGAGGCGGAGCATTCCTA 325
 Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 |||
 Db 326 GAGAGTACGATACCTCAATGACAGGTCCCCAAGCTCCACCTCCACTCGATTGAGC 385
 Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 |||
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACTGTGACGCGGTGTGTGGACCGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 |||
 Db 446 GCCACCTGCGCCAGATGACTGCTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
 |||
 Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGGTAA 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 |||
 Db 566 AACCGCTTTGCAAGCAAGGTAACTGTTGTTGCTAGACACCGGACCAAAATGAGCGGTAA 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 |||
 Db 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTTGCGGGCGCGCTGCGCGCGCTTCCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgTrpProGlnProGlnAlaProLeuTh 180
 |||
 Db 686 TTGTGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCCGCCACGACAGCGCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 |||
 Db 746 ATCCGGCTCACTTCTTCCAAAGGGGACACAAACATGGTGTGCGGGCGCGCTTGTATGCGC 805
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 |||
 Db 806 CCAGGGGGCGCGCTGCGGCGCGCGCTTC-CTGCCCCCGCGCGCGGCGGCGGCGGCGGCGG 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 |||
 Db 865 AGATGACGCTGGTCCCTGAGCGCGCGCGGGGCGCACTGTTCGTGGTGGTGGCGCA 924
 Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 |||
 Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
 Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 |||
 Db 985 CTACTCAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTCGGCGGTGCA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 |||
 Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGCAAGAGTGT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 |||
 Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGCGCGCTGTAAGCGCAGGG 1164
 Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 |||
 Db 1165 CCTTAAATCTGCGCACCTCTCTTCGTATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 |||
 Db 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTTGGCAGCTGTGTGCAACGCTCTCAGAGCCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 |||
 Db 1285 TCCACTGCAGAAAGATGGGTGCGGCTGCCCGCCCAACATTTAGGCTCGGCAGTGTTCATT 1344

```
QY 380 uAenAepGlyAspPheTyrPhePheLysGlyArgCysTyrAtgPheArgGlyProly 400
DB 1345 GAATGATGAGATTCTACTCTTCAAGGGGGTGGATGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCAGTGTGGGGTCTCCACAGCTGTGCCGGGCGAGGGGCGCTGCCCGCCATCTTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGGTGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrGl 460
DB 1525 GTGGCCCGAGGGGACTCAAGTGGAGCCCTACTACCCCGGAGTGTCTCAGAGCTGGGG 1584
QY 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProArgProArgPhePhePh 480
DB 1585 AGGCATCCCTGAGGAGTTCAGCGGGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCCCAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 154
ADM82323
ID ADM82323 standard; cDNA; 1985 BP.
XX
AC ADM82323;
XX
DT 03-JUN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
OS
XX Homo sapiens.
XX
PN US2003087355-A1.
XX
PD
XX 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127828.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
```

```
XX WPI: 2003-801140/75.
DR P-PSDB; ADM82324.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
XX diagnosing or treating tumor.
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting the uptake of
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells and
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 11 Gaps: 0
US-10-791-980-6 (1-520) x ADM82323 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTyrGlyHisLeu 20
DB 206 ATGGTCGGCGCGCTCGGCTCTCTGCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGAGGACCTTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGGTCCACCTCCATCCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
```

Db 446 GCCACCCCTGCCAGATGACTGTCCTCCCGCTGCGGGGGTTACAGATACAAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTGTGTTCTAGACACCGACCAAAATAGGCGGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAAAGCAGGTAAACAAATGGTACAGCAGACCTCTCTACCGGCTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGGCGAGTTTGGGGCGCGTGGCGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTACGCGCTGGAGTTCTGGGAGGGCCCCAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCTCTGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAGAGAGCGCCCTGAAACGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGGTGGAGCTGATGGCAACGTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGGGGGAGGGGGCTGGCCCCGCAATCTTCAGCG 1464
Qy 420 sAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
Qy 440 lleuAlaArgGlyLysLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGGGAGCTGCAAGTGGAGGCCCTTACTACCCCCGAACTCTGCAGGAGTGGG 1584

Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlelePhePh 480
Db 1585 AGGCATCCCTGAGAGGTACGGCGCCCTGCGGAGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTGGCGCTTCGACACGAGCAAACTCGAGCAACACCTCGGGCCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGCTGCTGCGATGCGCAACTCGGGGAGCGCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 155
ADN15722
ID ADN15722 standard; cDNA; 1985 BP.
XX AC ADN15722;
XX 17-JUN-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
XX US2003087353-A1.
XX 08-MAY-2003.
XX 22-APR-2002; 2002US-00127826.
XX 17-JUN-1998; 98US-0089532P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Deanyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801138/75.
XX P-FSDB; ADN15723.
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,

CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in chromo-
CC some interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 11 Gaps: 0

US-10-791-980-6 (1-520) x ADN15722 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTTCGCGCGGTGGCTCTCTGTCGCGCGCTGACGTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACGCCCGGAGCGCGGAGGCGGAGGCTGCGCAAGAGGCGGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTGACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGGTGTCCAGCTACCTGTGAGCGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGGTAAG 565
QY 121 LysArgPheAlaLysGlnLysAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGACGACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGACATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGGTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGCG 805

QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCGCTGCGCACGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgArgLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGTGTCCTCGAGCGCGCGCGGCGCAACCTGTTCTGTGTGTGCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGCGCGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGCTGGCGCGCGCGCTGCTAGCTGGGACGAGCTGCTGCGCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGGTCTAGTGGCGGTCCAGCTCCCAAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyr-SerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACCTTGAGACCTGGGACTCTACAGCCCCCAGAGGCGGCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCGCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGAGCCATTTCTGGGAGGTGGCAGCTGTGCAACAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGAGGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGGCAAGTGCATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGCGGCGAGGGGCGCTGCCCGCCCATCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTCTTCTTCTCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAACTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTGCGCGAGGCGCGATGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATACCGCTACTTGGCGCTCGACAGGCAAACTGCAGGCAACACCTTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGTGGCTGGCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 156
ADN16351
ID ADN16351 standard; cDNA; 1985 BP.
XX
AC ADN16351;

XX	17-JUN-2004	(first entry)
DT		
XX		
DE	Novel human secreted and transmembrane protein PRO4339 cDNA.	
XX		
KW	Human; secreted and transmembrane protein; PRO; gene; ss;	
KW	Tumour necrosis factor alpha release; TNF-alpha release;	
KW	glucose uptake modulator; FFA uptake modulator;	
KW	cell proliferation stimulator; cell differentiation stimulator;	
KW	cell differentiation inhibitor; cytokine release stimulator;	
KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;	
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;	
KW	gene therapy; chromosome identification; chromosome marker.	
XX		
OS	Homo sapiens.	
XX		
PN	US2003087385-A1.	
XX		
PD	08-MAY-2003.	
XX		
PF	28-AUG-2002; 2002US-00230417.	
XX		
PR	09-DEC-1999; 99US-0170262P.	
PR	01-DEC-2000; 2000WO-US032678.	
XX		
PR	19-DEC-2001; 2001US-00028072.	
XX		
PA	(GETH) GENENTECH INC.	
XX		
PI	Baker KP, Bersesini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;	
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AU, Sherwood S;	
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
XX		
DR	WPI: 2003-801153/75.	
DR	P-PSDB; ADN16352.	
XX		
PT	New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or	
PT	PRO4978, useful in molecular biology, chromosome and gene mapping, in	
PT	generating antisense RNA and DNA, and in gene therapy.	
XX		
PS	Claim 2; SEQ ID NO 143; 64app; English.	
XX		
CC	The invention describes 305 nucleic acids encoding PRO (secreted and	
CC	transmembrane) polypeptides (I). (I) is useful for stimulating the	
CC	release of TNF-alpha from human blood, for modulating the uptake of	
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for	
CC	stimulating the proliferation or differentiation of chondrocyte cells,	
CC	for stimulating the proliferation of or gene expression in pericyte	
CC	cells, for stimulating the release of proteoglycans from cartilage, for	
CC	stimulating the proliferation of inner ear utricular supporting cells,	
CC	for stimulating the proliferation of T-lymphocyte cells, for stimulating	
CC	the release of a cytokine from PMW cells, for inhibiting the binding of	
CC	A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte	
CC	cells, for stimulating proliferation of endothelial cells, for detecting	
CC	the presence of tumour in a mammal. The tumour is lung, colon, breast,	
CC	prostate, rectal, cervical or liver tumour. The oligonucleotide probes	
CC	are useful for isolating genomic and cDNA nucleotide sequences or	
CC	antisense probes. (I) is also useful as therapeutic agent. PRO is useful	
CC	in assays to identify other proteins or molecules involved in binding	
CC	interaction. A polynucleotide (II) encoding (I) is useful in chromosome	
CC	and gene mapping, in generation of antisense RNA and DNA, in the	
CC	preparation of PRO polypeptide, for generating transgenic animals or	
CC	knockout animals which in turn are useful in the development and	
CC	screening of therapeutically useful reagents, in gene therapy, for	
CC	chromosome identification, as chromosome marker, and for generating	
CC	probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.	
CC	detecting its expression in specific cells, tissues or serum, and for	
CC	affinity purification of PRO from recombinant cell culture or natural	
CC	sources. (I) and (II) are useful for tissue typing. This sequence encodes	
CC	a novel human secreted and transmembrane PRO polypeptide.	
XX		
SQ	Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;	

Alignment Scores:

QY 320 yProlystYrCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 Db 1165 CCTAAATAGTCCCACTCTCTCCATGATGCATCACTGTAGACAGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGACATTTCTGGAGAGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCACACATTGAGCTGCGGAGTGTCAIT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
 Db 1345 GAATGATGAGATTTCTACTTCTCAAGAGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGGTCTCCCAAGCTGTGCCGGCAGGGGGCCCTGCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
 Db 1465 CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCCCGTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 Db 1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGGCTGCAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGGTGAGGGCGCCCTGCCAGGCGCCGATGGCTCCATCATCTTCT 1644
 QY 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGCCCTACTGCGGCTCGACCAGGCCAACTGCAGGCAACCACTTCGGGGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAATCGGGGAGCGCCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 157
 ID ADN15170 standard; cDNA; 1985 BP.
 AC ADN15170;
 DT 17-JUN-2004 (first entry)
 XX Novel human secreted and transmembrane protein PRO4339 cDNA.
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX Homo sapiens.
 OS US2003087356-A1.
 PN 08-MAY-2003.
 PD 22-APR-2002; 2002US-00127830.
 XX 15-SEP-1998; 98US-0100390P.
 PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.
 PR 30-NOV-1999; 99WO-US028313.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.

PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-801141/75.
 DR P-PSDB; ADN15171.
 XX

XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 PS Claim 2; SEQ ID NO 143; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in paricycle
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMBC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 11 Gaps: 0

US-10-791-980-6 (1-520) x ADN15170 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTGCGCGCGCTCGGCTCTCTGCGGCCCTGACAGCTGCTACTGTGGGCGCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCAGCCCGCGGAGCGCGGAGCGAGGCTGCGCAAGAGCGCGGAGCATTCCTA 325
 QY 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGATTACG 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db |||||
386 GATGCATCAGACCGCTTTTCAGTGGGTGTCACAGCTACCTGTTCAGCGGGTGTGGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db |||||
446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGTTATGCG 505

Qy 101 AlanTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db |||||
506 GCTGGGCTGAGAGGATCAGTGACTTGTGTAGACACCGACCAAAATGAGGCGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db |||||
566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACTCTCCTCAGCGCTGGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db |||||
626 AACTGGCTGAGCATCTCCGGAGCGCGAGTTCCGGGGCGCGTCCGGCGCCCTTCCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db |||||
686 TTGTGGAGCAACGCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db |||||
746 ATCCGGCTCAGCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805

Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db |||||
806 CCAGGGGGCGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864

Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db |||||
865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTCTGGCGCA 924

Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db |||||
925 CGAGATCCGTACACGCTTGGCCTCACCCATCGCCCGCGCGCGCGCTCATGGCGCC 984

Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db |||||
985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGGTGCA 1044

Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db |||||
1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAGCTGTT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db |||||
1105 CACTGACTTTGAGACCTGGGACTCTCAGCCCCCAAGAAAGGCGCCCTGAAACGCAAGG 1164

Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db |||||
1165 CCCTAAATACTGCCACTCTCTCTTCGATGCCACTCACTGTAGACAGGCAACAGCAACTGTA 1224

Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db |||||
1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284

Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db |||||
1285 TCCACTCAGGAAGATGGGTGGGGTGGCGGCTGCCCCCCCAACATTGAGGCTGGCGAGTGCATT 1344

Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db |||||
1345 GAAATGATGGAGATTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404

Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db |||||
1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGAGGGGGCGCTGCCCGCCATCTCTGACGC 1464

Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db |||||
1465 CGCCCTCTTCTTCTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCTACTACGT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db |||||
1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAAGTCTGCAGGACTGGG 1584

Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db |||||
1585 AGGCATCCCTGAGGAGTTCAGCGCGCGCTCGCGAGGCCGATCGCTCCATCATCTTCTT 1644

Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db |||||
1645 CCGAGATGACCGCTACTGGCGCCTCGACGAGGCCAACTGCAGGCAACACCTCGGGCG 1704

Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db |||||
1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGCATGCCAACTCGGGGAGCGCCCTGTT 1764

Qy 520 e 520
Db |
1765 C 1765

RESULT 158
ADN14618
ID ADN14618 standard; cDNA; 1985 BP.
XX
AC ADN14618;
XX
DT 17-JUN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087357-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127832.
XX
PR 09-SEP-1998; 98US-0099536P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801142/75.
DR P-PSDB; ADN14619.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and

transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF- α from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 11 Gaps: 0

US-10-791-980-6 (1-520) x ADN14618 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTGGCGGGTGGCTCTGCTGGTGGCGGCTGACGTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
DB 266 GAGCGCCAGCCCGGAGCGCGGAGCGCGGAGCGCGGAGCGCGGAGCGCGGAGCGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCACCTCCACTCGATTCCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGCTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCGACATGACTCGTCCCGCTCGGGGTGTACAGATACCAACAGTTATCGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACCTGTTTGTAGACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGACATCTGCGGAGCGCGGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180

DB 686 TTGTGGAGCAAGCTCTCAGCGCTGAGATTCTGGAGGCCCCAGCCACAGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGTGGCAATGCCCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGGGGCGCTGGCGCACGCCCTTC-CTGGCCCGCGCGCGCGCGCTCATGGCGCC 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGCGCGCAACTGTTCTGTGGTCTGGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTCAACGCTTGGCTTCCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
DB 985 CTACTACAGAGGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGACGTCTGGCCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGTCTAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGI 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCAGACGCCCAAGAGGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCTAAATACTGCGCACTCTCTTCGATGCCATCACTGTAGACAGCGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyLysAsnValSerGluProAr 360
DB 1225 CATTTTTAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCGAGAAAGATGGGTGGGCTGCGCGCTGCCCAACATTGAGGTGGCGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGGTTCGATGCTGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCGCGCGCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGI 460
DB 1525 GCTGGCGCGGAGGAGTGTCAAGTGGAGCCCTACTATACCCCGAAGTCTGCGAGGAGTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGGGGGCTGCGCGGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCGCAAACTGCGAGGCAACCACTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGGCTTGGTGGGCTGTGTGCTGCAACTCGGGGAGCGCGCTTGT 1764
QY 520 e 520


```
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTGGCCCTACCCACTCGCCCGCGCGCTCATGCGGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAAGAGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGTCTGGCCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCGCCCAAGGAGCGCCTGAAACGCGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTTAATATCTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCAATTTCTGGAGGTGGCAGCTGATGCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAIT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTCCCGGAGGGGCCCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGI 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTGTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGAGGTGAGCGCGCCCTGCGAGGCCGCGGCTCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGGCCAACTGCAGGCAACACCCCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACGAGCTGCCCTGGATGGGCTGCTGGCATGCCACTCGGGGAGGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 160
ADI64793
XX ADI64793 standard; cDNA; 1985 BP.
XX ADI64793;
XX ADI64793;
XX ADI64793;
DE 16-DEC-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; lung; colon; breast; prostate;
```

```
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX Homo sapiens.
OS US2003207386-A1.
XX 06-NOV-2003.
XX 29-MAY-2002; 2002US-00157800.
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S,
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z,
XX WPI; 2003-901067/82.
DR P-PSDB; ADI64794.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX Claim 2; SEQ ID NO 143; 636pp; English.
```

```
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or PFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
```


Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGTGATGCTGGAGTTCCGGGGCCCCAA	1404	PR	20-NOV-1998;	98WO-US024855.
				PR	01-DEC-1998;	98WO-US025108.
QY	400	pProValTrpGlyLeuProGlnLeuCyeArGalaGlyGlyLeuProArGHisProAspAl	420	PR	05-JAN-1999;	99WO-US000106.
				PR	08-MAR-1999;	99WO-US005028.
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCAGGGGCTGCCCGCCCATCTGTACGC	1464	PR	10-MAR-1999;	99WO-US005190.
				PR	20-APR-1999;	99WO-US008615.
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheGlyAlaArgTyrTyrVa	440	PR	14-MAY-1999;	99WO-US010733.
				PR	02-JUN-1999;	99WO-US012252.
Db	1465	GCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTACGT	1524	PR	01-SEP-1999;	99WO-US020111.
				PR	08-SEP-1999;	99WO-US020594.
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460	PR	13-SEP-1999;	99WO-US020944.
				PR	15-SEP-1999;	99WO-US021090.
Db	1525	GCTGGCCCGAGGGGACTGCAGTGGAGCCCTACTACCCCGGAAGTCTCAGGACTGGGG	1584	PR	15-SEP-1999;	99WO-US021547.
				PR	05-OCT-1999;	99WO-US023089.
QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480	PR	29-NOV-1999;	99WO-US028214.
				PR	30-NOV-1999;	99WO-US028313.
Db	1585	AGGCATCCTGAGGAGGTCAAGCGGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT	1644	PR	01-DEC-1999;	99WO-US028409.
				PR	01-DEC-1999;	99WO-US028634.
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500	PR	02-DEC-1999;	99WO-US028551.
				PR	02-DEC-1999;	99WO-US028564.
Db	1645	CCGAGATGACCGCTACTCGCGCCTCGACGAGCCAACTGCAGGCCAACTCGGGCGG	1704	PR	02-DEC-1999;	99WO-US028565.
				PR	16-DEC-1999;	99WO-US030095.
QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520	PR	20-DEC-1999;	99WO-US030911.
				PR	20-DEC-1999;	99WO-US030999.
Db	1705	CTGGGCCACCGAGTGGCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGGCTGT	1764	PR	22-DEC-1999;	99WO-US030720.
				PR	30-DEC-1999;	99WO-US031243.
QY	520	e 520		PR	30-DEC-1999;	99WO-US031274.
				PR	05-JAN-2000;	2000WO-US000219.
Db	1765	C 1765		PR	06-JAN-2000;	2000WO-US000277.
				PR	06-JAN-2000;	2000WO-US000376.
RESULT 162				PR	11-FEB-2000;	2000WO-US003565.
ADD76328				PR	18-FEB-2000;	2000WO-US004341.
ID	ADD76328	standard; cDNA; 1985 BP.		PR	22-FEB-2000;	2000WO-US004414.
XX				PR	24-FEB-2000;	2000WO-US004914.
AC	ADD76328;			PR	01-MAR-2000;	2000WO-US005601.
XX				PR	02-MAR-2000;	2000WO-US005746.
DT	29-JAN-2004	(first entry)		PR	10-MAR-2000;	2000WO-US006319.
XX				PR	15-MAR-2000;	2000WO-US006884.
DE	Human PRO	polynucleotide #72.		PR	20-MAR-2000;	2000WO-US007377.
XX				PR	21-MAR-2000;	2000WO-US007532.
KW	Human; gene; ss; PRO;	secreted polypeptide; transmembrane polypeptide;		PR	30-MAR-2000;	2000WO-US008439.
KW	tumour necrosis factor-alpha;	TNF-alpha; chondrocyte cell; tumour;		PR	17-MAY-2000;	2000WO-US013705.
KW	cancer; adrenal; lung; colon;	breast; prostate; rectum; kidney; cervix;		PR	22-MAY-2000;	2000WO-US014042.
KW	liver; microvascular	endothelial cell; glucose; FFA;		PR	02-JUN-2000;	2000WO-US015264.
KW	skeletal muscle cell;	adipocyte cell; pericyte cell;		PR	28-JUL-2000;	2000WO-US020710.
KW	inner ear utricular	supporting cell; T-lymphocyte cell;		PR	11-AUG-2000;	2000WO-US022031.
KW	endothelial cell tube	formation; bone disorder; cartilage disorder;		PR	23-AUG-2000;	2000WO-US023522.
KW	sports injury; proteoglycan;	articular cartilage defect; osteoarthritis;		PR	24-AUG-2000;	2000WO-US023328.
KW	rheumatoid arthritis;	haemoglobin-associated disorder thalassaemia;		PR	08-NOV-2000;	2000WO-US030952.
KW	immune system cell	infiltration.		PR	10-NOV-2000;	2000WO-US030873.
XX	Homo sapiens.			PR	01-DEC-2000;	2000WO-US032678.
OS				PR	20-DEC-2000;	2000US-00747259.
XX				PR	20-DEC-2000;	2000WO-US034956.
PN	US2003100087-A1.			PR	28-FEB-2001;	2001US-00796498.
XX				PR	01-MAR-2001;	2001WO-US006666.
XX				PR	09-MAR-2001;	2001US-00802706.
PR	12-JUN-1998;	97WO-US005230.		PR	14-MAR-2001;	2001US-00808689.
PR	14-JUL-1998;	98WO-US012456.		PR	22-MAR-2001;	2001US-00816744.
PR	28-AUG-1998;	98WO-US014552.		PR	05-APR-2001;	2001US-00828366.
PR	10-SEP-1998;	98WO-US017888.		PR	10-MAY-2001;	2001US-00854208.
PR	14-SEP-1998;	98WO-US018824.		PR	10-MAY-2001;	2001US-00854280.
PR	14-SEP-1998;	98WO-US019093.		PR	18-MAY-2001;	2001US-00860216.
PR	14-SEP-1998;	98WO-US019177.		PR	25-MAY-2001;	2001US-00866028.
PR	16-SEP-1998;	98WO-US019330.		PR	25-MAY-2001;	2001US-00866034.
PR	17-SEP-1998;	98WO-US019437.		PR	01-JUN-2001;	2001US-00872035.
PR	07-OCT-1998;	98WO-US021141.		PR	01-JUN-2001;	2001WO-US017800.
PR	29-OCT-1998;	98WO-US022991.				
PR	29-OCT-1998;	98WO-US022992.				


```
Qy 360 gProLeuGlnGluArgTrrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyVAspPheTyrPhePheLeVsglyGlyVArgCysrrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGAGGGGCTGCCCGCCATCTCGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrrpGl 460
Db 1525 CTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyLeProGluGluValSerGlyAlaLeuProProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGGGCGCCCTGCCAGGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTrrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTCGCGCTCGACAGGCCAAACTGACGGCAACACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysrrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 163
ADD87692 ID ADD87692 standard; cDNA; 1985 BP.
AC ADD87692;
XX
XX 29-JAN-2004 (first entry)
XX
XX Human PRO polynucleotide #72.
DE
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
OS
XX US2003092113-A1.
PN
XX 15-MAY-2003.
PD
XX 16-MAY-2002; 2002US-00147523.
PF
XX 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI
```

```
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-020237/02.
DR P-PSDB; ADD87693.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
```

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADD87692 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTCGGCTCTCTGCTGGCGCCCTGCAGCTGTCTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGCGAGAGCTGCGAAGAGGGCGGAGGCATTCTCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAACTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACCTCGATTCCAG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
```

Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCTCCAGCTACCTGTCCAGCGCGGTGTTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTCGCCGAGATGACTCGTCCCGCTGCGGGGTTCACATATCAACACGTATTGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAATAGCGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCCCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTTGAGCATCTGCCGAGCGCGCAGTTTCGGGGCGCGCTGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGCTGGGCAATGCCITTTGATGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAAGCGACATTCGACCA 864
 QY 220 nAspGluArgTrpSerSerArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
 Db 865 AGATGAGCGCTGTCCTCAGCGCGCGCGCGGCGCAACCTGTTCTGTGGTCTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTCAACACCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 Db 985 CTACTACAGAGGCTGGCGCGCGACGCGTGTCTCAGCTGGGACGACGTCTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGAGACCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCGCTGAAACGCAGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCCTAAATAGTCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
 Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTCTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
 Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTCGAGGTTCCCGGGGCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGAGGGGGCTTCCCGCCCATCTCTGACGC 1464
 QY 420 alaLeuPhePheProProLeuArgGluIleLeuPheLysGlyAlaArgTyrTyrVa 440
 Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTACGT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 Db 1525 GCTGGCCCCAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGGAAGTCTGCAGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProArgGlySerIleIlePhePh 480
 Db 1585 AGGCATCCTTGAGGAGGTGAGCGGCGCCCTGCCGAGGCCCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGCCAACTGCAGGCCAACACCACTCGGGCCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetClyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 164
 ADD86096
 ID ADD86096 standard; cDNA; 1985 BP.
 XX
 AC ADD86096;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Human PRO polynucleotide #72.
 XX
 KW Human; gene; ss; PRO: secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW liver; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003203440-A1.
 XX
 PD 30-OCT-2003.
 XX
 PF 29-MAY-2002; 2002US-00157798.
 XX
 PR 05-JUN-2000; 2000US-0209832P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Pilvaroff B, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2004-021363/02.
 DR P-P5DB; ADD86097.
 XX
 XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 .XX
 PS Claim 2; Fig 143; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis

Pred. No.:	1-93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADE23120 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGCTCGCCCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCCGGAGCGCGGAGCCAGGAGCTGCGCAGGAGCGGAGGCAATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTCGCCGAGATGACTGTCTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGCTGAGAGGATCAGTGAATGTTGTTGTAGACACCGGACCAAAATGAGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnLysTyrTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACCGCTTTGCAAGCAAGGTAACTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTGAGCATCTGCGGAGCGGCGGAGTTTCGGGGCGCCGTCGGCGCCCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCGTGGAGTTCTGGGAGGCCCCAGCCAGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCCGCTCACCTTCTTCCAGGGGACCAACACGATGGGCTGGGCAATGCTTTGATGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgHisLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGCTGCGCA	924
Qy	240	aGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CCAGATCCGCTCACGCTTGGCTTCCACCTCGCCCGCGCGCGCGCTCATGCGGCC	984
Qy	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAGAGCGTGGGCGCGAGCGCGCTGCTCAGCTGGGACGAGCTGCTGGCCGTGA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACCTGACTTTGAGCTGGGACTCTCTACAGCCCCCAAGGAAGCGCGCTGAAACGAGGG	1164

Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTCCCACTCTTCCTTCATGTCCTACTCTAGTACAGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGAGGAAAGATGGTCCGGCTGCCCCCAACATTGAGGCTGCGGCACTGTCATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCATGCTGGAGGTTCCGGGGCCCCA	1404
Qy	400	gProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTCCGGGAGGGGCTGCCCGCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGACTTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh	480
Db	1585	AGGCATCTCTGAGGAGGTGAGCGGCGCTTCCGAGGCGCGATGCTCCATCATCTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATCACCGCTACTGGCGCTCGACCGAGCCAACTGCAGGCAACACCTCGGGCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 167			
ADE23672			
ID	ADE23672	standard; cDNA; 1985 BP.	
XX			
AC	ADE23672;		
XX			
DT	29-JAN-2004	(first entry)	
XX			
DE		cDNA encoding human PRO polypeptide #72.	
XX			
KW		Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;	
KW		tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;	
KW		cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;	
KW		liver; microvascular endothelial cell; glucose; PFA;	
KW		skeletal muscle cell; adipocyte cell; pericyte cell;	
KW		inner ear utricular supporting cell; T-lymphocyte cell;	
KW		endothelial cell tube formation; bone disorder; cartilage disorder;	
KW		sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	
KW		rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;	
KW		immune system cell infiltration.	
OS		Homo sapiens.	
XX			
PN		US2003092110-A1.	
XX			
PD		15-MAY-2003.	
XX			
PF		03-MAY-2002; 2002US-00137864.	
XX			

PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
DR P-PSDB; ADE23673.
XX WPI; 2004-020235/02.
DR P-PSDB; ADE23673.
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX Claim 2; Fig 143; 637pp; English.
PS
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
XX the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,938-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADE23672 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGCGCGCTCGGCTCTGCTGCGCGCCCTCGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCCAAGCCCGGAGCGCGAGGCCAGGAGCTGCGCAAGGAGGCGGAGGCATTTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGATACCTCAATGAACAGTGTCACCAAGCTCCACCTCCACATTCGATTGAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCAGCTACTGTACGCGCGGTGTGGACGCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTCAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG 565
QY 121 LysArgPheAlaLysGlnLysGlnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCNAAGCAAGGTACAAATGGTACANGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTCAGCATCTGCCGAGCGCGAGTTCGGGGCGCGTGCAGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGTGGAGGCCCGCAGCCAGGCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCGGCTCACCTTCTTCCAAGGGGACCAACAGTGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGGAGCGACCTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTTCCTGAGCCCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTTCACCACTCGCCCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGCGCGCGCGCGCGCGCTCAGCTGGGACGACGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTCTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGAGGCGCGCTGAAAGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACATGCGCACCTCTCTTCGATGCCATCAGCTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAGGGAGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTCGAGGAAAGATGGGTGCGGCTGCCCGCCCAACATTGAGGCTCGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATCTGGAGGTTCGGGGGCCCCCA 1404

```
Qy 400 sProValTrpGlyLeuProGlnLeuCyArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCTGCCCGCCATCTCTGACG 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuLeuPheLeuGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTAGCT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCCCGGAGGGAGCTGCAAGTGAGCCCTACTACCCCCGAAGTGTGAGAGCTGGGG 1584
Qy 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGTTCAGCGCGCTGCGAGGCCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGCCAACTGCAAGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 168
ADE24315
ID ADE24315 standard; cDNA; 1985 BP.
XX
AC ADE24315;
XX
DT 29-JAN-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated cartilage disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003092111-A1.
XX
PD 15-MAY-2003.
XX
PF 03-MAY-2002; 2002US-00137869.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
XX
DR WPI; 2004-020236/02.
DR P-PSDB; ADE24316.
XX
PT New secreted and transmembrane nucleic acid useful for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, acquired immunodeficiency
```

```
PT syndrome, or cancer.
XX
XX Claim 2; Fig 143; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
XX
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0
US-10-791-980-6 (1-520) x ADE24315 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTTCGGCGCGTCTCTGCGGCCCTCTGCGGCCCTGACGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGGAGCGGAGCTGCCAAGGAGCGCGGAGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCATCTCAGC 385
Qy 61 AspalalleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuParg 80
Db 386 GATCCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGGGTGTTCAGCCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGGCGTAAG 565
```

```
121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Dbb
566 AAACGCTTTGCAAGCAGAGTAAACAATGGTACAGCAGACACTCTCTACTACCGCTGGTG 625
Qy
141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Dbb
626 AACTGGCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy
160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Dbb
686 TTGTGGAGCAACGTCCTAGCGCTCGAGTTCGTGGAGGCGCCGACGACAGGCCCCGCTGAC 745
Qy
180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Dbb
746 ATCCGGCTCACTTCTTCCAAAGGGACCAACAACATGGCTGGCAATGCTTTGATGGC 805
Qy
200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Dbb
806 CCAGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA 864
Qy
220 nAspGluArgTrpSerLeuSerArgArgGlyValArgAsnLeuPheValValLeuAlaHi 240
Dbb
865 AGATAGAGCGCTGGTCCCTAGCGCGCGCGCGGCGCAACTGTTGTTGGTGGCTGGCGCA 924
Qy
240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Dbb
925 CGAGATCGGTACACGCTGGCTCACCACACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy
260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Dbb
985 CTACTACAAAGAGGCTGGGCGCGCGCTGCTAGCTGGGACGACGTGCTGGCGGTGCA 1044
Qy
280 nSerLeuTrpGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Dbb
1045 GAGCTGTATGGAAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy
300 eThrAspPheGluThrTrpAspSerTrpProGlnGlyArgArgProGluThrGlnG1 320
Dbb
1105 CACTGACTTTGAGACTGGGACTCTCAGCCCCCAAGAAAGGCGCCCTGAAACGCGAGG 1164
Qy
320 vProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Dbb
1165 CCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCACTGA 1224
Qy
340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Dbb
1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG 1284
Qy
360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Dbb
1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTCAIT 1344
Qy
380 uAsnAspGlyAspPheTrpPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Dbb
1345 GAATGATGAGATTCTACTTCTCAAAGGGGTGATGTCGAGGTTCCGGGGCCCCAA 1404
Qy
400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Dbb
1405 GCCAGTGTGGGTCTCCCAACAGCTGTGGCGGAGGGGCGCTGCCCCCGCATCTCGAGCG 1464
Qy
420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa 440
Dbb
1465 CGCCCTCTTCTTCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy
440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Dbb
1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAAGTCTGAGGACTGGGG 1584
Qy
460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleilePhePh 480
Dbb
1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCGGAGGCGCGATGGCTCCATCATCTTCTT 1644
```

480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
1645 CCAGATGACCGCTACTGCGCTCGACAGGCAAACTGCAGGCAACCACTTCGGGCGG 1704

500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
1705 CTGGGCAACGAGCTGCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764

520 e 520
1765 C 1765

RESULT 169
ADD87140
ID ADD87140 standard; cDNA; 1985 BP.
XX
AC ADD87140;
XX
29-JAN-2004 (first entry)
DE Human PRO polynucleotide #72.
XX
Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; i-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
Homo sapiens.
OS
XX
US2003203439-A1.
XX
30-OCT-2003.
XX
17-MAY-2002; 2002US-00147499.
XX
04-AUG-1998; 98US-0095301P.
PR 02-JUN-1999; 99WO-US012252.
PR 30-MAR-2000; 2000US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH) GENENTECH INC.
XX
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2004-021362/02.
DR P-PSDB; ADD87141.
XX
New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PR04978, useful in molecular biology, chromosome and gene mapping, in
generating antisense RNA and DNA, and in gene therapy.
XX
Claim 2; Fig 143; 648pp; English.
XX
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating

antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADB87140 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGTCTCTGCTGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgGlyGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCGCGAGCGCGGAGCCAGGAGCTGCGCAAGGCGGAGGCATTCTCTA	325
Qy	41	GluIysTyrGlyTyrLeuAsnGluGlnValProIysAlaProThrSerThrArgPheSer	60
Db	326	GAGAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGTTTCAGTGGGTGTCCAGCTACTCTGTCAGCGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGCACAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGMAACAGAGTTAACAATGGTACAGCAGACCTCTCTACTACGCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTTGAGCATCTGCGGAGCGCGCAGTTTCGGGGCGCGTGGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCATCGCGCTGGAGTTCTGGGAGGCCCCAGGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200

Db	746	ATCCGGCTCACTTCTCCAAAGGGGACCAACAACATGGGCTGGCAATGCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGln	220
Db	806	CCAGGGGGCGGCTTGGGGCAGCGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATGAGCGCTGGTCCCTGAGCCCGCGCGGGGCGCACTGTTCGTGGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTTCACCACTCGCCCGCGCGCGCTCATGCGGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGln	280
Db	985	CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGCTGA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGln	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACGACGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGCGCACCTCTCTCTTCGATGCCATCCTCTGTAGACAGGCAACAGCACTGA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGCCATTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCGAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGTGCGGCGAGTGTCAAT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProIy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAGGGGGTTCGATGTGGAGGTTCCCGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCCCGCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGln	460
Db	1525	GCTGGCGCGAGGGGACTGCAAGTGGAGCGCTACTATCCCCCGAAGTCTGCGAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh	480
Db	1585	AGGCATCTCTGAGAGGTCAGCGCGCGCTGCCGAGGCCCGGATGGCTCATCATCTCTCT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCTCGACAGGCCAAATCGCAGGCCAACCACTCGGGCGC	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGTCATGTCCAACTCGGGGAGGCCCTGT	1764
Qy	520	e 520	
Db	1765	C 1765	

RESULT 170
ADE89006

ID ADE89006 standard; cDNA; 1985 BP.
XX
AC ADE89006;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199062-A1.
XX
XX 23-OCT-2003.
XX
PF 17-APR-2002; 2002US-00124823.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019033.
PR 14-SEP-1998; 98WO-US019034.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005501.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-041360/04.
XX P-PSDB; ADE89007.
XX
XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
XX hypo-insulinemia, sports injuries, arthritis, obesity, heart
XX attack, various coagulation disorders, tumors.
XX
XX Claim 2; SEQ ID NO 143; 638pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems.
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADE89006 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGTGCGCGCGGTCTGGCTCTCTGCTGGCGCCCTGCAGCTCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCCAAGCCCGGAGCGCGGAGCCAGGAGCTGCGCAAGAGCGCGGAGGCATTCTCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GGAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCACCCTCCACTCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTCGCGCAGATCACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
 DB 506 GCTTGGGCTGAGAGATCAGTACATTGTTGTGTAGACACCGGACCAAAATGAGCGGTAA 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTCGAACGACAGGTAAACAAATGGTACAGACGACACTCTCTACCGCTGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 NAATGGCTGTAGCATCTGCCGAGCGCGAGTTCGGGGCGCGCTGCGGCGCGCTTCCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGAGGTTCTGGGAGGCCCCAGCACAGGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCCCTTGTATGCG 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CAGGGGGCGGCTGGCGACGCCCTTC-CTGCCCCCGCGCGGAGCGACCTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGCTCCCTGAGCCCGCGCGGGCGCAACCTGTTCTGTTGCTGGCGCA 924
 QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTCACCACTCGCGCGCGCGCGCTCATGCGCGC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCCTGAAACAGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 DB 1165 CCCTAAATACTGCGCACTCTCTTCGATGCCATCACTGTAGACAGGCAACACGAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTGCGAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGTGGCGGAGTGTCAAT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisPheAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
 DB 1465 CGCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCTTACTACCCCGGAGCTCTGAGAGCTGGGG 1584
 QY 460 yGlyLeuProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
 DB 1585 AGGATCTCTGAGAGAGGTACGCGGCGCTGCGGAGGCCGATGGCTCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACACGCGCAAACTGACAGGCAACCCACCTCGGGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGGCTTGT 1764

Qy 520 e 520
 Db 1765 C 1765

RESULT 171
 ADE18145
 ID ADE18145 standard; cDNA; 1985 BP.
 XX
 AC ADE18145;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Human PRO polynucleotide #72.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003194794-A1.
 XX
 PD 16-OCT-2003.
 XX
 PF 17-APR-2002; 2002US-00125805.
 XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019031.
 PR 14-SEP-1998; 98WO-US019034.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005190.
 PR 10-MAR-1999; 2000WO-US006319.
 PR 20-APR-1999; 99WO-US0008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 15-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.

30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 09-MAR-2001; 2001WO-US006566.
 PR 14-MAR-2001; 2001US-00802706.
 PR 22-MAR-2001; 2001US-00808689.
 PR 05-APR-2001; 2001US-00816744.
 PR 10-MAY-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 05-JUN-2001; 2001WO-US017800.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2004-021079/02.
 DR P-PSDB; ADE18146.
 DR
 XX
 PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, for use in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX

Claim 2; SEQ ID NO 143; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,938-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADE18145 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTCGGCGCGTGGCCCTCTGTGCGCGCCCTGCAGCTGCTACTGTGGGCGCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GACGCCACGCGCGAGCGCGAGCGCGAGAGCTGCGCAAGAGCGCGAGGCAATTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACG	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
DB	386	GATGCCATCAGACGGTTTCAGTGGGTGCCAGCTACCTGTGTCAGCGGGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTCGCGCAGATCACTCGTCCCGCTCGCGGGTTACAGATACCACAGATTATGCG	505
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
DB	506	GCTTGGGCTGAGAGGATCAGTACATTGTTGTGACACCGGACCAAAATGAGGCGTAAG	565
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140

DB	566	AAACGCTTTGCAAGCAAGGTAAACAATGGTTACAGCAGCACCTCTCTCTACCGCTGGTG	625
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCTTACGATCTGCGGAGCGCGCAGTTCGGGGCGCGTGGCGCGCTTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
DB	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGGCCCCAGCCACAGGCCCGCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACCTCTTCCAGGGGACACACAGATGGCTGGGCAATGCCCTTTGATGC	805
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
DB	806	CCAGGGGGCGCTGGCGCACGCTTC-CTGGCCCGCGCGCGGCGAGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi	240
DB	865	AGATGAGCGCTGGTCCCTGAGCCCGCGCGGGCGCAACCTGTTGTTGGTGGTGGCGCA	924
QY	240	sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGCGCGC	984
QY	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG	280
DB	985	CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGA	1044
QY	280	nSerLeuTrpGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPhe	300
DB	1045	GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCACGGAAGAGCTGT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG	320
DB	1105	CACTGACTTTGAGACCTCGGACTCTCTACAGCCCCCAAGGAAGCGCCCTGAAACGAGG	1164
QY	320	ypProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
DB	1165	CCCTAAATACATGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACACCACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyLysValSerGluProAr	360
DB	1225	CATTTTAAAGGAGCCATTTCTGGAGTGGCAGCTGATGCAACGCTCTAGAGCCCGG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe	380
DB	1285	TCCACTGCAGGAAGATGGTGGGCTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy	400
DB	1345	GAATGATGGAGATTCTACTCTTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCCAA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl	420
DB	1405	GCCAGTGGGGTCTCCACAGCTGTCCCGGGCAGGGGGGCTGCCCGCCCATCTCTGACGC	1464
QY	420	aAlaLeuPhePheProProLeuArgLeuLeuPheLysGlyAlaArgTyrTyrVa	440
DB	1465	CGCCCT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrTrpProArgSerLeuGlnAspTrpG	460
DB	1525	GCTGGCGGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCGAGGACTGGGG	1584
QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
DB	1585	AGGCATCTCTGAGGAGGTACGCGCGCTCTCCGAGGGCCCGATGGCTCCATCATCTTCT	1644
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500

Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACCGCCAAACTGAGCGCAACCTCGGCGCG 1704

Qy 500 gTTPAlaThrGluleuPTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764

Qy 520 e 520
1765 C 1765

Db

RESULT 172

AD888454

ID AD888454 standard; cDNA; 1985 BP.

XX AC AD888454;

XX 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #72.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; PFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; r-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

XX Homo sapiens.

XX US2003199054-A1.

XX 23-OCT-2003.

XX 12-APR-2002; 2002US-00121054.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 10-MAR-1999; 2000WO-US006319.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030995.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 03-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 11-FEB-2000; 2000WO-US000376.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 01-MAR-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 15-MAR-2000; 2000WO-US005841.

PR 20-MAR-2000; 2000WO-US006884.

PR 21-MAR-2000; 2000WO-US007377.

PR 30-MAR-2000; 2000WO-US007532.

PR 17-MAY-2000; 2000WO-US008439.

PR 22-MAY-2000; 2000WO-US013705.

PR 30-MAY-2000; 2000WO-US014042.

PR 02-JUN-2000; 2000WO-US014941.

PR 28-JUL-2000; 2000WO-US015264.

PR 11-AUG-2000; 2000WO-US020710.

PR 23-AUG-2000; 2000WO-US023522.

PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001US-00796498.

PR 28-FEB-2001; 2001WO-US006520.

PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.

PR 14-MAR-2001; 2001US-00808689.

PR 22-MAR-2001; 2001US-00816744.

PR 05-APR-2001; 2001US-00828366.

PR 10-MAY-2001; 2001US-00854280.

PR 10-MAY-2001; 2001US-00854280.

PR 18-MAY-2001; 2001US-00860216.

PR 25-MAY-2001; 2001US-00866028.

PR 25-MAY-2001; 2001US-00866034.

PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.

PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.

PR 14-JUN-2001; 2001US-00882836.

PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.

PR 21-JUN-2001; 2001US-00887879.

PR 22-JUN-2001; 2001WO-US020116.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.

PR 18-JUL-2001; 2001US-00908827.

PR 06-AUG-2001; 2001US-00924419.

PR 09-AUG-2001; 2001US-00927796.

PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritken ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-041356/04.

DR P-PSDB; ADE88455.

XX Novel secreted and transmembrane polypeptides, PRO useful for treating
PT bone disorders, arthritis, heart attack, injuries, tumors, and
PT stimulating release of TNF-alpha from human blood.

XX Claim 2; SEQ ID NO 143; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Score: No.:	1,93e-149	Length:	1985
Percent Similarity:	2792.00	Matches:	519
Best Local Similarity:	99.62%	Conservative:	0
Query Match:	99.62%	Mismatches:	1
DB:	98.52%	Indels:	2
	12	Gaps:	0

US-10-791-980-6 (1-520) x ADE88454 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGGCTGGCTCTCTGTCGGCCCTCGAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGCGAGCGCGAGCCGAGAGCTGCGCAAGGAGCGGAGGCGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTCTGAGCGGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGGCGAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505

QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGCAATCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCTGTCGCGACGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTyrSerLeuSerArgArgGlyArgAsnLeuPheValValAlaHis 240
DB 865 AGATGAGCCTGCTCCTGAGCGCGCGCGCGCAACCTGTTGCTGCTGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CCAGATCGGTCAACGCTTGGCTTCCACCTCGCGCGCGCGCTCATGCGCGC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuSerTyrAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGAGTGTGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAGCCCTTGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGCTGGAGCTCTTACAGCCCCCAAGGAGCGCCCTGAAACGCGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCTTAATACTGCCACTCTTCTTCCATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTyrGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGCACTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTyrValGlyLeuProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGTGGCTGCGCTGCCCCCAACATTGAGGCTGGCGAGTGCATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGCGGGCCCCAA 1404
QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCAGTGTGGGTCTCCCAAGCTGTGCGGGGAGGGGCTGCCCCCGCATCTCGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTGCGCGCTCATCTCTTCAAGGTGCGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1 460
DB 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
QY 460 vGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGCATCTCTGAGGAGGTGAGGGGCGCTGCGAGGCGCGGATGCTCATCTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCTCTCGACCGAGCCAACTGCAAGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTyrPheMetGlyCysTyrPheIleAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCGACCGAGCTGCCCTGGATGGCTGCTGGATGCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 174

ABE90885
ID ADE90885 standard; cDNA; 1985 BP.
XX
AC ADE90885;
DT 12-FEB-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.
OS Homo sapiens.
XX
PN US2003199061-Al.
XX
PD 23-OCT-2003.
XX
PF 16-APR-2002; 2002US-00123911.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 2000WO-US006319.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.

```
PR 11-FEB-2000; 200WO-US003565.
PR 18-FEB-2000; 200WO-US004341.
PR 18-FEB-2000; 200WO-US004342.
PR 22-FEB-2000; 200WO-US004342.
PR 24-FEB-2000; 200WO-US004914.
PR 24-FEB-2000; 200WO-US005004.
PR 01-MAR-2000; 200WO-US005601.
PR 02-MAR-2000; 200WO-US005746.
PR 02-MAR-2000; 200WO-US005841.
PR 15-MAR-2000; 200WO-US006884.
PR 20-MAR-2000; 200WO-US007377.
PR 21-MAR-2000; 200WO-US007532.
PR 30-MAR-2000; 200WO-US008439.
PR 17-MAY-2000; 200WO-US013705.
PR 22-MAY-2000; 200WO-US014042.
PR 30-MAY-2000; 200WO-US014941.
PR 02-JUN-2000; 200WO-US015264.
PR 28-JUL-2000; 200WO-US020710.
PR 11-AUG-2000; 200WO-US022031.
PR 23-AUG-2000; 200WO-US023522.
PR 24-AUG-2000; 200WO-US023328.
PR 10-NOV-2000; 200WO-US030952.
PR 01-DEC-2000; 200WO-US032678.
PR 20-DEC-2000; 200WO-US034729.
PR 20-DEC-2000; 200WO-US034956.
PR 28-FEB-2001; 200WO-US034958.
PR 28-FEB-2001; 200WO-US006520.
PR 01-MAR-2001; 200WO-US006666.
PR 09-MAR-2001; 200WO-US002706.
PR 14-MAR-2001; 200WO-US008689.
PR 22-MAR-2001; 200WO-US008674.
PR 05-APR-2001; 200WO-US008366.
PR 10-MAY-2001; 200WO-US00854208.
PR 10-MAY-2001; 200WO-US00854280.
PR 18-MAY-2001; 200WO-US0860216.
PR 25-MAY-2001; 200WO-US0860238.
PR 25-MAY-2001; 200WO-US0866034.
PR 25-MAY-2001; 200WO-US017092.
PR 01-JUN-2001; 200WO-US0082035.
PR 01-JUN-2001; 200WO-US017800.
PR 05-JUN-2001; 200WO-US0874503.
PR 14-JUN-2001; 200WO-US0882636.
PR 19-JUN-2001; 200WO-US0886342.
PR 20-JUN-2001; 200WO-US019692.
PR 21-JUN-2001; 200WO-US0887879.
PR 22-JUN-2001; 200WO-US020116.
PR 29-JUN-2001; 200WO-US021066.
PR 09-JUL-2001; 200WO-US021735.
PR 18-JUL-2001; 200WO-US090827.
PR 06-AUG-2001; 200WO-US0924419.
PR 09-AUG-2001; 200WO-US0927796.
PR 16-AUG-2001; 200WO-US0931836.
PR 19-DEC-2001; 200WO-US0028072.
XX (GETH ) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2004-041359/04.
DR P-PSDB; AD90886.
XX
XX New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
XX Claim 2; SEQ ID NO 143; 638pp; English.
PS
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
```

```
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPRO at seqdata.uspto.gov/sequence.html.
XX
```

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,93e-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADE90885 (1-1985)

Qy	1	MevValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGTCGGCTCCCTGCTGCGGCCCTGAGTGTACTGTGGGGCCACTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGCGGAGCGCGAGGCGAGGCTGCGCAAGGAGGCGGAGGCAATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATCCCATCAGAGGTTTCAGTGGGTGCCAGCTACTGTGACGGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGGCCAGATGACTCGTCCCGGTGCGGGGTTCACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisGlyThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTACTTGTTCCTAGACACCGGACCAAAATGAGCGGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTCAAAGCAAGGTAAACAATGGTTACAAGCAGCACCTCTCTCCATCCGCTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160

Db 626 AACTGCGCTGAGCATCTGCGGAGCGCGAGTTCGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCGCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGGCTGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGCGCACGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGCTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CAGATCGGTACACGCTTGGCTTACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGCTGCTGCGCGTGA 1044
Qy 280 nSerLeuTyGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGGAGCGCGCTCGAAACGACGGG 1164
Qy 320 yProLysTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerle 380
Db 1285 TCCACTGCAAGAAAGATGGTCTGGGCTGCCCGCCCAACATTGAGGCTGGCGCATGTATT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGTGATGCTGGAGGTTCCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgIleLeuPheLysGlyAlaArgTyTrpVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTAGCT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACCGAGCCAACTGCAAGGCAACCCACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

Db 1705 CTGGCCACCAGAGCTCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 175
ADE95026
ID ADE95026 standard; cDNA; 1985 BP.
XX
AC ADE95026;
XX
DT 12-FEB-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; bone disorder; cartilage disorder;
KW endothelial cell tube formation; bone disorder; cartilage defect; osteoarthritis;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199052-A1.
XX
PD 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121052.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US024855.
PR 20-NOV-1998; 98WO-US025108.
PR 01-DEC-1998; 98WO-US000106.
PR 05-JAN-1999; 99WO-US005028.
PR 08-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US074259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796439.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-041355/04.
DR P-PSDB; ADE95027.
XX New secreted and transmembrane nucleic acid, useful for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury.

PT infertility, birth defects, premature aging, acquired immunodeficiency
PT syndrome, or cancer.
XX Claim 2; Fig 143; 638pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADE95026 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCCTCTCTGCGCCCTCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCCGCGAGCGCGAGGCGGAGGCTGCGCAAGAGGCGGCGGCGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGCTCCCAAGCTCCACCTCCATTCAGC 385
Qy 61 AspalatleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACTCTGCAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

Db 506 GCTCGGCTGAGAGGATCAGTGACTTGTGTGTAGACACGGACCAAAATGAGCGCTAAG 565
Qy 121 LybAArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACACAGCAGCACTCTCTACCGCTGGTG 625
Qy 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTCTGAGCATCTGCGAGCGGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCACACAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCTTCTTCCAGGGGACACACAGATGGCTGGGCANTGCCCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpPheLeuProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGTGCTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACCTCTGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAAGAGCTGGGCGCGACGCGCTGTCTAGCTGGAGCGAGTCTGCGCGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCACGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAGGAGCGCGCTGAAACGACGG 1164
Qy 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340
Db 1165 CCCTAAATACTGCCACTTCTCTCGATGCCATCATCTGTAGACAGCAACACCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 pProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerle 380
Db 1285 TCCACTGCAGGAAAGATGGTTCGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAenAspGlyAspPheTrpPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 pProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGAGGGGCGCTGCCCCGCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValLcluproTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCGCTTACTACCCCCGAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644

Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACACAGGCCAAACTGACAGGCACCACTTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 176
ADE93136
ID ADE93136 standard; cDNA; 1985 BP.
XX
AC ADE93136;
DT 12-FEB-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199060-A1.
XX
PD 23-OCT-2003.
XX
PF 15-APR-2002; 2002US-00123771.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012452.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.

```

PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028851.
PR 02-DEC-1999; 99WO-US028854.
PR 02-DEC-1999; 99WO-US028856.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030878.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006566.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001US-00886342.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI

```

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2004-041358/04.
P-PSDB; ADE93137.

Novel PRO polypeptide useful for treating diabetes, hyper or hypo
insulinemia, sports injuries, arthritis, obesity, stroke, heart attack,
various coagulation disorders, tumors.

Claim 2; Fig 143; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems. PRO
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
Gaps: 0

US-10-791-980-6 (1-520) x ADE93136 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGGTCGGCTCTCTGTCGGCGCCCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGGAGCGGAGCTGCCAGAGTCCCAAGCTCCACCTCGATTGAGC 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCGATTGAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCGTTTCAGTGGGTGCCAGCTACCTGTCCAGCGCGGTGTGTGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
 DB 446 GCCACCTCGCGCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgArgLys 120
 DB 506 GCTCGGCTGAGAGGATCAGTGAATTGTTGTCTAGACACCGGACCAAAAATGAGCGCTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTTPTrpLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGGCTTGCAAGACAGGTAACTAATGGTACAGCAGCACTCTCTACCGCCCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCCTGAGCATCTGCGGAGCGCGCAGTTTCGGGGCGCGTGCAGCCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGGCCCAAGCCACAGCGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CCAGGGGGCGCCCTGAGCGACGCTTC-CTGCCCGCGCGGGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGCTCCTCAGCGCGCGCGGCGCAACCTGCTCGTGGTGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CCAGATCGGTACACGCTTGGCTTCACCCACTCGCCGCGCGCGCGCTCATGCGCGC 984
 QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAGAGGCTGGGCGCGGACGCGCTGCTCAGCTGGGACGCTGCTGGCGGTGA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGGAGCGCGCCCTGNAACGACGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 DB 1165 CCCTAAATAGTCCACTCTTCTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGCAATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerie 380
 DB 1285 TCCACTGCAAGAAAGATGGTGGGCTGCCCGCCCAACATTTAGGCTGGCGGAGTGTCAAT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProly 400
 DB 1345 GAATGATGAGATTTCTACTTTCTTAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTTCCCGCCATCTCTGACG 1464
 QY 420 alaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrpVa 440
 DB 1465 CGCCCTCTTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGGGTGCCGCTACTAGCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460

DB 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAGTCTCGAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProArgProArgGlySerIleIlePhePh 480
 DB 1585 AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCGAGGCCGATGGCTCCATCATCTCTTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar 500
 DB 1645 CCGAGATGACCCCTACTGGCGCTCGACGAGGCCAACTGACAGGCAACCACTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765
 RESULT 177
 ADF34717
 ID ADF34717 standard; cDNA; 1985 BP.
 XX
 AC ADF34717;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE cDNA encoding human PRO polypeptide #72.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003199029-A1.
 XX
 PD 23-OCT-2003.
 XX
 PF 22-MAY-2002; 2002US-00153840.
 XX
 PR 03-MAR-2000; 2000US-0187202P.
 PR 01-DEC-2000; 2000MO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2004-041352/04.
 DR P-PSDB; ADF34718.
 XX
 PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful for molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 PS Claim 2; Fig 143; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,938-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADF34717 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCGCTCGGCTCTCTGTCGCGCCCTGTCAGTCTACTGTGGGCGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCGCGGAGCGCGGAGCGGAGAGCTGCGCAAGGAGCGGAGGCATTTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GGAAGTACGGATACCTCAATGACAGAGTCCCAAGCTCCACCTCCACTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGCTTTCAGTGGGTGTCACAGCTACCTGTGAGCGGCTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCGCAGATACCTGCTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGTGAGAGATCAGTGACTTGTTGCTAGACACCGGACCCAAATGAGGGGTAAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTCAAAGCAAGGTAAACAAATGGTTACAAAGCAGCACCTCTCCTACCGCTGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTTGACATCTCCGCGAGCGCGAGTTCCGGGCGCGCTGCGCGCGCTTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180

Db	686	TTTGGAGCAACAGTCTCAGCGCTGGAGTTCTTGGAGAGCCCCAGCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCGGGCTACCTTCTTCCAAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
Db	806	CCAGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA	864
Qy	220	nasGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATGACGCTGGTCCCTGAGCGCGCGCGCGGCGCAACTGTTCGTGTGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACAGCTTGGCCTCACCCACTGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG	280
Db	985	CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCGCTGAAGCGCAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTTAAATACCTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCAGGAAAGATGGGTGCGGCTGCCCGCGCGCGCTTCCGGGCGAGTGTCAAT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTCGCGGCGAGGGGCGCTGCCCGCCATCTCGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCTCTTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCCTACTAGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG	460
Db	1525	GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTCCCCGAAAGTCTGAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTGAGCGCGCTGCCGAGGCCCGGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCTCGACCGAGCCCAACTGCAGGCAACCACTCGGGCGC	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGCGATGCCAACTCGGGGAGGGCCCTGT	1764
Qy	520	e 520	1

Db 1765 C 1765
RESULT 178
ADE92032
ID ADE92032 standard; cDNA; 1985 BP.
XX
AC ADE92032;
XX
DT 12-FEB-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW Cell proliferation stimulator; cell differentiation stimulator;
KW Cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
XX US2003199051-A1.
XX
XX 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121048.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000108.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021056.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-041354/04.
DR P-PSDB; ADE92033.
XX
XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
XX
PS Claim 2; SEQ ID NO 143; 638pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the

CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1, 93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADE92032 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTGGCGCGCTGGCTCTGGTGGCGCGCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCGCCAGCCCGGAGCGCGGAGCGCGAGAGCTGCGCAAGAGCGCGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACCGCTTTTCAGTGGGTGTCCACAGCTACCTGTGAGCGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGCTGAGAGGATCAGTCACTTGTGTGTAGACACCGGACCAAAATGAGGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTAAACAGCAGCACTCTCCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGACATCTGCCGAGCGCGGAGTTCGGGGCGCGTGGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180

DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACTCTTCTCCAAAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCCGCGGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGACGGCTGTCTCTGAGCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCCTCACCACTCGCCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGCGTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGAAACGCGAGG 1164
QY 320 YProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
DB 1165 CCCTAATACTGCGCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGTATGGCAACGCTCTCAGAGCCCG 1284
QY 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTCGAGAAAGATGGGTGGGCTGCGCCGCCCAACATTGAGGCTCGGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTTACTTCTTCAAAGGGGTGCGATGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTGTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCCCTACTAGCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCGAGGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGAGGTACGCGCGCCCTGCCGAGGCCCATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCCTCGACCAGGCCAACTGCAGGCGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheAlaHisSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACAGCTGCCCTGCATGGGTGTGTGGCATGCCAACTCGGAGGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 179
ADE90333
ID ADE90333 standard; cDNA; 1985 BP.
XX AC ADE90333;
XX DT 12-FEB-2004 (first entry)
XX DE Human PRO polynucleotide #72.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003199063-A1.
XX PD 23-OCT-2003.
XX PF 19-APR-2002; 2002US-00125931.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-041361/04.
DR P-PSDB; ADE90334.
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX Claim 2; SEQ ID NO 143; 636pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and

Db 1705 CTGGGACCGAGCTGCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 c 1765
RESULT 180
ADE91480
ID ADE91480 standard; cDNA; 1985 BP.
XX
AC ADE91480;
XX
DT 12-FEB-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003199058-A1.
XX
PD 23-OCT-2003.
XX
PF 15-APR-2002; 2002US-00123291.
XX
XX 31-MAR-1997; 99WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US020231.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI: 2004-041357/04.
DR P-PSDB; ADE91481.
XX
PT Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.

XX	Claim 2; SEQ ID NO 143; 638pp; English.	Db	626	AACTGGCCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCCGTCGGCGCGCTTCCAG	685
PS	The invention describes 305 nucleic acids encoding PRO (secreted and	Qy	160	rcysglyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
XX	transmembrane) polypeptides (I). (I) is useful for stimulating the	Db	686	TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCCTGGAGGAGCCCGCAGCCAGCGCCGCTGAC	745
CC	release of TNF-alpha from human blood, for modulating the uptake of	Qy	180	rserglySerProSerSerlysglyThrThrMetGlyTyrAlaMetProLeuMetAl	200
CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for	Db	746	ATCCGGCTCACCCTTCTTCCAAAGGGGACCAACAGATGGCTGGCAATGCTTGTATGGC	805
CC	stimulating the proliferation of or gene expression in pericyte	Qy	200	aglnGlyValaProTrpArgThrProPheLeuProArgArgGlyVgluAlaHisPheAspGl	220
CC	cells, for stimulating the release of proteoglycans from cartilage, for	Db	806	CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGAGCGACCTTCGACCA	864
CC	stimulating the proliferation of inner ear utricular supporting cells,	Qy	220	naspGluArTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
CC	for stimulating the proliferation of T-lymphocyte cells, for stimulating	Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGTGTGGCGCA	924
CC	the release of a cytokine from PBMC cells, for inhibiting the binding of	Qy	240	sgluileGlyHisThrleuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
CC	A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte	Db	925	CGAGATCGGTACACGCTTGGCTTCCACTCGCCCGCGCGCGCGCTCATGGCGCC	984
CC	cells, for stimulating proliferation of endothelial cells, for detecting	Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl	280
CC	the presence of tumour in a mammal. The tumour is lung, colon, breast,	Db	985	CTACTACAAGAGGCTGGCGCGCGCGCTCAGCTGGGAGCGACGTGTGGCGGTGCA	1044
CC	prostate, rectal, cervical or liver tumour. The oligonucleotide probes	Qy	280	nserLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh	300
CC	are useful for isolating genomic and cDNA nucleotide sequences or	Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGT	1104
CC	antisense probes. (II) is also useful as therapeutic agent. PRO is useful	Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
CC	in assays to identify other proteins or molecules involved in binding	Db	1105	CACGTGCTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGCGCCCTGAAACGCGGG	1164
CC	interaction. A polynucleotide (II) encoding (I) is useful in chromosome	Qy	320	yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
CC	and gene mapping, in generation of antisense RNA and DNA, in the	Db	1165	CCCTAAATACTGCGCCTCTCTTCGTGATGTCATCCTGTAGACAGCAACAGCACTGTA	1224
CC	preparation of PRO polypeptide, for generating transgenic animals or	Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyValSerGluProAr	360
CC	knockout animals which in turn are useful in the development and	Db	1225	CATTTTTAAAGGGAGGCCATTTCTGGAGGTGGAGCTGTATGGCAACGTCTCAGAGCCCG	1284
CC	screening of therapeutically useful reagents, in gene therapy, for	Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
CC	chromosome identification, as chromosome marker, and for generating	Db	1285	TCCACTCAGGAAAGATGGTTCGGCTGCCCGCCCAACATTGAGGCTGCGGAGTGTCAAT	1344
CC	probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.	Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy	400
CC	detecting its expression in specific cells, tissues or serum, and for	Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGGGGCCCCCA	1404
CC	affinity purification of PRO from recombinant cell culture or natural	Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl	420
CC	sources (I) and (II) are useful for tissue typing. This sequence encodes	Db	1405	GCCAGTGTGGGTCTCCACAGCTGTCCGGGAGGGGGCTGCCCGCCCATCTGAGGC	1464
CC	a novel human secreted and transmembrane PRO polypeptide.	Qy	420	aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa	440
XX	Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;	Db	1465	CGCCCTCTTCTTCCTCTCTGCGCGCTCATCTCTTCAAGGGTTCGGCGCTACTACGT	1524
SQ		Qy	440	lLeuAlaArgGlyLysLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Alignment Scores:		Db	1525	GCTGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTTACCCCCCAAGTCTGCHAGGACTGGG	1584
Pred. No.:	1-93e-149	Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh	480
Score:	2792.00	Db	1585	AGGCATCCCTGAGGAGGTTCAGCGCGCCCTGCCGAGGGCCGATGGCTCATCTTCT	1644
Percent Similarity:	99.62%	Qy	480	eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Best Local Similarity:	99.62%	Db	1645	CCGAGATGACCGCTACTGCGCGCTCGACCGAGCCAACTGCGAGGCAACCACTCGGGCGG	1704
Query Match:	98.52%	Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
DB:	12				
US-10-791-980-6 (1-520) x ADE91480 (1-1985)					
Qy	1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20			
Db	206 ATGGTCGCGCGTGGCTCTCTGTCGCGCCCTGACGTCTACTGTGGGGCCACCTG	265			
Qy	21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu	40			
Db	266 GAGCCCGAGCGCGGAGCGCGGAGCCAGAGCTGCGCAAGAGGCGGAGGCATTCCTA	325			
Qy	41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60			
Db	326 GAGAAGTACGGATACCTCAATGAACAGGTCCGCAAGGTCCCACTCCATCGATTACG	385			
Qy	61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80			
Db	386 GATGCCATCAGACGGTTTTCAGTGGGTGTCCTGAGCTACCTGTGAGCGCGGTGTGAGCCG	445			
Qy	81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100			
Db	446 GCCACCTCGCCAGATGACTGTCTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG	505			
Qy	101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgGlyLys	120			
Db	506 GCCTGGGCTGAGAGGATCATGTCCTTTGCTGTAGACACCGGACCAAAATGAGGGCGTAAG	565			
Qy	121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal	140			
Db	566 AAACGCTTTTGAAGCAAGGTAAACAATGGTACACAGCAGCACCTCTCTACCGCTGGTG	625			
Qy	141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160			

Db 865 AGATGAGCGCTGGTCCCTCGAGCGCGCGCGCGCGCAACTGTTCTGGTGGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACCATCTGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrIysArgLeuGlyArGAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGTCGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh 300
Db 1045 GAGCGTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGCCCCCNAGGAAGGCGCTTGAACGCAGGG 1164
Qy 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCAGTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGGCATTCTGGGAGGTGGCAGCTATGGCAACGCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArGTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGTGGGTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheIysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGAGGGGCTGCCCCGCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTACGGCGCCCTTCCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAGGCCAACTGCAGGCCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACCTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 182
ADG21845
ID ADG21845 standard; cDNA; 1985 BP.
XX
AC ADG21845;
XX
DT 26-FEB-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX

KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003207360-A1.
XX
XX 06-NOV-2003.
XX
XX 08-MAY-2002; 2002US-00141757.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-010596/01.
XX
XX P-PSDB; ADG21846.
XX
XX New nucleic acid encoding a secreted and transmembrane PRO polypeptide
XX useful for stimulating the release of tumor necrosis factor alpha from
XX human blood and in treating and detecting a tumor.
XX
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
XX cells, for stimulating differentiation of adipocyte cells, for
XX stimulating proliferation of or gene expression in pericyte cells, for
XX stimulating the proliferation of inner ear utricular supporting cells or
XX T-lymphocyte cells, for inducing endothelial cell tube formation and for
XX treating various bone and/or cartilage disorders such as sports injuries
XX and arthritis. PRO polypeptides which stimulate the release of
XX proteoglycans from cartilage are useful for treating sports-related joint
XX problems, articular cartilage defects, osteoarthritis and rheumatoid
XX arthritis. PRO polypeptides are also useful for treating various
XX mammalian haemoglobin-associated disorders such as various thalassemias
XX and conditions which may benefit from enhanced local immune system cell
XX infiltration. This sequence represents a human PRO polynucleotide of the
XX invention. Note: The sequence data for this patent is also available in
XX electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,938-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG21845 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuTTPGlyHisLeu 20
DB 206 ATGGTCGGCGCGCTCGGCTCTGCTGGCGGCTCGAGCTGTACTGTGGGCGCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaAlaPheLeu 40
DB 266 GACGCCAGCCCGGAGCGGAGGCGAGGCTCGCAAGGAGGCGGAGGCTTCCTA 325

QY 41 GluLysTyrGlyTyrLeuLeuGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGAGCTCCACCTCCACTCGATTTCAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGGCGGTGTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCGCAGATGACTCTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCTTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAANTGGTACAGACACCTCTCTACCGCGCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCGGAGCGGCGAGTTGCGGGCGCGTTCGCGCGCGCTTCCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCCGCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCCTTCTCCAGGGGACCAACAGATGGGCTGGGCANTGCCCTTTGATGC 805

QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCTGGCGCACGCTTC - CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATAGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTGTGTGGTGTGGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CAGATCGGTACACGCTGGCTTACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984

QY 260 tTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAGAGGCTGGGCGCGAGCGCGCTGTCTCAGCTGGGAGCGAGTGTGCGCGTGA 1044

QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCGTCCAGCTCCCGAGGAAGCTGTT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAGAGAGCGCCCTTGAACGCGAGG 1164

QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGAGCCATTTCTGGAGGTGCGAGCTGATGGCAACGTCTCAGAGCCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCACCTGCAAGAAAGATGGGTGGGCTGCCCCCAACATTGAGGCTGCGGAGTGTCAATT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTCGACGC 1464

QY 420 aAlaLeuPhePheProLeuArgLeuIleLeuPheLysGlyValAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGGCGCTCATCTCTTCAAGGGTGGCGCTTACTACT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCGCTTACTACCCCGAAGTCTGCAGGACTGGGG 1584

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGGCTCCATCTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCGCAAACTGCAGGCAACCACTTCGGGCGG 1704

QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACAGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764

QY 520 e 520
DB 1765 C 1765

RESULT 183
ADG19915
ID ADG19915 standard; cDNA; 1985 BP.
XX
AC ADG19915;
XX
DT 26-FEB-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003207376-A1.
XX

PD 06-NOV-2003.
XX 17-MAY-2002; 2002US-00147489.
XX 28-OCT-1998; 98US-0106030P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 98US-00403297.
PR 18-OCT-2000; 2000WO-US004342.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-096982/10.
DR P-PSDB; ADG19916.
XX New PRO nucleic acid, useful for diagnosing and treating cancer, for
PT chromosome mapping or for tissue typing.
XX Claim 2; Fig 143; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,936-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
Ds: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG19915 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20

```
Db 1285 TCCACTGCAGGAAGATGGCTCGGGCTGCCCCCAACATTGAGCGTGGCGAGTCATTT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheIysGlyGlyAiqCysTirArgPheArgGlyProIy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCGCCATCTTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGCCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGGAGTCTGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValserGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGGAGCGCGATGGCTTCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTirArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTTGGCGCTCGACCAAGGCCAAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTirAlaThrGluLeuProTirMetGlyCysTirPheHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 184
ADF97821
ID ADF97821 standard; cDNA; 1985 BP.
XX
AC ADF97821;
XX
XX
DT 26-FEB-2004 (first entry)
XX
XX Human PRO polynucleotide #72.
DE
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003207422-A1.
XX
XX 06-NOV-2003.
XX
XX 08-MAY-2002; 2002US-00141754.
XX
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99WO-US005190.
XX 20-APR-1999; 99WO-US008615.
XX 14-MAY-1999; 99WO-US010733.
XX 02-JUN-1999; 99WO-US012252.
XX 01-SEP-1999; 99WO-US020111.
XX 08-SEP-1999; 99WO-US020594.
XX 13-SEP-1999; 99WO-US020944.
XX 15-SEP-1999; 99WO-US021090.
XX 15-SEP-1999; 99WO-US021547.
XX 05-OCT-1999; 99WO-US023089.
XX 29-NOV-1999; 99WO-US028214.
XX 30-NOV-1999; 99WO-US028313.
XX 30-NOV-1999; 99WO-US028409.
XX 01-DEC-1999; 99WO-US028301.
XX 01-DEC-1999; 99WO-US028634.
XX 02-DEC-1999; 99WO-US028551.
XX 02-DEC-1999; 99WO-US028564.
XX 02-DEC-1999; 99WO-US028565.
XX 16-DEC-1999; 99WO-US030095.
XX 20-DEC-1999; 99WO-US030911.
XX 20-DEC-1999; 99WO-US030999.
XX 22-DEC-1999; 99WO-US030720.
XX 30-DEC-1999; 99WO-US031243.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US003565.
XX 18-FEB-2000; 2000WO-US004341.
XX 18-FEB-2000; 2000WO-US004342.
XX 22-FEB-2000; 2000WO-US004414.
XX 24-FEB-2000; 2000WO-US004914.
XX 24-FEB-2000; 2000WO-US005004.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005746.
XX 02-MAR-2000; 2000WO-US005841.
XX 10-MAR-2000; 2000WO-US006319.
XX 15-MAR-2000; 2000WO-US006884.
XX 20-MAR-2000; 2000WO-US007377.
XX 21-MAR-2000; 2000WO-US007532.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.
XX 22-MAY-2000; 2000WO-US014042.
XX 30-MAY-2000; 2000WO-US014941.
XX 02-JUN-2000; 2000WO-US015264.
XX 28-JUL-2000; 2000WO-US020710.
XX 11-AUG-2000; 2000WO-US022031.
XX 23-AUG-2000; 2000WO-US023522.
XX 24-AUG-2000; 2000WO-US023328.
XX 08-NOV-2000; 2000WO-US030952.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000WO-US034956.
XX 28-FEB-2001; 2001US-00796498.
XX 28-FEB-2001; 2001WO-US006520.
XX 01-MAR-2001; 2001WO-US006566.
XX 09-MAR-2001; 2001US-00802706.
XX 14-MAR-2001; 2001US-00806889.
XX 22-MAR-2001; 2001US-00816744.
XX 05-APR-2001; 2001US-00828366.
XX 10-MAY-2001; 2001US-00854208.
XX 10-MAY-2001; 2001US-00854280.
XX 18-MAY-2001; 2001US-00860216.
XX 25-MAY-2001; 2001US-00866028.
XX 25-MAY-2001; 2001US-00866034.
```

us-10-791-980-6.rng

[illegible]

D	b		566	AACCGCTTTGCAAGCAAGGTAAACAATGGTTCACAGCAGCACTCTCCCTACCCTGGTG	625
Q	y		141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaPrCcysAlaProProSerSe	160
D	b		626	AAC TGGGCTTGAGCATCTGCCGAGCCGGCNGTTCCGGGGCCCGTGC	685
Q	y		160	rCyseGlyAlaThrserGlnArgrTpserSerGlyArgProGlnProGlnAlaProLeuTh	180
D	b		686	TTGTGGAGCAACGTCTCAGCGCTGGAGTCTTGGGAGGCCCCACGCCACAGCCCGCTGAC	745
Q	y		180	rSerClyrSerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
D	b		746	ATCCGGGCTCACCTTCTTCCAAAGGGGACCAACAATGGGCTGGGCAATGCCCTTTGATGC	805
Q	y		200	aGlnGlyAlaProTrpArgrThrPropheLeuProArgArgGlyGluAlaHisPheAspGl	220
D	b		806	CCAGGGGGCGCCCTGGCGCACGCCCTTC- CTGGCCCGCGCGCGGGAAGCGCACATTCCACCA	864
Q	y		220	nAspGluArgrTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
D	b		865	AGATGAGCGCTGTGCTCCGTAGCCGCCCGCGGGCGCAACTGTTCTGTGTGTGGCGCA	924
Q	y		240	eGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
D	b		925	CGAGATCGGTACACGCTTGSCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984
Q	y		260	oTyrTrylYsArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
D	b		985	CTACTACAGAAGGCTGGGGCCCGCAGCGCGTCTCAGCTGGGACACAGTGTGGCCGTGCA	1044
Q	y		280	nSerLeuTyrrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
D	b		1045	GAGCCTGTATGGGAAGCCCCTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAGACTGTT	1104
D	b				

Db	1105	CACTGACITTTAGAGACCTGGGACTCTCAGCCGCCAAGGAAGGGCCCTGAAACGCCAGGG	1164
Qy	320	yProlystYrCybHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTACAGGGCAACAGCAACTGTGA	1224

```
QY      340  rlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
      |||
      1225  CATTTTTAAAGGAGGAGCATTTCTGGGAGGTGGGAGCTGATGGCAAGCTCTCAGAGCCCG 1284
QY      360  gProLeuGlnGluArTrpValGlyLeuProProAsenileGluAlaAlaValSerLe 380
      |||
      1285  TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTCGCGCAGTGTCATT 1344
QY      380  uAsnAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
      |||
      1345  GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGGCCCCAA 1404
QY      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
      |||
      1405  GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCGGCATCTCTGACGC 1464
QY      420  alaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyTrTyVa 440
      |||
      1465  CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGCCTACTACGT 1524
QY      440  lleuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
      |||
      1525  GCTGGCCCGAGGGGAGTGCAGAGTGGAGCCCTACTACCCCGAAGTCTCAGGAGCTGGGG 1584
QY      460  yGlyileProGluGluValSerGlyAlaLeuProArgProAspGlySerileilePhePh 480
      |||
      1585  AGGCATCCCTGAGGAGTTCAGCGGCCCTTCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
QY      480  eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
      |||
      1645  CCGAGATGACCGCTACTTGGCGCTCGACCGAGGCCAACTGCAGGCAACCCACCTCGGGCG 1704
QY      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
      |||
      1705  CTGGGCGACCGAGCTCCCTGGATGGGCTGCTGGCATGGCACTCGGGGAGCGCCCTGTT 1764
QY      520  e 520
      |||
      1765  C 1765

RESULT 185
ADG24038
ID  ADG24038 standard; cDNA; 1985 BP.
XX
XX  AC  ADG24038;
XX
XX  DT  26-FEB-2004 (first entry)
XX
XX  DE  Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
XX  KW  Human; secreted and transmembrane protein; PRO; secreted polypeptide;
      KW  transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
      KW  chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
      KW  rectum; kidney; cervix; liver; microvascular endothelial cell;
      KW  glucose uptake modulator; FFA uptake modulator; cell proliferation;
      KW  cell differentiation; skeletal muscle cell; adipocyte cell;
      KW  pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
      KW  endothelial cell tube formation; bone disorder; cartilage disorder;
      KW  sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
      KW  rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
      KW  immune system cell infiltration; chromosome mapping; gene mapping;
      KW  gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
XX  OS  Homo sapiens.
XX
XX  PN  US2003207426-A1.
XX
XX  PD  06-NOV-2003.
XX
XX  PF  09-MAY-2002; 2002US-00143113.
XX
XX  PP  31-MAR-1997; 97WO-US005230.
```


Db 1045 GAGCCTGTATGGAGACCCCTAGGGGGCTCAGTGGCCGCTCCAGCTCCAGGAAGAGCTGTT 1104
Qy 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACTTGGACTTCCTACAGCCCCCAAGGAAGCGCCCTGAAACGAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATACTGCACCTTCTCTCGATGCCATCCTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTyrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCATTTCTGGAGGTGGCAGCTGATGGCAACGCTTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCACCTGCAAGGAAGATGGGTGGGCTGCCCCCAACATTGAGGCTGCGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCTGCCCGCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGGCTCATCTCTTCAAGGGGTGCCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG 460
Db 1525 GTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCAAGGCGCCCTGCCAGGCGCGATGGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAAACTGCAGGCAACACCTCGGGCG 1704
Qy 500 gTyrAlaThrGluLeuProTyrMetGlyCysTyrPheHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCAACTCGGGAGGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 186
ADF98392
ID ADF98392 standard; cDNA; 1985 BP.
XX
AC ADF98392;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.

PN US2003208055-A1.
XX
PD 06-NOV-2003.
XX
PF 29-MAY-2002; 2002US-00157786.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.

QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGI 280
 DB 985 CTACTCAAGAGGCTGGCGCGGACGCGCTGCTCAGCTGGACGACGTGCTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGTGGCGCTCCAGCAAGAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyValArgProGlnThrGlnGI 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCTCAAGGAAGCGCGCTCAAAACGCGAGG 1164
 QY 320 yProLysTyrCyHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCCTAAATAGTCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGACCATTTCTGGGAGGTGGCAGCTGTAGTGGCAAGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTGTCAGGAAGATGGTGGGCTGCGCTGCCCCCAACATTTGAGGCTGCGGCACTGTCATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGAGGGTTCGATGCTGGAGGTTCGGGGCCCCCA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGCTGCCCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTTCTTCTTCTTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTTACTACTGTT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGI 460
 DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGGTCTGAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTTGGCGAGGCGGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCAGATGACCGCTACTTGGCGCTTCGACGAGGCCAACTGCGAGCAACCACTTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGTGGCTGGATGGCTGCTGGCATGCCNACTCGGGGAGCGGCTGTT 1764
 QY 520 e 520
 DB 1765 c 1765

RESULT 187

ADG03223

ID ADG03223 standard; cDNA; 1985 BP.

AC ADG03223;

XX ADG03223;

DT 26-FEB-2004 (first entry)

XX Human PRO polynucleotide #72.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; PFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.

XX Homo sapiens.

XX US2003207351-A1.

XX 06-NOV-2003.

XX 06-MAY-2002; 2002US-00140473.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2004-010589/01.

XX DR P-PSDB; ADG03224.

XX

XX New nucleic acid encoding a secreted and transmembrane PRO polypeptide
 useful in stimulating the proliferation or differentiation of chondrocyte
 cells and detecting a tumor.

XX Claim 2; SEQ ID NO 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful

reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for

stimulating differentiation of adipocyte cells, for stimulating
 proliferation of or gene expression in pericyte cells, for stimulating
 the proliferation of inner ear utricular supporting cells or T-lymphocyte
 cells, for inducing endothelial cell tube formation and for treating
 various bone and/or cartilage disorders such as sports injuries and

arthritis. PRO polypeptides which stimulate the release of proteoglycans
 from cartilage are useful for treating sports-related joint problems, PRO
 polypeptides are also useful for treating various mammalian haemoglobin-
 associated disorders such as various thalassemias and conditions which
 may benefit from enhanced local immune system cell infiltration. This
 sequence represents a human PRO polynucleotide of the invention. Note:

XX The sequence data for this patent is also available in electronic format
 from USPTO at seqdata.uspto.gov/sequence.html.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACCTGTCTCAGCGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTCGCCGAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGATTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaAraGHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCCAAGCAAGGTAAACNAATGGTACACAGCAGCACCTCTCTACCCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTGAGCATCTGCGGAGCCGCGAGTTCGGGGCGCGGTGCGCGCGCTTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCGCTGGAGTTCGGGAGGCGCCAGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCCCGCGCGGGAAGCGACCTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGCTCCCTCAGCGCGCGCGCGCAACCTGTTCTGTTGTCGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTCAACACGCTTTGGCCTCACCCACCTCGCCGCGCGCGCGCTCATGCGGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTAACAGAGCTGGGCGCGACGCGTGTCTAGCTGGGACGACGTCTGGCCGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGAAAGCCCTCAGTGGGGCTCAGTGGCGCTCCAGTCCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTGACTTTGAGACCTGGGACTCTCTACAGCCCGCCCAAGGAAGCGCGCTGAAACGCA	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAANTACTGCCACTCTTCTTGTGATGCCATCACTGTAGACAGGCAACAGCACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValaSerIle	380
Db	1285	TCCACTGCAGGAAGATGGTGGGCTGCGCGCCCAACATTGAGGCTGGCGAGTGTTCATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCAAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGCGGAGGGGCGCTGCCCCGCATCCTGACGC	1464
Qy	420	aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524

QY	440	IleuIalaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1	460	PR	13-SEP-1999;	99WO-US020944.
				PR	15-SEP-1999;	99WO-US021090.
Db	1525	GCTGCCCGAGGGGAGCTGCAAGTGGAGCCCTTACTACCCCGGAAGTCTGCAGGACTGGGG	1584	PR	15-SEP-1999;	99WO-US021547.
				PR	05-OCT-1999;	99WO-US023089.
QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProArgGlySerIleIlePhePh	480	PR	29-NOV-1999;	99WO-US028214.
				PR	30-NOV-1999;	99WO-US028313.
Db	1585	AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCCGAGGCCGATGGCTCAATCACTTCTT	1644	PR	30-NOV-1999;	99WO-US028409.
				PR	01-DEC-1999;	99WO-US028301.
QY	480	eAArgPhepAArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500	PR	01-DEC-1999;	99WO-US028634.
				PR	02-DEC-1999;	99WO-US028551.
Db	1645	CCGAGATGACCGCTACTGCGCGCTCGACCAGGCCAACTGCAGGCAACCCACCTCGGGCG	1704	PR	02-DEC-1999;	99WO-US028564.
				PR	16-DEC-1999;	99WO-US028565.
QY	500	gTrpAlaThrGluLeuProTrpTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520	PR	20-DEC-1999;	99WO-US030095.
				PR	20-DEC-1999;	99WO-US030311.
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764	PR	20-DEC-1999;	99WO-US030999.
				PR	22-DEC-1999;	99WO-US030720.
QY	520	e 520		PR	30-DEC-1999;	99WO-US031243.
				PR	30-DEC-1999;	99WO-US031274.
Db	1765	C 1765		PR	05-JAN-2000;	2000WO-US000219.
				PR	06-JAN-2000;	2000WO-US000277.
RESULT 189				PR	06-JAN-2000;	2000WO-US000376.
ADG16529				PR	11-FEB-2000;	2000WO-US003565.
ID	ADG16529	standard; cDNA; 1985 BP.		PR	18-FEB-2000;	2000WO-US004341.
XX				PR	18-FEB-2000;	2000WO-US004342.
AC	ADG16529;			PR	22-FEB-2000;	2000WO-US004414.
XX				PR	24-FEB-2000;	2000WO-US004914.
DT	26-FEB-2004	(first entry)		PR	24-FEB-2000;	2000WO-US005004.
XX				PR	01-MAR-2000;	2000WO-US005601.
DE				PR	02-MAR-2000;	2000WO-US005746.
KW				PR	02-MAR-2000;	2000WO-US005841.
KW				PR	10-MAR-2000;	2000WO-US006319.
KW				PR	15-MAR-2000;	2000WO-US006884.
KW				PR	20-MAR-2000;	2000WO-US007377.
KW				PR	21-MAR-2000;	2000WO-US007532.
KW				PR	30-MAR-2000;	2000WO-US008439.
KW				PR	17-MAY-2000;	2000WO-US013705.
KW				PR	22-MAY-2000;	2000WO-US014042.
KW				PR	30-MAY-2000;	2000WO-US014941.
KW				PR	02-JUN-2000;	2000WO-US015264.
KW				PR	28-JUL-2000;	2000WO-US020710.
KW				PR	11-AUG-2000;	2000WO-US022031.
KW				PR	23-AUG-2000;	2000WO-US023522.
OS				PR	24-AUG-2000;	2000WO-US023328.
XX				PR	08-NOV-2000;	2000WO-US030952.
XX				PR	10-NOV-2000;	2000WO-US030873.
XX				PR	01-DEC-2000;	2000WO-US032678.
XX				PR	20-DEC-2000;	2000WO-US034956.
XX				PR	28-DEC-2000;	2000WO-US034956.
XX				PR	28-FEB-2001;	2001WO-US006520.
XX				PR	01-MAR-2001;	2001WO-US006666.
XX				PR	09-MAR-2001;	2001WO-US006666.
XX				PR	14-MAR-2001;	2001US-00802706.
XX				PR	22-MAR-2001;	2001US-00806899.
XX				PR	05-APR-2001;	2001US-00816744.
XX				PR	10-MAY-2001;	2001US-00828366.
XX				PR	10-MAY-2001;	2001US-00854208.
XX				PR	18-MAY-2001;	2001US-00860216.
XX				PR	25-MAY-2001;	2001US-00866028.
XX				PR	25-MAY-2001;	2001US-00866034.
XX				PR	01-JUN-2001;	2001WO-US017092.
XX				PR	01-JUN-2001;	2001US-00872035.
XX				PR	05-JUN-2001;	2001WO-US017800.
XX				PR	19-JUN-2001;	2001US-00882636.
XX				PR	20-JUN-2001;	2001US-00886342.
XX				PR	21-JUN-2001;	2001WO-US019692.
XX				PR	22-JUN-2001;	2001US-00887879.
XX				PR	29-JUN-2001;	2001WO-US020116.
XX				PR	09-JUL-2001;	2001WO-US021066.
XX				PR	18-JUL-2001;	2001WO-US021735.
XX				PR	06-AUG-2001;	2001US-00908827.
XX				PR		2001US-00924419.


```
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGGCTTTGCCAAGCAAGTAAATGGTACAAGCAGCACTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGGCGAGCGGAGTTTCGGGGGGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACCTCTACGCGCTGGAGTTCTGGAGGCCCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCTTTCATGGC 805
QY 200 agnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTGGCGCAGCCTTTC-CTGGCCCCCGCGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCTCAGCGCGCGCGCGCGCAACCTGTTGTTGGTGTGGCGCA 924
QY 240 sGluLysGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTTCACAGCTTGGCTCACCCACTCGCCCGCGCGCGCTCATGCGGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGGAGCGCTGCTCAGCTGGGACGAGCTGTCGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGGAAGCGCGCTGAAACGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGCAGGAAGATGGCTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGTGGAGGTTCGGGGGCCCCAA 1404
QY 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCCACTGTGGCGGCGAGGGGCTGCCCCGCCATCTCTGAGCGC 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCTCTACTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGGCTTACTACCCCCGAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProArgProArgGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGCGAGGCGCGATGGCTCCATCATCTTCT 1644
```

```
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAAGGCCAACTGCGAGGCAACCACTCGGGCCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 c 1765
RESULT 191
ADG19255
ID ADG19255 standard; cDNA; 1985 BP.
XX
AC ADG19255;
XX
DT 26-FEB-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003207425-A1.
XX
PD 06-NOV-2003.
XX
PF 09-MAY-2002; 2002US-00142430.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
```

```
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US005666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872800.
PR 03-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908627.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
```

```
XX WPI; 2004-021502/02.
DR P-PSDB; ADG19256.
XX
PT New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT breast, prostate, rectal, cervical and/or liver tumors.
XX
PS Claim 2; Fig 143; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for a human PRO polypeptide is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
```

```
Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG19255 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTTCGCGCGCTCGGCTCTCTGTCGCGCCCTCGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGGCCAGCCCGGAGCGGAGCGGAGGCTGCGCAAGAGGGCGGAGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGACAGGTCCCCAAGCTCCCACTCCATCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCACAGCTACCTGTGTCAGCGGCGGTGTGGACGCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
```

446	Db		GCCACCCTGGCCAGATGACTGCTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG	505
101	Qy		AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
506	Db		GCCTGGGCTGAGAGGATCAGTGACTTGTGTCTAGACACCCGACCAAAATGAGGCGTAA	565
121	Qy		LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTyrArgLeuVal	140
566	Db		AAACGCCTTTCAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCGCTGGTG	625
141	Qy		AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
626	Db		AACTGGGCTGAGCATCTGCGCGAGCCGGCAGTTCGGGGCGCGTGCAGCGCGCTTCCAG	685
160	Qy		rCysGlyAlaThr-SerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
686	Db		TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTTGGAGAGGCCCCAGGCCAGGCCCGCTGAC	745
180	Qy		rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal	200
746	Db		ATCCGGCTCACCTTCTTCCAAGGGACCAACACGATGGGCTGGGCAATGCTTTGATGGC	805
200	Qy		aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
806	Db		CCAGGGGGCGCCTTGGCGCACGCGCTTC-CTGCCCCCGCGCGGAGCGACCTTCGACCA	864
220	Qy		AspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
865	Db		AGATGACCGTGTGCTCTGAGCCGCCCGCGGGCGCAACCTGTTGTGTGTGGCGCA	924
240	Qy		sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalPr	260
925	Db		CGAGATCGGTACACAGCTTGGCTCACCCACTGCGCCGCGCGCGCTCATGGCGCC	984
260	Qy		oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
985	Db		CTACTACAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGAGCACGTGTGCGCGTGCA	1044
280	Qy		nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh	300
1045	Db		GAGCCTGTATGGNAGCCCTTAGGGGCTCAGTGGCCGTGAGCTCCAGGAAAGCTGTT	1104
300	Qy		eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
1105	Db		CACGTGCTTTGAGACCTGGGACTCCTACAGCCCCCAGGAAGGCGCCCTGAACGCGAGG	1164
320	Qy		yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
1165	Db		CCCTAAATATCGCCACTCTTCTTCGATGCACTCAGTGTAGACAGGCAACAGCAACTGT	1224
340	Qy		rIlePheLysGlySerHisPheTrpGluValAlaIleAspGlyAsnValSerGluProAr	360
1225	Db		CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGTATGGCAACGTCTCAGAGCCCG	1284
360	Qy		sProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
1285	Db		TCCACTGCAGAAAGATGGTTCGGGCTGCCCCCCACATTTGAGGCTGCGCGAGTGCATT	1344
380	Qy		uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
1345	Db		GAATGATGGAGATTTCTTACTTCTTCAAAGGGGTTCGATGCTGGAGGTTCCGGGGCCCCA	1404
400	Qy		sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
1405	Db		GCCAGTGTGGGTCTCCCAACAGCTGTGCCGGGAGGGGGCTCTGCCCGCCCATCTGACGC	1464
420	Qy		aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440
1465	Db		CGCCCTCTTCTTCCCTCCTCTGGGCCGCTCATCTCTTCAAGGGTGCCCGCTACTACGT	1524
440	Qy		lLeuAlaArgGlyGlyLeuGlnValGluProTofTyrTrpProArgSerLeuGlnAspTrpGl	460

Db	1525	GCTGGCCCGAGGGGAGCTGCAAGTGGAGGCCCTACTACCCCCGGAAGTCTGCAGGACTGGGG	1584
Qy	460	YGIyleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGATCCCTGAGGAGGTGACGGCGCCCTGCCGAGGCCGCGATGCATCATCTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGGTACTTGGCGCCTCGACCAAGGCCAAATCGAGGCAACCACTCGGGCCG	1704
Qy	500	gTTPAlaThrChluLeuProTrpMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 192			
ADGI3092			
ID	ADGI3092 standard; cDNA; 1985 BP.		
XX			
AC	ADGI3092;		
XX			
DT	26-FEB-2004 (first entry)		
XX			
DE	cDNA encoding human PRO polypeptide #72.		
XX			
KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; FFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;		
KW	immune system cell infiltration.		
OS	Homo sapiens.		
XX			
PN	US2003207357-A1.		
XX			
PD	06-NOV-2003.		
XX			
PF	08-MAY-2002; 2002US-00141703.		
XX			
PR	10-MAR-1999; 99US-0123618P.		
PR	02-MAR-2000; 2000WO-US005841.		
PR	30-MAY-2000; 2000WO-US014941.		
PR	02-JUN-2000; 2000WO-US015264.		
PR	01-DEC-2000; 2000WO-US032678.		
PR	19-DEC-2001; 2001US-00028072.		
XX			
PA	(GETH) GENENTECH INC.		
XX			
PI	Baker KP, Bersini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;		
PI	Grissitts ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;		
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;		
XX			
DR	WPI; 2004-010593/01.		
XX			
DR	P-PSDB; ADGI3093.		
XX			
PT	New nucleic acid encoding a secreted and transmembrane PRO polypeptide		
PT	useful in detecting the presence of a tumor in a mammal, in treating		
PT	cancer, and stimulating the proliferation of inner ear utricular		
PT	supporting cells.		
XX			
PS	Claim 2; Fig 143; 637pp; English.		
XX			
CC	The invention relates to isolated human PRO polypeptides (secreted and		
CC	transmembrane polypeptides) and the polynucleotides encoding them. The		
CC	invention also relates to an antibody which specifically binds to a PRO		

Qy 520 e 520
Db 1765 C 1765

RESULT 193
ADG08149
ID ADG08149 standard; cdna; 1985 BP.
AC
AC ADG08149;
XX
DT 26-FEB-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cdna.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation inhibitor; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003207424-A1.
XX
PD 06-NOV-2003.
XX
PF 09-MAY-2002; 2002US-00142425.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 05-OCT-1999; 99WO-US021547.
PR 29-NOV-1999; 99WO-US023089.
PR 30-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-051521/05.
XX P-PSDB; ADG08150.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for the diagnosis, prevention and/or treatment of tumors,
XX such as lung, colon, breast, prostate, cervical and/or liver
XX tumors.
XX

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservatives: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADF96717 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTGGCGGGCTGGCTCTGCTGGCGCCCTGCAGCTCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
 DB 266 GAGCGCCAGCCCGGAGCGCGGAGCGCAGGAGCTGCGCAAGGCGGAGGCATTCCTA 325
 QY 41 GluLysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAAGTACGGATACCTCAATGAACAGAGTCCCCAAAGCTCCACCTCCACTCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACCGCTTTTCAGTGGGTGTCCCAAGCTACCTGTGTCAGCGGGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla 100
 DB 446 GCCACCTTGGCCCATGACTCGTCCCGCTCGGGGGTTACAGATACCACAGATTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCCAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTrpArgLeuVal 140
 DB 566 AAACCGCTTGCAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCGCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTTGACATCTCCGAGCGCGGAGTTCGGGGCGCGCTCGCGCGCCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGGAGGCGCCACAGCCACAGGCGCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCCGGCTCACCTTCTTCAAGGGGACCAACACGATGGGCTGGGCAATGCGCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240

DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGGTGGTCTGCGCA 924
 QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACAGCTTGGCCTCACCACTCGCGCGCGCGCGCTCATGCGCGC 984
 QY 260 oTyTrpLysArgLeuGlyArgAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 DB 985 CTACTACAAGAGGCTGGCGCGGAGCGCTGCTAGCTGGGACGACGTGCTGGCGGTGCA 1044
 QY 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCGCTGATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCCTGAAACACGAGG 1164
 QY 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
 DB 1165 CCTTAATACTGCCACACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerie 380
 DB 1285 TCCACTGTCAGGAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
 QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGCCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTrpTrpVa 440
 DB 1465 CGCCCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrpTrpProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGCTCTGCAAGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCCCTGAGGAGGTGAGCGCGCTCTCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACGAGCCAAACTGCAGGCAACCACTCTCGGGCGC 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGTGGCTGGATGGCTGGTGGCTGGTGGCTGGTGGTGGTGGTGGTGGT 1764
 QY 520 e 520
 DB 1765 C 1765

RESULT 196

ADG05902

ID ADG05902 standard; cDNA; 1985 BP.

XX

AC ADG05902;

XX

DT 26-FEB-2004 (first entry)

XX

DE Human PRO polynucleotide #72.

XX

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.
XX US2003207374-A1.
XX 06-NOV-2003.
XX 14-MAY-2002; 2002US-00145878.
XX 05-JUN-2000; 2000US-0209832P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-096981/10.
XX P-PSDB; ADG05903.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems, PRO
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX the sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores: 1.93e-149 Length: 1985
Pred. No.: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG05902 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGCTCGGCTCTCTGCTGGCGGCTCTAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGAGCTGCGCAAGGAGCGGAGGATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCCATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTACGGCGGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGTTACAAAGCAGCACCTCTCTCCCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGAGGCGCCAGCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTTCTCAAGGGGACCAACACATGGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGGCGCAGCCCTTC-CTGCCCGCGCGCGCGGAGGACATTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCCCTACCCATCTGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGAGCGCTCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGCTGATGGGAAGCCCTAGGGGGTCTAGTGGCGCTCCAGCTCCCGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320

```
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGGCACTCTCTTCGATGCGATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluAArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGCGAGGAAGATGGTGGCGCTGCCCCCAACATTGAGGTGGCGAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheThrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCGCTGCCCGCCATCTCGACGC 1464
Qy 420 alaIleuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGGCCCGAGGGGACTGCAAGTGAGGCCCTACTACCCCCCAAGTCTCAGAGCTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTTCAGCGCGCCCTGCGAGGCCGATGCTCATCATCTTCTT 1644
Qy 480 eArgPheAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCAAGCCAACTGCAGGCAACCACTCGGGCGC 1704
Qy 500 qTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGTGATGGCTGCTGGCATGCCAACTCGGGAGGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 197
ADG23486
ID ADG23486 standard; cdna; 1985 BP.
XX AC ADG23486;
XX 26-FEB-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4339 cdna.
XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX OS Homo sapiens.
XX PN US2003207389-A1.
XX DB
```

```
PD 06-NOV-2003.
XX 30-MAY-2002; 2002US-00158784.
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2004-021493/02.
DR P-PSDB; ADG23487.
XX New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor, for chromosome mapping or for tissue
typing.
```

Claim 2; SEQ ID NO 143; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or PFA (free fatty acid) by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG23486 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGCCACCTG 265

QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40	Db	1345	GAATGATGAGGATTTCTACTTCTTCAAGGGGTGATCTGGAGGTTCCGGGGCCCA	1404
Db	266	GACGCCAGCCGCGGAGCGGAGCGAGCTGCGAAGGAGCGGAGCATTCCTA	325	QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
QY	41	GluIysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60	Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCTGCCCGGCATCTGACGC	1464
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATCGATTGAGC	385	QY	420	aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyValaArgTyrTyrVa	440
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80	Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGTGCCTACTACGT	1524
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGACTACCTGTACGGGGGTGTGGACGC	445	QY	440	lLeuAlaIleArgGlyGlyGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100	Db	1525	GCTGGCCGAGGGGACTGCNAAGTGAGCCCTACTACCCCGCAAGTCTGCAGACTGGG	1584
Db	446	GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGATTATGCG	505	QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
QY	101	AlaTrpAlaGluArgIleSerAspIlePheAlaArgHisArgThrLysMetArgArgLys	120	Db	1585	AGGCATCCCTGAGAGGTCAAGCGGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT	1644
Db	506	GCTGGGTGAGAGGATCAGTGACTTGTGTGTACACCCGACCAAAATGAGGCGTAG	565	QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140	Db	1645	CCGAGATGACCGCTACTTGGCGCCTCGACAGGCCAAACTGCAGGCAACCACTCGGCGC	1704
Db	566	AAACGCTTGGCAAGCAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCGCTGGTG	625	QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160	Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGCATGCCAAGCTCGGGGAGCGCCTGTT	1764
Db	626	AACTGGCTGAGCATCTGCGGAGCGGCAGTTCGGGGCGCGTTCGCGCCGCTTCCAG	685	QY	520	e 520	
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180	Db	1765	c 1765	
Db	686	TTGTGAGCAAGCTCTACGCGTGGAGTCTGGAGGCCCCAGCCACAGGCCCGCTGAC	745	RESULT 198			
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200	ADG03775			
Db	746	ATCCGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGCAATGCCTTTGATGGC	805	ID	ADG03775	standard; cDNA; 1985 BP.	
QY	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220	XX	AC	ADG03775;	
Db	806	CCAGGGGGCGCCCTGCGCAGCGCCTTC-CTGCCCCCGCGCGAGCGCATTCGACCA	864	DT	26-FEB-2004	(first entry)	
QY	220	nAspGluArgTrpSerLysArgArgGlyArgAsnLeuPheValValLeuAlaHi	240	XX	Human PRO polynucleotide #72.		
Db	865	AGATGAGCGCTGTCTCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGCTGGCGCA	924	KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260	KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
Db	925	CGAGATCGGTCAACAGCTGGCCTCACCCACTCGCCGCGCGCGCTCATGGCGCC	984	KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280	KW	liver; microvascular endothelial cell; glucose; FFA;		
Db	985	CTACTCAAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCTGGCGTGCA	1044	KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300	KW	inner ear utricular supporting cell; T-lymphocyte cell;		
Db	1045	GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT	1104	KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnGl	320	KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
Db	1105	CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAGCGCCCTGAACGCGGG	1164	KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		
QY	320	yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340	XX	immune system cell infiltration.		
Db	1165	CCCTAANAATCGCCACTTCTTCGTGATGCCATCACTGTAGACAGGCAACAGCACTGTA	1224	OS	Homo sapiens.		
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360	XX	US2003207423-A1.		
Db	1225	CAITTTTAAAGGAGCAATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCCG	1284	PN	06-NOV-2003.		
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380	PD	08-MAY-2002; 2002US-00141760.		
Db	1285	TCCACTGCAGGAAGATGGTTCGGGCTGCCCCCAACATTTAGGCTGGCGACTGTCATT	1344	PF	31-MAR-1997; 97WO-US005230.		
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400	PR	12-JUN-1998; 98WO-US012456.		
				PR	14-JUL-1998; 98WO-US014552.		
				PR	28-AUG-1998; 98WO-US017888.		
				PR	10-SEP-1998; 98WO-US018824.		
				PR	14-SEP-1998; 98WO-US019093.		
				PR	14-SEP-1998; 98WO-US019094.		
				PR	14-SEP-1998; 98WO-US019177.		
				PR	16-SEP-1998; 98WO-US019330.		
				PR	17-SEP-1998; 98WO-US019437.		
				PR	07-OCT-1998; 98WO-US021141.		
				PR	29-OCT-1998; 98WO-US022991.		
				PR	29-OCT-1998; 98WO-US022992.		

PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005190.
 PR 20-APR-1999; 2000WO-US006319.
 PR 14-MAY-1999; 98WO-US008615.
 PR 02-JUN-1999; 98WO-US012252.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 05-OCT-1999; 98WO-US021547.
 PR 29-NOV-1999; 98WO-US023089.
 PR 30-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 22-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031243.
 PR 30-DEC-1999; 98WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US0796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 08-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
 XX
 DR WPI; 2004-051520/05.
 DR P-PSDB; ADG03776.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy for treating e.g. tumors, obesity, diabetes, hypo- or
 PT hyperinsulinemia, bone and/or cartilage disorders, stroke, or heart
 PT attack.

XX Claim 2; SEQ ID NO 143; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

```
US-10-791-980-6 (1-520) x ADG03775 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGAGCGGAGCGGAGAGCTGCGCAAGAGGAGCGGAGGCAATCTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGCTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCCACAGATACCTCGTCCCGCTGCGGGGTTCACAGATACCACACAGTTATGCG 505
Qy 101 AlaTrpAlaGluAtqIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCAACGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCGAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGTCTCAGCGCTGAGTTCGAGGAGGCGCCACGACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACACGATGGGCTGGGCAATGCTCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CAGGGGGCGCCTCGGCACGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATCAGCGCTGTCCTCAGCGCGCGCGCGGCGCAACCTGTTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCCACCACTCGCGCGCGCGCGCTCATGCGGCC 984
Qy 260 ofTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAGAGCTGGGCGCGCGCTGCTCAGCTGGGACGACGTCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGATGGAAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGCCCCCAAGGAGGCGCCCTGAAACGACGG 1164
Qy 320 vProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTTCGTATGCCATCACTGTAGACAGGCAACAGCAACTGA 1224
Qy 340 rIlePheLysGlySerHisPheThrProGluValAlaAlaAspGlyAsnValSerGluProAr 360
```


PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019337.
 PR 07-OCT-1998; 98WO-US021141.
 PR 23-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 03-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US0005028.
 PR 10-MAR-1999; 2000WO-US0005190.
 PR 10-MAR-1999; 99WO-US008615.
 PR 20-APR-1999; 99WO-US010733.
 PR 14-MAY-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US022089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004344.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 28-JUL-2000; 2000WO-US015264.
 PR 11-AUG-2000; 2000WO-US020710.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001WO-US0082706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2004-051523/05.
 DR P-PSDB; ADG24677.
 XX
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
 PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
 PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
 PT tumors.
 XX
 PS Claim 2; SEQ ID NO 143; 638pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 CC cells, for stimulating differentiation of adipocyte cells, for
 CC stimulating proliferation of or gene expression in pericyte cells, for
 CC stimulating the proliferation of inner ear utricular supporting cells or
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
 CC treating various bone and/or cartilage disorders such as sports injuries
 CC and arthritis. PRO polypeptides which stimulate the release of
 CC proteoglycans from cartilage are useful for treating sports-related joint
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid
 CC arthritis. PRO polypeptides are also useful for treating various
 CC mammalian haemoglobin-associated disorders such as various thalassemias
 CC and conditions which may benefit from enhanced local immune system cell
 CC infiltration. This sequence represents a human PRO polynucleotide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX

SQ	Sequence	1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:		
Pred. No.:	1..93e-149	Length: 1985
Score:	2792.00	Matches: 519
Percent Similarity:	99.62%	Conservative: 0
Best Local Similarity:	99.62%	Mismatches: 1
Query Match:	98.52%	Indels: 2
DB:	12	Gaps: 0
US-10-791-980-6 (1-520) x ADG24676 (1-1985)		
QY	1 MetValalaArgValGlyLeuLeuLeuLeuAlaLeuGlnLeuLeuTyrGlyHisLeu	20
Db	206 ATGTCTCGGGCGGTGGCCCTCTCTGTCGGCGCCTGCAGCTGCTACTGTGGGCCACCTG	265
QY	21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu	40
Db	266 GACGCCAGCCCGGAGCGCGGAGGCCAGGAGCTGCGCAAGAGGCGGAGGCAATTCCTA	325
QY	41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326 GAGAAGTACGGATACCTCAATGAACAAGTCCCCAAAGCTCCACCCTCCAATCGATTACG	385
QY	61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTCTCAGCGGGTGTTGGACCGC	445
QY	81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446 GCCACCTCGGCCAGATGACTCGTCCCCGTGGGGGTTACAGATACCAACAGTTATGCG	505
QY	101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506 GCCTGGGCTGAGAGCATCAGTACTGTTGTTGTAGACACCGGNACCAAAATGAGGCGTAAG	565
QY	121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCCCTGGTG	625
QY	141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626 AACGGCTGAGACATCTGCGGAGCCGGCAGTTCGGGGCGCCGTGCGCGCCCTTCCAG	685
QY	160 rCysGlyAlaThrSerGlnArgTrpSerSerglyArgProGlnProGlnAlaProLeuTh	180
Db	686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTTGGGAGGCCCCAGCCACAGGCCCGCTGAC	745
QY	180 rSerGlySerProSerSerysGlyThrThrMetGlyTyrAlaMetProLeuMetAl	200
Db	746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCCITTTGATGC	805
QY	200 aGlnGlyAlaProTrpArgThrPropheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806 CCAGGGGGCGCCTGGCGCAGCCTTC-CTGCCCCCGCGCGCGCAAGAGCGCACTTCGACCA	864
QY	220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865 AGATGAGGCTGGTCCCTGAGCCCGCGCGGCGCAACCTGTGTGGTGTGTCGGCGCA	924
QY	240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925 CGAGATCGGTACAGCTTGGCCTCACCCACTCGCCCCCGCGCGGCTCATGCGGCC	984
QY	260 oTyrTrilysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI	280
Db	985 CTACTACAAGAGGCTGGGCGCGCAGCGCGCTGCTCAGCTGGGAGCAGCTGTGGCCGTGCA	1044
QY	280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT	1104
QY	300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI	320

XX 09-DEC-1999; 99US-0170262P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
 PI Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2004-010588/01.
 DR P-PSDB; ADG06974.
 XX
 XX New nucleic acid encoding a secreted and transmembrane PRO polypeptide
 PT useful in stimulating the proliferation of inner ear utricular supporting
 PT cells and detecting a tumor.
 XX
 XX Claim 2; SEQ ID NO 143; 637pp; English.
 XX
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1,938-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG06973 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGGCGCGTGGCCCTCTCTGCGCGCCCTCGAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GAGCCCCAGCCCGGAGCGCGAGGCCAGGAGCTGGCAAGAGGAGCGGAGGCATTCTCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTGCCCAAGGTCCCAAGCTCCACCTCCAGTTACG 385

61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACTGTCTCAGCGGGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGGC 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db GCCTGGGCTGAGAGGATCAGTGACTTGTTCACACCGGAGTTCGCGCGCGCTTCCAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAGCAGCACCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSer 160
 Db AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db TTGTGGACCAACGCTCTAGCCGCTGAGGTCTGGGAGGCCCCAGCCAGGCCCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
 Db ATCCGGCTCACTTCTTCCAGGGGAGCACCAACGATGGCTGGGCAATGCCTTTCATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db CCAGGGGCGCGCTGGCGCGCGCTTC-CTGCCCGCGCGCGCGGCGGAGCGCACCTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
 Db AGATGAGCGCTGGTCTCCCTGAGCGCGCGCGCGCGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db CGAGATCGGTACACGCTTGGCTTCCACCTCGCCCGCGCGCGCGCGCTCATCGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 Db CTACTACAAGAGGTGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCNAGGAGGCGCCCTGAAACGACGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db CCCTAAATATCTGCACCTCTTCTTCTCGATGCCCTCACTGTAGACAGGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db CATTTTAAAGGGAGCCATTTCTGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db TCCACTGCAGAAAGATGGGTGGGCTGGCGCTGCCCCCAACATTCAGGCTGGCGGAGTGTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 Db GAATGATGGAGATTCTTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGCGGGGCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db GCCAGTGTGGGGTCTCCACACAGCTGTCCCGGGCAGGGGGCTGCCCGCCCATCTCCAGCG 1464
 QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440

Db	1465	CGCCCTCTTTCCCTCTGCGCGGCTCATCTCTTCAAGGGTCCCGCTACTACGT	1524
Qy	440	lIeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATACCGCTACTGCGCGCTCGACCAAGCCAACTGCAGGCAACCACTCGGGCGG	1704
Qy	500	gTrrAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGATGCCAACTCGGGGAGCGCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 201			
ID	ADG07525	standard; cDNA; 1985 BP.	
XX	AC	ADG07525;	
XX	DT	26-FEB-2004 (first entry)	
XX	DE	Novel human secreted and transmembrane protein PRO4339 cDNA.	
XX	KW	Human; secreted and transmembrane protein; PRO; gene; ss;	
KW	KW	Tumour necrosis factor alpha release; TNF-alpha release;	
KW	KW	glucose uptake modulator; FFA uptake modulator;	
KW	KW	cell proliferation stimulator; cell differentiation stimulator;	
KW	KW	cell differentiation inhibitor; cytokine release stimulator; tumour;	
KW	KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;	
KW	KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;	
KW	KW	gene therapy; chromosome identification; chromosome marker.	
OS	XX	Homo sapiens.	
XX	XX	US2003207356-A1.	
XX	XX	06-NOV-2003.	
XX	XX	08-MAY-2002; 2002US-00141699.	
XX	XX	03-MAR-2000; 2000US-0187202P.	
PR	PR	01-DEC-2000; 2000WO-US032678.	
PR	PR	19-DEC-2001; 2001US-00028072.	
XX	XX	(GETH) GENENTECH INC.	
XX	XX	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	
PI	PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PI	PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
XX	XX	WPI; 2004-010592/01.	
DR	DR	P-PSDB; ADG07526.	
XX	XX		
PT	PT	New nucleic acid encoding a secreted and transmembrane PRO polypeptide	
PT	PT	useful in detecting the presence of a tumor in a mammal and stimulating	
PT	PT	the proliferation or differentiation of chondrocyte cells.	
XX	XX	Claim 2; SEQ ID NO 143; 637bp; English.	
XX	XX	The invention describes 105 nucleic acids encoding PRO (secreted and	
CC	CC	transmembrane) polypeptides (I). (I) is useful for stimulating the	
CC	CC	release of TNF-alpha from human blood, for modulating the uptake of	
CC	CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for	

QY 180 rSerGlySerProSerSerGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCTTGTATGGC 805
 QY 200 aGlnGlyAlaProTyrArgThrProHelLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGGGCGCTGGCGCACGCTTC-CGTGCCCGCGCGCGAGAGCGCACTTCGACCA 864
 QY 220 nAspGluAlaTyrSerSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCTCGAGCGCGCGCGCGCAACCTGTTCTGTTGGTGTGGCGCA 924
 QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTCAACAGCTTGGCTCACCCCACTCGCCCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValG1 280
 DB 985 CTACTACAAGAGGCTGGCGCGCGACGCGCTGCTCAGCTGGGACGACGCTGCGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLeuProLeuGlyGlySerValAlaValGlnLeuProGlyLeuLeuPh 300
 DB 1045 GAGCTGTATGGAGACCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCCTGAAACGACGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
 DB 1165 CCTTAATATGCTCACTCTCTCTGATGCTCATCTAGTACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAenValSerGluProAr 360
 DB 1225 CATTTTTAAGGAGGACATTTCTGGGAGGTGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAenIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTGCAGGAAGAAGATGGTGGGCTGCCGCCCAACATTGAGGTGGCGAGTGTCTATT 1344
 QY 380 uAenAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGGCCCAA 1404
 QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisPheAspAl 420
 DB 1405 GCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGCGCTGCCCGCCATCTCTGAGCG 1464
 QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTTCTTCTCTCTGCGCGCTCATCTCTCAAGGTGGCGCTACTACTGCT 1524
 QY 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1 460
 DB 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCCAAGTCTGCAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGGAGGTGAGGGGGCGCTGCGGAGGCCGATGCTCATCTCTTCTT 1644
 QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGCCAACTGCGAGCAACCACTCGGGCGG 1704
 QY 500 gTyrAlaThrGluLeuProTyrPheGlyCysTyrTrpHisAlaAenSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCGCCAGAGTGCCTGGATGGGTGCTGGCATGCCAATCTGGGAGGCGCTGTT 1764
 QY 520 e 520
 DB 1765 c 1765
 RESULT 202

ADG55020
 ID ADG55020 standard; cDNA; 1985 BP.
 XX
 AC ADG55020;
 DT 11-MAR-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX
 KW human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuroptide; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
 XX
 OS Homo sapiens.
 XX
 PN US2003194778-A1.
 XX
 PD 16-OCT-2003.
 XX
 PF 29-MAY-2002; 2002US-00157796.
 XX
 PR 05-JUN-2000; 2000US-0209832P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2004-113266/12.
 DR P-PSDB; ADG55021.
 XX
 PT New secreted and transmembrane nucleic acids and polypeptides useful for
 PT detecting the presence of a tumor, stimulating the release of tumor
 PT necrosis factor alpha from human blood and treating inflammation.
 XX
 PS Claim 2; SEQ ID NO 143; 637pp; English.
 XX
 CC This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neuropeptides and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.82% Conservatives: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

DR P-PSDB; ADG60685.

XX New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor, for chromosome mapping or for tissue
 PT typing.

XX Claim 2; SEQ ID NO 143; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neuropeptides and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG60684 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGGCGGCTCGGCTCTCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCACGCCCGCGAGCGCGAGCGCCAGGAGCTGCGCAAGGAGCGGCGGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAGTACGGATACCTCATGAAACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACGCTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGGCGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCGCAGATGACTGTCTCCCGCTGCGGGGTTCACAGATPACCAACAGATTATCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGCTGAGAGATCAGTGACTTGTTCAGACACCGGACCAAAATGAGGCGTAAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAACCAAGGTAAACAAATGGTACAGACGACCTCTCTACCGCTGTGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCCTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCTGGAGGCCCCCAGGCACACAGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTCTTCCAAGGGGACCAACAGATGGCTGGGCAATGCTTGTATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 DB 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCCCGCGCGCGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGGCGCAACCTTGTGTGGTGGCGCA 924
 QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGCGCGC 984
 QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCACAGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACCGCAGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuThy 340
 DB 1165 CCCTAAATACCTGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerIe 380
 DB 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProly 400
 DB 1345 GAATGATGGAGATTTCTACTTTCTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGGGGTCTCCCAAGCTGTGCCGGGAGGGGGCTTGCCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrTrpProArgSerLeuGlnAspTrpGl 460
 DB 1525 GCTGGCCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCGAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGAGAGGTACGCGCGCGCTGCCGAGGCCGCGATGGCTCCATCATCTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCAACCTGCGAGCAACCACTCGGGCGC 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGTGGCTGGATGGGTGCTGTCATGTCACCACTCGGGGAGCGCCCTGTT 1764

Oy 520 e 520
Db 1765 C 1765
RESULT 204
ADG61788
ID ADG61788 standard; cDNA; 1985 BP.
XX
XX AC ADG61788;
XX
XX DT 11-MAR-2004 (first entry)
XX
XX DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
XX KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophin; hormone; cell receptor;
KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour; ss; gene.
XX
XX OS Homo sapiens.
XX
XX PN US2003207428-A1.
XX
XX PD 06-NOV-2003.
XX
XX PF 15-MAY-2002; 2002US-00146792.
XX
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028651.
PR 02-DEC-1999; 98WO-US028554.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 29-JUN-2001; 2001WO-US020116.
PR 09-JUL-2001; 2001WO-US021066.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX PA (GETH) GENENTECH INC.
XX
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WI PI; 2004-021503/02.
XX P-PSDB; ADG61789.
XX
XX PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
XX acids, useful for the diagnosis, prevention and/or treatment of tumors,
XX such as lung, colon, breast, prostate, cervical and/or liver
XX tumors.
XX
XX PS Claim 2; SEQ ID NO 143; 638pp; English.
XX
XX CC This invention relates to novel nucleic acids encoding human PRO secreted
XX and transmembrane proteins. Extracellular proteins play important roles

CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neuropeptides or hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.

SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG61788 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 206 ATGTGTCGCGCGCTGGCCCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCAGCCCGCGAGCGCGAGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACCTCGATTACAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
 DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACCTGTGAGCGGGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTGCGCCAGATGACTGTCCTCCCGCTCGGGGTTCACAGATACCAACAGTTATGGG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCCTGGGTGAGAGGATCAGTACTGTTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCANAGCAAGGTAAACAAATGGTAAAGAGCGACCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTTGAGCATCTGCGGAGCGCGCAGTTTCGGGGCGCGTGGCGCGCCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGTCTCAGCGCTGAGGTTCTGGAGAGGCCCCAGCCACAGGCCCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCCGGCTCACCTTCTTCAAGGGGAGCCACAAACAGATGGGCTGGGCAATGCCCTTTATGGC 805
 QY 200 aglnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220

DB 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCCCGCGCGGAGCGCACTTCACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGCTCCTCGAGCGCGCGCGGCGCAACCTGTTGTTGTTGTTGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCTTCCACCTTCGCGCGCGCGCGCGCTCATGCGGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 DB 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTAGCTGGAGCAGCTGCTGGCCGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGGTCTAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCAAGGAAGCGCCCTGAAACGCGGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCTAAATACTGGCACTCTTCTTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGTATGGAACAGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 DB 1285 TCCACTGAGGAAGATGGTGGCTGCCCTCCCAACATTGAGGCTGGCGAGTGTGCTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCGAGGGGCGCTGCCCGCCATCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
 DB 1465 GCGCTCTTCTTCTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAAGGACTGGGG 1584
 QY 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGGAGGTGAGCGCGCTCCCGAGGGCCGATGGCTCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCAAACTGAGGCAACACCTTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGTCGCAACTCGGGAGGCGCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765
 RESULT 205
 ADG81989
 ID ADG81989 standard; cDNA; 1985 BP.
 XX
 AC ADG81989;
 XX

DT	11-MAR-2004	(first entry)	CC	The sequence data for this patent is also available in electronic format
XX	Human PRO polynucleotide #72.		CC	from USPTO at seqdata.uspto.gov/sequence.html .
XX	Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		XX	Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;			
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;			
KW	liver; microvascular endothelial cell; glucose; PFA;			
KW	skeletal muscle cell; adipocyte cell; pericyte cell;			
KW	inner ear utricular supporting cell; T-lymphocyte cell;			
KW	endothelial cell tube formation; bone disorder; cartilage disorder;			
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;			
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;			
KW	immune system cell infiltration.			
XX	Homo sapiens.			
OS	US2003207358-A1.			
PN	06-NOV-2003.			
XX	08-MAY-2002; 2002US-00141706.			
PF	03-MAR-2000; 2000US-0187202P.			
XX	01-DEC-2000; 2000WO-US032678.			
PR	19-DEC-2001; 2001US-00028072.			
PR	(GETH) GENENTECH INC.			
XX	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;			
XX	Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;			
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;			
PI	WPI; 2004-010594/01.			
XX	P-PSDB; ADG81990.			
DR	New nucleic acid encoding a secreted and transmembrane PRO polypeptide			
XX	useful in stimulating the proliferation of inner ear utricular supporting			
PT	cell, detecting the presence of a tumor and in treating cancer.			
PT	Claim 2; SEQ ID NO 143; 637pp; English.			
PS	The invention relates to isolated human PRO polypeptides (secreted and			
XX	transmembrane polypeptides) and the polynucleotides encoding them. The			
CC	invention also relates to an antibody which specifically binds to a PRO			
CC	polypeptide, a method for stimulating the release of tumour necrosis			
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the			
CC	proliferation or differentiation of chondrocyte cells and a method for			
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,			
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The			
CC	polynucleotides are useful in molecular biology, including uses as			
CC	hybridisation probes, in chromosome and gene mapping, in generating			
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also			
CC	be used in preparing PRO polypeptides by recombinant techniques and in			
CC	generating either transgenic animals or knock-out animals which are			
CC	useful in the development and screening of therapeutically useful			
CC	reagents. The PRO polypeptides or antibodies are used in preparing a			
CC	medicament for treating a condition responsive to the polypeptides or			
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation			
CC	of human microvascular endothelial cells, for modulating the uptake of			
CC	glucose or PFA by skeletal muscle cells or adipocyte cells, for			
CC	stimulating differentiation of adipocyte cells, for stimulating			
CC	proliferation of or gene expression in pericyte cells, for stimulating			
CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte			
CC	cells, for inducing endothelial cell tube formation and for treating			
CC	various bone and/or cartilage disorders such as sports injuries and			
CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans			
CC	from cartilage are useful for treating sports-related joint problems,			
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO			
CC	polypeptides are also useful for treating various mammalian haemoglobin-			
CC	associated disorders such as various thalassaemias and conditions which			
CC	may benefit from enhanced local immune system cell infiltration. This			
CC	sequence represents a human PRO polynucleotide of the invention. Note:			

```
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrClnGl 320
Db 1105 CACTGACTTTGAGACCTTGGACTCTTACAGCCCCCAAGGAAGCGCCCTGAAACGCGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluAtrGTrpValGlyLeuProProAenIleGluAlaAlaValSerIle 380
Db 1285 TCACCTGCAGGAAGATGGTGGCTGGCTGCCCCCAACATTGAGGCTGGCGGAGTGTCA 1344
Qy 380 uAenAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCAGCGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTCCAGTGGAGCCCTACTACCCCGGAGTTCGAGAGCTGGGG 1584
Qy 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCGCCCTGCGAGGCCGATGGCTCCATCATCTTCT 1644
Qy 480 eArgPheAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCTACTTGGCGCTCGACAGGCCAAACTGCAGGCCAACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAATCTGGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 206
ADG57228
ID ADG57228 standard; cDNA; 1985 BP.
XX
AC ADG57228;
XX
DT 11-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophin; hormone; cell
KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003207362-A1.
XX
PD 06-NOV-2003.
XX
PF 08-MAY-2002; 2002US-00141762.
```

```
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Deenoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski RJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-010598/01.
DR P-PSDB; ADG57229.
XX
PT New nucleic acid encoding a secreted and transmembrane PRO polypeptide,
PT useful for detecting a tumor and inhibiting the differentiation of
PT adipocyte cells.
XX
PS Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
XX
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0
US-10-791-980-6 (1-520) x ADG57228 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTTCGGCGCGCTCGGCTCTCTGCTGGCGCCCTGACAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGCGCGAGAGCTGCGCAAGAGGCGGAGGCAATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGAGCTCCACCTCCACCTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATCCCATCAGAGGTTTCAGTGGGTGTCCAGCACTACTCTGTCAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGCCAGATGACTCGTCCCGCTCGGGGGTTACAGATACCAACAGATTATCG 505
```

QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120	QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	506	GCCTGGGCTGAGAGATCAGTACTTGTGTCTAGACACCGGACCAAAATGAGCGTAAG	565	Db	1585	AGGCATCCCTGAGGAGGTGAGCGGCCCTCGCGAGGCCCGGCTCATCATCTTCTT	1644
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140	QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	566	AAACGCTTGTCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCCTGGTG	625	Db	1645	CCGAGATGACCGCTACTGGCGCTCGACCGACCAAACTGCAGGCAACCCACCTCGGGCGG	1704
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe	160	QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	626	AACGGCTGTGAGCAATCTCCCGAGCGCGAGTTCGGGGCGCGTGGCGCGCTTCAG	685	Db	1705	CTGGGCCACGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180	QY	520	e 520	
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGGAGGCGCCAGCCACAGGCGCCGCTGAC	745	Db	1765	c 1765	
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200	RESULT 207			
Db	746	ATCCGGCTCACCTTCTTCAAGGGGACACCAACATGGGCTGGGCAATGCCCTTTGATGGC	805	ADG56676			
QY	200	agLInGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220	ID	ADG56676	standard; cDNA; 1985 BP.	
Db	806	CAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA	864	XX	ADG56676;		
QY	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240	XX	11-MAR-2004	(first entry)	
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCAACCTGTTGCTGTGGTGGCGCA	924	XX	Novel human secreted and transmembrane protein PRO4339 cDNA.		
QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260	KW	human; PRO; membrane bound protein; membrane bound receptor;		
Db	925	CGAGATCGGTACACGCTTGGCTTCCACCCTCGCGCGCGCGCGCGCTCATGGCGCC	984	KW	cell proliferation; cell migration; cell differentiation;		
QY	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280	KW	mitogenic factor; survival factor; cytotoxic factor;		
Db	985	CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGTCTGGCGCTGCA	1044	KW	differentiation factor; neuroptide; hormone; cell receptor;		
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300	XX	receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.		
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAAAGCTGT	1104	OS	Homo sapiens.		
QY	300	eThrAspPheGluThrTrpAspSerTyr-SerProGlnGlyArgArgProGluThrGlnGl	320	XX	US2003207364-A1.		
Db	1105	CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGAGGCGCCCTGAAACGACGG	1164	XX	06-NOV-2003.		
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340	XX	10-MAY-2002; 2002US-00142429.		
Db	1165	CCCTAAATACTGCCACTTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224	XX	05-JUN-2000; 2000US-0209832P.		
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360	PR	01-DEC-2000; 2000WO-US032678.		
Db	1225	CATTTTAAAGGGAGGCATTTCTGGGAGGTGGGAGCTGATGCAACGCTCTCAGACCCCG	1284	PR	19-DEC-2001; 2001US-00028072.		
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerie	380	XX	(GETH) GENENTECH INC.		
Db	1285	TCACCTGCGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGGCGAGTGTCAAT	1344	XX	Baker KP, Beresini M, DeForge L, Deanovers L, Filvaroff E, Gao W;		
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly	400	PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;		
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGCTCGATGCTGGAGTTCCTGGGGGCCCAA	1404	PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;		
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420	XX	WPI; 2004-051515/05.		
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGCGCTGCCCGCATCTTGACGC	1464	XX	P-PSDB; ADG56677.		
QY	420	aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa	440	PT	New PRO nucleic acid, useful for manufacturing a medicament for		
Db	1465	CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGCTTACTACGT	1524	PT	diagnosing or treating tumor, for chromosome mapping or for tissue		
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460	XX	typing.		
Db	1525	GCTGGCCCCGAGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGACGACTGGGG	1584	PS	Claim 2; SEQ ID NO 143; 637pp; English.		

This invention relates to novel nucleic acids encoding human PRO secreted and transmembrane proteins. Extracellular proteins play important roles in the formation, differentiation and maintenance of multicellular organisms. The fate of many individual cells (for example proliferation, migration or differentiation) is typically governed by information received from other cells and the immediate environment. The information is often transmitted by secreted polypeptides (for example mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuroptides and hormones) which are received and interpreted by diverse cell receptors or membrane bound proteins. These membrane bound proteins and receptors may be of use as pharmaceutical and diagnostic agents, such as in the blocking of receptor-ligand interactions. The current invention provides the amino acid sequences of novel human membrane bound receptors and proteins, along with the cDNA sequences encoding them. The novel

CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.

XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservatives: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG56676 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTCGCGCGGTGGCCCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGCGCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GACGCCAGCCCGGAGCGCGGAGGCCAGGAGCTGGCAAGGAGCGGCGGAGGCAATTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCCAAGCTCCCACTGCATTACAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
 DB 386 GATGCCATCAGACGGTTTCAGTGGGTGCCAGCTACCTGTGAGCGGCGGTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCCAGATGACTCTCCCGCTGCGGGGTTACAGATACCAACAGTTATGGG 505
 QY 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
 DB 506 GCCTGGGTGAGAGGATCAGTACCTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAACAGAGTTAAACATGTTACAAAGCAGACCTCTCTCCCGCCCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTTGAGCATCTGCGGAGCGGCGAGTTGCGGGCGCGTGGCGCCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAGCTCTCAGCGCTGGAGTTCTGGAGAGGCCCAAGCCACAGGCGCCCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTCTTCTCAAGGGGACCACAAACGATGGGCTGGGCAATGCCCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGGGAAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATAGCGCTGGTCTCCTGAGCGCGCGCGGCGCAACCTGTTGCTGGTGGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CAGATCGGTACACGCTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280

DB 985 CTACTACAAGAGCGCTGGCGCGAGCGCGCTGCTCAGCTGGGACGAGCTGCTGCCGTGCA 1044
 QY nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCAGCCCCCAAGAAAGCGCCCTTGAACCGCAGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCTAAATACCTGCCACTCTCTCTCGATGCCATCACTAGACAGCAACACCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGTAGCAACGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 DB 1285 TCCACTGCGAAGAGATGGTGGGCTGCCCCCCCAACATTGAGGCTGGGCAAGTGTCTT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCGAGGGGCGCTGCCCGCCATCTGACGC 1464
 QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTTCTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCCGCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGAGCTGCGAGACTGGGG 1584
 QY 460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCCTCAGGAGGTGAGCGCGCCCTCCGAGGCGCGATGGCTGCATCATCTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGGCGCCCTCGACCGCCAACTGCGGCAACCACTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765
 RESULT 208
 ADG55572
 ID ADG55572 standard; cDNA; 1985 BP.
 XX
 AC ADG55572;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 KW human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuropeptide; hormone; cell receptor;
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
 OS Homo sapiens.
 XX

Qy 240 sgluileGlyHisThrLeuGlyLeuThrHisSerProAlaPProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGCGCTCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTyrlsYsGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAAGAGCTGGCGCGCGCGCTCTCAGCTGGGACGACGTCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrlsYsProLeuGlyGlySerValAlaValLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAGAGCCCTAGGGGCTCAGTGGCGTCCAGCTCCAGAAAGCTGTT 1104
Qy 300 eThAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTCAGATGCCATCTCTGATAGACGGCAGCACTGTA 1164
Qy 320 yProlyTyrlsYsHisSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTCTCTGATGCCATCTCTGATAGACGGCAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTCATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGTCTCCACAGCTGTGGCGGAGGGGCTGCGCCGCCATCTCTGACGC 1464
Qy 420 alaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGTGGCGGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGGCGCTTACTACCGCCGAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGCATCTCTGAGGAGTCCAGCGGCGCTGCGAGGCGCGATGCTCCATCTCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGGCGCAACTGCGAGGCAACCACTCGGCGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGTCCCTGGATGGCTGCTGGCATGGCACTCGGGGAGCGCGCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 210
ADG70698
ID ADG70698 standard; cDNA; 1985 BP.
XX
AC ADG70698;
DT 11-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; lung; colon; breast; prostate;

KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX Homo sapiens.
XX US2003207420-A1.
XX 06-NOV-2003.
XX 07-MAY-2002; 2002US-00140865.
XX 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
XX 14-JUL-1998; 98WO-US014552.
XX 28-AUG-1998; 98WO-US017888.
XX 10-SEP-1998; 98WO-US018824.
XX 14-SEP-1998; 98WO-US019093.
XX 14-SEP-1998; 98WO-US019094.
XX 14-SEP-1998; 98WO-US019177.
XX 16-SEP-1998; 98WO-US019330.
XX 17-SEP-1998; 98WO-US019437.
XX 07-OCT-1998; 98WO-US021141.
XX 29-OCT-1998; 98WO-US022991.
XX 29-OCT-1998; 98WO-US022992.
XX 20-NOV-1998; 98WO-US024855.
XX 01-DEC-1998; 98WO-US025108.
XX 05-JAN-1999; 98WO-US000106.
XX 08-MAR-1999; 98WO-US005028.
XX 10-MAR-1999; 98WO-US005190.
XX 20-APR-1999; 98WO-US008615.
XX 14-MAY-1999; 98WO-US010733.
XX 02-JUN-1999; 98WO-US012252.
XX 01-SEP-1999; 98WO-US020111.
XX 08-SEP-1999; 98WO-US020594.
XX 13-SEP-1999; 98WO-US020944.
XX 15-SEP-1999; 98WO-US021090.
XX 15-SEP-1999; 98WO-US021547.
XX 05-OCT-1999; 98WO-US023089.
XX 29-NOV-1999; 98WO-US028214.
XX 30-NOV-1999; 98WO-US028313.
XX 30-NOV-1999; 98WO-US028409.
XX 01-DEC-1999; 98WO-US028301.
XX 01-DEC-1999; 98WO-US028634.
XX 02-DEC-1999; 98WO-US028551.
XX 02-DEC-1999; 98WO-US028564.
XX 02-DEC-1999; 98WO-US028565.
XX 16-DEC-1999; 98WO-US030095.
XX 20-DEC-1999; 98WO-US030911.
XX 20-DEC-1999; 98WO-US030999.
XX 22-DEC-1999; 98WO-US030720.
XX 30-DEC-1999; 98WO-US031243.
XX 30-DEC-1999; 98WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US003565.
XX 18-FEB-2000; 2000WO-US004341.
XX 18-FEB-2000; 2000WO-US004342.
XX 22-FEB-2000; 2000WO-US004914.
XX 24-FEB-2000; 2000WO-US005004.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005746.
XX 02-MAR-2000; 2000WO-US005841.
XX 10-MAR-2000; 2000WO-US006319.
XX 15-MAR-2000; 2000WO-US006884.

PR	20-MAR-2000;	2000WO-US007377.
PR	21-MAR-2000;	2000WO-US007532.
PR	30-MAR-2000;	2000WO-US008439.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	03-JUN-2000;	2000WO-US015264.
PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US022031.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030954.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000US-00743956.
PR	28-FEB-2001;	2001US-00796498.
PR	28-FEB-2001;	2001US-00796498.
PR	01-MAR-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	04-MAR-2001;	2001US-00802706.
PR	13-MAR-2001;	2001US-00808689.
PR	22-MAR-2001;	2001US-00816744.
PR	05-APR-2001;	2001US-00828366.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	18-MAY-2001;	2001US-00860216.
PR	25-MAY-2001;	2001US-00860628.
PR	25-MAY-2001;	2001US-00866034.
PR	25-MAY-2001;	2001WO-US017092.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	14-JUN-2001;	2001US-00826336.
PR	19-JUN-2001;	2001US-00846392.
PR	20-JUN-2001;	2001WO-US019692.
PR	21-JUN-2001;	2001US-00887879.
PR	22-JUN-2001;	2001WO-US020116.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	18-JUL-2001;	2001US-00906827.
PR	06-AUG-2001;	2001US-00924419.
PR	09-AUG-2001;	2001US-00927796.
PR	16-AUG-2001;	2001US-00931836.
PR	19-DEC-2001;	2001US-00032872.

generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at segdata.uspto.gov/sequence.html.

New secreted and transmembrane PRO polypeptides and nucleic acids, useful in gene therapy for treating e.g. tumors, obesity, diabetes, hypo- or hyperinsulinemia, bone and/or cartilage disorders, stroke, or heart attack.

QY 200 aGlnGlyAlaProThrArgThrProPheLeuProArgGlyGluAlaHisPheAspG1 220
 DB |||||
 DB 806 CAGGGGGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGCGAAGGCACATTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB |||||
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCTGGTGGTGGCGCA 924
 QY 240 sGluLeuGlyHisThrLeuLeuLeuHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB |||||
 DB 925 CCGATCCGTCACACGCTGGCGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
 DB |||||
 DB 985 CTACTACAGAGGCTGGCGCGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB |||||
 DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 DB |||||
 DB 1105 CACTGACTTTGAGACTGGGACTCTCAGCGCGCGCGCGCGCGCGCTGAAACGCGAGG 1164
 QY 320 YProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
 DB |||||
 DB 1165 CCTTAATACTGCACCTCTCTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB |||||
 DB 1225 CATTTTAAAGGAGGAGCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB |||||
 DB 1285 TCCACTGCGAGGAAGATGGTGGGCTGCGCGCGCGCGCGCGCGCGCTGAGTGTCTATT 1344
 QY 380 uAenAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
 DB |||||
 DB 1345 GAATGATGAGATTTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGCGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB |||||
 DB 1405 GCGAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCGCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
 DB |||||
 DB 1465 CGCCCTCTTCTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 DB |||||
 DB 1525 GCTGGCGCGAGGGGAGTGAAGTGGAGGCGCTACTACCGCGCGCGCGCGCTGCGAGCTGGGG 1584
 QY 460 YGlyVileProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
 DB |||||
 DB 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCGCGCGCGCGCGCGCGCGCGCTGCTCATCTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB |||||
 DB 1645 CCGAGATGACCGGCTACTGGCGCGCTCGACAGGCGCAACCTGCAGGCAACCACTCGGGCGG 1704
 QY 500 gTTPAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB |||||
 DB 1705 CTGGGCGACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAATCTCGGGGAGCGCCCTGTT 1764
 QY 520 e 520
 DB |
 DB 1765 C 1765
 RESULT 211
 ADG57780
 ID ADG57780 standard; cDNA; 1985 BP.
 XX

AC ADG57780;
 XX 11-MAR-2004 (first entry)
 DT Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX human; PRO; membrane bound protein; membrane bound receptor;
 XX cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neurotrophic; hormone; cell receptor;
 KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour; ss; gene.
 OS Homo sapiens.
 XX US2003207363-A1.
 PN 06-NOV-2003.
 PD 09-MAY-2002; 2002US-00142428.
 XX 03-MAR-2000; 2000US-0187202P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 DR WPI: 2004-010599/01.
 XX P-PSDB; ADG57781.
 PT New nucleic acid encoding a secreted and transmembrane PRO polypeptide
 PT useful for detecting a tumor and stimulating the proliferation or
 PT differentiation of chondrocyte cells.
 XX Claim 2; SEQ ID NO 143; 637pp; English.
 PS This invention relates to novel nucleic acids encoding human PRO secreted
 CC and transmembrane proteins. Extracellular proteins play important roles
 CC in the formation, differentiation and maintenance of multicellular
 CC organisms. The fate of many individual cells (for example proliferation,
 CC migration or differentiation) is typically governed by information
 CC received from other cells and the immediate environment. The information
 CC is often transmitted by secreted polypeptides (for example mitogenic
 CC factors, survival factors, cytotoxic factors, differentiation factors,
 CC neurotrophic factors and hormones) which are received and interpreted by diverse
 CC cell receptors or membrane bound proteins. These membrane bound proteins
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such
 CC as in the blocking of receptor-ligand interactions. The current invention
 CC provides the amino acid sequences of novel human membrane bound receptors
 CC and proteins, along with the cDNA sequences encoding them. The novel
 CC proteins of the invention may have cytostatic activities through the
 CC stimulation of chondrocytes. The nucleic acids of the invention may be
 CC useful for the manufacture of a medicament for diagnosing or treating a
 CC tumour in a mammal. In addition, they may be useful for measuring or
 CC detecting the expression of a tumour associated gene. The present
 CC sequence is a cDNA sequence which encodes a human PRO protein of the
 CC invention.
 XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 SQ Alignment Scores:
 Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0
 US-10-791-980-6 (1-520) x ADG57780 (1-1985)

PR	01-DEC-1998;	98WO-US025108.	PR	14-JUN-2001; 2001US-00882636.	PR	14-JUN-2001; 2001US-00882636.
PR	05-JAN-1999;	99WO-US000106.	PR	19-JUN-2001; 2001US-00886342.	PR	19-JUN-2001; 2001US-00886342.
PR	08-MAR-1999;	99WO-US005028.	PR	20-JUN-2001; 2001WO-US019692.	PR	20-JUN-2001; 2001WO-US019692.
PR	10-MAR-1999;	99WO-US0005190.	PR	21-JUN-2001; 2001US-00887879.	PR	21-JUN-2001; 2001US-00887879.
PR	20-APR-1999;	99WO-US0008615.	PR	22-JUN-2001; 2001WO-US020116.	PR	22-JUN-2001; 2001WO-US020116.
PR	14-MAY-1999;	99WO-US010733.	PR	29-JUN-2001; 2001WO-US021066.	PR	29-JUN-2001; 2001WO-US021066.
PR	02-JUN-1999;	99WO-US012252.	PR	09-JUL-2001; 2001WO-US021735.	PR	09-JUL-2001; 2001WO-US021735.
PR	01-SEP-1999;	99WO-US020111.	PR	18-JUL-2001; 2001US-00908827.	PR	18-JUL-2001; 2001US-00908827.
PR	08-SEP-1999;	99WO-US020594.	PR	08-AUG-2001; 2001US-00924419.	PR	08-AUG-2001; 2001US-00924419.
PR	13-SEP-1999;	99WO-US020944.	PR	09-AUG-2001; 2001US-00927796.	PR	09-AUG-2001; 2001US-00927796.
PR	15-SEP-1999;	99WO-US021090.	PR	16-AUG-2001; 2001US-00931836.	PR	16-AUG-2001; 2001US-00931836.
PR	15-SEP-1999;	99WO-US021547.	PR	19-DEC-2001; 2001US-00028072.	PR	19-DEC-2001; 2001US-00028072.
PR	05-OCT-1999;	99WO-US023089.	XX	(GETH) GENENTECH INC.	XX	(GETH) GENENTECH INC.
PR	29-NOV-1999;	99WO-US028214.	XX	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;	XX	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PR	30-NOV-1999;	99WO-US028313.	XX	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	XX	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PR	30-NOV-1999;	99WO-US028409.	PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
PR	01-DEC-1999;	99WO-US028301.	XX	WPI; 2004-021497/02.	XX	WPI; 2004-021497/02.
PR	01-DEC-1999;	99WO-US028634.	XX	P-PSDB; ADG53365.	XX	P-PSDB; ADG53365.
PR	02-DEC-1999;	99WO-US028551.	DR	New PRO nucleic acid, useful for manufacturing a medicament for	DR	New PRO nucleic acid, useful for manufacturing a medicament for
PR	02-DEC-1999;	99WO-US028564.	DR	diagnosing or treating tumor, for chromosome mapping or for tissue	DR	diagnosing or treating tumor, for chromosome mapping or for tissue
PR	02-DEC-1999;	99WO-US028565.	XX	typing.	XX	typing.
PR	16-DEC-1999;	99WO-US030095.	XX	Claim 2; SEQ ID NO 143; 637pp; English.	XX	Claim 2; SEQ ID NO 143; 637pp; English.
PR	20-DEC-1999;	99WO-US030911.	CC	This invention relates to novel nucleic acids encoding human PRO secreted	CC	This invention relates to novel nucleic acids encoding human PRO secreted
PR	20-DEC-1999;	99WO-US030999.	CC	and transmembrane proteins. Extracellular proteins play important roles	CC	and transmembrane proteins. Extracellular proteins play important roles
PR	22-DEC-1999;	99WO-US030720.	CC	in the formation, differentiation and maintenance of multicellular	CC	in the formation, differentiation and maintenance of multicellular
PR	30-DEC-1999;	99WO-US031243.	CC	organisms. The fate of many individual cells (for example proliferation,	CC	organisms. The fate of many individual cells (for example proliferation,
PR	30-DEC-1999;	99WO-US031274.	CC	migration or differentiation) is typically governed by information	CC	migration or differentiation) is typically governed by information
PR	05-JAN-2000;	2000WO-US000219.	CC	received from other cells and the immediate environment. The information	CC	received from other cells and the immediate environment. The information
PR	06-JAN-2000;	2000WO-US000277.	CC	is often transmitted by secreted polypeptides (for example mitogenic	CC	is often transmitted by secreted polypeptides (for example mitogenic
PR	06-JAN-2000;	2000WO-US000376.	CC	factors, survival factors, cytotoxic factors, differentiation factors,	CC	factors, survival factors, cytotoxic factors, differentiation factors,
PR	11-FEB-2000;	2000WO-US0003565.	CC	neuropeptides and hormones) which are received and interpreted by diverse	CC	neuropeptides and hormones) which are received and interpreted by diverse
PR	18-FEB-2000;	2000WO-US0004341.	CC	cell receptors or membrane bound proteins. These membrane bound proteins	CC	cell receptors or membrane bound proteins. These membrane bound proteins
PR	18-FEB-2000;	2000WO-US0004342.	CC	as and receptors may be of use as pharmaceutical and diagnostic agents, such	CC	as and receptors may be of use as pharmaceutical and diagnostic agents, such
PR	22-FEB-2000;	2000WO-US004414.	CC	as in the blocking of receptor-ligand interactions. The current invention	CC	as in the blocking of receptor-ligand interactions. The current invention
PR	24-FEB-2000;	2000WO-US004914.	CC	provides the amino acid sequences of novel human membrane bound receptors	CC	provides the amino acid sequences of novel human membrane bound receptors
PR	24-FEB-2000;	2000WO-US005004.	CC	and proteins, along with the cDNA sequences encoding them. The novel	CC	and proteins, along with the cDNA sequences encoding them. The novel
PR	01-MAR-2000;	2000WO-US0050601.	CC	proteins of the invention may have cytosstatic activities through the	CC	proteins of the invention may have cytosstatic activities through the
PR	02-MAR-2000;	2000WO-US0050746.	CC	stimulation of chondrocytes. The nucleic acids of the invention may be	CC	stimulation of chondrocytes. The nucleic acids of the invention may be
PR	02-MAR-2000;	2000WO-US00505841.	CC	useful for the manufacture of a medicament for diagnosing or treating a	CC	useful for the manufacture of a medicament for diagnosing or treating a
PR	10-MAR-2000;	2000WO-US00506319.	CC	tumour in a mammal. In addition, they may be useful for measuring or	CC	tumour in a mammal. In addition, they may be useful for measuring or
PR	15-MAR-2000;	2000WO-US0066884.	CC	detecting the expression of a tumour associated gene. The present	CC	detecting the expression of a tumour associated gene. The present
PR	20-MAR-2000;	2000WO-US007377.	CC	sequence is a cDNA sequence which encodes a human PRO protein of the	CC	sequence is a cDNA sequence which encodes a human PRO protein of the
PR	21-MAR-2000;	2000WO-US007532.	XX	invention.	XX	invention.
PR	30-MAR-20					

QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80	QY	420	aAlaLeuPhePheProLeuArgLeuIleLeuPheGlyAlaArgTyrTyrVa	440
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGCGTGTGGACGC	445	Db	1465	CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGCCCGTACTACGT	1524
QY	81	AlaThrLeuArgGlnMetThrArgProArgProCysGlyValThrAspThrAsnSerTyrAla	100	QY	440	IleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1	460
Db	446	GCCACCCCTCGCCAGATGACTCGTCCCGCTCGGGGTACAGATACCAACAGTTATGCG	505	Db	1525	GCTGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAGTCTGCAGGACTGGGG	1584
QY	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgGlyS	120	QY	460	YGLIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	506	GCTTGGCTTGAGAGGATCAGTCTGTTGTGTAGACACCGGACCAAAATGAGGGGTAAAG	565	Db	1585	AGGCATCCTGAGGAGGTGAGCGGCGCTGCCGAGGCGCGATGGCTCCATCATCTTCTT	1644
QY	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140	QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	566	AAACGCTTTGCAAGCAAGTAAACAATGGTACACAGCAGCAGCTCTCTACCGCTGGTG	625	Db	1645	CGAGATGACCGCTACTGCGGCTCGACGAGGCCAACTGCAGGCAACACCTCGGGCGG	1704
QY	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160	QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	626	AACTGGCTTGAGCATCTGCGGAGCGGCGAGTTGCGGGCGCGTTCGCGCGCTTCCAG	685	Db	1705	CTGGGCCACCGAGCTGCGCTGGATGGGTGTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180	QY	520	e 520	
Db	686	TTGTGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCCGCTGAC	745	Db	1765	C 1765	
QY	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200	RESULT 213			
Db	746	ATCCGGCTCACCCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCCCTTATGGC	805	ID	ADG71250	standard; cDNA; 1985 BP.	
QY	200	adGlnAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1	220	XX	ADG71250		
Db	806	CCAGGGGGCGCTGGCGCACGCCCTTC - CTGCCCCCGCGCGGCGGCACTTCGACCA	864	AC	ADG71250;		
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240	DT	11-MAR-2004	(first entry)	
Db	865	AGATGAGCGCTGGTCTTGAGCGCGCGCGGGGCGCAACCTGTGTGTGTCTGGCGCA	924	XX	Novel human secreted and transmembrane protein PRO4339 cDNA.		
QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260	XX	Human; secreted and transmembrane protein; PRO; secreted polypeptide;		
Db	925	CGAGATCGGTACACGCTTGGCTCACCACCTCGCCCGCGCGCGGCTCATGCGGCC	984	KW	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;		
QY	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1	280	KW	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;		
Db	985	CTACTACAAGAGCGTGGCGCGGCGCGCTGTCTAGCTGGGACGAGCTGTGGCGTGCA	1044	KW	rectum; kidney; cervix; liver; microvascular endothelial cell;		
QY	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300	KW	glucose uptake modulator; PFA uptake modulator; cell proliferation;		
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGGCTCAGTGGCGGCTCCAGCTCCAGGAAAGCTGT	1104	KW	cell differentiation; skeletal muscle cell; adipocyte cell;		
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1	320	KW	pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;		
Db	1105	CACCTGACTTTGAGACTTGGGACTCTCAGCGCCCGCCAGGAGCGCCCTGAAACCGAGGG	1164	KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340	KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
Db	1165	CCCTAAATACTGCCACTCTCTCTCGATGCCATCATCTGTAGACGGCAACAGCAACTGTA	1224	KW	rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;		
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360	KW	immune system cell infiltration; chromosome mapping; gene mapping;		
Db	1225	CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284	OS	Gene therapy; chromosome identification; chromosome marker; gene; ss.		
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380	XX	Homo sapiens.		
Db	1285	TCCACTGAGGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCATGTCAIT	1344	XX	US2003207421-A1.		
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400	XX	06-NOV-2003.		
Db	1345	GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA	1404	XX	08-MAY-2002; 2002US-00141701.		
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420	XX	31-MAR-1997; 97WO-US005230.		
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCCCGCCCATCTCTGAGCG	1464	XX	12-JUN-1998; 98WO-US012456.		
				XX	14-JUL-1998; 98WO-US014552.		
				XX	28-AUG-1998; 98WO-US017888.		
				XX	10-SEP-1998; 98WO-US018824.		
				XX	14-SEP-1998; 98WO-US019093.		
				XX	14-SEP-1998; 98WO-US019094.		
				XX	14-SEP-1998; 98WO-US019177.		
				XX	16-SEP-1998; 98WO-US019330.		
				XX	17-SEP-1998; 98WO-US019437.		
				XX	07-OCT-1998; 98WO-US021141.		
				XX	29-OCT-1998; 98WO-US022991.		
				XX	29-OCT-1998; 98WO-US022992.		
				XX	20-NOV-1998; 98WO-US024855.		
				XX	01-DEC-1998; 98WO-US025108.		
				XX	05-JAN-1999; 99WO-US000106.		
				XX	08-MAR-1999; 99WO-US005028.		
				XX	10-MAR-1999; 99WO-US005190.		

Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACCGCCGCGAGCGCGAGCCAGGAGCTGCGCAAGAGCGGAGGCATTCCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGATACCTCATGAACAGGTCCCAANGCTCCACCTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTTCAGCGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCCACAGATCACTCGTCCCGCTCGCGGTTCAGATATACCAAGTTATCGC	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGATCAGTGACTTGTTTGCTAGACACCGACCACAAATGAGGCGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAGGTAAACAAATGGTTACAAGCAGCACCTCTCTCTACCGCTGGT	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTCAGACATCTCCCGAGCCGCGAGTTCGGGCGCGCTGCGCGCGCTTCACG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTTGGAGACAACGTCTCAGCGCTGGAGTTCCTGGAGAGCCCGCAGCCACGAGCCCGCTGC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAAGGGAGCCACCAACGATGGGCTGGGCAATGCCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGCGCCTTGGCGCAGCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCCGCGCGCGGCGCAACCTGTTCGTGGTGTCTGGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTCAACAGCTTGCGCTCACCTCCCGCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTCAAGAGGCTGGGCGCGCAGCGCTGCTCAGCTGGGACCGACGCTGCTGGCGCGTCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGTGGCGCTCCAGCTCCGAGAA	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTTGGGACTCCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCGAGG	1164
Qy	320	yProLysTyrCyHisHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAATACTGCCACTCTTCCTTCGATGCCATCCTGTAGACAGGCCAACAGCAACTGTA	1224
Qy	340	rIlePheGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCGAGGAAGAATGGGTTCGGGCTGCCCGCCCAACATTTAGGCTTCGGCAGTGTCA	1344

Qy	390	uAnAspGlyAspPheTyrPhePheLeuGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGCGAGGGGGCTGCCCCCGCATCTGTACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLeuGlyAlaArgTyrTrpVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGCTGCAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGAGGTCAAGCGCGCCCTGCGAGGCGCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCCTCGACACAGGCCAACTCGAGCAACCACTCGGGCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGCCACCGAGTGCCTCGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCTGTT	1764
Qy	520	e 520	
Db	1765	c 1765	
RESULT 214			
ADG81437			
ID	ADG81437	standard; cDNA; 1985 BP.	
XX	AC	ADG81437;	
XX	DT	11-MAR-2004 (first entry)	
XX	DE	Human PRO polynucleotide #72.	
XX	KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;	
XX	KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;	
XX	KW	cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;	
XX	KW	liver; microvascular endothelial cell; glucose; PFA;	
XX	KW	skeletal muscle cell; adipocyte cell; pericyte cell;	
XX	KW	inner ear utricular supporting cell; T-lymphocyte cell;	
XX	KW	endothelial cell tube formation; bone disorder; cartilage disorder;	
XX	KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	
XX	KW	rheumatoid arthritis; haemoglobin-associated disorder thalassemia;	
XX	KW	immune system cell infiltration.	
OS		Human sapiens.	
XX	XX		
XX	XX	US2003207805-A1.	
XX	XX	06-NOV-2003.	
XX	XX		
XX	XX	28-MAY-2002; 2002US-00156843.	
XX	XX		
XX	XX	18-JUN-1997; 97US-0049911P.	
XX	XX	26-AUG-1997; 97US-0056974P.	
XX	XX	17-SEP-1997; 97US-0059113P.	
XX	XX	17-SEP-1997; 97US-0059115P.	
XX	XX	17-SEP-1997; 97US-0059117P.	
XX	XX	17-SEP-1997; 97US-0059122P.	
XX	XX	17-SEP-1997; 97US-0059184P.	
XX	XX	18-SEP-1997; 97US-0059263P.	
XX	XX	19-SEP-1997; 97US-0059352P.	
XX	XX	19-SEP-1997; 97US-0059588P.	
XX	XX	24-SEP-1997; 97US-0059836P.	
XX	XX	17-OCT-1997; 97US-0062250P.	

PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 24-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069211P.
PR 11-DEC-1997; 97US-0069278P.
PR 16-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077910P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 31-MAR-1998; 98US-0079728P.
PR 09-APR-1998; 98US-0080165P.
PR 14-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085523P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98US-0088810P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089539P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98US-00914552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98US-00981788.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98US-0099824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98US-0100903.
PR 14-SEP-1998; 98US-0100904.
PR 15-SEP-1998; 98US-01019177.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100390P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101474P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103328P.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98US-0106030P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98US-0112455.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113313P.

cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; pericyte; FFA;
skeletal muscle cell; adipocyte cell; glucose; FFA;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

KW Homo sapiens.
OS
XX
XX US2003077723-A1.
XX
XX 24-APR-2003.
XX
XX 16-MAY-2002; 2002US-00147500.
XX
XX 12-AUG-1998; 98US-0096329P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-080163/08.
DR P-PSDB; ADH30400.
DR
DR Two hundred and twenty five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. These
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

```
Db      1105  CACTGACTTTGAGACCTGGGACTCCTACAGCCGCCAAGGAAGCGCCCTGAAACGCGAGG 1164
Qy      320  YProLyVeTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCTAAATACTGACACTTCCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA 1224
Qy      340  rIlePheLyGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
Qy      360  gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTGCGAAGAAGATGGTCCGGCTGCCCCCAACATTGAGGCTCGCGACGTGTCATT 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLyGlyArgCysTrpAspPheArgGlyProLy 400
Db      1345  GAATGATGGAGATTTCTACTTCTTCAAGGGGTGCGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCAGGGGCTGCCCGCCATCTCTGACGC 1464
Qy      420  alaLeuPhePheProLeuArgArgLeuIleLeuPheLyGlyAlaArgTyrTrVa 440
Db      1465  CGCCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db      1525  GCTGGCCCCAGGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAAGTCTCGAGGACTGGGG 1584
Qy      460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCCCTGAGGAGGTGAGCGGCCCTGCGAGGCCGCGATGGCTCCATCATCTTCTT 1644
Qy      480  eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTGCGCCCTCGACAGGCCAACTGCAGGCAACCACTCGGGCCG 1704
Qy      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGGCCCTGTT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 216
ADH11766
ID      ADH11766 standard; cDNA; 1985 BP.
XX
AC      ADH11766;
XX
DT      11-MAR-2004 (first entry)
XX
DE      Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW      Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW      transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW      chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW      rectum; kidney; cervix; liver; microvascular endothelial cell;
KW      glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW      cell differentiation; skeletal muscle cell; adipocyte cell;
KW      pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW      endothelial cell tube formation; bone disorder; cartilage disorder;
KW      sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW      rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW      immune system cell infiltration; chromosome mapping; gene mapping;
KW      gene therapy; chromosome identification; chromosome marker; gene, ss.
XX
OS      Homo sapiens.
XX
PN      US2003207419-A1.
```



```
Db      985  |||||CTACTACAGAGGCTGGCGCGACGCGTGTCTCAGCTGGACGACGTGCTGCCGTGCA 1044
Qy      280  nSerLeuTyrGlyVysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCACGGAAGCTGTT 1104
Qy      300  eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyVatArgProGluThrGlnG 320
Db      1105  CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAGCGCCCTGAAACGGCAGG 1164
Qy      320  yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db      1165  CCTAAATATGCGCACTTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
Qy      360  gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTGCGAGGAAGATGGTGGGCTGCCCCCAACATTGAGCTGCCGCGCATGTTCAT 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyPro 400
Db      1345  GAATGATGAGATTTCTACTTCTTCAAGGGGTGCTGCTGGAGGTTCGGGGGCCCA 1404
Qy      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGCCCATCTGACGC 1464
Qy      420  aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyValArgTyrTrVa 440
Db      1465  CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGCCCGCTACTACGT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db      1525  GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTCAGGACTGGGG 1584
Qy      460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCCCTGAGGAGGTGAGCGGCGCTGCCGAGCGCGATGGCTCCATCATCTTCT 1644
Qy      480  eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr 500
Db      1645  CCGAGATGCCGCTACTGGCGCTCGACGAGGCCAACTGCAGGCCAACCCCTCGGGCG 1704
Qy      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 217
ADGS2188
ID  ADGS2188 standard; cDNA; 1985 BP.
XX
AC  ADGS2188;
XX
DT  11-MAR-2004 (first entry)
XX
DE  Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW  human; PRO; membrane bound protein; membrane bound receptor;
KW  cell proliferation; cell migration; cell differentiation;
KW  mitogenic factor; survival factor; cytotoxic factor;
KW  differentiation factor; neuropeptide; hormone; cell receptor;
KW  receptor-ligand interaction; cyostatic; chondrocyte; tumour; ss; gene.
XX
OS  Homo sapiens.
XX
```



```
Qy 320 yProLysTyTyCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATAGTGCACCTCTTCCTTCGATGCCATCACTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGG 1284
Qy 360 gProLeuGlnGluArgTIPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCGCCACATTTAGAGCTGGCGCATGTCATT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyGlyA-gCysTTPArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGCGATGTCGAGGTTCGGGGGCCCAA 1404
Qy 400 eProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisBProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyTyVa 440
Db 1465 CGCCCTCTTCTTCCTCTCTGGCGCGCTCATCTCTTCAAGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaA-gGlyGlyLeuGlnValGluProTyTyTyProArgSerLeuGlnAspTpgl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTyTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVa 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGCAGGCAACCACTTCGGGCGG 1704
Qy 500 gTTPAlaThrGluLeuProTTPMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGTCCCTGGATGGCTGCTGGCATGCCAATCTGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 218
ADGS3916
ID ADGS3916 standard; cDNA; 1985 BP.
XX
AC ADGS3916;
XX
DT 11-MAR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytosstatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003207416-A1.
XX
PD 06-NOV-2003.
XX
PF 06-MAY-2002; 2002US-00140023.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
```

```
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00860208.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00871092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001US-00871800.
PR 14-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-0019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001US-0020116.
PR 29-JUN-2001; 2001US-00201066.
PR 09-JUL-2001; 2001US-00201735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-059757/06.
DR P-PSDB; ADG53917.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping, or for tissue
PT typing.
XX
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC invention is a cDNA sequence which encodes a human PRO protein of the
XX
XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
SQ
Alignment Scores:
Pred. No.: 1.93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0
US-10-791-980-6 (1-520) x ADG53916 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
|||||
```

```
Db
206 ATGTCGGCGCGCTCGGCTCTCTGCTGGCGCCCTGCTGAGCTGCTACTGTGGGGCCACCTG 265
Qy
21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
|||
266 GAGCCCGCAGCCCGGAGCGGAGCGGAGCGGAGCTGGCAAGAGGCGGAGGCAATTCCTA 325
Db
41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
|||
326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACATTCAGC 385
Db
61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
|||
386 GATCCCATCAGAGCGTTTCAGTGGGTGCCAGTACTCTGTACGGGGGTGTGGACCGC 445
Db
81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
|||
446 GCCACCCCTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATCG 505
Qy
101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
|||
506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCGTAGACACCGGACCAAAATGAGGCGTAAG 565
Db
121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
|||
566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Db
141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
|||
626 AACTGGCTGAGCATCTGCCGAGCGCGAGTCTGGGGCGCGCTGCGCGCGCTTCAG 685
Qy
160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
|||
686 TTGTGGAGCAACGTCTCAGCGCTGAGTTCGTGGAGGCGCCGAGCAGCAGGCCCCGCTGAC 745
Db
180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
|||
746 ATCCGGCTCACCCTTCTTCAAGGGGACCAACAATGGGTGGGCAATGCTTGTATGGC 805
Qy
200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
|||
806 CCAGGGGCGCGCTTGGCGGACGCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 864
Db
220 nAspGluArgTrpSerLysSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
|||
865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGGCAACCTGTTCGTGGTGGCGCA 924
Qy
240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
|||
925 CGAGATCGGTACACAGCTTGGCTCACCCTCGCCCGCGCGCGCGCTCATGGCGCC 984
Db
260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
|||
985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy
280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
|||
1045 GAGCCTGTATGGGAAGCCCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGAAAGCTGT 1104
Db
300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
|||
1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCCTGAAACGACGG 1164
Qy
320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
|||
1165 CCCTAAATACTGCCCATCTCTTCATGTCATCTCAGTGGGACGCAACGACGCACTGTA 1224
Db
340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
|||
1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGAGCTGATGGCAACGCTCAGAGCCCCG 1284
Qy
360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
|||
1285 TCCACTGCAGGAAGATGGGTGGGCTGCCGCCCAACATTCAGGCTCGGCGAGTGTCTATT 1344
Db
```

```
OY 380 uAenAspGlyAspPheTyxPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
|||||
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTTCGGGGCCCCAA 1404

OY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
|||||
Db 1405 GCAGTGTGGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGGCATCTCTGACGC 1464

OY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
|||||
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGCCTACTACTACGT 1524

OY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrPProArgSerLeuGlnAspTrpGl 460
|||||
Db 1525 GCTGGCCCGAGGGGACTGCNAGTGAGGCCCTACTACCCCGGAGTCTGAGGACTGGGG 1584

OY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleilePhePh 480
|||||
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCTGCCGAGCGCGATGGCTCCATCATCTTCTT 1644

OY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
|||||
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACGAGGCCAACTGCAGGCAACCACTCGGGCGC 1704

OY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
|||||
Db 1705 CTGGGCGACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764

OY 520 e 520
Db 1765 C 1765

RESULT 219
ADG80885
ID ADG80885 standard; cDNA; 1985 BP.
XX
AC ADG80885;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human PRO polynucleotide #72.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194793-A1.
XX
PD 16-OCT-2003.
XX
PF 15-APR-2002; 2002US-00123214.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US02456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
```


Db 1225 CATTTTAAAGGAGGAGCTTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaValSerLe 380
Db 1285 TCACCTGCAGGAAGATGGTGGCTGGCTGCCCCCAACATTGAGGCTTCGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCGCCGATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrGl 460
Db 1525 GCTGGCCCGAGGGGAGTCAAGTGGAGCCCTACTACCCCGGAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTTCAGCGGCGCTTGGCGAGGCGGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CGAGATGACCGCTACTGCGGCTTCAGCAGGCGCAAACTGCAGGCAACCACTTCGGGGCG 1704
Qy 500 gTyrAlaThrGluLeuProTyrMetGlyCysTyrHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGTGCCTTGTGATGGCTGCTGGCATGCCAATCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 220
ADG56124
ID ADG56124 standard; cDNA; 1985 BP.
AC ADG56124;
XX 11-MAR-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO4339 cDNA.
DE human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
XX US2003207366-A1.
XX
XX 06-NOV-2003.
XX
XX 09-MAY-2002; 2002US-00143027.
XX
XX 03-MAR-2000; 2000US-0187202P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski FU, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

DR WPI; 2004-051516/05.
XX P-PSDB; ADG56125.
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
XX typing.
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
XX invention.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG56124 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTyrGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCTCTGAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCAAGCCCGGAGCGCGAGCGCCAGAGCTGCGCAAGGAGCGGAGGCATTCTCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTCAGTGGGTGCCAGGCTACCTGTCCAGCGGGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTyrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTTCCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAAGCTTTGCAAGCAAGGATTAACAAATGGTACAGCAGCACCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTyrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160

Db 626 AACTGGCCTGAGCATCTCGCGAGCCGCGAGTTTCGGGGCGCGTTCGCGCGCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGAGTTCTGGAGAGCCCGCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGAGCACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTyrArgTyrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCTGCGCGACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTyrSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATAGAGCGCTGCTCCTGAGCGCGCGCGGGCGCAACCTGTTCTGTTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaApr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGACACTGGGACTCTACAGCCCCCAGAGAGCGCCCTGAAACCCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlyLysSerHisPheTyrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAAGAAAGTGGTTCGGCTGCCCGCCCAACATTGAGGCTGGGAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTyrArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 gProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGGGGGAGGGGGCTGCGCCCGCCATCTCCAGCGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCTGCGGAGGCCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGGCCAACTGACGGCAACCACTCGGGCG 1704
Qy 500 gTyrAlaThrGluLeuProTyrMetGlyCysTyrHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764

Qy 520 e 520
Db 1765 C 1765

RESULT 221

ADH12390

ID ADH12390 standard; cDNA; 1985 BP.

XX ADH12390;

AC 11-MAR-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO4339 cDNA.

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
rectum; kidney; cervix; liver; microvascular endothelial cell;
glucose uptake modulator; FFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker; gene; ss.

XX Homo sapiens.

XX US2003207378-A1.

XX 06-NOV-2003.

XX 17-MAY-2002; 2002US-00147535.

XX 05-JUN-2000; 2000US-0209832P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2004-069292/07.

XX P-PSDB; ADH12391.

XX New PRO nucleic acids, useful in diagnosis and treatment of cancer, for
chromosome mapping or for tissue typing.

XX Claim 2; SEQ ID NO 143; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte

KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX
OS Homo sapiens.
XX
PN US2003207429-A1.
XX
PD 06-NOV-2003.
XX
PF 30-MAY-2002; 2002US-00158791.
XX
XX 31-MAR-1997; 97WO-US0052230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US024855.
PR 20-NOV-1998; 98WO-US025108.
PR 01-DEC-1998; 98WO-US000106.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 08-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000365.
PR 18-FEB-2000; 2000WO-US000431.
PR 18-FEB-2000; 2000WO-US000432.
PR 23-FEB-2000; 2000WO-US000414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US022322.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-021504/02.
DR P-PSDB; ADG61237.
XX
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
XX Claim 2; SEQ ID NO 143; 638pp; English.
XX
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a

CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 SQ

Alignment Scores:

Pred. No.: 1,936-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADH28323 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 DB 206 ATGGTGGCGCGTGGCCCTCTGTGGCGCGCTGACGTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 266 GAGCGCCAGCCCGGAGCGCGAGGCCAGGAGCTGGCGAAGCGGCGGAGGCATTTCCTA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAAATACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCACCTGATTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
 DB 386 GATGCCATCAGACGTTTCAGTGGGTGTCCTGAGCTACCTGTGAGCGGTGTGTGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTTGGCCAGATGACTCGTCCCGCTCGCGGGTTTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 506 GCTGGGCTGAGAGGATCAGTACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCANAGCAAGGTAAACAAATGTTAAAGACGACCTCTCTTACCGCCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTGAGCAATCTGCGCGCGCGGAGTTCGGGGCGCGTGGCGCGCCCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGGCGCCACAGCCAGCGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACACGATGGGCTGGGCAATGCGCTTGTATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGCGCTGGCGACGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGGCGCAACCTGTTCGTGGTGTGCGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260

DB 925 CGAGATCGTCCACACGCTGGCGCTCACCCACTCGCGCGCGCGCGCTCATGGCGC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 DB 985 CTACTACAAGAGGCTGGCGCGCGCGCTGTCTAGCTGGGACGACGTGTGCGCGCTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTATGGAAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACTTGGGACTCTCAGAGCCCAAGGAGCGCCCTGAAACGACGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCTAAATACTGCCACTCTTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1285 TCCACTGAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGGCACTGTATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTGCGATGTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGGGGGTCTTCCACAGCTGTGCGCGGAGGGGCGCTGCCCGCCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGGCCCTTACTACCGCCCAAGCTGTGAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGATCCTCAGGAGGTGAGCGCGCTTCCGAGGGCGCGATGGCTCCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGTACCGCTACTTGGCGCTCGACAGGCCCAACTGACAGGCAACCACTCGGGCGC 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGGGCGCTGTT 1764
 QY 520 e 520
 DB 1765 C 1765
 RESULT 224
 ADG54468
 ID ADG54468 standard; cDNA; 1985 BP.
 XX
 AC ADG54468;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 XX human; PRO; membrane bound protein; membrane bound receptor;
 KW cell proliferation; cell migration; cell differentiation;
 KW mitogenic factor; survival factor; cytotoxic factor;
 KW differentiation factor; neuroepithelial; hormone; cell receptor;


```
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
|
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTGCTGGTGGCGCA 924
|
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
|
Db 925 CGAGATCCGTCACACGCTGGCCCTCACCCTCTGGCCCGCGCGCGCTCATGGCGCC 984
|
QY 260 tYrTrpLysArgLeuGlyArgAspAlaLeuSerTrpAspValLeuAlaValGI 280
|
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
|
QY 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
|
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCGCTCCAGCTCCAGGAAGCTGTT 1104
|
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGI 320
|
Db 1105 CACTGACCTTTGAGACCTGGGACTCTCAGACCCCAAGAGGCCCTCGAAACGACGG 1164
|
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
|
Db 1165 CCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
|
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
|
Db 1225 CATTTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
|
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
|
Db 1285 TCACCTGCGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
|
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
|
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCCGGGGCCCAA 1404
|
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
|
Db 1405 GCAGTGTGGGGTCTCCACAGCTGTGGCGGCGAGGGGCTTGGCCCGCATCTCTGACGC 1464
|
QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa 440
|
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
|
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGI 460
|
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
|
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
|
Db 1585 AGGCATCCCTGAGGAGTTCAGGGGCGCTTGGCGAGGCCGATGGCTCCATCATCTTCTT 1644
|
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
|
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAAGGCGCAAACTGCAGGCAACCACTCGGGCGG 1704
|
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
|
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGGCATGGCAATCGGGAGGCGCCCTGTT 1764
|
QY 520 e 520
|
Db 1765 C 1765

RESULT 226
ADI80932
ID ADI80932 standard; cDNA; 1985 BP.
XX
AC ADI80932;
XX
DT 15-APR-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #72.
```

```
XX Human, gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX Homo sapiens.
XX US2003207361-A1.
XX 06-NOV-2003.
XX 08-MAY-2002; 2002US-00141759.
XX 03-MAR-2000; 2000US-0187202P.
XX 30-MAY-2000; 2000WO-US014941.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2004-010597/01.
XX P-PSDB; ADI80933.
XX New nucleic acid encoding a secreted and transmembrane PRO polypeptide
XX useful for stimulating the release of tumor necrosis factor alpha from
XX human blood and in treating and detecting a tumor.
XX Claim 2; Fig 143; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumor necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems, PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence encodes a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from
XX the USPTO website at seqdata.uspto.gov.
```


PF 07-MAY-2002; 2002US-00140927.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2004-090467/09.
DR P-PSDB; ADG09676.
XX
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
XX Claim 2; SEQ ID NO 143; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG09675 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGCGTGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCGCCAGCCCCGCGAGCGCGAGCCAGGAGCTGCGCAGAGCGCGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCCAAGAGCTCCCACTCCCACTCGATTACG 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGAGTACCTGTTCAGCGCGGTGTTCGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAspSerTyrAla 100
DB 446 GCCACCCCTGGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATCGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATCAGCGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCCTACCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTGCCGGAGCGGAGCTTGGGGCGCGCTGCGCGCCCTTCCAG 685
QY 160 rCysGlyValaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCCCCAGCACAGGCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCAGCTTCTCCAAAGGGGACACAAACATGGGTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyValaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGTCTCCTAGCGCGCGCGCAACCTGTTCGTGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACAGCTTGGCCTCACCCACTCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGTGGCGCGCGAGCGCTGCTCAGCTGGGACACGCTGCTGGCGTCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGAGGCGCCCTGAAACGCGAGG 1164
QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTTAATATCTGCCACTCTTCCTTCGATGCCATCCTCAGTAGACAGGCAACAGCACTGA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCCCCCAACATTGAGGCTCGGCAGTGTCAIT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGCCCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACACAGCTGTGCGGGCAGGGGGCTGCCCCGCCCATCTCTGACGC 1464

QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLeuLeuGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCTATCTCTTCAAGGCTGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTCAGGACTGGGG 1584
QY 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGTTCAGCGCGCTTCGCGAGCCGCGATGGCTCATCTCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGAGCCAACTGCAGGCAACCACTCGGGCG 1704
QY 500 GTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 228
AD115146
ID AD115146 standard; cDNA; 1985 BP.
XX AD115146;
AC AD115146;
XX
DT 22-APR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
rectum; kidney; cervix; liver; microvascular endothelial cell;
glucose uptake modulator; FFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
XX
PN US2003207382-A1.
XX
XX 06-NOV-2003.
XX
PF 21-MAY-2002; 2002US-00152381.
XX
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2004-032742/03.
DR
DR P-PSDB; AD115147.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 143; 647pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservativeness: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0
US-10-791-980-6 (1-520) x AD115146 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGCGCGCTCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGAGCGCGAGCGGAGCGAGAGCTGCGCAAGAGCGGCGGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCCACTGTACCTGTGCGGGCGGTGTGGACCC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCAGATGACTCGTCCCGCTGCGGGGTGTACAGATACCAACAGTGTATGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAA 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140

Db 566 AAACGCTTTGCAAGCAAGTAAACAAATGGTTACAGCAGCAGCTCTCTCCTACCGCCTGGTG 625
Qy 141 AenTrrpProGluuHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTACGATCTGCGGAGCGCGAGTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArqTrrpSerSerGlyArqProGlnProGlnAlaProLeuTh 180
Db 686 TTTGTGAGCAACGCTCTACGCGTGGAGTTCGGAGGGCCCCAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLyGlyThrThrThrMetGlyTrrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGAGCACCACAGGATGGCTGGGCAATGCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrrpArqTrrpProPheLeuProArqArgGlyGlyAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTGCGGACGCTTC-CTGCCCGCGCGCGGAGGCGCACTTCGAGCA 864
Qy 220 nAspGluArqTrrpSerLeuSerArqArgGlyArqGlnPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGGCGCAACCTGTTGGTGGTCTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArqAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACCACTCGCCGCGCGCGCGCTCATGCGGCC 984
Qy 260 oTrrpTrrpArqLeuGlyArqAspAlaLeuLeuSerTrrpAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGTCTAGCTGGGACGAGCTGTGGCGGTCA 1044
Qy 280 nSerLeuTrrpGlyLeuProLeuGlyGlySerValAlaValGlnLeuProGlyLeuLeuPh 300
Db 1045 GAGCTGTATGGAGAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrrpAspSerLySerProGlnGlyArqArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGACGCCCGCCAGGAGGCGCTGAAACGCGAGG 1164
Qy 320 yProlystTrrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACGTCCACTCTCTCCATGCCATCACTGTAGACAGGCAACGCACTGTA 1224
Qy 340 rIlePheLyGlySerHisPheTrrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArqTrrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTCCGGCTGCCCGCCCAACATTGAGGCTGGCGGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTrrpPhePheLyGlyGlyArqCysTrrpArqPheArqGlyProly 400
Db 1345 GAATGATGGAGATTTCTACTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArqHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACACAGCTGTGGGGAGGGGGCTGCCCCGCCATCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArqArgLeuIleLeuPheLyGlyAlaArqTrrpTrrpVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrrpTrrpProArgSerLeuGlnAspTrrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGCAAGCTGCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTTCAGCGGCGCTGCCGAGGCGCCGATGCTCCATCACTTCTT 1644
Qy 480 eArgAspAspArqTrrpTrrpArgLeuAspGlnAlaLyLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTGCGCGCTTCGACGAGGCCAAACTGCGAGGCCAACCACTCGGGCGG 1704

Qy 500 gTrrpAlaThrGluLeuProTrrpMetGlyCysTrrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 229
ADG09023
ID ADG09023 standard; cDNA; 1985 BP.
XX
AC ADG09023;
XX
DT 22-APR-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2004009547-A1.
XX
PD 15-JAN-2004.
XX
PF 23-APR-2002; 2002US-00128692.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032878.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TR, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WP1; 2004-090466/09.
DR P-PSDB; ADG09024.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; SEQ ID NO 143; 658pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMBC cells, for inhibiting the binding of
CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for treating
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome

CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.

XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1.93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservatives: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADG09023 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 DB 205 ATGGTCGCGCGTGGCTCTCTGCTGCGCGCTGCTACTGTGGGCGCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
 DB 266 GAGCGCCAGCCGCGAGCGCGAGCGCGAGCTGCGCAAGGCGCGGAGCATTCCTA 325
 QY 41 GluLeuTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 326 GAGAGTACGGATACCTCAATGACACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 DB 386 GATGCCATCAGACGCTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGTGTGGACCG 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 446 GCCACCTCGCGCAGATGACTCGTCCCGCTCGGGGTGTACAGATACCAACAGTATATCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgGly 120
 DB 506 GCCTGGCTGAGAGNATCAGTACTTGTGTGTAGACCCGACCCCAAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACTCTCCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCTTGAGCATCTGCGGAGCGCGGAGTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAAGTCTCAGCGTGTGGAGTTCGGAGGCCCGCCAGCCAGGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrPalaMetProLeuMetAl 200
 DB 746 ATCCGCTCACCTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGCG 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
 DB 806 CCAGGGGGCGCGCTGGCGACGCCCTTC-CTGGCCCGCGCGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCCCTGGTCTCTGAGCGCGCGCGCGGCGCAACCTTGTGTGGTGTCTGGCGCA 924
 QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260

DB 925 CGAGATCGGTCAACACGCTTGGCTTCCACCCACTCGCGCGCGCGCGCTCATGGCGC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
 DB 985 CTACTTACAGAGGCTGGGCGCGACGCGCTGCTAGCTGGGACGACGTGCTGGCGTGA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCCTGTATGGAAAGCCCTAGGGGCTCAGTGGCGCTCCAGTCCCAAGAAAGCTGT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCAGAGCCCAAGGAGCGCCCTTGAACACGCGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1165 CCTAAATACGCCACTCTTCTTCATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 DB 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCATGTCT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCTGCCCGCATCTCTGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 DB 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCCCAAGTGTGACAGCTGG 1584
 QY 460 yGlyIleProGluGluValSerGlyValLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTCAGGAGGTGACGGCGCTGCCGAGGCGCGATGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAAACTGCAGGCAACCCACCTCGGGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGAGGCGCCCTGT 1764
 QY 520 e 520
 DB 1765 C 1765
 RESULT 230
 ADI14478
 ID ADI14478 standard; cDNA; 1985 BP.
 XX
 AC ADI14478;
 XX 22-APR-2004 (first entry)
 DT
 DE Novel human secreted and transmembrane protein PRO4339 cDNA.
 KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;
 KW glucose uptake modulator; PFA uptake modulator; cell proliferation;


```
Db      1165  |||||CCCTAAATAGTCCCACTTCTCTCGATGCCATCTAGTGTAGACAGCAACAGCACTGTA 1224
Qy      340  |||||rilePheLySGlySerHisPheTrpGluValaAlaAAspGlyAAsnValSerGluProAr 360
Db      1225  |||||CATTTTAAAGGAGGCATTTCTGGGAGGTGGCAGCTGATGGCAACGTTCTCAGAGCCCG 1284
Qy      360  |||||gProLeuGlnGluArGTrpValGlyLeuProAAsnIleGluAlaAAlaValSerLe 380
Db      1285  |||||TCCACTGCAGGAAGATGGTGGGCTGCCGCCAACATTTAGGCTGCCGCGAGTGCATT 1344
Qy      380  |||||uAAspGlyAAspPheTrpPhePheLySGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345  |||||GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy      400  |||||sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  |||||GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCCCTGCCCGGCCATCTCTGACGC 1464
Qy      420  |||||aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLySGlyAlaArgTrpTyVa 440
Db      1465  |||||CGCCCTCTTCTTCCCTCTCTGGCGCCCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
Qy      440  |||||lleuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
Db      1525  |||||GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTCAGGACTGGGG 1584
Qy      460  |||||yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  |||||AGGCATCCCTGAGGAGTGCAGCGGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy      480  |||||eArgAspAspArgTyTrpArgLeuAspGlnAlaValLeuGlnAlaThrSerGlyAr 500
Db      1645  |||||CCGAGATGACCGCTACTGGCGCTCGACGAGCCAACTGCAGGCAACCACTTCGGGCGG 1704
Qy      500  |||||gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAAsnSerGlySerAlaLeuPh 520
Db      1705  |||||CTGGGCCACCGAGTGCCTCGATGGCTGCTGGCATGCCAACTGGGGAGCGCCCTGTT 1764
Qy      520  e 520
Db      1765  c 1765

RESULT 231
ADI18073
ID      ADI18073 standard; cDNA; 1985 BP.
XX
AC      ADI18073;
XX
DT      22-APR-2004 (first entry)
XX
DE      Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW      Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW      transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW      chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW      rectum; kidney; cervix; liver; microvascular endothelial cell;
KW      glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW      cell differentiation; skeletal muscle cell; adipocyte cell;
KW      pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW      endothelial cell tube formation; bone disorder; cartilage disorder;
KW      sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW      rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW      immune system cell infiltration; chromosome mapping; gene mapping;
KW      gene therapy; chromosome identification; chromosome marker; gene; as.
OS      Homo sapiens.
XX
PN      US2003207349-A1.
XX
PD      06-NOV-2003.
XX
PF      03-MAY-2002; 2002US-00137867.

31-MAR-1997; 97WO-US005230.
12-JUN-1998; 98WO-US012456.
14-JUL-1998; 98WO-US014552.
28-AUG-1998; 98WO-US017888.
10-SEP-1998; 98WO-US018824.
14-SEP-1998; 98WO-US019093.
14-SEP-1998; 98WO-US019094.
14-SEP-1998; 98WO-US019177.
16-SEP-1998; 98WO-US019330.
17-SEP-1998; 98WO-US019437.
07-OCT-1998; 98WO-US021141.
29-OCT-1998; 98WO-US022991.
29-OCT-1998; 98WO-US022992.
01-NOV-1998; 98WO-US024855.
01-DEC-1998; 98WO-US025108.
05-JAN-1999; 99WO-US000106.
08-MAR-1999; 99WO-US005028.
10-MAR-1999; 99WO-US005190.
20-APR-1999; 99WO-US008615.
14-MAY-1999; 99WO-US010733.
02-JUN-1999; 99WO-US012252.
01-SEP-1999; 99WO-US020111.
08-SEP-1999; 99WO-US020594.
13-SEP-1999; 99WO-US020944.
15-SEP-1999; 99WO-US021090.
15-SEP-1999; 99WO-US021547.
05-OCT-1999; 99WO-US023089.
29-NOV-1999; 99WO-US028214.
30-NOV-1999; 99WO-US028313.
30-NOV-1999; 99WO-US028409.
01-DEC-1999; 99WO-US028301.
01-DEC-1999; 99WO-US028634.
02-DEC-1999; 99WO-US028551.
02-DEC-1999; 99WO-US028564.
02-DEC-1999; 99WO-US028565.
16-DEC-1999; 99WO-US030095.
20-DEC-1999; 99WO-US030911.
20-DEC-1999; 99WO-US030999.
22-DEC-1999; 99WO-US030720.
30-DEC-1999; 99WO-US031243.
30-DEC-1999; 99WO-US031274.
05-JAN-2000; 2000WO-US000219.
06-JAN-2000; 2000WO-US000277.
06-JAN-2000; 2000WO-US000376.
11-FEB-2000; 2000WO-US003565.
18-FEB-2000; 2000WO-US004341.
18-FEB-2000; 2000WO-US004342.
22-FEB-2000; 2000WO-US004414.
24-FEB-2000; 2000WO-US004914.
24-FEB-2000; 2000WO-US005044.
01-MAR-2000; 2000WO-US005601.
02-MAR-2000; 2000WO-US005746.
10-MAR-2000; 2000WO-US005841.
15-MAR-2000; 2000WO-US006319.
15-MAR-2000; 2000WO-US006884.
20-MAR-2000; 2000WO-US007377.
21-MAR-2000; 2000WO-US007532.
30-MAR-2000; 2000WO-US008439.
17-MAY-2000; 2000WO-US013705.
22-MAY-2000; 2000WO-US014042.
30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
```

28-FEB-2001; 2001WO-US006520.
 01-MAR-2001; 2001WO-US006666.
 09-MAR-2001; 2001US-00802706.
 14-MAR-2001; 2001US-00808689.
 22-MAR-2001; 2001US-00816744.
 05-APR-2001; 2001US-00828366.
 10-MAY-2001; 2001US-00854208.
 18-MAY-2001; 2001US-00860216.
 25-MAY-2001; 2001US-00866028.
 25-MAY-2001; 2001US-00866034.
 01-JUN-2001; 2001WO-US017092.
 01-JUN-2001; 2001US-00872035.
 01-JUN-2001; 2001WO-US017800.
 05-JUN-2001; 2001US-00874503.
 14-JUN-2001; 2001US-00882636.
 19-JUN-2001; 2001US-00886342.
 20-JUN-2001; 2001WO-US019692.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 06-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 (GETH) GENENTECH INC.
 Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Geritseen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI; 2004-051513/05.
 P-PSDB; ADI18074.
 New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PRO978, useful in molecular biology, chromosome and gene mapping, in
 generating antisense RNA and DNA, and in gene therapy.
 Claim 2; SEQ ID NO 143; 638pp; English.
 The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
 cells, for stimulating differentiation of adipocyte cells, for
 stimulating proliferation of or gene expression in pericyte cells, for
 stimulating the proliferation of inner ear utricular supporting cells or
 T-lymphocyte cells, for inducing endothelial cell tube formation and for
 treating various bone and/or cartilage disorders such as sports injuries
 and arthritis. PRO polypeptides which stimulate the release of
 proteoglycans from cartilage are useful for treating sports-related joint
 problems, articular cartilage defects, osteoarthritis and rheumatoid
 arthritis. PRO polypeptides are also useful for treating various
 mammalian haemoglobin-associated disorders such as various thalassemias
 and conditions which may benefit from enhanced local immune system cell

CC infiltration. This sequence represents a human PRO polynucleotide of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;
 Alignment Scores:
 Pred. NO.: 1,93e-149 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservativity: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 12 Gaps: 0
 US-10-791-980-6 (1-520) x ADI18073 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGCGCGTGGCTCTCTCTGCGGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCCGAGCCCGCGAGCGCGAGCGAGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
 QY 41 GlulysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAGTACGGATACCTCATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGGTTTTCAGTGGGTGCTCCAGCTACTGTGTCAGCGCGGTGTTGGACGCG 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTATACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
 Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTGTGTAGACACCGGACCAAAATGAGGGGTAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
 Db 626 AACTGGGCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGCTGCGCGCCCTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACTTCTTCAAGGGGAGCACAAACATGGCTGGGCAATGCTTGTATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGly 220
 Db 806 CCAGGGGGCGCCCTGGGCGCAGCCCTTC-CTGCCCGCGCGGCGGAGCGCACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
 Db 865 AGATGAGCGTGGTCCCTGAGCCCGCGGGGCGCAACTGTTCGTGGTGTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTCAACACGCTGGCTCAGCCCACTCCCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrIleArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValIgl 280
 Db 985 CTACTACAAGAGGTGGGCGCGGCGCGTGTCTCAGCTGGGAGCGAGCTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300

```

Db      1045  |||||GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy      300  eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db      1105  CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGAAACGACGAGG 1164
Qy      320  yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCTTAATACTGCACCTCTTCTTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheThrTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG 1284
Qy      360  gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTTAGGCTGCGGCACTGTTCATT 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTyrTrpArgPheArgGlyProLy 400
Db      1345  GAATGATGAGATTTCTACTCTTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGCCATCTCTGACGC 1464
Qy      420  alaLeuPhePheProProLeuArgArgLeulleLeuPheLysGlyAlaArgTyrTrVa 440
Db      1465  CGCCCTCTTCTTCCCTCTCTTGGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTACGT 1524
Qy      440  lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db      1525  GCTGGCCCCAGGGGGACTGCAGTGGAGCCCTACTACCCCGGAGTCTCGAGACTGGGG 1584
Qy      460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCCGAGGCGCGATGGCTCATCTCTTCT 1644
Qy      480  eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTGCGCTCGACCGGCGCAAACTGCAGGCAACCACTCGGGCGC 1704
Qy      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCGCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 232
ID      ADJ63354 standard; cDNA; 1985 BP.
XX
AC      ADJ63354;
XX
DT      20-MAY-2004 (first entry)
XX
DE      Novel human secreted and transmembrane protein PRO4339 cDNA.
XX
KW      Human; secreted and transmembrane protein; PRO; gene; ss;
KW      Glucose uptake modulator; FFA uptake modulator;
KW      cell proliferation stimulator; cell differentiation stimulator;
KW      cell differentiation inhibitor; cytokine release stimulator; tumour;
KW      lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW      cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW      gene therapy; chromosome identification; chromosome marker.
XX
OS      Homo sapiens.
XX
PN      US2004039164-A1.

```

```

XX
PD      26-FEB-2004.
XX
PF      30-MAY-2002; 2002US-00158787.
XX
PR      05-JUN-2000; 2000US-0209832P.
PR      01-DEC-2000; 2000WO-US032678.
PR      19-DEC-2001; 2001US-00028072.
XX
PA      (GETH ) GENENTECH INC.
XX
PI      Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI      Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI      Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR      WPI; 2004-203291/19.
XX      P-PSDB; ADJ63355.
XX
PT      New PRO polypeptides and nucleic acids, useful in gene therapy, as
PT      molecular weight markers for protein electrophoresis, as hybridization
PT      probes or as therapeutic agents.
XX
PS      Claim 2; SEQ ID NO 143; 650pp; English.
XX
CC      The invention describes 305 nucleic acids encoding PRO (secreted and
CC      transmembrane) polypeptides (I). (I) is useful for stimulating the
CC      release of TNF-alpha from human blood, for modulating the uptake of
CC      glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC      stimulating the proliferation or differentiation of chondrocyte cells,
CC      for stimulating the proliferation of or gene expression in pericyte
CC      cells, for stimulating the release of proteoglycans from cartilage, for
CC      stimulating the proliferation of inner ear utricular supporting cells,
CC      for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC      the release of a cytokine from PBMC cells, for inhibiting the binding of
CC      A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
CC      cells, for stimulating proliferation of endothelial cells, for detecting
CC      the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC      prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC      are useful for isolating genomic and cDNA nucleotide sequences or
CC      antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC      in assays to identify other proteins or molecules involved in binding
CC      interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC      and gene mapping, in generation of antisense RNA and DNA, in the
CC      preparation of PRO polypeptide, for generating transgenic animals or
CC      knockout animals which in turn are useful in the development and
CC      screening of therapeutically useful reagents, in gene therapy, for
CC      chromosome identification, as chromosome marker, and for generating
CC      probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC      detecting its expression in specific cells, tissues or serum, and for
CC      affinity purification of PRO from recombinant cell culture or natural
CC      sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC      a novel human secreted and transmembrane PRO polypeptide.
XX
SQ      Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

```

```

Alignment Scores:
Pred. No.:      1,93e-149      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      98.52%      Indels:      2
DB:              12      Gaps:      0

US-10-791-980-6 (1-520) x ADJ63354 (1-1985)

Qy      1  MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db      206  ATGTGCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy      21  AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GACGCCACCGCGGAGCGGAGGAGGAGCTGCCAAGGAGGCGGAGGATTCCTTA 325

```

QY 41 GluLysTyrGlyTyrLeuAsnGluInValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCAGACTACCTGTGAGCGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCGCAGATGACTCGTCCCGCTCGGGGTTTACAGATACCAACAGATTATGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCTCGGGCTGAGAGATCAGTACACTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAAGCAGCACCTTCTTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTGCGGAGCGCGCAGTTGCGGGCGCGTTCGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGAGGTTCGGGAGGCCCCACAGCGCCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTGCGGCACGCCCTTC-CTGCCCGCGCGCGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGCGCAACCTGTTCGTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGTGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGGCGCGGACGCGCTGTCTAGCTGGGACGACGTGCTGGCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTTCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCCTACAGCCCCCAAGGAGCGCCCTGAAACGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCCACTCTCTCCGTGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGCCATTCTGGAGGTGGCAGCTGATGGCAACGTCCTAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
DB 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCCCAACTGATGAGCTGCGGAGTGTCAATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyClyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTCTTCCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420

DB 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCGCCCATCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCTCTTCTTCTCTCTCTGCGCGGCTCATCTCTTCAAGGGTGCCTACTAGCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCGAGGGAGCTGCAAGTGGAGCCCTACTACCCCCAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGAGGTACGCGCGCCCTGCCAGGCCCATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCCTCGACCAGGCCAACTGCAGGCNAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 c 1765
RESULT 233
ADJ77249
ID ADJ77249 standard; cDNA; 1985 BP.
XX ADJ77249;
AC ADJ77249;
DT 20-MAY-2004 (first entry)
XX Human PRO polynucleotide #72.
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS US2004038336-A1.
XX 26-FEB-2004.
XX 13-MAY-2002; 2002US-00144993.
XX 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI: 2004-203226/19.
DR P-PSDB; ADJ77250.
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT for detecting the presence of a tumor in a mammal or as therapeutic
XX targets for treating cancer, diabetes, obesity or arthritis.

Claim 2; SEQ ID NO 143; 637bp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1,936-149	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	12	Gaps:	0

US-10-791-980-6 (1-520) x ADJ77249 (1-1985)

QY	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu	20
DB	206	ATGGTTCGGCGCGTGGCCCTCTGTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
QY	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
DB	266	GAGCCCGACCGCGGAGCGCGGAGCCAGGAGCTGGCGAAGGGCGGAGGCATTTCCTA	325
QY	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
DB	326	GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCCATCTGATTCAGC	385
QY	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg	80
DB	386	GATGCCATCAGACGTTTCAGTGGGTGTCCTGAGCTACCTGTGAGGGGGTGTGGACCGC	445
QY	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
DB	446	GCCACCTCGCGCAGATGACTCGTCCCGCTCGGGGTGTACAGATACCAACAGTTATGCG	505
QY	101	AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys	120
DB	506	GCTGGGCTGAGAGGATCAGTGACTGTTGTTGTAGACACCGGACCAAAATGAGGGCTAAG	565
QY	121	LysArgPheAlaLysGlnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140

DB	566	AAACCGCTTTGCAAGCAAGGTAACTAATGGTACAGCAGCCTCTCTTACCGCTGGTG	625
QY	141	IenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
DB	626	AACTGGCTAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTGGCGCGCTTCCAG	685
QY	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuPh	180
DB	686	TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCGGAGGGCCCCAGCCACAGCCCGCTGAC	745
QY	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
DB	746	ATCCGGCTCACCTCTTCCAGGGGACACACAGATGGCTGGCAATGCTTGTATGCG	805
QY	200	aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG	220
DB	806	CCAGGGGGCGCTGGCGCAGCCCTTC-CTGCGCGCGCGCGCGAGCGCACTTCGACCA	864
QY	220	nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi	240
DB	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTTGTGTGTGGTGGCGCA	924
QY	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
DB	925	CGAGATCGTCCACACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC	984
QY	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG	280
DB	985	CTACTACAAGAGGCTGGGCGCGCGCGCTGTCTAGCTGGGAGCAGCTGTGCGCGTGA	1044
QY	280	nSerLeuTyrGlyLysProLeuGlyLysValValAlaValGlnLeuProGlyLysLeuPh	300
DB	1045	GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT	1104
QY	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG	320
DB	1105	CACGTACTTTCAGACCTGGGACTCTACAGCCCCCAGGAGGCGCCCTGAAACCGAGG	1164
QY	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
DB	1165	CCCTAAATACTGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
QY	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
DB	1225	CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTATGCAACAGTCTTCAGAGCCCG	1284
QY	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
DB	1285	TCCACTGGAGGAAGATGGGTGGGGTGCCTCCCNACATTGAGGCTGGGCGAGTGTATT	1344
QY	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy	400
DB	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGTCTGGAGTTCGCGGGCCCCAA	1404
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl	420
DB	1405	GCCAGTGGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCCCCCCTATCTCTGAGCGC	1464
QY	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
DB	1465	CGCCCTCTTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524
QY	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG	460
DB	1525	GCTGGCCGAGGGGAGTGCAGAGTGGAGCCCTACTACCCCCAGAGTCTGCAGGACTGGG	1584
QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
DB	1585	AGGCATCCCTGAGGAGGTACGCGCGCGCTGCCAGGGCCGATGGCTCCATCATCTTCTT	1644
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500

XX PD 25-MAR-2004.
 XX PF 06-MAY-2002; 2002US-00140024.
 XX XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022992.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 10-MAR-1999; 2000WO-US006319.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 18-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 01-MAR-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 15-MAR-2000; 2000WO-US005841.
 PR 20-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX XX
 PA (GETH) GENENTECH INC.
 XX XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
 XX XX
 DR WPI. 2004-345770/32.
 DR P-PSDB; ADM42232.
 XX XX
 PT New isolated PRO polypeptide, PRO182, PRO365, or PRO198 polypeptide for
 PT modulating uptake of glucose or free fatty acid by skeletal muscle cells
 PT and treating diabetes, or hyper- or hypo-insulinemia.
 XX XX
 PS Claim 2; Fig 143; 650pp; English.
 XX XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADM42231 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGCGCGGTCTGCTGTCGCGCCCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGGAGCGCGAGGCGCAGAGCTGGCGAGGAGCGGAGGCATTCTCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCACCTCCACATTCAGC	385
Qy	61	AspAlaLeuArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGCTTTTCAGTGGGTGCCACAGTACCTGTTCAGCGCGGTGTGACGCG	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgProCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTCGCCAGATGACTCGTCCCGCTCGGGGTTCAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGCTGAGAGGATCAGTACATTGTTGTAGACACCGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAATGGTACAAAGCAGCACCTCTCTACCGCCTGGT	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	NACTGGCTGACATCTGCCGAGCGCGGAGTTCCGGGGCGCGTCCGCGCCCTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCGCTGAGTTCTGGAGGCGCCACAGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCCGGCTCACCTCTTCCAGGGGACCAACACGATGGGCTGGGCAATGCCCTTGTATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1	220
Db	806	CCAGGGGGCGCCCTGGCGACGCGCTTC-CTGCCCCGCGCGGAGCGCATTCACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTGTTGGTGTGTCGCGCA	924
Qy	240	sGluLeuGlyHisThrLeuLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CCAGATTCGGTTCACGCTGGGCTCACCCACTCGCCCGCGCGCGCTCATGCGGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1	280

Db	985	CTACTACAGAGGTGGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnG1	320
Db	1105	CACGTACTTTAGACCTGGGACTCCTACGCCCCCAAGGAAGCGCCCTGAAACGACGGG	1164
Qy	320	yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTyr	340
Db	1165	CCCTAATACTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
Qy	360	qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCGAGAAAGATGGGTGCGGCTGCCCCCCCAACATTGAGGCTGCGGAGTGTCAIT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAAATGATGGAGATTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGCTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGCCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1	460
Db	1525	GCTGCGCGAGGGGAGTGCDAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlelePhePh	480
Db	1585	AGGCATCCTCAGGAGGTTCAGCGCGCGCTGCCGAGGCGCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGCGCGCTTCGACCGCCAACTGCAGGCAACCACTCGGGCGG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCGTGGATGGGCTGTGGCATGCACACTCGGGGAGCGCCTGTT	1764
Qy	520	e 520	
Db	1765	c 1765	
RESULT 237			
ADM28093			
ID	ADM28093	standard; cDNA; 1985 BP.	
XX	AC	ADM28093;	
XX	DT	15-JUL-2004 (first entry)	
XX	DE	cDNA encoding human PRO polypeptide #72.	
XX	KW	Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;	
KW	KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;	
KW	KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;	
KW	KW	liver; microvascular endothelial cell; glucose; FFA;	
KW	KW	skeletal muscle cell; adipocyte cell; pericyte cell;	
KW	KW	inner ear utricular supporting cell; T-lymphocyte cell;	
KW	KW	endothelial cell tube formation; bone disorder; cartilage disorder;	
KW	KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX

OS

XX

PN

XX

US2004077064-A1.

XX

PD

XX

22-APR-2004.

XX

17-MAY-2002; 2002US-00147536.

XX

31-MAR-1997; 97WO-US0005230.

PR

12-JUN-1998; 98WO-US012456.

PR

14-JUL-1998; 98WO-US014552.

PR

28-AUG-1998; 98WO-US017888.

PR

10-SEP-1998; 98WO-US018824.

PR

14-SEP-1998; 98WO-US019093.

PR

14-SEP-1998; 98WO-US019094.

PR

16-SEP-1998; 98WO-US019177.

PR

17-SEP-1998; 98WO-US019330.

PR

07-OCT-1998; 98WO-US019437.

PR

29-OCT-1998; 98WO-US022991.

PR

20-NOV-1998; 98WO-US022992.

PR

01-DEC-1998; 98WO-US025108.

PR

05-JAN-1999; 98WO-US000106.

PR

08-MAR-1999; 98WO-US005028.

PR

10-MAR-1999; 98WO-US005190.

PR

10-MAR-1999; 2000WO-US006319.

PR

20-APR-1999; 99WO-US0008615.

PR

14-MAY-1999; 99WO-US001733.

PR

02-JUN-1999; 99WO-US012252.

PR

01-SEP-1999; 99WO-US020111.

PR

08-SEP-1999; 99WO-US020594.

PR

13-SEP-1999; 99WO-US020944.

PR

15-SEP-1999; 99WO-US021090.

PR

15-SEP-1999; 99WO-US021547.

PR

05-OCT-1999; 99WO-US023089.

PR

29-NOV-1999; 99WO-US028214.

PR

30-NOV-1999; 99WO-US028313.

PR

01-DEC-1999; 99WO-US028409.

PR

01-DEC-1999; 99WO-US028301.

PR

01-DEC-1999; 99WO-US028634.

PR

02-DEC-1999; 99WO-US028551.

PR

02-DEC-1999; 99WO-US028564.

PR

02-DEC-1999; 99WO-US028565.

PR

16-DEC-1999; 99WO-US030095.

PR

20-DEC-1999; 99WO-US030911.

PR

22-DEC-1999; 99WO-US030999.

PR

22-DEC-1999; 99WO-US030720.

PR

30-DEC-1999; 99WO-US031243.

PR

30-DEC-1999; 99WO-US031274.

PR

05-JAN-2000; 2000WO-US000219.

PR

06-JAN-2000; 2000WO-US000277.

PR

06-JAN-2000; 2000WO-US000376.

PR

11-FEB-2000; 2000WO-US003565.

PR

18-FEB-2000; 2000WO-US004341.

PR

18-FEB-2000; 2000WO-US004342.

PR

22-FEB-2000; 2000WO-US004414.

PR

24-FEB-2000; 2000WO-US004914.

PR

24-FEB-2000; 2000WO-US005004.

PR

01-MAR-2000; 2000WO-US005601.

PR

02-MAR-2000; 2000WO-US005746.

PR

02-MAR-2000; 2000WO-US005841.

PR

15-MAR-2000; 2000WO-US006884.

PR

20-MAR-2000; 2000WO-US007377.

PR

21-MAR-2000; 2000WO-US007532.

PR

30-MAR-2000; 2000WO-US008439.

PR

17-MAY-2000; 2000WO-US013705.

PR

22-MAY-2000; 2000WO-US014042.

PR

30-MAY-2000; 2000WO-US014941.

PR

02-JUN-2000; 2000WO-US015264.

PR

PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US008520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 (GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 WPI: 2004-340004/31.
 P-PSDB; ADM28094.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PRO4978, useful in molecular biology, chromosome and gene mapping, in
 generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 143; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumour necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 12 Gaps: 0

US-10-791-980-6 (1-520) x ADM28093 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTGGCGCGTGGCTCTGCTGGCGCGCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCGCCAGCCCGGAGCGCGGAGCGCCAGAGCTGCGCAAGAGCGCGGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGAGTCCCCAAAGCTCCACCTCCACATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGTACCTGTGTCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTCGGGGTGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGACGACCTCTCCCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTACGATCTCGCGAGCGCGAGTTCGGGGCGCGTGGCGCGCCCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpAlaThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGTGTGCTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTGTGTCGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACACGCTTGGCCTCACCCATCTCCCGCGCGCGCGCTCAATGGGGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAGAGGTGGCGCGCGCGCTGCTCAGTGGAGACGACGTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACGCCCCCAAGGAGCGCGCTGAAACGCGAGG 1164
QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCTTAATATCTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGAGGAAAGATGGGTGGGCTGCCCGCCCAACATGAGGCTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyVGLYArgCysTrpArgPheArgGlyProLY 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGTGCGATGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGCTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGGCCATCCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAAGTGTGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTACGCGCGCTCCCGAGGCGCGATGGCTCCATCTCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAATGCGAGCAACACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheAlaHisSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCGCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 238
ADI95575
ID ADI95575 standard; cDNA, 1985 BP.
XX AC ADI95575;
XX DT 04-NOV-2004 (first entry)
XX DE cDNA encoding human PRO polypeptide #72.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 XX US2003077659-A1.
 XX
 PD 24-APR-2003.
 XX
 XX 17-APR-2002; 2002US-00124824.
 XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005190.
 PR 20-APR-1999; 98WO-US008615.
 PR 14-MAY-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012252.
 PR 01-SEP-1999; 98WO-US020111.
 PR 08-SEP-1999; 98WO-US020594.
 PR 13-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 22-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031243.
 PR 30-DEC-1999; 98WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2004-020216/02.
 P-PSDB; ADI95576.

Isolated nucleic acid used, e.g. on gene therapy, for chromosome identification, and for generating probes for polymerase chain reaction, has nucleic acid sequence identity to nucleotide sequence that encodes specific amino acid sequence.

Claim 2; Fig 143; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: the
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1985 BP; 403 A; 646 C; 604 G; 332 T; 0 U; 0 Other;

Alignment Scores:
Pred. No.: 1,93e-149 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 13 Gaps: 0

US-10-791-980-6 (1-520) x ADI95575 (1-1985)	
QY	1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
DB	206 ATGGTCGCGCGGCTCGGCTCTCTGTCGCGCGCTCTGCTACTGCTGCGGCGCCACTG 265
QY	21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgGlyGluAlaGluAlaPheLeu 40
DB	266 GACGCCCGCCGCGGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
QY	41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProLysAlaProThrArgPheSer 60
DB	326 GAGAAGTACGGATACCTCAATGAACAGGTCGCCAAAGCTCCACCTCCACTCGATTACGC 385
QY	61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB	386 GATGCCATCAGACGGTTTCAGTGGGTGCCAGCTACCTGTCCAGCGCGCTGTTGGACCGC 445
QY	81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB	446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
QY	101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB	506 GCCTGGGCTGAGAGGATCAGTGACTTTGTTCTAGACCGCGACCAAAATGAGCGGTAG 565
QY	121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB	566 AAACGCTTTCGAAGCAAGTAACAATGGTACAAAGCAGCACCTCTCCTACCGCCCTGGTG 625
QY	141 AsnTrpProGluHisLeu-Leu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB	626 AACTGGGCTGAGCATCTGCGCGAGCGCGAGTTGCGGGCGCGCTGCGCGCGCTCCAG 685
QY	160 rCysGlyValaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB	686 TTGTGGAGCAACAGTCTCAGCGCTGGAGTTCTGGGAGGCCCCCAGGCCACAGCCCGCTGAC 745
QY	180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB	746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGTATGGC 805

QY	200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB	806 CCAGGGGGCGGCGCTGGCGCACGCTTC-CTGGCCCGCGCGCGAGAGCGACATTCACCA 864
QY	220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB	865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCACTGTTGCTGCTGCTGGCGCA 924
QY	240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB	925 CGAGATCGGTCAACGCTTGGCTCACCGCTACCCACCTCGCCCGCGCGCGCTCATATGGCGCC 984
QY	260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB	985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCTGGCCGTGCA 1044
QY	280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB	1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY	300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB	1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGAAACGCGGG 1164
QY	320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB	1165 CCCTAAATACTGCGACATCTTCTTCATGCGCATCTGTTAGACAGGCAACAGCAACTGTA 1224
QY	340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB	1225 CATTTTTAAAGGAGGACCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY	360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB	1285 TCCACTCAGAGAAAGATGGGTGCGGCTGCCCGCCCAACATTTGAGGCTCGCGAGTGTCTT 1344
QY	380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB	1345 GAATGATGGAGATTTCTTACTTCTTCAAGGGGTCGATGCTGGAGGTTCCGGGCGCCCAA 1404
QY	400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB	1405 GCCAGTGTGGGCTCTCCACAGCTGTGCGGCGCAGGGGGCTGCCCGCCCAATCCTGACGC 1464
QY	420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB	1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY	440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB	1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCGCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
QY	460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleLePhePh 480
DB	1585 AGGCATCCCTGAGGAGGTACGCGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY	480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB	1645 CCGAGATGACCGCTACTGCGCGCTCGACCGCCCAAACTGCAGGCAACACCTCGGGCGC 1704
QY	500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB	1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY	520 e 520
DB	1765 c 1765
RESULT 239	
ADI96127	
ID	ADI96127 standard; cDNA; 1985 BP.
XX	
AC	ADI96127;

04-NOV-2004 (first entry)
Novel human secreted and transmembrane protein PRO4339 cDNA.

Human: secreted and transmembrane protein; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose uptake modulator; FFA uptake modulator; cell proliferation; cell differentiation; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia; immune system cell infiltration; chromosome mapping; gene mapping; gene therapy; chromosome identification; chromosome marker; gene; ss.

Homo sapiens.

US2003207354-A1.

06-NOV-2003.

07-MAY-2002; 2002US-00140863.

03-MAR-2000; 2000US-0187202P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Deenoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2004-010591/01.

P-PSDB; ADI96128.

New nucleic acid encoding a secreted and transmembrane PRO polypeptide useful for detecting the presence of a tumor and stimulating the proliferation of inner ear utricular supporting cells.

Claim 2; SEQ ID NO 143; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various

QY 280 nserLeuTyrgLyysProLeuGlyGlySerValaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCTGTATGGAGCCCTAGGGGCTCAGTGGCGCTCCAGTCCCGAGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgProGluThrGlnG1 320
 Db 1105 CACTGACTTTGAGACTCGGACTCTCAGAGCCCGCAGAGAGGGCCCTGAAACGCGAGGG 1164
 QY 320 yProLysTyCySHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
 Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCACCTGCCAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
 QY 380 uAsnAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyProLY 400
 Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCCATCTCCTGACGC 1464
 QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyVa 440
 Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGTGGCCGCTACTACTGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTyProArgSerLeuGlnAspTrpG1 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCGCTTACTACCCCGAGTCTGCAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATPCTTGGAGAGTTCAGCGCGCCCTGCGAGGCCGATGGCTCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACGAGGCCAACTGCAGGCAACCATCTCGGGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCAACTCGGGGAGCGCCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765

RESULT 240
 AAF81736
 ID AAF81736 standard; cDNA; 2241 BP.
 XX
 AC AAF81736;
 XX
 DT 12-JUN-2001 (first entry)
 XX
 DE Human protease and protease inhibitor PPIM-23 encoding cDNA.
 XX
 KW Human; protease; protease inhibitor; protease and protease inhibitor;
 KW PPIM; identification; diagnosis; anti-human immunodeficiency virus; HIV;
 KW antidiabetic; immunostimulant; immunomodulator; antiinflammatory;
 KW antithyroid; immunosuppressive; nephrotropic; antitox; thyromimetic;
 KW cytosaric; antibacterial; fungicide; protozoacide; antiarteriosclerotic;
 KW antiatherosclerotic; antipsoriatic; virucide; hepatotropic; gene therapy;
 KW autoimmune disorder; inflammatory disease; AIDS; Digeorge's syndrome;
 KW severe combined immunodeficiency disease; SCID; Chediak-Higashi syndrome;
 KW Cushing's disease; Addison's disease; autoimmune thyroiditis; gout;
 KW Crohn's disease; diabetes mellitus; Good pasture's syndrome; infection;

KW Grave's disease; Hashimoto's thyroiditis; Sjogren's syndrome; cancer;
 KW Werner's syndrome; cell proliferative disorder; arteriosclerosis;
 KW atherosclerosis; cirrhosis; hepatitis; psoriasis; ss.
 XX Homo sapiens.
 OS
 PN W0200110903-A2.
 XX
 PD 15-FEB-2001.
 XX
 XX 09-AUG-2000; 2000WO-US021878.
 XX
 XX 09-AUG-1999; 99US-0147986P.
 PR 21-OCT-1999; 99US-0160807P.
 XX
 XX (INCY-) INCYTE GENOMICS INC.
 XX
 XX Yue H. Lal P. Tang YT. Bandman O. Baughn MR. Azimzai Y. Lu DAM;
 PI Yang J;
 PI
 DR WPI; 2001-202760/20.
 DR P-PSDB; AAB74690.
 XX
 XX New protease (inhibitors) useful for diagnosis and treatment of
 PT autoimmune/inflammatory disorders such as acquired immunodeficiency
 PT syndrome, Cushing's disease, Addison's disease and cell proliferative
 PT disorders such as cancer.
 XX

Claim 5; Page 131; 134pp; English.

XX AAF81714 to AAF81740 encode the human proteases and protease inhibitors
 CC (PPIMs) given in AAB74668 to AAB74694. The PPIMs can have activities such
 CC as: anti-human immunodeficiency virus (HIV); antidiabetic; antithyroid;
 CC immunostimulant; immunomodulator; antiinflammatory; immunosuppressive;
 CC nephrotropic; antitox; thyromimetic; cytostatic; antibacterial;
 CC fungicide; protozoacide; antiarteriosclerotic; antiatherosclerotic;
 CC virucide; antipsoriatic; and hepatotropic. PPIM polynucleotide and
 CC protein sequences can be used in the diagnosis, treatment and prevention
 CC of autoimmune/inflammatory disorders such as AIDS, Digeorge's syndrome,
 CC severe combined immunodeficiency disease (SCID), Chediak-Higashi
 CC syndrome, Cushing's disease, Addison's disease, autoimmune thyroiditis,
 CC Crohn's disease, diabetes mellitus, Good pasture's syndrome, gout,
 CC Grave's diseases, Hashimoto's thyroiditis, Sjogren's syndrome, Werner's
 CC syndrome, viral, bacterial, fungal, parasitic, protozoal, and helminthic
 CC infections and cell proliferative disorder such as arteriosclerosis,
 CC atherosclerosis, cirrhosis, hepatitis, psoriasis and cancer. PPIM
 CC polynucleotide sequences can be used in somatic or germline gene therapy
 CC and in diagnosis of diseases. They can also be used in generating
 CC hybridisation probes useful in mapping the naturally occurring genomic
 CC sequences and in molecular biology techniques

XX SQ Sequence 2241 BP; 444 A; 705 C; 673 G; 419 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 2.19e-149 Length: 2241
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 4 Gaps: 0

US-10-791-980-6 (1-520) x AAF81736 (1-2241)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 35 ATGTGTCGGCGCGCTCGGCTCTCTGTGCGGCCCTCTGAGTGTCTACTGTGGGCCACCTG 94
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 Db 95 GAGCGCCAGCCCGCGAGCGCGAGGCCAGGAGTGTGCGCAGAGCGGAGCGGAGCATTCCTTA 154
 QY 41 GluLysTyrgLyTyLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60

Db 155 GAGAACTACGGATACCTCAATGACAGAGTCCCAAGAGCTCCACCTCCACTCGATTACG 214
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 215 GATGCCATTCAGACGGTTTTCAGTGGGTGTCCAGCTACCTGTCTAGCGCGGTGTGGACCG 274
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 275 GCCACCTCGCCGAGATGACTGTCTCCCGCTCGGGGTTTACAGATACCAACAGTTATGCG 334
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgArgLys 120
Db 335 GCGTGGGCTGAGAGGATCAGTCACTTGTGTGTAGACACCGGACCAAAATGAGGGCTAAG 394
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 395 AAACGCTTTTGAAAGCAAGGTAAACAATGGTAAAGCAGCACCTCTCCCTACCGCCTGGTG 454
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 455 AACTGGCCTGAGCATCTGCGGAGCGCGCAGTTTCGGGGCGCGTTCGGCGCGCTTCAG 514
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 515 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGGCGCCGCTGAC 574
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 575 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTGTATGGC 634
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 635 CCAGGGGGCGCTGGCGACGCTTC-CTGCGCGCGCGGGGAGCGCACCTTGCACCA 693
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 694 AGATGAGCGCTGCTCCCTCAGCGCGCGCGGGGCAACCTGTTCGTGGTCTGGCGCA 753
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 754 CCAGATCGGTACACGCTTGGCTTCCACCCACTCGCGCGCGCGCGCTCATGGCGCC 813
Qy 260 tTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 814 CTACTACAAGAGCTGGCGCGCGAGCGCTGTCTAGCTGGGACGAGTGTGCGCGTGA 873
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 874 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGGTCCAGCTCCAGGAAAGCTGT 933
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 934 CACTGACTTTGAGACTGGGACTCTACAGCCGCCCAAGGAGGCGCCCTGAAACGCGGG 993
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 994 CCTTAATACTGCCACTCTTCTTGTAGTCCATCTACTGTAGACAGCAGCAACTGTA 1053
Qy 340 rIlePheLysGlySerHisPheThrPgluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1054 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1113
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerle 380
Db 1114 TCACATGCAGGAAAGATGGGTGGGCTGCCCGCCCAACATTTAGGCTGGCGCATGCTCAT 1173
Qy 380 uAsnAspGlyAspPheThrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1174 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGTGATGCTGGAGGTTCGGGGCCCCA 1233
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1234 GCCAGTGTGGGTCTCCCCACAGCTGTGGCGGCGAGGGGCTGCGCGCCATCTCTGACGC 1293

Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1294 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCCTACTACGT 1353
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1354 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1413
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1414 AGGCATCTCTGAGGAGGTGAGCGGCGCTGCGAGGGCCGATGGCTCCATCATCTTCTT 1473
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1474 CCGAGATGACCCCTACTGGCGCTCGACGAGCCAACTGCAGGCAACCACTCGGGCGG 1533
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1534 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1593
Qy 520 e 520
Db 1594 C 1594
RESULT 241
ABK48980
ID ABK48980 standard; cDNA; 2527 BP.
XX AC ABK48980;
XX DT 02-JUL-2002 (first entry)
XX DE cDNA encoding novel matrix metalloproteinase 46798, long form.
XX KW Matrix metalloproteinase; MMP; 46798 long form; heart failure; tumour;
extracellular matrix degradation; cardiovascular disease; metastasis;
atherosclerosis; arthritis; nephritis; neurological disease; ischaemia;
periodontal disease; skin ulceration; liver fibrosis; emphysema; trauma;
fibrotic lung disease; bacterial infection; viral infection; psoriasis;
wound healing; chronic injury; autoimmune disorder; angiogenesis;
tissue invasion; gene; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
CDS 300..1862
FT /*tag= a
FT /*product= "46798"
FT /*note= "Novel matrix metalloproteinase. Specifically
claimed in claim 1"
XX PN WO200220739-A2.
XX PD 14-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028260.
XX PR 08-SEP-2000; 2000US-0231136P.
XX PA (MILL-) MILLENNIUM PHARM INC.
XX PI Curtis RAJ;
XX DR WPI; 2002-351776/38.
XX DR P-PSDB; AAU79810.
XX PT New human matrix metalloproteinase and polynucleotides useful for
diagnosing and treating atherosclerosis, bacterial and viral infections,
wound healing, chronic injury, traumatic, ischemia and psoriasis.
XX PS Claim 1; Fig 1A-D; 133pp; English.
XX

CC The invention describes a novel isolated human matrix metalloproteinase
 CC (MMP) polypeptide (I) 46798. (I) and the polynucleotide encoding it (II)
 CC are useful for evaluating the efficacy of a treatment of a disorder. (I)
 CC is useful as novel diagnostic target and therapeutic agent for
 CC prognosticating, diagnosing, preventing, inhibiting, alleviating or
 CC curing MMP-related disorders, where (I) functions in normal tissues to
 CC facilitate growth, repair, replacement or renewal of endothelial,
 CC epithelial, and neuronal tissues, by remodeling or degrading
 CC extracellular matrix through or into which new endothelial, epithelial,
 CC or neuronal cells must move, grow or proliferate. Examples of the
 CC disorders involving degradation of the extracellular matrix include
 CC cardiovascular diseases e.g. heart failure and atherosclerosis,
 CC arthritis, nephritis, neurological disease, periodontal disease, skin
 CC ulceration, liver fibrosis, emphysema, fibrotic lung disease, bacterial
 CC and viral infections, wound healing, chronic injury, acute disorder
 CC (autoimmune disorder), traumatic, ischemia, psoriasis, aberrant
 CC angiogenesis and tissue invasion and metastasis by tumour cells. This
 CC sequence encodes the long form of the novel human matrix
 CC metalloproteinase 46798 described in the invention
 XX
 SQ Sequence 2527 BP; 480 A; 817 C; 773 G; 457 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.: 2,49e-149 Length: 2527
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 6 Gaps: 0

US-10-791-980-6 (1-520) x ABK48980 (1-2527)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 DB 300 ATGGTCGCGCGGTGGGCTCTCGTGGCGGCTCGACGTCTACTGTGGGGCCACCTG 359
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 DB 360 GACGCCACGCCCGGAGCGCGGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCCTA 419
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 DB 420 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCACCCTCCACATTCAGC 479
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerClyValLeuAspArg 80
 DB 480 GATGCCATCAGAGCGTTTCAGTGGGTGTCCACAGTACCTGTTCAGCGCGGTGTGACCGC 539
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 DB 540 GCCACCTTGGCCACATGCTCTCCCGCTCGCGGGTTACAGATACCAACNGTTATGGG 599
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 DB 600 GCCTGGGCTGAGAGGATCAGTGACTGTGTTGTAGACACCGGACCAAAATGAGGGCTAAG 659
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 DB 660 AAACCGCTTGCNAAGCAAGGTAAACAAATGGTAAACAGACACCTCTCCACCGCTGGTG 719
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 720 NACTGGCTGACATCTCCGGAGCGCGGAGTTCCGGGGCGCGTGGCGCGCCCTTCCAG 779
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 780 TTGTGAGCAACGTCTCAGCGTGGAGTTCTGGGAGGCCACAGCCACAGGCCCGCTGAC 839
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 840 ATCCCGCTCACCTTCTCCAAAGGGGACCAACACGATGGGCTGGGCAATGCCCTTATGCG 899
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220

DB 900 CCAGGGGGCGCCTGGGGCAGCCCTTC-CTGCCCGCGCGCGGAGCGCATCTCGACCA 958
 QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 DB 959 AGATGAGCGCTGGTCCCTGAGCCGCGCGGGCGCAACCTGTTGCTGGTGGCGCA 1018
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 1019 CGAGATCGGTCAACAGCTTGGCCCTACCCACTCGCCCGCGCGCGCTCATGGCGCC 1078
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 DB 1079 CTACTACAAGAGGTGGGCGCGAGCGCTGCTCAGCTGGGACGACGTGGCGGTGCA 1138
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1139 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1198
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 DB 1199 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGAAAGCGCCCTGAAACCACGG 1258
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 DB 1259 CCCTAATATCTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA 1318
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 DB 1319 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1378
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 DB 1379 TCCACTGTCAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCAGTGTCTATT 1438
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1439 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGTTCCGGGGCCCCAA 1498
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1499 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCGCTGCCCGCCATCTCTGACGC 1558
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
 DB 1559 CGCCTCTTCTTCT 1618
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
 DB 1619 GCTGGCCCGAGGGGAGTGCAGAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1678
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1679 AGGCATCTCTGAGGAGGTTCAGCGCGCTCTCCAGGGCCGCTCCAGTGCATCTCTTCT 1738
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar 500
 DB 1739 CCGAGATGACCGCTACTGGCGCTCTCGACAGGCCCAACTGCAGGCAACACCACTCGGGCG 1798
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 DB 1799 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCCGAGGAGCGCCCTGTT 1858
 QY 520 e 520
 DB 1859 C 1859
 RESULT 242
 ABK91096
 ID ABK91096 standard; cDNA; 2527 BP.
 XX
 AC ABK91096;
 XX

29-NOV-2002 (first entry)

cDNA encoding human matrix metalloproteinase (MMP) 46798 #2.

Human; matrix metalloproteinase; MMP 46798; cell proliferation disorder; cell differentiation disorder; carcinoma; sarcoma; leukaemia; breast cancer; lung cancer; neurological disorder; schizophrenia; ischaemia; infarction; Parkinson's disease; Huntington's disease; inflammatory disorder; Crohn's disease; immune disorder; arthritis; diabetes mellitus; cardiovascular disorder; restenosis; tachycardia; rheumatic heart disease; motility disorder; developmental disorder; lung disorder; chronic bronchitis; pulmonary congestion; oedema; blood disorder; blood clotting disorder; cytostatic; immunomodulator; anti-inflammatory; cardiant; antiparkinsonian; nootropic; thrombolytic; neuroprotective; antidiabetic; antirheumatic; antiarthritic; vasotropic; gene; ss.

Homo sapiens.

Key Location/Qualifiers
CDS 300..1862
FT /*tag= a
FT /product= "MMP 46798 #2"
FT /note= "The coding region is specifically claimed in
FT Claim 6"

WO200266670-A2.

29-AUG-2002.

16-JAN-2002; 2002WO-US001546.

16-JAN-2001; 2001US-0262252P.

(MILL-) MILLENNIUM PHARM INC.

Curtis RAJ, Lora JM;

WPI; 2002-674955/72.
P-PSDB; ABG31460.

New human matrix metalloproteinase nucleic acid and polypeptide molecules, designated 46798, useful for diagnosing, preventing or treating cancers, ischemia, Parkinson's disease heart disease or edema.

Claim 6; Page 110-113; 117pp; English.

The present invention relates to the isolation of novel human matrix metalloproteinases (MMP), designated 46798, and the polynucleotide sequences encoding them. The MMP 46798 polypeptide and polynucleotide sequences are useful for diagnosing, preventing, alleviating or treating metalloproteinase-associated disorders such as cell proliferation and/or differentiation disorders (e.g. carcinoma, sarcoma, leukaemia, breast cancer, or lung cancer), neurological disorders (e.g. schizophrenia, ischaemia, infarction, Parkinson's disease or Huntington's disease), inflammatory disorders (e.g. Crohn's disease), immune disorders (e.g. diabetes mellitus or arthritis), cardiovascular disorders (e.g. restenosis, tachycardia or rheumatic heart disease), motility disorders, developmental disorders, lung disorders (e.g. chronic bronchitis, pulmonary congestion or oedema), and blood/blood clotting disorders. The present sequence encodes human MMP 46798 #2

Sequence 2527 BP; 480 A; 817 C; 773 G; 457 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	2,49e-149	Length:	2527
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	6	Gaps:	0

US-10-791-980-6 (1-520) x ABK91096 (1-2527)

Qy 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1379 TCCACTGCAGAAAGATGGGTGGGTGCGCCGCCCAACATTGAGGCTGGCGAGTGCATT 1438
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrPheArgPheArgGlyProLY 400
 Db 1439 GAATGATGGAGATTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1498
 Qy 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1499 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCCCTGCCCGCCATCTGACGC 1558
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
 Db 1559 CGCCCTCTTCTTCTTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1618
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrGl 460
 Db 1619 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1678
 Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1679 AGGCATCCCTGAGAGGTTCAGCGGCGCCCTGCGAGGCGCGATGCTCATCTTCTT 1738
 Qy 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1739 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAACTGCAGGCCAACCCCTCGGGCG 1798
 Qy 500 gTyrAlaThrGluLeuProTyrMetGlyCysTyrHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1799 CTGGGCCACCGAGTCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1858
 Qy 520 e 520
 Db 1859 C 1859
 RESULT 243
 ID ABL57676
 AC ABL57676 standard; DNA; 2275 BP.
 XX ABL57676;
 AC ABL57676;
 XX 15-JUL-2002 (first entry)
 XX Homo sapiens.
 DE Human matrix metalloprotease protein MMP-ABT gene.
 XX Human; MMP-ABT; matrix metalloprotease; cytostatic; anti-inflammatory;
 KW anti-arthritis; gene therapy; cancer; inflammatory disease; arthritis;
 KW Gene; ds.
 XX Homo sapiens.
 OS Homo sapiens.
 FH Key
 FT CDS
 FT Location/Qualifiers
 FT 46..1608
 FT /*tag= a
 FT /product= "MMP-ABT"
 FT polyA_signal
 FT 2203..2208
 FT /*tag= b
 XX US2002031817-A1.
 XX 14-MAR-2002.
 XX 07-SEP-1999; 99US-00391104.
 XX 11-MAR-1997; 97US-00814394.
 XX (FALD/) FALDUTO M T.
 PA (MAGN/) MAGNUSON S R.
 PA (MORG/) MORGAN D W.
 XX Faldueto MT, Magnuson SR, Morgan DW;
 XX

DR WPI; 2002-361182/39.
 DR P-PSDB; ABB77182.
 XX New human matrix metalloprotease gene and protein, useful for diagnosing,
 PT staging, preventing or treating cancer or inflammatory diseases (e.g.
 PT arthritis), as well as in screening drugs for treating these diseases.
 XX Claim 11; Fig 4; 44pp; English.
 XX The sequence encodes a human matrix metalloprotease protein. The
 CC invention relates to a novel polynucleotide, which comprises a nucleotide
 CC sequence encoding a human matrix metalloprotease protein (designated MMP-
 CC ABT). The protein of the invention has cytostatic, anti-inflammatory, and
 CC anti-arthritis activity. The polynucleotide may have a use in gene
 CC therapy. The MMP-ABT polynucleotides and proteins are useful for
 CC detecting, diagnosing, staging, monitoring, prognosing, preventing or
 CC treating cancer or inflammatory diseases (e.g. arthritis). The MMP-ABT
 CC proteins and polynucleotides are also useful developing therapeutic
 CC agents that affect MMP function
 XX Sequence 2275 BP; 466 A; 707 C; 677 G; 425 T; 0 U; 0 Other;
 SQ
 Alignment Scores:
 Pred. No.: 8.62e-148 Length: 2275
 Score: 2764.00 Matches: 514
 Percent Similarity: 99.23% Conservative: 3
 Best Local Similarity: 98.66% Mismatches: 3
 Query Match: 97.53% Indels: 2
 DB: 6 Gaps: 0
 US-10-791-980-6 (1-520) x ABL57676 (1-2275)
 Qy 1 MetValalaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTyrGlyHisLeu 20
 Db 46 ATGGTCGCGCGTCGGGCTTCTGCTGGCGCCCTGCAGTCTCTGTGGGGCCACTG 105
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 106 GACGCCAGCCCGCGAGCGCGAAGCGCAGGAGCTGCGAAGAGGGCGGAGGCATTCTTA 165
 Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 166 GAGAAGTACGGATACCTCAATGAACAGTCCCAAGCTCCCACTCCACATCGATTACG 225
 Qy 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 226 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGTACTCTGTGAGGGCGGTGTGGACGCG 285
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 286 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGTTATCG 345
 Qy 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 346 GCCTGGGTGAGAGGATCAGTACTTGTTCAGACACCGGACCAAAATGAGGCGTAAG 405
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 406 AAACGCTTTGCAAGCAAGGTGACAAATGGTACAGCAGCACCTCTCTACCGCTGTGTG 465
 Qy 141 AsnTyrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 466 NAATGGCCTGAGCATCTCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 525
 Qy 160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 526 TTGTGGAGCAAGCTCTCAGCGCTGAGTTCCTGGAGAGGCCACAGCCAGGCCCGCTGAC 585
 Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
 Db 586 ATCCGCGCTCACCTTCTTCAAGGGGACCAACAGTGGCTGGGCAATGCTTGTATGCG 645
 Qy 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220


```
Db 646 CCAGGGGGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGAATTTTACTTCGACCA 704
Qy 220 nAspGluAtrgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 705 AGATGAGCGTGTCTCTGAGCGCGCCCGCGGCGCAACTCTGTGTGTGTGTGGCGCA 764
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 765 CGAGATCGGTCAACAGCTTGGCTTCAACCACTCGCCCGCGCGCGCTCATGGCGCC 824
Qy 260 oTyTyTyLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db 825 CTACTACAAGAGAGCTGGCGCGCAGCGCTGTCTCAGCTGGGACGACGTGTGGCCGTGCA 884
Qy 280 nSerLeuTyTyGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 885 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 944
Qy 300 eThrAspPheGluThrTrpAspSerTyTySerProGlnGlyArgProGluThrGlnGI 320
Db 945 CACTGACTTTGAGACCTGGGACTCTTACAGCCCGCCAGGAGGCGCCCTGAAACGAGGG 1004
Qy 320 yProLysTyTyCyHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1005 CCCTAAATATGTCACACTTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1064
Qy 340 rIlePheLeuGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1065 CATTTTAAAGGAGGAGCATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1124
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db 1125 TCACCTGCAGGAAGATGGTGGGCTGCCCGCCACATTTAGGCTGGCGCAGTGTCTAT 1184
Qy 380 uAenAspGlyAspPheTyTyPhePheLysGlyArgCyTyTyTrpArgPheArgGlyProLy 400
Db 1185 GAATGATGAGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1244
Qy 400 sProValTrpGlyLeuProGlnLeuCySargAlaGlyGlyLeuProArgHisProAspAl 420
Db 1245 GCCAGTGTGGGGTCTCCCAACAGCTGTGGCGGGCAGGGGGCCCTGCCCGCCATCTTGACG 1304
Qy 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyTyVa 440
Db 1305 CGCCCTCTTCTTCCTCTCTGTGGCGCGCTCATCTCTTCNAGGGTGGCGCTACTACT 1364
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTyTyProArgSerLeuGlnAspTrpGI 460
Db 1365 GCTGGCCCGAGGGGAGCTGCNAGTGGAGCGCTACTACCCCGAAGTCTGCAGAGCTGGGG 1424
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleilePhePh 480
Db 1425 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGGCGAGGCGCGATGGCTCATCTTCTT 1484
Qy 480 eArgAspAspArgTyTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1485 CCGAGATGACCGCTACTTGGCGCTCTGACCAGGCCAATCTGCAGGCCAACCACTTCGGGCG 1544
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCyTyTyHisAlaAenSerGlySerAlaLeuPh 520
Db 1545 CTGGGCGACCGAGCTGCCCTGTGATGGCTGCTGGCATGCAACTCTGGGAGGCGCCCTGT 1604
Qy 520 e 520
Db 1605 c 1605
RESULT 244
ADQ63889
ID ADQ63889 standard; cDNA; 2336 BP.
XX
AC ADQ63889;
XX
```

```
DT 07-OCT-2004 (first entry)
XX Novel human cDNA sequence #1050.
XX ss; gene; osteopathic; neuroprotective; nootropic; antiparkinsonian;
KW cytosolic; gene therapy; diagnostic marker; morbid state; osteoporosis;
KW neurological disease; Alzheimer's disease; Parkinson's disease; dementia;
XX cancer.
XX Homo sapiens.
XX EP1440981-A2.
XX 28-JUL-2004.
XX 21-JAN-2004; 2004EP-00001196.
XX 21-JAN-2003; 2003JP-00102206.
XX 09-MAY-2003; 2003JP-00131392.
XX (REAS-) RES ASSOC BIOTECHNOLOGY.
XX Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
PI Yamamoto J, Isono Y, Nagai K, Irie R;
XX WPI: 2004-535376/52.
DR P-PSDB; ADQ66077.
XX Novel 2495 cDNA, useful for treating osteoporosis, neurological diseases,
PT Alzheimer's diseases, Parkinson's diseases, dementia and various cancers.
XX Claim 1; SEQ ID NO 1050; 2449pp; English.
XX The invention relates to 2495 novel polynucleotides (I) and their encoded
CC polypeptides, sequences hybridizing to these nucleotides, sequences
CC encoding partial polypeptides and sequences having 70% or 90% identity to
CC the nucleotide and protein sequences. The nucleotides and polypeptides
CC are useful as diagnostic markers or therapeutic target for the diseases
CC or morbid states. They are also useful for treating osteoporosis,
CC neurological diseases, Alzheimer's diseases, Parkinson's diseases,
CC dementia and various cancers. This sequence corresponds to a nucleotide
CC sequence of the invention.
XX
SQ Sequence 2336 BP; 423 A; 764 C; 728 G; 421 T; 0 U; 0 Other;
Alignment Scores:
Pred. No.: 2,448-145 Length: 2336
Score: 2721.00 Matches: 508
Percent Similarity: 97.70% Conservative: 1
Best Local Similarity: 97.50% Mismatches: 1
Query Match: 96.01% Indels: 12
DB: 12 Gaps: 1
US-10-791-980-6 (1-520) x ADQ63889 (1-2336)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 331 ATGGTCGGCGCGCTGGCTCTCTGTGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 390
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 391 GACGCCAGCCCGCGAGCGCGGAGAGCTGGCAGGAGCTGGCAGGAGCGGAGGCGCATTCCTA 450
Qy 41 GlutysTyTyGlyTyTyLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 451 GAGAAGTACGGATACCTCAATGAACAGGTGCCAAAGCTCCCACTCCACTCGATTCAGC 510
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 511 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTCTGTTCAGCGGCGGTGTGGACCGC 570
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
```

Db 571 GCCACCTGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 630
 Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 631 GCCTGGGCTGAGAGGATCAGTGACTGTGTTTCTAGACACCGGACCAAAATGAGGCGTAAG 690
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 691 AAACGCTTTGCAAAAGCAAGTAACAAATGGTTACAGCAGCACTCTCTTACCGCTGGTG 750
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 751 NACTGGCTGAGCATCTGCCGAGCGCGGTTCCGGGCGCGCTGCCGCGCTCCAG 810
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 811 TTGTGGAGCAACGTCACAGCGTGGAGTCTGGGAGGCCCCCAGCCAGGCCCCGCTGAC 870
 Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 871 ATCCGGCTCACCTCTTCCAGGGGACCCACACGATGGCTGGGCAATGCTTTGATGGC 930
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 Db 931 CCAGGGGGCGCTGCGGACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 989
 Qy 220 nAspGluArgTrpSerLysSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
 Db 990 AGATGAGCGTGGTCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTGCGCA 1049
 Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 1050 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGCGCGCC 1109
 Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 Db 1110 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGCGCGTGA 1169
 Qy 280 nSerLeuTyrGlyLeuPheProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1170 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGGTCCAGCTCCAGGAAGGTGTT 1229
 Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
 Db 1230 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAGCGCGCTGAACCGCAGGG 1289
 Qy 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1290 CCTTAATATGCACTCTTCTTCGATGCCATCACTGTA----- 1329
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1330 -----GGGAGCAATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1379
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1380 TCCACTGCAGAAAGATGGGTGCGGCTGCCCCCAACATTGAGCTCGGCGCTGTCATT 1439
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
 Db 1440 GAATGATGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCCAA 1499
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1500 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCCCGCCATCTCTGACG 1559
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
 Db 1560 CGCCCTCTTCTTCTCTCTGCGCGGCTCATCTCTTCAAGGGTTCGCGCTACTACTG 1619
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
 Db 1620 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTTACTACCCCGAAGTCTGCAAGGACTGGG 1679

Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1680 AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1739
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1740 CCGAGATGACCGCTACTTGGCGCTCGACCGAGCCAACTGCAGGCACACCTCGGGCG 1799
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1800 CTGGGCCACCGAGCTCCCTGGATGGCTGCTGGCATGCAACTCGGGAGGCGCTGTT 1859
 Qy 520 e 520
 Db 1860 C 1860
 RESULT 245
 ADE07322 standard; DNA; 1983 BP.
 XX ADE07322;
 AC ADE07322;
 XX 29-JAN-2004 (first entry)
 DT Novel coding sequence (useful for identifying genetic disorders) #388.
 DE novel gene; novel protein; tissue marker; molecular weight marker;
 KW chromosome marker; genetic disorder; gene; ds.
 KW Unidentified.
 OS WO2003054152-A2.
 XX 03-JUL-2003.
 PD 10-DEC-2002; 2002WO-US039555.
 PF 10-DEC-2001; 2001US-0339739P.
 PR 11-DEC-2001; 2001US-0339453P.
 PR 14-MAR-2002; 2002US-0365091P.
 PR 14-MAR-2002; 2002US-0365384P.
 PR 12-APR-2002; 2002US-0372381P.
 PR 12-APR-2002; 2002US-0372615P.
 PR 22-APR-2002; 2002US-00128558.
 PR 24-APR-2002; 2002US-0376045P.
 XX (HYSE-) HYSEQ INC.
 XX Tang YT, Asundi V, Goodrich RW, Ren F, Zhang J, Zhao QA, Wang J;
 PI Ghosh M, Xue AJ, Wehrman T, Wang G, Zhou P, Drmanac RI, Wang Z;
 PI Ma Y, Wang D, Chen R, Xu C, Boyle BU;
 XX WPI; 2003-569235/53.
 DR P-PSDB; ADE08233.
 XX New polynucleotides, useful for expressing recombinant proteins for
 PT analysis, characterization or therapeutic use, or as markers for tissues
 PT in which the corresponding protein is preferentially expressed.
 XX Claim 1; SEQ ID NO 388; 1177pp; English.
 CC The invention comprises the amino acid and coding sequences of novel
 CC proteins. The DNA and protein sequences of the invention are useful as:
 CC markers for tissues in which the corresponding protein is preferentially
 CC expressed; as molecular weight markers on gels; as chromosome markers or
 CC tags; to identify chromosomes or to map related gene positions; and to
 CC compare with endogenous DNA sequences in patients to identify potential
 CC genetic disorders. The present DNA sequence represents a gene of the
 CC invention.
 XX Sequence 1983 BP; 357 A; 640 C; 610 G; 376 T; 0 U; 0 Other;

Alignment Scores:

```

Pred. No.:      1.27e-136      Length:      1983
Score:          2566.00        Matches:      507
Percent Similarity: 94.61%    Conservative: 2
Best Local Similarity: 94.24%  Mismatches:    6
Query Match:     90.54%      Indels:       25
DB:              10          Gaps:         3

US-10-791-980-6 (1-520) x ADE07322 (1-1983)

QY      1 MetValAlaArg-ValGlyLeuLeuLeuArgAla-LeuGlnLeuLeuLeuTrp-GlyHis 19
DB      266 ATGGTCGGCGCTGTGGGCTCTCTGTGGCGCCCTTGAGCTGTACTGTGTGGGCCAC 325

QY      20 LeuAspAlaGlnProAlaGluArgGlyGlyGln-GluLeuArgLysGluAlaGluAlaPh 39
DB      326 CTGGAGCCCGAGCCCGGAGCGCGAGGCCAGTGAGCTGCGCAGAGAGCGGAGGCAIT 385

QY      39 eLeuGlu-----lystfyrGlyTyrLeuAsnGluGlnValPr 51
DB      386 CCTAGAGAATGTACTGTGATAGCTCAAGTGAAGCATGTGTCC-----CC 429

QY      51 olysAlaProThrSerThrArgPheSer-AspAlaIleArgAla-PheGlnTrpValSer 70
DB      430 AAATGCTCCACCTCCACTCGATTTCAGCTGATGCCATCAGAGCTGTTTCAGTGGGTGCC 489

QY      71 GlnLeu-ProValSer-GlyValLeu---AspArgAlaThrLeuArgGlnMetThrArgP 89
DB      490 CAGTACCCTGTGAGCTGGCGTGTGTGGACCTGCGCCACCTGCGCCAGATGACTCGTC 549

QY      89 roArgCysGlyValThrAspThrAsnSerTyrAlaAlaTrpAlaGluArgIleSerAspL 109
DB      550 CCGCTCGCGGGTTACAGATACCAACAGTTATGCGGCTTGGCTGAGAGATCAGTGACT 609

QY      109 euPheAlaArgHisArgThrLysMetArgArgLysLysArgPheAlaLysGlnGlyAsnL 129
DB      610 TGTTTGCTAGACACCGGACCAAAATGAGCGCTAAGAAACGCTTTGCAAGCAAGGTAA 669

QY      129 ystfTyrLysGlnHisLeuSerTyrArgLeuValAsnTrpProGluHisLeu-ArgSer 148
DB      670 AATGGTACAGCAGCACCTCTCTACCGCTGTGTGAACCTGGCTGAGCATCTGCCGAGC 729

QY      149 ArgGlnPheGlyAlaProCysAlaProProSerSerCysGlyValaThrSerGlnArgTrp 168
DB      730 CGGAGTTTCGGGGCGCGTGC CGCGCCCTTCAGTTGTGGAGCAACGCTCTCAGCGCTG 789

QY      169 SerSerGlyArgProGlnProGlnAlaProLeuThrSerGlySerProSerSerLysGly 188
DB      790 AGTTCTGGGAGGCCCCAGCCAGCCAGGCCCCGCTGACATCCGGCTCACCTTCTTCCAAGGG 849

QY      189 ThrThrThrMetGlyTTrpAlaMetProLeuMetAlaGlnGlyValaProTrpArgTrpPro 208
DB      850 ACCAACACATGGCTGGGCAATGCTTTGATGGCCAGGGGGCGCCCTGGCGCACGCT 909

QY      209 PheLeuProArgArgGlyGluAlaHisPheAspGlnAspGluArgTrpSerLeuSerArg 228
DB      910 TC-CTGCCCCCGCGCGGGAAGCGACATTCGACCAAGATGAGCGCTGGTCCCTGAGCGCG 968

QY      229 ArgArgGlyArgAsnLeuPheValValLeuAlaHisGluIleGlyHisThrLeuGlyLeu 248
DB      969 CGCCGCGGGCGCAACCTGTGTGCTGGTGTGGCGCACGAGATCGGTACACGCTTGGCCTC 1028

QY      249 ThrHisSerProAlaProArgAlaLeuMetAlaProTyrTyrLysArgLeuGlyArgAsp 268
DB      1029 ACCCACTCCCGCGCGCGCGCTCATGGCGCCCTACTCAAGAGGCTGGCGCGCGAC 1088

QY      269 AlaLeuLeuSerTrpAspAspValLeuAlaValGlnSerLeuTyrGlyLysProLeuGly 288
DB      1089 CGCGCTCTCAGCTGGGACACGCTGTGCTGGCGGTGCAGAGCGCTGTATGGNAGGCCCTAGGG 1148

QY      289 GlySerValAlaValGlnLeuProGlyLysLeuPheThrAspPheGluThrTrpAspSer 308
DB      1149 GGCTCAGTGGCGGTCCAGCTCCAGGAAAGCTGTTTCACTGACTTTTGGAGACCTGGGACTCC 1208

```

```

QY      309 TyrSerProGlnGlyArgArgProGluThrGlnGlnGlyProLysTyrCysHisSerSerPhe 328
DB      1209 TACAGCCCCAAGGAAGGGCCCTGAAACGAGGGGCCCTAAATACTATGCCACTTCTCTTC 1268

QY      329 AspAlaIleThrValAspArgGlnGlnGlnLeuTyrIlePheLysGlySerHisPheTrp 348
DB      1269 GATGCCATCACTGTAGACAGGCAACAGCAACTGTACATTTTAAAGGGAGCCATTCTCG 1328

QY      349 GluValAlaAlaAspGlyAsnValSerGluProArgProLeuGlnGlnArgTrpValGly 368
DB      1329 GAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGCTCCATCGCAGGAAAGATGGTGGG 1388

QY      369 LeuProProAsnIleGluAlaAlaAlaValSerLeuAsnAspGlyAspPheTyrPhePhe 388
DB      1389 CTGCCCCCCNACATTTAGAGCTCGGCAGTGTCTATGAAATGAGAGATTTCTACTTCTTC 1448

QY      389 LysGlyGlyArgCysTrpArgPheArgGlyProLysProValTrpGlyLeuProGlnLeu 408
DB      1449 AAAGGGGTGATGCTGGAGGTTCGGGGCCCCAAGCCAGTGTGGGTCTCCACAGCTG 1508

QY      409 CysArgAlaGlyGlyLeuProArgHisProAspAlaAlaLeuPhePheProProLeuArg 428
DB      1509 TGCCGGGCGAGGGGGCTGCCCCCATCTCTGACGCGCCCTCTTCTTCCCTCTCTCTGCGC 1568

QY      429 ArgLeuIleLeuPheLysGlyAlaArgTyrTyrValLeuAlaArgGlyGlyLeuGlnVal 448
DB      1569 GCCTTCATCTCTTTCNAGGTGCCCGCTACTACGTGTGGCCGAGGGGATGCAAGTG 1628

QY      449 GluProTyrTyrProArgSerLeuGlnAspTrpGlyGlyIleProGluGluValSerGly 468
DB      1629 GAGCCCTACTACCCCGGAAGTTTGAGGACTGGGGAGGATCCCTGAGAGGTGAGCGGC 1688

QY      469 AlaLeuProArgProAspGlySerIleIlePhePheArgAspAspArgTyrTrpArgLeu 488
DB      1689 GCCTTGGCGAGGCGCGATGGCTCCATCATCTTCTTCGAGATGACCGCTACTTGGCGCTC 1748

QY      489 AspGlnAlaLysLeuGlnAlaThrThrSerGlyArgTrpAlaThrGluLeuProTrpMet 508
DB      1749 GACCAAGGCANAACTGACGCAACCACTCGGGCCGCTTGGGCCACCGAGCTGCCCTGGATG 1808

QY      509 GlyCysTrpHisAlaAsnSerGlySerAlaLeuPhe 520
DB      1809 GGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTTT 1844

RESULT 246
AAV08170
ID      AAV08170 standard; DNA; 1717 BP.
XX
AC      AAV08170;
XX
DT      25-JAN-1999 (first entry)
XX
DE      MMP19 coding sequence.
XX
KW      MMP19; matrix metalloprotease 19; human; cancer; arthritis; inflammation;
KW      therapy; diagnosis; ds.
XX
OS      Homo sapiens.
XX
PN      WO9840475-A1.
XX
PD      17-SEP-1998.
XX
PF      11-MAR-1998; 98WO-US004694.
XX
PR      11-MAR-1997; 97US-00814394.
XX
PA      (ABBO ) ABBOTT LAB.
XX
PI      Faiduto M, Magnuson SR, Morgan DW;
XX
DR      WPI; 1998-531521/45.

```

DR P-PSDB; AAW73211.
 XX New isolated human matrix metalloproteinase gene - used to develop products
 PT for the diagnosis, prevention and treatment of e.g. cancer, arthritis or
 PT inflammation.

XX Claim 1; Page 56; 11pp; English.

XX This sequence encodes the human matrix metalloproteinase 19 (MMP19) of the
 CC invention. The DNA, protein, and antibodies against MMP19 can be used in
 CC the diagnosis, prognosis, prevention or treatment of individuals with
 CC conditions associated with the expression of the MMP19 gene, such as
 CC cancer, arthritis or inflammation, or to identify a predisposition to
 CC these conditions. The DNA can be fixed to a substrate and used to detect
 CC the presence of MMP19 in a sample. The sequences can be used to make
 CC primers for use in reverse transcription PCR to detect MMP19, they can
 CC also be used to identify inhibitors of MMP19

XX Sequence 1717 BP; 361 A; 547 C; 494 G; 315 T; 0 U; 0 Other;

Alignment Scores:
 Pred. No.: 1-78e-134 Length: 1717
 Score: 2527.00 Matches: 467
 Percent Similarity: 99.36% Conservative: 0
 Best Local Similarity: 99.36% Mismatches: 2
 Query Match: 89.17% Indels: 2
 DB: 2 Gaps: 0

US-10-791-980-6 (1-520) x AAV08170 (1-1717)

QY	52	LysAlaProThrSerThrArgPheSerAspAlaIleArgAlaPheGlnTrpValSerGln	71
DB	1	AAAGCTCCACCTCCACTCGATTACGCGATGCGATCAGAGCGTTTCAGTGGGTGCCAG	60
QY	72	LeuProValSerGlyValLeuAspArgAlaThrLeuArgGlnMetThrArgProArgCys	91
DB	61	CTACCTGTGAGGGCGTGTGGACCGCGCAACCTGGCCAGATGACTCGTCCCGCTGC	120
QY	92	GlyValThrAspThrAsnSerTyrAlaAlaThrAlaGluArgIleSerAspLeuPheAla	111
DB	121	GGGGTTTACAGATACCAACAGTTATGCGGCTGCGGCTGAGAGGATCAGTACTTGTTC	180
QY	112	ArgHisArgThrIleMetArgArgLysLysArgPheAlaLysGlnGlnValAsnLysTyr	131
DB	181	AGACACCGGACCAAAATAGGCGGTAAAGAACGCTTTGCAAGCAGGTAAACAAATGGTAC	240
QY	132	LysGlnHisLeuSerTyrArgLeuValAsnTrpProGluHisLeu-ArgSerArgGlnPh	151
DB	241	AACGAGCACCCTCTCTACCGCTGGTGGTGAACCTGGCCTGAGCATCTGCGGAGCGGCAGTT	300
QY	151	eGlyAlaProCysAlaProSerSerCysGlyAlaThrSerGlnArgTrpSerSerGln	171
DB	301	CGGGGGCGCGTGGCGCGCGCTTCCAGTTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTCG	360
QY	171	YArgProGlnProGlnAlaProLeuThrSerGlySerProSerSerLysGlyThrThrTh	191
DB	361	GAGCGCCCGGACCCAGCGCCCGCTGATCATCCGCTCACCTTCTTCCAGGGGACCAAC	420
QY	191	rMetGlyTrpAlaMetProLeuMetAlaGlnGlyAlaProTrpArgThrProPheLeuPr	211
DB	421	GATGGGCTGGCAATGCTTTGATGGCCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGGC	479
QY	211	oArgArgGlyGluAlaHisPheAspGlnAspGluArgTrpSerLeuSerArgArgGln	231
DB	480	CCGCGCGCGGGAAGCGACCTTCGACCAAGATGAGCGCTGTCTCCTGAGCCCGCGCGCG	539
QY	231	YArgAsnLeuPheValValLeuAlaHisGluIleGlyHisThrLeuGlyLeuThrHis	251
DB	540	CGCGCAACTGTCTGTGTGTGGCGCACGAGATCGGTACACGCTTGGCCCTCACCCACTC	599
QY	251	rProAlaProArgAlaLeuMetAlaProTyrTyrLysArgLeuGlyArgAspAlaLeuLe	271
DB	600	GCCCGCGCGCGCGCTCATGTGGCGCCCTACTACAGAGGCTGGGCGCGCGCGCTGCT	659

QY	271	uSerTrpAspAspValLeuAlaValGlnSerLeuTyrGlyLysProLeuGlyGlySerVa	291
DB	660	CAGCTGGGACGAGCTGTGGCGTGCGAGAGCTGTATGGGAAGCCCTTAGGGGGCTCAGT	719
QY	291	lAlaValGlnLeuProGlyLysLeuPheThrAspPheGluThrTrpAspSerTyrSerPr	311
DB	720	GGCGTCCAGCTCCAGGAAGCTGTTCACTGACTTTGAGACCTGGGACTCTCTACAGCCC	779
QY	311	oGlnGlyArgArgProGluThrGlnGlyProLysTyrCysHisSerSerPheAspAlaI	331
DB	780	CCAAGGAAGCGCCCTGAACAGCAGGCGCCCTAAATACTGCCACTCTTCTTTCATGCCAT	839
QY	331	eThrValAspArgGlnGlnLeuTyrIlePheLysGlySerHisPheThrGluValAl	351
DB	840	CATGTAGACAGGCAACAGCACTGTACATTTTAAAGGAGGCCATTTCTGGGAGGTGGC	899
QY	351	aAlaAspGlyAsnValSerGluProArgProLeuGlnGluArgTrpValGlyLeuProPr	371
DB	900	AGCTGATGGCAACGTTCTCAGAGCCCGCTCCACTGCAGGAAGATGGGTGCGGCTGCCCC	959
QY	371	oAsnIleGluAlaAlaValSerLeuAsnAspGlyAspPheTyrPhePheLysGlyG1	391
DB	960	CAACATTGAGCGTCCGCGCAGTGTCAATGAATGATGGAGATTTCTACTTCTTCAAGGGGG	1019
QY	391	YArgCysTrpArgPheArgGlyProLysProValTrpGlyLeuProGlnLeuCysArgAl	411
DB	1020	TCGATGCTGGAGGTTCGCGGCGCCCAAGCCAGTGTGGGTCTCCACAGCTGTGCCGGC	1079
QY	411	aglyGlyLeuProArgHisProAspAlaAlaLeuPhePheProLeuArgLeuI1	431
DB	1080	AGGGGGCTGCCCGCCATCTCAGCGCGCCCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT	1139
QY	431	eLeuPheLysGlyAlaArgTyrTrpValLeuAlaArgGlyGlyLeuGlnValGluProTy	451
DB	1140	CCTCTTCAAGGTGCCCGCTACTACGTGTGTCGCGCGCGGAGGACTGCAAGTGGAGCCCTA	1199
QY	451	rTyrProArgSerLeuGlnAspTrpGlyIleProGluGluValSerGlyAlaLeuPr	471
DB	1200	CTACCCCGAAGTCTGCGAGGACTGGGAGGCATCCCTGAGGAGGTGACGCGCGCCCTGCC	1259
QY	471	oArgProAspGlySerIlePhePheArgAspAspArgTyrTrpArgLeuAspGlnAl	491
DB	1260	GAGCGCGGATGGCTCCATCATCTTCTTCCGAGATGACCGCTACTTGGCGCCTCGACCCAGC	1319
QY	491	alysLeuGlnAlaThrThrSerGlyArgTrpAlaThrGluLeuProTrpMetGlyCysTr	511
DB	1320	CAAACTGAGCAACACCACTCGGCGCGCTGGGCCACCGAGCTGCCCTGGATGGGCTGCTG	1379

RESULT 247

ABK48982

ID ABK48982 standard; cDNA; 2310 BP.

XX AC ABK48982;

XX 02-JUL-2002 (first entry)

XX cDNA encoding novel matrix metalloproteinase 46798, short form.

XX Matrix metalloproteinase; MMP; 46798 short form; heart failure; tumour;
 KW extracellular matrix degradation; cardiovascular disease; metastasis;
 KW atherosclerosis; arthritis; nephritis; neurological disease; ischaemia;
 KW periodontal disease; skin ulceration; liver fibrosis; emphysema; trauma;
 KW fibrotic lung disease; bacterial infection; viral infection; psoriasis;
 KW wound healing; chronic injury; autoimmune disorder; angiogenesis;
 KW tissue invasion; gene; ss.
 XX Homo sapiens.

Db 1351 CGCCCTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGGCCCTACTACGT 1410
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1411 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAAGTCTGCAGGACTGGGG 1470
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1471 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCCGAGGCCGATGCTCCATCATCTTCTT 1530
Qy 480 eArgAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1531 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGAGGCAACACACTCGGGCGG 1590
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaLysSerGlySerAlaLeuPh 520
Db 1591 CTGGGCCACCGAGCTGCCCTGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1650
Qy 520 e 520
Db 1651 C 1651
RESULT 248
ABK91095
ID ABK91095 standard; cDNA; 2310 BP.
XX
AC ABK91095;
XX
DT 29-NOV-2002 (first entry)
XX
DE cDNA encoding human matrix metalloproteinase (MMP) 46798 #1.
XX
KW Human; matrix metalloproteinase; MMP 46798; cell proliferation disorder;
KW cell differentiation disorder; carcinoma; sarcoma; leukaemia;
KW breast cancer; lung cancer; neurological disorder; schizophrenia;
KW ischaemia; infarction; Parkinson's disease; Huntington's disease;
KW inflammatory disorder; Crohn's disease; immune disorder; arthritis;
KW diabetes mellitus; cardiovascular disorder; restenosis; tachycardia;
KW rheumatic heart disease; motility disorder; developmental disorder;
KW lung disorder; chronic bronchitis; pulmonary congestion; oedema;
KW blood disorder; blood clotting disorder; cytostatic; immunomodulator;
KW anti-inflammatory; cardiant; antiparkinsonian; nootropic; thrombolytic;
KW neuroprotective; antidiabetic; antirheumatic; antiarthritic; vasotropic;
KW gene; ss.
XX
OS Homo sapiens.
XX
FH Key
FT CDS
FT Location/Qualifiers
FT 317..1654
FT /*tag=a
FT /product= "MMP 46798 #1"
FT /note= "The coding region is specifically claimed in
FT Claim 6"
XX
WO200266670-A2.
XX
PN
XX
PD 29-AUG-2002.
XX
PF 16-JAN-2002; 2002WO-US001546.
XX
PR 16-JAN-2001; 2001US-0262252P.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Curtis RAJ, Lora JM;
XX
DR WPI; 2002-674955/72.
DR P-PSDB; ABG31458.
XX
PT New human matrix metalloproteinase nucleic acid and polypeptide
PT molecules, designated 46798, useful for diagnosing, preventing or
PT treating cancers, ischemia, Parkinson's disease heart disease or edema.
XX
XX

PS Claim 6; Page 102-104; 117pp; English.
XX
CC The present invention relates to the isolation of novel human matrix
CC metalloproteinases (MMP), designated 46798, and the polynucleotide
CC sequences encoding them. The MMP 46798 polypeptide and polynucleotide
CC sequences are useful for diagnosing, preventing, alleviating or treating
CC metalloproteinase-associated disorders such as cell proliferation and/or
CC differentiation disorders (e.g. carcinoma, sarcoma, leukaemia, breast
CC cancer, or lung cancer), neurological disorders (e.g. schizophrenia,
CC ischaemia, infarction, Parkinson's disease or Huntington's disease),
CC inflammatory disorders (e.g. Crohn's disease), immune disorders (e.g.
CC diabetes mellitus or arthritis), cardiovascular disorders (e.g.
CC restenosis, tachycardia or rheumatic heart disease), motility disorders,
CC developmental disorders, lung disorders (e.g. chronic bronchitis,
CC pulmonary congestion or oedema), and blood/blood clotting disorders. The
CC present sequence encodes human MMP 46798 #1
XX
SQ Sequence 2310 BP; 439 A; 749 C; 708 G; 414 T; 0 U; 0 Other;

Alignment Scores: 7.43e-123 Length: 2310
Pred. NO.: 2324.50 Matches: 444
Score: 85.22% Conservative: 0
Percent Similarity: 85.22% Mismatches: 1
Best Local Similarity: 82.02% Indels: 77
Query Match: 6 Gaps: 1
DB:

US-10-791-980-6 (1-520) x ABK91095 (1-2310)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 317 ATGTCGGCGCGTCGCGCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 376
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 377 GACGCCACGCCGCGAGCGCGAGCGAGCTGCGCAAGAGGCGGAGGCATTCCTA 436
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 437 GAGAAGTACGGATACCTCATGAACACAGTCCCCAAAGCTCCACCTCCATTGATCAGC 496
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 497 GATCCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTGTGTCAGCGCGGTGTGGACCGC 556
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 557 GCCACCTGCGCCAGATGACTCGTCCCGGTGCGGGGTACAGATACCAACAGTTATGCG 616
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 617 GCCTGGGCTGACGAGTACGTGACTTGTGCTAGACACCGGACCAAAATCAGGCGTAAG 676
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 677 AAACGCTTTGCAAAAG----- 691
Qy 141 AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSer 160
Db 691 ----- 691
Qy 161 CysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuThr 180
Db 691 ----- 691
Qy 181 SerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAla 200
Db 691 ----- 691
Qy 201 Gln-GlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 692 CAAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGGAGGCGCACTTCGACCA 750

Qy	220	nAspGluuArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	751	AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTCGTGGTGTGGCGCA	810
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	811	CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC	870
Qy	260	oTyrrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	871	CTACTACAAGAGGTGGCGCGCGCGCTGCTCAGCTGGAGCGAGCTGCTGGCGGTGCA	930
Qy	280	nSerLeuTyrrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	931	GAGCCGTGATGGGAAGCCCTAGGGGGCTCAGTGCCGCTCCAGCTCCAGGAAGCTGT	990
Qy	300	eThrAspPheGluThrTrpAspSerTyrrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	991	CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCAAGGAAGGCGCCCTGAAACGCAAGG	1050
Qy	320	yProLysTyrrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy	340
Db	1051	CCCTAAATACTGCCACTCTCTTCGATGCCATCACTGTAGCAGGCCAACAGCAACTGTA	1110
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1111	CAITTTTAAAGGGAGCAATTTTCGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGC	1170
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1171	TCCACTGCAGGAAGATGGGTGGGGCTGCCCGCCCAACATTAGAGCTCGCGCAGTGTCA	1230
Qy	380	uAsnAspGlyAspPheTyrrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1231	GAATGATGGAGATTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTTCGGGGCCCCAA	1290
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1291	GCCAGTGTGGGTCTCCACACAGCTGTGCCGGCAGGGGGCTCGATGCTGGAGGTTTCGGGGCCCCAA	1350
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrrVa	440
Db	1351	CGCCCTCTTCTTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGTGCCCGCTACTACGT	1410
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrrTyrrProArgSerLeuGlnAspTrpGl	460
Db	1411	GCTGGCCCGAGGGGACTGCDAGTGGAGGCTTACTACCCCGAAGTCTGGAGACTGGGG	1470
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1471	AGGCATCCCTGAGGAGTTCAGCGCGCCCTGCCGAGGCCGATGGCTCCCATCTTCTT	1530
Qy	480	eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1531	CCGAGATGACCGCTACTTGGCGCCTCGACCAAGGCCAAACTCGCAGCAACCACTCGGGCCG	1590
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1591	CTGGGCCACCGAGCTGCGCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT	1650
Qy	520	e	520
Db	1651	C	1651

protein modification and maintenance molecule; PMM; cytosolic; antiarteriosclerotic; anticonvulsant; nootropic; neuroprotective; cerebroprotective; vasotropic; anti-HIV; antiallergic; antimicrobial; antiinflammatory; endocrine-gen; thyromimetic; cell proliferative disorder; cancer; atherosclerosis; neurological disorder; epilepsy; Huntington's disease; stroke; immune disorder; inflammatory disorder; AIDS; allergy; developmental disorder; Hypothyroidism; Cushing's syndrome; infection human; gene; ds.

Homo sapiens.

WO2004009797-A2.

29-JAN-2004.

23-JUL-2003; 2003WO-US023249.

23-JUL-2002: 2002US-0398143P.

09-AUG-2002; 2002US-0402438P;
12-AUG-2002; 2002US-0403289P;

Z7-AUG-2002; 2002US-040847ZF.
06-SEP-2002: 2002US-0409354P.

(INCY-) INCYTE CORP.

ELLIOTT VS. SWARNAKAR A. GR.

Halatla AOA, Lee SI
Marquis JP, Jiang X

Wilson AD, Richardson IW, Tang J, Baughn MR, Gandhi AR, Ramkumar J, Kallick DA, Kearney L, Lu DAM, Gietzen KJ.

PAI FG, BLAKE JU,

WEI, Z004-123332/
P-P\$DB: ADJ71977.

New human protein modification and maintenance molecules (PMMM), useful for diagnosing, treating and preventing diseases or conditions associated with the aberrant PMMM expression e.g. cancer, AIDS, epilepsy, or infections.

Claim 5: SEQ ID NO 99: 387pp: English:

This invention relates to novel protein modification and maintenance molecules (PMMM) and polynucleotides which identify and encode PMMM. The invention may be useful for the development of compositions with a cyostatic, antiarteriosclerotic, anticonvulsant, neurotropic, neuroprotective, cerebroprotective, vasotropic, anti-HIV, anti-allergic, antimicrobial, anti-inflammatory, endocrine-gen or thymostimetic activity. The polypeptides and polynucleotides are useful in diagnosing, treating and preventing diseases or conditions associated with the decreased expression or overexpression of PMMM, such as cell proliferative (for example cancer, atherosclerosis), neurological (for example epilepsy, Huntington's disease, stroke), immune/inflammatory (for example AIDS, allergies) and developmental (for example Hypothyroidism, Cushing's syndrome) disorders, or infections. These are also useful in assessing the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of PMMM. The present sequence is that of a gene which encodes a human PMMM protein of the invention.

Sequence 1355 BP; 259 A; 440 C; 422 G; 234 T; 0 U; 0 Other;

Alignment Scores:

Pred. No.:	1.29e-103	Length:	1355
Score:	1981.00	Matches:	397
Percent Similarity:	76.05%	Conservative:	0
Best Local Similarity:	76.05%	Mismatches:	3
Query Match:	69.90%	Indels:	124
DB:	12	Gaps:	2

US-10-791-980-6 (1-520) x ADJ72039 (1-1355)

DE Human PMMM protein gene sequence SeqID99.

Db 1042 TGGGCCACGAGTGCCTGGATGGGTGCTGGCATGCAACTCGGGGAGCGCCCTGTTTC 1101

Search completed: November 14, 2005, 14:27:05
Job time : 1442 Secs

63	2792	98.5	1985	15	US-10-123-909-143	Sequence 143, App	136
64	2792	98.5	1985	15	US-10-123-910-143	Sequence 143, App	137
65	2792	98.5	1985	15	US-10-124-813-143	Sequence 143, App	138
66	2792	98.5	1985	15	US-10-124-817-143	Sequence 143, App	139
67	2792	98.5	1985	15	US-10-125-922-143	Sequence 143, App	140
68	2792	98.5	1985	15	US-10-125-924-143	Sequence 143, App	141
69	2792	98.5	1985	15	US-10-140-860-143	Sequence 143, App	142
70	2792	98.5	1985	15	US-10-142-417-143	Sequence 143, App	144
71	2792	98.5	1985	15	US-10-147-519-143	Sequence 143, App	145
72	2792	98.5	1985	15	US-10-157-782-143	Sequence 143, App	146
73	2792	98.5	1985	15	US-10-152-395-143	Sequence 143, App	147
74	2792	98.5	1985	15	US-10-128-926A-143	Sequence 143, App	148
75	2792	98.5	1985	15	US-10-125-930A-143	Sequence 143, App	149
76	2792	98.5	1985	15	US-10-127-831A-143	Sequence 143, App	150
77	2792	98.5	1985	15	US-10-127-837A-143	Sequence 143, App	151
78	2792	98.5	1985	15	US-10-127-838B-143	Sequence 143, App	152
79	2792	98.5	1985	15	US-10-127-842A-143	Sequence 143, App	153
80	2792	98.5	1985	15	US-10-127-843A-143	Sequence 143, App	154
81	2792	98.5	1985	15	US-10-127-845A-143	Sequence 143, App	155
82	2792	98.5	1985	15	US-10-127-846A-143	Sequence 143, App	156
83	2792	98.5	1985	15	US-10-127-848A-143	Sequence 143, App	157
84	2792	98.5	1985	15	US-10-127-849A-143	Sequence 143, App	158
85	2792	98.5	1985	15	US-10-127-850A-143	Sequence 143, App	159
86	2792	98.5	1985	15	US-10-127-851A-143	Sequence 143, App	160
87	2792	98.5	1985	15	US-10-128-684A-143	Sequence 143, App	161
88	2792	98.5	1985	15	US-10-128-686A-143	Sequence 143, App	162
89	2792	98.5	1985	15	US-10-128-690A-143	Sequence 143, App	163
90	2792	98.5	1985	15	US-10-128-691A-143	Sequence 143, App	164
91	2792	98.5	1985	15	US-10-131-819A-143	Sequence 143, App	165
92	2792	98.5	1985	15	US-10-131-829A-143	Sequence 143, App	166
93	2792	98.5	1985	15	US-10-131-836A-143	Sequence 143, App	167
94	2792	98.5	1985	15	US-10-146-729-143	Sequence 143, App	168
95	2792	98.5	1985	15	US-10-146-791-143	Sequence 143, App	169
96	2792	98.5	1985	15	US-10-147-484-143	Sequence 143, App	170
97	2792	98.5	1985	15	US-10-147-508-143	Sequence 143, App	171
98	2792	98.5	1985	15	US-10-147-512-143	Sequence 143, App	172
99	2792	98.5	1985	15	US-10-175-735-143	Sequence 143, App	173
100	2792	98.5	1985	15	US-10-121-040-143	Sequence 143, App	174
101	2792	98.5	1985	15	US-10-121-056-143	Sequence 143, App	175
102	2792	98.5	1985	15	US-10-121-063-143	Sequence 143, App	176
103	2792	98.5	1985	15	US-10-123-235-143	Sequence 143, App	177
104	2792	98.5	1985	15	US-10-124-818-143	Sequence 143, App	178
105	2792	98.5	1985	15	US-10-137-868-143	Sequence 143, App	179
106	2792	98.5	1985	15	US-10-147-492-143	Sequence 143, App	180
107	2792	98.5	1985	15	US-10-158-782-143	Sequence 143, App	181
108	2792	98.5	1985	15	US-10-123-905-143	Sequence 143, App	182
109	2792	98.5	1985	15	US-10-123-907-143	Sequence 143, App	183
110	2792	98.5	1985	15	US-10-124-815-143	Sequence 143, App	184
111	2792	98.5	1985	15	US-10-125-928A-143	Sequence 143, App	185
112	2792	98.5	1985	15	US-10-125-929A-143	Sequence 143, App	186
113	2792	98.5	1985	15	US-10-127-821A-143	Sequence 143, App	187
114	2792	98.5	1985	15	US-10-127-822A-143	Sequence 143, App	188
115	2792	98.5	1985	15	US-10-127-824A-143	Sequence 143, App	189
116	2792	98.5	1985	15	US-10-127-826A-143	Sequence 143, App	190
117	2792	98.5	1985	15	US-10-127-828A-143	Sequence 143, App	191
118	2792	98.5	1985	15	US-10-127-830A-143	Sequence 143, App	192
119	2792	98.5	1985	15	US-10-127-832A-143	Sequence 143, App	193
120	2792	98.5	1985	15	US-10-127-833A-143	Sequence 143, App	194
121	2792	98.5	1985	15	US-10-127-834A-143	Sequence 143, App	195
122	2792	98.5	1985	15	US-10-127-836A-143	Sequence 143, App	196
123	2792	98.5	1985	15	US-10-127-838A-143	Sequence 143, App	197
124	2792	98.5	1985	15	US-10-127-841A-143	Sequence 143, App	198
125	2792	98.5	1985	15	US-10-127-844A-143	Sequence 143, App	199
126	2792	98.5	1985	15	US-10-128-687A-143	Sequence 143, App	200
127	2792	98.5	1985	15	US-10-128-688A-143	Sequence 143, App	201
128	2792	98.5	1985	15	US-10-128-689A-143	Sequence 143, App	202
129	2792	98.5	1985	15	US-10-128-694A-143	Sequence 143, App	203
130	2792	98.5	1985	15	US-10-131-825A-143	Sequence 143, App	204
131	2792	98.5	1985	15	US-10-130-417-143	Sequence 143, App	205
132	2792	98.5	1985	15	US-10-131-815A-143	Sequence 143, App	206
133	2792	98.5	1985	15	US-10-131-817A-143	Sequence 143, App	207
134	2792	98.5	1985	15	US-10-131-821A-143	Sequence 143, App	208
135	2792	98.5	1985	15	US-10-131-822A-143	Sequence 143, App	209
136	2792	98.5	1985	15	US-10-123-909-143	Sequence 143, App	136
137	2792	98.5	1985	15	US-10-123-910-143	Sequence 143, App	137
138	2792	98.5	1985	15	US-10-124-813-143	Sequence 143, App	138
139	2792	98.5	1985	15	US-10-124-817-143	Sequence 143, App	139
140	2792	98.5	1985	15	US-10-125-922-143	Sequence 143, App	140
141	2792	98.5	1985	15	US-10-125-924-143	Sequence 143, App	141
142	2792	98.5	1985	15	US-10-140-860-143	Sequence 143, App	142
143	2792	98.5	1985	15	US-10-142-417-143	Sequence 143, App	144
144	2792	98.5	1985	15	US-10-147-519-143	Sequence 143, App	145
145	2792	98.5	1985	15	US-10-157-782-143	Sequence 143, App	146
146	2792	98.5	1985	15	US-10-152-395-143	Sequence 143, App	147
147	2792	98.5	1985	15	US-10-128-926A-143	Sequence 143, App	148
148	2792	98.5	1985	15	US-10-125-930A-143	Sequence 143, App	149
149	2792	98.5	1985	15	US-10-127-831A-143	Sequence 143, App	150
150	2792	98.5	1985	15	US-10-127-837A-143	Sequence 143, App	151
151	2792	98.5	1985	15	US-10-127-838B-143	Sequence 143, App	152
152	2792	98.5	1985	15	US-10-127-842A-143	Sequence 143, App	153
153	2792	98.5	1985	15	US-10-127-843A-143	Sequence 143, App	154
154	2792	98.5	1985	15	US-10-127-845A-143	Sequence 143, App	155
155	2792	98.5	1985	15	US-10-127-846A-143	Sequence 143, App	156
156	2792	98.5	1985	15	US-10-127-848A-143	Sequence 143, App	157
157	2792	98.5	1985	15	US-10-127-849A-143	Sequence 143, App	158
158	2792	98.5	1985	15	US-10-127-850A-143	Sequence 143, App	159
159	2792	98.5	1985	15	US-10-127-851A-143	Sequence 143, App	160
160	2792	98.5	1985	15	US-10-128-684A-143	Sequence 143, App	161
161	2792	98.5	1985	15	US-10-128-686A-143	Sequence 143, App	162
162	2792	98.5	1985	15	US-10-128-690A-143	Sequence 143, App	163
163	2792	98.5	1985	15	US-10-128-691A-143	Sequence 143, App	164
164	2792	98.5	1985	15	US-10-131-819A-143	Sequence 143, App	165
165	2792	98.5	1985	15	US-10-131-829A-143	Sequence 143, App	166
166	2792	98.5	1985	15	US-10-131-836A-143	Sequence 143, App	167
167	2792	98.5	1985	15	US-10-146-729-143	Sequence 143, App	168
168	2792	98.5	1985	15	US-10-146-791-143	Sequence 143, App	169
169	2792	98.5	1985	15	US-10-147-484-143	Sequence 143, App	170
170	2792	98.5	1985	15	US-10-147-508-143	Sequence 143, App	171
171	2792	98.5	1985	15	US-10-147-512-143	Sequence 143, App	172
172	2792	98.5	1985	15	US-10-175-735-143	Sequence 143, App	173
173	2792	98.5	1985	15	US-10-121-040-143	Sequence 143, App	174
174	2792	98.5	1985	15	US-10-121-056-143	Sequence 143, App	175
175	2792	98.5	1985	15	US-10-121-063-143	Sequence 143, App	176
176	2792	98.5	1985	15	US-10-123-235-143	Sequence 143, App	177
177	2792	98.5	1985	15	US-10-124-818-143	Sequence 143, App	178
178	2792	98.5	1985	15	US-10-137-868-143	Sequence 143, App	179
179	2792	98.5	1985	15	US-10-147-492-143	Sequence 143, App	180
180	2792	98.5	1985	15	US-10-158-782-143	Sequence 143, App	181
181	2792	98.5	1985	15	US-10-123-905-143	Sequence 143, App	182
182	2792	98.5	1985	15	US-10-123-907-143	Sequence 143, App	183
183	2792	98.5	1985	15	US-10-124-815-143	Sequence 143, App	184
184	2792	98.5	1985	15	US-10-125-928A-143	Sequence 143, App	185
185	2792	98.5	1985	15	US-10-125-929A-143	Sequence 143, App	186
186	2792	98.5	1985	15	US-10-127-821A-143	Sequence 143, App	187
187	2792	98.5	1985	15	US-10-127-822A-143	Sequence 143, App	188
188	2792	98.5	1985	15	US-10-127-824A-143	Sequence 143, App	189
189	2792	98.5	1985	15	US-10-127-826A-143	Sequence 143, App	190
190	2792	98.5	1985	15	US-10-127-828A-143	Sequence 143, App	191
191	2792	98.5	1985	15	US-10-127-830A-143	Sequence 143, App	192
192	2792	98.5	1985	15	US-10-127-832A-143	Sequence 143, App	193
193	2792	98.5	1985	15	US-10-127-833A-143	Sequence 143, App	194
194	2792	98.5	1985	15	US-10-127-834A-143	Sequence 143, App	195
195	2792	98.5	1985	15	US-10-127-836A-143	Sequence 143, App	196
196	2792	98.5	1985	15	US-10-127-838A-143	Sequence 143, App	197
197	2792	98.5	1985	15	US-10-127-841A-143	Sequence 143, App	198
198	2792	98.5	1985	15	US-10-127-844A-143	Sequence 143, App	199
199	2792	98.5	1985	15	US-10-128-687A-143	Sequence 143, App	200
200	2792	98.5	1985	15	US-10-128-688A-143	Sequence 143, App	201
201	2792	98.5	1985	15	US-10-128-689A-143	Sequence 143, App	202
202	2792	98.5	1985	15	US-10-128-694A-143	Sequence 143, App	203
203	2792	98.5	1985	15	US-10-131-825A-143	Sequence 143, App	204
204	2792	98.5	1985	15	US-10-130-417-143	Sequence	

Db	275	GCACCCCTGCCACGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG	334	
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120	
Db	335	GCCTGGGCTGAGAGGATCAGTGACTGTGTTTCTAGACACCGGACCAAAATGAGCGTAAG	394	
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTrpArgLeuVal	140	
Db	395	AAACGCTTTGCAAGCAAGTAACAAATGGTACAGCAGCACCTCTCTACCGCGCTGGTG	454	
Qy	141	AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSer	160	
Db	455	AACTGGCCTGAGCATCTCCGAGCGCGCAGTTTCGGGGCGCGCTGCGCGCCCTTCCAGT	514	
Qy	161	CysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuThr	180	
Db	515	TGTGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCCAGCCACAGCCCGCTGACA	574	
Qy	181	SerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAla	200	
Db	575	TCCGCTTACCTTCTCCAGGGGACACACAGATGGCTGGCAATGCTTTGATGCCC	634	
Qy	201	GlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGln	220	
Db	635	CAGGGGGCGCCCTGGCGCAGCGCTTCTCTGCCCGCGCGGCGAAGCGCACTTCGACCA	694	
Qy	221	AspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis	240	
Db	695	GATGAGCGTGTGTCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTGTCTGGCGCAC	754	
Qy	241	GluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPro	260	
Db	755	GAGATCGGTACACGCTTGGCTCACCACCTCGCCCGCGCGCGCGCTCATGGCGGCC	814	
Qy	261	TyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGln	280	
Db	815	TACTACAGAGGCTGGCGCGCACGCGCTGCTCAGCTGGGACGAGTGTGGCGGTGAG	874	
Qy	281	SerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPhe	300	
Db	875	AGCCTGTATGGAGAGCCCTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTTC	934	
Qy	301	ThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGly	320	
Db	935	ACTGACTTTGAGACCTGGGACTCTTACAGCCCGCCAGGAAGCGCGCTGAAACGAGGCG	994	
Qy	321	ProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp	340	
Db	995	CCTAAATATGCGCACCTCTCTTCGATGCCATCAGTGTAGACAGGCACGCACTGTAC	1054	
Qy	341	IlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProArg	360	
Db	1055	ATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCGT	1114	
Qy	361	ProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLeu	380	
Db	1115	CCACTGCAGAAAGATGGGTGGGCTGCCCGCCCAACATTTGAGGCTCGCGAGTGTATGT	1174	
Qy	381	AsnAspGlyAspPheTrpPhePheLysGlyValArgCysTrpArgPheArgGlyProLys	400	
Db	1175	AATGATGGAGATTTCTACTCTTCTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAAG	1234	
Qy	401	ProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAla	420	
Db	1235	CCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCGCTGCGCGCCATCTGACGCG	1294	
Qy	421	AlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpVal	440	
Db	1295	GCCT	1354	
Qy	441	LeuAlaArgGlyGlyLeuGlnValGluProTrpTrpProArgSerLeuGlnAspTrpGly	460	
Db	1355	CTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGA	1414	
Qy	461	GlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePhe	480	
Db	1415	GGCATCCTTGAGGAGTCAAGCGCGCCCTGCGAGGCGCGATGGCTCCATCTTCTTTC	1474	
Qy	481	ArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyArg	500	
Db	1475	CGAGATGACCGCTACTGGCGCTCGACACGAGGCCAACTGCAGGCAACCACTCGGCGCG	1534	
Qy	501	TrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPhe	520	
Db	1535	TGGGCCACCGAGTGCCTGGATGGCTGCTGCAATGCCAACTCGGGAGCGCCCTGTTC	1594	
RESULT 2				
US-10-791-980-3				
; Sequence 3, Application US/10791980				
; Publication No. US20040146499A1				
; GENERAL INFORMATION:				
; APPLICANT: Holmgren, Erik				
; APPLICANT: Kihlen, Mats				
; APPLICANT: Wood, Tim				
; APPLICANT: Ekblom, Jonas				
; TITLE OF INVENTION: Novel Matrix Metalloproteinases				
; FILE REFERENCE: 00014regUS				
; CURRENT APPLICATION NUMBER: US/10791,980				
; PRIOR FILING DATE: 2004-03-03				
; PRIOR APPLICATION NUMBER: US/09/862,631				
; PRIOR FILING DATE: 2000-05-22				
; PRIOR APPLICATION NUMBER: 206119				
; PRIOR FILING DATE: 2000-05-22				
; NUMBER OF SEQ ID NOS: 8				
; SOFTWARE: PatentIn version 3.0				
; SEQ ID NO 3				
; LENGTH: 1597				
; TYPE: DNA				
; ORGANISM: Homo sapiens				
US-10-791-980-3				
Alignment Scores:				
Pred. No.:	2,06e-266	Length:	1597	
Score:	2834.00	Matches:	520	
Percent Similarity:	100.00%	Conservative:	0	
Best Local Similarity:	100.00%	Mismatches:	0	
Query Match:	100.00%	Indels:	0	
DB:	24	Gaps:	0	
US-10-791-980-6 (1-520) x US-10-791-980-3 (1-1597)				
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20	
Db	35	ATGTCGCGCGCGTGGCTCTCTGTCGCGCCCTGCAGCTGTACTGTGGGGCCACCTG	94	
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40	
Db	95	GACGCCAGCCCGCGAGCGGAGCGGCGGAGGCTGCGCAAGGCGGCGGCGCATTCCTA	154	
Qy	41	GluLysTrpGlyTrpLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60	
Db	155	GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGGCTCCCACTCCATCGATTGAGC	214	
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80	
Db	215	GATGCCATCAGACGCTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGGGGTGTGGACCGC	274	
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla	100	
Db	275	GCCACCTCGCGCAGATGCTGCTCCCGCTGCGGGGTACAGATACCAACGATTATGCG	334	
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120	
Db	335	GCCTGGGCTGAGAGGATCAGTGACTGTGTTTCTAGACACCGGACCAAAATGAGCGTAAG	394	

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 395 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTACCGCTGGTG 454
QY 141 AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSer 160
DB 455 AACTGGCCTGAGCATCTCCGAGCCGCGCAGTTCGGGGCGCGCTCGCGCGCTTCAGT 514
QY 161 CysGlyAlaThrSerGlnArgTyrTrpSerSerGlyArgProGlnProGlnAlaProLeuThr 180
DB 515 TGTGGAGCAACGCTCTAGCGCTGGAGTTCGGAGAGCCCGCAGCCAGGCCCCCGCTGACA 574
QY 181 SerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAla 200
DB 575 TCCGGCTCACCTTCTCCAGGGGACACAAACATGGCTGGCAATGCTTTGATGGCC 634
QY 201 GlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGln 220
DB 635 CAGGGGGCGCCCTGGCGCACGCTTCTCTGCCCGCGCGGCGAAGCGCACTTCGACCAA 694
QY 221 AspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
DB 695 GATGAGGCTGGTCTCTAGCCCGCGCGCGCGCAACTGTTCGTGGTGTGGCGCAC 754
QY 241 GluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPro 260
DB 755 GAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCCC 814
QY 261 TyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGln 280
DB 815 TACTACAAGAGGTGGCGCGCAGCGCTCTCAGCTGGGACGACGCTGTGGCGGTGAC 874
QY 281 SerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPhe 300
DB 875 AGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTTC 934
QY 301 ThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGly 320
DB 935 ACTGACTTTGAGACCTTGGGACTCTACAGCCCCCAAGGAGCGCCCTGAAACGCGAGGC 994
QY 321 ProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 995 CCTAAATACTGGCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTAC 1054
QY 341 IlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProArg 360
DB 1055 ATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCGT 1114
QY 361 ProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLeu 380
DB 1115 CCACTGCAGGAAAGATGGGTGGGCTGCCCTCCCCACATTTGAGGCTGGCGCAGTGTATTG 1174
QY 381 AsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLys 400
DB 1175 AATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAAG 1234
QY 401 ProValTrpGluProGlnCysArgAlaGlyLeuProArgHisProAspAla 420
DB 1235 CCAAGTGTGGGGTCTCCACAGCTGTCCGGGGGAGGGGGCTGCCCGCCCATCTCAGCGCC 1294
QY 421 AlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVal 440
DB 1295 GCCCTCTTCTCCCTCTCTGGCGGCTCATCTCTTCAAGGGTGGCGCTACTACGTG 1354
QY 441 LeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGly 460
DB 1355 CTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGA 1414
QY 461 GlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePhe 480
DB 1415 GGCATCCCTTGGAGAGTACGGCGCCCTTGGCGAGCGCCGATGGGTCTCATCTCTTC 1474
QY 481 ArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyArg 500

DB 1475 CGAGATGACCGCTACTGGCGCTCGACCGAGCCAAACTCGAGCAACACCTCGGGCCG 1534
QY 501 TrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPhe 520
DB 1535 TGGGCCACCGAGCTGCCCTGGATGGCTGTCGCATGCCAACTCGGGAGCGCCCTGTTTC 1594
RESULT 3
US-09-950-510-3
; Sequence 3, Application US/09950510
; Patent No. US20020150978A1
; GENERAL INFORMATION:
; APPLICANT: Curtig, Rory
; TITLE OF INVENTION: 46798, A No. US20020150978A1el Human Matrix Metalloproteinase An
; FILE REFERENCE: 10147-45U1
; CURRENT APPLICATION NUMBER: US/09/950,510
; PRIOR FILING DATE: 2001-09-10
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3
; LENGTH: 1560
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-950-510-3
Alignment Scores:
Pred. No.: 2,53e-262 Length: 1560
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0
US-10-791-980-6 (1-520) x US-09-950-510-3 (1-1560)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 1 ATGTGTCGGCGCGCTCGGCTCTCTGTGGCGCCCTCGACGCTCTACTGTGGGGCCACCTG 60
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 61 GAGGCCACGCGCGGAGCGGAGGCGCAGGAGCTGGCAGAGGCGGAGGCGGAGGATTCCTA 120
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 121 GAGAAATACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGATTGAGC 180
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 181 GATGCCATCAGAGCGCTTTCAGTGGGTGTCCAGCTACCTGTGCGGGGTGTGTGGACCGC 240
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 241 GCCACCTTGGCCAGATGACTCGTCCCGCTGGCGGGTTACAGATACCAACAGTTATGGC 300
QY 101 AlaTrpAlaGluArgLysAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 301 GCCTGGCTGAGAGGATCAGTGACTTGTTCGTAGACACCGGACCCAAATAGGGCGTAAG 360
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 361 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTACCGCTGGTG 420
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 421 AACTGGCTTGGACATCTGCCGAGCGCGCAGTTCGGGGCGCGCTGGCGCGCCCTTCAG 480
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 481 TTGTGGACCAACGCTCTCAGCGCTCTGAGTTCCTGGGAGGCCCCCAGGCCACAGGCCCGCTGAC 540

Qy	180	r	Ser	Gly	Ser	Pro	Ser	Ser	Leu	Ser	Gly	Thr	Thr	Thr	Met	Gly	Trp	Ala	Met	Pro	Leu	Met	Al	200	
Db	541	A	T	C	G	G	T	C	A	C	T	T	T	T	C	C	A	A	A	G	A	T	G	G	600
Qy	200	a	G	I	n	G	i	y	A	l	a	P	r	o	T	r	p	r	o	P	h	e	L	e	220
Db	601	C	C	A	G	G	G	G	C	C	C	T	T	G	G	C	A	C	G	C	T	T	C		659
Qy	220	n	A	S	P	G	L	u	A	r	G	i	n	G	i	y	A	r	g	A	s	n	L	e	240
Db	660	A	G	A	T	G	A	G	C	G	T	G	T	C	C	T	G	A	G	C	G	C	G	C	719
Qy	240	s	G	L	i	e	G	L	y	H	i	s	T	h	r	L	e	u	P	r	o	A	r	g	260
Db	720	C	G	A	T	C	G	T	C	A	C	C	C	A	C	T	C	G	C	G	C	G	C	G	779
Qy	260	o	T	r	T	y	L	y	A	r	g	L	e	u	G	i	y	A	s	p	A	l	e	a	280
Db	780	C	T	A	C	T	A	C	A	G	A	G	G	T	G	G	C	T	G	C	T	G	G	C	839
Qy	280	n	S	e	r	L	e	u	T	r	G	i	y	S	e	r	V	a	L	a	V	a	L	e	300
Db	840	G	A	G	C	T	G	T	A	T	G	G	A	G	C	C	C	T	A	G	G	C	C	T	899
Qy	300	e	T	r	A	s	p	P	h	e	L	u	T	r	p	A	s	p	S	e	r	T	y	r	320
Db	900	C	A	C	T	G	A	C	T	T	T	G	A	C	C	C	C	C	C	C	C	C	C	C	959
Qy	320	y	P	r	o	L	e	u	T	r	C	y	H	i	s	S	e	r	P	h	e	A	s	p	340
Db	960	C	C	T	A	A																			

```
Db 601 CAGGGGGGGCCCTGGCGCAGCGCTTC-CTGCCCCCGCGCGGAGAGCGACCTTGAACA 659
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 660 AGATGAGCGCTGGTCTCTCAGCGCGCGCGCGCGCAACCTGTTGCTGCTGGCGCA 719
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProAlaLeuMetAlaPr 260
Db 720 CGAGATCGGTCAACGCTTGGCTTCAACCGACTCGCGCGCGCGCGCTCATGGCGCC 779
Qy 260 oTyrtYrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 780 CTACTACAGAGCGCTGGCGCGCGCGCTGCTGCTAGCTGGGACGAGCTGCGCGCTGCA 839
Qy 280 nSerLeuTyrtYrLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 840 GAGCGTGATGGAGAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCGAGGAAGCTGTT 899
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 900 CACTGACTTGGAGCTGGGACTCTCTACAGCCCCCAAGGAGCGCGCTGAAACGACGG 959
Qy 320 yProLysTyrtYrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 960 CCTAAATACTCCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1019
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1020 CATTTTAAAGGAGGACCATTTCTGGAGGTGGAGCTGATGCAACGCTCTAGAGCCCCG 1079
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1080 TCCACTGCAGGAAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGCTGGCGAGTGCATT 1139
Qy 380 uAsnAspGlyAspPheTyrtYrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1140 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1199
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuLeuProArgHisProAspAl 420
Db 1200 GCCAGTGGGGTCTCCACAGCTGTGCGGCGAGGGGCTGCCCCCGCATCTCTGAGCGC 1259
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpTrVa 440
Db 1260 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1319
Qy 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrtYrProArgSerLeuGlnAspTrpGl 460
Db 1320 GCTGGCGCGAGGGGACTGCAAGTGGAGCGCTTACTACCCCCGAAAGTCTGCAGGACTGGG 1379
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1380 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGGAGGCGCGATGGCTCCATCATCTTCTT 1439
Qy 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1440 CCGAGATGACCGCTACTGGCGCTCGACCGAGGCGCAACTGCGAGGCAACCACTCGGGCG 1499
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1500 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCGCTGTT 1559
Qy 520 e 520
Db 1560 C 1560
```

RESULT 5

US-09-737-353-1
; Sequence 1, Application US/09737353
; Patent No. US20010036648A1
; GENERAL INFORMATION:
; APPLICANT: Christopher Donald Southan
; APPLICANT: Stephen Anthony Hughes

; TITLE OF INVENTION: NOVEL COMPOUNDS
; FILE REFERENCE: GH-30222
; CURRENT APPLICATION NUMBER: US/09/737,353
; CURRENT FILING DATE: 2000-12-15
; PRIOR APPLICATION NUMBER: 0801898.6
; PRIOR FILING DATE: 2000-01-27
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 1563
; TYPE: DNA
; ORGANISM: HOMO SAPIENS
US-09-737-353-1

Alignment Scores:
Pred. No.: 2,538-262 Length: 1563
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 9 Gaps: 0

US-10-791-980-6 (1-520) x US-09-737-353-1 (1-1563)

```
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 1 ATGGTCGGCGCGCTCGGCTCTCTGTCGGCGCGCTGACGCTGCTACTGTGGGGCCACCTG 60
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 61 GACGCCACGCGCGGAGCGCGGAGCTGCGCAAGAGGCGGAGGCGGCAATTCCTTA 120
Qy 41 GluLysTyrtYrGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 121 GAGAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTACG 180
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 181 GATGCCATCAGAGCGTTTCAGTGGGTGTCACGACTACCTGTGCGGGGTGTGTGGACCGC 240
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla 100
Db 241 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 300
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 301 GCCTGGGCTGAGAGGATCAGTACTTGTTCCTAGACACCGGACCAAAATGAGGGCTAAG 360
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrtYrLysGlnHisLeuSerTyrtArgLeuVal 140
Db 361 AAACGCTTTGCNAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTACCGCCTGGTG 420
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 421 AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 480
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 481 TTGTGGAGCAACGTCCTCAGCGCTGAGTTCCTGGGAGGCGCCAGGACACAGGCGCGCTAC 540
Qy 180 rSerGlySerProSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 541 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACCATGGGCTGGGCAATGCTTTGATGGC 600
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 601 CCAGGGGCGCGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 659
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 660 AGATGAGCGTGGTCTCTCAGCGCGCGCGGCGCAACCTGTTGCTGTTGCTGGCGCA 719
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProAlaLeuMetAlaPr 260
```

```

; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 1563
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)...(1563)
US-10-050-216B-10

Alignment Scores:
Pred. No.:      2,53e-262      Length:      1563
Score:          2792.00        Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%    Mismatches: 1
Query Match:      98.52%        Indels:      2
DB:              15            Gaps:        0

US-10-791-980-6 (1-520) x US-10-050-216B-10 (1-1563)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 1 ATGGTCGCGCGTCGCGCTCTCTCTGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 60
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
Db 61 GACGCCACGCGCGGAGCGGAGGCGGAGGCTGCGCAAGGAGGCGGAGGCGGAGGCGGAGG 120
Qy 41 GluLysTyrGlyTyrLeuLeuLeuGlnValProLysAlaProThrSerThrArgPheSer 60
Db 121 GAGAAATACGATACCTCAATGAACAGGTGCTCCCAAGCTCCCACTCCGATTCGATTC 180
Qy 61 AspAlaLeuArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 181 GATGCCATCAGAGCGTTTCAGTGGGTGCTCCAGTACTCTGTACGCGGCTGTTGGACCGC 240
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 241 GCCACCTTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 300
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 301 GCCTGGGCTGAGAGGATCAGTACTTGTCTAGACACCGGACCAAAATGAGGCGTAAG 360
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 361 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGACCTCTCTCTCCGCTGTG 420
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 421 AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTTCGGCGCGCTTCCAG 480
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 481 TTGTGGAGCAACGTCCTCAGCGCTGAGGTTCTGGAGGCGCCAGCCACAGGCGCGCTGAC 540
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 541 ATCCGGCTCACCTCTTCCAAAGGGGACCAACATGGGCTGGGCAATGCCCTTTGATGGC 600
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 601 CCAGGGGCGCGCTGGGCGACGCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 659
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 660 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGGCAACTGTTTCGTTGGTGTGGCGCA 719
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 720 CGAGATCGTCAACGCTTGGCTCACCACTCGCCCGCGCGCGCGCTCATCGCGCC 779
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
```

RESULT 6

```

US-10-050-216B-10
; Sequence 10, Application US/10050216B
; Publication No. US20030039991A1
; GENERAL INFORMATION:
; APPLICANT: Curtis, Rory A.J., Lora, Jose M.
; TITLE OF INVENTION: 46798, A Human Matrix Metalloprotease and
; TITLE OF INVENTION: Uses Thereof
; FILE REFERENCE: MPI2001-014PIRNM
; CURRENT APPLICATION NUMBER: US/10/050,216B
; PRIORITY FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: 60/262,252
; PRIOR FILING DATE: 2001-01-16
; NUMBER OF SEQ ID NOS: 10
```

Db 780 CTACTACAAGAGGCTGGCGCGACGCGCTGCTCAGCTGGACGACGCTGGCGCGTGA 839
Qy 280 nSerLeuTyGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 840 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGTT 899
Qy 300 eThAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnGl 320
Db 900 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGGCCCTGAAACGCGAGG 959
Qy 320 YProLyTyTyCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 960 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1019
Qy 340 rIlePheLyGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1020 CATTTTAAAGGGAGCCATTCTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1079
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1080 TCCACTCCAGGAAGATGGTGGGCTGCCCCCNCACATTTAGGCTGGCGCATGTGTCATT 1139
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyArgCysTyTrpArgPheArgGlyProLy 400
Db 1140 GAATGATGGAGATTTCTACTTCTCAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1199
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1200 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGGCTGCCCGGCCATCTGCACGC 1259
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLyGlyAlaArgTyTrVa 440
Db 1260 CGCCCTCTTCTTCTCTCTGCGCCGCTTCTCTTCAAGGGTGGCCGCTACTACGT 1319
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpTyProArgSerLeuGlnAspTrpGl 460
Db 1320 GCTGGCCGAGGGGACTGCAAGTGGAGGCTTACTACCCCGAAGTCTGCAGGACTGGGG 1379
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1380 AGGCATCCCTGAGGAGGTCAGCGGGCCCTGCGGAGCGCGCTGCCATCATCTTCTT 1439
Qy 480 eAtsAspAspArgTyTrpArgLeuAspGlnAlaValLeuGlnAlaThrThrSerGlyAr 500
Db 1440 CCGAGATGACCGTACTTGGCCCTTCGACCGAGGCGCAACTGCAGCAACCACTCGGGCCG 1499
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1500 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1559
Qy 520 e 520
Db 1560 c 1560
RESULT 7
US-10-028-072-143
; Sequence 143, Application US/10028072
; Publication No. US20030004311A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang
; TITLE OF INVENTION:
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/028,072
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059836
; PRIOR FILING DATE: 1997-09-24
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062285
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062814
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/062816
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063045
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063082
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/063127
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063327
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063329
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063550
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063561
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063704
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063733
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063735
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063738
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063755
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064248
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/064809
; PRIOR FILING DATE: 1997-11-07
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065846
; PRIOR FILING DATE: 1997-11-17
; PRIOR APPLICATION NUMBER: 60/066364

[illegible]

QY 121 LysArgPheAlaLysGlnGlyAenLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGGCTTTTCAAGCAAGGTATCAAAATGGTACAGCAGCACCTCTCTCTACCGCCTGGTG 625
QY 141 AsnTyrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTTGAGCATCTCGGAGCCGCGAGTTTCGGGGCGCGTGGCGCGCCTTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACACACAGATGGCTGGCAATGCCITTCATGGC 805
QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCTGGCGCACGCTTTC - CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTyrSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTGTCTGGCGCA 924
QY 240 eGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTTCACACGCTTGGCTTCCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 ofTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGCGTGGCGCGCGAGCGCTGCTCAGCTGGAGCGACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGCTGATGGAGAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGAGCGCGCTGAAACGACAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTCTCTTCATGTCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTyrPheGluValAlaAlaAspGlyAsnValSerGluPrBar 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGCGAGCTGATGCAACGCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGCTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyCysArgCysTyrPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCAA 1404
QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACACAGCTGTGCGGGCAGGGGGCTTGGCCCCCATCTTCAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 GCGCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrGl 460
Db 1525 GCTGGCCCCGAGGGGACTTCAAGTGGAGCCCTTACTACCCCGAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGACGGCGCGCTGCCGAGGGCCCATGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTyrPheArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500

Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCAGGCCAAATCGAGGCAACCACTCGGGCGG 1704
QY 500 gTrrPalaThrGluLeuProTyrMetGlyCysTrrPheAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 8
US-10-140-808-143
; Sequence 143, Application US/10140808
; Publication No. US20030017563A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C182
; CURRENT APPLICATION NUMBER: US/10/140,808
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-808-143
Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-140-808-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTyrGlyHisLeu 20
Db 206 ATGTTCGCGCGCTGGCGCTCTCTGTCGCGCCCTGACGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGGAGCCAGAGCTGCGCAGAGGCGCGGAGGCACTTCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATCCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTTCAGCGCGCTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100


```
Db 326 GAGAGTACCGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCCGATTCCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTCCAGCTACCTGTGAGCGCGGTGTGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCGCAGATGACTCGTCCCGCTCGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgArgIys 120
Db 506 GCTCGGCTGAGAGGATCAGTACGTTGTTGTAGACACCGGACCAAAATGAGGGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACCGTTTGCAAGCAAGGTAAACAAATGGTACAGACGACCTCTCTTACCCTGTTGGT 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCGCGCAGTTTCGGGGCGCGTGGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGGCCCAAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCNAGGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTCGTGTCGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACCTCGCCCGCGCGCGCGCTCATGCGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGCCCCCAAGGAAGCGGCCCTGAAACGACAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATAGCTCACTCTCTTCATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrPgluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCGCCGCCATCCTGACGC 1464
```

```
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CCCCCCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCCGAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTGAGGAGGTGAGCGCGCGCTGCGAGGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVa 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAACTGCAGGCAACACCATCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAATCGGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 10
US-10-123-904-143
; Sequence 143, Application US/10123904
; Publication No. US20030022328A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C54
; CURRENT APPLICATION NUMBER: US/10/123,904
; CURRENT FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-904-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-904-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGGTGCGGCTCTCTGCGCGCTCTGCGAGCTGCTACTGTGGGGCCACCTG 265
```


DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-140-470-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGGCTCGCGCTTCCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCCAGCCCGGAGCGCGAGGCGCAGGAGCTCGGCNAGGAGCGGAGGCAATTCCTA 325
QY 41 GluLysTyGlyTyLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACCTGTGAGCGGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyAla 100
DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGATTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAenLysTrpTyLysGlnHisLeuSerTyArgLeuVal 140
DB 566 AAACCGCTTGGCAAGCAAGGTAAACAAATGGTACAGCAGCAGCTCTCTACCGCGCTGGTG 625
QY 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCCGCGCGCCCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCCGGCTCACCCTTCTCAAGGGGACCAACAAGATGGGCTGGCAATGCCCTTTGATGC 805
QY 200 aGlnGlyAlaProTrpAlaTrpPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CAGGGGGCGCCCTGGCGACACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
DB 865 AGATCAGCGCTGCTCCCTGAGCGCGCGCGCGCGCAACCTGTTCTGTTGCTGCGGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGGCTCACCACCTCGCCCGCGCGCGCTCATGCGGCC 984
QY 260 oTyTyLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAGAGCGTGGCGCGCGCGCGCTGCTGCTGAGCGAGCGTGTGGCGGTGCA 1044
QY 280 nSerLeuTyGlyLysProLeuGlyLysrValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCGCAAGGAGGCGCCCTGAAACGAGGG 1164
QY 320 yProLysTyCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTCCCACTTCTCTTCATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360

DB 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGTTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTCGAGGAAAGATGGTCCGGCTGCCCGCCCAACATTGAGGCTGCGGCAGTGCAAT 1344
QY 380 uAenAspGlyAspPheTyPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATCATGGAGATTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACACAGCTGTGCGGCGCAGGGGCGCTGCCCGCCATCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGGTGCCCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGAGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleilePhePh 480
DB 1585 AGGCATCCTGAGGAGGTGAGCGGCGCTGCGGAGGCGCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CGAGATGACCGCTACTGCGGCTCGACCGCCAAATGCAAGGCAACACCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGCCACCGAGTGGCTGCTGGATGGGTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 12

US-10-175-746-143
; Sequence 143, Application US/10175746
; Publication No. US20030027270A1

GENERAL INFORMATION:

; APPLICANT: Baker Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C353
; CURRENT APPLICATION NUMBER: US/10/175,746
; CURRENT FILING DATE: 2002-06-19
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-175-746-143

Alignment Scores:

Pred. No.:	3,356-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	79.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.55%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-175-746-143 (1-1985)

Qy	1	MetValalaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTGCGCGCGTCTGCTGCTGCGCGCCCTGAGTGTCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GAGCCCGAGCCCGGAGCGGAGGCGGAGCTGGCAGGAGCGGAGGCGATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGTCCCACTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTACGCGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla	100
Db	446	GCCACCTGCGCCAGATGACTCTGCTCCCGCTGGGGGTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaAargHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGCATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTTACCCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSer	160
Db	626	AACTGGCTTGAGCATCTGCCGAGCGCGCAGTTCGGGGCGCGTGGCGCGCTTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTAGCGCTGGAGTCTTGGGAGCGCCAGCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAGGGGACCAACAACATGGGTGGGCAATGCTTTGATGGC	805
Qy	200	adGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
Db	806	CCAGSGGGCGCCCTGGCGCACGCGCTTC-CTGCCCCCGCGCGCGGCAAGCGACATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATAGAGCGCTGGTCCCTTGAGCGCGCGCGGCGCAACCTGTGTGGTGGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCCTCACCCACTCTGCCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG	280
Db	985	CTACTACAAGAGCGTGGGCGCGACGCGCTGTCTAGCTGGGACGACGCTGTGGCGCGTGA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGAGAGCCCTTAGGGGGGTCTAGTGGCCGTCTCAGCTCCAGGAAAGCTGTT	1104
Qy	300	enrThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320

[illegible]

;
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-176-918-143

Alignment Scores:

Pred. No.: 3,358-262 Length: 1985
Score: 2752.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-176-918-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTCGCGCGGTGGCCCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgGlyGluAlaGluAlaPheLeu 40
DB 266 GACGCCCGCGCGAGCGCGAGGCCAGGAGCTGCGCAAGGCGGCGGAGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuGlnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTCAGTACCTGTGTCAGGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCTGCGCAGATGACTCGTCCCGCTCGGGGTTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGGTGAGAGGATCAGTACCTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTCGAAGCAGGTAAACAAATGGTACAGACACCGGACCAAAATGAGGCGTAAG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCGGAGCGCGGAGTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGAGTTCGGAGGCGGCGGACCGGACCGGCGCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTTCTCCAGGGGACCAACACAGATGGCTGGGCATGTCCTTTCATGGC 805
QY 200 acGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCGCTGGCGCACGCCCTTC-CTGCCCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGCTGGTGGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CCAGATCGGTACACGCTTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGGGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGA 1044
```

```
QY 280 sSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCCAAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTy+SerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACCTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTAAATACTGCGCACTCTTCTCGATGCCATCATCTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGCGCGAGTGTCAIT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTTGGCCCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGGAGTCTGCGAGACTGGGG 1584
QY 460 yGlyLeuProGluGluValSerGlyValAlaLeuProArgProAspGlySerIlePhePh 480
DB 1585 AGGCATCTCCGAGGAGGTGAGCGGGCGCTTGGCGGGCGCGATGGCTCCATCTCTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATCAGCGCTACTGCGCGCTCGACAGGCGCAAACTGCGAGGCAACCCACCTCGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
```

RESULT 14

US-10-176-921-143

; Sequence 143, Application US/10176921

; Publication No. US2003002726A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deanoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K

```
; APPLICANT: Wood,William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C288
; CURRENT APPLICATION NUMBER: US/10/176,921
; CURRENT FILING DATE: 2002-06-20
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-176-921-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-176-921-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTCCGGCTCTGTCGCGCGCTTCAGAGCTGCTACTGTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCGCGAGCGGAGCCAGGAGCTGCCAAGGAGCGGAGGCATTCTCTA 325

Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCGATTTCAGC 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGACTTACCTGTGAGCGGGGTGTGGACGCG 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGCAGATCAGTCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTGTAGACACCGGACCCAAAATGAGGCGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGACCTCTCTCCGCGCTGGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGSCCTGAGCATCTGCCGAGCCGCGAGTTCCGGGCGCGCTGCCGCGCTTCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGAGGTCTTGGGAGGCCCCAGCCACAGGCGCCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCAGAGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805

Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCCGCGCGCGGCGAAGCGCACTTCGACCA 864

Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATAGCGCTGGTCCCTGAGCCGCGCGCGGCGCAACCTGTTCTGGTGGTGGCGCA 924
```

```
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCCTCACCCACTCCCGCGCGCGCGCTCATGGCGGCC 984

Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGA 1044

Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGAGAAAGCTGT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCTGAAACGCGAGGG 1164

Qy 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTyr 340
Db 1165 CCCTAATATCTGCCACTCTTCTTCGATGCCACTCCTGTAGACAGGCAACAGCAACTGTA 1224

Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGAGCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCC 1284

Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTCGGCGAGTGTCAAT 1344

Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTTACTTTTCAAAGGGGTGCTGATGCTGGAGGTTCCGGGGCCCC 1404

Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGCGCAGGGGCGCTGCCCGCCATCCTGACGC 1464

Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
Db 1465 CGCCTCTTCTTCTCCTCTCTGCGCCGCTCATCTCTTCAAGGGTGGCGCTTACGTT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAAGGACTGGGG 1584

Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTGACGCGCGCTGCGAGCGCGCTGCGAGCGCGATGCCATCTTCT 1644

Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCGCAAACTGCAGGCAACCACTCGGGCG 1704

Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGTGGCATGTCCAACTCGGAGGCGCGCTTCTT 1764

Qy 520 e 520
Db 1765 c 1765

RESULT 15
US-10-137-865-143
; Sequence 143, Application US/10137865
; Publication No. US20030032155A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deanoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
```



```
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C154
; CURRENT APPLICATION NUMBER: US/10/137,865
; CURRENT FILING DATE: 2002-05-03
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-137-865-143

Alignment Scores:
Pred. No.: 3,358-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-137-865-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGTCGGCGCGTTCGGCTCTCTGCGCGCCCTGCGAGCTCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGAGCGCGGAGCGGAGAGCTGCGCAAGGAGCGCGGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCACCTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTGAGTCCAGTCTGTCAGCGCGGTGTGGACCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCCAGATGACTGTCCTCCCGCTGCGGGGTACAGATACCAACAGATTATGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGGCTGAGAGATCAGTCACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCAGCTCTCTACCGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCAITCTCGGAGCGCGCAGTTTCGGGGCGCGTTCGGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCCACAGGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGGCTCACCTCTTCCAGGGGAGCACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
```

```
DB 806 CCAGGGGGCGCGCTTCTGGCGCAGCGCTTC-CTGCCCCCGCGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTTGAGCGCGCGCGGGGGCGCAACCTGTTCTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACAGCTTGGCCTCACCACTCGCGCGCGCGCGCGGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTCGATGTCATCCTAGACAGGAGGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCTAAATACTGCGCACTCTCTCTCGATGTCATCCTAGACAGGCAACAGCAACTGTA 1224
QY 340 xIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGGTGCGGCTGCCCGCCCAACATTGAGGCTGCGGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysGlyCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATATTTACTTTCTCAAAGGGGGTTCGATGCTGGAGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCTCTTCTTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCGCGAGGGGAGTGTCAAGTGGAGCCCTACTACCCCGAAGTCTGCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCTCGAGGAGGTGAGCGCGCGCTCCCGAGGCGCGATGGCTCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCAGATGACCGCTACTGGCGCGCTCGACAGGCGCAAACTGCGAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheIleAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGTGCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
```

RESULT 16

US-10-140-474-143
; Sequence 143, Application US/10140474
; Publication No. US20030032156A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.

```

; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC162
; CURRENT APPLICATION NUMBER: US/10/140,474
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-140-474-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-140-474-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTGGCCCTCCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuAenGlnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGNACAGGTCCCAAGCTCCCACTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCACACCTCGCCGAGATGACTCTGTCGGGTGCGGGGTTCAGATACCAACAGTTATGGC 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTTGTTGTAGACACCGGACCAAAATGAGCGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAATAATGGTACAAAGCAGCACCTCTCTACCCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCAATCTGCCGAGCCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnAlaProLeuTh 180

```

```

Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGGCCCCAGCCACAGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGTGGCTGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACCGCTTC -CTGCCCGCCCGCGGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGCAACCTGTTCTGTTGCTGCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTTCACACGCTTGGCCTCACCCACCTGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGAGCGGCTGCTCAGCTGGAGCAGCTGCTGGCCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACACGCCCAAGGAAGGGCGCTGAAAGCGCAGGG 1164
QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAATACTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCATTTCTGGGAGGTGGCAGCTGATGGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCTACTCAGAAAGATGGGTGGGCTGGGCTGCCCCCAACATTGAGGCTGGCGCAGTGTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGAGATTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyVgLyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTCCGGGCAAGGGGCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTACAGGGCGCTGCCGAGGCGCGCGTGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpA-gLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

```


Db 1465 CGCCTCTTCTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTCCCCCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPGl 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGATCCCTCAGGAGGTCAGCGCGCCTCCGAGGCCGATGGCTCCATCTTCTT 1644
Qy 480 eArgAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAACTGCAGGCAACCACTCTGGGCCG 1704
Qy 500 gTTPAlaThrGluLeuProTTPMetGlyCyeTTPHisAlaLysSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACAGGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 20

US-10-123-262-143
; Sequence 143, Application US/10123262
; Publication No. US20030049816A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: ACIDS ENCODING THE SAME
; CURRENT APPLICATION NUMBER: US/10/123,262
; CURRENT FILING DATE: 2002-04-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-262-143

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-262-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTTPGlyHisLeu 20
Db 206 ATGGTGGCGCGGTCTCTGCTGGCGCCCTGTCAGTGTCTACTGTGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40

Db 266 GACGCCCCAGCCCGCGAGCGCGGAGCCACAGAGCTGCGCAAGGAGCGGAGGCATTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCATTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTACGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTCTTGTCTAGACACCGGACCAAAATGAGCGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTTPTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCAAAGCAAGGTAACAATGGTACAGCAGCACCTCTCTACCGGCTGTG 625
Qy 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyValAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTCAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGGAGGCCCGCAGCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCTTCTTCCAAAGGGACACACAGATGGGTGGGCAATGCCTTTGTATGGC 805
Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACTGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGTCTCCAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGGCGCCCTGAAACGCGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACCTCTTCTCGATGGCTGCCCGCCCAACATTCAGGCTGGCGCAGTGTCT 1344
Qy 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGGAAGATGGGTGGGCTGCCCGCCCAACATTCAGGCTGGCGCAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCyeTTPArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGATGTGGAGGTTCGCGGGGCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGCAGGGGCGCTCCCGGCATCTTGACGC 1464
QY 420 aAlaLeuPheProProLeuArgArgLeuLeuPheGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCTCCCTCTCTGCGCGCTCATCTCTCTTCAAGGGGTGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCCAGGGGGGACTCAAGTGGAGCCCTACTACCCCCGAAAGTCTCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGTTCAGCGCGCCCTGCGAGGCCCGCATCTCTCTCTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGAGGCCAACTGCAGGCCAACCCCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGTGCCTCGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 21

US-10-142-423-143
; Sequence 143, Application US/10142423
; Publication No. US20030049817A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC249
; CURRENT APPLICATION NUMBER: US/10/142,423
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-423-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-423-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGTCGGCGCGCTCTCTGCTCGCGCCCTTCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGAGCGCGAGGCTGCGCAAGAGGCTGCGCAAGAGGCGGAGGCAATTCCTTA 325
QY 41 GluIysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACATCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTTCAGCGGGGTGTGTGACCGCC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCGTAGACACCGGACCCAAATGAGGGGTAA 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAAGCCTTTGCAAGCAAGGTAAACAAATGGTACAGACGACACCTCTCTCCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGGAGGCCCCAGCCACAGTGGCCATGCTTTGATGGC 745
QY 180 rSerGlySerProSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCGCGCTCAGCTTCTTCCAAAGGGGACCAACGATGGGCTGGGCATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTGGGCGACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGGGGCGCAACCTGTTGCTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGGCGCGCGCGCTCTCAGCTGGGACCGACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGGCGCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGCCATTTCTGGAGGGTGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284

QY	360	gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaValSerLe	380	Score: 2792.00	Matches: 519
Db	1285	TCCACTGAGGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTCGCGAGTGTCATT	1344	Percent Similarity: 99.62%	Conservative: 0
QY	380	uAsnAspGlyAspPheTyrPhePheLeysGlyGlyArgCysTrpArgPheArgGlyProLy	400	Best Local Similarity: 99.62%	Mismatches: 1
Db	1345	GAATGATGGAGATTCTACTTCTTCNAAGGGGGTCGATGCTGGAGGTTCGGGGGCCCAA	1404	Query Match: 98.52%	Indels: 2
QY	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420	DB: 15	Gaps: 0
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCCGCCATCTCGAGCG	1464	US-10-791-980-6 (1-520) x US-10-121-050-143 (1-1985)	
QY	420	aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLeysGlyAlaArgTyrTyrVa	440	QY	1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu
Db	1465	CGCCCTCTTCTCCCTCTGCGCGGCTCATCTCTTCAAGGGTGCCTACTACTAGT	1524	Db	206 ATGGTCGCGGGCTCGGCCTCTCTGTGCGCGCCTCGAGCTGCTACTGTGGGGCCACCTG
QY	440	lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1	460	QY	21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu
Db	1525	GCTGCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCCGNAAGTCTGCAGGACTGGGG	1584	Db	266 GAGCCCCAGCCCGAGGCGCGAGGCCAGGAGCTGCGCAAGAGGCGGAGGCAATTCCTA
QY	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480	QY	41 GluLyTyxGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer
Db	1585	AGGCATCCCTGAGGAGGTGAGGGCGCCCTGCCGAGGCGCCGATGGCTCCATCATCTTCTT	1644	Db	326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGTCCCCACCTCCACTCGATTTCAG
QY	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500	QY	61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg
Db	1645	CCGAGATGACCGCTACTGCGCGCTCGACCAAGCCCAACTGCAGGCAACCACTCGGGCGG	1704	Db	386 GATGCCATCAGAGCGTTTCACTGGGTGCCAGTACCTGTCTAGCGCGGTGTGGACCGC
QY	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520	QY	81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla
Db	1705	CTGGGCCACCGAGCTGCCCTGTGTGGCTGTGGCATGCCAACTCGGGAGGCGCCCTGTT	1764	Db	446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGTTTACAGATACCAACAGTTATGCG
QY	520	e 520		QY	101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys
Db	1765	C 1765		Db	506 GCCTGGGCTGAGAGGATCAGTACTTGTGTGTAGACACCGGACCAAAATGAGCGGTAA
RESULT 22				QY	121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal
US-10-121-050-143				Db	566 AAACGCTTTGCAAGCAAGGTAAATAATGTGTACAGCAGCACCTCTCTACCGCCTGGTG
; Sequence 143, Application US/10121050				QY	141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe
; Publication No. US20030054516A1				Db	626 AACTGGCTTGAGCATCTGCCGAGCGGCGGAGTTTGGGGCGCGCTCGCGCGCTTCAG
; GENERAL INFORMATION:				QY	160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh
; APPLICANT: Baker, Kevin P.				Db	686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGGCCCCCAGCACGCCCCCGCTGAC
; APPLICANT: Beresini, Maureen				QY	180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl
; APPLICANT: Deforge, Laura				Db	746 ATCCGGCTCACCTTCTTCCAGGGGACCACACAGATGGGCTGGGCAATGCTTTGATGGC
; APPLICANT: Desnoyers, Luc				QY	200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1
; APPLICANT: Filvaroff, Ellen				Db	806 CCAGGGGCGCCCTGGCGCACGCCCTTC- CTGCCCGCGCGCGGAGAAAGCGCACCTTCGACCA
; APPLICANT: Gao, Wei-Qiang				QY	220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi
; APPLICANT: Gerritsen, Mary E.				Db	865 AGATGAGCGCTGGTCCCTTGAGCCCGCCCGCGGCGGCAACCTGTTCGTGGTGTGGCGCA
; APPLICANT: Goddard, Audrey				QY	240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr
; APPLICANT: Godowski, Paul J.				Db	925 CGAGATCGGTACACGCTTGGCCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC
; APPLICANT: Gurney, Austin L.				QY	260 oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaLg1
; APPLICANT: Sherwood, Steven				Db	985 CTACTACAAGAGGCTGGGCGCGCGAGCTGCTCAGCTGGGAGCAGCGTGTGGCGGTGCA
; APPLICANT: Smith, Victoria				QY	1044 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh
; APPLICANT: Stewart, Timothy A.				Db	1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCCGAGAAAGCTGT
; APPLICANT: Tamas, Daniel				QY	300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1
; APPLICANT: Watanabe, Colin K				Db	1105 CACTGACTTTGAGACCTGGGACTCTCCTCAGCCCCCAAGGAAGGCGCCCTCGAAACGACGG
; APPLICANT: Wood, William				QY	320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy
; APPLICANT: Zhang, Zemin				Db	
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC					
; TITLE OF INVENTION: ACIDS ENCODING THE SAME					
; FILE REFERENCE: P3330R1C20					
; CURRENT APPLICATION NUMBER: US/10/121,050					
; CURRENT FILING DATE: 2002-04-12					
; Prior Application removed - See File Wrapper or Palm					
; NUMBER OF SEQ ID NOS: 550					
; SEQ ID NO 143					
; LENGTH: 1985					
; TYPE: DNA					
; ORGANISM: Homo Sapien					
US-10-121-050-143					
Alignment Scores:					
Pred. No.:					
				3.35e-262	1985
				Length:	

```
Db 1165 CCCTAAATAGTCCACTCTTCTTCGATGCCATCCATCTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rtlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTCCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGGTCTCCCAAGCTGTGCCGGGAGGGGCCCTGCCCGCCATCTCGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyValaArgTrpTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGGCTCATCTCTTCAAGGTGCCCGCTACTACGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTrpTrpTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
Qy 460 vGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGGGGGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGTACTGGCGCTCGACCAGGCCAACTGCAGGCAACACCCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 c 1765
```

RESULT 23

```
US-10-141-755-143
; Sequence 143, Application US/10141755
; Publication No. US20030054517A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P33301C192
; CURRENT APPLICATION NUMBER: US/10/141,755
; PRIORITY FILING DATE: 2002-05-08
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
```

```
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-141-755-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-141-755-143 (1-1985)
```

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGCTGCGCGCTTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGGCCAGCCCGCGAGCGCGGAGCCAGGAGCTGCCGAGGAGCGCGGAGGCGGAGGCAATTCCTA 325
Qy 41 GluLysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCCACTCCCTCATTGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGCTGTGTGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla 100
Db 446 GCCACCTTGCAGATGATGCTGCTCCCGCTCGCGGGTTACAGATACCACACAGTTATGGC 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGCTAGACACCGGACCAAAATGAGGCGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTrpArgLeuVal 140
Db 566 AAACGCTTTGCAAAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCCGAGCGCGCAGTTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTTCTTCAAGGGGACCAACATGATGGGCTGGGCAATGCGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTTGGCGCAGCCCTTC-CTGCCCGCGCGGCGCAACCTGTTTGGTGGTGGCGCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGGCGCAACCTGTTTGGTGGTGGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCCCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGCGCGCGCGCTGCTCAGCTGGGAGCGACGCTGTGGCGCGCTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
```

```
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTAGTGGCGCTCAGCTCCAGTCCAGGAAGCTGTT 1104
Qy eThraSpPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTCAGACCTGGGACTCTCAGACCCCAAGGAAGCGCCCTGAAACGCAAGG 1164
Qy yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTCTGGAGTGGCAGCTGATGCAACGCTCAGAGCCCCG 1284
Qy gProLeuGlnGluArgTfTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
Qy uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCATCTGAGGC 1464
Qy aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTCTTCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
Qy lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGCGCCGAGGGGACTGCAAGTGGAGCCCTTACCCCCGAACTGTCAAGGACTGGGG 1584
Qy yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCCGAGGGCCGATGGCTCCATCATCTTCT 1644
Qy eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysIleuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACCGAGGCCAACTGCAGGCAACCACTCGGGCG 1704
Qy gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 24
US-10-143-032-143
; Sequence 143, Application US/10143032
; Publication No. US2003005909A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
```

```
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC245
; CURRENT APPLICATION NUMBER: US/10/143,032
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-143-032-143
Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-143-032-143 (1-1985)
Qy 1 MetValalaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCCCTCTGCTGCGCGCTGTCAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGGCCAGCCCGCGGAGCGCGGAGGCTGCGCAAGGAGGCGGAGGATTCCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACCGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCATTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTACGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGATCTGTCGCCGTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACTTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AACCGCTTTCGAAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCCGAGCGCGAGTTTCGGGGCGCGTGCAGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGAGTTCCTGGAGGCGCCCGAGCCACAGGCGCGTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTTCACCTCTTCCAAAGGGGACCAACCAATGGGCTGGCAATGCCCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCCTCACCCACTTCGCCCGCGCGCGGCTCATGGCGCC 984
```

Qy	260	oTyrrIySArgIeuGlyAqAspAlaLeuLeuSerTrpAspAspValIeuAlaValGI	280
Db	985	CTACTACAAGAGGCTGGGCCCGCAGCGCTCTCAGCTGGGACACAGTGCTGGCCGTGCA	1044
Qy	280	nSerLeuTyrrGlyLySProLeuGlyGIySerValAlaValGlnLeuProGlyLySLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGCCCTCCAGCTCCCGAAGACTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrrSerProGlnGlyArgArgProGluThrGlnGI	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTCAGCGCCCAAGGAAGCGCCCTGAAACGCAAGG	1164
Qy	320	yProLySyrCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCCAACAGCACTGTA	1224
Qy	340	rIlePheLySGLySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTTCTGGGAGTGGCAGCTGATGGCAACGTCTCAGAGCCCG	1284
Qy	360	qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe	380
Db	1285	TCCACTGCAGGAAGAATGGTGGGCTGCCCCCCACATTAGAGCTCGCGCAGTGTCA	1344
Qy	380	uAsnAspGlyAspPheTyrrPhePheLySGLyGIyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTTACTTCTTTCAAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGIyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGCAGGGGGCTGCCCGCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLySGLyAlaArgTyrrVrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTCGCGCCCTCATCTCTTCAAGGGTGCCCGCTACGT	1524
Qy	440	lLeuAlaArgGIyGlyLeuGlnValGluProTyrrTyrrProArgSerLeuGlnAspTrpGI	460
Db	1525	GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGCTGTCAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTTGAGAGAGTTCAGCGGCGCCCTGCCGAGGCCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLySLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTCTGGGCGCTTCGACCAGGCCAAACTGCAGGCCAACACCTCGGGCGC	1704
Qy	500	qTrpAlaThrGluLeuProTrpMetGIyCysTrpHisAlaAsnSerGIySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTCTGTGCATGCCAACCTCGGGGAGCCCTGTT	1764
Qy	520	e	520
Db	1765	C	1765

```

RESULT 25
US-10-123-108-143
; Sequence 143, Application US/10123108
; Publication No US20030068793A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Baresini, Maureen
; APPLICANT: DeForest, Laura
; APPLICANT: Deenoyers, Luc
; APPLICANT: Flivaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven

```

```
; PRIOR APPLICATION NUMBER: 60/065846
; PRIOR FILING DATE: 1997-11-17
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/066453
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066511
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/069212
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069278
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069334
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069694
; PRIOR FILING DATE: 1997-12-15
; PRIOR APPLICATION NUMBER: 60/072320
; PRIOR FILING DATE: 1998-01-23
; PRIOR APPLICATION NUMBER: 60/073612
; PRIOR FILING DATE: 1998-02-04
; PRIOR APPLICATION NUMBER: 60/074086
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/074092
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-02-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/081203
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081229
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081695
; PRIOR FILING DATE: 1998-04-14
; PRIOR APPLICATION NUMBER: 60/081817
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081818
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082999
; PRIOR FILING DATE: 1998-04-24
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/083545
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084627
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084637
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/085149
; PRIOR FILING DATE: 1998-05-12
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085338
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085339
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085697
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085704

; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086414
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/086430
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088730
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088741
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090538
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091982

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-108-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTCGGCCCTCCTGCTGGCGCCCTCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGGAGCGGAGCTGGCGAGGCGGAGGCGGAGGCGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProlyAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGCTCCCAAGCTCCCACTCCACTCGATTACGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGCGGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
```

Db 506 GCTGGGCTGAGAGGATAGTGACTTTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACTAATGGTACNAGCAGCACTCTCTTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGGCGAGCGGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCACGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCCCTTGTATGCG 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLysSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTGCTGTGCTGGCGCA 924
QY 240 eGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCTGGCGCGCGACGCGCTGTCTAGCTGGGACGAGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGATCTCTACAGCCCCCAGGAGGCGCTGAAACCGAGGG 1164
QY 320 yProLysTrpCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTrp 340
Db 1165 CCCTAAATACTGCCACTTCTCTGATGCCATCATCTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGCTCGGCTGCCCCCACCACATTGAGGCTGGGCGAGTGTGATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGGCAGGGGCGCTTGCCTCCGCACTCTGAGCG 1464
QY 420 aAlaLeuPheProProLeuArgGluLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTCGAAGTGGAGCCCTTACTACCCCCCAAGTCTCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCGGAGGCGCGATGGCTCCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACGAGGCCAAACTGCGAGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCGCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 26
US-10-123-236-143
; Sequence 143, Application US/10123236
; Publication No. US20030068795A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Collin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C33
; CURRENT APPLICATION NUMBER: US/10/123,236
; CURRENT FILING DATE: 2002-04-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-236-143
Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-123-236-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACAGCCCGGAGCGCGGAGGCTGGCGAAGGCGGAGGCGGCGCATTCCTA 325
QY 41 GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCACGAGCTACCTGTGAGCGGCTGTGGACCGC 445

Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	CCACCCCTGCCGACAGTACCTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCACAACAAGTAACAAATGGTACAGACGACCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	NACTGGCCTGAGCACTCTGCGGAGCGCGAGTTCGGGGCGCGTCCGCGCGCTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCACAGCGCTGGAGTTCCTGGGAGGCCCCAGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGCAATGCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1	220
Db	806	CCAGGGGGCGCGCTGCGCACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCTCCCTGAGCGCGCGCGCGGGCGCACTGTTCGTGTGCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTCAACGCTTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1	280
Db	985	CTACTACAAAGAGCTGGGGCGGACGCGCTGTCTAGCTGGGACGAGTCTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGAAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1	320
Db	1105	CACAGCTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAGCGCGCTGAAACGCGAGG	1164
Qy	320	yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATCTGCATCTCTTCCTTCATGCGCATCTGTAGACGCAACAGCACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CAITTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGATGGTTCGGGCTGCCCCCAACATTGAGCGCTGGCGAGTGTCATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGAGGGGGCTCTCCCGCGCATCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuLeLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCTCTGCGCGCGCTCATCTCTTCAAGGGTTCGGCTTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1	460
Db	1525	GCTGGCCCCGAGGGGAGTCAAGTGGAGCCCTTACTACCCCCGAGTCTGCAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTCAGGAGGTCAAGGGGCGCTGCGGAGCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVar	500
Db	1645	CCGAGATGACCGCTACTGCGCTCCGACGAGCAAACTGCAGGCAACCACTTCGGGCGG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCACCGAGCTGCGCTGGATGGCTGCTGGCATGCNACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	

RESULT 27

US-10-123-261-143
 ; Sequence 143, Application US/10123261
 ; Publication No. US20030068796A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE OF INVENTION: ACIDS ENCODING THE SAME
 ; FILE REFERENCE: P3330R1C42
 ; CURRENT APPLICATION NUMBER: US/10/123,261
 ; CURRENT FILING DATE: 2002-04-15
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 ; US-10-123-261-143

Alignment Scores:
 Pred. No.: 3,35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-261-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCGTGGCGCTCTCTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGCGGAGCGGAGGCGGAGGCTGCGCAAGGAGCGGAGGCATTCCTA	325

QY 41 GluLeuTyrGlyTyrLeuAsnGluInValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCACACCTCCACTCGATTACGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGCTTTCAGTGGGTGTCCTCCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGGCAGATGACTGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgArgLys 120
DB 506 GCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGGTAAAG 565
QY 121 LysArgPheAlaLysGlnIleAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGGCAAGCAAGGTAAACAAATGGTATCAAGCAGCAGCTCTCTTACCGCCCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCCCTTGTATGCG 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGln 220
DB 806 CAGGGGGGGCGCTGGCGCACCCCTTC-CTGGCCCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
DB 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGCGCAACCTGTTCTGTTGCTCGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTTCCACCCACTCGCCCGCGCGCGCTCATGCGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGln 280
DB 985 CTACTACAAGAGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGAGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGln 320
DB 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCGCCCAAGGAAGCGCCCTCGAAACGACGGG 1164
QY 320 vProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCTTAATACTGCCACTCTTCTTCATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGCAACGCTCCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProbenIleGluAlaAlaValSerIle 380
DB 1285 TCCACTGCAGGAAGATGGTGGGTGCGGCCCAACATTAGGCTGGCGGAGTGTCAATT 1344
QY 380 uAsnAspGlyAspPheThrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLys 400
DB 1345 GAATGATGAGATTTCTACTCTTCAAGGGGGGTGATGCTGGAGGTTCGGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420

DB 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGCGGCGAGGGGCGCTGCCCGCCATCTTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGGTGCGCGTACTACGT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGln 460
DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAAAGTCTGCAGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePhe 480
DB 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTGCGGAGGCGCGATGCTCCATCATCTCTTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATACCGCTACTGCGCGCTCGACCAAGCCAAATGCAAGGCAACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGCCACCGAGCTGCCCTGTGATGGGTGTGGCATGCCAACTCGGGAGGCGCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 28
US-10-140-921-143
; Sequence 143, Application US/10140921
; Publication No. US20030068797A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C175
; CURRENT APPLICATION NUMBER: US/10/140,921
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-921-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-140-921-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20

Db 206 ATGTCGCGCGCTGGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGlyAlaGluAlaPheLeu 40
 Db 266 GACGCCACGCGCGGAGCGCGGAGCCAGAGCTGCGCAAGGAGGCGGAGGCAATCTTA 325
 Qy 41 GluIysTyrGlyTyrLeuAsnGlnGlnValProIysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCGATTCGATCAGC 385
 Qy 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGACCGCTTCAGTGGGTGCCAGCTACCTGTGACGGGGCTGTGGACGC 445
 Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
 Qy 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCTCGGCTGAGAGATCAGTACTGTGTGTGACACCGGACCAAAATGAGCGCTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
 Db 566 AAACGCTTTGMAAGCAAGGTAACTAATGTTACAGACGACCTCTCTACCGCTGGTG 625
 Qy 141 AsnTyrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGTGGCGCGCGCTTCCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGTCTCAGCGCTGAGATTTCTGGAGGCGCCACAGCCAGGCCCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
 Db 746 ATCCCGCTCACCTTCTTCCAGGGGACCCACACGATGGCTGGGCAATGCTTTGATGCG 805
 Qy 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGCGCTGGCGCACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTyrSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCTCCTGAGCGCGCGCGCGGGGCGCAACCTGTTCGTGGTGGTGGCGCA 924
 Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
 Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValGl 280
 Db 985 CTACTACAAGAGGCTGGGCGCGAGCGCTGTCTAGCTGGGACGAGCTGGCGCGTGA 1044
 Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCTGTATGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
 Qy 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAAGGCGCGCTGAAACGAGGG 1164
 Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCTAAATATCGCACTTCTTCCTTCGATGCCATCTCTGTAGACGAGCAACAGCAACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTyrGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGCAATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCCG 1284
 Qy 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerLe 380

Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCGCCCAACATTGAGGCTGCGCAGTGTCAAT 1344
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTyrArgPheArgGlyProLy 400
 Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
 Qy 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCATCTCGACGC 1464
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
 Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCTATCTCTTCAAGGGTGGCGCTACTACGT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrGl 460
 Db 1525 GCTGGGCCGAGGGGAGTGCAGAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
 Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGCATCTCTTGAGAGGTTCAGCGCGCCCTGCGGAGCCCGATGGCTCCATCTTCTT 1644
 Qy 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCAGATGACCGCTACTTGGCGCTCGACACGAGGCAAACTGCAGGCAACCCACTCGGGCCG 1704
 Qy 500 gTyrAlaThrGluLeuProTyrMetGlyCysTyrHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACGAGTGGCTGGATGGCTGGATGGCTGGCACTGCCAACTCGGGGAGCGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 C 1765

RESULT 29

US-10-140-928-143
 ; Sequence 143, Application US/10140928
 ; Publication No. US20030068798A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Deenoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330P1C186
 ; CURRENT APPLICATION NUMBER: US/10/140,928
 ; PRIORITY FILING DATE: 2002-05-07
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 ; US-10-140-928-143
 Alignment Scores:
 Pred. No.: 3.35e-262 Length: 1985
 Scores: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0

APPLICANT:	Tumas, Daniel	
APPLICANT:	Watanabe, Colin K	
APPLICANT:	Wood, William	
APPLICANT:	Zhang, Zemin	
TITLE OF INVENTION:	SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC	
TITLE OF INVENTION:	ACIDS ENCODING THE SAME	
FILE REFERENCE:	P3330R1C51	
CURRENT APPLICATION NUMBER:	US/10/123,903	
Prior FILING DATE:	2002-04-16	
Prior Application removed -	See File Wrapper or Palm	
NUMBER OF SEQ ID NOS:	550	
SEQ ID NO	143	
LENGTH:	1985	
TYPE:	DNA	
ORGANISM:	Homo Sapien	
US-10-123-903-143		
Alignment Scores:		
Pred. No.:	3.35e-262	
Score:	2792.00	
Percent Similarity:	99.62%	
Best Local Similarity:	99.62%	
Query Match:	98.52%	
DB:	15	
US-10-791-980-6 (1-520) x US-10-123-903-143 (1-1985)		
Qy	1 MetValAlaArgValGlyLeuLeuAuaArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu	20
Db	206 ATGTCGCGCGCTGCGGCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21 AspAlaGlnProAlaGluAuaArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266 GACGCCACGCCGCGGAGCGCGGAGGCGCAGAGCTGCGCAAGGAGCGGAGGCATTCCTA	325
Qy	41 GluLysTyrGlyTyrLeuAuaGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326 GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAAAGCTCCACCTCCACATCGATTACG	385
Qy	61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACCTGTTCAGCGGCGTGTGGACCGC	445
Qy	81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446 GCCACCTTCGCGCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATCGC	505
Qy	101 AlaThrAlaGluAuaArgLysAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506 GCCTGGGTGAGAGATCAGTACATGTGTGTGTACACCGACCAAAATGAGGCGTAAAG	565
Qy	121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566 AAACGCTTTGCAAGCAAGGTAACAAATGGTAAAGCAGCACCTCTCTCTACCGCTGGTG	625
Qy	141 AsnTyrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626 AAATCGCCTGAGCATCTGCGGAGCGCGCAGTTCGGGGCGCGCTGCGCGCCCGCTTCAG	685
Qy	160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686 TTGTGTGAGCAAGCTCTCAGCGCTGGAGTCTTGGAGGCCCGCCAGCCACAGCCCGCTGAC	745
Qy	180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl	200
Db	746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC	805
Qy	200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
Db	806 CCAGGGGGGGCGCCCTGCGGACGCGCTTC-CTGCCCCCGCGCGGCAAGCGCATCTTCACCA	864
Qy	220 nAepGluAuaArgTyrSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240

```
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C65
; CURRENT APPLICATION NUMBER: US/10/124,819
; CURRENT FILING DATE: 2002-04-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-124-819-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-124-819-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGTCGCGCGGTGGCTCTGCTGTCGCGCGCTGCACTGCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACGCCGCGAGCGCGAGCGCGAGAGCTGCGCAAGAGCGCGAGGCAATTCCTA 325
QY 41 GluLysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrLysMetArgLys 60
DB 326 GAGAGTAGCGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACCTCGATTACAG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCAGTACCTGTGTCAGCGCGGTGTGGACGCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgProArgCysGlyValThrAspThrAsnSerTyra 100
DB 446 GCCACCTTCGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGCTGAGAGATCAGTACCTGTTGTGTACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrlsGlnHisLeuSerTyArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCAGCTCTCCTACCGCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTCCGAGAGCGCGAGTTCGCGGGCGCGGTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGAGCAAGTCTCAGCGCTGAGTTCCTGGAGGCGCCACAGCCAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
```

RESULT 34

US-10-124-822-143

; Sequence 143, Application US/10124822

; Publication No. US20030073214A1

```
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGGCGCCCTGGCGACAGCCCTTC-CTGCCCCCGCGCGGAGGACACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGCGGCGCAACCTGTTGCTGCTGTCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGCGCGC 984
QY 260 oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
DB 985 CTACTACAGAGGCTGGGCGCGCGAGCGCTGCTGAGCTGGGACGAGCTGCTGGCGTGA 1044
QY 280 nSerLeuTyrglyLysProLeuGlyLysrValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGTCCCAAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyTrpProGlnGlyArgArgProGluThrGlnG 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGAAACGCGAG 1164
QY 320 yProLysTyTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTAATACTAGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACACAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTCATGGCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
DB 1285 TCCATCTGAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGTGGCGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyTrpPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTTCTTCAAAGGGGTGCGATGCTGGAGGTTCGCGGGCC 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGCTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyTrVa 440
DB 1465 CGCCTCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyLysLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTTACTACCCCGAAGCTGCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTACGGGCGCTCGCGAGGCGCGATGGCTCCATCATCTCTCT 1644
QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGCGCAAACTGCGAGGCAACACCTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGCGATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
```



```

; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C64
; CURRENT APPLICATION NUMBER: US/10/124,822
; CURRENT FILING DATE: 2002-04-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-124-822-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-124-822-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 206 ATGTCGCGCGCGTGGCCCTCTGCTGCGCGCGCTGCGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACCGCGGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGACAGGTCCTCCCAAGCTCCCACTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCCCTGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACTGTTCCTGCTGCGGGTACAGATACCAACAGTTATGCG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACCGCTTTGCAAGCAAGGTAAATAATGGTACAGCAGCAGCCTCTCTTACCGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTGCGGAGCGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685

```

```

160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGGCGCCACAGCCACAGGCCCCGTGAC 745
180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
746 ATCCGGCTCACCTTCTCCAAAGGGGACCAACAGATGGGTGGGCAATGCTTTGTATGGC 805
200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgArgGlyGluAlaHisPheAspGl 220
806 CCAGGGGGCGCGCTGGCGCACGCTTC - CTGCCCCCGCGCGGAGGAGCGACACTTCACCA 864
220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCGCACTGTTCTGTGTGTGGCGCA 924
240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
925 CGAGATCGGTACACGCTTGGCGCTCACCTCCACCTCGCGCGCGCGCGCTCATGGCGCC 984
260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
985 CTACTCAAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGAGCAGCGTGTGGCGGTGCA 1044
280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGAGAAAGCTGTT 1104
300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
1105 CACTGACTTTGAGACCTGGGACTCTTACAGCGCCCAAGAGGCGCGCTTCAAACGCGAGGG 1164
320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
1165 CCCTAAATACTGCGCACCTCTCTTCGATGCCATCCTCTAGACAGGCAACAGCAACTGTA 1224
340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
1285 TCCACTCAGAGAAAGATGGGTGGGCTGCGCGCCCAACATTTAGAGCTGCGGAGTGTCAAT 1344
380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGCGGGGCCCA 1404
400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
1405 GCCAGTGTGGGCTCTCCACAGCTGTGCGGCGCAGGGGCGCTGCGCGCCCAATCCAGCGC 1464
420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
1465 CGCCCTCTTCTTCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCGCGCTACTAGT 1524
440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCGCTACTACCCCGAAAGTCTGCAGGACTGGGG 1584
460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
1585 AGGCATCCCTGAGGAGGTACGCGCGCGCTGCCGAGGCGCGATGCTCCATCATCTTCTT 1644
480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
1645 CCGAGATGACCGCTACTGCGCGCTCGACAGCGCCAACTGCAGGCAACCACTCGGGCGC 1704
500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGATGATGCCCACTCGGGGAGCGCGCTGTT 1764
520 e 520

```


Db	1645	CCGAGATGACCGCTACTGGCGCCCTCGACACGAGCCAAACTCGAGGACCAACCACTCTGGGCGCG	1704
Qy	500	gTPrAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGCCACCGAGCTGCCTCGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 36			
US-10-160-498-143			
; Sequence 143, Application US/10160498			
; Publication No. US20030073216A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Desnoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tumas, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			
; APPLICANT: Zhang, Zemin			
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC			
; TITLE OF INVENTION: ACIDS ENCODING THE SAME			
; FILE REFERENCE: P3330RIC451			
; CURRENT APPLICATION NUMBER: US/10/160,498			
; CURRENT FILING DATE: 2002-05-30			
; Prior Application removed - See File Wrapper or Palm			
; NUMBER OF SEQ ID NOS: 550			
; SEQ ID NO 143			
; LENGTH: 1985			
; TYPE: DNA			
; ORGANISM: Homo Sapien			
US-10-160-498-143			
Alignment Scores:			
Pred. No.: 3 35e-262 Length: 1985			
Score: 2792.00 Matches: 519			
Percent Similarity: 99.62% Conservative: 0			
Best local Similarity: 99.62% Mismatches: 1			
Query Match: 98.52% Indels: 2			
DB: 15 Gaps: 0			
US-10-791-980-6 (1-520) x US-10-160-498-143 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGCGCGGTTCGGCTCTCTGCTGGCGCCCTCGACGCTCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaAlaPheLeu	40
Db	266	GACGCCACCCCGGAGCGCGAGGCCAGAGAGCTGGCGAAGAGGCGGAGCATTCCTTA	325
Qy	41	GluLysTyrGlyTyrIleuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAGTACGGGATACCTCAATCAACAGGTCCCAAAGCTCCCACTCCACTCGATTTCAG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACCTGTACGCGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCGAGCGCGGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGGCTCGACGAGGCAAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTPAlaThrGluLeuProTPMetGlyCysTPHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 37

US-10-124-824-143
; Sequence 143, Application US/10124824
; Publication No. US20030077659A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC68
; CURRENT APPLICATION NUMBER: US/10/124,824
; CURRENT FILING DATE: 2002-04-17
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-124-824-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-124-824-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTTCGGCGCGCTCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCGAGCCCGGAGCGCGGAGGCGGAGAGCTGGCGAGGAGCGGAGGCGCATTCCTA 325
QY 41 GluLysTyrglyTyLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGGTCCCAAGGTCCCACTCCACTTCGATTCAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGGTTTCACTGGGTGTCCCAAGCTACCTGTGAGCGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyAla 100
DB 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTPAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTAGACACCGGACCAAAATGAGGGGTAAAG 565
QY 121 LysArgPheAlaLysGlnGlyAenLysTrpTyLysGlnHisLeuSerTyArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGACGACACCTCTCTACCGCTGGTG 625
QY 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTCCGAGCGCGCAGTTGCGGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGGCCACAGGCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTACCTCTTCCAAGGGGACCAACGATGGGCTGGGCAATGCCCTTTGATGCC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGCGCCCTGGGCGACGCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAenLeuPheValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGGTGTCTGCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyTyLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGTGGCGCGCGCTGCTCAGCTGGGAGCGAGCTGTGGCGCTGCA 1044
QY 280 nSerLeuTyrglyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCAGCGCCCGGAGGAGGCGGCTGGAACCGAGGG 1164
QY 320 yProLysTyrcysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACCTCTCTTCGATGCCATCCTGATAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGAGGAAAGATGGGTGGGGCTGCCCGGCGGCGGCTGAGGTGCGGAGTGTCAIT 1344
QY 380 uAenAspGlyAspPheTyPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGGATGCTGGAGGTTCGCGGGCCCCAA 1404
QY 400 pProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGACTGTGCGGGGAGGGGGCTGCGCGGCCCTCTCTGAGCG 1464


```
Db 1045 GAGCGTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTTGAGACCTGGGACTCTTACAGCCGCCCAAGGAAGCGCCCTGAAACGAGGG 1164
Qy 320 YProLysTyCyHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
Db 1165 CCCTAAATAGTCCACTTCTTCGTGATGCCATCACTGTAGACAGGCACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGTAGTGGCAAGTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAAGAAGATGGTTCGGCTGCCCCCAACATTTAGGCTGCGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGTCTGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCCGCTCACTCTTCAAGGGTGGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGGCTTACTACCCCGAAGTCTGAGAGCTGGGG 1584
Qy 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTTGGCGAGGCGCGATGGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCGCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCGACGAGTCCCTTGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 39

```
US-10-127-829A-143
; Sequence 143, Application US/10127829A
; Publication No. US2003007711A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
```

```
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RJC85
; CURRENT APPLICATION NUMBER: US/10/127,829A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-829A-143
```

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-127-829A-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGCGCGCTCGGCTCTCTGCTGCGCGCTTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GAGCGCCAGCCCGGAGCGCGAGCGCCAGAGCTGCCNAGGAGCGGAGGCATTCTTA	325
Qy	41	GluLysTyTrpGlyLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACATCGATT	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCTGTCAGCGGTGTTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla	100
Db	446	GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTACTTGTCTAGACACCGGACCAAAATGAGGGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyLysGlnHisLeuSerTyArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGACGACCTCTCTCCGCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160

626	Db	AACTGGCGCTGAGCATCTGCGGAGACCGGAGTTCGGGGCGCGCTGGCGCGCGCTTCCAG	685
160	Qy	rCyAGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
686	Db	TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTTGGGAGGCGCCAGCCAGGCCCGCTGAC	745
180	Qy	rSerGlySerProSerSerIysGlyThrThrTrpMetGlyTrpAlaMetProLeuMetal	200
746	Db	ATCCGGGTCACTTCTTCCAAAGGGGACCAACACATGGCTGGGCAATGCTTTGATGGC	805
200	Qy	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
806	Db	CCAGGGGGCGCTTGGCGCAGCCCTTC-CTGCCCCCGCGCGGGAAGGCACATTCGACCA	864
220	Qy	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
865	Db	AGATGAGCGCTGTGCTTCCATGAGCCCGCGCGGCGCAACCTGTTCGTGTGTGTGGCGCA	924
240	Qy	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalaPr	260
925	Db	CGAGATCGGTCAACAGCTTGTGGCTTCAACCCTTCGCCCGCGCGCGCTCATGTGGCGCC	984
260	Qy	oTyTrIyAsArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
985	Db	CTACTACAAGAGGTGGGCGCGCAGCGCTGCTCAGCTGGGACGACGTGTGGCGGTGCA	1044
280	Qy	nSerLeuTyrcIlyIysProLeuGlyGlySerValaValaValGlnLeuProGlyIysLeuPh	300
1045	Db	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCAGAGAAAGCTGTT	1104
300	Qy	eThrAspPheGluThrTrpAspSerTyrsSerProGlnGlyArgArgProGluThrGlnGl	320
1105	Db	CACGTACTTTCAGACCTGGGACTCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCGAGG	1164
320	Qy	yProIysTyrcYsiHisSerSerPheAspAlaIleThrValaIspArgGlnGlnLeuTy	340
1165	Db	CCCTAAATACCTGCCACTTCTCCTTCGATGCCATCACTGTACAGAGGCAACAGCAACTGT	1224
340	Qy	rIlePheIysGlySerHisPheTrpGluValaIalaAspGlyAsnValSerGluProAr	360
1225	Db	CATTTTAAAGGAGCCATTCTTCGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCGC	1284
360	Qy	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaIalaValSerLe	380
1285	Db	TCCACTGCAGGAAAGATGGGTGGGGTGGCGGCGTCCGCCCAACATTCAGAGCTCGCGCAGTGT	1344
380	Qy	uAsnAspGlyAspPheTyrrPhePheIysGlyIyArgCysTrpArgPheArgGlyProLy	400
1345	Db	GAATGATGGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA	1404
400	Qy	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyIyLeuProArgHisProAspAl	420
1405	Db	GCCAGTGTGGGTCTCCACAGCTGTGCGCGGCGAGGGGCGCTGCCCGCCATCTCTGACGC	1464
420	Qy	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrrVa	440
1465	Db	CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTACGT	1524
440	Qy	lLeuAlaArgGlyGlyLeuGlnValGluProTyrrProArgSerLeuGlnAspTrpGl	460
1525	Db	GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGG	1584
460	Qy	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
1585	Db	AGGCATCTCTCAGGAGGTCAGCGGCGCGCTCGCCGAGGGCCGATGGCTCCATCATCTTCT	1644
480	Qy	eArgAspAspArgTyrrTrpArgLeuAspGlnAlaIyLeuGlnAlaThrThrSerGlyAr	500
1645	Db	CCGAGATACCGCTACTGGCGGCTTCGACAGCGCCAACTGCAGGCACACACTCGGGCGC	1704
500	Qy	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
1705	Db	CTGGGCCACGAGTGCCTCGATGGGTGTGTGGCATGCCAACTCGGGGAGCGGCGCTGTT	1764

Qy 520 e 520
Db 1765 C 1765

RESULT 40

US-10-127-835A-143
; Sequence 143, Application US/10127835A
; Publication No. US20030077712A1

APPLICANT:	Baker, Kevin P.
APPLICANT:	Beresini, Maureen
APPLICANT:	DeForge, Laura
APPLICANT:	Desnoyers, Luc
APPLICANT:	Filvaroff, Ellen
APPLICANT:	Gao, Wei-Qiang
APPLICANT:	Gerritsen, Mary E.
APPLICANT:	Goddard, Audrey
APPLICANT:	Godowski, Paul J.
APPLICANT:	Gurney, Austin L.
APPLICANT:	Sherwood, Steven
APPLICANT:	Smith, Victoria
APPLICANT:	Stewart, Timothy A.
APPLICANT:	Tumas, Daniel
APPLICANT:	Watanabe, Colin K
APPLICANT:	Wood, William
APPLICANT:	Zhang, Zemin

FILE. DNR
; ORGANISM: Homo
US-10-127-835A-143

US-10-791-980-6 (1-520) x US-10-127-835A-143 (1-1985)

Qy 1 MetValAlaArgValcIyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
nb 206 ATGGTCGCGCGCGTGGCCCTCTGCTGCGCGCCCTGAGCTGCTACTGTGGGCCACCTG 285

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGAGCGCGAGGCGCAGGAGTGCAGCAAGAGCGCGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCATCGATTACAG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTCAGCTACCTGTACGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCCCTGCGCCAGATGACTCGTCCCGCTCGGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCTCGGGCTGAGAGGATCAGTGTGTTTGTGTAGACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAACTGTTTGTAAAGCAGCACTCTCTTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 NAATGGCTGAGCAATCTGCGGAGCGCGAGTTCGGGGCGCGTGGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTCTTCCAGAGGACCAACAAGATGGGCTGGCAATGCCCTTTGATGCG 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTCTGTTGGTGTGTCGCGCA 924
QY 240 eGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGCTGGGCGCGAGCGCGTGTCTAGCTGGAGCAGCTGTGGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCAAGAGCGCGCGCTGAAACGCAAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACGCCACTCTCTTCATGCTGCCATCTGTAGACGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnLysArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCGAAGAAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGCTGCGGAGGTGTCATT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGAGGTTCGGGGCCCCAA 1404
QY 400 bProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGCGGCGAGGGGCTTGCCTCCGCGCATCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCTGCTACTACGT 1524
QY 440 lleAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATCACCGCTACTGGCGCTCGACGAGCCAAACTGCAGGCAACCCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 41
US-10-127-839A-143
; Sequence 143, Application US/10127839A
; Publication No. US20030077713A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330P1C105
; CURRENT APPLICATION NUMBER: US/10/127,839A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17

```
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-839A-143

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      99.52%      Indels:      2
DB:              15          Gaps:      0

US-10-791-980-6 (1-520) x US-10-127-839A-143 (1-1985)

QY      1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB      206 ATGGTCGGCGCGTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265

QY      21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB      266 GACGCCAGCCCGCGAGCGCGAGCGCCAGGAGCTGCGCAGGAGCGGAGGCATTCTCTA 325

QY      41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB      326 GAGAAGTACGGATACCTCAATGAACAGGTGCCAAAGCTCCACACCTCCATTCAGTCAGC 385

QY      61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB      386 GATGGCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGCGTGTGGACCGC 445

QY      81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB      446 GCCACCTTGGCCAGATGACTGCTCCCGCTCGCGGGTTACAGATACCAACAGATTATGCG 505

QY      101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB      506 GCCTGGGCTGAGAGGATCAGTACTGTTTGTGTAGACACCGGACCCAAATGAGCGGTAAAG 565

QY      121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB      566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCAGCTCTCTACCGCTGGTG 625

QY      141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB      626 AACTGSCCTTGAGCATCTGCGGAGCGCGAGTTCGGGCGCGCTGCGCGCGCTTCCAG 685

QY      160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB      686 TTGTGGAGCAACGCTCTACGCGTGGAGTTCTGGGAGGCGCCACAGCGCCCGCTGAC 745

QY      180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB      746 ATCCGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCCCTTTGATGGC 805

QY      200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB      806 CCAGGGGGCGCGCTGCGCACGCTTC-CTGCGCGCGCGCGAGCGCACTTCGACCA 864

QY      220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB      865 AGATAGCGCTGGTCTCCCTGAGCGCGCGCGCGCAACCTGTTCTGTTGGTCTGCTGGCGCA 924

QY      240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
```

```
DB      925 CGAGATCGGTACACAGCTTGGCCTCACCCACTGCGCGCGCGCGCGCTCATGGCGCC 984
QY      260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
DB      985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGAGCGACGCTGTGGCCGTGCA 1044
QY      280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB      1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGTT 1104
QY      300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB      1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGGCGCTGAAACGCGGG 1164
QY      320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB      1165 CCCTAAATACTGCGCACTCTTCTTCGATGCGCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY      340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB      1225 CATTTTTAAAGGGAGGCCATTCTTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG 1284
QY      360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB      1285 TCCACTCGAGGAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTGCGGCGAGTGTCAAT 1344
QY      380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
DB      1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGCGGGCCCCAA 1404
QY      400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
DB      1405 GCCAGTGTGGGCTCTCCACAGCTGTCCGGGCGAGGGGCTGCGCGCCCATCTCTGAGCG 1464
QY      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB      1465 CGCCTCTCTCTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCTACTACTAGT 1524
QY      440 lLeuAlaArgGlyLysLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB      1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCGCTCTATACCCCGAAGCTGCGAGGACTGGGG 1584
QY      460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB      1585 AGGCATCCCTGAGAGGTCAGCGCGCGCTGCGGAGCGCGCGATGGCTCCATCATCTTCTT 1644
QY      480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB      1645 CCGAGATGACCGCTACTTGGCGCTCGACCGAGCCAAACTGCAGGCAACCACTCGGGCGG 1704
QY      500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB      1705 CTGGGCGCACCGAGCTGCCCTGGATGGGCTGTGTGCAATGCCAACTCGGGGAGCGCGCTGTT 1764
QY      520 e 520
DB      1765 C 1765

RESULT 42
US-10-127-901A-143
; Sequence 143, Application US/10127901A
; Publication No. US2003007714A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
```

;	APPLICANT:	Gurney,Austin L.
;	APPLICANT:	Sherwood,Steven
;	APPLICANT:	Smith,Victoria
;	APPLICANT:	Stewart,Timothy A.
;	APPLICANT:	Tumas,Daniel
;	APPLICANT:	Watanabe,Colin K
;	APPLICANT:	Wood,William
;	APPLICANT:	Zhang,Zemin
;	TITLE OF INVENTION:	SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;	TITLE OF INVENTION:	ACIDS ENCODING THE SAME
;	FILE REFERENCE:	P3330R1C86
;	CURRENT APPLICATION NUMBER:	US/10/127,901A
;	CURRENT FILING DATE:	2002-10-15
;	PRIOR APPLICATION NUMBER:	60/049911
;	PRIOR FILING DATE:	1997-06-18
;	PRIOR APPLICATION NUMBER:	60/056974
;	PRIOR FILING DATE:	1997-08-26
;	PRIOR APPLICATION NUMBER:	60/059113
;	PRIOR FILING DATE:	1997-09-17
;	PRIOR APPLICATION NUMBER:	60/059115
;	PRIOR FILING DATE:	1997-09-17
;	PRIOR APPLICATION NUMBER:	60/059117
;	PRIOR FILING DATE:	1997-09-17
;	PRIOR APPLICATION NUMBER:	60/059122
;	PRIOR FILING DATE:	1997-09-17
;	PRIOR APPLICATION NUMBER:	60/059184
;	PRIOR FILING DATE:	1997-09-17
;	PRIOR APPLICATION NUMBER:	60/059263
;	PRIOR FILING DATE:	1997-09-18
;	PRIOR APPLICATION NUMBER:	60/059352
;	PRIOR FILING DATE:	1997-09-19
;	PRIOR APPLICATION NUMBER:	60/059588
;	PRIOR FILING DATE:	1997-09-19
;	Remaining Prior Application data removed - See File Wrapper or PALM.	
;	NUMBER OF SEQ ID NOS:	550
;	SEQ ID NO 143	
;	LENGTH:	1985
;	TYPE:	DNA
;	ORGANISM:	Homo Sapien
;	US-10-127-901A-143	
Alignment Scores:		
Pred. No.:	3,35e-262	Length: 1985
Score:	2792.00	Matches: 519
Percent Similarity:	99.62%	Conservative: 0
Best Local Similarity:	99.62%	Mismatches: 1
Query Match:	98.52%	Indels: 2
DB:	15	Gaps: 0
US-10-791-980-6 (1-520) x US-10-127-901A-143 (1-1985)		
Qy	1 MetValAlaArgValGlyLeuLeuLauAlaLeuLeuLeuLeuLeuTrpGlyHisLeu	20
Db	206 ATGGTCGCGCGGTGGCCCTCTGTCGCGGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21 AspAlaGlnProAlaGluAlaArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266 GAGCCCCAGCCCGGAGCGCGGAGCCAGANGTGCAGAGAGAGCGGAGGCATTTCCTA	325
Qy	41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326 GAGNAGTAGCATACCTCAATGAACAGGTCCCAGAGCTCCACCCTCCATCGATTTCAGC	385
Qy	61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386 GATGCCATCAGACGCTTTTCAGTGGGTGTCACGAGTACCTGTGCAGCGCGTGTTGGACCGC	445
Qy	81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446 GCCACCCTGGCCAGATGACTCGTCCCCTGTCGGGGTTACAGATACAACAGTTATGCG	505
Qy	101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120


```
Qy 340 rlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyAlaGlyCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGGCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTGCGCGCCCTCATCTCTTCAAGGGTGCCTGCTACTACGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGTGCAGTGGAGCCCTACTACCCCGAAGTCTGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCCGAGGCCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACGAGGCCAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 44

```
US-10-131-813A-143
; Sequence 143, Application US/10131813A
; Publication No. US2003007716A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC139
; CURRENT APPLICATION NUMBER: US/10/131,813A
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
```

```
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-813A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-131-813A-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGTCGGCGCGTCTGCTGTCGCGCGCTCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGGCCCGAGCGCGGAGCGCGGAGGCTGGCAAGAGGCGGAGGCGGATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAGAGTCCCAACCTCCATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCCAAGTACCTGTGAGCGGCGTGTGGACCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTGCAGAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCCGAGCGCGGAGTTCGGGGCGCGCTGCGGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCAGCGCTGAGTTCCTGGGAGGCGCCAGCCAGCCAGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTTCTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
```

Db 806 CAGGGGGCGCTGGCGACGCCCTTC-CTGCCCCCGCGCGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyYargAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCGTGGTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuLeuGlyLeuThrHisSerProAlaProAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTGAGTGGAGCGAGCTGGCGGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTGCGAGTGGCAAGAGGGCGCTCGAAACGCGAGG 1164
Qy 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTCTCTCGATGCCATCACTGTACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGACCTTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGTCAGGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyYargCysTrpArgPheArgGlyProLy 400
Db 1345 GNATGATGGAGATTCTACTTCTTCAAAGGGGTGATGCTGGAGTTCGGGGGCCCAA 1404
Qy 400 pProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpTyVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCGCTGCGGAGGCGCGATGGCTCATCTCTTT 1644
Qy 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACGAGGCCAACTGCAAGGCAACCACTTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 45
US-10-131-818A-143
; Sequence 143, Application US/10131818A
; Publication NO. US2003007717A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C141
; CURRENT APPLICATION NUMBER: US/10/131,818A
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-818A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-131-818A-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTCGGCTCTGTCGGCGCCCTCGAGCTGTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACCCCGAGCCCGAGCGCGAGCTGCGCAAGGAGCGGAGGCGGAGGCGGATTCCTA 325
Qy 41 GluLysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80

Db 386 GATGCCATCAGACGCTTTCAGTGGGTGCCAGCTACCTGTCCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCGACAGTACTCTCCCGCTCGGGGTACAGATACCAACAGTTATGGC 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCGGCAGTTCGGGGGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGCTGGGCAATGCCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGGGCCCTGGCGCACCGCTTC-CTGCCCCCGCGCGGGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTGCTCCCTCAGCGCGCGCGCGCAACCTGTTCTGCTGCTGCGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCACCCCACTCGCGCGCGCGCGCTCATGCGCGC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCTGGCGCGCGACCGCTGCTCAGCTGGGACGAGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyValGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCGCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTTCTCTCGATGCCATCACTGTAGACAGCAACACACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGTCAGCTGATGCAACGCTCAGAGCCCG 1284
Qy 360 gProLeuGlnLysArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGTGGCGGCACTGCT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCCAACAGCTGTGCGGGGAGGGGCGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
Db 1465 CGCCCTCTTCTTCCCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGGAGGCCCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGTACTGCGCGCTCGACCAGGCCAAATGCAGGCAACCACTCGGCGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGGCGCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 46
US-10-131-823A-143
; Sequence 143, Application US/10131823A
; Publication No. US2003007718A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C143
; CURRENT APPLICATION NUMBER: US/10/131.823A
; PRIOR FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA

; ORGANISM: Homo Sapien			
US-10-131-823A-143			
Alignment Scores:			
Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0
US-10-791-980-6 (1-520) x US-10-131-823A-143 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGCTCGCTCGCGCGCTCGAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCGCGAGCGCGAGCGAGAGCTGCCAAGAGCGCGAGGCATTCTCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAGTACGGATACCTCAATGAACAGGTCCTCCAAAGCTCCACCTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGCTTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCCGACATGACTGCTCCCGCTCGCGGGTTACAGATACCACAGTTATGCG	505
Qy	101	AlaTrrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCTCGGCTGAGAGGATCAGTCACTTGTGTGTAGACACCGGACCAAAATCAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCCTCTCTCCGCGCTGTG	625
Qy	141	AsnTrrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	NACTGGCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGTTCGGCGCGCTTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGAGGCCCCACAGCCCGCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrrpAlaMetProLeuMetAl	200
Db	746	ATCCGCGCTCACCTTCTTCNAGGGGACCAACAGATGGGCTGGGCATGCTTGTATGGC	805
Qy	200	aGlnGlyAlaProTrrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCTGGCGCACGCCCTTC-CTGCCCCCGCGCGCGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrrpSerLysSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCTCCTGAGCGCGCGCGCGCGCAACCTGTGTGGTGTGCGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTTCACCCACTCGCCCGCGCGCGCGCTCATCGCGCC	984
Qy	260	oTrrpTrrpLysArgLeuGlyArgAspAlaLeuLeuSerTrrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAAGAGCGCTGGGCGCGGACGCGCTGTCTCAGCTGGGACGACGTCTGGCGGTGA	1044
Qy	280	nSerLeuTrrpGlyProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAACCCCTAGGGGGCTCAGTGGCGGCTCCAGCTCCCGAGGAAGCTGTT	1104

Qy	300	eThrAspPheGluThrTrrpAspSerTyrSerProGlnGlyArgProGluThrGlnGl	320
Db	1105	CACTGACTTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG	1164
Qy	320	YProLysTrrpCysHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy	340
Db	1165	CCCTAATACTGCGCACTCTTCTTCGATGCTCATCTGTAGACAGCAACAGCAACTGTGA	1224
Qy	340	rIlePheLysGlySerHisPheTrrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CAITTTTAAAGGGAGGCAATTTCTGGAGGTGGCAGCTGTATGGCAACGCTCTCAGAGCCCG	1284
Qy	360	qProLeuGlnGluArgTrrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe	380
Db	1285	TCACATGACAGAAAGATGGGTGGGCTGCCCCCAACATTTAGAGCTGGCGCAGTGTCAIT	1344
Qy	380	uAsnAspGlyAspPheTrrpPhePheLysGlyArgCysTrrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTTCTACTTCTCAAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA	1404
Qy	400	sProValTrrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTGCCCGCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaAlaArgTrrpVa	440
Db	1465	CGCCTCTTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTrrpTrrpProArgSerLeuGlnAspTrrpGl	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCGCTACTACCCCGCAAGTCTGCAGGACTCGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGAGGTGAGCGCGCCCTGCCGAGGCCGATGGCTTCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTrrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCTCGACACAGGCCCAACTGCAGGCAACCACTCGGGCG	1704
Qy	500	gTrrpAlaThrGluLeuProTrrpMetGlyCysTrrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGTCCCTGGATGGGTGCTGTCATGTCACCAACTCGGGGAGCGCCCTGT	1764
Qy	520	e 520	
Db	1765	c 1765	
RESULT 47			
US-10-131-824A-143			
; Sequence 143, Application US/10131824A			
; Publication No. US20030077719A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Desnoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tuman, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			
; APPLICANT: Zhang, Zemin			
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC			
; TITLE OF INVENTION: ACIDS ENCODING THE SAME			
; FILE REFERENCE: P3330R1C126			

```
; CURRENT APPLICATION NUMBER: US/10/131,824A
; CURRENT FILING DATE: 2002-04-24
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-824A-143

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00        Matches:     519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      98.52%        Indels:      2
DB:               15           Gaps:        0

US-10-791-980-6 (1-520) x US-10-131-824A-143 (1-1985)

QY      1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB      206 ATGGTCGGCGCGCTCGGCTCTCTGTCGGCGGCTGCACTGCTACTGTGGGGCCACCTG 265
QY      21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaLeu 40
DB      266 GAGCGCCAGCCCGGAGCGCGAGCGCTGCGGAGCTGCGCAAGAGCGGAGGCAATTCCTA 325
QY      41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB      326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCCACTCCACTCGATTCCAGC 385
QY      61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB      386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCCAAGTACCTGTCTGAGCGGCTGTGGACCGC 445
QY      81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB      446 GCCACCTCGCCGACATGACTCGTCCCGCTCGGGGTGTACAGATACCAACAGTTATTCG 505
QY      101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB      506 GCCTGGCTGAGAGGATCAGTACCTGTTTGTGTAGACACCGGACCAAAATGAGGGCTAAG 565
QY      121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB      566 AAACGCTTTGCAAGCAAGTAAACAAATGGTAAACAGCACCTCTCTACCGCTGGTGT 625
QY      141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB      626 AACTGGCTTGACATCTGCGGAGCGGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
QY      160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
```

```
DB      686 TTGTGGAGCAACGTTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGCCCGCTGAC 745
QY      180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal 200
DB      746 ATCCGGCTCACCTTCTTCAAGGGGACCACCAACGATGGGCTGGGCAATGCCCTTATGGC 805
QY      200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB      806 CCAGGGGGGGCGCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGGAAGCGCACTTCGACCA 864
QY      220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB      865 AGATGAGCGCTGGTCCCTGAGCCGCGCGGCGCAACCTGTTTCGTGGTGTGGCGCA 924
QY      240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB      925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
QY      260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB      985 CTACTACAGAGGCTGGCGCGGACGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
QY      280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB      1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAAAGCTGT 1104
QY      300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB      1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTCGAAACACAGGG 1164
QY      320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
DB      1165 CCTATAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY      340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB      1225 CATTTTAAAGGAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY      360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB      1285 TCCACTGTCAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGTGGCGGAGTGTCAAT 1344
QY      380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyValArgCysTrpArgPheArgGlyProLy 400
DB      1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGCTGCTGGAGGTTCGGGGGCCCA 1404
QY      400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB      1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCCATCTCTGACGC 1464
QY      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB      1465 CGCCCTCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGTGCGCGCTACTAGT 1524
QY      440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB      1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGAGGAGCTGGG 1584
QY      460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
DB      1585 AGGCATCCCTGAGGAGGTACGCGCGCCCTCGCGAGGCCGATGGCTCCATCATCTTCT 1644
QY      480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB      1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCGAAATTCGAGGCAACCACTTCGGGGCG 1704
QY      500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB      1705 CTGGGCCACCAGCTGCCCTGGATGGGTGTGTGGCTGCCAATGCCAATCGGGAGGCGCCCTGT 1764
QY      520 e 520
```

```

Alignment Scores:
Pred. No.:      3.35e-262      Length:      1985
Score:          2792.00      Matches:     519
Percent Similarity: 99.61%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches:  1
Query Match:      98.52%      Indels:      2
DB:               15          Gaps:        0

US-10-791-980-6 (1-520) x US-10-131-830A-143 (1-1985)

Qy      1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db      206 ATGGTCGCGCGGTCGGCCCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy      21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40

```

```
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGGCTCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLeuPheLeuGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGAGTGAAGTGGAGCCCTACTACCCCGAAGTCTCGAGACTGGGG 1584
QY 460 yGlylleProGluGluValSerGlyAlaLeuProArgProAspGlySerllePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCCCTGCGAGGCCGATGGTTCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGGCCAACTGCAGGCCAACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 49

```
US-10-131-837A-143
; Sequence 143, Application US/10131837A
; Publication No. US2003007721A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P33301C131
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
```

```
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-837A-143
```

Alignment Scores:

```
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-131-837A-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGNAGTACGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCCATCTCGATTGACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGCCAGTACCTGTCCAGCGGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTGTACAGATACCAACAGTATTGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AACCGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTTACCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCCGAGCGGAGTTCGGGGCGCGCTGCGCGCGCTTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGACCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCACGACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACATGGGCTGGGCAATGCTCTTGTATGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGAGCGGAGGAGGAGGAGG 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGGCAACCTGTTGTCGTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTGCACAGCTTGGCTTGCCTCACCCACTCGCCCGCGCGCGGCGGCTCATGGCGCC 984
```

```

Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGI 280
Db 985 CTACTACAAGAGGCTGGCGCGCGAGCGCTGCTCAGCTGGACGACGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTATGGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACCTTGGACCTGGACTCTCAGCCCCCAAGAAAGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCCTGTAGACAGGCACACGAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTTCCAAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGGCGGCGAGGGGCTGCCGCCCATCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCCTCTTCTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGI 460
Db 1525 GTGGCGCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAAGTCTGCAAGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGAGGCGCGATGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlalysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGCCAACTGCAGGCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGTGCCTGGATGGGCTGCTGGCATGGCAACTCGGGAGGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

```

RESULT 50

```

US-10-137-872A-143
; Sequence 143, Application US/10137872A
; Publication No. US2003007722A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria

```

```

; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: F330R1C150
; CURRENT APPLICATION NUMBER: US/10/137, 872A
; CURRENT FILING DATE: 2002-05-03
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-137-872A-143

```

```

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

```

US-10-791-980-6 (1-520) x US-10-137-872A-143 (1-1985)

```

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGAGCGCGAGCTGCGCAAGAGCGGAGGCGGATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCATGAACAGCTCCCAAGCTCCCACTCCACTGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTGTGTCAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTGTCGCCCGCTGCGGGGTACAGATACCAACAGTTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 CCCTGGGCTGAGAGGATCAGTGACTTGTTCCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140

```

Db 566 AAACGCTTTGGCAAGCAAGTAAACAAATGGTAAAGCAGCACCTCTCCTACCGCGCTGGTG 625
Qy 141 AantTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGCTGCGGGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGGAGGCCCAAGCCACAGGCCCGCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCCGGCTACCTTCTTCAAGGGGACCACAAACGATGGGCTGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTTPArTPrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTCGCGCAGCCCTTC-CTGCCCCCGCGCGGAGGCGACCTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCAACCTGTTGCTGGTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTyTyLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTAGCTGGGACGAGTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyTyGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTySerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAAAGGCGCCCTGAACGCGAGG 1164
Qy 320 yProLysTyTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyTyPhePheLysGlyGlyArgCysTyTyPArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGTGATGCTGGAGTTCCGGGGCCCCAA 1404
Qy 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTCGACG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTyTyProArgSerLeuGlnAspTTPG1 460
Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAAGTGTGCGAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTTCAGGGGCGCTTCCCGAGGCCGATGGCTCCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTyTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500

Db 1645 CCGAGATGACCGCTACTGTGGCGCTCGACCAAGGCCAAACTCGAGGCCAACCACTCGGGCCG 1704
Qy 500 qTTPAlaThrGluLeuProTTPMetGlyCysTyTyPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 51
US-10-147-500-143
; Sequence 143, Application US/10147500
; Publication No. US2003007723A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC325
; CURRENT APPLICATION NUMBER: US/10/147,500
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-500-143
Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-147-500-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTTPGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCCCTCTGCTGCGCGCCCTGAGCTGCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGCGGAGCGCGGAGCTGCGCAAGGAGCGGAGGCATTCTTA 325
Qy 41 GluTyTyTyGlyTyTyLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGGATACCTCAATGAACAGGTCCCAAGAGTCCCACTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100

Db 446 GCCACCCCTGCGCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
 Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGATCAGTGACTGTTGCTAGACACCGAGCAAAATAGAGCGTAA 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
 Db 566 AAACGCTTTCAGAGCAAGGTAAACAATGTTACAGCAGCACCTCTCTACCGGCTGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCATCTCCGAGCGCGAGTTCGGGGCGCGTGGCGCGCGCTTCCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCCTGGGAGCGCCAGCCAGCCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTCTTCCAGGGGACCAACATGGGCTGGGCAATGCTTTGATGGC 805
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGCCCTGGCGACCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGGGCGCAACCTTCTGCTGGTGGCGCA 924
 Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CDAGATCGGTACACGCTGGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
 Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 Db 985 CTACTACAAGGCTGGGCGCGAGCGCTGCTCAGCTGGGACGAGCTGCTGGCGGTCA 1044
 Qy 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGAGAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTrpProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGAGCGCGCTGAAACCGAGG 1164
 Qy 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTrp 340
 Db 1165 CCTTAATAGTGCACCTCTTCTTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCCCAACATTTAGGCTGGCGAGTGCAIT 1344
 Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
 Db 1345 GAATGATGGAGATTTCTACTTCTCAAGGGGTCGATGTGGAGGTTCCGGGGCCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGTCTCCCAAGCTGTGCGGGGAGGGGCTGCCCCCGCATCTTCCAGCG 1464
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa 440
 Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTTACTACGT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCGAGCTGGGG 1584

Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGTTCAGGGCGCCCTGCGAGGCCCGATGGCTCCATCATCTTCT 1644
 Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCAGATGACCGCTACTTGGCGCTCGACCGAGGCAAACTGCGAGGCAACCCACCTCGGCG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTCCCTGGATGGCTGCTGGCATGCAACTCGCGGAGCGCCCTGT 1764
 Qy 520 e 520
 Db 1765 C 1765
 RESULT 52
 US-10-147-502-143
 ; Sequence 143, Application US/10147502
 ; Publication No. US2003007774A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Deenoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C326
 ; CURRENT APPLICATION NUMBER: US/10/147,502
 ; CURRENT FILING DATE: 2002-05-16
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 US-10-147-502-143
 Alignment Scores:
 Pred. No.: 3,35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: Gaps: 0
 US-10-791-980-6 (1-520) x US-10-147-502-143 (1-1985)
 Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCCGAGCCCGCGAGCGCGAGGCTGCCAAGAGGCGCGGAGGCAATTCCTA 325
 Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGAGTCCCAACCTCCACTCGATTACG 385


```
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTCTCCAGTACCTGTGACGGCGGTGTGGACCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgArgLys 120
DB 506 GCGTGGGCTGAGAGGATCAGTCTGTTGTGTAGACACCGGACCAAAATGAGGCGTAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGTTACACAGCAGCACTCTCTCCACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTTCGGCGCGCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTTCTCCAGGGGACCAACAGATGGGCTGGGCAATGCCCTTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC -CTGCCCCCGCGCGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTGTCTGGTGTCTGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CCAGATCGGTACAGCTTGGCTTACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGCGTGGGCGCGAGCGCGCTGTCTAGCTGGGACGAGCTGTGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGACTCTTACAGCCCGCCCAAGAGCGCGCTGAAACGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCATAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGACCAATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGAGATTTCTACTTCTCAAGGGGGTGTGATGCTGGAGGTTCCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCGCCCGCCCATCTCTGAGCG 1464
```

```
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGCCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCTCAGGAGGTGACGGCGCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCGCTCGACGAGGCCAAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
```

RESULT 53

```
US-10-147-515-143
; Sequence 143, Application US/10147515
; Publication No. US2003007725A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C342
; CURRENT APPLICATION NUMBER: US/10/147,515
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-515-143
```

```
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-147-515-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGCGCGCGTGGGCTCTCTGTGCGCGCCTGCAGCTGCTACTGTGGGCGCACCTG 265
```


; APPLICANT: Zhang, Zemin									
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC									
; TITLE OF INVENTION: ACIDS ENCODING THE SAME									
; FILE REFERENCE: P3330R1C9									
; CURRENT APPLICATION NUMBER: US/10/121,041									
; CURRENT FILING DATE: 2002-04-11									
; Prior Application removed - See File Wrapper or Palm									
; NUMBER OF SEQ ID NOS: 550									
; SEQ ID NO 143									
; LENGTH: 1985									
; TYPE: DNA									
; ORGANISM: Homo Sapien									
US-10-121-041-143									
Alignment Scores:									
Pred. No.: 3,35e-262 Length: 1985									
Score: 2792.00 Matches: 519									
Percent Similarity: 99.62% Conservative: 0									
Best Local Similarity: 99.62% Mismatches: 1									
Query Match: 98.52% Indels: 2									
DB: 15 Gaps: 0									
US-10-791-980-6 (1-520) x US-10-121-041-143 (1-1985)									
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20						
Db	206	ATGTCGCGCGCGTCTGCCTCTCTCTGCGCGCCCTCAGCTACTGTGGGGCCACCTG	265						
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu	40						
Db	266	GAGCCCGACCGCGGAGCGCGAGGCGCAGAGCTGCGCAAGAGGCGGAGGAGATTCCTA	325						
Qy	41	GluValTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60						
Db	326	GAGAATGACGATACCTCATGAACAGAGTCCCAAGCTCCCACTCCACTCGATTTCAGC	385						
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80						
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCACAGTACTCTGTCAGCGCGGTGGACCGC	445						
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100						
Db	446	GCCACCTCGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505						
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120						
Db	506	GCCTGGGCTGAGAGGATCAGTGACTGTGTTGCTAGACACCGGACCAAAATGAGCGTAA	565						
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140						
Db	566	AAACGCTTTGCCAAGCAGAGTAAACAATGGTACAGCAGCACCTCTCTACCGCTGGTG	625						
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSer	160						
Db	626	AACTGGCTGAGCATCTGCGGAGCGCGCAGTTGGGGCGCGGTGCGCGCGCTTCCAG	685						
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180						
Db	686	TTGTGGAGCAACGTCCTCAGCGCTGAGTTCCTGGGAGGCCCCCAGGCACAGCCCCGCTG	745						
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetal	200						
Db	746	ATCCGGCTCACCTTCTTCCNAGGGGACCAACGATGGCTGGCAATGCTTTTGATGCG	805						
Qy	200	gGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGln	220						
Db	806	CCAGGGGCGCCCTTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCGAGCGACATTCGACCA	864						
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyValArgAsnLeuPheValValLeuAlaHi	240						
Db	865	AGATGAGCGCTGGTGCTCTGAGCCGCCCGCGCGCGCAACTGTTCGTGGTGTGGCGCA	924						
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalPr	260						


```

; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C4
; CURRENT APPLICATION NUMBER: US/10/121,047
; CURRENT FILING DATE: 2002-04-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-121-047-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 1
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-121-047-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCTCGCGCGTGGGCTCTCTGCTGCGCCCTCTACTGTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGGAGCGCGGAGGCCAGAGCTGGCGAAGGAGCGGAGGCAATTCCTA 325

Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCATGACAGTCCCCAAGAGCTCCACCTCCACTCGATTCAGC 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTACGCGCGTGTGGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGG 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACATTGTTGCTAGACACCGGACCAAAATGAGCGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACCGCTTTCGAAGCAAGGTAAACAAATGGTACAAAGCAGCAGCACTCTCTACCGCCTGGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGAGCGCGCAGTTCGGGGCGCGCTTCGCGCGCGCTTCCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACTCTCAGCGCTGGAGTTCTGGAGGCCCGCAGCAGCAGCCCGCTGAC 745

```

RESULT 60

US-10-123-215-143
 ; Sequence 143, Application US/10123215
 ; Publication No. US2003007780A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P33301C41
 ; CURRENT APPLICATION NUMBER: US/10/123,215
 ; CURRENT FILING DATE: 2002-04-15
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 US-10-123-215-143

Alignment Scores:

Pred. No.: 3,356-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservatives: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-215-143 (1-1985)

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 DB 626 AACTGGCCCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCGTTCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 DB 686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCCTGGAGAGGCCCGCAGCCAGCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 DB 746 ATCCGGCTCACCTCTTCCAAAGGGAGCACCAACGATGGGCTGGGCAATGCTTTGATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 DB 806 CCAGGGGGCGCCCTGGGCGACGCTTC-CTGCCCGCGCGCGCGCGCTCATGGCGCC 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
 DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTGCTGGTGTGGCGCA 924
 QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 DB 925 CGAGATCGGTACACGCTTGGCCCTCACCCACTCCCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyTyLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 DB 985 CTACTACAGAGGCTGGGCGCGCGCGCGCTGCTCAGCTGGGACGCGTGTGGCGTGA 1044
 QY 280 nSerLeuTyTrpGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
 DB 1045 GAGCTGTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGTCCCGAGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyTrpSerProGlnGlyArgArgProGluThrGlnG1 320
 DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGGGCGCTCGAAACGACGAG 1164
 QY 320 yProLysTyTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 DB 1165 CCCTAATATCTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
 DB 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
 DB 1285 TCCACTCGAGAAAGATGGGTGGGCTGGGCTGCCCGCGCGCGCGCTCGGAGGTTCGGGCGCCCA 1344
 QY 380 uAsnAspGlyAspPheTyTrpPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
 DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATCTGGAGGTTCGGGGCGCCCA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 DB 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGCGGAGGGCGCTGCCCGCGCATCTCGACGC 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
 DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGGTGGCGCTACTACGT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpTyTrpArgSerLeuGlnAspTrpG1 460
 DB 1525 GCTGGCCCGAGGGGGATGCAAGTGGAGCCCTACTACCCCGAAGTCTGCGAGGACTGGGG 1584
 QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 DB 1585 AGGCATCTCTGAGGAGGTGAGCGCGCCCTGCCGAGGCCCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 DB 1645 CCGAGATGACCGCTACTTGGCGCTTCGACCGAGCCCAAACTGCGAGGCAACCACTCGGCGC 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

```
Db 1705 CTGGCCACCGAGCTCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 61
US-10-123-902-143
; Sequence 143, Application US/10123902
; Publication No. US20030077781A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C47
; CURRENT APPLICATION NUMBER: US/10/123,902
; CURRENT FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-902-143

Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-902-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGCTCGGCTCTGCTGGCGCGCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaAlaPheLeu 40
Db 266 GACGCCACCGCCGCGGAGCGCGGAGCCAGAGCTGCGCAAGAGGCGGAGGCATTCCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCATGAACAGAGTCCCCAAGCTCCCACTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACCGCTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGCGCTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGGCAGATGACTGTCCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
```

```
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTTTGTAGACACCGGACCAAAATAGCGCGTAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTTACAAGCAGCACCTCTCTCCACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCGCGAGCGGAGTTTGGGGCGCGCTGCGCGCGCTCCAG 685
Qy 160 rCysGlyValaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCCGCAGCCAGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACACACGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAAGCGCATTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGGCAACTGTTCTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCACTGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTGAGCTGGGACGACGTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGNAAGCTTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCGCTGAAACGCGAGG 1164
Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATATCTGCCACTTCTTCTGATGCAATCCTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCATCTCAGGAAAGATGGGTGGGCTGCCCGCGCGCGCGCAACATTTGAGGCTCGCGAGTGCATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGCGATGTGGAGGTTCGGGGGCCCCNA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGCGGAGGGGGCTGCGCGCGCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGGGGGGACTGCAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
```

Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACCAAGGCCAACTGAGGACCAACCTTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGACCGAGCTGCGCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 c 1765
RESULT 62
US-10-123-908-143
; Sequence 143, Application US/10123908
; Publication No. US2003007782A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tomas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C44
; CURRENT APPLICATION NUMBER: US/10/123,908
; PRIORITY FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-908-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-123-908-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACCGCGCGAGCGCGAGCGGAGGCTGCGCAAGGAGGCGGAGGCGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGAGTACTCTCAATGAACAGGTCCCCCAAGGTCCCACTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80

Db 386 GATGCCATCAGAGCGCTTTTCAGTGGGTGTCACAGTACCTGTTCAGCGGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCGCAAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTATTATGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCGTACACACCGGACCAAAATGAGGGCTAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCGAGGCGGAGTTCGGGGCGCGTTCGGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGACCAAGCTCTCAGCGCTGGAGTTCGGGAGGCGCCACAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCCAAGGGGACCAACAGATGGCTGGGCAATGCTTTCATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGGCGCACGCTTC-CTGCGCGCGCGCGGCGGCAATGCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGGCAACTGTTCGTGGTGGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTCACCACTCGCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACCTGCGCACCTCTCTTCGATGCGCATCACTGTAGACAGGCAACAGCACTGA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCGCCCAACATTTAGAGGTGCGGCGAGTTCATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGCGGCGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCGCGCCCATCTTCAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGGCGGCTACTAGCT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
 QY 460 yGlyIleProGluGlnValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
 QY 480 eArgAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTGGCGCCCTGCACCGCCAACTGCAGCAACCCCTCGGGCCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCyTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765

RESULT 63
 US-10-123-909-143
 ; Sequence 143, Application US/10123909
 ; Publication NO. US20030077783A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; TITLE OF INVENTION: ACIDS ENCODING THE SAME
 ; FILE REFERENCE: P33301C49
 ; CURRENT APPLICATION NUMBER: US/10/123,909
 ; CURRENT FILING DATE: 2002-04-16
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 US-10-123-909-143

Alignment Scores:
 Pred. No.: 3,35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-909-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGGCGCGCTCGCCCTCTGCTGCGCGCCCTGCGAGTGTCTGTGGGCGCCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCAGCCCGCGAGCGCGAGGCGCAGGAGCTGCGCAAGGAGCGGAGGCGCATTCCTA 325

QY 41 GluLysTyrGlyTyrIleuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGAGCTCCCACTCCACTCCACTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCAGGTACCTGTCCAGCGCGCTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluAileSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCTGGGCTGAGAGATCAAGTGTCTAGACACCGGACCAAAATAGAGCGCTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
 Db 566 AAACGGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCCGTGCGCGCCGCTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCCTGGAGGCGCCCGACGACAGCCCGCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGTATGGC 805
 QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
 Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCCCGCGGCGAGCGACTTCGACCA 864
 QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCCCGCGGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
 QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACGCTTGGCCTCACCCCTCCCGCGCGCGCGCGCTCATGGCGCC 984
 QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
 Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
 QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
 QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
 Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAAAGGCGCCCTGAAACGCGAGG 1164
 QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
 Db 1165 CCTTAAATCTGCCACTCTTCTTCGATGCTCATCTAGACAGGCAACAGCAACTGTA 1224
 QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTATTAAGGAGGAGCCATTTCTGGAGGTGGGAGCTGATGCAACGCTCTAGAGCCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
 Db 1285 TCCACTGAGGAAAGATGGGTGGGCTGCCCGCCCAACATTCAGGCTGCGGCGAGTGCATT 1344
 QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLys 400
 Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCTCGGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGCTGCCCCGCATCTTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLeuGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGTGGCGCCCTCATCTCTTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTCGAGACTGGGG 1584
QY 460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCCCTGCGGAGGCCGATGGCTCATCTCTTCTT 1644
QY 480 eArgAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACCAGGCCAACTGCAGGCCAACCTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGTCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTGT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 64

US-10-123-910-143
; Sequence 143, Application US/10123910
; Publication No. US2003007784A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P33301C45
; CURRENT APPLICATION NUMBER: US/10/123,910
; CURRENT FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-910-143

Alignment Scores:

Pred. No.:	3,356-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-123-910-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTTCGGCGCGTGGGCTCTCTGTGGCGGCCCTGCAGTCTGCTACTGTGGGGCACCTTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGCGAGCGCGGAGGCTGGCAAGAGCTGGCAAGAGCGGAGGCGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAenGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGTCCCACCTCCACTCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGACTACCTGTCAAGCGGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
Db 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTCGGGGTTCACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTGTAGACCCGACCAAAATGAGGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCNAAGCAAGGTAACTGGTACACAGCAGCAGCTCTCTACCGCTGGTG 625
QY 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGTGGAGGGCCCCAGCCAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCCTTCTCCAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGCG 805
QY 200 aGlnAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGCGCGCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTTGGCTTCCACCACTTCGCCCGCGCGCGCGCTCATGCGGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCNAGNAGGGCCCTGAAACCGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATACTGCGCCTCTCTTCGATGCCATCCTCAGTACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProAenIleGluAlaAlaValSerLe 380

Db 1285 TCCACTGCAGAAAGATGGGTGCGGCTGCCCGCCCAACATTGAGGCTCGCGAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCNAAGGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGGCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTGCGCGCCCTCATCTCTTCAAGGGTGCCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerllellePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGGGCGCCCTGCCGAGGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCCNAATGCGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 65
US-10-124-813-143
; Sequence 143, Application US/10124813
; Publication No. US2003007785A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC67
; CURRENT APPLICATION NUMBER: US/10/124,813
; CURRENT FILING DATE: 2002-04-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-124-813-143
Alignment Scores: 3.35e-262 Length: 1985
Pred. No.: 2792.00 Matches: 519
Score:

Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-124-813-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTPrGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGCTGCGCGCTCTGAGCTGTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGACGCCCGGAGCGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTTCAG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACGACTACCTGTGAGCGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgAtgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTTGTTTGTAGACACCGGACCCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTACAAATGTTACAGCAGCACCCTCTCTACCGCCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTCGAGCATCTGCGGAGCGGCGAGTTTCGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCTTGGGAGGCGCCAGCAGCAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrMetGlyTyrTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGCGCGCTCATGGCGCC 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTGCTGAGCCCGCGCGCGCGCGCGCAACTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTGGCTCACCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGAGCAGCGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGAGGCGCCCTGAAACGACGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340


```
Db 1165 CCCTAAATACTGCCACTCTTCTCCGATGCCATCATCTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTAGAGCCCGG 1284
Qy 360 gProLeuGlnGluArGTrpValGlyLeuProProHenilleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGAGTGGTGGGCTGCCCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGGTCTCCACAGCTGTGGCGGCGAGGGGCTTCCCGCCATCTCTGAGCG 1464
Qy 420 sAlaLeuPhePheProProLeuArgGluLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAACTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGSAGGTGAGCGGCGCCCTGCGGAGGCCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCGCTACTGGCGCTCGACAGGCCAAATGTCAGGCAACACCTCTGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 66

```
; Sequence 143, Application US/10124817
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C56
; CURRENT FILING DATE: 2002-04-17
; CURRENT APPLICATION NUMBER: US/10/124,817
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
```

```
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-124-817-143
Alignment Scores: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-124-817-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGCTGGGCTCTCTGTCGGCGCCCTGACAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGACTACCTGTGAGCGGCGTGTGGACCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCTGTCGCCGCTGGGGGTACAGATACCAACAGTTATGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCAGCTCTCTTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTTGGCGCAGCCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCCTGAGCGCGCGCGGCGCAACCTGTTCGTGTGTCGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGGAGCGCTGCTCAGCTGGGAGCAGCTGCTGCCCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGTCCAGCTCCAGGAAAGCTGTT 1104
```

```
Qy 300 eThraAspPheGluThrTrpAspSerTy-SerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACCTTGGACCTGGGACTCTCAGACCCCAAGAGGCCCTGAAACGACGGG 1164
Qy 320 yProLysTyrcysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGA 1224
Qy 340 xIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCATGCTGATGGCAACGCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlycylArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlycylLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACACAGCTGTGCCGGGCAGGGGGCCCTGCCCGCCCATCCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGTGCCCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTyTyProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGSCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGlnGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGACGGCGCCCTGCCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVa 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAATCTGAGGCCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 c 1765
```

RESULT 67

```
US-10-125-922-143
; Sequence 143, Application US/10125922
; Publication No. US2003007787A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filwaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
```

```
; FILE REFERENCE: P3330R1C73
; CURRENT APPLICATION NUMBER: US/10/125,922
; CURRENT FILING DATE: 2002-04-19
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-125-922-143
Alignment Scores:
Pred. No.: 335e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-125-922-143 (1-1985)
```

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCGGCCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGGAGCCAGAGCTGCGAAGAGGCGGAGGCATTCTCTA 325
Qy 41 GlulysTyrglyTyrglyLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTCCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTGTGTACGCGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCCGTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGCTTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrlsGlnHisLeuSerTyArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGAGCGCGAGATTTCGGGGCGCGCGCGCCCTTCAG 685
Qy 160 rCysGlyValaThr-SerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGCCCGCCAGCCACAGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAAATGGGTGGGCAATGCTTGTGATGGC 805
Qy 200 aGlnGlyValaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGACGCTGTGTCCTGAGCGCGCGCGGCGCAACCTGTTCTGTGTGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGCGGCC 984
```

```
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGI 280
Db 985 CTACTACAAAGAGCTGGCGCGCGCTGCTCAGCTGGACACAGTGTGGCCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgTrpGluThrGlnGI 320
Db 1105 CACTGACTTGGAGCTGGGACTCTCAGACCCCAAGGAGGCGCCCTGAACGACGAG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATAGTCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGAAGAAAGATGGTGGGCTGCCCCCAACATTTAGGCTCGGCGAGTGTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCCGCCATCTCTGAC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTCTTCCCTCTCTGCGCGCTCTATCTCTTCAAGGTGCGCGCTACTACT 1524
QY 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGI 460
Db 1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAAGTCTGCAGGACTGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGAGGCGCCGATGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGGCGCAAACTGCAGGCAACCCACCTCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 68

US-10-125-924-143

; Sequence 143, Application US/10125924

; Publication No. US2003007788A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

```
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P33301C75
; CURRENT APPLICATION NUMBER: US/10/125,924
; CURRENT FILING DATE: 2002-04-19
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-125-924-143
```

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-125-924-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGCGCGCGCTCGGCTCTCTGCTGGCGCGCTTCTACTGTGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGGAGCGCGGAGGAGCTGGCGAAGAGCGGAGGAGCATTTCTCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTAGCGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGACTACCTGTTCAGCGCGGTGTGGACCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCCAGATGACTCGTCCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGACCGGACCTCTCTCCCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCAGCGCTGGAGTTCTGGGAGGCGCCCGACAGCCAGGCCCTGCAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTGTATGCG 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGI 220
Db 806 CCAGGGGCGCGCTGGCGCACGCCCTTC-CTGCCCCCGCGCGGAGCGGAGCTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
```

Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGGGCGCAACCTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTGGCCCTACCCATCCGCCCGCGCGCGGTCTATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAAGAGCTGGCGCGCGAGCGCTCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGACTCTCTACAGCCCCCAGAGAGGGCGCCCTGAAACGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACCTGCAGGAAGAAGTGGTGGCTGCCCTCCCTCCCAACATTGAGGCTGGCGAGTGTCA 1344
Qy 380 uAenAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCTTGGCCCCCATCTCCAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrvA 440
Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTTCAGCGGCGCTTGGCGAGGCGCGATGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTTCGACAGGCGCAAACTGCAGGCAACCCACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCGCCAGAGCTGCCCTGGATGGGCTGCTGGCATGGCACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 69
US-10-140-860-143
; Sequence 143, Application US/10140860
; Publication No. US2003007789A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P330R1C189
; CURRENT APPLICATION NUMBER: US/10/140, 860
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-860-143
Alignment Scores: 3 35e-262 Length: 1985
Pred. No.: 2792.00 Matches: 519
Score: 99.62% Conservatives: 0
Percent Similarity: 99.62% Mismatches: 1
Best Local Similarity: 99.62% Indels: 2
Query Match: 98.52% Gaps: 0
DB: 15

US-10-791-980-6 (1-520) x US-10-140-860-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCCCTCTGTCGCGCGCTGTCAGCTGTCTGTCGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGGAGCCAGAGCTGCGAAGAGGCGGAGGCATTCTTA 325
Qy 41 GlulysTyrGlyTyrLeuAenGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGCTCCCCAAAGCTCCACCTCCAGTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTACGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGATCTCTGCCCGCTGCGGGGTACAGATACCAACAGTTATCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGGCGTA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCGCGCTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGAGCGCGGAGTTCGGGGCGCGGTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGGAGGCGCCAGCCACAGGCCCCCTG 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200

Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGCAATGCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTfPArqThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCCCTGGGCGACGCCCTTC-CTGGCCCGCGCGGAGGCGCACTTCGACCA 864
Qy 220 nAspGluArgTfPArqThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 240
Db 865 AGATGAGGGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTGCTGGTGGTGGCGCA 924
Qy 240 aGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGGCTCACCCACTGGCCCGCGCGCGGCTCATGCGGCC 984
Qy 260 tTfPArqThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTGAGCTGGGACGAGCTGGTGGCGGTGA 1044
Qy 280 sSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTfPArqThrProPheLeuProArgArgGlyGluAlaHisPhe 320
Db 1105 CACTGACTTGGAGCTGGGACTCTTACAGCCCCCAAGGAGGCGCGCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaThrValAlaAspGlyAsnValSerGluProAr 340
Db 1165 CCCTAATACTGCCACTCTTCTTCTGATGCCATCACTGTAGACGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTfPArqThrProGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTfPArqThrProPheLeuProArgArgGlyGluAlaHisPhe 380
Db 1285 TCCACTGAGGAAAGATGGTGGGCTGGCGCTGCCCCCAACATTCAGGCTGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysValArgCysTfPArqPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTCTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTfPArqThrProGlnLeuCysArgAlaGlyGlyLeuProArgHisPheAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGGCGGCGAGGGGCTGCCCCCGCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTfPAr 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACCCCGGAGCTGCGAGGACTGGGG 1584
Qy 460 yGlyTfPArqThrProGlnValSerGlyAlaLeuProArgProArgGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGGGGCTTCCCGAGGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTfPArqLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAAATGCGAGGCAACCACTCGGGCGG 1704
Qy 500 gTfPArqThrGluLeuProTfPArqMetGlyCysTfPArqHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 70

US-10-142-417-143

; Sequence 143, Application US/10142417

Publication No. US20030077790A1
GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RLC232
; CURRENT APPLICATION NUMBER: US/10/142,417
; CURRENT FILING DATE: 2002-05-09
; Prior application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-417-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-417-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuLeuLeuLeu 20
Db 206 ATGTTCGCGCGCTGGCCCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGCTGGCAAGAGGCTGGCGAAGAGCGGAGGCATTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCAGTTTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTfPArqValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTCAGTGGTGTCCAGCTACTGTTCAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTfPArqAlaArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTTCCTAGACACCGGACCAAAATGAGCGGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTfPArqTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAAGCTTTGCNAAGCAAGGTACAAATGGTACAAAGCAGACCTCTCTCCACCGCTGGT 625
Qy 141 AsnTfPArqGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGGAGTTCGGGGCGCGTTCGCGCGCGCTTCCAG 685

```
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTGGGAGGCGCCAGCGCACAGGCGCCGCTGAC 745

QY 180 rSerGlySerProSerSerGlyThrThrThrMerGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTTCTTCAAGGGGACCCACAAACATGGGCTGGCAATGCTTTGATGGC 805

QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGCGAAGCGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGGTGGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCCGTCACACGCTTGGCTCACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984

QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044

QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAGCTGT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGCCCCCAGAGGCGCCCTGAAACGCGAGG 1164

QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224

QY 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGCAGTGTCTATT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCCNACAGCTGTGCGGGCAGGGGCTGCCCCGCCATCTCAGCGC 1464

QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTACGT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGGCGCCAGGGGAGCTCAAGTGGAGGCCCTTACCCCCCGAAGTCTGCAGGACTGGGG 1584

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCGGAGGCCGATGGCTCCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGTCGCGCTCGACCAAGGCCAACTGCAGGCAACCCACCTCGGGCG 1704

QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCCAGAGCTGCCCTGGATGGGCTGCTGGCATGCCAATCTGGGGAGCGCCCTGTT 1764
```

QY 520 e 520
Db 1765 c 1765

RESULT 71

US-10-147-519-143
; Sequence 143, Application US/10147519
; Publication No. US2003007791A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: F3330R1C346
; CURRENT APPLICATION NUMBER: US/10/147,519
; PRIOR FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-519-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-519-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCGGCTCTCTGTCGCGCCCTGTCAGCTGTCTACTGTGGGGCCACTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCGCGCGAGCGCGAGAGCTGCGCAAGGAGCGGAGGCATTCTTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCACCTCCACTCGATTGAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTCAGTGGGTGTCCAGCTACTGTCTCAGCGCGGTGTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCTGTCGCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGGCGTAAG 565
```

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGGCTTTGCAAGCAAGGTAAACAAATGATCAACAGCAGCACTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGSCCTGAGCATCTGGCGAGCGGAGTTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGGCAATCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCCCTGCTCCCTGAGCGCGCGCGGCGCAACCTGTTGCTGCTGCTGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTCAACGCTTGGCTTCAACCTCGCGCGCGCGCGCGCTCATGCGGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGCTGGCGCGCGACGCGCTGCTCAGCTGGGACGACGCTGCGCGGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAGAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGGAGCGCCCTGNAACGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGCCATTTCTGGAGGTGGGAGCTGATGCCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGCTGGGCTGCCCCCAACATTGAGGTGGCGGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGCTGATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCCAACAGCTGTGCGGGGAGGGGGCTTGGCCCCGCTCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTACTACCCCCCAAGTGTGACGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGAGGGGGCGCTTGGCGAGGCGCGATGGCTCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500

DB 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCCAACTGCAGGCAACACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCTGT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 72
US-10-157-782-143
; Sequence 143, Application US/10157782
; Publication No. US2003007792A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C431
; CURRENT APPLICATION NUMBER: US/10/157,782
; CURRENT FILING DATE: 2002-05-29
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-157-782-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-157-782-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGCGCGCGCTCGGCTCTCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACGCGCGGAGCGCGGAGCGGAGGCTGCGCAAGGAGCGGAGGCATTCTCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAAAGTCCCACTCCACCTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGGTTTCAGTGGGTGTCACGAGTACTGTGACGGCGGTGTGTGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100


```
Db 446 GCCACCTCGCCGACGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTTPAlaGluAArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCGTGGGTGAGAGGATCAGTGACTGTTTGTGTAGACACCGGACCAAAATGAGGGGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCCTACCGCCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGACATCTCCCGAGCGCGCAGTTCGGGGCGCGTCCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGGCCCCAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCTCGCGCACGCTTC-CTGCCCCCGCGCGGGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTGTCCTCGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 tTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGTCTAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAGAGAGGCCCTGGAACGACGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGCCCAATTTCTGGAGGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284
Qy 360 pProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTTCGGCTCGCCCCCACCACATTGAGGCTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTCGATGCTGGAGTTCCGGGGCCCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTTCCACACAGCTGTGCCGGCAGGGGCGCTGCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTAGCT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
```

```
Db 1525 GCTGGCCGAGGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGAGGACTGGG 1584
Qy 460 yGlylProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCGAGGAGGTGAGCGGCGCTCGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACCGCCAAACTGCAGGCAACCACTCGGGCGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGGCAACTCGGGGAGCGCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 73
US-10-152-395-143
; Sequence 143, Application US/10152395
; Publication No. US20030078377A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C405
; CURRENT APPLICATION NUMBER: US/10/152,395
; CURRENT FILING DATE: 2002-05-21
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-152-395-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-152-395-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGCTCGCGCCTCTGCTCGCGCCTCTGCTCGCGCCTGCTACTGTGGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGCGGAGGCGCAGGAGCTGCGCAGGAGGAGGCGGCGCATTTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
```

Db 326 GAGAGTACCGATACCTCAATGAAACAGAGTCCCCAAAGCTCCCACTCCATCGATTGACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCTTTCAGTGGGTGTCACAGTACCTGTGACGGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCGACAGATGACTCGTCCCGCTCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIlysMetArgArgLys 120
Db 506 GCTGGGCTGAGAGATCAGTGTCTGTGTGTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTrpLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCGAAGCAGAGTAAACAATGGTACAGCAGCCTCTCTACCCCTTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCGCGAGCGGAGTTCGGGGCGCGTGGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCCACAGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetal 200
Db 746 ATCCGCTCACCCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTGTATGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
Db 806 CCAGGGGGCGCTGGCGCAGCGCTTC-CTGCCCGCGCGGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCGTGTGTGCGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaP 260
Db 925 CGAGATCGGTACACCTTGGCTTCCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
Db 985 CTACTACAGAGCGTGGCGCGCGAGCGCTGTCTAGCTGGGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCGCAAGGAGCGCGCTTGAACCGAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATACTGCCACTCTCTCTCGATGCCATCTGTAGACAGCGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 pProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerie 380
Db 1285 TCCACTGCAAGGAAGATGGTGGGCTGCGGCTGCCCCCAACATTTAGGTGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGTGATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCCGCGCATCTCTGACG 1464

Qy 420 aAlaLeuPhePheProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTTGGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG 460
Db 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGGCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCTGCGGCGCGGATGCGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGGCGCAACCTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGCTGGCTGGCTGGCATGCCAATCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 c 1765

RESULT 74

US-10-125-926A-143
; Sequence 143, Application US/10125926A
; Publication No. US20030082686A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C80
; CURRENT APPLICATION NUMBER: US/10/125,926A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.

```

; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-125-926A-143

```

Alignment Scores:

Assignment: 5000.00:	3.35e-262	Length:	1985
Pred. No.:	2792.00	Matches:	519
Score:	99.62%	Conservative:	0
Percent Similarity:	99.62%	Mismatches:	1
Best Local Similarity:	99.62%	Indels:	2
Query Match:	98.55%	Gaps:	0
DB:	15		

US-10-791-980-6 (1-520) x US-10-125-926A-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCTCGGGCGTGGCGCTCTGCTCGGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGGAGCGCGGAGGCGCAGAGCTGCGCAAGAGGCGGAGGATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTGACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTCTGTACAGCGCGTGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCTGCGCAGATGACTCTGTCCTCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCTTGGGCTGAGAGGATCAGTGACTTGTGTGCTAGACACCGGACCAAAATGAGCGGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGACGAAGGTAAACAATGGTACAAAGCAGCACCTCTCTACCGCTGGT	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTGAGCATCTGCCGAGCCGCGAGTTCGGGGCGCGGTGCGCGCGCTTCACG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTTGGAGGCGCCCGAGCCAGCGCCCGCTGAC	745
Qy	180	rSerGlySerProSerLysGlyThrThrMetGlyTyrAlaMetProLeuMetAl	200
Db	746	ATCCGGCTACCTCTTCCAAAGGGAGCCACAACCATGGCTGGGCAATGCTTTGATGGC	805
Qy	200	agLndGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGGCGCAGCGCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA	864
Qy	220	nasGluuArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATGAGCGCTGGTCCCTTGAGCCCGCGCGGCGCAACCTGTTCTGGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGNTCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGCTGGGCCGCGACCGCTGCTCAGCTGGGACGACGCTGTGGCCGTGCA	1044

Qy	280	nSerLeuTyrGlyVLeuProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CAC TGACTTTTGAGACCTGGGACTCCTACAGCCCCAAGGAAGCGCCCTGAAACGCAGGG	1164
Qy	320	YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACCTGCACCTCTTCCTTCGATGCCAATCACTGTAGACAGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe	380
Db	1285	TCCACTGCAGGAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGCGGCAGTGTCAAT	1344
Qy	380	aAsnAspGlyAspPheTyrPhePhelysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCGCCATCCTCAGCGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440
Db	1465	CGCCCTCTTCTCCCTCCTCTGGCGCGCTCATCTCTTCCAGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyVgLyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCCGAGGGGACTGCAGTGGAGCCCTACTACCCCCGAAGCTCGCAGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGTCAAGCGCGCCCTGCGGAGCCCGATGGCTCCATCATCTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGTACTTGGGCGCTCGACACAGGCCAATCTGCAGGAACCACTCGGGCCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGCATGCCAACTCGGGGAGCGCCTGTT	1764
Qy	520	e	520
Db	1765	c	1765
RESULT 75			
US-10-125-930A-143			
; Sequence 143, Application US/10125930A			
; Publication No. US20030082687A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Deanoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tumas, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			

	Db	 626 AACTGGCGCTCAGCATCTGCCGGAACCGGCAGTTTCGGGGCCGCGTGCAGCGCCCTTCAG 685
	Qy	rCySGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
	Db	TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTTGGAGGCCCCCAGCACACAGGCCCGCTGCAC 745
	Qy	rSergLysProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal 200
	Db	ATCCGGCTCACCTTCTTCCAAGGGAGCACACACGATGGCTGGGCAATGCCTTTGATGGC 805
	Qy	aGInGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
	Db	CCAGGGGGCCCTGGCGCACGCGCTTC - CTGCCCCCGCCGCGGAACGCGACATTCGACCA 864
	Qy	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
	Db	AGATGAGCGCTGGTCCCTGAGCGCCCGCGGGCGCAACTGTTGTGTGTGTGGCGCA 924
	Qy	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalPr 260
	Db	CGAGATCGGTACACGCTTGCGCTCACCCACTCGCCCGCGCGCTCATGGCGCC 984
	Qy	oTyrrYrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspaspValLeuAlaValGl 280
	Db	CTACTACAAGAGCTGGCGCCGACGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
	Qy	nSerLeuTyrgLyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
	Db	GAGCTGTATTGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGT 1104
	Qy	eThrAspPheGluThrTrpAspSerTyrrSerProGlnGlyArgArgProGluThrGlnGl 320
	Db	CAC TGACTTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGAAACGCAAGG 1164
	Qy	yProLysTyrcyHisSerSerPheAspAlalleThrValAspArgGlnGlnLeuTy 340
	Db	CCCTAAATACTGCACCTCTTCTTCGATGCCATCCTCTGTAGACAGGCAACAGCAACTGTA 1224
	Qy	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
	Db	CATTTTTAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCC 1284
	Qy	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
	Db	TCCACTGCAGGAAGAATGGTTCGGCTGCCCGCCCAACATTGAGGCTGCGGCAAGTGTCA 1344
	Qy	uAsnAspGlyAspPheTyrrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
	Db	GAATGATGGAGATTTCTACTTCTCAAAGGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA 1404
	Qy	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
	Db	GCCAGTGTGGGGTCTCCCAAGCTGTGCCGGGAGGGGGCTGCCCGCCGCATCTCTGACGC 1464
	Qy	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrrVa 440
	Db	CGCCCTCTTCTTCCCTCCTCTGGCGCGCTCATCTCTTCAAAGGGTGGCCGCTACTACGT 1524
	Qy	lLeuAlaArgGlyGlyLeuGlnValGluProTyrrTyrrProArgserLeuGlnAspTrpGl 460
	Db	GCTGGCCCGAGGGGACTGCAAGTGGAGCGCTACTACCCTCCCAAGTCTGCAGGACTGGGG 1584
	Qy	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
	Db	AGGCATCCCTTGAGGAGGTGAGCGGGCCCTTGGCGAGGGCCGATGGGTCTCCATCATCTTC 1644
	Qy	eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
	Db	CCGAGATGACCGTACTTGGCGCTTCGACCAAGGCCAACTGCAGGCAACCACTTCGGGCGC 1704
	Qy	gtfTpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520


```
QY 380 uAenAepGlyAspPheTyrPhePheLysGlyArgCysTyrPArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGCCCA 1404
QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCGCCGCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CCGCTCTTCTTCCCTCTCTGCGGGCTCATCTCTTCAAGGGGTGCGCCGTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGGCGCTACTACCCCGAGTCTGCAGACTGGGG 1584
QY 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCAAGGCGGCGCTGCGAGGCGGATGGCTCCATCATCTTCTT 1644
QY 480 eArgPhePheArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACCAAGCCAACTGCAGGCAACCTCGGGCGG 1704
QY 500 gTrrPalaThrGluLeuProTyrMetGlyCysTrrPheHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCGCAACTCGGGAGCGCCCTGTT 1764

QY 520 e 520
Db 1765 C 1765

RESULT 77
US-10-127-837A-143
; Sequence 143, Application US/10127837A
; Publication No. US20030082690A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC96
; CURRENT APPLICATION NUMBER: US/10/127,837A
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
```

```
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-837A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-837A-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
Db 206 ATGTGTCGCGCGGTCTCTGTCGCGCCCTGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCAAGCCGCGGAGCGGAGGCGGAGGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGACAGGTCCCAAGGCTCCACCTCCATCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGCCAGTACCTGTGTCAGCGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
QY 101 AlaTrrPalaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTCTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrrPyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCGAAAGCAAGGTAAACAAATGGTACAGAGCAGCAGCTCTCTACCGCTGGTG 625
QY 141 AsnTrrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGGAGTTCGGGGCGCGCTGCGCGCGCTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrrPrrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGGAGGGCCCGGACAGGCGCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrrPalaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCATATGCCCTTTCATGGC 805
QY 200 aGlnGlyAlaProTrrArgTrrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGGCGCACGCTTC-CTGCCCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrrPrrSerSerArgArgArgGlyArgAsnLeuPheValLeuAlaHis 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGGCGGCAACCTGTTTCGTGGTGTGTCGCGCA 924
```


Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGGCTAGACACCGGACCAAAATGAGCGCTAAG 565
QY 121 LysArgPheAlaIysGlnGlyAsnLysTTPtLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGGCTTTGCAAGACAGGTAAACAATGTACAGCAGCACTCTCTCCACCGCCCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 NACTGGCCTGAGCATCTGCCGAGCGCGCAGTTTCGGGGCGCGTGCAGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCACAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTCCAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCGCTGGCGCACGCTTC -CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCTGCTGCTGGCGCA 924
QY 240 sGluileGlyHisLeuLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCACCCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 tTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAAGAGCTGGGCGCGGACGCGCTGCTCAGCTGGGACGAGCTGCTGGCGTGCA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAGTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTAGACTGGGATCTCTACAGCCCGCCAGGAGCGCGCTGAAACGCGAGG 1164
QY 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340
Db 1165 CCCTAAATCTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerle 380
Db 1285 TCCACTGAGGAAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGTGGCGGAGTGTCATT 1344
QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyValGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATCATGGAGATTCTACTCTTCAAGGGGCTGATGCTGGAGGTTCCGGGGGCCCA 1404
QY 400 aProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGGGAGGGGCGCTGCCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CCGCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh 480

Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCGCTACTGGCGCTCGACCGAGCCAAACTGCGAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGGCGCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 79
US-10-127-842A-143
; Sequence 143, Application US/10127842A
; Publication No. US20030082692A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zhen
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C100
; CURRENT APPLICATION NUMBER: US/10/127,842A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-842A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0

[illegible]

Qy	340	rIlePheGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CAITTTTAAAGGGAGCCATTCTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCGAGGAAGATGGGTGGGCTGCCCCCAACATTGAGGCTGGCGCAGTGTCAATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheTysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCCTACTTCTTCAAAGGGGTTCGATGCTGGAGGTTCGGGGCCCGCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCAGGGGGCTGCCCCCGCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGGGCCCTCATCTCTTCAAGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGGG	1584
Qy	460	yGlyLeProGlnGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGAGAGTCAGCGCGCCCTGCGAGGGCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGGGCTCTGACAGGCCAATCTGCAGGCACCACTCGGGCGC	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	c 1765	
RESULT 80			
US-10-127-843A-143			
; Sequence 143, Application US/10127843A			
; Publication No. US20030082693A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Deenoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tumas, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			
; APPLICANT: Zhang, Zemin			
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC			
; TITLE OF INVENTION: ACIDS ENCODING THE SAME			
; FILE REFERENCE: P33301C99			
; CURRENT APPLICATION NUMBER: US/10/127,843A			
; CURRENT FILING DATE: 2002-04-22			
; PRIOR APPLICATION NUMBER: 60/049911			
; PRIOR FILING DATE: 1997-06-18			
; PRIOR APPLICATION NUMBER: 60/056974			
; PRIOR FILING DATE: 1997-08-26			
; PRIOR APPLICATION NUMBER: 60/059113			

```

; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-843A-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-843A-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTGGCGCGGTGGCGCTCTCTGTCGCGCGCCCTGCACTGCTACTGTGGGGCCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCGCCAGCCCGGAGCGCGGAGCCAGAGCTGCGCAAGAGCGCGGAGGCATTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCACTCGATTGAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGGTGTCCCACTGCTCAGCGCGGTGTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGTTATGGG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTGTTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565

QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTAAACAGACGACCTCTCTCCACCGCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGACATCTGCCGAGCGCGAGTTCTGGGGCGCGCTGCGCGCCCTTCAG 685

QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGAGATTCTGGAGGCGCCACAGCCACAGGCCCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTCCAGGGGACCAACAGATGGGCTGGGCAATGCTTTCATGGC 805

```

RESULT 81

US-10-127-845A-143

; Sequence 143, Application US/10127845A

; Publication No. US20030082694A1

; GENERAL INFORMATION:

```

QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGI 220
DB 806 CCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCCCGCGCGGGAAGCGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGCAACCTGTTCTGTGTGTGCGCGCA 924

QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCACCTGCGCGCGCGCGCGCGCTCATGCGCGC 984

QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
DB 985 CTACTACAAGAGCTGGCGCGCGCGCGCTGCTGCTGAGTGGGACGAGCTGCGCGTGA 1044

QY 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGGAAGCTGT 1104

QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCAGCCCCCAAGAGCGCGCTTGAACCGCGG 1164

QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGTGCAACAGCTCTCAGAGCCCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGAGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGTGGCGAGTGTCTATT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisPheAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGCGCGAGGGGCGCTGCCCGCCATCTTGACGC 1464

QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTACGT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGI 460
DB 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGCTTCGAGGACTGGGG 1584

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCAGGAGGTGAGCGCGCGCTGCCAGGCGCGATGGCTGCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATACCGCTACTGGCGCGCTCGACAGGCGCAAACTGAGGCAACACCTCGGGCGG 1704

QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGTCATGTCGCAACTCGGGAGCGCGCTGT 1764

QY 520 e 520
DB 1765 C 1765

```


Db 1465 CCGCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTTCAAGGGTGCCTACTTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGGACTGCAAGTGGAGCGCTACTACCCCGGAAAGTCTCAGACTGGGG 1584
QY 460 yGlyIleProGluGluValserGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTTCAGCGCGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCTCGACCAAGGCCAACTGCAGGCCAACCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 82

US-10-127-846A-143
; Sequence 143, Application US/10127846A
; Publication No. US20030082695A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC94
; CURRENT APPLICATION NUMBER: US/10/127,846A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985

; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-846A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-127-846A-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTGGCGCGCTCGGCTTCTGTCGCGCCCTGACAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCGCGGAGCGCGGAGCTGCGCAAGGAGCGCGGAGCATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTGCTCCAGTGTGAGCGGCTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTGTTGTAGACACCGGACCAAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGGAGCATCTGCGGAGCCGCGAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCCAGCCAGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGGCTGGCGCACGCTTC-CTGCCCGCGCGCGGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgHisLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGGGCGCAACCTGTTCGTGGTGTGTCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCGCTCACCCACTCGCGCGCGCGCGCGCTCATGCGCGCC 984
QY 260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGGAGCGCTGCTCAGCTGGGACGACGCTGCTGGCCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCAGTGTCCAGCTCCCGAGAAAGCTGT 1104

```
Qy 300 eThraSpPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACATTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGGCCCTGAAACGCAAGG 1164
Qy 320 yProLysTyrCyshHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCTACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGTGAGAAAGATGGGTGGGCTGCCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATCGAGATTCTTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTTCCACAGCTGTGCCGGGCAGGGGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
Db 1465 GCCTCTTCTTCTCTCTCTGCGCGCCCTCATCTCTTCAAGGGGTGCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCAAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTGAGCGGGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspAlaAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGGCTCGACGAGCCAAATGAGGCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTGCTGGATGCGCTGCAACTCGGGAGGCGCTGT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 83

```
US-10-127-848A-143
; Sequence 143, Application US/10127848A
; Publication No. US20030082696A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; ACIDS ENCODING THE SAME
```

```
; FILE REFERENCE: P3330R1C106
; CURRENT APPLICATION NUMBER: US/10/127,848A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-848A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-127-848A-143 (1-1985)
```

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGCGCTCTCTGCTGGCGCCCTGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGCGGAGCTGGCGCAAGGAGGCGGAGGCATTTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCCAAGCTCCCACTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTCTCCAGCTACTGTCCAGCGCGCTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCACAGATGACTCGTCCCGGGTTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCATGTACTTGTGTAGACACCGGACCAAAATGAGGGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTTACAAAGCAGCACCTCTCTACCGCTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGAGTTTCGGGGCGCGCTTCGCGCGCGCTTCAG 685
```

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGGCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerIysGlyThrThrThrMetGlyTTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCCCTTGTATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGCGCACGCTTC-CTGCCCGCGCGGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCCCTGAGCGCGCGCGGGCGCAACCTGTTCTGTCGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACCTTTGGCTTACCACCTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTrpIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGCGTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGCGCGTGA 1044
Qy 280 nSerLeuTyGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAAGCCCTAGGGGCTCAGTGGCGTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTGTAGAGCTGGGACTCTACAGCCCGCAAGAGCGCGCTGAAACCGCAGGG 1164
Qy 320 yProIysTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACCTCCACTTCTCTCGATGCCATCTACTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGCGAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGTGCGGAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCTGCGCGGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 GCCTCTTCTTCTCTCTGCGCGGCTCATCTCTTCAAGGTGCGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGGCCCTTACTACCCCGCAAGTCTGCAAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTCAGCGGCGCTTCCCGAGGCGCGGATGGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAAATGCAAGGCCAACCTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520

Db 1765 C 1765

RESULT 84

US-10-127-849A-143
; Sequence 143, Application US/10127849A
; Publication No. US20030082697A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC103
; CURRENT APPLICATION NUMBER: US/10/127,849A
; CURRENT FILING DATE: 2002-04-23

; PRIOR APPLICATION NUMBER: 60/049911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059115

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059117

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059122

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059184

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059263

; PRIOR FILING DATE: 1997-09-18

; PRIOR APPLICATION NUMBER: 60/059352

; PRIOR FILING DATE: 1997-09-19

; PRIOR APPLICATION NUMBER: 60/059588

; PRIOR FILING DATE: 1997-09-19

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 143

; LENGTH: 1985

; TYPE: DNA

; ORGANISM: Homo Sapien

US-10-127-849A-143

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-849A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20

Db 206 ATGTCGCGCGCGCTGCGCCCTCTGTCGCGGCCCTGCTACTGTGGGCGACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnLeuArgLysGluAlaGluAlaPheLeu 40

Qy	260	oTyrTyrlYsArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGCGCGACGCGCTGCTCAGCTGGGACGACGTGCTGGCCGTGCA	1044
Qy	280	nSerLeuTyrlGlylsBProLeuGlyGlySerValAlaValGlnLeuProGlylsLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CATGACTTTTGAGACCTGGGACTTCCTACAGCCCCCAAGGAAGCGCCCTGAAACGCAGGG	1164
Qy	320	yProLyTyrlCyseHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATAGTGCACCTCTTCCTTCGATGCCATCAGCTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLyGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAAGGAGGACCATTTCTGGGAGGTGGCAGCTGTAGGCAACGTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTCGACGAAGATGGGTGCGGTGCCCCCAACATTTAGAGCTCGGCGAGTGTCAAT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLyGlyArgCyseTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGCGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCyseArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGGAGGGGCGCTGCCCCGCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgLeuIleLeuPheLyGlyAlaAargTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTTCAGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaAargGlyYGlYLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGCTCGCAGGACTGGGG	1584
Qy	460	yGlyLeProGluGluValSerGlyAlaLeuProArProAspGlySerIlelePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCGGAGGCGCCGATGGCTCCCATCTCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLyLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCTTCGACCAAGGCCAAACTCAGGCAACCACTCGGGCGG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCyseTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGCCNACTCGGGGAGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 86			
US-10-127-851A-143			
; Sequence 143, Application US/10127851A			
; Publication No. US20030082699A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: Derofge, Laura			
; APPLICANT: Desnoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			

Qy	1	MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGTCTCTGTCGGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GAGCCCCAGCCCGAGCGCGAGGCCAGAGCTGCGCAAGGAGCGCGAGGCATTTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGATCCCCAAAGCTCCCACCTCCATCGATTACGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACGCTTTTCAGTGGGTGTCCCACTACTCTGCAGCGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuAcqGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCACCCCTGGCCAGATGACTGTCTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCTGGCTGTAGAGATCAGTGACTGTGTTCCTAGACACCGGACCAAAATGAGCGCTAAG	565

Db 1645 CCAGATGACCGCTACTGCGCGCTCGACAGGCGCAAACTGCAGGCAACCACTCGGCGC 1704
Qy 500 gTTPAlaThrGluLeuProTTPMetClyCysTTPHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCGCACGAGCTGCCCTGTGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764

Qy 520 e 520

Db 1765 C 1765

RESULT 87

US-10-128-684A-143
; Sequence 143, Application US/10128684A
; Publication No. US20030082700A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin

TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

FILE REFERENCE: P3330RIC118

CURRENT APPLICATION NUMBER: US/10/128,684A

CURRENT FILING DATE: 2002-04-23

PRIOR APPLICATION NUMBER: 60/049911

PRIOR FILING DATE: 1997-06-18

PRIOR APPLICATION NUMBER: 60/056974

PRIOR FILING DATE: 1997-08-26

PRIOR APPLICATION NUMBER: 60/059113

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059115

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059117

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059122

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059184

PRIOR FILING DATE: 1997-09-17

PRIOR APPLICATION NUMBER: 60/059263

PRIOR FILING DATE: 1997-09-18

PRIOR APPLICATION NUMBER: 60/059352

PRIOR FILING DATE: 1997-09-19

PRIOR APPLICATION NUMBER: 60/059588

PRIOR FILING DATE: 1997-09-19

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 143

; LENGTH: 1985

; TYPE: DNA

; ORGANISM: Homo Sapien

US-10-128-684A-143

Alignment Scores:

Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-128-684A-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTGGCGCGCTCGCGCTCTCTGTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGGAGCCAGAGCTGGCGAGGCGGAGGCAGTCCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAenGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGCTTTTCAGTGGGTGCTCCAGCTACCTGTGAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTGCTCCCGCTGCGGGGTTCAGATACCAACAGTTATGGC 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAenLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCAGCTCTCTACCGCTGGTG 625
Qy 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCGAGAGCGGAGGTTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCCAGCCAGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCTCAGCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTTPArgTrpPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGGAGGCGCATTGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGCTGCGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGCGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTCAAGAGGCTGGGCGCGCGCGCTGCTGAGCTGGGACGAGCTGCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCGCCCAAGGAGGCGCCCTCGAAACAGCGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuThy 340
Db 1165 CCCTAAATACGTGCCACTCTTCTTCGATGCCATCTACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAenValSerGluProAr 360

```
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyValArgCysTTPArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGCATGCTGGAGGTTCCGGGGCCCA 1404
Qy 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGCAGGGGCGCTGCCGCCCATCTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGGCGGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPGl 460
Db 1525 GCTGCCCGGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTTCCCGAGGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGCCAACTGCAGGCAACACCTCGGGCG 1704
Qy 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764

Qy 520 e 520
Db 1765 C 1765

RESULT 88
US-10-128-686A-143
; Sequence 143, Application US/10128686A
; Publication No. US20030082701A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeGeorge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C119
; CURRENT APPLICATION NUMBER: US/10/128,686A
; CURRENT FILING DATE: 2002-04-23
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
```

```
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-128-686A-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-128-686A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuLeuTTPGlyHisLeu 20
Db 206 ATGCTCGCGCGCTCGGCCCTCTCTGCTGGCGCCCTCCAGCTGCTACTGTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCGCGGAGCGCGAGGCTGCGCAAGGAGGCGGAGGATTCCTA 325

Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCAGTTCAGT 385

Qy 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTCTCAGCGGCGTGTGGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505

Qy 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTTTGTAGACACCGGACCAAAATGAGCGGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTTPTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCTCCGCGCTGGTG 625

Qy 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGGAGTTCGGGGCGCGTGGCGCGCCCTTCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyVaArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGAGGCGCCCGACGACAGGCCCCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCGGCTCACCTTCTTCCAAAGGGGACCAACACATGGGCTGGGCAATGCCCTTTGATGCG 805

Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCTTGGCGCAGCGCTTC-CTGCCCGCGCGGCGGAGCGCACTTCGACCA 864
```

```
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCTGAGCGCGCGCGCGCGCAACTCTGCTGCTGCTGCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGCGCTCCACCACTCGCGCGCGCGCGCTCATGTCGCGC 984
QY 260 oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAGAGAGCTGGCGCGCGCGCGCTGCTCAGCTGGAGCAGCTGTCGCGCGTGA 1044
QY 280 nSerLeuTyGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCGCCAAGGAAGCGCCCTGAAACGCGAG 1164
QY 320 yProLysTyrcyHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATCTGCACCTCTCTTCATGCTCCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCAATTTCTGGAGGTGGCGAGCTGATGCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACCTGCAGGAAGATGGTGGGCTGCGCCGCCCAACATTGAGCTGCGCGAGTGCATT 1344
QY 380 uAsnAspGlyAspPheTyrcPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTCTTCAAGAGGGGTGATGCTGAGAGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCCCGCCATCTTGACGC 1464
QY 420 alaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyTrpVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGGCCCCGAGGGGAGCTGCAAGTGGAGCGCTTACTACCCCGCAAGTCTGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTGAGCGGCGCTGCGAGGCGCGCTGCGAGGCGCGATGCTCATCTTCT 1644
QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGAGCCAACTGCGAGGCAACCCACCTCGCGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaIleuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 89

```
US-10-128-690A-143
; Sequence 143, Application US/10128690A
; Publication No. US20030082702A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
```

```
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C122
; CURRENT APPLICATION NUMBER: US/10/128,690A
; CURRENT FILING DATE: 2002-04-23
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-128-690A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-128-690A-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTGCGCTCTCTGTCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGAGCGCGAGCGCGAGAGCTGCCAAGGAGCGGAGGAGCATTCCTTA 325
QY 41 GluLysTyrcGlyTyrcLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGAGTCCCAAGAGTCCCAAGTCCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCTCCAGGCTACCTGTCAGCGCGGTGTTGGACCGC 445
```

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCCACAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTTGCTAGACACCGACCAAAATGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGACCTCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCCGAGCGGAGGTTTGGGGCGCGGTGGCGCGCGCTTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTACGCGTGGAGTTCTGGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCAAGGGGACCAACAGATGGGCTGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGCGGCTGGCGAGCGCTTC-CTGCCCGCGCGCGGCGCAACTGTTGTTGGTGGCGCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACTGTTGTTGGTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTGGCTCAGCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTGCTGAGTGGAGCGAGTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGTATGGAAGCCCTAGGGGGCTCAGTGGCGCTCAGCTCCCGAGGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGAGCGCGCGCGCGCGCGCGCGCGCGCGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGNACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCACATGCAGGAAGATGGTGGGCTGCCCGCGCGCGCGCGCGCGCGCGCGCGCGCG 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCGCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCGAGGGGCGCTGCCCGCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPheProProLeuArgGluLeuLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460

Db 1525 GCTGGCCCGAGGGGAGTCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGCATCTCTTGGAGAGGTGAGCGCGCTTGCAGGCGCGCGATGGCTCCATCTCTTCT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTTGGCGCTTGCACAGGCGCAAACTGCAGGCAACCACTTGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 c 1765

RESULT 90
US-10-128-691A-143
; Sequence 143, Application US/10128691A
; Publication No. US20030082703A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C123
; CURRENT APPLICATION NUMBER: US/10/128,691A
; PRIOR FILING DATE: 2002-04-23
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-128-691A-143

Alignment Scores:			
Pred. No.:	3.35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0
US-10-791-980-6 (1-520) x US-10-128-691A-143 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuAArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCTCGGCTCTCTGCTGGCGCCCTGCAGCTGCTACTGTGGGGCCACTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgIysGluAlaGluAlaPheLeu	40
Db	266	GAGCCCCAGCCCGCGAGCGCGGAGGCGAGAGCTGGCGCAAGGAGGCGAGCATTCCTA	325
Qy	41	GluIysTyrGlyTyrLeuAenGluGlnValProIysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGAGCTCCCACTCCACTCGATTGAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCACTGAGGGTGTCCAGCTACTCTGACGGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgArgIys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTGTGTCTAGACACCGGACCAAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrIysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAAGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTACCGCTCGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSer	160
Db	626	AACTGGGCTGAGCATCTGCCGAGCGCGCAGTTCCGGGCGCGGTGCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCCTCAGCCCTGGAGTTCGGAGGCGCCAGCCAGGCGCCGCTGAC	745
Qy	180	rSerGlySerProSerSerIysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAGGGGACCAACAACGATGGGCTGGGCAATGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
Db	806	CCAGGGGCGCCCTGGGGCGACGCCCTTC-CTGCCCGCGCGCGCGCAAGCGACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGACGCCCGCGCGGGCGCAACTGTGTGGTGGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGSCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG	280
Db	985	CTACTACAAGAGGCTGGGCGCGCAGCGGCTGCTCAGCTGGGACACAGCTGCTGGCGCGTGA	1044
Qy	280	nSerLeuTyrGlyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCCCTAGTGGGGCTCAGTGGCGTCCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG	320

```
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-819A-143

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      99.52%      Indels:      2
DB:              15          Gaps:      0

US-10-791-980-6 (1-520) x US-10-131-819A-143 (1-1985)

Qy      1  MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db      206  ATGTGCGCGCGTGGCGCTCTGTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265

Qy      21  AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GAGCGCCAGCCGCGAGCGCGGAGCCAGAGCTGCGCAGAGGCGCGAGGCAATTCCTA 325

Qy      41  GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326  GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAAAGCTCCACCTCCACTCGATTACG 385

Qy      61  AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386  GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGAGTACCCTGTGACGCGCGTGTGGACCGC 445

Qy      81  AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db      446  GCCACCTTGGCCAGATGACTGCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505

Qy      101  AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db      506  GCCTGGGTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565

Qy      121  LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566  AAACGCTTTGCAAGCAAGGTAACAAATGGTACAGACAGCACCTCTCCCTACCGCTGGTG 625

Qy      141  AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626  AACTGGCTTGAGCATCTCCCGAGGCGCGAGTTCGGGGCGCGTGGCGCGCCCTCCAG 685

Qy      160  rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686  TTGTGGAGCAACGTCTCAGCGTGGAGTTCTGGGAGGCCCCAGGCACAGGCCCGCTGAC 745
```

```
Qy      180  rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db      746  ATCCGGCTCACCTTTCTCAAGGGGACCAACATGGGCTGGCAATGCTTTGATGGC 805

Qy      200  aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db      806  CCAGGGGGCGGCTGGGGCAGCCCTTC-CTGCCCGCGCGCGGCGAGGCACTTCGACCA 864

Qy      220  nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db      865  AGATGAGCGCTGTGCTCCTGAGCGCGCGCGCGCAACCTGTTCGTGTGTGTGGCGCA 924

Qy      240  sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925  CGAGATCGGTACACGCTTGGCCTCAGCCCATCCTCCCGCGCGCGCGCTCATGGCGCC 984

Qy      260  oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db      985  CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044

Qy      280  nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104

Qy      300  eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db      1105  CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCGCTGAAACGCGAGG 1164

Qy      320  yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCTTAATACTGCGCACTCTCTTCGATGTCATCCTGTAGACAGGCAACAGCAACTGTA 1224

Qy      340  rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284

Qy      360  gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db      1285  TCCACTCGAGAAAGATGGGTGGGCTGCCCGCCCAACATTTGAGGCTCGGCGAGTGTCA 1344

Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345  GAATGATGGAGATTTCTACTTCTTCAAAAGGGGTGCGATGCTGGAGGTTCGGGGCCCA 1404

Qy      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGCTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCGGCCATCCTCGACGC 1464

Qy      420  aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db      1465  CGCCCTCTTCTTCCTCTCTGGCGCCCTCATCTCTTCAAGGGTGGCGCTACTACTGT 1524

Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db      1525  GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584

Qy      460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db      1585  AGGCATCCCTGAGAGGTGAGCGCGCTCCCGAGGCGCGATGGCTCCATCATCTCTT 1644

Qy      480  eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTGGCGCCTCGACACGAGGCAAACTGAGGCAACACCTCGGGCG 1704

Qy      500  gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACCGAGCTGCCCTGGATGGCTGTCGATGTCGCACTGCGGAGCGCCCTGT 1764

Qy      520  e 520
Db      1765  C 1765
```

RESULT 92

```
US-10-131-829A-143
; Sequence 143, Application US/10131829A
; Publication No. US20030082705A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC138
; CURRENT APPLICATION NUMBER: US/10/131,829A
; CURRENT FILING DATE: 2002-04-27
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-829A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-131-829A-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTCTGCTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCCCGCGGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCATTTCCTA 325
```

```
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACACCTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuArg 80
Db 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCACAGTACCTGTGAGGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCTCCCGCTCGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTAGACACCGGACCAAAATAGGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTTACCGCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCGAGCGCGAGTTCGGGGCGCGTTCGGCGCCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGGCCCCCAGGCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTGTATGTC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGCGGCTGGCGACGCTTC-CTGCCCCCGCGCGGAGCGGAGCCACTTTCACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlyArgLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTTGTTGTCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACACTCGCGCGCGCGCGCGCTCTATGCGCGC 984
QY 260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGGCGCGCGCTGCTCAGCTGGGAGCAGCTGCTGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCACAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCCTGAAACAGCGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCATAAACTGCGCACTCTCTCTCGATGCCATCACTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGTGGGCGCAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATCGAGATTTCTACTTTCTTCAAAGGGGGTGCATGTGAGAGGTTCGGGGGGCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
```



```
Db 985 CTACTACAAGAGCGTGGCGCGCGCTGCTCAGCTGGGACGAGTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGACTGTT 1104
Qy 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCGCCCAAGGAAGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTyrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGCCATTTCTGGAGGTGCAGCTGATGCAACGTCCTAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTyrValGlyLeuProProhenlleGluAlaAlaValSerle 380
Db 1285 TCCACTGCAGGAAGATGGTGGCTGCCGCCCAACATTGAGGTGGCGCAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyCysTyrArgPheArgGlyProIly 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCCNACAGCTGTGCCGGCAGGGGCCCTGCCGCCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1 460
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCCGAGGGCCGATGGCTCCATCATCTT 1644
Qy 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTyrAlaThrGluLeuProTyrMetGlyCysTyrHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 94
US-10-146-729-143
; Sequence 143, Application US/10146729
; Publication No. US20030082708A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Denoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
```

```
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zenin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P330R1C318
; CURRENT APPLICATION NUMBER: US/10/146,729
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-146-729-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-146-729-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTyrGlyHisLeu 20
Db 206 ATGTGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGGAGCGGAGCTGCCAAGGAGCGGAGGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGTCCCACTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTACGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCCGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTCTAGACACCCGACCCAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AACCGCTTTCAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCCGAGCCCGCAGCTTGGGGGCGCGTGGCGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTCGAGTTCCTGGGAGGCGCCCGACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTyrTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACATGGGCTGGGCAATGCGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCGCTTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGGAGCGCATTCGACCA 864
Qy 220 nAspGluArgTyrSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTGGTGTCTGGGCGCA 924
```

Qy 240 sGluIedGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrIysArgLeuGlyArgAspAlaLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGTGGCGCGCGCGCTTCTCAGCTGGGACGACGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAGCCCTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACCTTTCAGACCTGGGACTCTACAGCCCCCAGGAAGGGCGCCCTGAAGCGCAGG 1164
Qy 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTTCTCTTCGATGCCATCACTGTAGACGGCAACGACACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGGAAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGTTCGATCTGGAGGTTCCGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGGCTGCGGAGGCGCGATGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGGCGAACTGCAAGGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 95

US-10-146-791-143

; Sequence 143, Application US/10146791

; Publication NO. US20030082709A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C320
; CURRENT APPLICATION NUMBER: US/10/146,791
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-146-791-143

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) X US-10-146-791-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGCGCTCTGCTCGCGCCCTGCAGCTGTACTGTGGGGCCACTGT 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACCCCGAGCCCGCGAGCGCGGAGCGCAGAGCTGCGAAGAGGCGGAGGCGATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATCCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTGCGGGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCAAAGCAAGGTAAACAAATGGTACAGCAGACCTCTCTCCCGCTGTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGCAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGGTTCTGGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGTGGGCTGGGCAATGCCCTTTGATGGC 805

```
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC - CTGCCCGCGCGCGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCCCTGGTCCCTGAGCGCGCGCGCGGCAACCTGTGTCTGGTGTCTGGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGTTCACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGC 984
QY 260 tTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGCGCTGGCGCGCGACGCGTGTCTCAGCTGGGACGACGTCTGGCGGTGCA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCAAGAGAGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCATTCTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCACCTGCAAGAAAGATGGTGGGCTGCCCCCAACATTGAGCTGCGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCCAAGCTGTGCGGGGAGGGGCGCTGCCCGCGCATCTCGACG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTACG 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCNAAGTGGAGGCCCTACTACCCCGAGTCTGCAGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCGGAGCCGATGGCTCATCATCTTCTT 1644
QY 480 eArgAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCAAGCCAAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCNACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 96

US-10-147-484-143

; Sequence 143, Application US/10147484

; Publication No. US20030082710A1

; GENERAL INFORMATION:

```
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C328
; CURRENT APPLICATION NUMBER: US/10/147,484
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-484-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-147-484-143 (1-1985)
```

```
QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGTCGCGCGCTCGGCTCTCTGTCGCGCGCTTGTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGGAGGAGCTGCCAGAGAGCTGCCAGAGCGGAGGAGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTCAGTGGGTGTCCAGACTACCTGTCTCAGCGGCTGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyraLa 100
Db 446 GCCACCTTGGCCGAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTATTGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCCTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAGCAGCAGCCTCTCTCCACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGluPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACGGCTGTAGCATCTCCGAGAGCGGAGTTCGGGGCGCGCTGCGGCGCCCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
```


Db 686 ITGTGGAGCAAGCTCTCAGCGCTGAGGTTCTGGAGGCGCCAGCACAGGCCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLySgLyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTCTTCTCAAGAGGACACAAACATGGGCTGGCAATGCGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyYargAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGGTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTGGCCCTCACCACTCGCGCGCGCGCGCGCTCATGGGCGCC 984
Qy 260 oTyTrLySArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGGCGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrgLySProLeuGlyGlySerValAlaValGlnLeuProGlyLySLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrsSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGAAAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLySvTyrcYsHisSerSerPheAspAlaileThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCACAGCACTGTA 1224
Qy 340 rIlePheLySgLySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGTCAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGCGGCGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLeuLySgLyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTCTGATCTGGAGGTTCCGGGCCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuileuPheLySgLyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCCGAGGCCGATGGCTCCATCTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLySleuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCAAACTGAGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCCTGGATGGGCTGTGGCATGTCCACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520 |

Db 1765 C 1765
RESULT 97
US-10-147-508-143
; Sequence 143, Application US/10147508
; Publication No. US20030082711A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Wacanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1G330
; CURRENT APPLICATION NUMBER: US/10/147,508
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-508-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-147-508-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTGCGCCCTCTGCTGCGCGCCCTGCTACTGTGCGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLySgLyAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGGAGCGCGGAGCCAGGAGCTGCGAAGGCGGAGGCGGCAATTCTTA 325
Qy 41 GluLySvTyrgLyTyTrLeuAsnGluValProLySgLyAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGACAGGTCCCCAAGCTCCACCTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTCACTGGGTGCTCCAGCTACCTGTGTCAGCGCGGTGTTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
Db 446 GCCACCCCTGGCGCAGATGACTGTGTCCTCCCGCTGGGGGTTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLySvMetArgLyS 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTTGTTGCTAGACACCGGACCAAAATGAGCGGTAA 565
Qy 121 LysArgPheAlaLySgLyGlnTyAsnLyTrpTyTrLySgLyGlnHisLeuSerTyArgLeuVal 140

Db 566 AAACGCTTTTCAAGCAAGGTAAACAATGGTACAAGCAGCACCCTCTCTACCGCCCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCACTCTCGGAGCCGCGAGTTTCGGGGCGCGTTCGGCGCCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGCCCGCGCTGAC 745
Qy 180 rSerGlySerProSerSerIysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCCGCTCACCCTTCTCAAGGGGACCAACGATGGCTGGCAATCCCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTTGGCGCAGCGCTTC -CTGCCCGCGCGCGGCAACGCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTCTGCTGCTGCTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCTGGCGCGGACGCGCTGCTAGCTGGGACGAGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGACCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGCTGGGACTCTTACAGCCGCCCAAGGAGCGCGCTGAAACGCGGG 1164
Qy 320 vProLysTrpCysHisSerSerPheAspAlaThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTCTCTTGATGCCATCTACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnAluArgTrpValGlyLeuProProLeuGlnGlyAlaAlaValSerLe 380
Db 1285 TCCACTGCGAGGAAGATGGGTGGGCTGCCCCCAACATTTGAGGCTGGCGCAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACACAGCTGTGCGGGCAGGGGGCTGCCCCCGCATCTCTGAGCG 1464
Qy 420 aAlaLeuPheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyTrpVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lIleuAlaArgGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGGCCCCGAGGGGACTGCAAGTGGAGCCCTTACCCCCGAGTGTGCGAGGATGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCGAGGGCCGATGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTGGCGCTCGAGCCAGGCCAACTGCAGGCCAACTGCCTGGCGCG 1704

Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCAGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 98
US-10-147-512-143
; Sequence 143, Application US/10147512
; Publication No. US20030082712A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C332
; CURRENT APPLICATION NUMBER: US/10/147,512
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-512-143
Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-147-512-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTCGAGCTGCTACTGTGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGGAGCTGCGCAAGGAGCGGAGCATTCCTTA 325
Qy 41 GluLysTrpGlyTrpLeuAsnGluValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGCGCTTCAGTGGGTGTCACGACTACCTGTTCAGCGGGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATCGC 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGATCAGTGAATGTTTCTAGACACCGGACCAAAATGAGCGTAAG 565
 Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTrpArgLeuVal 140
 Db 566 AAACGCTTTGCAAGCAAGATGAACAAATGGTACAGCAGACCTTCTCTACCGCTCGGTG 625
 Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCTTGAGCATCTCCGAGCGCGCAGTTCGGGGCGCGTGGCGCGCTTCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGAGGCGCCAGCGCACAGGCGCGCTGAC 745
 Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCCACACGATGGGCTGGGCAATGCCCTTTGATGGC 805
 Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGCGGCGGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCTCTCAGCGCGCGCGCGCGGCGCAACCTGTTCGTGGTGGCGCA 924
 Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGTTCACAGCTTTGGCTCACCACTCGCGCGCGCGCGCGCTCATGGGCGCC 984
 Qy 260 ofTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 Db 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGTCGGCGTGCA 1044
 Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
 Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACTTGGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCTGAAACGCGAGG 1164
 Qy 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340
 Db 1165 CCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
 Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTATGGCAACGCTCAGAGCCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGCTGGCGAGTGTATT 1344
 Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
 Db 1345 GAATGATGAGATTTCTACTCTCTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCAGTGTGGGTCTCTCCACAGCTGTGGCGGAGGGGGCTGCCCCGCCATCTCGAGCG 1464
 Qy 420 alaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTrpTrpVa 440
 Db 1465 CGCCCTCTTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrpTrpProArgSerLeuGlnAspTrpGl 460
 Db 1525 GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAAGTGTGAGGACTGGG 1584

Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGCATCCCTTCAGAGGTCAGCGGCCCTTCGCCAGCGCGGCTCATATCTCTT 1644
 Qy 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCAGATGACCGCTACTGGCGCTCGACCGGCAAACTGCAGCAACCACTCGGGCG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCAACGAGCTGCCCTGGATGGCTGTCATGCCAACTCGGGGAGCGCCCTGTT 1764
 Qy 520 e 520
 Db 1765 c 1765
 RESULT 99
 US-10-175-735-143
 ; Sequence 143, Application US/10175735
 ; Publication No. US20030082715A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C451
 ; CURRENT APPLICATION NUMBER: US/10/175,735
 ; CURRENT FILING DATE: 2002-06-19
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 ; US-10-175-735-143
 Alignment Scores:
 Pred. No.: 3,35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 15 Gaps: 0
 US-10-791-980-6 (1-520) x US-10-175-735-143 (1-1985)
 Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGTCAGCTGTCTACTGTGGGCGCACCTG 265
 Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCAGCCCGCGGAGCGCGAGCTGCGAGCGAGAGTGGCGAGGCGGCGCATTCCTA 325
 Qy 41 GluLysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAGTACGGATACCTCATGACAGGTCCCCAAGCTCCCACTCCGATTTCAGC 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGGGTGTTCAGCCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACCTGTTTGTGTAGACACCGGACCAAAATGAGGGGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAAGCAGCCTCTCTCTACCGCTGTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGTAGCATCTGCGGAGCGGCGAGTTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTTTCAGCGCTGGAGTTCTGGAGAGCCCGCCAGCCAGGCGCCCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyValArgHisLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTTCACACGCTTGGCTTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGAGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGGAGCGCCCTGAAACGACAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGGCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGGCTGCGCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440

Db 1465 GCCTCTTCTTCCCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGTGAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGATCCCTCAGGAGGTTCAGGGCGCTTCGCGAGGGCCCGATGGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACGAGCAAACTGCAGGCAACACCTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGGCTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 100
US-10-121-040-143
; Sequence 143. Application US/10121040
; Publication No. US20030082759A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C7
; CURRENT APPLICATION NUMBER: US/10/121,040
; CURRENT FILING DATE: 2002-04-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-121-040-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-121-040-143 (1-1985)
Qy 1 MetValalaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCTCGCGCGCTCGCGCTCTCTCTCGCGCTCTCTCTCTCTCTCTCTCTCTCTCTCT 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40

Db 266 GACGCCAGCCGCGGAGCGCGAGGCTGCGCAAGGAGCGGAGCGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluInValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACATTCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGluTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTGAGCTACCTGTACGCGGCGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTGTGTGTGCTAGACACCGGACCAAAATGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGAAAGCAAGTAAACAAATGGTACAGCAGACCTCTCTACCGCTGTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCGCGAGCGCGCAGTTCGGGGCGCGTTCGGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCCAGAGGAGCACCAACGATGGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCCGCGCGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACAGCTTTGGCTTCCACCATCTGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGACGCGCTGCTCAGCTGGGACGACGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTCCAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGAGGCGCCCTGAAAGCGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGGAGCTGAGTCAACGCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGGTGGGCTGCCCCCCCAACATTGAGGCTGGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400

Db 1345 GAATGATGGAGATTCTTACTTTCTTCAAAGGGGTCGATGCTGGAGGTTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrPrArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACGCGCGCTGCGGAGCGCCGATGGCTCCATCTCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCNAGTACCGCTACTTGGCGCTCGACAGGCGCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGTGCCTGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 101
US-10-121-056-143
; Sequence 143 Application US/10121056
; Publication No. US20030082760A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deenoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C25
; CURRENT APPLICATION NUMBER: US/10/121,056
; CURRENT FILING DATE: 2002-04-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-121-056-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; TITLE OF INVENTION: ACIDS ENCODING THE SAME

FILE REFERENCE: P3330R1C62

CURRENT APPLICATION NUMBER: US/10

;
; CURRENT FILING DATE: 2002-04-17

; Prior Application removed

NUMBER OF S

: SEO ID NO 14

```

; SEQ ID NO 1
; LENGTH: 15

```

LENGTH: 1200
TYPE: DNA

TYPE: DNA
ORGANISM: Homo

..Alignment Scores:

Argument Scores:					
Pred. No. :	3.35e-262	Length:	1985		
Score:	2792.00	Matches:	519		
Percent Similarity:	99.62%	Conservative:	0		
Best Local Similarity:	99.62%	Mismatches:	1		
Query Match:	99.53%	Indels:	2		
DB:	15	Gaps:	0		

US-10-791-980-6 (1-520) x US-10-124-818-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGCGCGGTGGCGCTCTCGTGTGGCGCCCTGCACTGTCAGCTGTACTGTGTGGGCGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GAGCCCGCCGCGGAGCGCGGAGCCAGAGAGCTGGCAAGAGAGCGGAGGCAATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTGCCAAAGCTCCACCTCCACTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCCATCAGACGCTTCAGTGGGTGTGCCAGCTACCTGTACGCGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCACCCCTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGATCAGTCACCTGTGTGTGTAGACACCGGACCAAAATAGGCGCTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGACAGGTAACAAAATGGTACAGAGCACCTCTCTCTACCGCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSer	160
Db	626	AACTGGCCTGAGCATCTGCCGAGCGCGCAGTTGGGGCGCGGTGGCGCGCGCTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCACGCGTGGAGTTCTGGGAGGCCACAGCCAGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGCTCACCTTCTTCCACGGGAGCACCAACGATGGGCTGGCAATGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
Db	806	CCAGGGGGGGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGGCGAAGCGCATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATAGAGCGTGTGTCTCTGAGCGCGCGCGGGCGCAACTGTTCGTGGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260

US-10-147-492-143
; Sequence 143, Application US/10147492
; Publication No. US20030082765A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Boresini, Maureen
; APPLICANT: DeForce, Laura

```
; APPLICANT: Desnovers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Collin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C347
; CURRENT APPLICATION NUMBER: US/10/147,492
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-492-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-492-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrrpGlyHisLeu 20
Db 206 ATGTGTCGCGCGGTGGGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGGGAGCCAGAGCTGCGCAAGAGGGCGGAGGCATTCTTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGGTGTGGACGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCACAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAGCAGACCTCTCCTACCGGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGGAGCCGCGCAGTTTCGGGGCGCGGTGGCGCCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTTGGGAGGCCCCCAGGCACAGGCCCGCTGAC 745
```

```
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCACACGATGGGTGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCCGCCCGCGCGCGGCTCATGGGGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGACGCGCTGCTCAGCTGGGACGACGTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACCTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
Db 1165 CCCTAAATACTGCCACCTCTTCTTCGATGCATCCTGTCAGACGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCACTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAAAGATGGGTGCGGCTGCCCCCAACATTTGAGGCTCGGCAGTGTCATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGGCGAGGGGCGCTGCCCGCCCATCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCCTCTGCGCCGCTCTATCCTCTTCAAGGCTGCCCTACTAGCT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCCAGCGCGCTGCGGAGGCGCGGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTTCGACCGGCCCAAACTGCAGGCAACCACTCTGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGTCCAACTCGGAGGCGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 107

US-10-158-782-143
; Sequence 143, Application US/10158782
; Publication No. US20030082766A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C457
; CURRENT APPLICATION NUMBER: US/10/158,782
; CURRENT FILING DATE: 2002-05-30
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; Prior Application remove - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-158-782-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-158-782-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTGGCGCGTGGCTCTCTGCGCGCTGCGAGTCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCACAGCCCGCGAGCGCGGAGCGCGAGAGTGGCGCAAGAGCGGAGGCATTTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACCTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGGTTTCAGTGGGTGCCAGCTACCTGTGTCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACTTGTGTGACACCGGACCCAAATGAGGGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAGACGACCTCTCTACCGCTGGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTCGCGAGCGGAGTTCGGGGCGCGTTCGGCGCCCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCTGGAGAGGCCCCAGCCAGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACACACGATGGGCTGGGCAATGCTTGTATGCG 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGGCGAGCGCATTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGCGCAACCTGTTCTGGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGTCAACGCTTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGTCTGGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGNAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGAGGCGCCCTGAAACCGCAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACGTGCACACTCTTCTCGATGCCATCCTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGCGAGCTGATGGCAACGCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGCAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGGAGATTCTTACTTTCTTCAAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGTCTCCACAGCTGTCCCGGGGAGGGGGCTGCCGCCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCTCTTCTTCT 1524
QY 440 lLeuAlaArgGlyLysLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCGGAGGGGAGCTGCAAGTGGAGGCCCTACTACCCCCCAAGTCTGCGAGGACTGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGAGGAGTTCAGCGCGCGCTGCCGAGGGCCGATGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGGCGCTCGACCGGCGCAACCTGCGAGGCAACCACTCGGGCGG 1704

```
Qy 500 gTnpAlaThrGluLeuProTnpMetGlyCysTrpHisAlaIshSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACAGAGCTGCCCTGGATGGCTGCTGGATGCCAATCGGAGCGGCCCTGTT 1764

Qy 520 e 520
Db 1765 C 1765

RESULT 108
US-10-123-905-143
; Sequence 143, Application US/10123905
; Publication No. US20030087344A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RLC48
; CURRENT APPLICATION NUMBER: US/10/123.905
; CURRENT FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-905-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-905-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACAGCCGCGAGCGCGGAGCGCAGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCATGAACAGGTCCCAAGCTCCACCTCCACCTCGAATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTTTCACTGGGTGTCCACAGCTACCTGTGCAGCGGCGTGTGGACGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGCCAGATACCTCGTCCCCCGCTGCGGGGTATACAGATACCAACAGTTATGCG 505
```

```
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAAGCTTTGCAAGCAAGGTAAACAATGGTACAAAGCAGCACCTCTCTCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGGAGCTTGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCCTGGAGAGCCCCCAGCAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCCAAGGGGACCAACAACGATGGCTGGGCAATGCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACTGTTCTGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCTTCCCTACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACAGCTGTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCGCTCTGAACCGCAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATATCTGCCACTCTTCTTCGATGCCATCCTACTGTAGACAGCAACAGCAACTGT 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGNGCCATTTCTGGGAGGTGGGAGCTGTATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGGAAAGATGGGTGCGGCTGCCCGCCCAACATTTGAGGCTCGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAAGGGGTGCGATGTGGAGGTTCGCGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCGCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTCCTCTCTGCGCGCCCTCATCTCTTCAAAGGGTGCCTACTACTACT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTCGAGAGCTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
```

Db 1585 AGGCATCCCTGAGGAGTCCAGCGGCGCCCTGCGAGGCCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAapArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCCAAACTGCAGGCCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAATCGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 109

US-10-123-907-143
; Sequence 143, Application US/10123907
; Publication No. US20030087345A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Berseni, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC50
; CURRENT APPLICATION NUMBER: US/10/123,907
; CURRENT FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-907-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-123-907-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTTCGGCGGCTCGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACCGCGGAGCGCGGAGCTGCGCAAGAGCGCGGAGGCAATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACACCTCCACATTCGATCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80

Db 386 GATGCCATCAGAGCGTTCAGTGGGTGTCCAGAGCTACCTGTCCAGCGCGTGTGTGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTTGGGCTGAGAGGATCAGTACTTGTTCGTAGACACCGGACCCAAATGAGGGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAAGCGTTTGCAAGCAAGGTAAACAAATGGTACAAGCAGCACCTCTCTCAGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGAGCGGCACTCGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyVArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGGAGGCCCCAGCCACAGGCCCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTCCAAAGGGGACCAACAGATGGGTGGGCAATGCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyVArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCTCCCTAGCGCGCGCGCGGCGCAACTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCCTCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAGGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGGGCGCTTGAACCGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCGCCTCTTCTTCATGTCATCCTCAGTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCAATTTCTGGAGGTGGCAGCTGATGCGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGCGGCTGCCCGCCCAACATTCAGGCTGCGCGCAGTGTCT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGCTCTCCACAGCTGTGCGGGGAGGGGCTTGGCCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440


```
Db 1465 GCGCTCTTCTCCCTCTCTCGCGCGCCTCATCTCTTTCAAGGTGGCGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGACTGCAAGTGGAGCGCTACTACCCCGAAGTCTGCAAGSACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTTCAGCGGGCGCCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCCTCGACCGGCAAACTGCAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAAGAGCTGCCCTGGATGGGTCTGGCATGCCCAACTCGGGGAGCGCGCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 110
US-10-124-815-143
; Sequence 143, Application US/10124815
; Publication No. US20030087346A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC57
; CURRENT APPLICATION NUMBER: US/10/124,815
; CURRENT FILING DATE: 2002-04-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-124-815-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-124-815-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGGTGGGCTCTGCTGGCGCGCCCTGCGAGCTGCTACTGTGGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
```

```
Db 266 GAGCCCGAGCCCGCGGAGCGCGGAGCGCAGAGCTGCGCAAGGAGCGGAGGCATTCTCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGAGTACCTCAATGAACAGGTCCCAAAAGCTCCCACTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTACGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGCCAGATGACTGTCCTCCCGCTGGCGGCTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAAAGCAAGGTACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGGAGTTTCGGGGCGCGGTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGAGCCCGCAGCCAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCACACGATGGGTGGGCAATGCTTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCGCCGCGCGCGGAGCGACACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGCGGGCGCAACTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTCCAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCGCAAGGAGGCGCCCTGAAACGCGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCGCACCTCTTCTTCGATGCGCATCCTCTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGCGGCTGCCCGCCCAACATTTAGGAGCTCGCGCAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
```

```
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGCGCTGCCCGCCATCTTGACGC 1464
QY 420 aAlaLeuPheProProLeuArgLeuLeuLeuPheLeuGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCCCGCCCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lleuAlaArgGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GTGGCCCGAGGGGACTGCAGTGGAGCCCTACTACCCCGGAGTCTCAGGACTGGGG 1584
QY 460 yGlyleProGluGluValserGlyAlaLeuProArgProAspGlySerileilePhePh 480
Db 1585 AGGCATCCTTGAGGAGGTGAGCGGCCCTGCCGAGGCCGATGGCTCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACGAGGCCAACTGCAGGCCAACCCCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 111
US-10-125-921A-143
; Sequence 143, Application US/10125921A
; Publication No. US20030087347A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: DeBresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC76
; CURRENT APPLICATION NUMBER: US/10/125,921A
; PRIORITY FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
```

```
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-125-921A-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-125-921A-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCCGCTCTCTGCTGCGCGCTTCTGCTGCGCGCTTCTGCTGCGCGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCGCGGAGCGCGGAGCTGCCAAGAGGCGGAGGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGAGTACCTGTCCAGCGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATCGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCCAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCCGAGCCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCCCCAGCCACAGGCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCGCTCACTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGGCTTGGCGCACGCTTC-CTGCCCGCGCGGCGGAGGCGACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTGCTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTTGCTGGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACCTCCTCCCGCGCGCGCGCGCTCATGGCGCC 984
```


Db 566 AAACGCTTTTGCAGCAAGCTATCAAAATGGTATCAAGCAGCAGCTCTCTCTACCGCCTGGTG 625
Qy 141 AenTtpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGCGCTAGCATCTGCCGAGCGCGGAGTTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTpsSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTtpAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCCCTTGTATGCG 805
Qy 200 aGlnGlyAlaProTtpAtgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTTGGCGCACGCTTC-CTGCCCGCGCGCGCGCAACCTTTCAGCA 864
Qy 220 nAspGluArgTtpSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGCGCAACCTTTCGTGGTCTGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTCAACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 ofTyTrLysArgLeuGlyArgAspAlaLeuLeuSerTtpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCGTGGCGCGCGCGCTGTCTCAGCTGGGACGACGTCTGCGCGTGA 1044
Qy 280 nSerLeuTyGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAGGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTtpAspSerTySerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTCGGACTCTTACAGCCCGCAAGAGGCGCGCTGAAACGCA 1164
Qy 320 yProLysTyCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTTCTCTTCATGCTCCATCTGTAGACAGGCAACAGCACTGA 1224
Qy 340 rIlePheLysGlySerHisPheTtpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGCCATTTCTGGAGGTGCGACTGATGGCAACGTCTCAGACCCCG 1284
Qy 360 gProLeuGlnGluArgTtpValGlyLeuProProAenIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGCTGCGCGTCCCGCCCAACATTGAGGCTGCGGCACTCAT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyLysArgCysTtpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCA 1404
Qy 400 eProValTtpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGCGAGGGGCGCTGCGCCGCCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTyVa 440
Db 1465 CGCCCTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGTGGCGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyLeuGlnValGluProTyTyTyProArgSerLeuGlnAspTtpGl 460
Db 1525 GTGGCGCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGCAAGCTCTCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGCGCTGCGGAGGCGCGATGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTyTyArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500

Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGGCCAAACTGCAGGCAACACCACTCGGGCG 1704
Qy 500 gTtpAlaThrGluLeuProTtpMetGlyCysTtpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 113
US-10-127-821A-143
; Sequence 143, Application US/10127821A
; Publication No. US20030087350A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC92
; CURRENT APPLICATION NUMBER: US/10/127.821A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SEQ ID NO 143
; NUMBER OF SEQ ID NOS: 550
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-821A-143
Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-821A-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTCTGGCGCTCTGCTGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGGAGCGCGGAGCCAGAGAGCTGCCAGAGGAGCGGAGGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGATACCTCAATGAACAGGTCCCAAGCTCCACACCTCCACATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACCTGTCCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTCGGGGGTTACAGATACCACAGTTATCGC 505
QY 101 AlanTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCCGGAGCGCGAGTTCGGGGCGCGTTCGGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGCGCCACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGTGTCTGGCGCA 924
QY 240 eGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCATCTCGCGCGCGCGCGCTCATGCGCGCC 984
QY 260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGAGCAGCGTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGTGGCGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGCGCCCAAGGAAGGCGCGCTGAAACGCGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCATCTGTAGACGACGACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCGCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaIleValSerLe 380
Db 1285 TCCACTCAGAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCATCTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGCTCTCCACAGAGCTGTCCGGGAGGGGCGCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGTCAAGCGCGCGCTGCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTTCGACCGAGGCAAACTGCAGGCAACACCTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 114
US-10-127-822A-143
; Sequence 143, Application US/10127822A
; Publication No. US20030087351A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C91
; CURRENT APPLICATION NUMBER: US/10/127, 822A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117

```
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-822A-143

Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-822A-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTTCGCGCGCTGGCGCTCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGCGCGAGCGCGAGGCCAGGAGCTGCGCAAGAGCGCGAGGCATTTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCTCCAGCTACCTGTGTCAGCGCGGTGTGGACCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTTTACAGATACCAACAGTTATGCG 505
QY 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgGlyLys 120
Db 506 GCTGGGCTGAGAGATCAGTACGTGTTGTCTAGACACCGGACCAAAATAGGCGTAAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACCTTTGCAAGCAAGGTAAACAAATGGTACAGAGCAGCCTCTCTACCGCCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGCATCTGCGGAGCGCGAGTTCGGGGCGCGTTCGGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGAGATTCTGGAGGGGCCCCAGCCAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCCACACAGTGGCTGGGCAATGCCCTTCATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGCGGAGGCGCACTTCGACCA 864
```

```
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGCGGCGCAACCTGTTCTGTTGCTGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGTCAACACGCTTGGCCTCACCACCTCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCACAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCGCAAGAGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTCTTCGATGCCATCACTGTAGACAGGCAACACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerIe 380
Db 1285 TCCACTGCGAGGAAGATGGGTCGGGCTGCCCGCCCAACATTGAGGTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTTCTTAAAGGGGGTTCGATGCTGGAGGTTCCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCCCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGAGCTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTGCGGAGGGCCGATGGCTCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCGCAAACTGCAGGCAACACACCTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 c 1765

RESULT 115
US-10-127-824A-143
; Sequence 143. Application US/10127824A
; Publication No. US20030087352A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
```


Db 1525 GCTGGCCCCAGGGGACTCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCCCTGCGAGGCCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCTCGACCGAGCCAACTGCAGGCAACCCACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaLeuSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTGGCATGCCAACTCGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 116

US-10-127-826A-143
; Sequence 143, Application US/10127826A
; Publication No. US20030087353A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C90
; CURRENT APPLICATION NUMBER: US/10/127,826A
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-826A-143

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-127-826A-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGTCGCGCGCTGCGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCNAGCCCGGAGCGGAGGCGGAGGCTGCGCAAGGAGGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGCGGTGTGGACGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCTGCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATCAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AACGCTTTGCAAGCAAGGTAAACAAATGGTGTACAAAGCAGCACCTCTCTCCACCGCTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCCGAGCGCGGAGCTTCCGGGCGCGCTGCGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGGCGCCCGCCACGAGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACACAAACGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
Db 806 CCAGGGGCGCCCTGGCGCACGCGCTTC-CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGGCAACCTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACTCGCCCGCGCGCGCTCATGGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGAGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlnArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAGGCGCCCTGAAAGCGCAGGG 1164

```
Qy 320 yProlystYrCysHisSerSerPheAspAlaIleThrValaspArgGlnGlnLeuTy 340
Db 1165 CCCATAATACGGCCACTCTCTCGATGCGCATCACTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTCTGGAGGTGGCAGTGTGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyCysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTCTTCCAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCGCCCATCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCTTACTACCCCCGAAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCTAGGAGGTGACGGGGCCCTGCCGAGGCGCGATGGCTCCATCATCTTCT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGluAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTGGCGCTCGACACGCGCAAAATGCAGGCAACACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACGAGCTGCGCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 117
US-10-127-827A-143
; Sequence 143, Application US/10127827A
; Publication No. US20030087354A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC83
; CURRENT APPLICATION NUMBER: US/10/127,827A
; CURRENT FILING DATE: 2002-10-16
; PRIOR APPLICATION NUMBER: 60/049911
```

```
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-827A-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-827A-143 (1-1985)
```

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGTCGGCGGTGCGGCTCTCTGTCGGCGCTCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGCCGCGGAGCGGAGCGGAGCTGCGCAAGGAGGCGGAGGCGCATTCCTA 325
Qy 41 GlulysTyTrpGlyLeuLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCACCTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCTTTTCAGTGGGTGTCCAGCTACTGTGTCAGCGGCGGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyTrAla 100
Db 446 GCCACCTTGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTCTAGACACCGGAGCAAAATGAGGCGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTyTrArgLeuVal 140
Db 566 AACGCTTTGCAAGCAAGGTAAACAAATGGTACAGAGCACCTCTCTCCCGCTGTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGGTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCGCCCGACAGGCGCCGCTGAC 745
```

```
Qy 180 rSerGlySerProSerSerSerGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGCAATGCCCTTTCATGCG 805
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGGCCCGCGCGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTTTCGTGGTCTCTGGCGCA 924
Qy 240 sGlnLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTACCCCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh 300
Db 1045 GAGCTGTATGGAAGCCCTTGGGGCTCAGTGGCGGTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGGAGCGCCCTGAACCGCAGGG 1164
Qy 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACCTGCCACTCTTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCACTTCTGGAGGTGGCAGCTGATGCAACAGTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCCCCAACATTGAGGCTGGCGAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheIysGlyIysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTCTGATCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 aProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGGCAGGGGCTGCCCCGCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTGCGCGGCTCATCTCTTCAAGGTGCGCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGCGCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGCAAGTCTGCGAGGCTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCTTCCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCGCAACTGCGAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 118
```

```
US-10-127-828A-143
; Sequence 143, Application US/10127828A
; Publication No. US20030087355A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deanoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C101
; CURRENT APPLICATION NUMBER: US/10/127,828A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SEQ ID NO 143
; NUMBER OF SEQ ID NOS: 550
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-828A-143
```

```
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-127-828A-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeuLeu 20
Db 206 ATGGTCGCGCGCTCGCCCTCTGCTCGCGCCCTGCTGCTGCTGCTGCTGCTGCTGCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGAGGCGCGAGGCGCGAGGCGCGAGGCGCGAGGCGCGATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProIysAlaProThrSerThrArgPheSer 60
```

Db 326 GAGAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACCTCGATTACG 385
Qy 61 AspAlaileArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCGCACATGACTCTCCCGCTGCGGGTTACAGATACCAACAGATTATCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTCGGCTGAGAGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGTTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCCGAGCGCGAGTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCGGGAGCGCCCGACACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTCAAGGGGACCAACATGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 agInGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGCGCAACCTGTTGGTGTGGCGCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTTCCCTGAGCGCGCGCGCGCGCAACCTGTTGGTGTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCCACCTCGCGCGCGCGCGCTCATGGCGGC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTCAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGAGCGCCCAAGGAGGCGCCCTGAACGCGAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaileThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATCTGCCACTCTTCTTCGATGCCATCAGTGTAGACAGGCACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACCAATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGGTGGGCTGCCCGCCCAACATGAGGCTCGCGCAGGTGTCATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420

Db 1405 GCCAGTGTGGGTCTCCACAGACTGTGCGGGGAGGGGGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCTGCGCGCCTCATCTCTTCAAGGGTCCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGTCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyileProGluValSerGlyAlaLeuProArgProAspGlySerIlelePhePh 480
Db 1585 AGGATCCCTGAGAGGTTCAGCGCGCTGCGGAGGCCCGATGGCTTCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACCGCAACTGCAGGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 119
US-10-127-830A-143
; Sequence 143, Application US/10127830A
; Publication No. US20030087356A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C112
; CURRENT APPLICATION NUMBER: US/10/127, 830A
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19


```
; APPLICANT: Wood,William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C109
; CURRENT APPLICATION NUMBER: US/10/127.832A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-832A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 15 Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-832A-143 (1-1985)
```

```
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGCGAGATTGCGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGAGCCCGCAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGCAATGCTTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGGCGCAGCGCTTC-CTGCCCGCGCGGGGAGAGGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGCGCTCACCCACTCGCCCGCGCGCGCTCATATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGGACGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACGCCCCCAAGGAGGCGCTTGAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAATATCTGCCACTCTTCTTCGATGTCATCCTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAGAAAGATGGGTGCGGCTGCCCCCCCAACATTGAGGCTCGGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTTACTTCTTCAAAGGGGTTCGATGTGGAGGTTCCGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGCTCTCCACAGCTGTCCGCGGAGGGGCTGCGCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAAGGTCGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTGAGCGCGCTTCCGAGGCGCGGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTTGGCGCTCTGACAGGCGCAACTGCGAGCAACACCTCGGCGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
```

Db 1705 CTGGGCGACCGAGCTGCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764

Qy 520 e 520
Db 1765 c 1765

RESULT 121

US-10-127-833A-143
; Sequence 143, Application US/10127833A
; Publication No. US20030087358A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tamas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P3330R1C95

; CURRENT APPLICATION NUMBER: US/10/127,833A

; CURRENT FILING DATE: 2002-10-15

; PRIOR APPLICATION NUMBER: 60/049911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059115

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059117

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059122

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059184

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059263

; PRIOR FILING DATE: 1997-09-18

; PRIOR APPLICATION NUMBER: 60/059352

; PRIOR FILING DATE: 1997-09-19

; PRIOR APPLICATION NUMBER: 60/059588

; PRIOR FILING DATE: 1997-09-19

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 143

; LENGTH: 1985

; TYPE: DNA

; ORGANISM: Homo Sapien

US-10-127-833A-143

Alignment Scores:

Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-127-833A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuTrpGlyHisLeu 20

Db	206	ATGTGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGAGTGTCTACTGTGGGCGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCGCGAGCGCGAGGAGCTGCGCAAGGAGCGGAGGCAATTCCTTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCATGAAACAGGTCCCAAGCTCCACCTCCACTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGACCGCTTTCAGTGGGTGTCACAGCTACCTGTTCAGCGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTGCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGGC	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTTCAGACACCGGACCCAAATAGGGCGTAAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCNAAAGCAAGGTAACAAATGGTACAAAGCAGCACCTCTCTACCGCCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTGAGCATCTCCGAGCGCGAGTTCGGGGCGCGCTGCGGCGCCTTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyVArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCCCCAGCCACAGGCCCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetal	200
Db	746	ATCCGGCTCACCTTCTCCNAGGGGACCAACAGATGGCTGGGCAATGCTTTCATGTC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl	220
Db	806	CCAGGGCGCGCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyVArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTGAGCCCGCGCGCGGCGGCAACCTGTTTCGTGGTGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGCGCGC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGGCGCGAGCGGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAACCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCNAGGAAGGCGCCCTGAAACCGAGGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATATCTGCGACCTCTTCCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGGCCATTTCTGGAGGTGGAGCTGATGGCAACGCTCTCAGAGCCCCCG	1284
Qy	360	qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380


```
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTGGCTCCACCCACTCGCCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrIysArgLeuGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAGAGAGCTGGCGCGCGCTGTCTAGCTGGGACGACGTCTGGCGCGTGA 1044
QY 280 nSerLeuTyrGlyIysProLeuGlyIysSerValAlaValGlnLeuProGlyIysLeuPh 300
Db 1045 GAGCTGTATGGAAGACCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGGAGCGCCCTGAAACCGAGGG 1164
QY 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCTCACTCTTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheIysGlySerHisPheTrpGluValAlaIleAspGlyAsnValSerGluProAr 360
Db 1225 CATTITTAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGGCGGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheIysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTGCATGTGGAGGTTCGGGGGCCCAA 1404
QY 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCGCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lleuAlaArgGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGI 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGGAACTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTGAGGAGTGCAGCGCGCCCTGCGGAGGCGCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCGCAACTGCGAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 123
; Sequence 143, Application US/10127836A
; Publication No. US20030087360A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
```

```
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C97
; CURRENT APPLICATION NUMBER: US/10/127,836A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-836A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-836A-143 (1-1985)
```

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTCTGCGGCCCTGAGCTGTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnLeuArgIysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
QY 41 GluIysTyrGlyTyrLeuAsnGluGlnValProIysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCAGTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTCTGTGCGGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
```


Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
Caps: 0

US-10-791-980-6 (1-520) x US-10-127-841A-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGCGCGCTCGGCTCTCTGCTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCGAGCCCGGAGCGCGAGGCCAGGAGCTGCGCAAGAGGCGGAGGCATTCCTTA 325
QY 41 GluLysTrpGlyTrpLeuAenGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACACTCCACTGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
DB 446 GCCACCCTCGCCGAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCTCGGGCTGAGAGGATCAGTACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGTG 625
QY 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTGCGGAGCGGCGAGTTCTGGGGCGCGCTGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCGCCGCTGCGCGCTTCAG 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCCAAAGGAGGACCAACAGATGGCTGGGCAATGCCCTTGA 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
DB 806 CCAGGGGCGCGCTGCGCGCACGCTTC - CTGCCCCCGCGCGCGGAGGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpTrpSerLeuSerArgArgArgGlyArgAenLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCTCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTCTGCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CCAGATCGGTACACGCTTGGCTTACCCACTTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGGCGCGAGCGCGCTGCTCAGCTGGGAGCGGTGCTGCGCGTGA 1044
QY 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGAAGCCCTTAGGGGCTCAGTGGCGGTCCAGCTCCCGAGCAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCCTACAGCCCCCAAGAGCGCCCTGAAACCGAGGG 1164
QY 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340
```

```
DB 1165 CCCTAAATACTGCCACTCTCTTCCTCGATGCCATCATCTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTAGAGCGCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTCGAGGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTCGGCGAGTGTCA 1344
QY 380 uAenAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATCATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGGCCCAA 1404
QY 400 gProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGGAGGGGCGCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuLeuIleLeuPheLysGlyAlaArgTyrTrpVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCGCTACTAC 1524
QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTTACTACCCCGAGTCTGACGAGCTGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
DB 1585 AGGCATCCCTGAGGAGGTGACGGCGCCCTGCGGAGGGCCGATGGCTCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCCAACTGACAGGCAACACCTCGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765
```

RESULT 125

US-10-127-844A-143

; Sequence 143 Application US/10127844A

; Publication No. US20030087362A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: DeNoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Collin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P3330R1C104

; CURRENT APPLICATION NUMBER: US/10/127,844A

; CURRENT FILING DATE: 2002-10-15

; PRIOR APPLICATION NUMBER: 60/049911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

```
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-127-844A-143

Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-127-844A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGTCTGGCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACAGCCCGGAGCGCGGAGCGCAGGAGCTGCGCAAGAGGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCACAGCTACCTGTCCAGCGCGGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCACAGATTATCGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTGTTGTAGACACCGGACCAAAATGAGGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTTACAAAGCAGCACCTCTCCACCGCCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCGCGGAGCGGCGAGTTCTGGGGCGCGTCCGCCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCCTTTGATGCG 805
```

```
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGGAGCGCACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGTGGTCTCTGAGCGCGCGCGGGGCGCAACTGTTCTGTGTGTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGTGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAGCGCGCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAAATATCGCACCTCTCTTCGATGCACTACTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGGACATTTCTGGGAGGTGGCAGCTGATGTGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaIleAlaValSerLe 380
Db 1285 TCACACTCAGGAAAGATGGGTGGGCTGCCCGCCCACTATGAGGCTCGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCTCTCTGCGCGCCCTCATCTCTTCAAGGGGTGCCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCGCTACTACCCCGAGTCTGCAGGAGTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTCAGAGGTCAGCGCGCGCTGCCGAGGCGCGATGGCTCCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACCGGCGCAACTGCAGGCAACACCTCGGGCCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGGCTGGATGGGCTGTGTCATGCCAATCGGAGCGCGCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 126
US-10-128-687A-143
; Sequence 143, Application US/10128687A
; Publication No. US20030087363A1

Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCACGTACTCTGTACGGCGGTGTGTGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTCGCGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGNAGAGGATCAGTACTGTGTGTCTAGACACCGACCAAAATGAGGCGGTNAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSer	160
Db	626	AAC TGGGCTTGAGCATCTGCGCGAGCCGGCAGTTCTCGGGCGCGCTGCGCGCGCTTCGAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTTGGGAGGCCCCAGGCCACAGGCCCGCTGCAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTTCTTCCAAGGGGACCAACAACGATGGGCTGGGCAATGCCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAAGGGGGCGCCCTGGCGCACCGCTTC-CTGCCCCCGCGCGCGAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGACCGCTGGTCCCTGAGCGCGCCCGCGGGCGCAACTGTTCTGTGTCTGGCGCA	924
Qy	240	sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACAGCTTGGCTTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACTAAGAGAGCTGGCGCGCACGCGCTGCTCAGCTGGGAGCACGTGCTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GACCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CAC TGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGNAACGCAGGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGCACACTCTTCCTTCGATGCGCATCATCTGTAGACGGCAACAGCAACTGTGA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAAGGGAGGCATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGTTCGGCTGCCCCCAACATTTAGGCTGCGCGCAGTGTCAATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLys	400
Db	1345	GAATGATGAGATTTCTACTTCTTCAAAGGGGTTCGATGCTGAGAGTTCTCGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCCGCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa	440

Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTCCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGATCCCTCAGGAGGTCAGCGCGCCCTGCCAGGCCCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACGAGCCAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCyTrpHisAlaLysSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

US 10 128 688A 143
; Sequence 143, Application US/10128688A
; Publication No. US20030087364A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C125
; CURRENT APPLICATION NUMBER: US/10/128,688A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143

; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-128-688A-143
Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-128-688A-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGCGCTCTCTCTGCGCGCTCGAGCTGTACTGTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGGAGCGCAGAGCTGCGAAGAGGCGGAGGCGATTCTCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGGTACTCTGTACGCGCGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAspSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGATCTGTCGCCGTGCGGGTTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCGCGCTGTG 625
Qy 141 AsnTrpProGluHisLeuArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGACCGCGCAGTTGCGGGCGCGTGGCGCGCCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTCGAGTTCTGGGAGGCGCCCGCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetClyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACATGGGTGGGCAATGCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGGGCAGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGGCGCAACCTGTTCTGTTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCCTCACCCACTCCCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValCl 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300


```
Db 1045 GAGCCTGTATGGAAGCCCTAGGGGCTCAGTGGCCGCTCCAGCTCCCAAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACTGGGATCTCTACAGCCCCNAGGAAGCGCCCTGAAACGAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGCGAGCTGATGCACACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGCGGCAAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGGCCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCTCTCTCGCGCCCTCTCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCGCTACTACCCCGAAGCTTCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGTGCAGCGCGCCCTGCGAGGCGCGCATGCTGCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCCCTACTGCGCCTCGACAGGCCAACTGCAAGGCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCCCTGATGGCTGCTGGCATGCCAACTCGGGAGGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 128
US-10-128-689A-143
; Sequence 143, Application US/10128689A
; Publication No. US20030087365A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
```

```
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C117
; CURRENT APPLICATION NUMBER: US/10/128,689A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-128-689A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-128-689A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuLeuLeuLeuLeuLeuLeu 20
Db 206 ATGTCGCGCGCTGGCCCTCTCTGTCGCGCCCTGACAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGCTGCGCAAGAGCGGAGGCGGAGGCGGAGGCGGAGGCGG 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCTCCAAAGCTCCACCTCCACCTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATCCCATCAGAGCGTTTCAGTGGGTGTCACGACTACTGTGAGGGGCTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCNAAGCAGGTAAACAAATGGTACAGCAGCACCTCTCTCCGCGGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGGAGTTCGGGCGCGGCGTTCGGGCGCGGCGGCGGCTTCAG 685
```

Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTTGGGAGGCCCCAGCCACAGGCCCGCTGCAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTACACTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGCGCCTTGGCGCAGCGCTTC-CTGCCCCCGCGCGGAGCGACTTCGACCA	864
Qy	220	nAspLnuArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGCTGGTCCCTTGAGCGCGCGCGCGCAACTGTTGTGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCCGCGCGCGGCTCATGTGGCGCC	984
Qy	260	oTyrTrlylsArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGGCGCGAGCGCTGCTCAGCTGGGACGACGTCGTGGCGTGA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCCGCTCAGCTCCGAGGAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCTCGAAACGCAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTTGCACACTCTTCTTCGATGCCATCACTGTAGCAGGCAACAGCAACTGT	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTCTTGGAGGTGCGAGCTGATGGCAACGCTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGGTGCGGCTGCCCCCAACATTGAGGCTCGCGCAGTGTCA	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTACTTCTTCAAAGGGGTCTGATGCTGGAGGTTCGGGGGCCCA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGCTTCCACAGCTGTGCGGGCAGGGGGCGCTGCCCGCCATCTCGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa	440
Db	1465	CGCCCTCTTCTTCCTCTCTGCGCCGCTCATCCTCTTCAAGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGGTGAGCGGCGCTGCGGAGGCCGATGGCTCCATCATCTTC	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCTTCGACCAAGGCCAAACTGCAGGCAACCACTCGGCGC	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGCAATGCCAATCGGGAGCGCCTGT	1764

Qy 520 e 520
Db 1765 c 1765

RESULT 129
US-10-128-694A-143
; Sequence 143, Application US/10128694A
; Publication No. US20030087366A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DePoige, Laura
; APPLICANT: Deenoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C121
; CURRENT APPLICATION NUMBER: US/10/128,694A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-128-694A-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-128-694A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
|||
Db 206 ATGGTCGCGCGGTTCGGCTCTTCGTGCGCGCCTGCAGCTGCTACTGTGGGGCCACCTG 265


```
; Publication No. US20030092103A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC145
; CURRENT APPLICATION NUMBER: US/10/131.815A
; CURRENT FILING DATE: 2002-04-24
; PRIORITY APPLICATION NUMBER: 60/049911
; PRIORITY FILING DATE: 1997-06-18
; PRIORITY APPLICATION NUMBER: 60/056974
; PRIORITY FILING DATE: 1997-08-26
; PRIORITY APPLICATION NUMBER: 60/059113
; PRIORITY FILING DATE: 1997-09-17
; PRIORITY APPLICATION NUMBER: 60/059115
; PRIORITY FILING DATE: 1997-09-17
; PRIORITY APPLICATION NUMBER: 60/059117
; PRIORITY FILING DATE: 1997-09-17
; PRIORITY APPLICATION NUMBER: 60/059122
; PRIORITY FILING DATE: 1997-09-17
; PRIORITY APPLICATION NUMBER: 60/059184
; PRIORITY FILING DATE: 1997-09-17
; PRIORITY APPLICATION NUMBER: 60/059263
; PRIORITY FILING DATE: 1997-09-18
; PRIORITY APPLICATION NUMBER: 60/059352
; PRIORITY FILING DATE: 1997-09-19
; PRIORITY APPLICATION NUMBER: 60/059588
; PRIORITY FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-815A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-131-815A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGTCGCGCGTGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGACGGAGCCAGAGCTGCGCAGAGGAGCGGCGGCAATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGGTCCACCTCCACTCGATTGAGC 385
```

```
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTACGCGCGTGTTCGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACTTCTGTTTGTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCANTCTGCGGAGCGGAGTTGCGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGCGCCAGCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTCTTTCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGGCGCAGCCTTC-CTGCCCGCGCGGCGGAGGAGGACACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgA-GlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTCTGCTGCTGGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCCTACCCACTCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTTAATATCTGCCACTCTTCTTCGATGCCATCCTCTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CAITTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCGAGAAAGATGGGTGCGGCTGCCCGCCCAACATGAGGCTGCGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGTTCGATGCTGGAGGTTCGCGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCCAAGCTGTGCGGGGAGGGGGCTGCCCGGCCCATCTCGACGC 1464
```

QY 420 aAlaLeuPheProProLeuArgArgLeuLeuLeuPheLeuPheLeuGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGTGCGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrGl 460
Db 1525 GCTGCGCGAGGGGACTGCAAGTGGAGCGCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 vGlyIleProGluGluValSerGlyAlaLeuProArgProArgGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGAGGTGAGCGGCGCTGCGAGGCGCGATGGCTCATCATCTTCTT 1644
QY 480 eArgAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCGAGCCAACTGCAGGCAACACCTCGGCGG 1704
QY 500 gTrrAlaThrGluLeuProTrrMetGlyCysTrrHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCGCGCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCGTGT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 133

US-10-131-817A-143
; Sequence 143. Application US/10131817A
; Publication No. US20030092104A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C129
; CURRENT APPLICATION NUMBER: US/10/131,817A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-817A-143

Alignment Scores: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservativeness: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-131-817A-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrrGlyHisLeu 20
Db 206 ATGGTTCGCGCGCTGCGCGCTCTCTGTCGCGCGCTGACAGTGTCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGCTGCGCAAGAGCGCGAGCATTCCTA 325
QY 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACATCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrrValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGAGTACCTGTTCAGCGCGCTGTGGACGCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCCTAGACACCGGACCAAAATCAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrrTrrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCTACCGCTGTG 625
QY 141 AsnTrrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGAGCTTCGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGGCGCCAGCCAGGCGCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrrPalaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACACAAACATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrrPargThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGCGCGCACGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrrSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGGCAACCTGTTCTGTGTGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACAGCTTGGCTTCCCTACCTCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrrLysArgLeuGlyArgAspAlaLeuLeuSerTrrPalaAspValLeuAlaValGl 280
Db 985 CTACTCAAGAGGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300

Db 626 AACTGGCCCTGAGCATCTGCCGAGCGCGAGTTCCGGGCGCGCTGCGCGCCGCTTCCAG 685
 Qy 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCCCCCAGCCACAGGCCCGCTGAC 745
 Qy 180 rSerGlySerProSerSerGlyGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGGCTGGGCAATGCCCTTGTATGC 805
 Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
 Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGGCCCCCGCGCGCAAGCGCACTTCGACCA 864
 Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
 Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGGCGCAACCTGTTCGTGGTCTGGCGCA 924
 Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTCAACGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGGCGCC 984
 Qy 260 oTyTrpYrlyArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
 Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGTGTGGCGGTGCA 1044
 Qy 280 nSerLeuTyGlyYrlyArgProLeuGlyYrlySerValAlaValGlnLeuProGlyYrlyLeuPh 300
 Db 1045 GAGCTGTATGGAGAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCACGAAAGCTGT 1104
 Qy 300 eThrAspPheGluThrTrpAspSerTyTrSerProGlnGlyArgArgProGluThrGlnGl 320
 Db 1105 CACTGACITTTAGACTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGAAACGCGGG 1164
 Qy 320 yProlyTyTrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
 Db 1165 CCTAAATACTGCTCACTCTCTCCATGTCATCATCTGTAGACAGGCAACAGCAACTGTA 1224
 Qy 340 rIlePheYrlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
 Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGACCCCG 1284
 Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTCGAGAAAGATGGTGGGCTGCCCCCAACATTGAGGTGGCGGAGTGTCTATT 1344
 Qy 380 uAsnAspGlyAspPheTyPhePheYrlyGlyArgCysTrpArgPheArgGlyProLy 400
 Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
 Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGGGTCTCCACAGCTGTGGCGGAGGGGCGTGGCCCCGCACTCTGAGCGC 1464
 Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheYrlyGlyAlaArgTyTrVa 440
 Db 1465 CGCCCTCTTCTCTCTCTGCGCGCTCTATCTCTTCAAGGGTGGCGGCTACTAGT 1524
 Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrProArgSerLeuGlnAspTrpGl 460
 Db 1525 GCTGGCGGAGGGGACTGCAAGTGGAGCGCTTACTACCCCGGAACTGTCAGGACTGGGG 1584
 Qy 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIlePhePh 480
 Db 1585 AGGCATCCTTGAGAGGCTCAGCGGGCGCTTGGCGAGGGCGGATGCTCCATCATCTTCT 1644
 Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaYrlySerLeuGlnAlaThrThrSerGlyYr 500
 Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCGCAACTGTCAGGCAACCACTCGGGCGG 1704
 Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764

Qy 520 e 520
 Db 1765 C 1765

RESULT 135

US-10-131-822A-143
 ; Sequence 143, Application US/10131822A
 ; Publication No. US20030092106A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zhenin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C127
 ; CURRENT APPLICATION NUMBER: US/10/131,822A
 ; PRIORITY FILING DATE: 2002-04-24
 ; PRIOR APPLICATION NUMBER: 60/049911
 ; PRIOR FILING DATE: 1997-06-18
 ; PRIOR APPLICATION NUMBER: 60/056974
 ; PRIOR FILING DATE: 1997-08-26
 ; PRIOR APPLICATION NUMBER: 60/059113
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059115
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059117
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059122
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059184
 ; PRIOR FILING DATE: 1997-09-17
 ; PRIOR APPLICATION NUMBER: 60/059263
 ; PRIOR FILING DATE: 1997-09-18
 ; PRIOR APPLICATION NUMBER: 60/059352
 ; PRIOR FILING DATE: 1997-09-19
 ; PRIOR APPLICATION NUMBER: 60/059588
 ; PRIOR FILING DATE: 1997-09-19
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; SEQ ID NO 143
 ; NUMBER OF SEQ ID NOS: 550
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 US-10-131-822A-143

Alignment Scores:
 Pred. No.: 3,35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.82% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-131-822A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCGCTGACGCTGCTACTGTGGGGCCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGAGCGGAGCGGAGCGCAGAGCTGCGCAAGGAGGCGGAGGCATTCCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGATACCTCAATGACAGAGTCCCCAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGAGCTACCTGTGAGCGCGGTGTTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCCAGATGACTGTCTCCCGCTGCGGGGTTACAGATACCACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAGCAGCACCTCTCCTACCGGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTCCCGAGCCGCGAGTTTCGGGGCGCGTGGCGCCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCCAGCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAAGGGGACCACCAACGATGGGCTGGGCAATGSCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGGGCCCTGGCGACGCCCTTC-CTGCCCGCCCGCGGCGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGGCGCAACCTGTTTCGTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTTCACACGCTTGGCCTCACCACCTCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 ofTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
DB 985 CTACTACAGAGGCTGGCGCGGACCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGATGGAAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCAAGGAGGCGCCCTGAAACGACGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCCACTCTCTTCGTGATGCCATCATCTGTAGACGCGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTTAAAGGAGGCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCGC 1284
QY 360 pProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCGAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAIT 1344

QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GANTGATGGAGATTTCTACTTCTTCAAAGGGGTCCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGCGGCGAGGGGCTGCCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTCGCCGCGCTTCATCTCTTCAAGGGGTGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrPrArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGGAAGTCTCGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGCATCCCTGAGAGGTCTAGCGCGCCCTCGCGAGCGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCCTCGACACGAGGCAAACTCGAGCAACACCTCGGCGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGCCACCGAGTGCCTGGATGGCTGCTGTCATGTCCTGCGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 136
US-10-131-828A-143
; Sequence 143, Application US/10131828A
; Publication No. US20030092107A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C140
; CURRENT APPLICATION NUMBER: US/10/131,828A
; CURRENT FILING DATE: 2002-04-24
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17

```
; PRIORITY APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-828A-143

Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-131-828A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGCGCGCGCTCGGCTCTCTGCGCGCCCTGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGAGCGCGAGCGGAGGAGCTGCGCAAGAGGCGGAGCGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGATACCTCAATGAACAGGTGCCCAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCAGCTACCTGTGCGGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCAGATGACTGCTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGACCTCTCTACCGCTGTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTCGCGAGCGCGCAGTTCCGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTACGCGCTGAGTGTCTGGGAGGCGCCGACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCCTTCTTCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGGCGCAGCGCTTC-CTGCCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCGAGCCCGCGCGCGCAACCTGTTCGTGGTGGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
```

```
Db 925 CGAGATCGTCAACACGCTTGGCTCACCACTCGCGCGCGCGCGCTCATGCGCGC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCAGCTCCAGCAAGAACTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACCTGCGCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCACTGA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGCGAGAAAGATGGGTGCGGCTGCCCGCCCAACATTGAGGCTGCGGCGCTCAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLys 400
Db 1345 GAATGATGGAGATTTCTACTTTTCAAAGGGGGTTCGATGTCTGGAGGTTCCGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1524
Qy 440 lLeuAlaArgGlyLysLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCGCGAGGGGACTGCAAGTGGAGCGCTTACTCCCGCGAAAGTCTGCGAGGACTGG 1584
Qy 460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGATTCCTTGGAGGAGTACGCGCGCTCTCCCGAGGCGCGCTCTCTCTCTCTCTCTCT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGGCGCTCGACCGCGCAAACTGCGAGGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCGCAGGAGTGGCTGGATGGGCTGTGGCACTGCCAACTCGGGGAGCGCGCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 137
US-10-131-835A-143
; Sequence 143, Application US/10131835A
; Publication No. US20030092108A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deenoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
```

```
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P330R1C132
; CURRENT APPLICATION NUMBER: US/10/131,835A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-131-835A-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 98.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-131-835A-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGCGCGCGTCTGGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGAGCGCGAGCGCGAGCTGCGCAAGAGCGGAGCGGCATTCTCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTAGCGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCATCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCACAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
```

```
Db 506 GCCTGGGCTCAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
Db 626 AACTGGCTCAGCATCTCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGAGCCCGCAGCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATCGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGGCGCAGCGCTTC-CTGCCCCCGCGCGGCGAGGCGACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGACGCTGGTCCCTGAGCGCGCGCGCGCAACCTGTTCTGTTGTTGTTGTTGTTGTTG 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACCTCGCCCGCGCGCGCGCTCATGGCGGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCTTGAACGCGAGGG 1164
Qy 320 YProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
Db 1165 CCCTAATACTGCGACCTCTTCTTCGATGCCATCCTCAGTACAGCAAGCAACAGCACTGA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CAITTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAGAAAGATGGGTGCGGCTGCGCCCCCAACATTTAGGCTCGGCGAGTGTCAIT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGCGTGTGGAGGTTCGCGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCGCTGCGCGCCCATCTCAGCGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCGGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTGCGCGCGCGCTGCGAGGCGCGATGGCTCCATCTTCTTCTTCTT 1644
```

Qy	480	eAtgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGly	500
Db	1645	CCGAGATGACCGCTACTTGGCGCCTCGACACAGGCCAAATCTCAGGCACACCACTCGGCGC	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeu	520
Db	1705	CTGGGCCACCAAGCTGCGCTCGATGGCGCTGTCGCATGCCAACTCGCGGAGCGCCCTGTT	1764

RESULT 139

US-10-137-864A-143

; Sequence 143, Application US/10137864A

; Publication No. US20030092110A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: Deforge, Laura

; APPLICANT: Deenoys, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: F3330R1C148

; CURRENT APPLICATION NUMBER: US/10/137,864A

; CURRENT FILING DATE: 2002-05-02

; PRIOR APPLICATION NUMBER: 60/049911

; PRIOR FILING DATE: 1997-06-18

; PRIOR APPLICATION NUMBER: 60/056974

; PRIOR FILING DATE: 1997-08-26

; PRIOR APPLICATION NUMBER: 60/059113

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059115

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059117

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059122

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059184

; PRIOR FILING DATE: 1997-09-17

; PRIOR APPLICATION NUMBER: 60/059263

; PRIOR FILING DATE: 1997-09-18

; PRIOR APPLICATION NUMBER: 60/059352

; PRIOR FILING DATE: 1997-09-19

; PRIOR APPLICATION NUMBER: 60/059588

; PRIOR FILING DATE: 1997-09-19

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 143

; LENGTH: 1985

; TYPE: DNA

; ORGANISM: Homo Sapien

US-10-137-864A-143

Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0
US-10-791-980-6 (1-520) x US-10-137-864A-143 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu	20
Dd	206	ATGGTCGGCGGTGGCCCTCCTGCTCGCGCCCTGCAGCTGCTACTTGTGGCGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluPheLeu	40
Dd	266	GACGCCCAGCCC CGGAGCGCGGAGGCCAGGAGCTGCGCAAGGAGCGGAGCATTCCTA	325
Qy	41	GluIysTyrcGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Dd	326	GAGAAGTACGGATACCTCAATGAACAAGTCCCCAAAGCTCCACCCTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Dd	386	GATGCCCATCAGAGCTTTAGTGGTGTCCACGACTACTGTGCAGCGGCTGTTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Dd	446	GCCACCCTCGCCAGATGACTCGTCCCGCTCGGGGTTCACAGATACCAACAGTTATSCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Dd	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Dd	566	AACCGCTTTGCAAGCAGGTATCAAAATGTTACNAGCAGCACCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Dd	626	AACTGGCCTGAGCATCTGCGGAGCGCGCATGTCGGGCGCGGTGCGCGCCCTTCACG	685
Qy	160	rCysGlyAlaThr-SerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Dd	686	TTGTGAGCANACGTCTCAGCGCTGGAGTCTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Dd	746	ATCCGGCTCACCTTCTTCCAAGGGGACCACACGATGGGCTGGGCAATGCCTTTGATGCG	805
Qy	200	aGlnGlyAlaProTrpArgThrPropheLeuProArgArgGlyGluAlaHisPheAspGl	220
Dd	806	CCAGGGGGCGCCCTGGCGCACGCGCTTC-C-TGCGCCCGCGCGCGGCAAGCGCATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyValArgAsnLeuPheValValLeuAlaHi	240
Dd	865	AGATAGCGCTGTGCTCCTGAGCCGCGCCCGCGGCGCACTGTTCGTGTGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuthrHisSerProAlaProArgAlaLeuMetAlaPr	260
Dd	925	CGAGATCGGTCAACGCTGGCTTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Dd	985	CTACTACAAAGAGCTGGGCGCGACGCGCTGCTCAGCTGGGAGCAGACGTGCTGGCGCGTGA	1044
Qy	280	nSerLeuTyrGlyLVsProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Dd	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Dd	1105	CACCTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGAAACGCAGGG	1164
Qy	320	yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy	340
Dd	1165	CCCTAAATCTGCACCTTCTTCATGTCATCTACTGTAGACAGGCAACAGCAACTGTA	1224

```
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTCTGGAGGTGGCAGCTGATGCAACGTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATCTCGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuVleuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCCGCCATCTCGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrpTrpTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGATCTCTGAGGAGGTTCAGGGCGCCCTGCCAGGCGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGAGGCAAACTGCAGGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 139

```
US-10-137-869A-143
; Sequence 143, Application US/10137869A
; Publication No. US20030092111A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C147
; CURRENT APPLICATION NUMBER: US/10/137,869A
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
```

```
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-137-869A-143
Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-137-869A-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCGGCCCTCTGCTCGCGCGCCCTGCAGCTGTACTGTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGCGAGCGCGGAGGCGGAGGCTGCGAAGGAGGCGGAGGCAATTCCTA 325
Qy 41 GlulysTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCTCCCAAGCTCCACCTCCATCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTCAGAGGATCAGTCTGTTGTTGTAGACACCGGACCAAAATGAGCGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAAACGCTTTGCAAGCAAGGTAAATAATGGTACAAAGCAGACACCTCTCTCCCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGCGAGCGCGGAGTTTGGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACCTCTCAGCGCTGGAGTTCTGTGGAGGCCCGCAGCACAGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGTGGGCAATGCTTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgGlyGluAlaHisPheAspGl 220
```



```
Db      806  CCAGGGGGCGCGCTGGCGACGCCCTTC-CTGGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy      220  nAepGluArgTtpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db      865  AGATGAGCGCTGGTCTCTGAGCGCGCGCGCGCGCAACCTGTGTGGTGTCTGGCGCA 924
Qy      240  sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProAlaLeuMetAlaPr 260
Db      925  CGAGATCGTACACGCTGGGCTCACCCACTCGCCCGCGCGCGCGCTCATGCGGCC 984
Qy      260  oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGI 280
Db      985  CTACTACAAGAGCGTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCGCGCTGCA 1044
Qy      280  nSerLeuTyrGlyLysProLeuGlyGlySerValalaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCCTGTATGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCAGGAAAGCTGT 1104
Qy      300  eThrAspPheGluThrTrpAspSerTy+SerProGlnGlyArgArgProGluThrGlnGI 320
Db      1105  CACTGACITTAGACTGGGACTCTACAGCCCCCAAGGAGGCCCTTGAAACGACGAG 1164
Qy      320  yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheTrpGluValalaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy      360  pProLeuGlnGluArgTtpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTGCAGGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGACGTGTA 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345  GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCA 1404
Qy      400  sProValTrpGlyLeuProGlnLeuCysArgnIleGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCTCCACAGCTGTGGCGGCGAGGGGGCTTGGCCCCGCCATCTCTG 1464
Qy      420  aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
Db      1465  CGCCCTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGI 460
Db      1525  GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAAGTCTGCAAGGACTGG 1584
Qy      460  yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCTCTGAGGAGGTGACGGCGCGCTGCGCGAGGCGCGATGCTCTCATCTCTCT 1644
Qy      480  eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTGCGCGCTTCGACAGGCGCAACTGACGGGCAACCACTCTGG 1704
Qy      500  gTrpAlaThrGluLeuProTftrMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCCCAGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy      520  e 520
Db      1765  C 1765
```

RESULT 140

US-10-147-523-143

; Sequence 143, Application US/10147523

; Publication No. US20030092113A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

```
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deanovers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; CURRENT APPLICATION NUMBER: P3330R1C327
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-523-143
```

Alignment Scores:

Pred. No.:	3.35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.52%	Conservative:	0
Best Local Similarity:	99.52%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	15	Gaps:	0

US-10-791-980-6 (1-520) x US-10-147-523-143 (1-1985)

```
Qy      1  MetValalaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db      206  ATGGTCGCGCGCTGCGGCTCTCTCTGCGGCGCTTCTGAGCTGTACTGTGGGGCCACCTG 265
Qy      21  AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GACCCCGAGCCCGCGAGCGCGAGGCTGGCAGGAGCTGGCAGGAGCGGAGGCAATTCCTA 325
Qy      41  GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326  GAGAAGTACGATCACTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTACG 385
Qy      61  AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386  GATGCCATCAGAGCGTTTCAGTGGGTGTCCGAGCTACCTGTGTCAGCGGCGTGTGGACCGC 445
Qy      81  AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db      446  GCCACCTTGGCGCAGATGACTCTGCCCGCTTCCCGGGTTACAGATACCAACAGTTATGCG 505
Qy      101  AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506  GCCTGGGCTGAGAGGATCAGTACTTGTGTTGTAGACACCGGACCAAAATGAGGCGTAA 565
Qy      121  LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566  AAACGCTTTCAGCAAGAGGTAACAAAATGGTACAAAGCAGCACCTCTCTCCACCGCTGTG 625
Qy      141  AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626  AACTGGGCTGAGCATCTGCGGAGCCGCGAGTTCGGGGCGCGCTTCCGCGCGCTTCCAG 685
Qy      160  rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
```

Db 686 TTGTGGAGCAAGCTCTCAGCGCTGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTCAAGGGGACCACACAGATGGCTGGGCAATGCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CAGGGGGGGCCCTGGCGACGCCCTTC-CTGCCCCCGCGCGCGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCAACCTGTTCTGGTGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCACTCGCGCGCGCGCGCGCTCATGGCGGCC 984
Qy 260 oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAAAGGGCGCCCTGAACGCGAGG 1164
Qy 320 yProLysTrpCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTTCTCTCGATGCCATCAGTGTAGACAGGCAACGACACTGTGA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCGC 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGCGGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCCCTGCCCGCCATCTGTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrpVa 440
Db 1465 GCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGCCTACTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCGAGGCTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACAGGCCAAACTGCGAGGCAACCTCGGGCCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 141

US-10-158-785-143
; Sequence 143, Application US/10158785
; Publication No. US20030092115A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C459
; CURRENT APPLICATION NUMBER: US/10/158,785
; CURRENT FILING DATE: 2002-05-30
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-158-785-143
Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0

US-10-791-980-6 (1-520) x US-10-158-785-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCGGCCTCCTGCTGCGCGCCTGCAGCTGTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGGAGCGCGAGGCTGCGAAGGAGGGCGGAGCATTCCTA 325
Qy 41 GlulysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCATGAACAGGTCCCAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTACGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTTTGTCTAGACACCGGACCAAAATGAGCGGTAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyTrpLysGlnHisLeuSerTyArgLeuVal 140
Db 566 AAACGCTTTGCAAAAGCAAGGTAAACAAATGTTACAAAGCAGCACCTCTCTCCCGCGCTGTG 625

QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSerSe-160
DB 626 AACTGGCCCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGGCCCCAGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerSerSerSerSerSerSerSerSerSerSerSerSerSer 200
DB 746 ATCCGGCTCACCTTCTTCCAGGGGACACACAGATGGCTGGGCATATGCTTATGGC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGGCGCGCTGGCGCACGCTTC - CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCGCAACCTGTTGCTGGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGTACACGCTTGGCTTACCCACTGCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
DB 985 CTACTACAGAGCGCTGGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCTGGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTGCCAGCTCCCGAAGAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
DB 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGAGCGCCCTGAAACCGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCATCTGTAGACAGCAAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGGAGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCTCTGAGGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCGGCGAGGGGCGCTGCCCCGCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CCGCCTCTTCTTCTCTCTGCGCGCTCTATCTCTTCAAGGGTGGCGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG 460
DB 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGCTCTGAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTGAGCGGGCGCTGCGGAGGGCCGATGCTCCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGCGCTCTGACAGAGCCCAACTGACAGGCAACCACTTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 142
US-10-121-051-143
; Sequence 143, Application US/10121051
; Publication No. US2003092147A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C6
; CURRENT APPLICATION NUMBER: US/10/121,051
; CURRENT FILING DATE: 2002-04-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-121-051-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 15 Gaps: 0
US-10-791-980-6 (1-520) x US-10-121-051-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGCGCGCTCGCGCTCCTGTCGCGCCCTCGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGGAGCGCGGAGCTGCGCAAGGAGCGGAGCATTTCTCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCACTGGGTGTCCAGCTACTGTGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCCAGATGACTCTGCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

506	Db	GCCTGGGCTCAGAGGATCACTGACTTGTGTTCCTAGACACCGGACCAAAATGAGCGCGTAAG	565
121	Qy	LYsAqPheAlaLysGlnGlyAenLYsTrrPtyLYsGlnhiStieuSerTYrArgLieuVal	140
566	Db	AAACGCTTTTCCAAGCAAGGTAAACAATGTGTAACAGCAGCACTCTCTACCGCTGGTG	625
141	Qy	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
626	Db	AACTGGGCTCAGCATCTGCCGAGCGCGCATTTCCGGGGCGCGTGC	685
160	Qy	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
686	Db	TTGTGGAGCAACGTCTCAGCGCTGGAGTCTCTGGAGGCCCCACGCCACGCCCGCTGAC	745
180	Qy	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetal	200
746	Db	ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGGCAATGCCTTTGATGC	805
200	Qy	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
806	Db	CCAGGGGGCGCCTTGGCGCACGCTTC-CTGGCCCGCGCGGAAAGCGCACTTCACACA	864
220	Qy	nAspGluArTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
865	Db	AGATGACGGCTGGTCCCTGAGCGCCCGCGGGGGCACTGTTGGTGGTGGCGCA	924
240	Qy	sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalApr	260
925	Db	CGAGATCGGTCAACAGCTTGGCTCAOCCACTTGGCCGCGCGCGGCGCTCATGGCGCC	984
260	Qy	oTYrTYrAArgLeuGlyVArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
985	Db	CTACTACAAGAGGTGGGCGCGAGCGCTGCTCAGCTGGAGCAAGCTGTGGCGCTGCA	1044
280	Qy	nSerLeuTYrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
1045	Db	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGCAAGCTGTT	1104
300	Qy	eThrAspPheGluThrTrpAspSerTYrSerProGlnGlyArgArgProGluThrGlnGl	320
1105	Db	CACGTACTTTGAGACCTTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGAAACGCA	1164
320	Qy	yProLYsTYrCYHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTY	340
1165	Db	CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCCAACAGCAACTGT	1224
340	Qy	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
1225	Db	CATTTTTAAAGGAGCATTCTTGGGAGGTGGCAGCTGTATGGCAACGTCTCAGAGCCCG	1284
360	Qy	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe	380
1285	Db	TCCACTGCAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTCATT	1344
380	Qy	uAsnAspGlyAspPheTYrPhePheLysGlyGlyArgCYsTrpArgPheArgGlyProLY	400
1345	Db	GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGGGGGCC	1404
400	Qy	sProValTrpGlyLeuProGlnLeuCYsAtrqAlaGlyLeuProArgHisProAspAl	420
1405	Db	GCCAGTGGGGGTCTCCACAGCTGTGCCGGGCGAGGGGGCTGCCCGCCATCTCTGACGC	1464
420	Qy	aAlaLeuPhePheProProLeuArgArgLeuileLeuPheLysGlyAlaArgTYrTYrVa	440
1465	Db	CGCCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTACGT	1524
440	Qy	lLeuAlaArgGlyGlyLeuGlnValGluProTYrTYrProArgSerLeuGlnAspTrpGl	460
1525	Db	GCTGGCCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGACGAGCTGGG	1584
460	Qy	yGlyileProGluGluValSerGlyAlaLeuProArgProAspGlySerIlellePhePh	480

Db 1585 AGGCATCCCTGAGAGAGGTGAGCGCGCCCTGCGCAGCGCCGATGGCTCCATCATCATCTTCTT 1644
 QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
 Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACACGAGGCCAAATGCGAGCAACACCTCGGCGCG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGCGCACCGAGCTGCCCTGGATGGGCTGCTGGCATGGCAACTCGGGGAGCGCCCTGTT 1764
 QY 520 e 520
 Db 1765 C 1765
 RESULT 143
 US-10-121-042-143
 ; Sequence 143, Application US/10121042
 ; Publication No. US20030096386A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: Deforge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; TITLE OF INVENTION: ACIDS ENCODING THE SAME
 ; FILE REFERENCE: P3330R1C10
 ; CURRENT APPLICATION NUMBER: US/10/121.042
 ; CURRENT FILING DATE: 2002-04-11
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 US-10-121-042-143
 Alignment Scores:
 Pred. No.: 3.35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 15 Gaps: 0
 US-10-791-980-6 (1-520) x US-10-121-042-143 (1-1985)
 QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTGTCGCGCGGTGCGGCTCTCTGCTGCGCGCCCTGTCAGCTGTCTGTGGGGCACCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCAGCCCGCGGAGCGCGGAGGCGAGAGTGGCAAGGAGGCGGAGCATTCCTCA 325
 QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCAATGAACAGTCCCAAGCTCCCAAGCTCCCACTCGATTTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80

Db 386 GATGCCATCAGACGGCTTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyraAla 100
Db 446 GCCACCTCGCCAGATGACTGTCTCCCGCTCGGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIleMetArgArglys 120
Db 506 GCTCGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaGlyGlnGlyAsnLysTrpTyrlLysGlnHisLysSerTyraArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACTGTTCAAGCAGCAGCTCTCTACCGCTGTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGTGGCGCCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTTCTTCAAGGGGACCAACAAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTCGCGCACCCCTTC-CTGCCCGCGCGCGCAACCTGTTGGTGTCTGGCGCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGCGCAACCTGTTGGTGTCTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCCACCTCGCCCGCGCGCGCTCATGCGCGC 984
Qy 260 oTyrlLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGCGTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGTGA 1044
Qy 280 nSerLeuTyrlLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGAGAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrlSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTTGGACTCTACAGCCCCCAAGGAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrlCysHisSerPheAspAlaThrValLeuAspGlyAsnValSerGluProAr 340
Db 1165 CCTAAATACTGCCACTCTTCTTCGTGCGCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnLeuGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrlPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGGTGATGCTGGAGGTTCGGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTCGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrlTyra 440
Db 1465 CGCCCTCTTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrlTyrlProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAAGCTTCGACGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrlTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAACTGACAGGCAACACCCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGAGGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 144
US-10-123-912-143
; Sequence 143, Application US/10123912
; Publication No. US20030100087A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C55
; CURRENT APPLICATION NUMBER: US/10/123,912
; CURRENT FILING DATE: 2002-04-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-123-912-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-123-912-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTCGACGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCCGGAGCGCGGAGGCTGCGAGGCTGCGCAAGGAGGCGGCGCATTCCTA 325

QY 41 GluLysTyrGlyLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAAACAGGTGCCAAAGCTCCACCTCCACATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACCGCTTTCAGTGGGTGCCAGCTACCTGTCCAGGGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCGCAGATCACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
QY 101 AlaTrpAlaGluAraGlnSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCGCGAGCGCGCAGTTCGGGGCGCGTTCGGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerClyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGGTTCCTGGGAGGCGCCACAGGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCAGAGGGGACCAACAGTGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgAcqArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGCGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGCGCGCGACGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGTCCAGTCCAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGAGGCGCCCTGAAACGCAAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACCTGCCACTCTTCCTTCGATGCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTNAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAIT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCCGGCGAGGGGGCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCTCTTCTTCCCTCTCTCGCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCGCTACTATCCCCCAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTCTCAGCGCGCTCGCGAGCGCGATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACAGGCAACCTGCAGGCAACCTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGTGGCTGGATGGCTGTGGCATGCCCAACTCGGAGCGCGCTGTT 1764
QY 520 e 520
Db 1765 c 1765
RESULT 145
US-10-192-007-143
; Sequence 143 Application US/10192007
; Publication No. US20030104544A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deenoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C281
; CURRENT APPLICATION NUMBER: US/10/192,007
; CURRENT FILING DATE: 2002-07-09
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19

[illegible]


```
; APPLICANT: Smith,Victoria
; APPLICANT: Stewart,Timothy A.
; APPLICANT: Tumas,Daniel
; APPLICANT: Watanabe,Colin K
; APPLICANT: Wood,William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C315
; CURRENT APPLICATION NUMBER: US/10/194,359
; CURRENT FILING DATE: 2002-07-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-194-359-143

Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-194-359-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db ATGGTCGCGCGGTCGCGCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
Db GACGCCACGCCCGCGAGCGCGGAGGCCAGGAGCTGCCAAGAGCGGAGCGGAGGCATTTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProLysAlaProLysSerThrArgPheSer 60
Db GAGAGTAGCGATACCTCANTGACAGAGTCCCAAGCTCCCAAGCTCCCACTCCATCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db GATGCCATCAGACGCTTCAGTGGGTGTCAGTACCTGTCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db GCCACCTCGCGCCAGATGACTCGTCCCGCTGCGCGGTTCACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db GCCTGGGCTGAGAGGATCAGTACGTGTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db AAACCTTTGCAAGCAAGGTAAACAAATGGTACAGACGACCTCTCTACCGCTGCTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db NAATGGCTTGAGCATCTGCGGAGCGCGGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db TTGTGGAGCAACGCTCTCAGCGCTGAGGTTCGGAGGCGCCACAGCCAGGCGCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db CCAGGGGGCGCCCTGGCGCACGCCCTTC-TGCCCCCGCGCGCGGAGCGCACTTCGACCA 864
```

```
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCAACCTGTTCTGTTGCTGCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db CGAGATCGGTACACGCTTGGCTTCCACCACTCGCGCGCGCGCGCTCATGCGCGC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCACAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db CACTGACTTTGAGACCTGGGACTCTCAGACGCCCAAGAGAGCGCCCTGAAACGCGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTh 340
Db CCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACACCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db TCCACTGTCAGGAAGATGGGTGGGCTGCCGCCCAACATTTGAGGTGGCGGCACTGTCATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTyrTrpArgPheArgGlyProLy 400
Db GAATGATGGAGATTTCTACTTCTTCAAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db GCCAGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db CTGCGCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db AGGCATCTCTGAGGAGGTGAGCGCGCTGCGCGAGGGCCGATGGCTCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db CCGAGATGACCGCTACTTGGCGCTCGACAGCGCAAACTGCAGGCAACCACTCGGGCGC 1704
QY 500 qTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 147
US-10-127-847A-143
; Sequence 143. Application US/10127847A
; Publication No. US20030119103A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
```


Db 1525 GTGGCCCCGAGGGGAGCTCAAGTGGAGCCCTACTACCCCGAAGTCTCGAGGCTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePheph 480
Db 1585 AGGCATCCCTGAGGAGCTCAGGGGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspA-gTTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCCCTCGACCAAGCCAACTGCAGGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 148
US-10-137-866-143
; Sequence 143, Application US/10137866
; Publication No. US20030129689A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC151
; CURRENT APPLICATION NUMBER: US/10/137,866
; CURRENT FILING DATE: 2002-05-03
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-08-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059836
; PRIOR FILING DATE: 1997-09-24
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062285
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062814
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/062816
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063045
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063082
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/063127
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063327
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063329
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063550
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063561
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063704
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063733
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063735
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063738
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063755
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064248
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/064809
; PRIOR FILING DATE: 1997-11-07
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065846
; PRIOR FILING DATE: 1997-11-17
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/066453
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066511
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/069212
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069278
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069334
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069694
; PRIOR FILING DATE: 1997-12-16
; PRIOR APPLICATION NUMBER: 60/072320
; PRIOR FILING DATE: 1998-01-23
; PRIOR APPLICATION NUMBER: 60/073612
; PRIOR FILING DATE: 1998-02-04
; PRIOR APPLICATION NUMBER: 60/074086
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/074092
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-02-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/081203

1	PRIOR FILING DATE: 1998-04-09	2
2	PRIOR APPLICATION NUMBER: 60/081229	3
3	PRIOR FILING DATE: 1998-04-09	4
4	PRIOR APPLICATION NUMBER: 60/081695	5
5	PRIOR FILING DATE: 1998-04-14	6
6	PRIOR APPLICATION NUMBER: 60/081817	7
7	PRIOR FILING DATE: 1998-04-15	8
8	PRIOR APPLICATION NUMBER: 60/081818	9
9	PRIOR FILING DATE: 1998-04-15	10
10	PRIOR APPLICATION NUMBER: 60/082999	11
11	PRIOR FILING DATE: 1998-04-24	12
12	PRIOR APPLICATION NUMBER: 60/083322	13
13	PRIOR FILING DATE: 1998-04-28	14
14	PRIOR APPLICATION NUMBER: 60/083545	15
15	PRIOR FILING DATE: 1998-04-29	16
16	PRIOR APPLICATION NUMBER: 60/084600	17
17	PRIOR FILING DATE: 1998-05-07	18
18	PRIOR APPLICATION NUMBER: 60/084627	19
19	PRIOR FILING DATE: 1998-05-07	20
20	PRIOR APPLICATION NUMBER: 60/084637	21
21	PRIOR FILING DATE: 1998-05-07	22
22	PRIOR APPLICATION NUMBER: 60/085149	23
23	PRIOR FILING DATE: 1998-05-12	24
24	PRIOR APPLICATION NUMBER: 60/085323	25
25	PRIOR FILING DATE: 1998-05-13	26
26	PRIOR APPLICATION NUMBER: 60/085338	27
27	PRIOR FILING DATE: 1998-05-13	28
28	PRIOR APPLICATION NUMBER: 60/085339	29
29	PRIOR FILING DATE: 1998-05-13	30
30	PRIOR APPLICATION NUMBER: 60/085579	31
31	PRIOR FILING DATE: 1998-05-15	32
32	PRIOR APPLICATION NUMBER: 60/085697	33
33	PRIOR FILING DATE: 1998-05-15	34
34	PRIOR APPLICATION NUMBER: 60/085704	35
35	PRIOR FILING DATE: 1998-05-15	36
36	PRIOR APPLICATION NUMBER: 60/086414	37
37	PRIOR FILING DATE: 1998-05-22	38
38	PRIOR APPLICATION NUMBER: 60/086430	39
39	PRIOR FILING DATE: 1998-05-22	40
40	PRIOR APPLICATION NUMBER: 60/087106	41
41	PRIOR FILING DATE: 1998-05-28	42
42	PRIOR APPLICATION NUMBER: 60/088026	43
43	PRIOR FILING DATE: 1998-06-04	44
44	PRIOR APPLICATION NUMBER: 60/088730	45
45	PRIOR FILING DATE: 1998-06-10	46
46	PRIOR APPLICATION NUMBER: 60/088741	47
47	PRIOR FILING DATE: 1998-06-10	48
48	PRIOR APPLICATION NUMBER: 60/088810	49
49	PRIOR FILING DATE: 1998-06-10	50
50	PRIOR APPLICATION NUMBER: 60/088858	51
51	PRIOR FILING DATE: 19/98-06-11	52
52	PRIOR APPLICATION NUMBER: 60/089532	53
53	PRIOR FILING DATE: 1998-06-17	54
54	PRIOR APPLICATION NUMBER: 60/089599	55
55	PRIOR FILING DATE: 1998-06-17	56
56	PRIOR APPLICATION NUMBER: 60/089907	57
57	PRIOR FILING DATE: 1998-06-18	58
58	PRIOR APPLICATION NUMBER: 60/089947	59
59	PRIOR FILING DATE: 1998-06-19	60
60	PRIOR APPLICATION NUMBER: 60/090349	61
61	PRIOR FILING DATE: 1998-06-23	62
62	PRIOR APPLICATION NUMBER: 60/090429	63
63	PRIOR FILING DATE: 1998-06-24	64
64	PRIOR APPLICATION NUMBER: 60/090445	65
65	PRIOR FILING DATE: 1998-06-24	66
66	PRIOR APPLICATION NUMBER: 60/090538	67
67	PRIOR FILING DATE: 1998-06-24	68
68	PRIOR APPLICATION NUMBER: 60/090863	69
69	PRIOR FILING DATE: 1998-06-26	70
70	PRIOR APPLICATION NUMBER: 60/091360	71
71	PRIOR FILING DATE: 1998-07-01	72
72	PRIOR APPLICATION NUMBER: 60/091519	73
73	PRIOR FILING DATE: 1998-07-02	74

```
; PRIOR APPLICATION NUMBER: 60/091982

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00        Matches:     519
Percent Similarity: 99.62%    Conservative: 0
Best Local Similarity: 99.62% Mismatches:   1
Query Match:      98.52%     Indels:      2
DB:              16           Gaps:       0

US-10-791-980-6 (1-520) x US-10-137-866-143 (1-1985)

Qy 1 MetValalaArgValGlyLeuLeuAraAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCCCTCCTGCTCGCGCCCTGCAGCTGTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluAraGrgGlyGlnGlnLeuAraGlysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGCGGAGCGCAGAGAGTGGCGCAAGGAGGCGGAGCATTCCTA 325
Qy 41 GlulystYrGlyTyVrLeuAenGluGlnValProlysaIaPrOrThrSerThrArqPheSer 60
Db 326 GAGNAGTACGATACCTCAATGAACAGGTCCCCAAAGCTCCCACCTCCACTCGATTGAGC 385
Qy 61 AspaIaileAraAlaPheGlnTrpValserGlnLeuProValserGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACGCTACTCTGCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProAraGryCyseGlyValThrAspThrAsnSeryTyrAla 100
Db 446 GCCACCCTTGCCGCAGATGACTCGTCCCGCTGGCGGGTTACAGATACAACAGTTATGCG 505
Qy 101 AlatrPaIaGluAraGlieSerAspLeuPheAlaAraHisaThrgThrysMetArqArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTAGACTTGTTGTGTAGACACCGGACCAAATAAGAGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyTpTyLzysGlnHisLeuSeryTyrArgLeuVal 140
Db 566 AAACGCTTTGCMAAGCAAGGTAAACAATGTTACAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu - ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTCGCGAGCGCGCAGTTCGGGGCGCGTGCAGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnAraGrpSerSerGlyArqProGlnProGlnAlaProLeuTh 180
Db 686 TTTGGAGAACAGTCTCAGCGCTGGAGTCTTGGAGGCCCCCAGCCACAGGCCCGCGTGCAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAAGATGGGCTGGGCATGCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArqArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACCGCTTC - CTGCCCGCGCGGCGAAGCGCACCTTCGACCA 864
Qy 220 nAspGluArqTrpSerLeuSerArqArgGlyArqAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTGTCCCTGAGCCGCGCGCGCGCGCAACCTGTGTGTGTGTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArqAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGCCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTyTyLyArqLeuGlyArqAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCGTGGCGCGCAGCGCTGTCTCAGCTGGGACGACGCTGGCGCGTGCA 1044
Qy 280 nSerLeuTyGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGGCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyvSerProGlnGlyVarqArgProGluThrGlnGl 320
```

```
Db 1105 CACTGACTTTGAGCGTGGGACTCTCTACAGCCGCCCAAGGAAGCGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATACTGCCACTCTCTCTCGATGCCATCACTCTAGACAGCGCAACACAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGTGTATGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTCGAGGAAGATGGTGGGCTGCGGCCCAACATTAGGCTGCGGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTCTACTCTTCAAGGGGTGATGCTGGAGGTTCGCGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCTTCCCGGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCCCGGAGGGGACTCAAGTGGAGCCCTACTACCCCCGAAGTGTGCAGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGTTCAGCGGCGCTTCCGAGGCCGATGGCTCATCATCTTCTT 1644
Qy 480 eArgAspArgTyrTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACCAGGCCAAATGCGAGGCAACCCACCCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCCGTGGATGGGTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 149

```
US-10-146-726-143
; Sequence 143, Application US/10146726
; Publication No. US20030129690A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C308
; CURRENT APPLICATION NUMBER: US/10/146,726
```

```
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-146-726-143

Alignment Scores: 3.35e-262 Length: 1985
Pred. No.: 2792.00 Matches: 519
Score: 79.62% Conservative: 0
Percent Similarity: 99.62% Mismatches: 1
Best Local Similarity: 98.52% Indels: 2
Query Match: 16 Gaps: 0
DB: 16

US-10-791-980-6 (1-520) x US-10-146-726-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGGTTCGGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGCTGCGCAAGAGCGCGAGGCATTCCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTTCCTCCAGCTACCTGTGTCAGCGCGCTGTGGACCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgGlyLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCGTAGACACCGGACCAAAATGAGGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAGGTAAACAAATGGTACAGCAGCAGCTCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCCCCCAGGCACAGGCCCTGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGAGCACCAACGATGGGCTGGGCAATGCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGGCGACGCCCTTC-CTGCCCGCGCGCGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGGCGCAACCTGTTTCGTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTTGGCTTCCACCTCTGCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
```

Db 985 CTACTACAAGAGCGTGGCGCGCGCTGCTCAGCTGGGACGACGTGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyCysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCGTCCAGCTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACCTTTGAGACTGGGACTCTCAGCCCCCAGAGAGGCCCTGAAACGACGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACGCAACTGTA 1224
Qy 140 illePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 160 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1485 TCCACTTGCAGAAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyCysTyrArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAGGGGTGATGTGGAGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGGCAGGGGGCTGCCGCCCATCTCCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGTGGCCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCTGAGGAGGTGAGCGGGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATCAGCGCTACTGGCGCTCGACAGGCCAACTGAGGCAACCACTCGGGCCG 1704
Qy 500 gTrpAlaThrGluLeuProTyrMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 150

US-10-146-727-143
; Sequence 143, Application US/10146727
; Publication No. US20030129691A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C312
; CURRENT APPLICATION NUMBER: US/10/146,727
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-146-727-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-146-727-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGGCGTGGCCCTCTGCTCGGCGCCCTGCAGCTGCTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGCGGAGCGCGGAGCTGCGAAGGGGCGGAGGCATTCTCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTCTCCAGCTACTGTTCAGCGCGCTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCACACCTGCGCCAGATGACTCGTCCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTTGCTAGACACCGGACCAAAATGAGCGGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTACAAATGGTACAAAGCAGCACCTCTCTCCACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGAGCGGAGTTCGGGGCGCGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGGAGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGGGCCCTTGGCGCACGCCCTTC-CTGCCCGCGCGGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCTCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGCTGGCGCA 924


```
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTTCACACGCTGGCTCCACCCACTCGCCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
Db 985 CTACTACAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044
QY 280 nSerLeuTyrGlyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGGAAGCGCCCTGAAACCGAGG 1164
QY 320 yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGCAGCTGATGGCAACGCTCTAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCGAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTCAATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheIysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGCTCGATGTGAGGTTCCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGCTCTCCACAGCTGTGGCGGCGAGGGGCTGCCCCGCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCTCTCTGGCGGCTCATCTCTTCAAGGTGGCGCTACTAGT 1524
QY 440 lleuAlaArgGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGI 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGGCGCCCTGCCGAGGCGCCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGTACCGCTACTTGGCGCTCGACAGGCCAAACTGCAGGCAACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 151

```
US-10-146-788-143
; Sequence 143, Application US/10146788
; Publication No. US20030129693A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
```

```
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zenin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C322
; CURRENT APPLICATION NUMBER: US/10146.788
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-146-788-143
```

Alignment Scores:

Pred. No.:	3.35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.52%	Indels:	2
DB:	16	Gaps:	0

US-10-791-980-6 (1-520) x US-10-146-788-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTTCGCGCGCTCGCGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCNAGCCGCGGAGCGCGGAGCCAGAGCTGCCAAGAGGCGCGGAGGCATTCTCTA 325
QY 41 GluIysTyrGlyTyrLeuAsnGluGlnValProIysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAAAGTCCCACTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValIleuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCAGATGACTCTGTCGCCGCTCGCGGGTTACAGATACCAACAGTTATGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTCTTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnIysTrpTyrIysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTTGCAAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCGCTGTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCCGCGAGCTTGGGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTACCTTTCTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCGCTTTGATGGC 805
```

Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGln	220
Db	806	CCAGGGCGCGCCTTGGCGACGCGCTTC-CTGCCCCCGCGCGCAAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgAtqArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATGAGCGCTGGTCCCTTGAGCGCGCGCGGGCGCAACTGTTCTGTGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPro	260
Db	925	CGAGATCGGTACACAGCTTGCCCTCACCCACTCGTCCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTrpIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGln	280
Db	985	CTACTACAAGAGGTGGCGCGCGACGCGCTGTCAGCTGGGACACACGTCGTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlnGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPhe	300
Db	1045	GAGCCTGTATGGGAAGCCCCCTAGGGGGCTCAGTGGCCCTCCAGCTCCCGAAGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGln	320
Db	1105	CACGTACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGCGCCCTGAAACGCAAGG	1164
Qy	320	yProIysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGTCCACACTCTCTCTCGATGGCCATCACTGTAGCAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGACCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGAATGGGTGGGTGGCGCTGCCCCCAACATTGAGGCTGCGGCAAGTCA	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTTTCTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACACAGCTGTGCGCGGCGAGGGGGCCCTGCCCGCCATCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCTGCTACTAGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGln	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePhe	480
Db	1585	AGGCATCCCTGAGGAGGTACGCGGGCCCTGCCGAGGCCCCGATGGCTCCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCCTCGACCCAGGCGCAAACTGCAGGCAACCACTCTCGGGCGG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPhe	520
Db	1705	CTGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	e	520
Db	1765	C	1765

RESULT 152
US-10-152-380-143
; Sequence 143, Application US/10152380
; Publication No. US20030129694A1
; GENERAL INFORMATION:

```

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deenoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C397
; CURRENT APPLICATION NUMBER: US/10/152,380
; CURRENT FILING DATE: 2002-05-21
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-152-380-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-152-380-143 (1-1985)

```

```
Db 686 TTGTGGAGCAACGCTCTCAGCGTGGAGTTCTGGAGGCCCCCAGCCACAGGCCCGCGTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCCTCTTCACAGGGACCAACAGATGGCTGGGCAATGCCCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC - CTGCCCCCGCGCGCGGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCAACCTGTTCTGGTGGTCTGGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTACACGCTTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGCGTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAGCTGT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTCTCAGATGCCATCACTGTAGACAGCAACAGCACTGT 1224
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGCAACAGCACTGT 1224
Qy 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerle 380
Db 1285 TCCACTGAGGAAAGATGGTGGCGCTGCCCGCCCAACATTGAGGTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTTPArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 pProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGTGGCGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
Db 1525 GCTGGCCCCAGGGGAGCTGCAAGTGGAGCCCTTACCCCCCGAAGTCTGCAAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGCGCTTCCCGAGGCGCGGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCTGACAGGCGCAACTGCAAGGCAACCACTCGGGCGG 1704
Qy 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
```

```
Db 1765 C 1765
RESULT 153
US-10-153-934-143
; Sequence 143, Application US/10153934
; Publication No. US20030129695A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C412
; CURRENT APPLICATION NUMBER: US/10/153,934
; CURRENT FILING DATE: 2002-05-22
; Prior Application removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-153-934-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-153-934-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTTPGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGCGCGCCCTGCGAGCTGTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCGCGCGGAGCGCGAGCGAGCTGCGCAAGAGGCGCGGAGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluLeuValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATCTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCTTTTCAGTGGGTGTCCAGCTACCTGTGCGGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATCG 505
Qy 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTTCCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTTPTyrLysGlnHisLeuSerTyrArgLeuVal 140
```

Db	566	AAACGC	TTTTGCAAAAGCAAGGTAAACAAATGGTACAAGCAGCACCTCTCTCTACTACCGCTGGTG	622
Qy	141	AsnTrpProGluHisLeu-	ArgSerArgGlnPheGlyAlaProCysAlaProProSerSer	160
Db	626	AAC	TGGCTTGAGCATCTGCCGAGCCGCGAGTTCCGGGGCGCGTGGCGCGCCCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnA-	gTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTTCA	GCCTCAGCGCTGGAGTCTCTGGGAGGCCACAGCCACAGGCCCCGCTGCAC	745
Qy	180	rSerGlySerProSerSer	LeuGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTT	CCAAAGGGAGCCACAACATGGGCTGGCAATGGCTTTGATGGC	805
Qy	200	gGlnGlyAlaProTrpArg	ThrProPheLeuProArgArgGlyGluAlaHisPheAspG	220
Db	806	CCAGGGGGCGCTTGCG	CACGCCCTTC-CTGCCCGCCCGCGAAGCGCACTTCGACCA	864
Qy	220	nAspGluArgTrpSerLeu	SerArgArgGlyArgAsnLeuPheValValLeuAlaHi	244
Db	865	AGATGAGCGCTGGTCC	CTGAGCGCGCGCGGCGCAACCTGTTCTGGTGGTCTGGCGCA	924
Qy	240	sGluileGlyHisThrLeu	GlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTCAACAG	CTTGCCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyTrTyrIysArgLeuG	lyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG	280
Db	985	CTACTACNAGAGCTGG	CCCGACGCGCTCAGCTGGGACGACGTCGTGGCGGTGCA	1044
Qy	280	nSerLeuTyGlyIysPro	LeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh	300
Db	1045	GAGCCTGTATGSGAAG	CCCCCTAGGGGCTCAGTGGCCGTCCAGCTCCAGGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrp	AspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CAC	TGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAAAGGCGCCCTGAAAGCGCAGG	1164
Qy	320	yProIysTyrcYshHis	SerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATAC	TGGCACCTCTCTCTCGATGGCCATCAGCTGACAGGCAACAGCAACTGTGA	1224
Qy	340	rIlePheIysGlySerHis	PhetripGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGCA	CTTTCTGGAGGTGCGAGCTGATGGCAACGCTCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluArgTrp	ValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGAT	GGGTTCGGGCTGCCCGGCGAGGGGCTGCCCGCCATCTCGACGC	1344
Qy	380	uAsnAspGlyAspPheTy	rPhePheIysGlyIlyArgCysTrpArgPheArgGlyProly	400
Db	1345	GAATGATGGAGATTTC	TACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuPro	GlnLeuCysArgAlaGlyIlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCC	CCACAGCTGTGCCGGGCGAGGGGCTGCCCGCCATCTCGACGC	1464
Qy	420	aAlaLeuPhePheProPro	LeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTrVa	440
Db	1465	CGCCCTCTTCTTCCT	CTCTCTGCGCGCGCTCATCTCTTCAAGGGTGC	1524
Qy	440	lLeuAlaArgGlyGlyLeu	GlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGAC	TGCAAGTGGAGCCCTACTACCCCCGAAAGTCTGCAAGACTCGGG	1584
Qy	460	yGlyIleProGluGluVal	SerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGAG	GTACAGCGGCTCTGCCAGGCCCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrp	ArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACT	TGGCGCTTCGACAGGCGCAACTGCAAGCAACCACTCGGGCG	1704

QY 500 gTTPAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGTGCCTCGATGGGCTCTGGCATGGCAACTCGGGGAGGCCCTGTT 1764

QY 520 e 520
 Db 1765 C 1765

RESULT 154
 ; US-10-140-807-143
 ; Sequence 143, Application US/10140807
 ; Publication No. US20030134354A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Deenoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; TITLE OF INVENTION: ACIDS ENCODING THE SAME
 ; FILE REFERENCE: P3330R1C174
 ; CURRENT APPLICATION NUMBER: US/10/140,807
 ; CURRENT FILING DATE: 2002-05-07
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 US-10-140-807-143

Alignment Scores:
 Pred. No.: 3.35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-140-807-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTCTCGCGCGCTGCGCCCTCTCTGCTGGCGCCCTGCTACTGCTGTGGGCGCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GAGCCCGAGCCCGGAGCGCGAGGCCAGGAGCTCGCAAGGAGCGGAGGCAATTCCTA 325

QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACCGGATACCTCAATGAAACAGGTCCCAAGAGTCCCACTCCGATTCAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCCATCAGACGGTTTCAGTGGGTGCCAGCTACCTGTCTAGCGCGCGTGTGGACCCG 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSertyrAla 100
 Db 446 GCCACCTCGCGCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAGATTCAGTATGG 505

Alignment Scores:		
Pred. No.:	3 350-262	1985
Score:	2792.00	519
Percent Similarity:	99.62%	Conservative: 0
Best Local Similarity:	99.62%	Mismatches: 1
Query Match:	99.52%	Indels: 2
DB:	16	Gaps: 0

US-10-791-980-6 (1-520) x US-10-141-698-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTTCGCGCGCTGGCGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgGlyGlyAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGGAGCCAGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGATACCTCAATGAACAGGTCCCAAAAGCTCCACACCTCCACATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGACTACCTGTGACGGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCAGATGCTGTCCTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGluPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCGAGGCGCGCAGTTCGGGGCGCGTGGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCCTGGAGGCGCCACAGCCACAGGCGCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTTCACCTTCTCCAAAGGGACCAACAACGATGGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCGCTGGCGCAGCCTTC-CTGCCCGCGCGCGGCGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCAACCTGTTGCTGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrIleuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGGCGCGGACCGCTGCTCAGCTGGAGACGACGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAAGCCCTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCCTCAGCCCCCAAGAAAGGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
Db 1165 CCCTAATACTGCCACTCTCTCTTCGATGCCATCACTGTAGACGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCCG 1284
```

```
Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAGAAAGATGGGTGGGCTGGCCCCCAACATTGAGGCTGGGAGTGTCAIT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyVGLYArgCysTrpArgPheArgGlyProLY 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGCGCTGCCCGCCCATCCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCCCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTCAGCGCGCGCTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyVa 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCCAAATCGCAGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGTCGSCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 158

US-10-141-702-143

; Sequence 143, Application US/10141702

; Publication No. US20030134358A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tamas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P3330R1C208

; CURRENT APPLICATION NUMBER: US/10/141,702

; CURRENT FILING DATE: 2002-05-08

; Prior Application removed - See Palm or File Wrapper

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 143

; LENGTH: 1985

; TYPE: DNA

; ORGANISM: Homo Sapien

US-10-141-702-143

Alignment Scores:

```

RESULT 159
US-10-141-143
; Sequence 143, Application US/10141704
; Publication No. US20030134359A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Baresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRAN
; TITLE OF INVENTION: ACIDS ENCODING
; FILE REFERENCE: P330R1C209
; CURRENT APPLICATION NUMBER: US/10/14
; CURRENT FILING DATE: 2002-05-08
; Prior Application removed - See Palm
; NUMBER OF SEQ ID NOS: 550

```

```
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-141-704-143

Alignment Scores:
  Pred. No.:      3,35e-262      Length:      1985
  Score:          2792.00      Matches:      519
  Percent Similarity: 99.62%      Conservative: 0
  Best Local Similarity: 99.62%      Mismatches: 1
  Query Match:      98.52%      Indels:      2
  DB:              16          Gaps:      0

US-10-791-980-6 (1-520) x US-10-141-704-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGCTCGGCTCTCTGCTGCGCGCTGACGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGCGCGCGGAGCGGAGCGGAGGCTGCGCAAGGAGCGCGGCGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCCACTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACCGCTTTCAGTGGGTGCTCCAGCTACCTGTGAGCGGGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCGCGAGATCACTCGTCCCGCTGCGGGGTATCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTGTAGACACCGGACCCAAATGAGCGGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGAGCAAGTAACAAATGGTACAGCAGCACCTCTCTCAACGCGCTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCCGAGCGCGAGGTTCGGGGCGCGCTGCGCGCGCTTCGAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCCAGAGGAGCACCAACATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGGCGCGACGCGCTTC-CTGCGCGCGCGGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGTTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCACTCGCGCGCGCGCGCTCATGGGCGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGAGCGCTGCTCAGCTGGGAGCGAGCTGGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
```

```
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGTCCAGTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATATCGCCACTCTTCTTCGATGCGCATCCTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGAGCTGTAGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGGTGCGGCTGCGCCCAACATTGAGGCTGCGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCGCGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCTGCCCCGCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTCCTCTCTGCGCGCTCATCTCTTCAAAGGTGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCGCTACTACCCCGAAGTCTGCGAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleLePhePh 480
Db 1585 AGCATCTCTGAGGAGTCTGAGCGGCGCTGCGGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGGCGCAACTGCGAGGCAACCACTCGGCGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCGCCAGCTGCTGCGTGGAGTGGCTCTGTCATGTCGCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 160
US-10-142-421-143
; Sequence 143, Application US/10142421
; Publication No. US20030134360A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
```

;; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
;; FILE OF INVENTION: ACIDS ENCODING THE SAME
;; FILE REFERENCE: P3330RIC1218
;; CURRENT APPLICATION NUMBER: US/10/142,421
;; CURRENT FILING DATE: 2002-05-09
;; Prior Application removed - See File Wrapper or Palm
;; NUMBER OF SEQ ID NOS: 550
;; SEQ ID NO 143
;; LENGTH: 1985
;; TYPE: DNA
;; ORGANISM: Homo Sapien
US-10-142-421-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-421-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgGlyGluAlaGluAlaPheLeu 40
DB 266 GAGCCCGCCCGGAGCGCGGAGCGCGAGGAGCTGCGCAAGGCGGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCACCTCCATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGCGCTGTGGACGCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCGACAGTACTCGTCCCGCTCGGGGTGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGCTGAGAGGATCAGTACTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTGCAAAGCAAGGTAAACAAATGGTACAAGCAGCACCTCTCCTACGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGTAGCATCTGCGGAGCGCGAGTTCGCGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGTCTCAGCGCTGAGTTCTGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTCCAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCACCCCTTC-CTGCCCCCGCGCGCGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGGTGTGGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProAlaLeuMetAlaPr 260

DB 925 CGAGATCGGTCAACGCTTGGCTTCCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGCTGGGCGCGCTGCTAGCTGGGACGAGCTGCTGGCGGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCGTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCCTACAGCCCCCAAGAGGCGCCCTGAAACGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGAGCCATTTCTGGAGGTGGCAGCTCATGGCAAGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCGAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGCAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTCTTCAAAGGGGGTGCATGTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGCGAGGGGCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTyVa 440
DB 1465 CGCCCTCTCTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCGGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCCCTCAGGAGGTGACGCGCGCTTCCGAGGCGCCGATGGCTCCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGCCAAACTGCGAGGCAACCACTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGGCTTGGTGGCTGTGTCATGCGCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 161
US-10-142-432-143
; Sequence 143, Application US/10142432
; Publication No. US20030134361A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.

APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE OF INVENTION: ACIDS ENCODING THE SAME
FILE REFERENCE: P3330R1C241
CURRENT APPLICATION NUMBER: US/10/142,767
CURRENT FILING DATE: 2002-05-10
Prior Application removed - See Palm or File Wrapper
NUMBER OF SEQ ID NOS: 550
SEQ ID NO 143
LENGTH: 1985
TYPE: DNA
ORGANISM: Homo Sapien
US-10-142-767-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-142-767-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTGTCGCGCGTGTGGCCCTCTCTGTCGCGCGCCCTGACGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCGAGCGCGGAGCGGAGGCGGAGGAGTGGCGCAAGGAGGCGGAGGCAATTCCTTA 325
QY 41 GluLysTyrGlyTyrLeuLeuGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGAGTCCCAAGAGTCCACACCTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGTACCTGTGTCAGCGCGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgLys 120
DB 506 GCGTGGGCTGAGAGGATCAGTCTGTTTGTGTAGACACCGGACCAAAATGAGGCGTAAAG 565
QY 121 LysArgPheAlaLysGlnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAATAATGGTACAGCAGCAGCTCTCTCCACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTTGAGCATCTGCGGAGCGCGGAGTTCGGGGCGCGTGGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGTGGAGTTCTGGAGGCGCCAGCCAGCCAGCCCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetal 200
DB 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGCTGGGCAATGCGCTTTGATGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG 220
DB 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAenLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCAACCTGTTGCTGGTGTCTGGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalPr 260
DB 925 CGAGATCGTTCACACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG 280
DB 985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGAGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCCGCTCCAGCTCCACGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
DB 1105 CACTGACCTTTCAGACCTGGGACTCTACAGCCCCCAAGGAGGCGCTGAAACGACGAG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGAAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGGCGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyClyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTTCTACTTTCTTCAAAGGGGGTGCATGCTGGAGGTTCCCGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisPheAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGCGCAGGGGCGCTGCCCCGCCATCTGTAGCC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
DB 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG 460
DB 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAGTCTGCGAGGCTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleilePhePh 480
DB 1585 AGGCATCTCAGGAGGTGAGCGCGCTCCCGAGGCGCCGATGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGCGGCTCGACCGGCAAACTGCAGGCAACACCACTCGGGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 163

```

US-10-143-033-143
; Sequence 143, Application US/10143033
; Publication No. US20030134363A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P33301C246
; CURRENT APPLICATION NUMBER: US/10/143,033
; PRIORITY FILING DATE: 2002-05-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-143-033-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
Db: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-143-033-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCTCGCGCGTGGGCTCTCTGTCGGCCCTCGAGCTGTCTACTGTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGAGCGCGGAGCTGCAGAGCTGCAGAGCTGCAGAGCGGAGGCAATTCCTA 325

Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCACTCGATTTCAGC 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTCTGTACGCGCGGTGTTGGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGGC 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTTGGGCTTGAGAGGATCAGTGACTTGTTCCTAGACACCGGACCAAAATGAGCGCTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAMCGCTTTGCAAGCAAGGTACAAATGGTACAGCAGCACCTCTCTTACCGCCCTGGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSe 160

```


Db 1705 CTGGGACCGAGCTGCCCTGGATGGGCTCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 164
US-10-144-994-143
; Sequence 143, Application US/10144994
; Publication No. US20030134364A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P33301C257
; CURRENT APPLICATION NUMBER: US/10/144,994
; PRIOR FILING DATE: 2002-05-13
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059836
; PRIOR FILING DATE: 1997-09-24
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062285
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062814
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/062816
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063045
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063082
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/063127
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063327
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063329
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063550
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063561
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063704
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063733
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063735
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063738
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063755
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064248
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/064809
; PRIOR FILING DATE: 1997-11-07
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065846
; PRIOR FILING DATE: 1997-11-17
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/066453
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066511
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/069212
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069278
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069334
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069694
; PRIOR FILING DATE: 1997-12-16
; PRIOR APPLICATION NUMBER: 60/072320
; PRIOR FILING DATE: 1998-01-23
; PRIOR APPLICATION NUMBER: 60/073612
; PRIOR FILING DATE: 1998-02-04
; PRIOR APPLICATION NUMBER: 60/074086
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/074092
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-02-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/081203
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081229
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081695
; PRIOR FILING DATE: 1998-04-14
; PRIOR APPLICATION NUMBER: 60/081817
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081818
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082999
; PRIOR FILING DATE: 1998-04-24
; PRIOR APPLICATION NUMBER: 60/083322

1	PRIOR FILING DATE: 1998-04-28
2	PRIOR APPLICATION NUMBER: 60/083545
3	PRIOR FILING DATE: 1998-04-29
4	PRIOR APPLICATION NUMBER: 60/084600
5	PRIOR FILING DATE: 1998-05-07
6	PRIOR APPLICATION NUMBER: 60/084627
7	PRIOR FILING DATE: 1998-05-07
8	PRIOR APPLICATION NUMBER: 60/084637
9	PRIOR FILING DATE: 1998-05-07
10	PRIOR APPLICATION NUMBER: 60/085149
11	PRIOR FILING DATE: 1998-05-12
12	PRIOR APPLICATION NUMBER: 60/085323
13	PRIOR FILING DATE: 1998-05-13
14	PRIOR APPLICATION NUMBER: 60/085338
15	PRIOR FILING DATE: 1998-05-13
16	PRIOR APPLICATION NUMBER: 60/085339
17	PRIOR FILING DATE: 1998-05-13
18	PRIOR APPLICATION NUMBER: 60/085579
19	PRIOR FILING DATE: 1998-05-15
20	PRIOR APPLICATION NUMBER: 60/085697
21	PRIOR FILING DATE: 1998-05-15
22	PRIOR APPLICATION NUMBER: 60/085704
23	PRIOR FILING DATE: 1998-05-15
24	PRIOR APPLICATION NUMBER: 60/086414
25	PRIOR FILING DATE: 1998-05-22
26	PRIOR APPLICATION NUMBER: 60/086430
27	PRIOR FILING DATE: 1998-05-22
28	PRIOR APPLICATION NUMBER: 60/087106
29	PRIOR FILING DATE: 1998-05-28
30	PRIOR APPLICATION NUMBER: 60/088026
31	PRIOR FILING DATE: 1998-06-04
32	PRIOR APPLICATION NUMBER: 60/088730
33	PRIOR FILING DATE: 1998-06-10
34	PRIOR APPLICATION NUMBER: 60/088741
35	PRIOR FILING DATE: 1998-06-10
36	PRIOR APPLICATION NUMBER: 60/088810
37	PRIOR FILING DATE: 1998-06-10
38	PRIOR APPLICATION NUMBER: 60/088858
39	PRIOR FILING DATE: 19/98-06-11
40	PRIOR APPLICATION NUMBER: 60/089532
41	PRIOR FILING DATE: 1998-06-17
42	PRIOR APPLICATION NUMBER: 60/089599
43	PRIOR FILING DATE: 1998-06-17
44	PRIOR APPLICATION NUMBER: 60/089907
45	PRIOR FILING DATE: 1998-06-18
46	PRIOR APPLICATION NUMBER: 60/089947
47	PRIOR FILING DATE: 1998-06-19
48	PRIOR APPLICATION NUMBER: 60/090349
49	PRIOR FILING DATE: 1998-06-23
50	PRIOR APPLICATION NUMBER: 60/090429
51	PRIOR FILING DATE: 1998-06-24
52	PRIOR APPLICATION NUMBER: 60/090445
53	PRIOR FILING DATE: 1998-06-24
54	PRIOR APPLICATION NUMBER: 60/090538
55	PRIOR FILING DATE: 1998-06-24
56	PRIOR APPLICATION NUMBER: 60/090863
57	PRIOR FILING DATE: 1998-06-26
58	PRIOR APPLICATION NUMBER: 60/091360
59	PRIOR FILING DATE: 1998-07-01
60	PRIOR APPLICATION NUMBER: 60/091519
61	PRIOR FILING DATE: 1998-07-02
62	PRIOR APPLICATION NUMBER: 60/091982

Alignment Scores:		
Pred. No.:	3,358-262	1985
Score:	2792.00	519
Percent Similarity:	99.63%	Conservative: 0
Best Local Similarity:	99.63%	Mismatches: 1
Query Match:	98.53%	Indels: 2
DB:	16	Gaps: 0

US-10-791-980-6 (1-520) x US-10-144-994-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTCGCGCGCTCTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACCGCCGGAGCGCGAGCGCAGGAGCTGGCAAGGAGGGAGGCATATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAGACTCCCACTCCACTCGATTTCAGC	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTTCAGCGGGGTGTTCGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCTCGCCACAGATGACTCGTCCCGCTGCGGGGTTCAGATATCCAAACAGTATTCGC	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheIleArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTCTAGACACCGGACCAAAATGAGGCGGTAAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTyrTrpLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAGCAAGGTAAACAATGGTTACAAGCAGCACCTCTCTCTACCGCCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGGCTCAGCATCTCGCGAGCGCGCAGTTCCGGCGCGCGTGCAGCGCGCTTCACAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCCTCAGCGCTGGAGTCTTGGAGGCCCCAGGCCACAGGCCCGCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTCTTCCAAGGGGACCAACAAGATGGGCTGGGCANTGCTTTGATGGC	805
Qy	200	gGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGGGCGACGCCCTTC-CTGCCCGCGCGCGCGAAGCGCATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHis	240
Db	865	AGATGAGCGCTGGTCCCTGAGCGCCCGCGCGGGCGCAACGTGTCGTGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGCGCGCAGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCCCTCAGCTCCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGNACCTTGGGACTCTACAGCCCCCAAGGAAGGGCCCTGTAAACGCGAGGG	1164
Qy	320	yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACCTCTTCTTCGATGCCATCAGCTGTAGACAGGCCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGGAGCCATTCTTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG	1284
Qy	360	qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380

Db 1285 TCCACTGCAAGGAAGATGGTTCGGCTGCGCCCAACATTGAGGCTGCGGCATGTCATT 1344
Qy 380 uAenAspGlyvAspPheTyPhePheLysGlyvArgCysvTpaAqPheArgGlyvProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGTTCGATGCTGGAGGTTCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGCGAGGGGCTTGCCCCGCATCTTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuLeuPheLysGlyvAlaArgTyTrvVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGGTGCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyvGlyLeuGlnValGluProTyTrvProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCAGGGGGACTGCAGTGGAGCCCTACTACCCCCCAAGTCTCGAGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlyvSerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTTCAGCGGCCCTTGCCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACGAGGCCAAACTGCAAGGCCAACCCACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysvTrpHisAlaAsnSerGlyvSerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 165

US-10-145-628-143
; Sequence 143, Application US/10145628
; Publication No. US20030134365A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P33301C271
; CURRENT APPLICATION NUMBER: US/10/145,628
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550.
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-628-143
Alignment Scores: 3.35e-262 Length: 1985
Pred. No.: 2792.00 Matches: 519
Score:

Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-628-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTTCGGCGGGTTCGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACAGCCCGGAGCGCGAGGAGCTGCGCAAGGAGCGGAGGCGGAGGCATTCCTA 325
Qy 41 GluIleTyTrvGlyvTyTrvLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCCACTCCACTCGATTTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyvValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCACAGCTACCTGTGAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGGGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyvAsnLysTrpTyTrvLysGlnHisLeuSerTyTrvArgLeuVal 140
Db 566 AAACGCTTTCANAGCAAGGTAAACAAATGGTACAGCAGACCTCTCTACCGCCCTGGTG 525
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGAGCGCGAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyvArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGAGCAACGTCCTCAGCGCTGAGTTCCTGGGAGGCCCCACAGCCAGGCCCGCTGAC 745
Qy 180 rSerGlyvSerProSerSerLysGlyvThrThrMetGlyvTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyvGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyvArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyvLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACTCGCCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyTrvTyLysArgLeuGlyvArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyTrvGlyvProLeuGlyvSerValAlaValGlnLeuProGlyvLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAACGTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyTrvSerProGlnGlyvArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCNAGAGGGGCCCTTGAAACGACGG 1164
Qy 320 yProLysTyTrvCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340

Db 1165 CCCTAAATAGTCCACTCTTCTCGATGCGCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArGTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGTGGCTGCCCCCAACATTGAGGCTGGCAGGTGTCAIT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGATGCTGGAGTTCCGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTTCCACAGCTGTGCCGGGCGAGGGGCGCTGCCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTrpTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCCGCTCATCTCTTCAAGGTGTCCTACTACTGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTATACCCCGAAGTCTGCAAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTGAGGAGGTGAGGGGCGCTGCCGAGGCGCGATGGCTCCATCATCTTCT 1644
Qy 480 eArgAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAATCTGAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 166
; Sequence 143, Application US/10145746
; Publication No. US20030134366A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Collin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C269
; CURRENT APPLICATION NUMBER: US/10/145,746
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985

; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-746-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-746-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCCCTCTGCTCGGCCCTGCTGAGCTGTACTGTGGGCGACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGAGCGCGGAGCGCGAGGCTGCGAAGGAGGCGGAGGCGGATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGTCCCCAAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTGTGACGGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCACACCTGCGCCAGATGACTCTGTCCTCCGCTGCGGGGTATACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTTGCTTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTTACAAAGCAGCACCTCTCTCCACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCANCTGCGGAGCGCGAGTTGCGGGCGCGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCTCAGCGCTGGAGTCTTGGGAGGCGCCAGCCAGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACACAAACGATGGGCTGGGCAATGGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyValGluAlaHisPheAspGl 220
Db 806 CCAAGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGAGCGACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTTCCTGAGCGCGCGCGCGCAACCTGTTCTGTTGCTGGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCTACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGAGACAGCTGTGGCCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGCAAGAGCTGTT 1104

```
Oy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTTGAGACCTGGGACTCTCAGACCCCAAGAGGCGCTCTGAACGCGAGG 1164
Oy 320 yProlytYrCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
Oy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGAGCTGATGCAACGCTCTCAGAGCCCCG 1284
Oy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGTGCGCTGCCCAACATTCAGGCTGCGGAGTGTCAAT 1344
Oy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCyTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Oy 400 sProValTrpGlyLeuProGlnLeuCyAsArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 CCAAGTGTGGGGTCTCCACAGCTGTGCCGGGCAAGGGGCTGCCCCGCCATCTGTAGCG 1464
Oy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 GCGCTCTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
Oy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 CCTGCTCTCGAGGGGACTGCAAGTGGAGCGCTTACTACCCCGCAAGTCTGCAGGACTGGG 1584
Oy 460 wGlyValSerGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTTCCAGAGCGCGATGGCTCCATCATCTTCTT 1644
Oy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAGCCCAACTGCAGGCAACCACTCGGGCGG 1704
Oy 500 gTrpAlaThrGluLeuProTrpMetGlyCyTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGGCTTGT 1764
Oy 520 e 520
Db 1765 C 1765
```

RESULT 167

```
US-10-145-748-143
; Sequence 143, Application US/10145748
; Publication No. US20030134367A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: DeNoyers, Luc
; APPLICANT: Flivaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Geritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhong, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
```

```
; FILE REFERENCE: P3330R1C283
; CURRENT APPLICATION NUMBER: US/10/145,748
; PRIOR FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-748-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-145-748-143 (1-1985)

```
Oy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCCCTCTCTGCTCGCGCGCTGCTACTGTGGGGCCACCTG 265
Oy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCCGCGAGCGCGAGGCGCAGAGGCTGCGCAAGAGGGGAGGCAATTCCTA 325
Oy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCTCCCAAGCTCCCACTCCACTCGATTTCAGC 385
Oy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGGTTTCAAGTGGGTGTCACGCTACTGTACGCGCGCTGTTGGACCGC 445
Oy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCTGCCCGTGGGGGTTACAGATACACAGATTATGCG 505
Oy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTGTTGTAGACACCGGACCAAAATGAGCGCTAAG 565
Oy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACTAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Oy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGGAGTTTCGGGGCGCGCTGCGCGCGCTTCAG 685
Oy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTCTGGAGCAACGCTCTCAGCGCTGGAGTTCTGCGAGGCCCCAGCACAGGCCCGCTGAC 745
Oy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCTTCTTCCAAAGGGGACCAACAGCATGGGCTGGGCAATGCTTTGATGGC 805
Oy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGGCGCTTGGCGACGCTTC-CTGCCCGCGCGCGGAGCGGAGCGCACTTCGACCA 864
Oy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCTCCCTGAGCGCGCGCGCGCGCAACCTGTTCGTGCTGTGGCGCA 924
Oy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACACGCTTGGCTTCCCACTCCCACTCGCGCGCGCGCGCTCATGGCGCC 984
```



```
Db      865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTTGCTGCGCA 924
Qy      240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925 CGAGATCGGTACACACCTTGGCTTACCCACATCGCCCGCGCGCGCTCATGCGCGC 984
Qy      260 oTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 280
Db      985 CTACTACAGAGGCTGGGCGCGGACGCGTCTGCTGAGTGGGACGAGTCTGCGCGTGA 1044
Qy      280 nSerLeuTyGlyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 300
Db      1045 GAGCCTGTATGGAAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGT 1104
Qy      300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnG 320
Db      1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGAAACGAGGG 1164
Qy      320 yProTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 340
Db      1165 CCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
Qy      340 rIlePheTyGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225 CATTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAACGTCCTCAGAGCCCG 1284
Qy      360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerle 380
Db      1285 TCCACTGCAGGAAAGATGGTGGGCTGCCGCCCAACATTTAGGCTGGCGCATGTCAAT 1344
Qy      380 uAsnAspGlyAspPheTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 400
Db      1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTGTGATGCTGGAGGTTCGGGGGCCCA 1404
Qy      400 gProValTrpGlyLeuProGlnLeuTyCysArgAlaGlyLeuProArgHisProAspAl 420
Db      1405 GCCAGTGGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCGCCATCTCTGACGC 1464
Qy      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheTyTyTyTyTyTyTyTyTyTyTy 440
Db      1465 CGCCCTCTTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1524
Qy      440 lIleAlaArgGlyGlyLeuGlnValGluProTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 460
Db      1525 GCTGCGCGGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy      460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGGAGGCGCGATGCTCCATCATCTTCTT 1644
Qy      480 eArgAspAspArgTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 500
Db      1645 CCGAGATGACCGCTACTGGCGCTCGACGAGCCAAACTGCAGGCAACCACTCGGGCGC 1704
Qy      500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db      1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCGCAACTCGGGAGGCGCCCTGTT 1764
Qy      520 e 520
Db      1765 C 1765
```

RESULT 169

```
US-10-145-826-143
; Sequence 143, Application US/10145826
; Publication No. US20030134369A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
```

```
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C284
; CURRENT APPLICATION NUMBER: US/10/145,826
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-145-826-143

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00      Matches:     519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      98.52%      Indels:      2
DB:              16          Gaps:          0

US-10-791-980-6 (1-520) x US-10-145-826-143 (1-1985)
```

```
Qy      1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db      206 ATGTCGCGCGCGTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGCGCACCTG 265
Qy      21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266 GACGCCACGAGCCCGGAGCGCGGAGGCTGCGCAAGGAGCGCGGAGCATTCCTTA 325
Qy      41 GluLysTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 60
Db      326 GAGAAGTACGATACCTCATGAACAGGTCCCAAGCTCCCACTCCCTCGATTTCAGC 385
Qy      61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACCTGTCCAGCGCGTGTGGACCGC 445
Qy      81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
Db      446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATCGC 505
Qy      101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506 GCCTGGGCTGAGAGGATCAGTCACTTGTTCCTAGACACCGGACCAAAATGAGGGCTAAG 565
Qy      121 LysArgPheAlaLysGlnGlyAsnLysTrpTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 140
Db      566 AAACGCTTTCAGCAAGAGGTAAACAATGGTTACAAGCAGCACCTCTCTCCGCGCTGTG 625
Qy      141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626 AACTGGGCTGAGCATCTGCGGAGCGCGAGTTCGCGGCGCGCTGCGCGCGCTTCAG 685
Qy      160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCGTGGAGGGCCCCCAGCCACAGGCCCTGAC 745
Qy      180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
```



```
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCACACAGATGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTTPArGThrPrPheLeuProArGArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCCCTGGCGACAGCCCTTC-CTGCGCGCGCGCGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgGlyValArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGGGCGCAACTGTTCTGGTGGTCTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTrpIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCGCTGCTCAGCTGGACGACGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyIysProLeuGlyGlySerValAlaValGlnLeuProGlyIysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAAGAAAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProIysTyrCysHisSerSerPheAspAlaThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCACAGCAACTGTA 1224
Qy 340 rIlePheIysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheIysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTGGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheIysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAAGGGTGGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 CTGGCCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGAAGTCTGCAAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTACGGCGGCGCTCCCGAGGCCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaIysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCCTCGACCGAGGCCAAATGCGAGCAACCACTCGGGCCG 1704
Qy 500 qTrpAlaThrGluLeuProTTPMetGlyCysTrpPheIleAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCNACCGAGTGGCTGGATGGGCTGTGGATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 170

US-10-145-870-143

; Sequence 143, Application US/10145870

```
; Publication No. US20030134370A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary B.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C274
; CURRENT APPLICATION NUMBER: US/10/145,870
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-870-143
```

```
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-145-870-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGCTCGGCTCTCTGTCGCGCGCCCTCGAGCTGTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgIysGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCGCGGAGCGCGAGGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
Qy 41 GluIysTyrGlyTyrLeuAsnGluGlnValProIysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGGATACCTCAATGAACAGGTCCCAAAAGTCCCACTCCATCGATTCCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTTCAGTGGGTGTCCACGACTCTGTACGGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgArgIys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTTGTTGTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaIysGlnGlyAsnIysTrpTyrIysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTACAAATGGTACAGCAGCACCTCTCTACCGGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGGAGGTTTCGGGGCGCCGTCGCGCGCTTCCAG 685
```

```
QY 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGCGCCGCTGAC 745

QY 180 rSerGlySerProSerSerIysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATCCCTTTGATGCG 805

QY 200 aGlnGlyAlaProTrpAlaThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCCCGCGCGGGAAGCGCACTTCGACCA 864

QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGGCGCAACCTGTTCTGCTGCTGCTGGCGCA 924

QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984

QY 260 oTyTrVLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGCTGGGCGCGACGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044

QY 280 nSerLeuTyGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAGGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104

QY 300 eThrAspPheGluThrTrpAspSerTySerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGAAACGCAAGG 1164

QY 320 vProLysTyCysHisSerPheAspAlaThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTTCTCTTGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224

QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284

QY 360 gProLeuGlnGluArgTrpValGlyLeuProProLeuGlnGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGGAAGAAGATGGTCGGCTGCCCCCAACATTGAGGTGCGGCACTGTCATT 1344

QY 380 uAsnAspGlyAspPheTyPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGGAGATTCTTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGGCCCA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACACAGCTGTGCGGGCAGGGGGCTGCCCCCGCATCTCAGCGC 1464

QY 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524

QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCCCGGAGGGGACTGCAAGTGGAGCCCTTACTACCCCCGAAGTCTGCAGGACTGGGG 1584

QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGGGGGCTCTGCGAGGGCCGATGCTCATCATCTTCTT 1644

QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGAACCGAGCCAACTGCAGGCAACCCACCTCGGGCGC 1704

QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCAACGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
```

```
QY 520 e 520
Db 1765 C 1765

RESULT 171
US-10-145-876-143
; Sequence 143, Application US/10145876
; Publication No. US20030134371A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC304
; CURRENT APPLICATION NUMBER: US/10/145,876
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-876-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-876-143 (1-1985)
```

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuLeuLeuLeu 20
Db 206 ATGTTCGCGCGCTCGGCTCTCTGTCGCGCCCTGACAGCTGCTACTGTGGGGCCACCTG 265

QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGAGGCTGCGCAAGGAGCGGAGGCGGAGCATTCCTA 325

QY 41 GluLysTyTrpGlyLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATSAACAGGTCCCAAGGCTCCACCTCCGATTCAGC 385

QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGTTTCAGTGGGTGTCCAGCTACTGTCCAGCGCGTGTGTGGACCGC 445

QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCCCGCTGCGGGTTACAGATACCAACAGATTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
```



```
Db 446 GCACCCCTCGCCAGATGCTGCTCCCGCTCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTTPAlaGluArgHisSerAspLeuPheAlaArgHisArgThryMetArgArgIys 120
Db 506 GCCTGGCTGAGAGGATAGTACCTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACTAATGTTACACAGCAGCCTCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCGGCGAGTTCGGGGCGCGTTCGGCGCCCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGATTCTGGAGGGCCCCAGCCACAGGCCCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTCTGGCGCA 924
Qy 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGCGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGTCTGGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCTCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGAGCGCCCTGAAACCGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATAGTCCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAAGATGGGTGGGCTGCCCCCCCAACATTGAGGTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCCAACAGCTGTGGCGGCGAGGGGGCTTGGCCCCGCCATCTCCGAGCG 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
```

```
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCAGTCTCTGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGATCTCTGAGGAGGTACGGCGCCCTGCCGAGGCCCGATGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCAAGGCCCAAACTGCAGGCAACCCACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGTGGCATGCCAACTCGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 173
US-10-146-724-143
; Sequence 143, Application US/10146724
; Publication No. US2003013473A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C317
; CURRENT APPLICATION NUMBER: US/10/146,724
; CURRENT FILING DATE: 2002-05-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-146-724-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-146-724-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCTCGCGCGCTCGCGCCCTCTCTGCGCCCTCTGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACAGCCCGGAGCGCGGAGGCTGGCAAGGAGGCGGAGGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
```


DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-146-795-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGGCGCGCTCGCTCGCGCGCTCGAGTCTACTGTGGGCGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuLeuArgGlyGlnAlaAlaPheLeu 40
Db 266 GAGCGCCAGCCCGCGAGCGCGAGCGCGAGAGCTGCGCAAGAGCGCGAGGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGNAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGCTTTCAGTGGGTGTCACAGCTACCTGTGAGCGCGGTGTGGACGCG 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCGCCAGATGACTGTCCTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGTGAGAGGATCAGTGACTTGTGCTAGACACCGGACCAAAATGAGCGGTAAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAAAGCAGCACCTCTCTCCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCACTCTCGCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGAGCAACGCTCTCAGCGCTGGAGTTCCTGGGAGGCGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCTCAGCTTCTTCAAGGGGACCAACATGGCTGGCGTGGCAATGCTTGTATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGCGCGCTGGCGCAGCGCTTC-CTGCCCCGCGCGCGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGAGCGCTGCTCAGCTGGGACGACGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGTCCAGCTCCACAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCCTACAGCCCCCAAGAAAGGCGCGCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATATGTCACACTTCTCTCGATGCCATCAGTGTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360

Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGAGCTGTATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAGAAAGATGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGTGGGT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTGCATGTGGAGGTTCGGGGGCCCA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCGGGGCAGGGGGCTGCGCGCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTTCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAAAGTCTGCAGAGACTGGGG 1584
QY 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGCATCCCTGAGGAGGTGAGCGGCGCTGCGGAGCGCGCTGCGGCTCCATCTCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACACGAGGCGGCAACCTGCAGGCAACCACTCGGCGCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCGCACGAGCTGCCCTGGATGGCTGCTGGCAACTCGGAGGCGCGCTCTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 176
US-10-147-495-143
; Sequence 143, Application US/10147495
; Publication No. US20030134376A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: F3330R1C371
; CURRENT APPLICATION NUMBER: US/10/147,495
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-495-143


```

; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-501-143

```

Alignment Scores:

Pred. No.:	3,358-252	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	98.53%	Indels:	2
DB:	16	Gaps:	0

US-10-791-980-6 (1-520) x US-10-147-501-143 (1-1985)

Qy	1	MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGTTGCGCGCGTGGCGCTCTCTGTGGCGCGCTGCAGCTGCTACTGTGGGCGCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCACGCCGCGAGCGCGAGCCAGAGCTGCGCAAGGAGCGGAGCATTCCTCA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCACTCGATTCCAG	385
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTTACCTGTGAGCGGCGTGTGACGCG	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCTTCGCCAGATGACTCGTCCCGCTTCGGGGTTACAGATCCACAGTTATTGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTTGGGTGAGAGGATCAGTGTACTTGTTCAGACACCGGACCCAAATGAGGCGTAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCTTTGCAAAAGCAAGGTAAACAATGGTACAAAGCAGCACCTCTCTCTACCGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCTGAGCATCTGCCGGAGCGCGCAGTTCCGGGCGCGCTGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCCTCAGCGCTCGAGTTCCTGGGAGGCCCCAGCCACAGCCCGCTGCAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCCAGGGGAGCACAAACATGGGCTGGGCAATTCCTTTGATGCG	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1	220
Db	806	CCAGGGGGCCCTTGCGCAGCCCTTC-CTGCCCCCGCGCGGAGGCGCATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGTGGTCCCTTGAGCCCGCGCGCGCAACCTGTTCGTGGTGTCTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTCAACAGCTTGACCTCACCCATCTCCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1	280
Db	985	CTACTCAAGAGGTGGGCGCGCAGCGCTCTCAGCTGGGACGACGCTGTGGCGCTGCA	1044

RESULT 178

```

US-10-147-504-143
; Sequence 143, Application US/10147504
; Publication No. US20030134378A1
; GENERAL INFORMATION:
; APPLICANT: Baker Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K

```

```
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P333013C372
; CURRENT APPLICATION NUMBER: US/10/147,504
; PRIOR APPLICATION REMOVED - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-504-143

Alignment Scores:
Pred. No.:      3 35e-262      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      16          Indels:      2
DB:              16          Gaps:      0

US-10-791-980-6 (1-520) x US-10-147-504-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGGCTCGGCTCTGTCGCGCGCTCGACGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGCGGAGCGCGGAGCGGAGGAGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAACTACGATACCTCAATGAACAGGTCCTCCCAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCTCCAGCTACCTGTCCAGCGGCGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCGCAGATCACTGCTCCCGCTGCGGGGTTCACAGATACCAACAGCTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTGTCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAACGAAGTAACAAATGGTACAGCAGCAGCCTCTCTACCGCTGTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGTGAGTTCTGGGAGGCGCCCGCCAGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTCTTCCAGGGGACCAACAGATGGCTGGGCAATGCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGGCTGGCGCAGCCCTTC-CTGCCCCGCGCGCGGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGGCAACCTGTTCGTGGTGGTGGCGCA 924
```

```
240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
925 CGAGATCGGTCAACACGCTTGGCCTCACCACTCGCGCGCGCGCGCTCATGGCGC 984
260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCTGCA 1044
280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
1045 GAGCTGTGTGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGAAAGGCGCCCTGAAACCGAGG 1164
320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
1165 CCCTAAATACCTGCGCACCTCTTCCTTCGATGTCATCACTGTAGACGGCAACAGCACTGT 1224
340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
1225 CATTTTAAAGGAGCCATTTCTGGGAGTGGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
1285 TCCACTGCGAGAAAGATGGGTGGGCTGCCGCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
1345 GAATGATGGAGATTCTACTTTCTCAAAGGGGGTGCATGCTGGAGGTTCCGGGGGCCCAA 1404
400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
1405 GCCAGTGTGGGCTCTCCACAGCTGTGCCGGGAGGGGGCTGCCGCCCATCTCGACGC 1464
420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
1465 CGCCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGCT 1524
440 lLeuAlaArgGlyLysLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
1525 GCTGGCGCGAGGGGAGCTGCAAGTGGAGCGCTACTACCCCGAAGTCTGCAGGAGCTGGGG 1584
460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
1585 AGGCATCTCTGAGAGGAGTACGCGCGCGCTGCCAGGCGCCGATGGCTCATCATCTTCTT 1644
480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
1645 CCGAGATGACCGCTACTGGGCGCTCGACGAGGCCAAACTGCAGGCAACCACTCGGGCGC 1704
500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheAlaAsnSerGlySerAlaLeuPh 520
1705 CTGGGCCACCGAGTGGCTGGATGGGCTGCTGCATGCCCAACTGCGGAGCGCCCTGT 1764
520 e 520
1765 C 1765

RESULT 179
US-10-147-506-143
; Sequence 143, Application US/10147506
; Publication No. US20030134379A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
```

```

; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C344
; CURRENT APPLICATION NUMBER: US/10/147,506
; PRIOR FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-506-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
Dbs: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-506-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ARGTCGCGCGGTTCGGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCGAGCCGCGAGCGCGGAGGCGAGAGCTGCGCAGAGGCGGCGGCGCATTCCTA 325

Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCGATTCGATCAGC 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTTACCTGTGTCAGCGCGGTGTGGACGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTTGCTAGACACCGGACCAAAATGAGCGGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAAAGCTTTGCAAGCAAGATGACAAATGGTACAGAGCACCTCTCTACCGCGCTGGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCCGCGAGTTCGGGGCGCGGTGCGCGCGCTTCCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCCGCCAGCCACAGGCCCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTCTCTCCAGAGGGGACCAACCAATGGCTGGGCATGCTTTGATGGC 805

Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgGlyGluAlaHisPheAspG1 220

```

```

Db 806 CCAGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGGCAACCTGTTCTGTTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCAGCCACTCGCCCGCGCGCGCTCATGCGGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGTGGCGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGCGCGCTGAAACGCGAGG 1164
Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAATATCTGCCACTCTTCTTCGATGCATCCTCTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGTGGCGCTGCCCGCCCAACATTTGAGCTGCGCAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGCGCGGCGAGGGGCTGCCCGCCCATCTCGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGGTGCGCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrTrpArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGAGTGCAGAGTGGAGCCCTACTACCCCGCAAGTCTGCAGACTGGG 1584
Qy 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGAGGTGAGCGCGCTTCCAGCGCGCGCTGCGAGCGCGCTGCTGCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTTGGCGCTTCCAGCGCGCGCTGCGAGCGCGCTGCTGCTCTTCTT 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAATCTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 c 1765

```

RESULT 180
 US-10-147-509-143
 ; Sequence 143, Application US/10147509
 ; Publication No. US20030134380A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.

APPLICANT: Beresini, Maureen
APPLICANT: DeForge, Laura
APPLICANT: Desnoyers, Luc
APPLICANT: Filvaroff, Ellen
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Gurney, Austin L.
APPLICANT: Sherwood, Steven
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K
APPLICANT: Wood, William
APPLICANT: Zhang, Zemin
TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
FILE REFERENCE: P33301C331
CURRENT APPLICATION NUMBER: US/10/147,509
CURRENT FILING DATE: 2002-05-16
PRIOR FILING DATE: 1997-06-18
PRIOR APPLICATION NUMBER: 60/049911
PRIOR FILING DATE: 1997-08-26
PRIOR APPLICATION NUMBER: 60/056974
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059113
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059115
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059117
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059122
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059184
PRIOR FILING DATE: 1997-09-17
PRIOR APPLICATION NUMBER: 60/059263
PRIOR FILING DATE: 1997-09-18
PRIOR APPLICATION NUMBER: 60/059352
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059588
PRIOR FILING DATE: 1997-09-19
PRIOR APPLICATION NUMBER: 60/059836
PRIOR FILING DATE: 1997-09-24
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/062285
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/062287
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/062814
PRIOR FILING DATE: 1997-10-24
PRIOR APPLICATION NUMBER: 60/062816
PRIOR FILING DATE: 1997-10-24
PRIOR APPLICATION NUMBER: 60/063045
PRIOR FILING DATE: 1997-10-24
PRIOR APPLICATION NUMBER: 60/063082
PRIOR FILING DATE: 1997-10-31
PRIOR APPLICATION NUMBER: 60/063127
PRIOR FILING DATE: 1997-10-24
PRIOR APPLICATION NUMBER: 60/063327
PRIOR FILING DATE: 1997-10-27
PRIOR APPLICATION NUMBER: 60/063329
PRIOR FILING DATE: 1997-10-27
PRIOR APPLICATION NUMBER: 60/063550
PRIOR FILING DATE: 1997-10-28
PRIOR APPLICATION NUMBER: 60/063561
PRIOR FILING DATE: 1997-10-28
PRIOR APPLICATION NUMBER: 60/063704
PRIOR FILING DATE: 1997-10-29
PRIOR APPLICATION NUMBER: 60/063733
PRIOR FILING DATE: 1997-10-29
PRIOR APPLICATION NUMBER: 60/063735
PRIOR FILING DATE: 1997-10-29
PRIOR APPLICATION NUMBER: 60/063738
PRIOR FILING DATE: 1997-10-29
PRIOR APPLICATION NUMBER: 60/063755
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064248
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/064809
PRIOR FILING DATE: 1997-11-07
PRIOR APPLICATION NUMBER: 60/065186
PRIOR FILING DATE: 1997-11-12
PRIOR APPLICATION NUMBER: 60/065846
PRIOR FILING DATE: 1997-11-17
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/066453
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/066511
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/066770
PRIOR FILING DATE: 1997-11-24
PRIOR APPLICATION NUMBER: 60/069212
PRIOR FILING DATE: 1997-12-11
PRIOR APPLICATION NUMBER: 60/069278
PRIOR FILING DATE: 1997-12-11
PRIOR APPLICATION NUMBER: 60/069334
PRIOR FILING DATE: 1997-12-11
PRIOR APPLICATION NUMBER: 60/069694
PRIOR FILING DATE: 1997-12-16
PRIOR APPLICATION NUMBER: 60/072320
PRIOR FILING DATE: 1998-01-23
PRIOR APPLICATION NUMBER: 60/073612
PRIOR FILING DATE: 1998-02-04
PRIOR APPLICATION NUMBER: 60/074086
PRIOR FILING DATE: 1998-02-09
PRIOR APPLICATION NUMBER: 60/074092
PRIOR FILING DATE: 1998-02-09
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-02-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081695
PRIOR FILING DATE: 1998-04-14
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081818
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082999
PRIOR FILING DATE: 1998-04-24
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085149
PRIOR FILING DATE: 1998-05-12
PRIOR APPLICATION NUMBER: 60/085323

1	PRIOR FILING DATE: 1998-05-13
2	PRIOR APPLICATION NUMBER: 607/085338
3	PRIOR FILING DATE: 1998-05-13
4	PRIOR APPLICATION NUMBER: 607/085339
5	PRIOR FILING DATE: 1998-05-13
6	PRIOR APPLICATION NUMBER: 607/085579
7	PRIOR FILING DATE: 1998-05-15
8	PRIOR APPLICATION NUMBER: 607/085697
9	PRIOR FILING DATE: 1998-05-15
10	PRIOR APPLICATION NUMBER: 607/085704
11	PRIOR FILING DATE: 1998-05-15
12	PRIOR APPLICATION NUMBER: 607/086414
13	PRIOR FILING DATE: 1998-05-22
14	PRIOR APPLICATION NUMBER: 607/086430
15	PRIOR FILING DATE: 1998-05-22
16	PRIOR APPLICATION NUMBER: 607/087106
17	PRIOR FILING DATE: 1998-05-28
18	PRIOR APPLICATION NUMBER: 607/088026
19	PRIOR FILING DATE: 1998-06-04
20	PRIOR APPLICATION NUMBER: 607/088730
21	PRIOR FILING DATE: 1998-06-10
22	PRIOR APPLICATION NUMBER: 607/088741
23	PRIOR FILING DATE: 1998-06-10
24	PRIOR APPLICATION NUMBER: 607/088810
25	PRIOR FILING DATE: 1998-06-10
26	PRIOR APPLICATION NUMBER: 607/088858
27	PRIOR FILING DATE: 19798-06-11
28	PRIOR APPLICATION NUMBER: 607/089532
29	PRIOR FILING DATE: 1998-06-17
30	PRIOR APPLICATION NUMBER: 607/089599
31	PRIOR FILING DATE: 1998-06-17
32	PRIOR APPLICATION NUMBER: 607/089907
33	PRIOR FILING DATE: 1998-06-18
34	PRIOR APPLICATION NUMBER: 607/089947
35	PRIOR FILING DATE: 1998-06-19
36	PRIOR APPLICATION NUMBER: 607/090349
37	PRIOR FILING DATE: 1998-06-23
38	PRIOR APPLICATION NUMBER: 607/090429
39	PRIOR FILING DATE: 1998-06-24
40	PRIOR APPLICATION NUMBER: 607/090445
41	PRIOR FILING DATE: 1998-06-24
42	PRIOR APPLICATION NUMBER: 607/090538
43	PRIOR FILING DATE: 1998-06-24
44	PRIOR APPLICATION NUMBER: 607/090863
45	PRIOR FILING DATE: 1998-06-26
46	PRIOR APPLICATION NUMBER: 607/091360
47	PRIOR FILING DATE: 1998-07-01
48	PRIOR APPLICATION NUMBER: 607/091519
49	PRIOR FILING DATE: 1998-07-02
50	PRIOR APPLICATION NUMBER: 607/091982

Alignment Scores:		
Pred. No.:	3,356-262	1985
Score:	2792.00	Matches: 519
Percent Similarity:	99.62%	Conservative: 0
Best Local Similarity:	99.62%	Mismatches: 1
Query Match:	98.52%	Indels: 2
DB:	16	Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-509-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGTGGGCTCTGTGCGGCCCTGCAGCTGTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCGAGCGCGAGGCCAGAGCTGCGCAAGGAGCGGAGGCATTCCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATCGATTTCAGC 385

Qy	61	AspAlaileArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACTGTACGGCGGTGTTCGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCTCGCCACAGATGACTCGTCCCGCTCGGGGTTCAGATATCCAAACAGTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgArgIys	120
Db	506	GCCTGGGCTGAGAGGATCAGTGACTTGTGTCTAGACACCGGACCAAAATGAGCGGTAAAG	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrIysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAACGCITTTGCAAGCAAGGTAAACAATGGTACAAAGCAGCACCTCTCTACCGGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AAC'TGGGCTGAGCATCTCGCGGAGCGGCAGTTCCGGGCGCGGTGCGCGCGCTTCACG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTTGGAGACAAACGTCTCAGCGCTGGAGTTCTGGGAGGCCCGACGACAGGCCCGCTGCAC	745
Qy	180	rSerGlySerProSerSerIysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCCGGCTCACCTTCTTCAAAGGGGACCAACAAGATGGGCTGGGCATGTCTTTGATGGC	805
Qy	200	gGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGCGCGCTTGGCGCACGCGCTTC-C'GCGCCGCGCGCGGCGAAGCGCAC'TTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGAGCGTGGTCCCTGTAGCGCGCGCGCGCGGCGCAACGTGTCTGTGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACAGCTTGGCGCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrIysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGCGCGCGACGCGCTGTCTCAGCTGGGAGCACGTGTGTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyIysProLeuGlyIysSerValAlaValGlnLeuProGlyIysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CAC'TGACTTTTGAGACCTTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCCTCGAAAGCGCAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr	340
Db	1165	CCCTAAATACTGCGCACCTTCTTCGTATGATGCATCACTGTAGACAGGCAACAGCAACTGT	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAAGGGAGACCATTTCTGGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGAAAGATGGTTCGGGCTGCCCCCCACATTTGAGGCTGGCGCAGTGTTCATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyIysArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAAGGGGTCGATGTCTGGAGGTTCGGGGGCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGGTCTCCCAACAGTGTGGCGGAGGGGGCTCGCCCCGCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpTrpVa	440

Db 1465 CGCCCTCTTCTTCCCTCCTCTGCGCGCCCTCATCTCTTCAAGGGTGCCTACTACT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCCAGGGGAGTCAAGATGAGGAGCTACTACCCCCGAAGTCTCGAGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTCAAGCGGCGCTGCGAGGCGCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTCGCGCTCGACGAGGCCAACTGCAGGCCAACCCCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGTGCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 181

US-10-147-510-143
; Sequence 143, Application US/10147510
; Publication No. US20030134381A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC370
; CURRENT APPLICATION NUMBER: US/10/147,510
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-510-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-510-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ARGGTGCGCGGTGGCGCTCTGCTGCGCGCCCTGCTGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40

Db 266 GACGCCAGCCCGCGAGCGCGAGCGAGCTGCGCAAGAGAGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTTCAGTGGGTGCCCAGCTACCTGTTCAGCGCGGTGTGGACCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAenSerTyrAla 100
Db 446 GCCACCTTCGCGCAGATCACTCGTCCCGCTCGCGGGTTACAGATACCACCAACGTTATGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCGTAGACACCGGACCCAAATAGGGGTAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AenTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCCGAGCGCGCAGTTCGGGGCGCGTTCGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGAGGTTCTGGGAGGCCCCAGCCACAGGCCCTGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCCCTTGCATGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCGCTGGCGCAGCCCTTC-CTGCCCGCGCGCGGCGAAGCGCACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGGCGCAACCTGTTCTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGCGGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAACCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGAGGCGCCCTGAAACCGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTCTCTTCGATGCCATCACTGTAGACAGGCCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGAGCTGATGGCAACGCTGCTCAGAGCCCCG 1284
Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAenIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCGGCTGCCCCCCACACATTGAGGCTGGCGGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400

Db 1345 GAATGATGAGATTTCTACTTCTCAAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGGGCAGGGGCGCTGCCGCCCATCTCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuileLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCTCTCTCTGGCGGCTCATCTCTTCAAGGTGCGCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
Db 1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAACTCTGCAGGACTGGGG 1584
Qy 460 vGlyIleProGluGluValSerGlyAlaLeuProArgProArgProArgPhePhePhe 480
Db 1585 AGGCATCCCTGAGGAGGTGAGGGCGCTGCGGAGGCGCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGCCAAACTGCGAGCAACACTCTGGGCG 1704
Qy 500 gTPAlaThrGluLeuProTPMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 182

US-10-147-511-143
; Sequence 143, Application US/10147511
; Publication No. US20030134382A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C356
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-511-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-511-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTTPGlyHisLeu 20
Db 206 ATGTCGCGCGCTGCGGCTCTCTCTCGCGGCCCTGTCAGCTGCTACTTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCAGCGCGCGAGCGCGAGGCTGCGAGGCTGCGAAGGCGGAGGCGGATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGCTCCCCAAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCAGCTACCTGTCTGAGCGCGGTGTTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCCGCTGCGGGGTTCAGATACCAACAGATTATGCG 505
Qy 101 AlaTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTCAGAGGATCAGTGACTTCTTTGTAGACACCGGACCAAAATGAGCGGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACTTGTGTTGTAGACACCGGACCAAAATGAGCGGTAAAG 625
Qy 141 AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTCAGCATCTGCGGAGCGCGGAGTTGCGGGCGCGCTGCGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTTCTCAGCGCTGGAGTTCTGGGAGGCCCGCAGCACAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGTATGGC 805
Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGGCGCAGCGCTTC-CTGCCCCCGCGCGGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATGGGTTCACAGCTTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGAGCAGCTGCTGGCCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAGGCGCGCTCAAGACGCGAGG 1164
Qy 320 YProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTTAATACTGCGCACTCTTCTTCATGTCATCCTGTAGACAGGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCAATTTCTGGGAGGTGGCAGCTGTATGGCAAGCTCTCAGAGCGCCG 1284

```
QY 360 gProLeuGlnGluArgTrrpValGlyLeuProProAenilleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTrrpPhePheLysGlyArgCysTrrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGAGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGTCTCTCCACAGCTGTGCCGGGAGGGGCCCTGCCCGCCATCTCTGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLleLeuPheLysGlyAlaArgTrrpVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCTCATCTCTTCAGGGGTGCCCGCTACTAGT 1524
QY 440 lleuAlaArgGlyLeuGlnValGluProTrrpTrrpProArgSerLeuGlnAspTrrpGl 460
Db 1525 GCTGGCCCCAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584
QY 460 vGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCCCTGCGGAGGCCGATGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTrrpTrrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACGAGCCCAAACTGCAGGCAACCCACCTCGGGCG 1704
QY 500 gTrrpAlaThrGluLeuProTrrpMetGlyCysTrrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 183
US-10-147-529-143
; Sequence 143, Application US/10147529
; Publication No. US20030134383A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P33301C133
; CURRENT APPLICATION NUMBER: US/10/147,529
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-529-143
Alignment Scores:
```

```
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-147-529-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGTGGCTCTCTGTCGCGCCCTGTCAGCTGCTACTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGGAGCTGCGAAGAGCGCGAGGCATTCCTA 325
QY 41 GluLysTrrpGlyTrrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGGTTTTCAGTGGGTGTCCAGAGCTACCTGTTCAGCGCGGTGTGGACGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCAGGATGACTCTGTCGCCGTTCGCGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTTCGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrrpTrrpLysGlnHisLeuSerTrrpArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGACACCTCTCTACCGCTGGTG 625
QY 141 AsnTrrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGAGCGGAGCTTCGGGGCGCGCTGCGCGCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGCCCCAGCCACAGGCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGTGGGCTGGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGGCTGGCGCAGCCTTC-CTGCCCGCGCGCGGCGGAGCGCAATTCGACCA 864
QY 220 nAspGluArgTrrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGGCGCAACCTGTTCTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACCTCTGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTrrpTrrpArgLeuGlyArgAspAlaLeuLeuSerTrrpAspAspValLeuAlaValGl 280
Db 985 CTACTCAAGAGGCTGGGGCGGAGCGGCTGCTCAGCTGGAGACGCTGCTGGCGCGTGCA 1044
QY 280 nSerLeuTrrpGlyLysProLeuGlyLysValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrrpAspSerTrrpProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCCCTCTGAAGCGCAGGG 1164
```

```
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAACTGCGCACTCTTCCTTCGATGCCATCACTGTAGACAGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaPheGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCACCTGTCAGGAAAGATGGTCGGCTGCCCCCAACATTGAGGCTGGCGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCA 1404
QY 400 gProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTTCCACAGCTGTGCCGGCAGGGGCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCCCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAAGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGGCTGCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGCCAAACTGCGGGAACACCACTCGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 184

```
US-10-152-397-143
; Sequence 143, Application US/10152397
; Publication No. US2003013484A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C380
; CURRENT APPLICATION NUMBER: US/10/152,397
; CURRENT FILING DATE: 2002-05-20
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
```

```
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-152-397-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-152-397-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGCGCTCTGCTGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGCGCAGAGCTGCGCAAGGAGCGGAGCGGATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProIleAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGATTGAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGCTCCAGCTACCTGTGAGCGCGGTGTTGGACGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGGCGCAGATGACTCGTCCCGCTGGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTGGGCTGAGAGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGGTAA 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGCTTTCAAAGCAAGGTAAACAAATGTTACAAAGCAGCACCTCTCTCCAGCGCTGGT 625
QY 141 AsnTrpProLuhisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCCTGAGCATCTGCGGAGCGCGCAGTTTCGGGGCGCCGTCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThr-SerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGGCGGAGCGACCTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCTGAGCGCGCGCGCGCGGCGCACTGTTCGTGTTGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGACGCGTGTCTGAGTGGAGCAGCGTGTGTCGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
```

Db 1045 GAGCCTGTATGGAAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAGCTGT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCAAGAGAGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGTCCGGCTGCCCCCAACATTGAGGTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGAGATTTCTACTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTTPGlyLeuProGlnLeuGlyArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTCCGGGCGAGGGGCTGCCCCGCCATCTCTGACGC 1464
Qy 420 sAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
Db 1465 GCGCCTCTTCTTCCCTCTCTGCGCGCTCTATCTCTTCAAGGGTGGCGCTACTACGT 1524
Qy 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG 460
Db 1525 GCTGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGCTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCGCTGCGGAGGCGCATGCTGCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCGCAAACTGACAGGCAACCACTCGGGCG 1704
Qy 500 gTPAlaThrGluLeuProTTPMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 185

US-10-153-586-143

; Sequence 143, Application US/10153586

; Publication No. US20030134385A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C413
; CURRENT APPLICATION NUMBER: US/10/153,586
; CURRENT FILING DATE: 2002-05-22
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-153-586-143

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-153-586-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGAGCGCGAGGCTGCGCAAGGAGCGGAGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCTCCCAAGGCTCCACCTCCACTCGATTGAC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGAGTACCTGTTCAGCGCGGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCCAGATGACTCTGTCGCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACTTGTGTGTAGACACCGGACCAAAATCAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTrpLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCTACCGCTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysValaProProSerSe 160
Db 626 AACTGGGCTGAGCATCTGCGGAGCGCGAGTCTCGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTCTTGGGAGGCGCCCGCAGCCAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACATGGGCTGGGCAATGCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGGCGACGCGCTTC-CTGCCCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGGCGCAACCTGTTCGTGTGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
|||||

Db	925	CGAGATCGGTACACGCTTGGCGCTCACCCACTCGCGCCCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrrLySArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGTGGCGCGCAGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA	1044
Qy	280	nSerLeuTyrrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCGAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTCAGACCTGGGACTCCTACAGCGCCCAAGGAAGCGCCCTGAAACGACGAGG	1164
Qy	320	yProLysTyrrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy	340
Db	1165	CCCTAAATACTCGCCACTCTTCCTTCGATGCCATCACGTGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTAAAGGAGCCATTTCCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCGC	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGGCAGTGTCA TT	1344
Qy	380	uAsnAspGlyAspPheTyrrPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCCTACTCTTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGCGCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACACAGCTGTGCCGGGCGAGGGGGCTGCCCGCCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrrVa	440
Db	1465	CGCGCTCTCTTCCTCTCGCGCGCCTCATCTCTTCAAGGGTGCCCGCTACTACTGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrrTyrrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCGCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGCATCCCTGAGGAGTTCAGCGCGCGCCTGCCGAGGCGCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTTGGCGCCTTCGACCAAGGCCAAACTGCAGGCAACACCACTCGGGCGC	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGTGCCTCGATGGGCTGCTGGCATGCCAATCTGGGGAGCGCCCTGTT	1764
Qy	520	e	520
Db	1765	C	1765

RESULT 186

US-10-158-786-143

; Sequence 143, Application US/10158786

; Publication No. US20030134791A1

; GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.

APPLICANT: Beresini, Maureen

APPLICANT: DeForge, Laura

APPLICANT: Desnoyers, Luc

APPLICANT: Filvaroff, Ellen

APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E
: APPLICANT: Goddard Andrew

APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.

APPLICANT: GODOWSKI, PAUL J.
APPLICANT: Gurney, Austin L.

1. **АВТОРСКИЕ ПРАВА:** © 1999, 2000 г. г.

```

; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
; FILE OF INVENTION: P3330R1C458
; CURRENT APPLICATION NUMBER: US/10/158,786
; CURRENT FILING DATE: 2002-05-30
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-158-786-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 99.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-158-786-143 (1-1985)

```

```
QY 220 nAspGluArgTyrSerLeuSerArgArgArgGlyValValValLeuAlaHi 240
|
|
|
Db 865 AGATGAGCGTGTCTCTGAGCGCGCGCGCGCGCAACCTGTTGTTGTTGCGCGCA 924
|
|
|
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
|
|
|
Db 925 CGAGATCGGTACACAGCTGTGGCTCCACCTCCCGCGCGCGCGCGCTCATGCGCGC 984
|
|
|
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGI 280
|
|
|
Db 985 CTACTACAAGAGCTGGCGCGCGCGCGCTGCTCAGCTGGAGCGAGCTGCTGGCGCGTGA 1044
|
|
|
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
|
|
|
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGTCTCCAGGAAGCTGTT 1104
|
|
|
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGI 320
|
|
|
Db 1105 CACTGACTTTGAGACCTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGMAACGCGAGG 1164
|
|
|
QY 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
|
|
|
Db 1165 CCTAATAACTGCTCCTCTCTTCGATGCCATCACTAGTAGACAGCAACAGCAACTGTA 1224
|
|
|
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
|
|
|
Db 1225 CATTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
|
|
|
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
|
|
|
Db 1285 TCACCTGTCAGGAAGATGGTGGGCTGCGGCTGCCCCCAACATTGAGGCTGCGGCACTGTCATT 1344
|
|
|
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
|
|
|
Db 1345 GAATGATGAGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCA 1404
|
|
|
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
|
|
|
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCCGCATCTTGACGC 1464
|
|
|
QY 420 alaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
|
|
|
Db 1465 CGCCTCTTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACT 1524
|
|
|
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGI 460
|
|
|
Db 1525 GCTGGCCCCAGGGGAGTCAAGTGGAGGCCCTACTACCCCGGAAGTCTGCAGGACTGGGG 1584
|
|
|
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
|
|
|
Db 1585 AGGCATCCCTGAGGAGTCAAGCGGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
|
|
|
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
|
|
|
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACCCAGGCCAACTGCAGGCAACCCACCTCGGGCG 1704
|
|
|
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
|
|
|
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
|
|
|
QY 520 e 520
|
|
|
Db 1765 C 1765
```

RESULT 187

```
US-10-137-870-143
; Sequence 143, Application US/10137870
; Publication No. US20030138883A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
```

```
; APPLICANT: Desnoyers, Luc
; APPLICANT: Pilvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P33301C155
; CURRENT APPLICATION NUMBER: US/10/137,870
; CURRENT FILING DATE: 2002-05-03
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-137-870-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-137-870-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
|
|
|
Db 206 ATGTGTCGGCGGTCTCGCTCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
|
|
|
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
|
|
|
Db 266 GAGCCCAAGCCCGCGAGCGCGGAGCCAGAGCTGCCAGAGGCGCGGAGGCATTCTTA 325
|
|
|
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
|
|
|
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGATTTCAGC 385
|
|
|
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
|
|
|
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTCTGTGCGGGGTGTGTGGACCGC 445
|
|
|
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
|
|
|
Db 446 GCCACCTTGCAGATGACTCGTCCCGCTGCGGGTTACAGATACCAACAGATTATGCG 505
|
|
|
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
|
|
|
Db 506 GCCTGGGTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAA 565
|
|
|
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
|
|
|
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCCGCTGGTG 625
|
|
|
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
|
|
|
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGCAGTTCGGGGCGCGCTGCGCGCCGCTTCCAG 685
|
|
|
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
|
|
|
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGTGAGTTCCTGGGAGGCGCCAGGCACAGGCCCGCTGAC 745
```

```
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
|
|
|
Db 746 ATCCGGCTCACCTCTTCCAAAGGGACCAACAGATGGCTGGCAATGCTTTGATGGC 805
|
|
|
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
|
|
|
Db 806 CCAGGGGGCGCCCTGGCGACGCTTC-CTGCCCCGCGCGCGAAGCGCACTTCGACCA 864
|
|
|
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyVArgAsnLeuPheValValLeuAlaHi 240
|
|
|
Db 865 AGATAGAGCGCTGGTCCCTAGAGCCGCGCGGGCGCAACCTGTTCGTGGTGTGGCGCA 924
|
|
|
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
|
|
|
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
|
|
|
QY 260 oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
|
|
|
Db 985 CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
|
|
|
QY 280 nSerLeuTyTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
|
|
|
Db 1045 GAGCTGTATGGAAGCCCTTAGGGGGCTCAGTGGCCGTCCAGCTCCAGGAAGCTGTT 1104
|
|
|
QY 300 eThrAspPheGluThrTrpAspSerTyTrpSerProGlnGlyArgArgProGluThrGlnG1 320
|
|
|
Db 1105 CACTGACTTTGAGACTCGGACTCTACAGCCCCCAAGNAGGCCCTGGAACGCAGGG 1164
|
|
|
QY 320 yProLysTyTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
|
|
|
Db 1165 CCCTAAATACTGCCACTCTCTTCGATGCCACTCACTGTAGACAGGCAACGCAACTGTA 1224
|
|
|
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
|
|
|
Db 1225 CATTTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAACGTCCTCAGAGCCCCG 1284
|
|
|
QY 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
|
|
|
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCGCCCAACATTGAGGTGGCGGAGTGTCAAT 1344
|
|
|
QY 380 uAsnAspGlyAspPheTyTrpPheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
|
|
|
Db 1345 GAATGATGGAGATTTCTACTCTTCTCAAAGGGGGTGGATGCTGGAGGTTCCGGGGCCCCAA 1404
|
|
|
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyValLeuProArgHisProAspAl 420
|
|
|
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGGCTGCCCGGCCATCTGAGCG 1464
|
|
|
QY 420 aAlaLeuPheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrpVa 440
|
|
|
Db 1465 CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
|
|
|
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpG1 460
|
|
|
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGGG 1584
|
|
|
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
|
|
|
Db 1585 AGGCATCTCAGGAGGTACGGCGCCCTGCCAGGGCCCATGCTCCATCATCTCTT 1644
|
|
|
QY 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
|
|
|
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAAGCCAAACTGCAGGCAACACCATCTCGGGCCG 1704
|
|
|
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
|
|
|
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
|
|
|
QY 520 e 520
|
|
|
Db 1765 C 1765
```

RESULT 188

```
US-10-140-018-143
; Sequence 143. Application US/10140018
; Publication No. US20030139885A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deanoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C158
; CURRENT APPLICATION NUMBER: US/10/140,018
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-018-143
```

```
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-140-018-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
|
|
|
Db 206 ATGTCTCGCGCGCTGCGCCCTCTGCTGCGGCCCTGCAGCTGTCTACTGTGGGGCCACTG 265
|
|
|
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
|
|
|
Db 266 GACGCCAGCCCGGGAGCGCGAGAGCTGCGCAAGGAGGCGGAGGCATTCTTA 325
|
|
|
QY 41 GluLysTyTrpGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
|
|
|
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAAAGCTCCCACTCCATTCCAGT 385
|
|
|
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
|
|
|
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTGACGGCGGTGTGGACCGC 445
|
|
|
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
|
|
|
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
|
|
|
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
|
|
|
Db 506 GCCTGGGCTCAGAGGATCAGTACTTGTGTTGTAGACACCGGACCAAAATGAGCGTAAG 565
|
|
|
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyTrpLysGlnHisLeuSerTyArgLeuVal 140
|
|
|
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTCCCGCTCGTG 625
|
|
|
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
```


Db 626 AACTGGCCCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTTCGGCGCCCTTCCAG 685
Qy |||||
Db 160 rCysGlyAlaThrSerGlnArgTrpSerGlyArgProGlnProGlnAlaProLeuTh 180
|||
Db 686 TTGTGGAGCAAGCTCTCAGCGCTGAGATTCTGGAGGCCCGCCAGCCAGCGCCCGCTGAC 745
|||
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
|||
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGTGGCTGGCAATGCTTTGATGGC 805
|||
Qy 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
|||
Db 806 CCAGGGGGCGCCCTGGCGCACGCCCTTC-CTGGCCCGCGCGCGAGCGCACTTCGACCA 864
|||
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
|||
Db 865 AGATAGAGCGCTGGTCCCTGAGCGCGCGCGGGGCGCAACCTGTTGGTGTCTGGCGCA 924
|||
Qy 240 aGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProAlaLeuMetAlaPr 260
|||
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
|||
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
|||
Db 985 CTACTACAAGAGCGTGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGA 1044
|||
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
|||
Db 1045 GAGCCTGTATGGAGAGCCCTTAGGGGGCTCAGTGGCGCTGCTGAGTCCCGAGAAAGCTGT 1104
|||
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
|||
Db 1105 CACTGACCTTGAGACTGGGACTCTACAGCCCCCAAGAGGCGCCCTGAAACGCGAGG 1164
|||
Qy 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
|||
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCCTGTAGACGGCAACAGCAACTGTA 1224
|||
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
|||
Db 1225 CATTTTAAAGAGGAGCCATTTCTGGAGGTGCGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
|||
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIle 380
|||
Db 1285 TCCACTGCAGGAAAGATGGTTCGGCTGCCCGCCCAACATTGAGGTGCGGAGTGTCAAT 1344
|||
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
|||
Db 1345 GAATGATGGAGATTTCTACTCTTCCAAAGGGGGTCTGATGCTGAGGTTCCGGGGCCCCA 1404
|||
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
|||
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCGCCCGCCATCTCGACGC 1464
|||
Qy 420 aAlaLeuPhePheProProLeuArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
|||
Db 1465 CGCCCTCTTCTCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCCCGCTACTACT 1524
|||
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
|||
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGAGTCTGCGAGGACTGGGG 1584
|||
Qy 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIleIlePhePh 480
|||
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCGCTGCGGAGGCGCGATGGCTCCATCATCTTCTT 1644
|||
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
|||
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCGCAACTGCGAGGCAACCACTTCGGGCGG 1704
|||
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
|||

Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 189
US-10-140-021-143
; Sequence 143, Application US/10140021
; Publication No. US20030138886A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C167
; CURRENT APPLICATION NUMBER: US/10/140,021
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-021-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-140-021-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCTCGCGCGCTCGGCGCTCTCTGTCGCGCCCTGCGAGCTGCTACTGTGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCCAGCCCGGAGCGCGGAGGCGGAGGCTGCGCAAGAGGCGGAGGCATTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGAGTCCCAAGAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGCTACTGTTCAGCGCGCTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCCAGATGACTCTGTCGCCGTTCGGGGTTACAGATACCAACAGTTATCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
|||


```
QY      81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB      446 GCCACCCTCGCCGACAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGG 505
QY      101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrIysMetArgIys 120
DB      506 GCCTGGGCTGAGAGGATCAGTACATTGTTGTGTAGACACCGGACCAAAATGAGGGCTAAG 565
QY      121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
DB      566 AAACCGCTTTTGCAAGACAGGTAAACAATGGTACAGCAGCAGCTCTCTTACCGCCTGGTG 625
QY      141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB      626 AACTGGCTTGAGCATCTGCGGAGCGCGCAGTTGCGGAGCGCGTGGCGCGCGCTTCAG 685
QY      160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB      686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGAGGCGCCAGCCACAGCGCCCGCTGAC 745
QY      180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
DB      746 ATCCGCTCAGCTCTCTTCAAGGGGACCAACAGATGGGCTGGCAATGCCCTTTGATGGC 805
QY      200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB      806 CCAGGGGGCGCTGGCGCACCGCTTC-CTGCGCGCGCGCGCGGAGCGCAGCTTCGACCA 864
QY      220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB      865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGCGCAACCTGTTTCGTGGTGTGGCGCA 924
QY      240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB      925 CGAGATCGGTACACGCTTGGCTTCCACCGCTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY      260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB      985 CTACTACAGAGGCTGGCGCGGACGCGCTGTCTAGCTGGGACGAGCTGTGGCGCGTGA 1044
QY      280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB      1045 GAGCGCTGTATGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY      300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB      1105 CACTGACTTTGAGACTTGGACTTCTACAGCCCCCAAGGAAGGCGCGCTGAAACGACGGG 1164
QY      320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB      1165 CCCTAAATAGTCCACTCTTCTTCATGTCATCTGTAGNACAGCAACAGCTGTA 1224
QY      340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB      1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCG 1284
QY      360 gProLeuGlnArgTrpValGlyLeuProAsnIleGluAlaAlaValSerIe 380
DB      1285 TCCACTGAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
QY      380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
DB      1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
QY      400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB      1405 GCCAGTGGGGTCTCCACAGCTGTGCGGCGAGGGGCGCTGCGCGCCCATCTCTGACGC 1464
QY      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB      1465 GCCTCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGGCTTCTACGT 1524
```

```
QY      440 lIleAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB      1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCCGAACTCTGCAGGACTGGGG 1584
QY      460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB      1585 AGGCATCCCTGAGGAGGTGAGCGCGCTGCGAGGCGCGATGGCTCCATCATCTTCTT 1644
QY      480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB      1645 CCGAGATGACCGCTACTGGCGCTCGACGAGCCAACTGCAGGCAACCCACTCGGGCGG 1704
QY      500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB      1705 CTGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
QY      520 e 520
DB      1765 C 1765

RESULT 191
US-10-140-922-143
; Sequence 143, Application US/10140922
; Publication No. US2003013889A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C179
; CURRENT APPLICATION NUMBER: US/10/140,922
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-922-143

Alignment Scores:
Pred No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-140-922-143 (1-1985)
QY      1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB      206 ATGCTCGCGCGCTCGGCTCTCTGCTGGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
QY      21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
DB      266 GACGCCAGCGCGCGGAGCGCGGAGCTGGCGAGCTGGCGAAGGAGCGGCGGATTCCTA 325
```

QY 41 GluLysTyrGlyTyrLeuAsnGluInValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCATGACAGGTCCCAAAGCTCCACCTCCACATCGATTACGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGACGCTTTCAGTGGGTGTCACAGCTACCTGTCAGCGGGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCCAGATGACTGCTCCCGCTGCGGGTTACAGATACCAACAGATTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGCTGAGAGATCAGTGACTTGTGTGACACCGGACCAAAATGAGGCGTAAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGTAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCCCGAGCGGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnAlaProLeuTh 180
DB 686 TTGTGGACCAAGTCTCAGCGCTGAGTTCGTGGAGGGCCCCCAGCCAGGCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGCTCACCTTCTCAAGGGGACCAACAGATGGCTGGCAATGCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGGCACTGTTCGTGTGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTTGGCGCTCACCACTCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAGAGGCTGGGCGCGGCGCGCGCTCTCAGCTGGGACGCGTGGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCAGCGCCCAAGGAGCGCGCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATCTGCCACTCTCTCCATGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTCAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTCGCGCAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTTACTCTTCAAAGGGGTCGATGCTGGAGGTTCGGGGGCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420

DB 1405 GCCAGTGTGGGTCCTCCACAGCTGTCCGCGCAGGGGGCTGCCCCGCCATCTCCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCGCTACTACCCCGGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGCATCCCTGAGGAGTCAAGCGCGCTGCGAGCGCGCTGCGAGCGCGCTCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACAGCGGCAAACTGCAGGCAACCACTCGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAATCGGGGAGCGCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 192
US-10-145-631-143
; Sequence 143, Application US/10145631
; Publication No US20030138891A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C273
; CURRENT APPLICATION NUMBER: US/10/145, 631
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-631-143
Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-631-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20

i	ORGANISM: Homo Sapien				
US-10-158-783-143					
<hr/>					
Alignment Scores:					
Pred. No.:	3.35e-262	Length:	1985		
Score:	2792.00	Matches:	519		
Percent Similarity:	99.62%	Conservative:	0		
Best Local Similarity:	99.62%	Mismatches:	1		
Query Match:	98.52%	Indels:	2		
DB:	16	Gaps:	0		
<hr/>					
US-10-791-980-6 (1-520) x US-10-158-783-143 (1-1985)					
Qy	1	MetValAlaArgValGlyLeuLeuLeuAraAlaLeuGlnLeuLeuTyrGlyHisLeu	20		
Dd	206	ATGGTCGGCGCGCTCCTGCTGGCGCCCTGCAGCTGCCTACTGTGGGGCACCTG	265		
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu	40		
Dd	266	GACGCCAGCCCGGAGCGGAGCCAGAGCTGGCGCAGGAGGCGGAGGCATTCTCTA	325		
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60		
Dd	326	GAGAAGTACGATACCTCAATGAACAGTGCCCCAAAGCTCCACCTCCACTCGATTCA	385		
Qy	61	AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg	80		
Dd	386	GATGCCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTGCAGCGCGTGTGGAC	445		
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyxAla	100		
Dd	446	GCCACCCTGCGCAGATGACTCGTCCCGCTCGGGGTTCAGATATCCAACAGTTATGCG	505		
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120		
Dd	506	GCCTGGCTCAGAGGATCAGTAGCTGTGTTGCTAGACACCGACCAAAATGAGCGTA	565		
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140		
Dd	566	AACAGCTTTGCCAAGCAAGGTAAACAATGGTTACAAGCAGCACCTCTCTTACCGCT	625		
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyValaProCysAlaProProSerSe	160		
Dd	626	AATGGCTCAGCANCTTCGGAGCCCGCAGTTCGGGGCGCGCTGCGCGCGCTTCAG	685		
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuth	180		
Dd	686	TTCGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGGAGGCGCCGAGCCACAGGCCC	745		
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200		
Dd	746	ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGGCATGGCTTTGATGG	805		
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220		
Dd	806	CCAGGGGGCGCCTGGCGCACGCTTC-CTGCCCGCGCGGAGAGGCGACTTCGACCA	864		
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240		
Dd	865	AGATGAGCGTGTGTCCCTGAGCGCCCGCGCGGCGCAAACCTGTTCTGTGTGTGGG	924		
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260		
Dd	925	CSAGATCGGTACACGCTTGCGCTTCACCCACTTCGCCCGCGCGCGCTCATGGCGCC	984		
Qy	260	tTyrtYrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280		
Dd	985	CTACTCAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCGT	1044		
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300		
Dd	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGAACGCTGTT	1104		


```
; CURRENT APPLICATION NUMBER: US/10/140,274
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-274-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 99.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-140-274-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGCGCGCGTCTGCGCTCTGCGCGCGCTGCGAGCTGCTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGlyAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGGAGCGGAGCGGAGAGCTGCGCAAGGAGGCGGAGGCAATTCCTA 325
Qy 41 GluIstYrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCATCGATCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGGTTCCTGAGTGGGTGTCAGAGCTTACCTGTGAGCGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTGTCCTCCCGCTGCGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTTCTAGACACCGGACCAAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGGAGTTTCGGGGCGCGTTCGGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGAGTTCTGGGAGGCGCCAGCCAGCGCGCGCTTCAG 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAAATGCGGCTGGGCAATGCGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTTGGGGCAGCGCTTC-CTGCCCGCGCGGCGGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTGTGTGCTGGCGCA 924
Qy 240 sGluIleGlyHisThrIleuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCGCTACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
```

```
Db 985 CTACTACAAGAGCTGGCGCGCGCTGCTCAGCTGGGACGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCAGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGCGCGCTGAAACGCGAGG 1164
Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGGAAAGATGGGTGCGGCTGCCCGCCCAACATTTGAGGCTCGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCCTCCACAGCTGTGCCGGCAGGGGGGCTGCCCGGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCTCTCTCTGCGCGCTCATCTCTTCAAAGGGTGCCTGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGGCCGAGGGGAGTGAAGTGGAGCCCTACTACCCCGGAGTCTGCAGGAGTGGGG 1584
Qy 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGCATCCCTGAGAGGTGAGCGCGCTGAGCGCGCTGCCAGCGCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGAGATGACCGTACTTGGCGCTCGACACGAGGCAAACTGCAGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 196
US-10-140-019-143
; Sequence 143, Application US/10140019
; Publication No. US20030148423A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Sherwood, Steven L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
```

```
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC170
; CURRENT APPLICATION NUMBER: US/10/140,019
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - see file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-140-019-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-140-019-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGAGCGCGGAGCCAGAGCTGCCAAGGAGCGGAGGCGCATTCCTA 325

Qy 41 GluLysTrpGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCCACTCGATTACG 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGCTTCAGTGGGTGTCCAGCTACCTGTGAGCGGCGTGTGGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCACAGTACTCTCCCGCTGCGGGGTACAGATACCAACAGTTATCGG 505

Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGACCAAAATGAGGCGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGACCTCTCTCCCGCGCTGGT 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCGCGAGGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCGTGGAGGCGCCAGCCACAGGCGCCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGAGCCACCAACAGTGGGCTGGGCAATGCCCTTTGATGGC 805

Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGGCTGCGGCGACGCTTC-CTGCCCCCGCGCGGAGGCGACTTCGACCA 864

Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
```

```
Db 865 AGATGAGCGCTGGTCCCTGTAGCCCGCGCGGGCGCAACCTGTGTGGTGTGGCGCCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrClyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAGGAAGGCGCCCTGAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTTAATATCTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCGAGGAAGATGGGTGGGCTGCCCGCCCAACATTTAGGCTGGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTTCTTCAAAGGGGTGATGCTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrpClyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTCGGGCGAGGGGCTGCCCGCCCATCTCGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyLysArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyLeuProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTACAGCGCGCTTCCCGAGGCGCCGATGGCTCCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTTCCAGCGCCAACTGCAGGCAACCACTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGTCATGTGCCAACTCGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 197
US-10-140-022-143
; Sequence 143, Application US/10140022
; Publication No. US20030148424A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
```



```
Db      1645  CCGAGATGACCCGCTACTGGCGCTCGACACAGGCCAAACTGCAGGCAACACACCTCGGGCGG 1704
Qy      500  gTTPAlaThrGluLeuProTTPMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db      1705  CTGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGAGGCCCTGTT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 200
US-10-141-697-143
; Sequence 143, Application US/10141697
; Publication No. US20030148427A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Bersini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC202
; CURRENT APPLICATION NUMBER: US/10/141,697
; CURRENT FILING DATE: 2002-05-08
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-141-697-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-141-697-143 (1-1985)

Qy      1  MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db      206  ATGGTCGGCGCGGTGGGCTCTGCTGCGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
Qy      21  AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgGlyGluAlaGluAlaPheLeu 40
Db      266  GACGCCACGCCCGGAGCGCGAGGCGAGGCTGCGCAAGGAGGCGGAGGCGCATTCCTA 325
Qy      41  GluIysTyrGlyTyrLeuAsnGluGlnValProIysAlaProThrSerThrArgPheSer 60
Db      326  GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACATCGATTACAG 385
Qy      61  AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386  GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGACGGCGGTGTGGACCGC 445
Qy      81  AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db      1525  GCTGGCCCGAGGGGAGCTGCAAGTGGAGGCTACTACCCCGGAAGTCTGTCAGGAGCTGGG 1584
```

```
Db      446  GCCACCCCTGCGCAGATGACTCGTCCCGCTCGGGGTTACAGATACCAACACATTATGGC 505
Qy      101  AlaTTPAlaGluAtrqIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506  GCCTGGGCTGAGAGATCAGTGACTTTGTTGTACACACCGGACCAAAATGAGGGCGTAAG 565
Qy      121  LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566  AAACGCTTTGCAAGCAAGGTAACAAATGGTACAGCAGCACCTCTCTACCGCCTGGTG 625
Qy      141  AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626  AACTGGCCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy      160  rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686  TTGTGGAGCAACGCTCTAGCGCTGGAGTTCGTGGAGGCGCCACGACAGGCCCTCTGAC 745
Qy      180  rSerGlySerProSerSerLysGlyThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db      746  ATCCGGCTCACCTTCTTCCNAGGGGACCAACAGATGGCTGGGCAATGCTTTCATGGC 805
Qy      200  aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db      806  CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGGAGCGCACTTCGACCA 864
Qy      220  nAspGluArgTTPSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db      865  AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGGTGGCTGGCGCA 924
Qy      240  sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925  CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy      260  oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaVal 280
Db      985  CTACTACAAGAGGCTGGGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044
Qy      280  nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
Qy      300  eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db      1105  CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCNAGGAGGCGCCCTGAAACGACGG 1164
Qy      320  yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCCTAAATACTGCGCACTCTTCTCGATGCCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGGGAGCCATTTCTGGGAGGTGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy      360  gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTACGAGAAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTGGGCGAGTGTCAAT 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345  GAATGATGGAGATTTCTACTTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCTGGGGCCCA 1404
Qy      400  sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCGCTGCCCGCCCATCTCTGACGC 1464
Qy      420  aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db      1465  CGCCTCTTTCTTCCCTCTCTGCGCGCCCTCATCTCTTTCNAGGGTGGCGCCCTACTAGT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPGl 460
Db      1525  GCTGGCCCGAGGGGAGCTGCAAGTGGAGGCTACTACCCCGGAAGTCTGTCAGGAGCTGGG 1584
```

```
Qy 460 yGlvleProGluValSerGlyAlaLeuProArgProAspGlySerllellePhePh 480
Db 1585 AGGCATCCCTAGAGAGTACAGCGCGCCCTCCCGAGGCCGATGCTCCATCATCTTCTT 1644

Qy 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCCTCGACCGCCCAACTGCGAGCAACCCCTCGGCGCG 1704

Qy 500 gTtpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAlaSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACAGAGCTGCCCTGGATGGCTGTGGCATGATGCCAATCTCGGGAGCGCCCTGT 1764

Qy 520 e 520
Db 1765 C 1765

RESULT 201
US-10-141-700-143
; Sequence 143, Application US/10141700
; Publication No. US20030148428A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C205
; CURRENT APPLICATION NUMBER: US/10/141,700
; CURRENT FILING DATE: 2002-05-08
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-141-700-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-141-700-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGACAGTGTACTTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACCGCGGAGCGCGGAGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCTCTA 325

Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTGCCCAAGCTCCACCTCCATTCGATTTCAGC 385
```

```
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTACGCGCGTGTGGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505

Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTCAGAGGATCAGTACTTGTGTTGTAGACACCGGACCAAAATGAGCGCTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAATGGTACAAGCAGCACCTCTCTACCGCTCGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGCAGTTTCGGGGCGCGTGGCGCGCTTCCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCGCAGCACAGGCCCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCTCTTTCGAAGGGGACCACAAGATGGGTGGCAATGCTTGTATGTCG 805

Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGGAGCGCACCTTCGACCA 864

Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCTGAGCGCGCGCGGCGCACTGTTCGTGTGTGTGGCGCA 924

Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTTCACAGCTTGGCTCACCACTGCCCGCGCGCGCGCTCATGGCGCC 984

Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044

Qy 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCTGNAACGCGAGG 1164

Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCGCACTCTTCTCGATGCGCATCCTGTAGACAGGCAACAGCAACTGTA 1224

Qy 340 rLlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCC 1284

Qy 360 qProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAGAAAGATGGGTGGGCTGCCCGCCCAACATTCAGGCTGGCGCAGTGTCA 1344

Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGGTTCGATGTGTGGAGGTTCCGGGGCCCAA 1404

Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGCTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCCGCCATCTCTGACGC 1464
```


Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheIysGlyAlaArgTyrTyrVa	440
Db	1465	GCCCCTCTTCTTCCCTCTCTGCGCCGCTCATCTCTCAAGGGTGC	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGCTG	1584
Qy	460	yGlylProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGGATCCCTGAGAGGCTACGGGGCCCTGCCGAGGCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGGGGCCCTCGACAGCCAACTGCAGGCAACCACTCGGCGCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT	1764
Qy	520	a 520	
Db	1765	C 1765	

```

RESULT 202
US-10-141-705-143
; Sequence 143, Application US/10141705
; Publication No. US20030148429A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: E330R1C201
; CURRENT APPLICATION NUMBER: US/10/141.705
; CURRENT FILING DATE: 2002-05-08
; Prior Application removed - See file wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-141-705-143

```

Alignment Scores:			
Pred. No.:	3,35e-262	Length:	1985
Score:	2792.00	Matches:	519
Percent Similarity:	99.62%	Conservative:	0
Best Local Similarity:	99.62%	Mismatches:	1
Query Match:	99.52%	Indels:	2
DB:	16	Gaps:	0
US-10-791-980-6 (1-520) x US-10-141-705-143 (1-1985)			
Qy	1	MctValAlaArgValGlyLeuLeuLeuAraGAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGGCGCGCTCGGCCCTCTGCTCGCGGCCCTGCAGCTGCTACTGTGGGGCCACCTG	265

Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCCAGCCCGCGAGCGCGAGAGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCCTA	325
Qy	41	GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer	60
Db	326	GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGTCCCACTCCACTCGATTACG	385
Qy	61	AspAlaIleArgAlaPheGlnTTrpValSerGlnLeuProValSerGlyValLeuAspArg	80
Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGCCAGCTACTCTGTCAGCGCGGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCCTGGGCCAGATACACTCGTCCCGCTGCGGGGTTCAGATATCCAACTATATCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTTGGGCTCAGAGGATCAGTGACTTGTGTGCTAGACACCGGACCAAAATGAGGCGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	ANACGCTTTCGAAAGCAAGGTACAAATGGTACAAAGCAGCACTCTCTCTACCGCGCTGGT	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProSerSe	160
Db	626	AACTGGGCTCAGCATCTGCCGAGCGCGAGTTCGGGGCGCGGTGCGCGCGCTTCAG	685
Qy	160	rCysGlyAlaThrSerClnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGCTCTCAGCGCTGGAGTCTCTGGAGGCCCGCAGCCAGGCCCGCTGC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCGGCTCACCTTCTTCCAAAGGGGACCAACGATGGGTGGGCANTGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCCCTGGCGCACGCGCTTC-CTGCGCCGCGCGCGGGAAGCGCACATTCGACCA	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATGACGCTGTGTCTGAGCGCGCCGCGGGCGCAACTGTGTGTGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGGTACACGGTTGGCTTCACCCACTTGCCTCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGGCGCGCAGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA	1044
Qy	280	nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCGTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CATGACTTTGACACTGGGACTCTTACAGCCCCCAAGGAAGGGCCCTGAAACGCAAGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACCTGCCACTCTTCTTCGATGCCATCCTGTAGACAGGCAACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAAGGGAGGCATTTCTTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGAATGGTCTGGGCTGCCCCCAACATTGAGCTCGCGAGTGTCATT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysGlyArgCysTrpArgPheArgGlyProLy	400

```

Db 1345 GAATGATGAGATTCTACTTCTTCAAGGGGGTGCATGCTGGAGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCGCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLeuPheLeuArgVa 440
Db 1465 GCCTCTTCTTCTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGCCTCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGAGGACTGGG 1584
Qy 460 yGlyLeuProGlnGluValSerGlyAlaLeuProArgProAspGlySerLeuPhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaValSerGlyLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACAGGCCAAACTGCGAGCAACCTCTCGGGCCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaValSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGTCGCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

```

RESULT 203

```

US-10-141-753-143
; Sequence 143, Application US/10141753
; Publication No. US20030148430A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C193
; CURRENT APPLICATION NUMBER: US/10/141,753
; CURRENT FILING DATE: 2002-05-08
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-141-753-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservatives: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

```

```

US-10-791-980-6 (1-520) x US-10-141-753-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCCGGCGGTGCGGCTCTCTGCTGCGGCCCTGCAGCTGCTACTGTGGGGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCCAGCCGCGAGCGCGAGGCGAGGCTGGCGAAGGAGGCGGAGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACCGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTGAGC 385
Qy 61 AspAlaLeuArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTACGGCGGTGTTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCGCCAGATGACTCGTCCCGCTGGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTGGGCTGAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGTTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGCGAGCGGCGAGTTGCGGGCGCCGCTGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTCTTGGAGGCCCCAGCCAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACATGGGTGGGCAATGCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTTGGCGCACCGCTTC-CTGCCCGCGCGGGAAGCGACCTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCTCCCTGAGCCCGCGCGCGGCGCAACTGTTCTGTGTGTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTGCACACGCTTGGCTCACCCACTCGCGCGCGCGCGCTCATGCGGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTCAAGAGGCTGGGGCGCGACGCGTGTCTGAGCTGGGAGCGAGCTGTGCGCGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCGCACTCTTCTTCTGATGCTACCTGTAGACAGGCAACGCAACTGTA 1224
Qy 340 rLlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360

```

```
Db 1225 CATTCTTAAAGGAGCCATTTCTGGGAGGTGGCAGCTGATGCAACGTCCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTyrValGlyLeuProAenilleGluAlaAalaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCCCAACATTGAGGTGGCGAGTGTCAAT 1344
QY 380 uAenAepGlyAaspPheTyrPhePheLysGlyArgCysTyrArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAaspAl 420
Db 1405 GCAGGTGGGGTCTCCCAAGCTGTGGCGGCGAGGGGCCCTGCCCGCCATCTCGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGGCGCCCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAaspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
QY 460 yClylleProGluGluValSerGlyAlaLeuProArgProAaspGlySerIlelePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCCCTGCGGAGGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAaspArgTyrTyrTrpArgLeuAaspGlnAlaLysLeuGlnAlaThrThrSerGlyVa 500
Db 1645 CCGAGATGACCCCTACTGTGGCTCTGACCGGCCAACTGCAAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAenSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCCAGAGTGCCTGGATGGGCTGCTGGCATGCCAATCGGGAGGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 204
US-10-141-758-143
; Sequence 143, Application US/10141758
; Publication NO. US20030148431A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C194
; CURRENT APPLICATION NUMBER: US/10/141,758
; CURRENT FILING DATE: 2002-05-08
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-141-758-143
```

Alignment Scores:

```
Pred. No.: 3,356-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-141-758-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGCTGCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGCGAGCGCGGAGCGTGGCAAGGAGGCGGAGGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCACTCCACTCGATTCCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
Db 386 GATGCCATCAGAGCGCTTTTCAGTGGGTGTCCAGACTACCTGTGAGCGGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCAGTACCTGCTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGTTACAAAGCAGCACCTCTCTACCGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTCCCGAGCGCGCAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGACCAACGCTCTCAGCGCTGGAGTTCCTGGAGGCGCCCGAGCCACAGGCCCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCCAAAGGGGACCAACGATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCCCGCGCGCGGCGGCGCTCATGGCGCC 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGCTGCTGGCGCA 924
QY 240 sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAACCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGGCGCGCTGAAACGAGGG 1164
```

```
Qy 320 yProLysTyrCyHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGCACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGTGTGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCGCCCAACATTGAGGCTGGCGAGTGTCAATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATCGAGATTCTACTTCTTCNAAGGGGTGCATGCTGGAGGTTCCGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGTGTGCGGGCAGGGGCTGCCCCGCCATCTGTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 CGCCCTCTTCTTCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGTGCAGTGGAGCCCTACTACCCCCAAGTCTGCGAGGACTGGGG 1584
Qy 460 yGlyLeProGluGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTGACGGCGCTGCCGAGGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTTGGCGCTCGACACAGGCCAAATGACAGCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGTGCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 205
US-10-142-418-143
; Sequence 143, Application US/10142418
; Publication No. US20030148433A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330P1C247
; CURRENT APPLICATION NUMBER: US/10/142,418
; CURRENT FILING DATE: 2002-05-10
; Prior Apploication removed - See File Wrapper or Palm
```

```
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-418-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
```

```
US-10-791-980-6 (1-520) x US-10-142-418-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGCTCGCGCGCTCGGCCTCTCTGCTGCGGCCCTGCTACTGTGCGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCCAGCCGCGAGCGCGAGGCGCAGGAGCTGCGCAAGGAGGCGGAGGCAATTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGATACCTCAATGAACAGGTCCCCAAGCTCCACCTCCACTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTCTCCAGCTACCTGTGACGGCGGTGTTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCGCAGATGACTCGTCCCGCTGCGGGGTTTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAANTGAGCGGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAATGGTTACAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGCGAGTTTGGGGCGCGCGTCCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGAGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgTrpPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGTGTGCTCCCTGAGCGCGCGCGGGGGGCAACTGTGCTGTGCTGGGGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGAGCGGCTGCTCAGCTGGGACGACGTGTGCGCGGTGCA 1044
```

```
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
|
|
|
Db 1045 GAGCCTGTATGGAGACCCCTAGGGGCTCAGTGGCGCTCCAGTCCAGGAAGCTGTT 1104
|
|
|
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG 320
|
|
|
Db 1105 CACTGACTTTGAGACTGGGACTCTTACAGCCCCCAAGGAAGCGCCCTGAAACGAGGG 1164
|
|
|
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
|
|
|
Db 1165 CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTAGACAGCAACAGCACTGTA 1224
|
|
|
QY 340 rIlePheLysGlySerHisPheThrProGluValAlaAlaAspGlyAsnValSerGluProAr 360
|
|
|
Db 1225 CATTTTTAAAGGAGGACATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
|
|
|
QY 360 sProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
|
|
|
Db 1285 TCACCTGCGAGGAAGATGGTGGGCTGCCCCCAACATTGAGGCTGCCGCGAGTGTCAAT 1344
|
|
|
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
|
|
|
Db 1345 GAATGATGGAGATTCTACTCTTCAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
|
|
|
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
|
|
|
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGCTGCCCGGCCATCTCTGACGC 1464
|
|
|
QY 420 alaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrzVa 440
|
|
|
Db 1465 CCGCCTCTTCTTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
|
|
|
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG 460
|
|
|
Db 1525 GTGGCCCGAGGGGAGCTCAAGTGGAGCCCTACTACCCCGAGTGTGCAGACTGGGG 1584
|
|
|
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
|
|
|
Db 1585 AGGCATCCCTGAGGAGTCAAGCGGCGCTGCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
|
|
|
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
|
|
|
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAAACTGCAGGCAACACCCCTCGGGCG 1704
|
|
|
QY 500 qTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
|
|
|
Db 1705 CTGGGCCACCGAGTGCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
|
|
|
QY 520 e 520
|
|
|
Db 1765 C 1765

RESULT 206
US-10-142-420-143
; Sequence 143, Application US/10142420
; Publication No. US20030148434A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
```

```
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C235
; CURRENT APPLICATION NUMBER: US/10/142,420
; CURRENT FILING DATE: 2002-05-09
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-142-420-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-420-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
|
|
|
Db 206 ATGTGCGCGCGCTCGGCTCTCTGCTGCGGCGCTGAGCTGCTACTGTGGGGCCACCTG 265
|
|
|
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
|
|
|
Db 266 GACGCCACCGCGCGAGCGCGAGGCTGCGCAAGGAGCGGAGGCGGAGCATTCCTTA 325
|
|
|
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
|
|
|
Db 326 GAGAGTACAGATACCTCAATGAACAGGTCCCAAGTCCCACTCCACTCGATTCAGC 385
|
|
|
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
|
|
|
Db 386 GATGCCATCAGAGCGCTTTCAGTGGGTGTCACAGTACCTGTGAGCGGCGTGTGGACCG 445
|
|
|
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
|
|
|
Db 446 GCCACCTGCGCGCAGATGACTGCTCCCGCTGCGGGGTACAGATACCAACATGATGCG 505
|
|
|
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
|
|
|
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTGCTAGACCGGACCAAAATGAGGGCGTAAG 565
|
|
|
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
|
|
|
Db 566 AAACGCTTTCNAAGCAAGGTAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
|
|
|
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
|
|
|
Db 626 AACTGGCTGAGCATCTCCCGAGCGCGAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
|
|
|
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
|
|
|
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGGAGGCCCCAGCCAGGCCCGCTGAC 745
|
|
|
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetal 200
|
|
|
Db 746 ATCCGGCTCACCTTCTCCNAGGGGACCAACAGATGGGCTGGGCAATGCTTGTATGGC 805
|
|
|
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
|
|
|
Db 806 CCAGGGGCGCCCTGGCGCAGCCCTTC-CTGCGCCCGCGCGGCGAAGCGCACTTCGACCA 864
|
|
|
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlnArgGlnLeuPheValValLeuAlaHi 240
|
|
|
Db 865 AGATGAGCGCTGGTCCCTCGAGCCCGCGCGGCGCAACCTGTGTGGTGGCTGGCGCA 924
|
|
|
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalApr 260
```

Db 925 CGAGATCGGTACAGCTTGGCTTCCACCATTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrlsArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGCGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrlsGlyProLeuGlyGlySerValAlaValAlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrlsProGlnGlyArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGACGCCCCNAGAGGGCCCTGAAACGCGAGG 1164
Qy 320 yProLysTyrlsCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCAGTGTAGACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGANAGATGGGTGGGCTGCCGCCCAACATTCAGGCTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrlsPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTCTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGGCAAGGGGCTGCCGCCCAATCTGACGC 1464
Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrlsVa 440
Db 1465 CGCCCTCTTCTTCTTCTTCTGGCGCGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrlsTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCCCTACTATCCCCCGAAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTGAGCGGCGCTTCCGAGGCCCATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspArgTyrlsTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCGGCCAACTGCAGGCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCCAGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 c 1765

RESULT 207

US-10-142-422-143
; Sequence 143, Application US/10142422
; Publication No. US20030148435A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P330R1C226
; CURRENT APPLICATION NUMBER: US/10/142,422
; PRIOR APPLICATION DATE: 2002-05-09
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-422-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-422-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGGTTCGGCTTCTTCTGCGCGCCCTGCGAGCTGTACTGTGGGGCCACTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGGAGCGCGGAGCGCAGAGCTGCGCAAGGAGCGGAGGCATTCTTA 325
Qy 41 GluLysTyrlsTyrlsLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACCGATACCTCAATGAACAGGTCTCCCAAGCTCCCACTCCACCTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTCTCCAGACTACTCTCAGCGGCGTGTGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrlsAla 100
Db 446 GCCACCTGCGCCAGATGACTCGTCCCGCTTGGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTCAGAGGATCAGTGACTTGTGTGTAGACACCGGACCAAAATGAGCGGTAA 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrlsGlnHisLysSerTyrlsArgLeuVal 140
Db 566 AAAGCTTTGCNAAGCAAGGTACAAATGGTACAGCAGCACCTCTCTCCACCGCTTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTTTCGGGGCGCGTGTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGAGTTCCTGGAGAGCCCCCAGCAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCAACAGATGGGCTGGGCAATGCTTTTGTATGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220

Db 806 CCAGGGGGCCCTGGCGACGCCCTTC-CTGCCCGCGCGCGAAGCGCACTTCGACCA 864
Qy 220 nAepGluArgTTPSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATAGGGCTGGTCCCTGAGCGCGCGCGGGGCAACCTTGTGTGGTGTGGCGCA 924
Qy 240 eGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTGGCGCTCACCCACTCGCGCGCGCGCGCTCATGCGGCC 984
Qy 260 oTyTyRlyArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGCTGGCGGTGA 1044
Qy 280 nSerLeuTyRlyGlyLeuProLeuGlyGlySerValAlaValGlnLeuProGlyLeuLeuPh 300
Db 1045 GAGCTGTATGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyRserProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCGCCCAAGGAGCGCCCTGAAACGACGG 1164
Qy 320 yProLysTyRysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaPheGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGACGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyRlePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAAGGGGTGATGCTGGAGGTTCCGGGGCCCA 1404
Qy 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTCCGGGAGGGGGCTGCCCGCCCATCTCTGAGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyRTrVa 440
Db 1465 CGCCCTCTTCTCTCTCTGCGCGCTCATCTCTTCAAGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyRTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTGAGCGCGCGCTGCCGAGGCGCCATGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyRTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACACGGCCAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaLeuSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 208

US-10-142-427-143

; Sequence 143, Application US/10142427

; Publication No. US20030148436A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C231
; CURRENT APPLICATION NUMBER: US/10/142.427
; CURRENT FILING DATE: 2002-05-09
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-427-143

Alignment Scores:
Pred. No.: 3.35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-427-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db. 206 ATGTCTCGCGCGCTCGCGCTCTCTCGCGCGCTCTGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGCGCGGAGCGCGGAGCGCTGCCAAGGAGCGGAGGCGGAGGCGCATTCCTA 325
Qy 41 GluLysTyRlyTyRLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAATACGGATACCTCAATGAACAGGTGCCCAAAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyRAla 100
Db 446 GCCACCTTGGCCAGATGACTCTGTCGCCGTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyRlySerGlnHisLeuSerTyRArgLeuVal 140
Db 566 AAACGCTTTCGAAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTCCGCGCTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGGAGCTTCCGGGGCGCGCTGCGCGCGCTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGGCTTCTGGGAGGCGCCCGCAGCCACAGGCGCGCTGAC 745

QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCTTCAGAGGACCAACAAGATGGCTGGCAATGCCCTTTGATGGC 805
QY 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCCCTGGCGCACGCCCTTC-CTGCCCGCGCGCGGGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTTPSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTGTTGGTGGTGGCGCA 924
QY 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTGGCTCACCACCTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGCGCGCGACGCGCTGCTCAGCTGGGACGAGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTCGGACTCTCAGACCCCAAGAGGCGCCCTGAAACGCGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCGCATCACTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTCGAGNAAGATGGTGGCTGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTTPArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGTGATGCTGGAGTTCCGGGGCCCCAA 1404
QY 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGTCTCCACAGCTGTGCCGGGCAAGGGGCGCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
DB 1525 GCTGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTGACGGCGCCCTGCCAGGGCCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACCGCCCAACTGACGCAACCCACTCTCGGGCGG 1704
QY 500 gTTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGTGGCATGCCCACTCGGGAGCGGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 209

US-10-142-760-143
; Sequence 143, Application US/10142760
; Publication No. US20030148437A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C239
; CURRENT APPLICATION NUMBER: US/10/142,760
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-760-143
Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-142-760-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTTPGlyHisLeu 20
DB 206 ATGGTCGCGCGCTCGGCGCTCTCTGCTGCGCGCGCTGCAGCTGTACTGTGGGGCCACTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCGAGCCCGGAGCGCGAGGCTGCGAAGGAGGCGGAGGAGGCGGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCACCTCCACTCGATTCCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACTGTACGGCGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGGCGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACTGTTGCTTAGACACCGGACCAAAATGAGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTTPTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAAAGCAAGGTAAACNAATGGTACAAAGCAGCACCTCTCCTACCGCGCTGGT 625

QY 141 AenTrrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCCTGAGCATCTGCCGAGCGCGCAGTTCCGGGGCGCGTGGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAAGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCCTTCTTCAGAGGGACCAACAGATGGCTGGGCATGTCCTTTGATGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGCGAGGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTGTGGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTACACGCTGGGCTCACCCACTGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGGCGCGAGCGCGCTGCTCAGCTGGGACGACGTCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTCAGCCCCCAAGAGCGCCCTGAAACCGACGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCATCTGTAGACGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCG 1284
QY 360 pProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTTACTTCTTCAAGGGGGTGGATGCTGGAGTTCCGGGGCCCAA 1404
QY 400 aProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGCGCAGGGGGCGCTGCCCGCCCATCTCAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyVa 440
DB 1465 GCCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
DB 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAGTCTGCGAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTGAGCGGCGCCCTGCCGAGGGCCGATGGCTCCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTGGCGCTCGACAGCCCAACTGAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520

DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
RESULT 210
US-10-145-821-143
; Sequence 143, Application US/10145821
; Publication No. US20030148438A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C286
; CURRENT APPLICATION NUMBER: US/10/145,821
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-821-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-821-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGGCGCGTCGGCCCTCCTGCTCGCGCCCTGCTGAGCTGCTACTGTGGGGCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCCCGAGCCCGCGGAGCGCGGAGCGCAGAGCTGCGAAGGAGCGGCGGAGGCGCATTCCTA 325
QY 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAGTACGGATACCTCAATGAACAGTCCCCAAAGCTCCACCTCCACTCGATTCCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTTCAGTGGGTCTCCAGCTACTGTCCAGCGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGGGGGTTCAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120

```
Db 506 GCGTGGCTGAGAGTACGTGTTGTTGCTAGACACCGGACCAAAATGAGGGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLysSerTrpArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGTTACAAAGCAGCACCTCTCTCAACGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGTGGCGCGCTTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGAGCAACGCTCTACGCGTGGAGTTCGGAGGCGCCACGACACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGCTCACCTTCTTCAAGGGGACCAACGATGGGCTGGGCAATGCTTTCATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCTGGCGACGCTTC-CTGCCCCCGCGCGGCGCAACTGTTCTGGTGTCTGGCGCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACTGTTCTGGTGTCTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTTCCACCTCCACCACTCGCGCGCGCGCTCATGGCGCC 984
Qy 260 cTrpTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGCGCGGCGCGCTGCTCAGCTGGGACGACGTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGGTCTAGTGGCGGTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGGCGCTGAAACGCGAGG 1164
Qy 320 yProLysTrpCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAAATACTGCCACTTCTCTCGATGCCATCACTGTAGACAGGCACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTCGGCGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTTCTTCAAGGGGTGATGTGTGGAGGTTCGGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCCGGCAGGGGGCGCTGCCCGCCATCTCAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpYrVa 440
Db 1465 CGCCTCTTCTTCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTrpTrpTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCGAGGGGAGTGCAGTGGAGCTTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIlePhePh 480
```

```
Db 1585 AGGCATCCCTCAGGAGGTACAGCGGCGCTCCGAGGCCGATGGCTCCATCTTCTT 1644
Qy 480 eArgAspAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGGCGCTTCGACCGCCAAACTGCAGGCAACCACTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTCTGTGCAATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 211
US-10-152-531-143
; Sequence 143, Application US/10152531
; Publication No. US20030148439A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P330R1C378
; CURRENT APPLICATION NUMBER: US/10/152,531
; CURRENT FILING DATE: 2002-05-20
; Prior Application removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-152-531-143

Alignment Scores:
Pred. No.: 3 35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 16 Gaps: 0

US-10-791-980-6 (1-520) x US-10-152-531-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCGCCAGCCCGCGAGCGCGGAGCCAGGAGCTGCGCAAGGAGCGGAGGCAATTCCTA 325
Qy 41 GluLysTrpGlyTrpLeuAsnGluValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATCTCAATGACAGGTCCCCAAGCTCCCACTCCATTCGATTGAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
```

Db 386 GATGCCATCAGACGCTTTTCAGTGGGTGTCCTGCTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCGCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTCGGCTGAGAGGATCAGTGACTGTTGTGTAGACACCGGACCAAAATGAGCGGTAA 565
Qy 121 LysArgPheAlaLysGlnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACTGTTCAAGCAGCAGCTCTCCCTACCGCTGTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGGCGAGTTCGGGGCGCGTTCGGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGAGGCGCCAGCCAGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCGGCTCACCTTCTTCCAGGGGACCAACAGATGGGCTGGGCAATGCCCTTTGATGCG 805
Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CAGGGGGCGGCTCGGCGACCCCTTC-CTGCCCCCGCGCGGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGCTGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCACCCACTCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGACGCCCAAGGAGCGCGCTGAAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerPheAspAlaThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTTCCTTCGATGCCATCACTGTAGACGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCACAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAAAGATGGTGGGCTGCGCGCCCAACATTGAGGTGGCGGAGTGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTTCCACAGCTGTGCGGGCAGGGGCGCTGCCCCGCCATCTCAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCGCGCTACTACGT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 CTTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGCTTCGACGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTCAGGAGGTGAGCGGCGCTGCGAGGCGCGATGGCTCCATCATCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATACCGCTACTGCGCGCTCGACGCGCAAACTGACGGCAACACCCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACCGAGCTGCCCTGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 212
US-10-127-840A-143
; Sequence 143, Application US/10127840A
; Publication No. US2003015303A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C114
; CURRENT APPLICATION NUMBER: US/10/127,840A
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA

; CURRENT APPLICATION NUMBER: US/10/142,424
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-424-143

Alignment Scores:
Pred. No.: 3,356-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-424-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
Db 206 ATGGTCGGCGGCTGGCCCTCTCTGTCGGCGCCCTCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCCAGCCGCGGAGCGCGGAGCCAGAGCTGCGCAAGGAGCGCGGAGGCATTCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCCAAGCTCCACCTCCATCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTCAGTGGGTGTCCTGAGCTACCTGTGAGCGGCTGTGTGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTGCTCCCGCTGCGGGGTTACAGATACCAACAGATTATGG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTGTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCNAAAGGTAACAAATGGTACAAAGCAGCACCTCTCTACCGCCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGCAGTTTCGGGGCGCGTTCGCGCGCCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCTGGAGGCGCCAGCCACAGGCGCCCGCTCAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGAGCCACACAGATGGGCTGGGCAATGCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCCCGCGCGGAGCGCATTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTGCTGGTGGTGGCGCA 924
Qy 240 sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGGCTTCCACCTCTCGCCCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280

Db 985 CTACTACAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGACGCTGCGCGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCNAGNAGGCCCTTGAACCGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGGTGGGCTGCGGCTGCCCCCAACATTGAGGCTGGCGCAGTCTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTTCTCAAAGGGGTGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCTCTTCTTCTCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyLeuProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGAGGTCAGCGCGCCCTGCCAGGCCGATGGCTCCATCTCTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCCTCGACCGCCAACTGCAGGCAACACCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpPheIleAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGTGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 214

US-10-142-761-143
; Sequence 143, Application US/10142761
; Publication No. US20030157601A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.


```
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: F3330R1C243
; CURRENT APPLICATION NUMBER: US/10/142,763
; CURRENT FILING DATE: 2002-05-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-763-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-142-763-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGGCTCGGCTCTCTGCTGCGCGGCTCGAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACCGCGGAGCGGGAGGCGAGGAGCTGCGCAAGAGCGGAGGCGGAGGATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGAACAGGTCCTCCCAAGCTCCCAAGCTCCCACTGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTCAGCTACCTGTGAGCGGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCACCTCGCCAGATGACTCGTCCCGCTCGGGGTTCACAGATACCAACAGTATTATGG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGCTGAGAGGATCAGTGCATTGTTGTAGACACCGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACTCTCTACCGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCGGCGAGTTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCGCCCGACAGCCCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAGGGGACCAACAGATGGGCTGGGCAATGCTTTCATGGC 805
```

```
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCTGGCGCACGCTTC -CTGCCCCGCGCGCGAGACGACCTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTTGCTGGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTACACGCTTGGGCTTACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
QY 260 tTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAAAGAGGCTGGGCGCGCGCGCTGCTGCTGAGTGGAGGACGCTGCTGCCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCCTGAAACGCGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTAAATACTGCCACTCTTCTTTCGATGCCATCACTGTAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCACACTGAGGAAGATGGTGGGCTGCCCGCGCGAGCTTGAAGGTGGCGAGTGCATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GNATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCCA 1404
QY 400 pProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCAGTGTGGGTCTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCCAGGGGAGCTGCAAGTGGAGCCCTTACCCCCGNAAGTCTGACAGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTGAGGAGGTGAGCGGCGCTTCCGAGGCGCGAGTGGCTCCATCATCTCTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCCAAACTGACAGGCAACCCCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 216
US-10-142-765-143
; Sequence 143, Application US/10142765
; Publication No. US20030157603A1


```
Db      1645  CCGAGATGACCGCTACTGGCGCCTCGACCGAGCCAAACTGCGAGGCAACCACTCGGCGCG 1704
Qy      500  gTTPAlaThrGluLeuProTTPMetGlyCyTTPHiAAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGTCGCAACTCGGGGAGCGCCCTGTT 1764
Qy      520  e 520
Db      1765  C 1765

RESULT 218
US-10-142-888-143
; Sequence 143, Application US/10142888
; Publication No. US20030157606A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330RIC227
; CURRENT APPLICATION NUMBER: US/10/142,888
; CURRENT FILING DATE: 2002-05-09
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-142-888-143

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      98.52%      Indels:      2
DB:              17          Gaps:        0

US-10-791-980-6 (1-520) x US-10-142-888-143 (1-1985)

Qy      1  MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTTPGlyHisLeu 20
Db      206  ATGGTTCGGCGCGTGGGCTCTCTGTGGCGCCCTGCGAGCTGCTACTGTGGGCCACCTG 265
Qy      21  AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GACGCCACGCCCGGAGCGCGGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCTCTA 325
Qy      41  GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326  GAGAGTAGCGGATACCTCAATGAACAGGTCCTCCCAAGCTCCCACTCCATCTGATTACG 385
Qy      61  AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386  GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGCGGTGTGGACCGC 445
Qy      81  AlaThrLeuArgGlnMetThrArgProArgProCysGlyValThrAspThrAsnSerTyrAla 100
|||||
```

```
Db      446  GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy      101  AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506  GCCTGGGCTGAGAGGATCAAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGCGGTAA 565
Qy      121  LysArgPheAlaLysGlnGlyAsnLysTTPTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566  AAACGGCTTTGCAAGCAAGTAACAAATGGTACAAGCAGCACCTCTCTACCGCCTGGTG 625
Qy      141  AsnTTPProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626  AACTGGCCTGAGCATCTGCCGAGCGCGCAGTTTCGGGGCGCCGCTGCGCGCGCTTCCAG 685
Qy      160  rCysGlyAlaThrSerGlnArgTTPSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686  TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCCTGGAGGCCCCAGCCACAGCCCCCGCTGAC 745
Qy      180  rSerGlySerProSerSerLysGlyThrThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db      746  ATCCGGCTCACCTTCTTCCAAGGGGACCACACGATGGGCTGGGCAATGCTTTGATGGC 805
Qy      200  aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db      806  CCAGGGGGCGCCCTGGCGCACCGCTTC-CTGGCCCGCGCGCGGCAAGCGCACCTCGACCA 864
Qy      220  nAspGluArgTTPSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db      865  AGATGAGCGCTGGTCCCTGAGCCCGCCCGCGCGGCGCACTGTTCTGTGTGTGGCGCA 924
Qy      240  sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925  CGAGATCGGTCACAGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984
Qy      260  oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValGl 280
Db      985  CTACTACAAGAGGCTGGGCGCGCAGCGCTGCTCAGCTGGGAGCAGCTGTGGCGGTGCA 1044
Qy      280  nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCCTGTATGGGAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGTT 1104
Qy      300  eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db      1105  CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGCGCTCAAAACGCGAGG 1164
Qy      320  yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db      1165  CCCTAAATATCTGCCACACTCTCTCTTCGATGCCATCCTGTAGACAGGCAACAGCACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
Qy      360  gProLeuGlnGluArgTTPValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTCAGAGAAAGATGGGTTCGGGCTGCCGCCCAACATTTGAGGCTCGCGCAGTGTCA 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyValArgCysTTPArgPheArgGlyProLy 400
Db      1345  GAATGATGGAGATTCTTACTTCTTCAAGGGGTCGATGTGGAGGTTCCGGGGCCCCAA 1404
Qy      400  sProValTTPGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGTGGGTCTCCACAGCTGTGCCGGCAGGGGGCGCTGCCGCCCATCTCTGACGC 1464
Qy      420  aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db      1465  CGCCCTCTCTTCTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGTGCCTCTACTAGT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPGl 460
Db      1525  GCTGGCCGAGGGGAGCTGCNAAGTGGAGCCCTACTACCCCGAAGTGTGCAGGACTGGGG 1584
```


Db 1345 GAATGATGAGATTCTACTCTTCAAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 eProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGGCGGCAGGGGGCTTGCCTCCGCCATCTCTGAGCGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuLeuLeuPheLeuPheLeuPheLeuPheLeuVa 440
Db 1465 CGCCCTCTTCT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 yGlyLeuProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTTCAGCGGCGCCCTGCGAGGGCCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAGGCCAACTGCGAGGCAACCACTTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 221

US-10-143-117-143
; Sequence 143, Application US/10143117
; Publication No. US20030157609A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Auscin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C221
; CURRENT APPLICATION NUMBER: US/10/143,117
; CURRENT FILING DATE: 2002-05-09
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-143-117-143

Alignment Scores:
Pred. No.: 3,358-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
Dbs: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-143-117-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTGCGCGCGCTGGGCTCTCTGTCGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGGGAGCGGAGGCTGCGCAAGGAGCGGAGGCATTCCTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGTCCACCTCCATTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuPheArg 80
Db 386 GATGCCATCAGAGCGTTTCACTGGGTGTCCAGCTTACCTGTGAGCGGGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCCTCAGATGACTCTGTCCTCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGACCCAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTCCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCGCGGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAAGTCTCAGCGCTGAGTTCCTGGGAGGCGCCAGCCACAGGCGCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACATGGGCTGGGCAATGCGCTTCATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGGCGCACGCTTC-CTGCCCCCGCGCGGAGGCGGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGTGGTGTGTCGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCACTCCCGCGCGCGCGGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGGCGCGCGCGCTGCTCAGCTGGGAGCGGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGTT 1104
Qy 300 eThrAppPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGAAAGGCGCCCTGAAACACAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACCTGGCACCTCTCTTCGATGCCATCTACTGTAGACGCAACGAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360


```
QY 320 yProlystYrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTCGATGCCATCACTAGACAGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTTGCGAGCTGATGCCAACGTCCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGAATGGCTGGCTGCCCTCCCAACATTGAGGCTGGCGAGTGTGATT 1344
QY 380 uAsnAspGlyAspPheTrpPhePheLysGlyGlyArgCysTrpPheArgGlyProly 400
Db 1345 GAATGATGAGATTCTTACTTCTCAAGGGGTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGCTCTCCACAGCTGTGCGGGCAGGGGGCTTGGCCCGCCATCTCCTGAGCG 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTrpVa 440
Db 1465 CGCCCTCTTCTTCTCTCTCGCGCCCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
QY 440 lIleAlaArgGlyGlyLeuGlnValGluProTrpTrpTrpArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGCGCCGAGGGGACTGCAAGTGGAGGCCCTACTACCCCGAAGCTTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGGCCCTGCGGAGGCGCGATGCTCATCATCTTCTT 1644
QY 480 eArgAspArgTrpTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGGCTCGACAGGCGCAACTGAGGCGCAACACCTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGCTGCCCTGGATGGGCTGCTGGGATGCCAACTCGGGAGCGCCCTGT 1764
QY 520 e 520
Db 1765 C 1765
```

RESULT 223

```
US-10-144-992-143
; Sequence 143, Application US/10144992
; Publication No. US20030157611A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C259
; CURRENT APPLICATION NUMBER: US/10/144,992
; CURRENT FILING DATE: 2002-05-13
; Prior Application removed - See File Wrapper or Palm
```

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 143

; LENGTH: 1985

; TYPE: DNA

; ORGANISM: Homo Sapien

US-10-144-992-143

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985

Score: 2792.00 Matches: 519

Percent Similarity: 99.62% Conservative: 0

Best Local Similarity: 99.62% Mismatches: 1

Query Match: 98.52% Indels: 2

DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-144-992-143 (1-1985)

```
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGCGAGCGCGAGCTGCGCAAGGAGCGCGGCATTCCTTA 325
QY 41 GluLysTrpGlyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCNATGAACAGGTCCCAAGTCCACCTCCATCGATTGACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGTTTCACTGGGTGTCAGCTACCTGTCAGCGCGGTGTTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTrpAla 100
Db 446 GCCACCTTGCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCACAGTATTGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTACTTGTTCCTAGACACCGGACCCAAATGAGGGGTAA 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTrpLysGlnHisLeuSerTrpArgLeuVal 140
Db 566 AACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGCGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGAGTTCGTGGAGGCGCCCGACACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACACAAACGATGGGCTGGGCAATGCTTTGATGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGGCACGCCCTTC-CTGCCCGCGCGCGGCAAGCGCACTTCGACC 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTGTCCTCTGAGCCCGCGCGGCGCAACCTGTTCTGTGTGTGTCGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCACTCGCCCGCGCGCGCTCATGCGGCC 984
QY 260 oTrpTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGCGCGCGAGCGCTGCTCAGCTGGGACGACGCTGTGCGCGTCA 1044
```

```
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValaValaValaGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGATGGGAAGCCCTAGGGGGCTCAGTGGCGGTCCAGTCCCGAGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTCAGACCTGGGACTCTCAGACCCCCAGGAGGGCCCTGAAACGCAGGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACATGCCACTCTCTCTTCGATGCCATCAGTACAGAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValaValaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTTAAAGGGAGGCCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGAGGAGAGATGGGTGGGCTGCCCCCAACATTCAGGCTGGGGCAGTGCATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTCCGGGAGGGGGCTTCCCCGCCATCTTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
Qy 440 lleuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GGTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGCAAGTCTGCAAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCTTGAGGAGGTGAGCGGCGCTTCCGAGGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTCGCGCTCGACCGAGCCAACTGCAAGGCCAACCACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 224

US-10-145-015-143

; Sequence 143, Application US/10145015

; Publication No. US20030157612A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

```
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C253
; CURRENT APPLICATION NUMBER: US/10/145,015
; CURRENT FILING DATE: 2002-05-13
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
```

; SEQ ID NO 143

; LENGTH: 1985

; TYPE: DNA

; ORGANISM: Homo Sapien

; US-10-145-015-143

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985

Score: 2792.00 Matches: 519

Percent Similarity: 99.62% Conservative: 0

Best Local Similarity: 99.62% Mismatches: 1

Query Match: 98.52% Indels: 2

DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-015-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGCTCGGCCCTCTGCTGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GAGCCCCAGCCGCGGAGCGCGAGGCGAGAGCTGCGCAAGGAGGCGGAGGCATTCTCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCACTCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGGGTTTCAGTGGGTGTCCAGCTACTGTTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACTTGTCTGCTAGACACCGACCAAAATCAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTGCGGAGCCGCGAGTTCGGGGCGCGGTGCGCGCCCTTCCAG 685
Qy 160 rCysGlyValaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCCTGGGAGGGCCCCCAGCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACACCAACATGGGCTGGGCAATGCGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGCAACCTGTTCTGCTGGTGTGCGCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGCAACCTGTTCTGCTGGTGTGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
```

```
Db 925 CGAGATCGGTACACGCTTGGCCTCACCCACTCGCGCGCGCGCGCTCATGCGGCC 984
Qy 260 oTyrrlyvArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGAGTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrrGlyvProLeuGlyvSerValAlaValGlnLeuProGlyvLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThraPheGluThrTrpAspSerTyrrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCAGACGCCCAAGAGGCGCCCTGAAAGCGCAGG 1164
Qy 320 yProlyvTyrrCyvHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTy 340
Db 1165 CCTTAATACTGCCACTCTCTTCGATGCCATCACTGTAGACGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlyvSerHisPheTrpGluValAlaAlaAspGlyvAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAACGTTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCCGCCCAACATTCAGGCTGGCGCAGTGTCAAT 1344
Qy 380 uAsnAspGlyvAspPheTyrrPhePheLysGlyvGlyArgCyvTrpArgPheArgGlyvProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTCTCCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyvLeuProGlnLeuCyvArgAlaGlyvLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGGCCATCTGAGCG 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyvAlaArgTyrrVa 440
Db 1465 CGCCCTCTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTAGT 1524
Qy 440 lLeuAlaArgGlyvGlyvLeuGlnValGluProTyrrTyrrProArgSerLeuAspTrpG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTTACTACCCCGCAAGTCTGCAAGGACTGGGG 1584
Qy 460 yGlyvLeuProGluValSerGlyvAlaLeuProArgProAspGlyvSerIleIlePhePh 480
Db 1585 AGGATCCCTCAGGAGGTTCAGCGCGCTTCCGAGGGCCGCTGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGGCCAAACTGCGAGGCCAACACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyvCyvTrpHisAlaAsnSerGlyvSerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGGCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 225

US-10-145-090-143

; Sequence 143, Application US/10145090

; Publication No. US20030157613A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: Deforge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

```
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C260
; CURRENT APPLICATION NUMBER: US/10/145,090
; CURRENT FILING DATE: 2002-05-13
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-090-143
```

Alignment Scores:

```
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-145-090-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyvLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCGCTCGGCTCTCTGTCGCGCCCTGCTGCTGCTGCTGCTGCTGCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyvGlyvGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCCGCGCGGAGCGCGAGCGAGAGTGGCGAAGAGGCGGCGGAGGCGCATTCCTA 325
Qy 41 GluLysTyrrGlyvTyrrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGTACCTCAATGAACAGGTCCCCAAGCTCCCACTCCCTCCTCATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyvValLeuAspArg 80
Db 386 GATCCCATCAGAGCGTTTTCAGTGGGTGTCCAGTACCTACCTGTCAGCGGCGTGTGGACCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCyvGlyvValThrAspThrAsnSerTyrrAla 100
Db 446 GCCACCTTGGCGCCAGATGACTCGTCCCGCTGCGGGGTTCACAGATACCAACAGTTATCG 505
Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGTCTTGTTCAGACACCGGACCAAAATGAGGCGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyvAsnLysTrpTyrrLysGlnHisLeuSerTyrrArgLeuVal 140
Db 566 AAACGCTTTGCAAGAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyvAlaProCyvAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGCTGCGCGCGCTTCAG 685
Qy 160 rCyvGlyvAlaThrSerGlnArgTrpSerSerGlyvArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGGAGTTCCTGGAGAGGCCCGCAGCCACAGGCCCCCTGAC 745
Qy 180 rSerGlyvSerProSerSerLysGlyvThrThrMetGlyvTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGTGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyvAlaProTrpArgThrProPheLeuProArgArgGlyvGluAlaHisPheAspG1 220
```

```
Db      806  CCAGGGGCGCCCTGGCGCACGCTTC-CTGCCCCCGCGCGGAGCGCACTTCGACCA 864
Qy      220  nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db      865  AGATGAGCGCTGGTCCCTAGCGCGCGCGGGCGCAACCTGTTGCTGGTGCCTGGGCA 924
Qy      240  sGluLeuGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925  CGAGATCGGTACACGCTTGGCCCTACCCACTCGCCCGCGCGCGCGCTCATGGGCGC 984
Qy      260  oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db      985  CTACTACAAGAGGTGGCGCGCGCGCTCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
Qy      280  nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045  GAGCGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGCTCAGCTGCCAGAAAGCTGTT 1104
Qy      300  eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db      1105  CACTGACTTTGAGACCTGGGACTCTCAGCGCCCCCAGGAAGCGCCCTGAAACGCAAGG 1164
Qy      320  yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db      1165  CCCTAAATACTGCCACTCTCTCTCGATGCGCATCACTGTAGACAGGCAACAGCAACTGTA 1224
Qy      340  rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db      1225  CATTTTAAAGGGAGGCCATTTCTGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy      360  gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db      1285  TCCACTGCAGAAAGATGGTGGGCTGCCCGCCCCCAACATTGAGGCTCGGGCAGTGTATT 1344
Qy      380  uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345  GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy      400  sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405  GCCAGTGGGGGTCTCCACAGCTGTGCCGGGAGGGGGCTGCCCGGCCCATCTCGACGC 1464
Qy      420  aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db      1465  CGCCCTCTCTCTCTCTCGCGCGCTCATCTCTTCAAGGGTGGCGGCTACTACTAGT 1524
Qy      440  lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db      1525  GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTAGCCCCGAAAGTCTGCAGGAGCTGGG 1584
Qy      460  yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db      1585  AGGCATCTCTGAGGAGGTACGGCGCCCTCCGAGGCGCGATGGCTCCATCATCTTCTT 1644
Qy      480  eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db      1645  CCGAGATGACCGCTACTGGCGCCTCGACAGGCCAAACTGCAGCAACCACTCTCGGCGCG 1704
Qy      500  gTrpAlaThrGlnLeuProTrpMetGlyCysTrpPheAlaAsnSerGlySerAlaLeuPh 520
Db      1705  CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764
Qy      520  e 520
Db      1765  C 1765
```

RESULT 226

```
US-10-145-091-143
; Sequence 143, Application US/10145091
; Publication No. US20030157614A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
```

```
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C258
; CURRENT APPLICATION NUMBER: US/10/145,091
; CURRENT FILING DATE: 2002-05-13
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
; US-10-145-091-143

Alignment Scores:
Pred. No.:      3,35e-262      Length:      1985
Score:          2792.00      Matches:      519
Percent Similarity: 99.62%      Conservative: 0
Best Local Similarity: 99.62%      Mismatches: 1
Query Match:      98.52%      Indels:      2
DB:              17          Gaps:         0

US-10-791-980-6 (1-520) x US-10-145-091-143 (1-1985)
```

```
Qy      1  MetValAlaArgValGlyLeuLeuLeuLeuAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db      206  ATGCTCGCGCGCGTCCGCCCTCTGCTGCGCGCCCTGCGCTGCTACTGTGGGGCCACTG 265
Qy      21  AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db      266  GAGCGCCAGCCCGCGGAGCGCGGAGCCAGAGCTGCGCAAGAGGCGGAGGCACTTCTTA 325
Qy      41  GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326  GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAGCTCCCACTCCACTCGATTTCAGC 385
Qy      61  AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386  GATGCCATCAGACGGTTTACGTGGGTGCCAGCTACCTGTCAGCGCGGTGTTGGACCGC 445
Qy      81  AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db      446  GCCACCTCGCCAGATGACTCGTCCCGCTGGCGGGGTACAGATACCAACAGATTATGCG 505
Qy      101  AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506  GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGCGTAAG 565
Qy      121  LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566  AAACGCTTTGCAAAAGCAAGGTAACTAAGCAGCACCTCTCTCTACCGCGCTGGTG 625
Qy      141  AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626  AACTGGCCTGAGGATCTTCGCGGAGCGCGGATGTTGGGGCGCCGTCGCGCGGCTTCAG 685
Qy      160  rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686  TTGTGGGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCCAGCCACAGCCCCCGCTGAC 745
```



```
Db 506 GCGTGGGCTGAGAGGATCAGTCTGTTTGTGTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAenLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAACGGCTTTGCAAGCAAGGTACAAATGGTACAGCAGCAGCTCTCCCTACCGCCCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 NAATGGCTGAGCATCTGCGGAGCGCGAGTTCGGGGCGCGTGGCGCGCCCTTCAG 585
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGAGGCCCCAGCCACAGCGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCAAGGGGACACACAGATGGGCTGGGCAATGGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCTGGGCGACGCCCTTC-CTGCCCCCGCGCGGGAAGCGCATTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGCTGCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGCTGCGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CCAGATCGGTTCACGCTTGGGCTCACCCACTCGCCCGCGCGCGCTCATGCGGCC 984
Qy 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGCGTGGGCGCGAGCGGCTGCTCAGCTGGGACGACGTGCTGGCGCTGCA 1044
Qy 280 nSerLeuTrpGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCGTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCAGACCCCGCAAGGAGCGCCCTGAAACGACAGG 1164
Qy 320 yProLysTrpCysHisSerSerPheAspAlaThrValAspArgGlnGlnGlnLeuTy 340
Db 1165 CCTAAATACTGCCACTCTTCTTCATGCCATCACTGTAGACGCAACAGCAACTGTA 1224
Qy 340 rPheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCCATTTCTGGGAGGTGGCAGCTGATGGCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnLeGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAAGAAAGATGGTGGGCTGCGGCCCAACATTGAGGCTGGCGGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTrpPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATCGAGATTCTACTTCTTCAAAGGGGCTGATGCTGGAGGTTCGGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCCATCTCGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCCTCTTCTTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524
Qy 440 lIleuAlaArgGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTTACTACCCCGCAAGCTTCGCAAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyValAlaLeuProArgProAspGlySerIlePhePh 480
```

```
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCCTGCGGAGGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgPheAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACAGGCCAAACTGCAAGCAACACCCTCGGGCGG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGAGGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 229
US-10-145-747-143
; Sequence 143, Application US/10145747
; Publication No. US20030157618A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RLC300
; CURRENT APPLICATION NUMBER: US/10/145,747
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-747-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-747-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCGCTCTCTGTCGGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCGCCGCGAGCGCGAGGCTGGCAGAGCTGGCAAGGAGGCGGAGGCATTCTCTA 325
Qy 41 GluLysTrpGlyTrpLeuAsnGluValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCACCTCCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
```

Db	386	GATGCCATCAGAGCGTTTCAGTGGGTGTCACGACTCCTGTACGCGCGTGTGGACCGC	445
Qy	81	AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla	100
Db	446	GCCACCCCTGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG	505
Qy	101	AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys	120
Db	506	GCCTGGGCTGAGAGGATCAGTACTGTGTTGCTAGACACCGGACCAAAATGAGCGGTAA	565
Qy	121	LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal	140
Db	566	AAAGCCTTTGCAAGCAAGGTAAATGTTACAAATGTTACAGCAGACACCTCTCTACCGGCTGGTG	625
Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCCTGAGCATCTGCGGAGCGCGCATCTCGGGGCGCGGTGCGCGCGCTTCCAG	685
Qy	160	rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTTCTCAGCGCTGAGTTCTGGAGAGGCCCGCAGCCACAGGCGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl	200
Db	746	ATCGGCTCAGCTTCTTCAAGGGGACACACAGATGGGCTGGCAATGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspGl	220
Db	806	CCAGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGCGCGCGCTCATGGCGCC	864
Qy	220	nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATAGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCGCAACTGTTCGTGGTGTGGCGCA	924
Qy	240	sGluileGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr	260
Db	925	CGAGATCGTTCACAGCTTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGCGTGTGGCGCGTGA	1044
Qy	280	nSerLeuTrpGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCCGCTCAGCTCCAGGAAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACTGACTTTGAGACTTGGACTCTCAGAGCCCGCCAGGAGGCGCCCTGAAAGCGCAGGG	1164
Qy	320	yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACGGCAACAGCACTGA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAAGGAGGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCAGAGCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAAGATGGTGGCTGCGGCTGCCCGCCCAACATTGAGGCTGGCGGATGTCAT	1344
Qy	380	uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGGGGTCTCCACAGCTGTGCGGCGAGGGGGCTGCCCGCCATCTCTGACGC	1464
Qy	420	aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCCGCTACTAGCT	1524
Qy	440	lleuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGGCCCGAGGGGACTCAAGTGGAGCCCTACTACCCCGGAAGTCTGCAGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1585	AGCATCCCTGAGAGGTACGGCGCCCTGCGGAGGCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATGACCGCTACTGCGCGCTCGACAGGCGCAACTGCAGGCAACCCCTCGGGCCG	1704
Qy	500	gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh	520
Db	1705	CTGGGCCACCGAGCTGCCCTGGATGGCTGCTGGCATGCCAACTCGGAGGCGCCCTGTT	1764
Qy	520	e 520	
Db	1765	C 1765	
RESULT 230			
US-10-145-752-143			
; Sequence 143, Application US/10145752			
; Publication No. US20030157619A1			
; GENERAL INFORMATION:			
; APPLICANT: Baker, Kevin P.			
; APPLICANT: Beresini, Maureen			
; APPLICANT: DeForge, Laura			
; APPLICANT: Desnoyers, Luc			
; APPLICANT: Filvaroff, Ellen			
; APPLICANT: Gao, Wei-Qiang			
; APPLICANT: Gerritsen, Mary E.			
; APPLICANT: Goddard, Audrey			
; APPLICANT: Godowski, Paul J.			
; APPLICANT: Gurney, Austin L.			
; APPLICANT: Sherwood, Steven			
; APPLICANT: Smith, Victoria			
; APPLICANT: Stewart, Timothy A.			
; APPLICANT: Tumas, Daniel			
; APPLICANT: Watanabe, Colin K			
; APPLICANT: Wood, William			
; APPLICANT: Zhang, Zemin			
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC			
; FILE REFERENCE: P333081C292			
; CURRENT APPLICATION NUMBER: US/10/145,752			
; CURRENT FILING DATE: 2002-05-14			
; Prior Application removed - See File Wrapper or Palm			
; NUMBER OF SEQ ID NOS: 550			
; SEQ ID NO 143			
; LENGTH: 1985			
; TYPE: DNA			
; ORGANISM: Homo Sapien			
US-10-145-752-143			
Alignment Scores:			
Pred. No.: 3,35e-262 Length: 1985			
Score: 2792.00 Matches: 519			
Percent Similarity: 99.62% Conservative: 0			
Best Local Similarity: 99.62% Mismatches: 1			
Query Match: 98.52% Indels: 2			
DB: 17 Gaps: 0			
US-10-791-980-6 (1-520) x US-10-145-752-143 (1-1985)			
Qy	1	MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu	20
Db	206	ATGGTCGCGCGTGGGCTCTCTGTCGGCGCCCTCCTGTCGGCGCCCTGCTACTGTGGGGCCACCTG	265
Qy	21	AspAlaGlnProAlaGluArgGlyGlyGlnLeuArgLysGluAlaGluAlaPheLeu	40
Db	266	GACGCCAGCCCCCGGAGCGCGGAGGCTGCGCAAGGAGCGGAGGCATTCCTA	325

QY 41 GluYsYrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACACCTCCACTCGATTACG 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCACGCTACCTGTGAGCGGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGTAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTTGAGCATCTCCGAGCGCGGAGTTCCGGGCGCGTTCGGCGCCGCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTACGCTGGAGTTCTGGGAGGCGCCACGACAGGCGCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCAACAGATGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGCGCCCTGGCGCACGCTTC-CTGCGCGCGCGCGGCGGCAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGCGGCAACCTGTTCGTGTGTCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGGCGCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysrValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTCAGACCTGGGACTCTCTACAGCCCCCAAGGAGCGGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATACTGCCACTCTCTCTTCGATGTCATCTCAGTACAGGCAACGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheThrTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGGAGTGGAGCTGATGGCAACGCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerIe 380
Db 1285 TCCACTGCAGAAAGATGGTGGGCTGCGGCTGCGGCTGCGGCGAGTGTCTATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGTGATGCTGGAGGTTCCGGGGCCCCAA 1404

QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGCTCTCCACACAGCTGTGCGGCGCAGGGGCGCTGCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db 1465 GCCT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGCGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGCTTGCAGGACTGGGG 1584
QY 460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCTCCCGAGGCGCGATGGCTCCATCATCTCTTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACGACGCAAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGTGGCATGCTGCAACTCGGGGCGCTGTT 1764
QY 520 e 520
Db 1765 C 1765

RESULT 231
US-10-145-754-143
; Sequence 143, Application US/10145754
; Publication No. US20030157620A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C287
; CURRENT APPLICATION NUMBER: US/10/145,754
; PRIORITY FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-754-143

Alignment Scores:
Pred. NO.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-754-143 (1-1985)

Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-755-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
DB 206 ATGGTTCGGCGGCGTTCCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuLeuArgGlyGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCGCGAGCGCGAGGCCAGGAGCTGCGCAAGAGCGCGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAAGTACGGATACCTCAATGAACAGAGTCCCAAGCTCCACCTCCACCTCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTyrValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCTGCTGAGCGGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCGCAGATGACTCGTCCCGCTCGCGGTTCACAGATACCAACAGTTATGCG 505
QY 101 AlaThrAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGATCAGTACGTTGTTGTGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAenLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACCGCTTTCGAAGCAGGTAACTAATGTGTACAGCAGCAGCTCTCTACCGCCCTGGTG 625
QY 141 AenTyrProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCCTGAGCATCTGCGGAGCGCGAGTTCGGGCGCGCTGCGCGCGCCCTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTyrSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCGGGAGGCGCCACAGCGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTyrAlaMetProLeuMetAl 200
DB 746 ATCCCGCTCACCTTCTTCAGGGGACCAACAGATGGCTGGCAATGCCCTTTGATGCG 805
QY 200 aGlnGlyAlaProTyrArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
DB 806 CCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCCCGCGCGCGAGCGCACTTCGACCA 864
QY 220 nAspGluArgTyrSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTCAGCGCGCGCGCGCGCAACCTGTTTCGTGGTGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlApr 260
DB 925 CGAGATCGGTACACGCTTGGCTCACCCACTGCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTyrAspAspValLeuAlaValG1 280
DB 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGAGCTGTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGGAAGCTGT 1104
QY 300 eThrAspPheGluThrTyrAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
DB 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGAGGCGCCCTGAAACCGAGGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340

DB 1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTAGACAGGCAACAGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTyrGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGGAGGCCAATTTCTGGAGGTGGACGTGATGCAACGCTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTyrValGlyLeuProProAsnIleGluAlaAlaAlaValSerLe 380
DB 1285 TCCACTGCAGGAAGATGGGTGGGTCGCCCCCAACATTGAGGCTGCGGCGAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTyrArgPheArgGlyProly 400
DB 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGCATGCTGGAGGTTCGCGGGGCCAA 1404
QY 400 sProValTyrGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGGGGGTCTCCACAGCTGTGCGGGCAGGGGCGCTGCCCGCCATCTTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCTCTTCTTCCCTCTCTGCGCGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTyrG1 460
DB 1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAGTCTGCAGGAGCTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGATCTCTGAGGAGGTGAGCGGCGCTGCCGAGGCGCGATGCTCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTyrArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCGAGATGACCGCTACTTGGCGCTCGACCGCCAACTGCAGGCAACACCTCGGGCG 1704
QY 500 gTyrAlaThrGluLeuProTyrMetGlyCysTyrHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
QY 520 e 520
DB 1765 C 1765

RESULT 233
US-10-145-818-143
; Sequence 143, Application US/10145818
; Publication No. US20030157622A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C290
; CURRENT APPLICATION NUMBER: US/10/145,818
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985

TYPE: DNA
ORGANISM: Homo Sapien
US-10-145-818-143

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-818-143 (1-1985)

Qy 1 MetValAlaAtqValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTyrGlyHisLeu 20
Db 206 ATGTCGCGCGCGTCTGCTGCGCGCCCTGCAGCTGCTACTGTGGGCGCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCGCGAGCGCGAGCGCCAGGAGCTGCGCAGGAGCGCGGCGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuLeuGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAAGTACGGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTACG 385
Qy 61 AspAlaIleAtqAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCACAGCTACCTGTGAGCGCGGTGTGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACTGTTGTGTAGACACCGGACCCAAATGAGCGCTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTCGAAAGCAGATTAACAAATGGTACAGCAGCACCTCTCTCCGCGCTGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTCAGCATCTCCGAGCGCGCATGTTGGGGCGCGCTGCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGGTTCTGGGAGGCGCCACAGCCACAGGCGCGCTGAC 745
Qy 180 rSerGlySerProSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCAGCTTCTTCAGAGGAGCACCAACATGGGCTGGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCGCTGGCGCACGCTTC-CTGCCCGCGCGCGCGGAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCGCAACCTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCATCTCGCCCGCGCGCGCGGCTCATGGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGGCTCAGTGGCGGTCCAGCTCCAGGAAAGCTGTT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGGCGCCTGTAACGCGAGG 1164
Qy 320 YProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
Db 1165 CCCTAATACTGCCACTCTCTCTTCGATGCATCCTGTAGACAGGCAACAGCAACTGTGA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGCCATTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCAGAAAGATGGGTGCGGCTGCCCGCCCAACATTGAGGCTCGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTCCGCGCAGGGGGCTGCCCGCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCTCTCTTCTCCCTCTCTGCGCGCCCTCACTCTTCAAGGGGTGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 YGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTCAGAGGTCAGCGCGCTCTGCGAGCGCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTGCGCGCTCTGACACAGGCAAACTCGAGCAACACCTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACAGCTGCCCTGGATGGCTGCTGCGCATGCCCACTCGGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 c 1765

RESULT 234

US-10-145-820-143
; Sequence 143, Application US/10145820
; Publication No. US20030157623A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3330R1C276
; CURRENT APPLICATION NUMBER: US/10/145,820
; CURRENT FILING DATE: 2002-05-14
; PRIOR APPLICATION NUMBER: 60/049911
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: 60/056974
; PRIOR FILING DATE: 1997-08-26
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059115
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059117
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059122
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059184
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/059263
; PRIOR FILING DATE: 1997-09-18
; PRIOR APPLICATION NUMBER: 60/059352
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059588
; PRIOR FILING DATE: 1997-09-19
; PRIOR APPLICATION NUMBER: 60/059836
; PRIOR FILING DATE: 1997-09-24
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062285
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/062814
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/062816
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063045
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063082
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/063127
; PRIOR FILING DATE: 1997-10-24
; PRIOR APPLICATION NUMBER: 60/063327
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063329
; PRIOR FILING DATE: 1997-10-27
; PRIOR APPLICATION NUMBER: 60/063550
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063561
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/063704
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063733
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063735
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063738
; PRIOR FILING DATE: 1997-10-29
; PRIOR APPLICATION NUMBER: 60/063755
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064248
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/064809
; PRIOR FILING DATE: 1997-11-07
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065846
; PRIOR FILING DATE: 1997-11-17
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/066453
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066511
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/069212
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069278
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069334
; PRIOR FILING DATE: 1997-12-11
; PRIOR APPLICATION NUMBER: 60/069694
; PRIOR FILING DATE: 1997-12-16
; PRIOR APPLICATION NUMBER: 60/072320
; PRIOR FILING DATE: 1998-01-23
; PRIOR APPLICATION NUMBER: 60/073612
; PRIOR FILING DATE: 1998-02-04
; PRIOR APPLICATION NUMBER: 60/074086
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/074092
; PRIOR FILING DATE: 1998-02-09
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079663
; PRIOR FILING DATE: 1998-02-27
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; PRIOR APPLICATION NUMBER: 60/080165
; PRIOR FILING DATE: 1998-03-31
; PRIOR APPLICATION NUMBER: 60/081203
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081229
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/081695
; PRIOR FILING DATE: 1998-04-14
; PRIOR APPLICATION NUMBER: 60/081817
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/081818
; PRIOR FILING DATE: 1998-04-15
; PRIOR APPLICATION NUMBER: 60/082999
; PRIOR FILING DATE: 1998-04-24
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/083545
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084627
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084637
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/085149
; PRIOR FILING DATE: 1998-05-12
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085338
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085339
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085697
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085704
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/086414
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/086430
; PRIOR FILING DATE: 1998-05-22
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/088026

; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088730
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088741
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090538
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091982

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-820-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGTTCGGCGCGTGGCGCTCTGCTGCGCGCCCTGCGAGCTGCTACTGTGGGGCCACTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GACGCCAGCCCGCGAGCGCGAGGCGGAGCTGCGCAGGAGGCGGAGGCATTCTTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACCTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGTTTCAGTGGGTTCCTGAGCTACCTGTCCAGCGCGTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCCTGGGCTGAGAGGATCAGTACTGTTTGTCTAGACACCGGACCAAAATGAGCGCTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTGGAAAGCAGGTAAATGTTGATCAGCAGGACCTCTCTACCGCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160

DB 626 AACTGGCCTGAGCATCTGCCGAGCCGCGAGTTCGGGGCGCCGTCGCGCGCCCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCGTGGAGGCCCCCAGCCACAGGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTTCCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTGGGCGCAGCCCTTC-CTGCCCGCGCGGGCGAAGCGACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGCGGCGCAACCTGTTCTGCTGCTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGGTCAACACGCTTGGCCTCACCCACTCGCCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTCGCCGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGCTCCAGGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGGAAGCGCCCTCAAAACGCAAGG 1164
QY 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnGlnLeuTy 340
DB 1165 CCTTAATATCTGCCACTCTCTTCGATGCGATCACTGTATAGACAGGCAACAGCACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
DB 1225 CATTTTAAAGGAGGCCATTCTTGGAGGTGGGAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
DB 1285 TCCACTGCGAGAAAGATGGGTGGGTGCGGCTGCCCCCAACATTGAGGCTGCGGAGTTCATT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyArgCysTrpArgPheArgGlyProLy 400
DB 1345 GAATGATGGAGATTCTACTTCTTCAAAGGGGTTCGATGCTGGAGGTTCGCGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGCGAGGGGCTGCCCGCCCATCTCTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTCTTCCCTCTCTGCGCGCTCTCATCTCTTCAAGGGGTGCGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGGGCGAGGGGAGTGCAGTGGAGGCCCTACTACCCCGGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
DB 1585 AGGCATCTCTGAGGAGGTGAGCGCGCTTCCCGAGGCGCGATGGGTTCATCATCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CCAGATGACCGCTACTGGCGCTCTGACGAGGCAAACTGCAGGCAACCACTCTGGGCGC 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGTCTGTGCATGCCAACTCTCGGGAGCGCCCTGTT 1764

```
QY      520 e 520
Db      1765 C 1765

RESULT 235
US-10-145-872-143
; Sequence 143, Application US/10145872
; Publication No. US20030157624A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C294
; CURRENT APPLICATION NUMBER: US/10/145,872
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-872-143

Alignment Scores:
Pred. No.: 3,356-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-872-143 (1-1985)

QY      1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuLeuLeuLeuLeuTrpGlyHisLeu 20
Db      206 ATGTGTCGGCGCGTCTCTGTCGGCGCCCTGCGAGCTGCTACTGTGGGGCCACCTG 265

QY      21 AspAlaGlnProAlaGluArgGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db      266 GAGCGCCAGCCCGCGAGCGCGAGAGCTGCGAAGAGCGCGAGCATTCCTA 325

QY      41 GlutylsTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db      326 GAGAAAGTACGGATACCTCAATGAACAGGTGCCCCAAAGCTCCACCTCCACATTCAGC 385

QY      61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db      386 GATGCCATCAGAGCGCTTTTCAGTGGGTGTCCACAGCTACCTGTGTCAGCGCGTGTGGACCGC 445

QY      81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db      446 GCCACCTTCGCCGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATCGG 505

QY      101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db      506 GCCTGGGCTGAGAGGATCAGTGACTTGTGTTGCTAGACACCGGACCAAAATGAGGCGTAAG 565

QY      121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db      566 AAACGCTTTTGCAAAAGAGTAACAAATGGTACAAAGCAGACCTCTCTCCACCGCTGGTG 625

QY      141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db      626 AACGGGCTGAGCATCTCCGAGCGCGCAGTTCCGGGGCGCGTGGCGCGCCTTCCAG 685

QY      160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db      686 TTGTGGACAAACGCTCTCAGCGCTGGAGTTCTGGGAGGCGCCAGCCACAGCCCGCTGAC 745

QY      180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db      746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCTTTGATGGC 805

QY      200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db      806 CCAGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGGGAAGCGCACTTCGACCA 864

QY      220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
Db      865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGCTGCTGCGCGCA 924

QY      240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db      925 CGAGATCGGTACACAGCTTGGCCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984

QY      260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db      985 CTACTACAAGAGGCTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGCTGCA 1044

QY      280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db      1045 GAGCTGTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCAGTCTCCAGCTCCAGGAAAGCTGT 1104

QY      300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db      1105 CACTGACTTTGAGACCTGGGACTCTCTAGCGCCCAAGAAAGCGCCCTCGAAACCGAGGG 1164

QY      320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTrp 340
Db      1165 CCTTAATATCTGCCACCTCTTCTTCGATGCTCATCTACTGTAGACAGCAACAGCAACTGTA 1224

QY      340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAenValSerGluProAr 360
Db      1225 CATTTTAAAGGAGGACCAATTTCTGGAGGTGGCAGCTGATGCAACGCTCTCAGAGCCCGC 1284

QY      360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaAlaValSerie 380
Db      1285 TCCACTCGAGAAAGATGGGTGGGCTGCCCGCGCCCAACATTAGGCTGGCGGAGTGTGATT 1344

QY      380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db      1345 GAATGATGGAGATTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGGCCCA 1404

QY      400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db      1405 GCCAGTGTGGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCGCCCATCTCTGACGC 1464

QY      420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db      1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCCTCATCTCTTCAAGGGTGGCGCGCTACTAGT 1524

QY      440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db      1525 GCTGGCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGCAAGCTCTGCAAGGACTGGGG 1584

QY      460 yGlyIleProGluValSerGlyAlaLeuProArgProAspGlySerIleLeuPhePh 480
Db      1585 AGGCATCCCTGAGGAGGTACGCGCGCCCTGCCCGGCGCCGATGGCTCCATCATCTTCTT 1644
```

```
Qy 480 eArgAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACCAGGCCAAACTGCAGGCAACACCTCGGGCCG 1704

Qy 500 gTtpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGCCACACGAGCTGCGCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764

Qy 520 e 520
Db 1765 C 1765

RESULT 236
US-10-145-873-143
; Sequence 143, Application US/10145873
; Publication No. US20030157625A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C305
; CURRENT APPLICATION NUMBER: US/10/145,873
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-873-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-873-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGTACTGTGGGGCGCCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCCGGAGCGCGAGGCGCAGAGCTGCGCAAGAGGCGGAGGCATTCTTA 325

Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGCTCCACCTCCACTCGATTCCAGC 385

Qy 61 AspAlaLeuArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTCTGAGCGGCGTGTGGACGCG 445
```

```
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCCCTGCGCCAGATGACTGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505

Qy 101 AlaTrpAlaGluArgLysSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTCAGAGGATCAGTGACTTGTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565

Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLysSerTyrArgLeuVal 140
Db 566 AAAACGCTTTGCAAGCAAGGTAACAAATGGTACAAAGCAGCACCTCTCTACCGCTGGTG 625

Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCCGAGCGCGCAGTTCCGGGCGCCGTGCGCGCGCTTCCAG 685

Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCACAGGCCCGCTGAC 745

Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGGCTTTGATGGC 805

Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCTTGGGCGCACGCTTC-CTGCCCGCGCGGCGGAGCGACATTCGACCA 864

Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGTCTCCAGCGCGCGCGCGGCGCAACCTGTTCGTGTGTGTGGCGCA 924

Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTGCACGCTTGGCCTCACCCACTCGCCCGCGCGCGCTCATGGCGCC 984

Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044

Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCAGTCCAGCAAGAAAGCTGTT 1104

Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAGCGCCCTGAAACGCGAGG 1164

Qy 320 YProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCTTAATATCTGCACCTCTTCTTCGNTGCGATCCTGTAGACNGGCAACAGCAACTGTA 1224

Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGCATTTCTGGGAGGTGGCAGCTGTATGGCAACGCTCAGAGCCCG 1284

Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGAAAGATGGGTGGGCTGCCCGCCCAACATTTGAGGCTCGCGCAGTGTCAAT 1344

Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyLysProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAAAGGGGTTCGATGTGGAGGTTCGGGGGCCCAA 1404

Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGCTCTCCACAGCTGTGCCGCGAGGGGCTGCGCCGCCCATCTCCAGCGC 1464

Qy 420 aAlaLeuPhePheProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrpVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCGCTCACTCTTCAAGGGGTGCCCGCTACTACGT 1524

Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
```

```
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGGG 1584
Qy 460 YGLYILEProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGGAGGTGAGCGCGCCCTGCGAGGCCGCGATGCTCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCTCGACCAGGCCAACTGCAGGCCAACCCACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaLeuSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCGTGAGTGGCTGCTGGCATGCCAAGTGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 237
US-10-147-481-143
; Sequence 143, Application US/10147481
; Publication No. US20030157626A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C360
; CURRENT APPLICATION NUMBER: US/10/147,481
; CURRENT FILING DATE: 2002-05-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-481-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-147-481-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCCCGCGAGCGCGAGCGCAGAGCTGCGCAAGGAGCGGCGGCATTCCTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
```

```
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCAAAAGCTCCACACCTCCATTCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGAGTACCTGTGAGCGGGCGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTTGTCTAGACACCGGACCAAAATGAGGCGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AACGCTTTGCAAGCAAGGTAAACAAATGGTACAGCAGCACCTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCGGAGCGGCGAGTTCGGGGCGCGTGGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCGTGGAGGCGCCAGCCACAGGCCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCCAAAGGGGACCAACATGGGCTGGGCAATGCGCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGCGCCCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGCGGAGCGACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCGCGCGCGGCGCAACCTGTTCTGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCCTCACCCACTCCCGCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGCGCGCGCGCTGCTCAGCTGGGACGCGCTGTGGCGCTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTCCAGCTCCAGGAAAGCTGTT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACCTGGGACTCCTACAGCCCCCAAGGAAGGCGCGCTGAAAGCGCAGGG 1164
Qy 320 YProLysTyrCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuLeuTy 340
Db 1165 CCCTAAATATGCGCACTCTTCTTCGATGCCATCCTGTAGACAGGCGACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGGAGGACCATTTCTGGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTCGAGAAAGATGGGTGCGGCTGCCCGCCCAACATTGAGGCTCGGCAGGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGTGATGTGGAGGTTCGGGGGCCCA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
```



```
QY 380 uAnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProly 400
DB 1345 GAATGATGAGATTCTACTCTTCAAGGGGTGATGCTGGAGGTTCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
DB 1405 GCCAGTGTGGGGTCTCCACAGCTGTCCGGGCGAGGGGGCTGCCCGGCATCTTGACGC 1464
QY 420 aAlaLeuPhePheProLeuArgArgLeuLeuLeuPheLysGlyAlaArgTyrTyrVa 440
DB 1465 CGCCCTCTTCTTCCCTCTCTGCGCCGCTCATCTCTTCAAGGGGTGCCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
DB 1525 GCTGGCCCCAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAGTCTGAGGACTGGGG 1584
QY 460 yGlylleProGluGluValSerGlyAlaLeuProArgProAspGlySerlleilePhePh 480
DB 1585 AGGCATCCCTGAGAGGTTCAGCGGCGCTGCCGAGCCGATGGCTCCATCATCTTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
DB 1645 CGAGATGACCGCTACTGGCGCTCGACCAAGGCCAAATGCGAGGCCAACCTCGGGCCG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
DB 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAATCGGGGAGCGCCCTGTT 1764
QY 520 e 520
DB 1765 C 1765
```

RESULT 239

```
US-10-147-503-143
; Sequence 143, Application US/10147503
; Publication NO. US20030157628A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: Deforge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC335
; CURRENT APPLICATION NUMBER: US/10/147,503
; CURRENT FILING DATE: 2002-05-16
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-147-503-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
```

```
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0
US-10-791-980-6 (1-520) x US-10-147-503-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
DB 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
DB 266 GAGCGCCACAGCCCGGAGCGCGAGGCGCAGGAGCTGCGCAAGGAGCGCGAGGCATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
DB 326 GAGAAGTACGGATACCTCATGACAGGTCCCAAGCTCCCACTCCCTCCACTCGATTTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
DB 386 GATGCCATCAGAGCGCTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGCGCTGTGGACCGC 445
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
DB 446 GCCACCTCGCGCAGATGACTCGTCCCGCTCGGGGTTCACAGATACCAACAGTTATGCG 505
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
DB 506 GCTGGGCTGAGAGGATCAGTGACTTGTGTAGACCCGACCAAAATAGGCGGTAAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
DB 566 AAACGCTTTGCAAGCAAGGTAAACAAATGGTACAAAGCAGCAGCTCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
DB 626 AACTGGCTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGCTGCGCGCCCTTCCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
DB 686 TTGTGGAGCAACGTCTCAGCGCTGGAGTTCTGGAGAGCCCCCAGCCACAGCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
DB 746 ATCCGGCTCACCTCTTCCAAAGGGGACCAACAGATGGCTGGCAATGCTTGTATGTC 805
QY 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl 220
DB 806 CCAGGGGGCGCCCTGGCGCAGCCCTTC-CTGCCCGCGCGCGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgGlnLeuPheValValLeuAlaHi 240
DB 865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGCGCGCAACCTGTGTGTGGTGGCGCA 924
QY 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
DB 925 CGAGATCGTTCACACGCTTGGCTCACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
DB 985 CTACTACAAGAGGTGGGCGCGCGCGCTGCTCAGCTGGGACGACGTCTGCGCGCTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlySerValAlaValGlnLeuProGlyLysLeuPh 300
DB 1045 GAGCCTGATGGGAAGCCCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCAAGAAAGCTGTT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
DB 1105 CACTGACTTTGAGACCTGGGACTCTCTACAGCCCCCAAGAGCGCCCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTyr 340
DB 1165 CCCTAAATACTGCCACTCTCTCTCGATGCCATCATCTAGTACAGGCAACAGCAACTGTA 1224
```



```
Db 1105 CACTGACCTTGGAGCTGGGACTCTACAGCCCGCCCAAGGAGCGCCCTCGAAACGACGGG 1164
Qy 320 yProlystYrCyHisSerSerPheAspAlaIleThrValLeuArgGlnGlnLeuTy 340
Db 1165 CCTAAATACCTGCCACTCTTCCTTCGATGCCATCACTAGACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheThrGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTCAGAGCCCG 1284
Qy 360 gProLeuGlnLysArgTrpValGlyLeuProAsnIleGluAlaAlaValSerIle 380
Db 1285 TCCACTGAGGAAGATGGTGGGCTGCCCGCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheTyPhePheLysGlyValArgCySerTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTCTTCTTCAAGGGGGTGCATGCTGGAGGTTCGGGGGCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCyArgAlaGlyGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCTCCACAGCTGTGCCGGSCAGGGGCGCTGCCCGCCATCTCTGACGC 1464
Qy 420 aAlaLeuPheProProLeuArgLeuIleLeuPheLysGlyAlaArgTyTrVa 440
Db 1465 CGCCCTCTTCTCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTAGCT 1524
Qy 440 lIleuAlaArgGlyGlyLeuGlnValGluProTyTrpProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGGCCCTACTACCCCGAACTCTGCAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGGTACGGGGCGCTTCCCGAGGGCCGATGGCTCCATCACTTCTT 1644
Qy 480 eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCGCTCGACGAGGCCAACTGCAGGCCAACTCGGGCGC 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGGTGGCATCCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765
```

RESULT 241

```
US-10-152-401-143
; Sequence 143, Application US/10152401
; Publication No. US20030157630A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3330R1C385
; CURRENT APPLICATION NUMBER: US/10/152,401
```

```
; CURRENT FILING DATE: 2002-05-20
; Prior Application removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-152-401-143
```

```
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0
```

US-10-791-980-6 (1-520) x US-10-152-401-143 (1-1985)

```
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGAGGCTGCGCAAGAGCGCGAGGCATTTCCTA 325
Qy 41 GluLysTyTrpGlyTyTrpLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAAGCTCCACCTCCACATCGATTACG 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGCTACCTGTTCAGCGGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGGATCAGTGACTGTGTTCCTAGACACCGGACCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyLysGlnHisLeuSerTyArgLeuVal 140
Db 566 AAACGCTTTGCAAAGCAAGGTAAACAATGGTACAGCAGCACCTCTCTACCGCTTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGTCCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGTCCTCAGCGCTGAGTTCGGAGGGCCCGCAGCCACAGGCCCCCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACTTCTTCCAAAGGGGACCAACCAATGGGCTGGGCAATGCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGGCGCCCTGGCGCACGCTTC-CTGCCCGCGCGCGCGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTCAGCGCCCGCGCGCGCAACCTGTTCGTGGGTGGCGCCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGTTCACAGCTTGGCCCTCACCACTCCCGCGCGCGCGGCGCTCATGGCGCC 984
Qy 260 oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
```


QY 240 sGluileGlyHisThrLeuGlyLeuThHisSerProAlaProArgAlaLeuMetAlaPr 260
 Db 925 CGAGATCGGTACACGCTGGCTGCTACCCACTCGCCGCGCGCGGCTCATGGCGCC 984
 QY 260 oTy 280
 Db 985 CTACTACAAGAGCGCTGGCGCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1044
 QY 280 nSerLeuTy 300
 Db 1045 GAGCTGTATGGAAGCGCTTCTAGGGGCTCATGGCGCTGCTGCTGCTGCTGCTGCTG 1104
 QY 300 eThrAspPheGluThrTrpAspSerTy-SerProGlnGlyArgArgProGluThrGlnG 320
 Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAGAGAGCGCCCTGAAACCGAGGG 1164
 QY 320 yProTy 340
 Db 1165 CCCTAAATACTGCCACTCTTCTCGATGCCATCACTGTAGACAGCAACAGCAACTGTA 1224
 QY 340 rIlePheTy 360
 Db 1225 CATTTTAAAGGAGCGCACTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCG 1284
 QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
 Db 1285 TCCACTGCAGGAAAGATGGTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCT 1344
 QY 380 uAsnAspGlyAspPheTy 400
 Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTGGATGCTGGAGGTTCGGGGCCCCAA 1404
 QY 400 sProValTrpGlyLeuProGlnLeuGlnArgAlaGlyGlyLeuProArgHisProAspAl 420
 Db 1405 GCCAGTGTGGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGGCGCGCATCTCTGAGCG 1464
 QY 420 aAlaLeuPhePheProProLeuArgArgLeuLeuPheTyTyTyTyTyTyTyTyTyTy 440
 Db 1465 CGCCCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1524
 QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyTyTyTyTyTyTyTyTyTyTyTyTyTy 460
 Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGGCGCTTACTACCCCGAGCTTGCAGGACTGGGG 1584
 QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
 Db 1585 AGGCATCCCTGAGGAGGTGAGCGGCGCGCTGCGGAGGCGCGATGGCTCCATCATCTTCT 1644
 QY 480 eArgAspAspArgTy 500
 Db 1645 CCGAGATGACCGCTACTGCGCTCGACAGGCGCAACTGCGAGGCAACCAACCTCGGGCGG 1704
 QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGT 1764
 QY 520 e 520
 Db 1765 C 1765

RESULT 243
 US-10-792-143
 ; Sequence 143, Application US/10158792
 ; Publication No. US20030157632A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Desnoyers, Luc
 ; APPLICANT: Filvaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tamas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; FILE REFERENCE: P3330R1C460
 ; CURRENT FILING DATE: 2002-05-30
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 US-10-158-792-143
 Alignment Scores:
 Pred. No.: 3,35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 17 Gaps: 0
 US-10-791-980-6 (1-520) x US-10-158-792-143 (1-1985)

QY 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTGTCGCGCGCTGGCTCTCTGTCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 265
 QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCAGCCCGCGAGCGCGGAGCCGAGAGCTGCCAAGAGGCGGAGGCGCATTCCTA 325
 QY 41 GluTy 60
 Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAAAGCTCCACACCTCCACATTCGATTCAGC 385
 QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGTCCAGAGCTACCTGTCCAGCGCGCTGTGGACCGC 445
 QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyAla 100
 Db 446 GCCACCTTGGCCCGAGATGACTGTCGCCCGCTGCGGGGTTACAGATACCAACAGTTATGCG 505
 QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
 Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTGTTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
 QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyTyTyTyTyTyTyTyTyTyTyTyTyTyTy 140
 Db 566 AAACGCTTTGCAAGAGCAAGGTAAACAAATGGTACAGCAGCAGCCTCTCTCCCGCTGGTG 625
 QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
 Db 626 AACTGGCCTGAGCATCTGCCGAGCGCGAGTTCGGGGCGCGCTGCGGGCGCGCTTCCAG 685
 QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
 Db 686 TTGTGGAGCAAGCTCTCAGCGCTGAGTTCCTGGGAGGCGCCCGAGCCCGCCCTGAC 745
 QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
 Db 746 ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGCTGGGCAATGCCTTTGATGCC 805

```
QY 200 aGlnGlyAlaProTtpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db |||||
806 CCAGGGGGCGCCTGGCGACGCCCTTC-CTGCCCCCGCGCGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTtpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db |||||
865 AGATGAGCGCTGGTCCCTGAGCGCGCGCGGGCGCAACCTGTTCTGTTGTTGTCGGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db |||||
925 CGAGATCGGTACACGCTTGGCCTCACCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 cTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db |||||
985 CTACTACAGAGCGTGGCGCGCGCGCGCTGCTCAGCTGGGACGACGCTGCTGGCGGTGCA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db |||||
1045 GAGCCTGTATGGGAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAAGAGTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db |||||
1105 CACTGACTTTGAGACTCGGACTCTTACAGCGCCCCCAAGAAAGCGCGCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db |||||
1165 CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGCAACGCAACTGTGA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db |||||
1225 CATTTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGCTCTCAGAGCCCCG 1284
QY 360 gProLeuGlnGluArgTtpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db |||||
1285 TCCACTCGAGAAAGATGGTGGCGCTGCCCGCCCCCAACATTGAGGCTGGCGCAGTGTCA 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db |||||
1345 GAATATGGAGATTCTACTCTTCTCAAAGGGGGTTCGATCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl 420
Db |||||
1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGCAGGGGGCTGCCCCGCCATCTCGAGCG 1464
QY 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrVa 440
Db |||||
1465 CGCCCTCTTCTTCCCTCTCTGCGCGCCTCATCTCTTCAAGGGTGGCGCTACTAGT 1524
QY 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpG1 460
Db |||||
1525 CTTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCAGGACTGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db |||||
1585 AGGCATCCTCGAGAGGTGACGGCGCCCTGCCGAGGCCCGCATGGCTCCATCATCTTCT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db |||||
1645 CCGAGATACCGCTACTTGGCGCCTCGACAGGCGCAAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTtpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db |||||
1705 CTGGCCACCGAGTGGCTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 1764
QY 520 e 520
Db |
1765 C 1765
```

RESULT 244
US-10-158-462-143
; Sequence 143, Application US/10158462
; Publication No. US20030158104A1
; GENERAL INFORMATION:

```
; APPLICANT: Baker, Kevin P.  
; APPLICANT: Beresini, Maureen  
; APPLICANT: DeForge, Laura  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Sherwood, Steven  
; APPLICANT: Smith, Victoria  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Watanabe, Colin K  
; APPLICANT: Wood, William  
; APPLICANT: Zhang, Zemin  
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
; FILE REFERENCE: P3330R1C439  
; CURRENT APPLICATION NUMBER: US/10/158,462  
; CURRENT FILING DATE: 2002-05-29  
; NUMBER OF SEQ ID NOS: 550  
; SEQ ID NO 143  
; LENGTH: 1985  
; TYPE: DNA  
; ORGANISM: Homo Sapien  
US-10-158-462-143  
  
Alignment Scores:  
Pred. No.: 3,35e-262 Length: 1985  
Score: 2792.00 Matches: 519  
Percent Similarity: 99.62% Conservative: 0  
Best Local Similarity: 99.62% Mismatches: 1  
Query Match: 98.52% Indels: 2  
DB: 17 Gaps: 0  
  
US-10-791-980-6 (1-520) x US-10-158-462-143 (1-1985)  
  
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20  
Db |||||  
206 ATGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCTACTGTGGGGCCACCTG 265  
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40  
Db |||||  
266 GAGCCCGAGCCCGGAGCGCGAGCGCAGGAGCTGCGCAAGGAGCGGAGGATTCCTA 325  
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60  
Db |||||  
326 GAGAGTACGGATACCTCAATGACAGGTCTCCCAAGCTCCACCTCCATCGATTGAGC 385  
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80  
Db |||||  
386 GATGCCATCAGAGCGTTTCACTGGTGTCTCCAGCTACCTGTGAGCGCGTGTGGACCGC 445  
QY 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100  
Db |||||  
446 GCCACCTCGCGCAGATGACTCGTCCCGCTGGGGGTTACAGATACCAACAGTTATGCG 505  
QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120  
Db |||||  
506 CCTGGGCTGAGAGATCAGTGACTTGTCTTGTAGACACCGGACCAAAATAGGCGGTAG 565  
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140  
Db |||||  
566 AAACGCTTTGAAAGCAAGGTAACAAATGGTACAAAGCAGCACCTCTCTCCGCGCTGGTG 625  
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160  
Db |||||  
626 AACTGGCCTGAGCATCTGCGGAGCGGCAAGTTTCGGGGCGCGCTGCGCGCGCTTCCAG 685  
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180  
Db |||||
```

Db 686 TTGTGGAGCAACGCTCTCAGGGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCGCGTGAC 745
Qy 180 rSerGlySerProSerSerSerysGlyThrThrMetGlyTTPAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCACACGATGGGCTGGCAATGCCITTTGATGC 805
Qy 200 aGlnGlyAlaProTTPArgThrProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CCAGGGGGGGCGCTGGCGCACGCTTC - CTGGCCCGCGCGGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTTPSerSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHis 240
Db 865 AGATGAGCGCTGTCTTCTGAGCGCGCGCGCGCAACCTGTTCGTGTGTGGCGCA 924
Qy 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACAGCTTTGGCTTACCCACTCGCCCGCGCGCGCGCTCATGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTTPAspAspValLeuAlaValG1 280
Db 985 CTACTACAAGAGGCTGGCGCGGACGCGCTGTCTCAGCTGGGACGACGCTGCGCGGTGA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGAAAGCCCTAGGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
Qy 300 eThrAspPheGluThrTTPAspSerTyrSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTCTACAGCCCCCAGAGGCGGCTTGAACGCGAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaLeuThrValAspArgGlnGlnLeuTyr 340
Db 1165 CCCTAAATAGTCCACTTCTCTCGATGCCATCTAGTACAGGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTTPGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGCATTTCTGGAGGTGGCAGCTGATGCCAACGCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTTPValGlyLeuProProAsnLeuGluAlaAlaValSerLe 380
Db 1285 TCCACTGCGGAAAGATGGGTGGCTGCGCTGCCCCCAACATTGAGGTGGCGAGTGTCA 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTTPArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTTPGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGGCGGCGAGGGGCGCTGCCCGCCATCTTGAGCG 1464
Qy 420 aAlaLeuPheProProLeuArgArgLeuLeuPheLysGlyAlaAlaTyrTyrVa 440
Db 1465 CGCCCTCTTCTTCTTCTGCGCGCTCTATCTTCTTCAAGGGTGGCGCTACTACTGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTTPG1 460
Db 1525 GCTGGCCCGAGGGGACTGCAAGTGGAGCCCTACTACCCCGAGTCTCGAGGACTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCCCTGAGSAGGTGAGCGGCGCTTGGCGAGGCGCGATGCGCAACACCTTCGGCGG 1644
Qy 480 eArgAspAspArgTyrTTPArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGCCCTACTGGCGCTCGACGAGGCCAACTGCGAGGCAACACCTTCGGCGG 1704
Qy 500 gTPAlaThrGluLeuProTTPMetGlyCysTTPHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCCCGAGCTGCCCTGGATGGGTGCTGGCATGCCAACTCGGGGAGCGCCCTGT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 245

US-10-143-035-143

; Sequence 143, Application US/10143035

; Publication No. US20030166071A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE OF INVENTION: ACIDS ENCODING THE SAME

; FILE REFERENCE: P3330R1C219

; CURRENT APPLICATION NUMBER: US/10/143, 035

; CURRENT FILING DATE: 2002-05-09

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 143

; LENGTH: 1985

; TYPE: DNA

; ORGANISM: Homo Sapien

US-10-143-035-143

Alignment Scores:

Pred. No.: 3,35e-262 Length: 1985

Score: 2792.00 Matches: 519

Percent Similarity: 99.62% Conservative: 0

Best Local Similarity: 99.62% Mismatches: 1

Query Match: 17 Indels: 2

DB: 0 Gaps: 0

US-10-791-980-6 (1-520) x US-10-143-035-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTTPGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCTCTCTGTCGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCACGCGCGGAGCGGAGGCTGCGCAAGGAGCGGAGGCGGAGCATTTCTTA 325
Qy 41 GlulysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGATACCTCAATGAACAGGTCCCAAGGCTCCCACTCCATCGATTCAGC 385
Qy 61 AspAlaIleArgAlaPheGlnTTPValSerGlnLeuProValSerGlyValLeuAspArg 80
Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCCAAGCTACCTGTTCAGCGGCGTGTGGACGCG 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTGCGCCAGATGACTGTGCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505
Qy 101 AlaTTPAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTACGTTGTTGCTAGACACCCGAGCCCAAAATGAGGCGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAATGGTAAAGCAGCACCTCTCTCTACCGCTGTG 625

Qy	141	AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe	160
Db	626	AACTGGCGCTAGACATCTGCCGAGCGCGCAGTTCGGGGCGCGTGC	685
Qy	160	rCysGlyAlaIathSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh	180
Db	686	TTGTGGAGCAACGTCTCAGCGCTGGAGTTCCTGGAGGCGCCAGCCACAGGCCCGCTGAC	745
Qy	180	rSerGlySerProSerSerIysGlyThrThrMetGlyTrpAlaMetProLeuMetal	200
Db	746	ATCCGGCTCACCTTCTTCCAAAGGGGACCAACAGATGGGTGGGCAATGCTTTGATGGC	805
Qy	200	aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGlyAlaHisPheAspGl	220
Db	806	CCAGGGGGCGCGCTGGCGCAGCGCTTC-CTGCCCGCGCGCGGAGAGCGACATTCGACCA	864
Qy	220	nAspGluAArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi	240
Db	865	AGATAGCGGTGGTGCCTTGAGCGCGCGCGCGGCGCAACTCTGTGTGTGTGTGGCGCA	924
Qy	240	sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetalApr	260
Db	925	CGAGATCGGTCAACGCTTGCGCTCAACCCACTCGCCGCGCGCGCGCTCATGGCGCC	984
Qy	260	oTyTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl	280
Db	985	CTACTACAAGAGGCTGGCGCGCAGCGCTGCTCAGCTGGGACGAGTGCTGCCCGTGCA	1044
Qy	280	nSerLeuTyGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh	300
Db	1045	GAGCCTGTATGGGAAGCGCCCTAGGGGGCTCAGTGGCGCTCAGCTCCAGGNAAGCTGT	1104
Qy	300	eThrAspPheGluThrTrpAspSerTyTrpSerProGlnGlyArgArgProGluThrGlnGl	320
Db	1105	CACGTACTTTGAGACCTTGGNCTCTCTACAGCCCCCAAGGAGGCGCCTCGAAGCGCAGG	1164
Qy	320	yProLysTyTrpCysHisSerPheAspAlaIleThrValAspArgGlnGlnLeuTy	340
Db	1165	CCCTAAATACTGCCACTCTTCTTCGATGCCATCACTGTAGACAGGCACAGCAACTGTA	1224
Qy	340	rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr	360
Db	1225	CATTTTTAAGGGAGCATTCTCGGAGGTGGAGCTGATGGCAACGTCTCAGAGCCCCG	1284
Qy	360	gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe	380
Db	1285	TCCACTGCAGGAAGATGGGTGGGCTGCCCGCCCAACATTGAGGCTCGGCGAGTGTCATT	1344
Qy	380	uAsnAspGlyAspPheTyTrpPhePheLysGlyArgCysTrpArgPheArgGlyProLy	400
Db	1345	GAATGATGGAGATTCTTACTTCTTCAAAGGGGGTTCGATGTGTGGAGGTTCGCGGGCCCCAA	1404
Qy	400	sProValTrpGlyLeuProGlnLeuCysArgAlaGlyGlyLeuProArgHisProAspAl	420
Db	1405	GCCAGTGTGGGTCTCCACAGCTGTGCCGGGCGAGGGGGCTGCCCGCCATCTCTGACGC	1464
Qy	420	aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyTrpVa	440
Db	1465	CGCCCTCTTCTTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGCCCGCTACTACGT	1524
Qy	440	lLeuAlaArgGlyGlyLeuGlnValGluProTyTyTrpProArgSerLeuGlnAspTrpGl	460
Db	1525	GCTGCGCGGAGGGGACTGCAAGTGGAGCCCTACTAGCCCCGAAGTCTGACGAGACTGGGG	1584
Qy	460	yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh	480
Db	1595	AGGCATCCCTGAGAGGFTACGCGCGCCCTGCGGAGGCCCGATGGCTCCATCATCTTCTT	1644
Qy	480	eArgAspAspArgTyTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr	500
Db	1645	CCGAGATCACCGCTACTTGGCGCTCGACAGCGCAAACTGAGGCAACCACTCGGGCGCG	1704

Qy 500 gTPrAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
 Db 1705 CTGGGCCACCGAGCTGCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT 1764

Qy 520 e 520
 Db 1765 c 1765

RESULT 246
 US-10-145-751-143
 ; Sequence 143 Application US/10145751
 ; Publication No. US20030166074A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Baker, Kevin P.
 ; APPLICANT: Beresini, Maureen
 ; APPLICANT: DeForge, Laura
 ; APPLICANT: Deenoyers, Luc
 ; APPLICANT: Flivaroff, Ellen
 ; APPLICANT: Gao, Wei-Qiang
 ; APPLICANT: Gerritsen, Mary E.
 ; APPLICANT: Goddard, Audrey
 ; APPLICANT: Godowski, Paul J.
 ; APPLICANT: Gurney, Austin L.
 ; APPLICANT: Sherwood, Steven
 ; APPLICANT: Smith, Victoria
 ; APPLICANT: Stewart, Timothy A.
 ; APPLICANT: Tumas, Daniel
 ; APPLICANT: Watanabe, Colin K
 ; APPLICANT: Wood, William
 ; APPLICANT: Zhang, Zemin
 ; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
 ; TITLE OF INVENTION: ACIDS ENCODING THE SAME
 ; FILE REFERENCE: P3330R1C301
 ; CURRENT APPLICATION NUMBER: US/10/145,751
 ; CURRENT FILING DATE: 2002-05-14
 ; Prior Application removed - See File Wrapper or Palm
 ; NUMBER OF SEQ ID NOS: 550
 ; SEQ ID NO 143
 ; LENGTH: 1985
 ; TYPE: DNA
 ; ORGANISM: Homo Sapien
 US-10-145-751-143

Alignment Scores:
 Pred. No.: 3.35e-262 Length: 1985
 Score: 2792.00 Matches: 519
 Percent Similarity: 99.62% Conservative: 0
 Best Local Similarity: 99.62% Mismatches: 1
 Query Match: 98.52% Indels: 2
 DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-751-143 (1-1985)

Qy 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuTrpGlyHisLeu 20
 Db 206 ATGTCGGCGCGTCGCGCCCTCTGCTGGCGCCCTGTCAGCTGCTACTGTGGGGCCACCTG 265

Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgIysGluAlaGluAlaPheLeu 40
 Db 266 GACGCCACCGCCGGCGAGCGCGAGGCCAGGAGCTGCGCAAGGAGCGGAGGCATTCCTA 325

Qy 41 GluIysTrpGlyTyrLeuAsnGlnValProIlysAlaProThrSerThrArgPheSer 60
 Db 326 GAGAAGTACGGATACCTCATATGAACAGGTCCCCAAAGCTCCCACTCCACTCGATTGAGC 385

Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80
 Db 386 GATGCCATCAGAGCGTTTTCAGTGGGTGCCAGCTACTCTGTTCAGCGCGTGTTCGACCGC 445

Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
 Db 446 GCCACCTTCGCCCAATGACTCGTCCCGCTGCGGGGTTCAGATACCAACAGTTATGCG 505

QY 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGCTGAGAGGATCAGTGACTGTTGTTGTAGACACCGGACCAAAATGAGGCGTAAG 565
QY 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAAACAAATGTTACAAAGCAGCACCTCTCTACCGCTGGTG 625
QY 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGAGCATCTCGCGAGCGCGAGTTCGGGGCGCGCTGCGGGCCGCTTCAG 685
QY 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTCAGCGCTGAGTTCGGAGGGCCCCAGCCACAGGCCCCGCTGAC 745
QY 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCAAGGGGACCCACAAACGATGGCTGGGCAATGCCCTTTGATGCC 805
QY 200 aGlnGlyAlaProTrpArgTrpProPheLeuProArgArgGlyGluAlaHisPheAspG1 220
Db 806 CAGGGGGGGCCCTGGCGACCCCTTC-CTGCCCCCGCGCGGCGAAGCGCACTTCGACCA 864
QY 220 nAspGluArgTrpSerLeuSerArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATCAGCGCTGCTCCCTGAGCGCGCGCGCGGCGCAACCTGTTCTGTTGCTGCGCGCA 924
QY 240 sGluLeGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTCAACGCTTGGCTTCACCCACTCGCGCGCGCGCGCGCTCATGGCGCC 984
QY 260 oTyrTrpLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValG1 280
Db 985 CTACTACAGAGGCTGGGCGCGCGCGCTGCTCAGCTGGGACGACGTGTCGCGCGTGA 1044
QY 280 nSerLeuTyrGlyLysProLeuGlyLysSerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTAGGGGCTCAGTGGCGCTCCAGCTCCCGAGAAAGCTGT 1104
QY 300 eThrAspPheGluThrTrpAspSerTrpSerProGlnGlyArgArgProGluThrGlnG1 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGGAGCGCGCTGAAACGCGAGG 1164
QY 320 yProLysTyrCysHisSerPheAspAlaThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATCTGCCACTCTCTCTCGATGCCATCACTGTAGACAGGCAACGCAACTGTA 1224
QY 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGCAGCTGATGGCAACGTCTCAGAGCCCG 1284
QY 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGCTGCCGCCCAACATTCAGGTGGCGGAGTGTCAAT 1344
QY 380 uAsnAspGlyAspPheTyrPhePheLysGlyLysArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTTCTACTTCTTCAAGGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
QY 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLysLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCACAGCTGTGCGGGGAGGGGGCTGCCCCGCCATCTTCGAGCG 1464
QY 420 aAlaLeuPhePheProLeuArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGGCTCATCTCTTCAAGGGTGGCGCTACTACGT 1524
QY 440 lLeuAlaArgGlyLysLeuGlnValGluProTyrTrpProArgSerLeuGlnAspTrpG1 460
Db 1525 GCTGGCCCCGGGGGACTGCAAGTGGAGCCCTTACTACCCCGCAAGTCTTCGAGGACTGGGG 1584
QY 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480

Db 1585 AGGCATCCTCAGGAGGTTCAGCGGCGCTGCCGAGGCCCATCATCTCTCTT 1644
QY 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGGCGCCTCGACGAGGCCAAACTGCAGGCAACCACTCGGGCGG 1704
QY 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGTGCCTGGATGGGCTGCTGGCATGCCAACTCGGGAGGCCCTGTT 1764
QY 520 e 520
Db 1765 C 1765
RESULT 247
US-10-145-822-143
; Sequence 143, Application US/10145822
; Publication No. US20030166075A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C302
; CURRENT APPLICATION NUMBER: US/10/145,822
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-822-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-822-143 (1-1985)
QY 1 MetValAlaArgValGlyLeuLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGTCGCGGCGCTCGGCTCTCTGTCGGCGCCCTGCAGCTGCTACTGTGGGGCCACCTG 265
QY 21 AspAlaGlnProAlaGluArgGlyGlyGlnGlnLeuArgLysGluAlaGluAlaPheLeu 40
Db 266 GACGCCAGCCCGCGGAGCGCGGAGCTGCGAAGGAGCGGAGGCAATTCCTA 325
QY 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACTCCGATTCGATTCAGC 385
QY 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValSerGlyValLeuAspArg 80

Db 386 GATGCCATCAGAGCGTTTCAGTGGGTGTCCAGACTACCTGTCCAGGGCGTGTTCGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTTCGCCAGATGACTCGTCCCGCTGCGGGGTACAGATACCAACAGATTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCCTGGGCTGAGAGATCAGTGACTTGTCTTCTAGACACCGGACCAAAATGAGCGGTAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTrpTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACAAATGGTACAGCAGCACCTCTCTCCAGCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCCTGAGCATCTGCGGAGCGGACGTTGCGGGCGCGTTCGCGCGCGCTTCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGACCAAGCTCTCAGCGCTGAGGTTCTGGAGAGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTCTTCCAAGGGGACCACCAACGATGGCTGGCAATGCCCTTTGATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGl 220
Db 806 CCAGGGGCGCCCTGGCGACGCTTC-CTGCCCGCGCGCGGCGAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValLeuAlaHi 240
Db 865 AGATGAGCGCTGGTCCCTGAGCCCGCGCGCGGGCGCAACTGTTCGTGGTGTGGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTTGGCCTCACCACTCGCCCGCGCGCGCTCATGCGGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGl 280
Db 985 CTACTACAAGAGGTGGGCGCGACGCGCTCTCAGCTGGGACGACGCTGTGGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGTCCAGCTCCAGGAAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACCTGGGACTCTACAGCCCCCAAGGAAGCGCCCTGAAACGCAAGG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTTCCTTCGATGTCATCTCAGTACAGCAACAGCAACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGCCATTTCTGGAGGTGGAGCTGATGCAACGCTCTCAGAGCCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAGGAAGATGGTGGCTGCCCCCCCAACATTAGGCTGGCGGAGTGTATT 1344
Qy 380 uAsnAspGlyAspPheTyrPhePheLysGlyGlyArgCysTrpArgPheArgGlyProLy 400
Db 1345 GAATGATGGAGATTCTACTCTTTCAAGAGGGGTTCGATGCTGGAGGTTCCGGGGCCCCAA 1404
Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 CCCAGTGTGGGCTTCCCAAGAGCTGTGCCGGGCGAGGGGCTTGCCTCCGCCATCTTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTrVa 440

Db 1465 CGCCTCTTCTCCCTCTCTCGCGCGCTCATCTCTTCAAGGGTCCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGGCCCGAGGGGAGCTGCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGGACTGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGCATCCCTGAGGAGGTGAGCGGCGCTCGCGAGGCCCGATGGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCAGATGACCGCTACTTGGCGCTCGACACGAGGCAAACTGCAGGCAACCACTCGGCGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACGAGTGCCCTGGATGGCTGTGCATGCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765
RESULT 248
US-10-145-824-143
; Sequence 143, Application US/10145824
; Publication No. US20030166076A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Fillvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCES: P3330R1C280
; CURRENT APPLICATION NUMBER: US/10/145,824
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-145-824-143
Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0
US-10-791-980-6 (1-520) x US-10-145-824-143 (1-1985)
Qy 1 MetValAlaArgValGlyLeuLeuArgAlaLeuGlnLeuLeuLeuTrpGlyHisLeu 20
Db 206 ATGGTCGCGCGCTCGGCGCTCTCTGCTGCGCGCCCTGAGCTGCTACTGTGGGGCCACCTG 265
Qy 21 AspAlaGlnProAlaGluArgGlyGlyGlnGluLeuArgLysGluAlaGluAlaPheLeu 40

Db 266 GAGCCGCCAGCCGCGAGCGCGAGGACGAGGAGCTGCGCAAGGAGGCGGAGGCAATTCCTTA 325
Qy 41 GluLysTyrGlyTyrLeuAsnGluGlnValProLysAlaProThrSerThrArgPheSer 60
Db 326 GAGAGTACGGATACCTCAATGACAGGTCCCAAGCTCCACCTCCACTCGATTACGC 385
Qy 61 AspAlaIleArgAlaPheGlnTrpValSerGlnLeuProValIserGlyValLeuAspArg 80
Db 386 GATGCCATCAGACGCTTTCAGTGGGTGTCCAGCTACCTGTGTCAGCGCGGTGTGGACCGC 445
Qy 81 AlaThrLeuArgGlnMetThrArgProArgCysGlyValThrAspThrAsnSerTyrAla 100
Db 446 GCCACCTCGCCGACAGTACTCGTCCCGCTCGCGGGTTACAGATACCAACAGTTATGCG 505
Qy 101 AlaTrpAlaGluArgIleSerAspLeuPheAlaArgHisArgThrLysMetArgArgLys 120
Db 506 GCTTGGCTGTAGAGGATCAGTACTTGTGTGTAGACACCGGACCAAAATGAGGGGTAAAG 565
Qy 121 LysArgPheAlaLysGlnGlyAsnLysTyrTyrLysGlnHisLeuSerTyrArgLeuVal 140
Db 566 AAACGCTTTGCAAGCAAGGTAACTAAATGTTACACAGCAGCACTCTCTACCGCTGGTG 625
Qy 141 AsnTrpProGluHisLeu-ArgSerArgGlnPheGlyAlaProCysAlaProProSerSe 160
Db 626 AACTGGCTGTAGCATCTGCGGAGCGCGAGTTTCGGGGCGCGTTCGCGCGCTTCCAG 685
Qy 160 rCysGlyAlaThrSerGlnArgTrpSerSerGlyArgProGlnProGlnAlaProLeuTh 180
Db 686 TTGTGGAGCAACGCTCTACGCTGTGAGTTCTGGAGGGCCCCAGCCACAGGCCCGCTGAC 745
Qy 180 rSerGlySerProSerSerLysGlyThrThrThrMetGlyTrpAlaMetProLeuMetAl 200
Db 746 ATCCGGCTCACCTTTCTCCAGGGGACCAACAGATGGCTGGGCAATGCCCTTGTATGGC 805
Qy 200 aGlnGlyAlaProTrpArgThrProPheLeuProArgArgGlyGluAlaHisPheAspGi 220
Db 806 CCAGGGGGCGCTGCGGCACGCCCTTC-CTGCCCCCGCGCGCGCAAGCGCACTTCGACCA 864
Qy 220 nAspGluArgTrpSerLeuSerArgArgArgGlyArgAsnLeuPheValValLeuAlaHi 240
Db 865 AGATAGCGCTGGTCCCTGAGCGCGCGCGCGCGGCGCAACCTGTGTGTGTGTGTGTGTGCGCA 924
Qy 240 sGluIleGlyHisThrLeuGlyLeuThrHisSerProAlaProArgAlaLeuMetAlaPr 260
Db 925 CGAGATCGGTACACGCTGGCTCACCACCTCGCGCGCGCGCGCGCTCATGTGGCGCC 984
Qy 260 oTyrTyrLysArgLeuGlyArgAspAlaLeuLeuSerTrpAspAspValLeuAlaValGi 280
Db 985 CTACTACAAGAGGCTGGGCGCGGACGCGCTGTCTAGCTGGGACGACGTGTGCGCGGTGCA 1044
Qy 280 nSerLeuTyrGlyLysProLeuGlyGlySerValAlaValGlnLeuProGlyLysLeuPh 300
Db 1045 GAGCCTGTATGGGAAGCCCTTAGGGGCTCAGTGGCGCTGCCAGCTCCAGCAAGAGCTGT 1104
Qy 300 eThrAspPheGluThrTrpAspSerTyrSerProGlnGlyArgArgProGluThrGlnGl 320
Db 1105 CACTGACTTTGAGACTGGGACTCTACAGCCCCCAAGAGGCGCCCTGAAACCCAGCG 1164
Qy 320 yProLysTyrCysHisSerSerPheAspAlaIleThrValAspArgGlnGlnLeuTy 340
Db 1165 CCCTAAATACTGCCACTCTCTTCATGTCATCCTGATGTCATGTCAGACGCAACAGCACTGTA 1224
Qy 340 rIlePheLysGlySerHisPheTrpGluValAlaAlaAspGlyAsnValSerGluProAr 360
Db 1225 CATTTTAAAGGAGGACATTTCTGGAGGTGGCAGCTGATGCCAAGCTCTTCAGAGCCCG 1284
Qy 360 gProLeuGlnGluArgTrpValGlyLeuProAsnIleGluAlaAlaValSerLe 380
Db 1285 TCCACTGCAAGAAAGATGGTGGGCTGCCCCCAACATTGAGGCTGGCGAGTGTCAAT 1344
Qy 380 uAsnAspGlyAspPheThrPhePheLysGlyArgCysTrpArgPheArgGlyProly 400
Db 1345 GAATGATGAGATTTCTACTTCTTCAAGGGGGGTGATGCTGGAGGTTCCGGGGGCCCCNA 1404

Qy 400 sProValTrpGlyLeuProGlnLeuCysArgAlaGlyLeuProArgHisProAspAl 420
Db 1405 GCCAGTGTGGGTCTCCCAACAGCTGTGCGGGCAGGGGCGCTGCCCCCATCTCTGACGC 1464
Qy 420 aAlaLeuPhePheProProLeuArgArgLeuIleLeuPheLysGlyAlaArgTyrTyrVa 440
Db 1465 CGCCCTCTTCTCCCTCTCTGCGCGCGCTCATCTCTTCAAGGGTGGCCGCTACTACGT 1524
Qy 440 lLeuAlaArgGlyGlyLeuGlnValGluProTyrTyrProArgSerLeuGlnAspTrpGl 460
Db 1525 GCTGCGCCGAGGGGAGTCAAGTGGAGCCCTACTACCCCGAAGTCTGCAGAGCTGGGG 1584
Qy 460 yGlyIleProGluGluValSerGlyAlaLeuProArgProAspGlySerIleIlePhePh 480
Db 1585 AGGCATCTCTGAGGAGTACAGCGCGCTGCCGAGGCCGATGCTCCATCATCTTCTT 1644
Qy 480 eArgAspAspArgTyrTrpArgLeuAspGlnAlaLysLeuGlnAlaThrThrSerGlyAr 500
Db 1645 CCGAGATGACCGCTACTGCGCCTCGACCCAGGCCAACTGCAGGCAACCCACCTCGGGCG 1704
Qy 500 gTrpAlaThrGluLeuProTrpMetGlyCysTrpHisAlaAsnSerGlySerAlaLeuPh 520
Db 1705 CTGGGCCACCGAGCTGCCCTGATGGGCTGCTGGCATGCCAACTCGGGAGCGCCCTGTT 1764
Qy 520 e 520
Db 1765 C 1765

RESULT 249

US-10-145-827-143
; Sequence 143, Application US/10145827
; Publication No. US20030166077A1

GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Deanoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tamas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C265
; CURRENT APPLICATION NUMBER: US/10/145,827
; CURRENT FILING DATE: 2002-05-14
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 143
; LENGTH: 1985
; TYPE: DNA
; ORGANISM: Homo Sapien

US-10-145-827-143

Alignment Scores:
Pred. No.: 3,35e-262 Length: 1985
Score: 2792.00 Matches: 519
Percent Similarity: 99.62% Conservative: 0
Best Local Similarity: 99.62% Mismatches: 1
Query Match: 98.52% Indels: 2
DB: 17 Gaps: 0

US-10-791-980-6 (1-520) x US-10-145-827-143 (1-1985)

THIS PAGE BLANK (USPTO)